



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/48		A2	(11) International Publication Number: WO 00/22430
			(43) International Publication Date: 20 April 2000 (20.04.00)

<p>(21) International Application Number: PCT/US99/23573</p> <p>(22) International Filing Date: 8 October 1999 (08.10.99)</p> <p>(30) Priority Data: 60/103,794 9 October 1998 (09.10.98) US 60/132,068 30 April 1999 (30.04.99) US</p> <p>(71) Applicant (for all designated States except US): CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): FRAZER, Claire, M. [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). HICKEY, Erin [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). PETERSON, Jeremy [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). TETTELIN, Herve [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). VENTER, J., Craig [US/US]; 4569 Horton Street, Emeryville, CA 94608-2916 (US). MASIGNANI, Vega [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). GALEOTTI, Cesira [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). MORA, Marirosa [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). RATTI, Giulio [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100</p>	<p>Siena (IT). SCARSELLI, Maria [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). SCARLATO, Vincenzo [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). RAPPUOLI, Rino [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT). PIZZA, Mariagratia [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100 Siena (IT).</p> <p>(74) Agent: HARBIN, Alisa, A.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
---	--

(54) Title: NEISSERIA GENOMIC SEQUENCES AND METHODS OF THEIR USE

(57) Abstract

The invention provides methods of obtaining immunogenic proteins from genomic sequences including *Neisseria*, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of *Neisseria meningitidis B*. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

A

919 (46 kDa)

PURIFICATION

MI 919

B

919 (46 kDa)

WESTERN BLOT

OMV TP PP

C

919 (46 kDa)

FACS

D

919 (46 kDa)

BACTERICIDAL ASSAY

Time	preimmune	GST	919
t ₀	200	200	200
t ₁	300	200	100

E

919 (46 kDa)

ELISA assay: positive

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

NEISSERIA GENOMIC SEQUENCES AND METHODS OF THEIR USE

This application claims priority to provisional U.S. applications serial nos. 60/103,794, filed 9 October, 1998 and 60/132,068, filed 30 April, 1999, both of which are
5 incorporated in full herein by reference.

This invention relates to methods of obtaining antigens and immunogens, the antigens and immunogens so obtained, and nucleic acids from the bacterial species: *Neisseria meningitidis*. In particular, it relates to genomic sequences from the bacterium; more particularly its "B" serogroup.

10

BACKGROUND

Neisseria meningitidis is a non-motile, gram negative diplococcus human pathogen. It colonizes the pharynx, causing meningitis and, occasionally, septicaemia in the absence of meningitis. It is closely related to *N. gonorrhoea*, although one feature that clearly
15 differentiates meningococcus from gonococcus is the presence of a polysaccharide capsule that is present in all pathogenic meningococci.

N. meningitidis causes both endemic and epidemic disease. In the United States the attack rate is 0.6-1 per 100,000 persons per year, and it can be much greater during outbreaks. (see Lieberman *et al.* (1996) Safety and Immunogenicity of a Serogroups A/C *Neisseria*
20 *meningitidis* Oligosaccharide-Protein Conjugate Vaccine in Young Children. *JAMA* 275(19):1499-1503; Schuchat *et al* (1997) Bacterial Meningitis in the United States in 1995. *N Engl J Med* 337(14):970-976). In developing countries, endemic disease rates are much higher and during epidemics incidence rates can reach 500 cases per 100,000 persons per year. Mortality is extremely high, at 10-20% in the United States, and much higher in
25 developing countries. Following the introduction of the conjugate vaccine against *Haemophilus influenzae*, *N. meningitidis* is the major cause of bacterial meningitis at all ages in the United States (Schuchat *et al* (1997) *supra*).

Based on the organism's capsular polysaccharide, 12 serogroups of *N. meningitidis* have been identified. Group A is the pathogen most often implicated in epidemic disease in
30 sub-Saharan Africa. Serogroups B and C are responsible for the vast majority of cases in the United States and in most developed countries. Serogroups W135 and Y are responsible for

- 2 -

the rest of the cases in the United States and developed countries. The meningococcal vaccine currently in use is a tetravalent polysaccharide vaccine composed of serogroups A, C, Y and W135. Although efficacious in adolescents and adults, it induces a poor immune response and short duration of protection, and cannot be used in infants (e.g., Morbidity and Mortality weekly report, Vol. 46, No. RR-5 (1997)). This is because polysaccharides are T-cell independent antigens that induce a weak immune response that cannot be boosted by repeated immunization. Following the success of the vaccination against *H. influenzae*, conjugate vaccines against serogroups A and C have been developed and are at the final stage of clinical testing (Zollinger WD "New and Improved Vaccines Against Meningococcal Disease". In: *New Generation Vaccines*, supra, pp. 469-488; Lieberman *et al* (1996) *supra*; Costantino *et al* (1992) Development and phase I clinical testing of a conjugate vaccine against meningococcus A (menA) and C (menC) (*Vaccine* 10:691-698)).

Meningococcus B (MenB) remains a problem, however. This serotype currently is responsible for approximately 50% of total meningitis in the United States, Europe, and South America. The polysaccharide approach cannot be used because the MenB capsular polysaccharide is a polymer of $\alpha(2-8)$ -linked *N*-acetyl neuraminic acid that is also present in mammalian tissue. This results in tolerance to the antigen; indeed, if an immune response were elicited, it would be anti-self, and therefore undesirable. In order to avoid induction of autoimmunity and to induce a protective immune response, the capsular polysaccharide has, for instance, been chemically modified substituting the *N*-acetyl groups with *N*-propionyl groups, leaving the specific antigenicity unaltered (Romero & Outschoorn (1994) Current status of Meningococcal group B vaccine candidates: capsular or non-capsular? *Clin Microbiol Rev* 7(4):559-575).

Alternative approaches to MenB vaccines have used complex mixtures of outer membrane proteins (OMPs), containing either the OMPs alone, or OMPs enriched in porins, or deleted of the class 4 OMPs that are believed to induce antibodies that block bactericidal activity. This approach produces vaccines that are not well characterized. They are able to protect against the homologous strain, but are not effective at large where there are many antigenic variants of the outer membrane proteins. To overcome the antigenic variability, multivalent vaccines containing up to nine different porins have been constructed (e.g., Poolman JT (1992) Development of a meningococcal vaccine. *Infect. Agents Dis.* 4:13-28).

- 3 -

Additional proteins to be used in outer membrane vaccines have been the opa and opc proteins, but none of these approaches have been able to overcome the antigenic variability (e.g., Ala'Aldeen & Borriello (1996) The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. *Vaccine* 14(1):49-53).

A certain amount of sequence data is available for meningococcal and gonococcal genes and proteins (e.g., EP-A-0467714, WO96/29412), but this is by no means complete. The provision of further sequences could provide an opportunity to identify secreted or surface-exposed proteins that are presumed targets for the immune system and which are not antigenically variable or at least are more antigenically conserved than other and more variable regions. Thus, those antigenic sequences that are more highly conserved are preferred sequences. Those sequences specific to *Neisseria meningitidis* or *Neisseria gonorrhoeae* that are more highly conserved are further preferred sequences. For instance, some of the identified proteins could be components of efficacious vaccines against meningococcus B, some could be components of vaccines against all meningococcal serotypes, and others could be components of vaccines against all pathogenic *Neisseriae*. The identification of sequences from the bacterium will also facilitate the production of biological probes, particularly organism-specific probes.

It is thus an object of the invention is to provide Neisserial DNA sequences which (1) encode proteins predicted and/or shown to be antigenic or immunogenic, (2) can be used as probes or amplification primers, and (3) can be analyzed by bioinformatics.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the products of protein expression and purification of the predicted ORF 919 as cloned and expressed in *E. coli*.

Fig. 2 illustrates the products of protein expression and purification of the predicted ORF 279 as cloned and expressed in *E. coli*.

Fig. 3 illustrates the products of protein expression and purification of the predicted ORF 576-1 as cloned and expressed in *E. coli*.

Fig. 4 illustrates the products of protein expression and purification of the predicted ORF 519-1 as cloned and expressed in *E. coli*.

Fig. 5 illustrates the products of protein expression and purification of the predicted ORF 121-1 as cloned and expressed in *E. coli*.

Fig. 6 illustrates the products of protein expression and purification of the predicted ORF 128-1 as cloned and expressed in *E. coli*.

5 Fig. 7 illustrates the products of protein expression and purification of the predicted ORF 206 as cloned and expressed in *E. coli*.

Fig. 8 illustrates the products of protein expression and purification of the predicted ORF 287 as cloned and expressed in *E. coli*.

10 Fig. 9 illustrates the products of protein expression and purification of the predicted ORF 406 as cloned and expressed in *E. coli*.

Fig. 10 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 919 as cloned and expressed in *E. coli*.

Fig. 11 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 279 as cloned and expressed in *E. coli*.

15 Fig. 12 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 576-1 as cloned and expressed in *E. coli*.

Fig. 13 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 519-1 as cloned and expressed in *E. coli*.

20 Fig. 14 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 121-1 as cloned and expressed in *E. coli*.

Fig. 15 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 128-1 as cloned and expressed in *E. coli*.

Fig. 16 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 206 as cloned and expressed in *E. coli*.

25 Fig. 17 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 287 as cloned and expressed in *E. coli*.

Fig. 18 illustrates the hydrophilicity plot, antigenic index and AMPHI regions of the products of protein expression the predicted ORF 406 as cloned and expressed in *E. coli*.

- 5 -

THE INVENTION

The invention is based on the 961 nucleotide sequences from the genome of *N. meningitidis* shown as SEQ ID NOs:1-961 of Appendix C, and the full length genome of *N. meningitidis* shown as SEQ ID NO. 1068 in Appendix D. The 961 sequences in Appendix C represent substantially the whole genome of serotype B of *N. meningitidis* (>99.98%). There is partial overlap between some of the 961 contiguous sequences ("contigs") shown in the sequences in Appendix C, which overlap was used to construct the single full length sequence shown in SEQ ID NO. 1068 in Appendix D, using the TIGR Assembler [G.S. Sutton et al., *TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects*, Genome Science and Technology, 1:9-19 (1995)]. Some of the nucleotides in the contigs had been previously released. (See ftp://ftp.tigr.org/pub/data/n_meningitidis on the world-wide web or "WWW"). The coordinates of the 2508 released sequences in the present contigs are presented in Appendix A. These data include the contig number (or i.d.) as presented in the first column; the name of the sequence as found on WWW is in the second column; with the coordinates of the contigs in the third and fourth columns, respectively. The sequences of certain MenB ORFs presented in Appendix B feature in International Patent Application filed by Chiron SpA on October 9, 1998 (PCT/IB98/01665) and January 14, 1999 (PCT/IB99/00103) respectively.

In a first aspect, the invention provides nucleic acid including one or more of the *N. meningitidis* nucleotide sequences shown in SEQ ID NOs:1-961 and 1068 in Appendices C and E. It also provides nucleic acid comprising sequences having sequence identity to the nucleotide sequence disclosed herein. Depending on the particular sequence, the degree of sequence identity is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more). These sequences include, for instance, mutants and allelic variants. The degree of sequence identity cited herein is determined across the length of the sequence determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following parameters: gap open penalty 12, gap extension penalty 1.

The invention also provides nucleic acid including a fragment of one or more of the nucleotide sequences set out herein. The fragment should comprise at least n consecutive nucleotides from the sequences and, depending on the particular sequence, n is 10 or more

- 6 -

(e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 75, 100 or more). Preferably, the fragment is unique to the genome of *N. meningitidis*, that is to say it is not present in the genome of another organism. More preferably, the fragment is unique to the genome of strain B of *N. meningitidis*. The invention also provides nucleic acid that
5 hybridizes to those provided herein. Conditions for hybridizing are disclosed herein.

The invention also provides nucleic acid including sequences complementary to those described above (e.g., for antisense, for probes, or for amplification primers).

Nucleic acid according to the invention can, of course, be prepared in many ways (e.g., by chemical synthesis, from DNA libraries, from the organism itself, etc.) and can take
10 various forms (e.g., single-stranded, double-stranded, vectors, probes, primers, etc.). The term "nucleic acid" includes DNA and RNA, and also their analogs, such as those containing modified backbones, and also peptide nucleic acid (PNA) etc.

It will be appreciated that, as SEQ ID NOs:1-961 represent the substantially complete genome of the organism, with partial overlap, references to SEQ ID NOs:1-961 include
15 within their scope references to the complete genomic sequence, e.g., where two SEQ ID NOs overlap, the invention encompasses the single sequence which is formed by assembling the two overlapping sequences. Thus, for instance, a nucleotide sequence which bridges two SEQ ID NOs but is not present in its entirety in either SEQ ID NO is still within the scope of the invention. Additionally, such a sequence will be present in its entirety in the single full
20 length sequence of SEQ ID NO. 1068.

The invention also provides vectors including nucleotide sequences of the invention (e.g., expression vectors, sequencing vectors, cloning vectors, etc.) and host cells transformed with such vectors.

According to a further aspect, the invention provides a protein including an amino
25 acid sequence encoded within a *N. meningitidis* nucleotide sequence set out herein. It also provides proteins comprising sequences having sequence identity to those proteins. Depending on the particular sequence, the degree of sequence identity is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more). Sequence identity is determined as above disclosed. These homologous proteins include mutants and allelic variants, encoded
30 within the *N. meningitidis* nucleotide sequence set out herein.

The invention further provides proteins including fragments of an amino acid sequence encoded within a *N. meningitidis* nucleotide sequence set out in the sequence listing. The fragments should comprise at least n consecutive amino acids from the sequences and, depending on the particular sequence, n is 7 or more (e.g., 8, 10, 12, 14, 16,
5 18, 20 or more). Preferably the fragments comprise an epitope from the sequence.

The proteins of the invention can, of course, be prepared by various means (e.g., recombinant expression, purification from cell culture, chemical synthesis, *etc.*) and in various forms (e.g. native, fusions *etc.*). They are preferably prepared in substantially isolated form (*i.e.*, substantially free from other *N. meningitidis* host cell proteins).

10 Various tests can be used to assess the *in vivo* immunogenicity of the proteins of the invention. For example, the proteins can be expressed recombinantly or chemically synthesized and used to screen patient sera by immunoblot. A positive reaction between the protein and patient serum indicates that the patient has previously mounted an immune response to the protein in question; *i.e.*, the protein is an immunogen. This method can also
15 be used to identify immunodominant proteins.

The invention also provides nucleic acid encoding a protein of the invention.

In a further aspect, the invention provides a computer, a computer memory, a computer storage medium (e.g., floppy disk, fixed disk, CD-ROM, *etc.*), and/or a computer database containing the nucleotide sequence of nucleic acid according to the invention.
20 Preferably, it contains one or more of the *N. meningitidis* nucleotide sequences set out herein.

This may be used in the analysis of the *N. meningitidis* nucleotide sequences set out herein. For instance, it may be used in a search to identify open reading frames (ORFs) or coding sequences within the sequences.

In a further aspect, the invention provides a method for identifying an amino acid
25 sequence, comprising the step of searching for putative open reading frames or protein-coding sequences within a *N. meningitidis* nucleotide sequence set out herein. Similarly, the invention provides the use of a *N. meningitidis* nucleotide sequence set out herein in a search for putative open reading frames or protein-coding sequences.

Open-reading frame or protein-coding sequence analysis is generally performed on a
30 computer using standard bioinformatic techniques. Typical algorithms or program used in the analysis include ORFFINDER (NCBI), GENMARK [Borodovsky & McIninch (1993)]

Computers Chem 17:122-133], and GLIMMER [Salzberg et al. (1998) *Nucl Acids Res* 26:544-548].

A search for an open reading frame or protein-coding sequence may comprise the steps of searching a *N. meningitidis* nucleotide sequence set out herein for an initiation codon and searching the upstream sequence for an in-frame termination codon. The intervening
5 codons represent a putative protein-coding sequence. Typically, all six possible reading frames of a sequence will be searched.

An amino acid sequence identified in this way can be expressed using any suitable system to give a protein. This protein can be used to raise antibodies which recognize
10 epitopes within the identified amino acid sequence. These antibodies can be used to screen *N. meningitidis* to detect the presence of a protein comprising the identified amino acid sequence.

Furthermore, once an ORF or protein-coding sequence is identified, the sequence can be compared with sequence databases. Sequence analysis tools can be found at NCBI
15 (<http://www.ncbi.nlm.nih.gov>) e.g., the algorithms BLAST, BLAST2, BLASTn, BLASTp, tBLASTn, BLASTx, & tBLASTx [see also Altschul *et al.* (1997) Gapped BLAST and PSI-BLAST: new generation of protein database search programs. *Nucleic Acids Research* 25:2289-3402]. Suitable databases for comparison include the nonredundant GenBank, EMBL, DDBJ and PDB sequences, and the nonredundant GenBank CDS translations, PDB,
20 SwissProt, Spupdate and PIR sequences. This comparison may give an indication of the function of a protein.

Hydrophobic domains in an amino acid sequence can be predicted using algorithms such as those based on the statistical studies of Esposti *et al.* [Critical evaluation of the hydropathy of membrane proteins (1990) *Eur J Biochem* 190:207-219]. Hydrophobic
25 domains represent potential transmembrane regions or hydrophobic leader sequences, which suggest that the proteins may be secreted or be surface-located. These properties are typically representative of good immunogens.

Similarly, transmembrane domains or leader sequences can be predicted using the PSORT algorithm (<http://www.psort.nibb.ac.jp>), and functional domains can be predicted
30 using the MOTIFS program (GCG Wisconsin & PROSITE).

The invention also provides nucleic acid including an open reading frame or protein-coding sequence present in a *N. meningitidis* nucleotide sequence set out herein.

Furthermore, the invention provides a protein including the amino acid sequence encoded by this open reading frame or protein-coding sequence.

5 According to a further aspect, the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means known to those skilled in the art.

The antibodies of the invention can be used in a variety of ways, e.g., for confirmation that a protein is expressed, or to confirm where a protein is expressed. Labeled antibody
10 (e.g., fluorescent labeling for FACS) can be incubated with intact bacteria and the presence of label on the bacterial surface confirms the location of the protein, for instance.

According to a further aspect, the invention provides compositions including protein, antibody, and/or nucleic acid according to the invention. These compositions may be suitable as vaccines, as immunogenic compositions, or as diagnostic reagents.

15 The invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (e.g., as vaccines) or as diagnostic reagents. It also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of (i) a medicament for treating or preventing infection due to Neisserial bacteria (ii) a diagnostic reagent for detecting the presence of Neisserial bacteria or of
20 antibodies raised against Neisserial bacteria. Said Neisserial bacteria may be any species or strain (such as *N. gonorrhoeae*) but are preferably *N. meningitidis*, especially strain A, strain B or strain C.

In still yet another aspect, the present invention provides for compositions including proteins, nucleic acid molecules, or antibodies. More preferable aspects of the present
25 invention are drawn to immunogenic compositions of proteins. Further preferable aspects of the present invention contemplate pharmaceutical immunogenic compositions of proteins or vaccines and the use thereof in the manufacture of a medicament for the treatment or prevention of infection due to Neisserial bacteria, preferably infection of MenB.

The invention also provides a method of treating a patient, comprising administering
30 to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.

- 10 -

According to further aspects, the invention provides various processes.

A process for producing proteins of the invention is provided, comprising the step of culturing a host cell according to the invention under conditions which induce protein expression. A process which may further include chemical synthesis of proteins and/or
5 chemical synthesis (at least in part) of nucleotides.

A process for detecting polynucleotides of the invention is provided, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting said duplexes.

A process for detecting proteins of the invention is provided, comprising the steps of:
10 (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.

Another aspect of the present invention provides for a process for detecting antibodies that selectably bind to antigens or polypeptides or proteins specific to any species or strain of
15 *Neisseria* bacteria and preferably to strains of *N. gonorrhoeae* but more preferably to strains of *N. meningitidis*, especially strain A, strain B or strain C, more preferably MenB, where the process comprises the steps of: (a) contacting antigen or polypeptide or protein according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.

20 Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

Methodology - Summary of standard procedures and techniques.

25 General

This invention provides *Neisseria meningitidis* MenB nucleotide sequences, amino acid sequences encoded therein. With these disclosed sequences, nucleic acid probe assays and expression cassettes and vectors can be produced. The proteins can also be chemically synthesized. The expression vectors can be transformed into host cells to produce proteins.
30 The purified or isolated polypeptides can be used to produce antibodies to detect MenB proteins. Also, the host cells or extracts can be utilized for biological assays to isolate

- 11 -

agonists or antagonists. In addition, with these sequences one can search to identify open reading frames and identify amino acid sequences. The proteins may also be used in immunogenic compositions and as vaccine components.

The practice of the present invention will employ, unless otherwise indicated,
5 conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature e.g., Sambrook *Molecular Cloning: A Laboratory Manual, Second Edition* (1989); *DNA Cloning, Volumes I and ii* (D.N Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed, 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Transcription and Translation* (B.D. Hames & S.J. Higgins eds. 1984); *Animal Cell Culture* (R.I. Freshney ed. 1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide to Molecular Cloning* (1984); the *Methods in Enzymology* series (Academic Press, Inc.), especially volumes 154 & 155; *Gene Transfer Vectors for Mammalian Cells* (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987),
10 *Immunochemical Methods in Cell and Molecular Biology* (Academic Press, London); Scopes, (1987) *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.), and *Handbook of Experimental Immunology, Volumes I-IV* (D.M. Weir and C.C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are used in this specification.

20 All publications, patents, and patent applications cited herein are incorporated in full by reference.

Expression systems

The *Neisseria* MenB nucleotide sequences can be expressed in a variety of different
25 expression systems; for example those used with mammalian cells, plant cells, baculoviruses, bacteria, and yeast.

i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any
30 DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g., structural gene) into mRNA. A

- 12 -

promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an
5 upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation (Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In *Molecular Cloning: A Laboratory Manual*, 2nd ed.).

Mammalian viral genes are often highly expressed and have a broad host range;
10 therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated
15 (inducible). Depending on the promoter selected, many promoters may be inducible using known substrates, such as the use of the mouse mammary tumor virus (MMTV) promoter with the glucocorticoid responsive element (GRE) that is induced by glucocorticoid in hormone-responsive transformed cells (see for example, U.S. Patent 5,783,681).

The presence of an enhancer element (enhancer), combined with the promoter
20 elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more
25 than 1000 nucleotides from the promoter (Maniatis et al. (1987) *Science* 236:1237; Alberts et al. (1989) *Molecular Biology of the Cell*, 2nd ed.). Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer (Dijkema et al (1985) *EMBO J.* 4:761) and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus
30 (Gorman et al. (1982b) *Proc. Natl. Acad. Sci.* 79:6777) and from human cytomegalovirus (Boshart et al. (1985) *Cell* 41:521). Additionally, some enhancers are regulatable and

- 13 -

become active only in the presence of an inducer, such as a hormone or metal ion (Sassone-Corsi and Borelli (1986) *Trends Genet.* 2:215; Maniatis et al. (1987) *Science* 236:1237).

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid
5 at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a
10 leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a
15 leader sequence that provides for secretion of a foreign protein in mammalian cells.

Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation
20 (Birnstiel et al. (1985) *Cell* 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) *Trends Biochem. Sci.* 14:105). These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from
25 SV40 (Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*).

Usually, the above-described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may
30 also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of

- 14 -

stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 (Gluzman (1981) *Cell* 23:175) or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 (Kaufman et al. (1989) *Mol. Cell. Biol.* 9:946) and pHEBO (Shimizu et al. (1986) *Mol. Cell. Biol.* 6:1074).

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

ii. Plant Cellular Expression Systems

There are many plant cell culture and whole plant genetic expression systems known in the art. Exemplary plant cellular genetic expression systems include those described in patents, such as: U.S. 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30:3861-3863 (1991). Descriptions of plant protein signal peptides may be found in addition to the references described above in Vaulcombe et al., *Mol. Gen. Genet.* 209:33-40 (1987); Chandler et al., *Plant Molecular Biology* 3:407-418 (1984); Rogers, *J. Biol. Chem.* 260:3731-3738 (1985); Rothstein et al., *Gene* 55:353-356 (1987); Whittier et al., *Nucleic Acids*

- 15 -

Research 15:2515-2535 (1987); Wirsal et al., *Molecular Microbiology* 3:3-14 (1989); Yu et al., *Gene* 122:247-253 (1992). A description of the regulation of plant gene expression by the phytohormone, gibberellic acid and secreted enzymes induced by gibberellic acid can be found in R.L. Jones and J. MacMillin, Gibberellins: in: *Advanced Plant Physiology*,

- 5 Malcolm B. Wilkins, ed., 1984 Pitman Publishing Limited, London, pp. 21-52. References that describe other metabolically-regulated genes: Sheen, *Plant Cell*, 2:1027-1038(1990); Maas et al., *EMBO J.* 9:3447-3452 (1990); Benkel and Hickey, *Proc. Natl. Acad. Sci.* 84:1337-1339 (1987)

Typically, using techniques known in the art, a desired polynucleotide sequence is
10 inserted into an expression cassette comprising genetic regulatory elements designed for operation in plants. The expression cassette is inserted into a desired expression vector with companion sequences upstream and downstream from the expression cassette suitable for expression in a plant host. The companion sequences will be of plasmid or viral origin and provide necessary characteristics to the vector to permit the vectors to move DNA from an
15 original cloning host, such as bacteria, to the desired plant host. The basic bacterial/plant vector construct will preferably provide a broad host range prokaryote replication origin; a prokaryote selectable marker; and, for *Agrobacterium* transformations, T DNA sequences for *Agrobacterium*-mediated transfer to plant chromosomes. Where the heterologous gene is not readily amenable to detection, the construct will preferably also have a selectable marker
20 gene suitable for determining if a plant cell has been transformed. A general review of suitable markers, for example for the members of the grass family, is found in Wilmink and Dons, 1993, *Plant Mol. Biol. Repr.*, 11(2):165-185.

Sequences suitable for permitting integration of the heterologous sequence into the plant genome are also recommended. These might include transposon sequences and the like
25 for homologous recombination as well as Ti sequences which permit random insertion of a heterologous expression cassette into a plant genome. Suitable prokaryote selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions may also be present in the vector, as is known in the art.

30 The nucleic acid molecules of the subject invention may be included into an expression cassette for expression of the protein(s) of interest. Usually, there will be only

- 16 -

one expression cassette, although two or more are feasible. The recombinant expression cassette will contain in addition to the heterologous protein encoding sequence the following elements, a promoter region, plant 5' untranslated sequences, initiation codon depending upon whether or not the structural gene comes equipped with one, and a transcription and translation termination sequence. Unique restriction enzyme sites at the 5' and 3' ends of the cassette allow for easy insertion into a pre-existing vector.

A heterologous coding sequence may be for any protein relating to the present invention. The sequence encoding the protein of interest will encode a signal peptide which allows processing and translocation of the protein, as appropriate, and will usually lack any sequence which might result in the binding of the desired protein of the invention to a membrane. Since, for the most part, the transcriptional initiation region will be for a gene which is expressed and translocated during germination, by employing the signal peptide which provides for translocation, one may also provide for translocation of the protein of interest. In this way, the protein(s) of interest will be translocated from the cells in which they are expressed and may be efficiently harvested. Typically secretion in seeds are across the aleurone or scutellar epithelium layer into the endosperm of the seed. While it is not required that the protein be secreted from the cells in which the protein is produced, this facilitates the isolation and purification of the recombinant protein.

Since the ultimate expression of the desired gene product will be in a eucaryotic cell it is desirable to determine whether any portion of the cloned gene contains sequences which will be processed out as introns by the host's splicosome machinery. If so, site-directed mutagenesis of the "intron" region may be conducted to prevent losing a portion of the genetic message as a false intron code, Reed and Maniatis, *Cell* 41:95-105, 1985.

The vector can be microinjected directly into plant cells by use of micropipettes to mechanically transfer the recombinant DNA. Crossway, *Mol. Gen. Genet*, 202:179-185, 1985. The genetic material may also be transferred into the plant cell by using polyethylene glycol, Krens, et al., *Nature*, 296, 72-74, 1982. Another method of introduction of nucleic acid segments is high velocity ballistic penetration by small particles with the nucleic acid either within the matrix of small beads or particles, or on the surface, Klein, et al., *Nature*, 327, 70-73, 1987 and Knudsen and Muller, 1991, *Planta*, 185:330-336 teaching particle bombardment of barley endosperm to create transgenic barley. Yet another method of

- 17 -

introduction would be fusion of protoplasts with other entities, either minicells, cells, lysosomes or other fusible lipid-surfaced bodies, Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79, 1859-1863, 1982.

The vector may also be introduced into the plant cells by electroporation. (Fromm et al., *Proc. Natl. Acad. Sci. USA* 82:5824, 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and form plant callus.

All plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be transformed by the present invention so that whole plants are recovered which contain the transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugarcane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Some suitable plants include, for example, species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersion*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Hererocallis*, *Nemesia*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Lolium*, *Zea*, *Triticum*, *Sorghum*, and *Datura*.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts containing copies of the heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced from the protoplast suspension. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is fully reproducible and repeatable.

- 18 -

In some plant cell culture systems, the desired protein of the invention may be excreted or alternatively, the protein may be extracted from the whole plant. Where the desired protein of the invention is secreted into the medium, it may be collected.

Alternatively, the embryos and embryoless-half seeds or other plant tissue may be mechanically disrupted to release any secreted protein between cells and tissues. The mixture may be suspended in a buffer solution to retrieve soluble proteins. Conventional protein isolation and purification methods will be then used to purify the recombinant protein. Parameters of time, temperature pH, oxygen, and volumes will be adjusted through routine methods to optimize expression and recovery of heterologous protein.

iii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an

- 19 -

intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its own set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, *Virology* (1989) 17:31.

The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, 42:177) and a prokaryotic ampicillin-resistance (*amp*) gene and origin of replication for selection and propagation in *E. coli*.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g., structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlcek et al., (1988), *J. Gen. Virol.* 69:765.

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al.

- 20 -

(1988) *Gene*, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, 5 leaders of non-insect origin, such as those derived from genes encoding human (alpha) α -interferon, Maeda et al., (1985), *Nature* 315:592; human gastrin-releasing peptide, Lebacqz-Verheyden et al., (1988), *Molec. Cell. Biol.* 8:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA*, 82:8404; mouse IL-3, (Miyajima et al., (1987) *Gene* 58:273; and human glucocerebrosidase, Martin et al. (1988) *DNA*, 7:99, can also be used to provide for 10 secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG 15 start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign 20 protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of 25 the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.* (1983) 3:2156; and 30 Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a

- 21 -

restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays* 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

5 The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing
10 recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 μ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells
15 infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. *Current Protocols in Microbiology* Vol. 2 (Ausubel
20 et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, *supra*; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and *Trichoplusia ni* (PCT Pub. No. WO 89/046699; Carbonell et al.,
25 (1985) *J. Virol.* 56:153; Wright (1986) *Nature* 321:718; Smith et al., (1983) *Mol. Cell. Biol.* 3:2156; and see generally, Fraser, *et al.* (1989) *In Vitro Cell. Dev. Biol.* 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith
30 *supra*.

- 22 -

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product
5 will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be
10 further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant
15 protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

iv. Bacterial Systems

20 Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase
25 binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative
30 regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the

RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) (Raibaud *et al.* (1984) *Annu. Rev. Genet.* 18:173). Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

5 Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) (Chang *et al.* (1977) *Nature* 198:1056), and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) (Goeddel *et al.* (1980) *Nuc. Acids Res.* 8:4057; Yelverton *et al.* (1981) *Nucl.*
10 *Acids Res.* 9:731; U.S. Patent 4,738,921; EPO Publ. Nos. 036 776 and 121 775). The beta-lactamase (*bla*) promoter system (Weissmann (1981) "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I. Gresser)), bacteriophage lambda PL (Shimatake *et al.* (1981) *Nature* 292:128) and T5 (U.S. Patent 4,689,406) promoter systems also provide useful promoter sequences.

15 In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter (U.S. Patent 4,551,433). For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and
20 *lac* operon sequences that is regulated by the *lac* repressor (Amann *et al.* (1983) *Gene* 25:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci.* 80:21). Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high
25 levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system (Studier *et al.* (1986) *J. Mol. Biol.* 189:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci.* 82:1074). In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO Publ. No. 267 851).

30 In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome

binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine *et al.* (1975) *Nature* 254:34). The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of *E. coli* 16S rRNA (Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberger)). To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site, it is often necessary to optimize the distance between the SD sequence and the ATG of the eukaryotic gene (Sambrook *et al.* (1989) "Expression of cloned genes in *Escherichia coli*." In *Molecular Cloning: A Laboratory Manual*).

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* or *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene (Nagai *et al.* (1984) *Nature* 309:810). Fusion proteins can also be made with sequences from the *lacZ* (Jia *et al.* (1987) *Gene* 60:197), *trpE* (Allen *et al.* (1987) *J. Biotechnol.* 5:93; Makoff *et al.* (1989) *J. Gen. Microbiol.* 135:11), and *Chey* (EPO Publ. No. 324 647) genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated (Miller *et al.* (1989) *Bio/Technology* 7:698).

- 25 -

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria (U.S. Patent 4,336,336). The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) (Masui *et al.* (1983), in: *Experimental Manipulation of Gene Expression*; Ghayeb *et al.* (1984) *EMBO J.* 3:2437) and the *E. coli* alkaline phosphatase signal sequence (*phoA*) (Oka *et al.* (1985) *Proc. Natl. Acad. Sci.* 82:7212). As an additional example, the signal sequence of the alpha-amylase gene from various *Bacillus* strains can be used to secrete heterologous proteins from *B. subtilis* (Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. No. 244 042).

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will

- 26 -

generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline (Davies *et al.* (1978) *Annu. Rev. Microbiol.* 32:469). Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: *Bacillus subtilis* (Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541), *Escherichia coli* (Shimatake *et al.* (1981) *Nature* 292:128; Amann *et al.* (1985) *Gene* 40:183; Studier *et al.* (1986) *J. Mol. Biol.* 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907), *Streptococcus cremoris* (Powell *et al.* (1988)

- 27 -

Appl. Environ. Microbiol. 54:655); *Streptococcus lividans* (Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655), *Streptomyces lividans* (U.S. Patent 4,745,056).

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl₂ or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. (See e.g., use of *Bacillus*: Masson *et al.* (1989) *FEMS Microbiol. Lett.* 60:273; Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; use of *Campylobacter*: Miller *et al.* (1988) *Proc. Natl. Acad. Sci.* 85:856; and Wang *et al.* (1990) *J. Bacteriol.* 172:949; use of *Escherichia coli*: Cohen *et al.* (1973) *Proc. Natl. Acad. Sci.* 69:2110; Dower *et al.* (1988) *Nucleic Acids Res.* 16:6127; Kushner (1978) "An improved method for transformation of *Escherichia coli* with ColE1-derived plasmids. In *Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering* (eds. H.W. Boyer and S. Nicosia); Mandel *et al.* (1970) *J. Mol. Biol.* 53:159; Taketo (1988) *Biochim. Biophys. Acta* 949:318; use of *Lactobacillus*: Chassy *et al.* (1987) *FEMS Microbiol. Lett.* 44:173; use of *Pseudomonas*: Fiedler *et al.* (1988) *Anal. Biochem* 170:38; use of *Staphylococcus*: Augustin *et al.* (1990) *FEMS Microbiol. Lett.* 66:203; use of *Streptococcus*: Barany *et al.* (1980) *J. Bacteriol.* 144:698; Harlander (1987) "Transformation of *Streptococcus lactis* by electroporation, in: *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss III); Perry *et al.* (1981) *Infect. Immun.* 32:1295; Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655; Somkuti *et al.* (1987) *Proc. 4th Eur. Cong. Biotechnology* 1:412.

v. Yeast Expression

Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS),

which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

5 Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and
10 pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast *PHO5* gene, encoding acid phosphatase, also provides useful promoter sequences (Myanohara *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:1).

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the
15 transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the *ADH2*, *GAL4*, *GAL10*, OR *PHO5* genes, combined with the transcriptional
20 activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, *inter alia*, (Cohen *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:1078; Henikoff *et al.* (1981) *Nature* 283:835; Hollenberg *et al.* (1981) *Curr. Topics Microbiol. Immunol.* 96:119; Hollenberg *et al.* (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast *Saccharomyces cerevisiae*," in: *Plasmids of Medical, Environmental and Commercial Importance* (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon *et al.* (1980) *Gene* 11:163; Panthier *et al.* (1980) *Curr. Genet.* 2:109;).

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence
30 may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the

- 29 -

ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, plant, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (e.g., WO88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62:096,086) and the A-factor gene (U.S. Patent 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; EPO Publ.

- 30 -

No. 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alpha factor. (See e.g., PCT Publ. No. WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 (Botstein *et al.* (1979) *Gene* 8:17-24), pCI/1 (Brake *et al.* (1984) *Proc. Natl. Acad. Sci USA* 81:4642-4646), and YRp17 (Stinchcomb *et al.* (1982) *J. Mol. Biol.* 158:157). In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake *et al.*, *supra*.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome (Orr-Weaver *et al.* (1983) *Methods in Enzymol.* 101:228-245). An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for

- 31 -

inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced (Rine *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:6750). The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or
5 two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed.
10 Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as *ADE2*, *HIS4*, *LEU2*, *TRP1*, and *ALG7*, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of *CUP1* allows yeast to grow in the
15 presence of copper ions (Butt *et al.* (1987) *Microbiol. Rev.* 51:351).

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

20 Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors and methods of introducing exogenous DNA into yeast hosts have been developed for, *inter alia*, the following yeasts: *Candida albicans* (Kurtz, *et al.* (1986) *Mol. Cell. Biol.* 6:142); *Candida maltosa* (Kunze, *et al.* (1985) *J. Basic Microbiol.* 25:141);
25 *Hansenula polymorpha* (Gleeson, *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302); *Kluyveromyces fragilis* (Das, *et al.* (1984) *J. Bacteriol.* 158:1165); *Kluyveromyces lactis* (De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:737; Van den Berg *et al.* (1990) *Bio/Technology* 8:135); *Pichia guilliermondii* (Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141); *Pichia pastoris* (Cregg, *et al.* (1985) *Mol. Cell. Biol.* 5:3376; U.S.
30 Patent Nos. 4,837,148 and 4,929,555); *Saccharomyces cerevisiae* (Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163); *Schizosaccharomyces*

- 32 -

pombe (Beach and Nurse (1981) *Nature* 300:706); and *Yarrowia lipolytica* (Davidow, *et al.* (1985) *Curr. Genet.* 10:380471 Gaillardin, *et al.* (1985) *Curr. Genet.* 10:49).

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated
 5 with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz *et al.* (1986) *Mol. Cell. Biol.* 6:142; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; *Candida*]; [Gleeson *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302; *Hansenula*]; [Das *et al.* (1984) *J. Bacteriol.* 158:1165; De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:1165; Van den Berg *et al.* (1990) *Bio/Technology* 8:135; *Kluyveromyces*]; [Cregg *et al.* (1985) *Mol. Cell. Biol.*
 10 5:3376; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555; *Pichia*]; [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163 *Saccharomyces*]; [Beach and Nurse (1981) *Nature* 300:706; *Schizosaccharomyces*]; [Davidow *et al.* (1985) *Curr. Genet.* 10:39; Gaillardin *et al.* (1985)
 15 *Curr. Genet.* 10:49; *Yarrowia*].

Definitions

A composition containing X is "substantially free of" Y when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by
 20 weight of the total of X+Y in the composition, more preferably at least about 95% or even 99% by weight.

The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can
 25 function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a mouse host cell.

An "origin of replication" is a polynucleotide sequence that initiates and regulates replication of polynucleotides, such as an expression vector. The origin of replication behaves as an autonomous unit of polynucleotide replication within a cell, capable of replication
 30 under its own control. An origin of replication may be needed for a vector to replicate in a particular host cell. With certain origins of replication, an expression vector can be

- 33 -

reproduced at a high copy number in the presence of the appropriate proteins within the cell. Examples of origins are the autonomously replicating sequences, which are effective in yeast; and the viral T-antigen, effective in COS-7 cells.

A “mutant” sequence is defined as a DNA, RNA or amino acid sequence differing
5 from but having homology with the native or disclosed sequence. Depending on the particular sequence, the degree of homology between the native or disclosed sequence and the mutant sequence is preferably greater than 50% (e.g., 60%, 70%, 80%, 90%, 95%, 99% or more) which is calculated as described above. As used herein, an “allelic variant” of a nucleic acid molecule, or region, for which nucleic acid sequence is provided herein is a
10 nucleic acid molecule, or region, that occurs at essentially the same locus in the genome of another or second isolate, and that, due to natural variation caused by, for example, mutation or recombination, has a similar but not identical nucleic acid sequence. A coding region allelic variant typically encodes a protein having similar activity to that of the protein encoded by the gene to which it is being compared. An allelic variant can also comprise an
15 alteration in the 5' or 3' untranslated regions of the gene, such as in regulatory control regions. (see, for example, U.S. Patent 5,753,235).

Antibodies

As used herein, the term “antibody” refers to a polypeptide or group of polypeptides
20 composed of at least one antibody combining site. An “antibody combining site” is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows a binding of the antibody with the antigen. “Antibody” includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanized antibodies, altered antibodies, univalent
25 antibodies, Fab proteins, and single domain antibodies.

Antibodies against the proteins of the invention are useful for affinity chromatography, immunoassays, and distinguishing/identifying *Neisseria* MenB proteins. Antibodies elicited against the proteins of the present invention bind to antigenic polypeptides or proteins or protein fragments that are present and specifically associated with
30 strains of *Neisseria meningitidis* MenB. In some instances, these antigens may be associated with specific strains, such as those antigens specific for the MenB strains. The antibodies of

- 34 -

the invention may be immobilized to a matrix and utilized in an immunoassay or on an affinity chromatography column, to enable the detection and/or separation of polypeptides, proteins or protein fragments or cells comprising such polypeptides, proteins or protein fragments. Alternatively, such polypeptides, proteins or protein fragments may be
5 immobilized so as to detect antibodies bindably specific thereto.

Antibodies to the proteins of the invention, both polyclonal and monoclonal, may be prepared by conventional methods. In general, the protein is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of
10 labeled anti-rabbit and anti-goat antibodies. Immunization is generally performed by mixing or emulsifying the protein in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 µg/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline,
15 preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by *in vitro* immunization using methods known in the art, which for the purposes of this invention is considered equivalent to *in vivo* immunization. Polyclonal antisera is obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25°C for one hour, followed by incubating at 4°C for 2-18 hours. The serum is recovered by
20 centrifugation (e.g., 1,000g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.

Monoclonal antibodies are prepared using the standard method of Kohler & Milstein (*Nature* (1975) 256:495-96), or a modification thereof. Typically, a mouse or rat is immunized as described above. However, rather than bleeding the animal to extract serum,
25 the spleen (and optionally several large lymph nodes) is removed and dissociated into single cells. If desired, the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen. B-cells that express membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension. Resulting B-cells, or all dissociated
30 spleen cells, are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (e.g., hypoxanthine, aminopterin, thymidine medium,

- 35 -

“HAT”). The resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the immunizing antigen (and which do not bind to unrelated antigens). The selected MAb-secreting hybridomas are then cultured either *in vitro* (e.g., in tissue culture bottles or hollow fiber reactors), or *in vivo* (as ascites in mice).

If desired, the antibodies (whether polyclonal or monoclonal) may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly ^{32}P and ^{125}I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3',5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. “Specific binding partner” refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor. Other specific binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. It should be understood that the above description is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example, ^{125}I may serve as a radioactive label or as an electron-dense reagent. HRP may serve as enzyme or as antigen for a MAb. Further, one may combine various labels for desired effect. For example, MAbs and avidin also require labels in the practice of this invention: thus, one might label a MAb with biotin, and detect its presence with avidin labeled with ^{125}I , or with an anti-biotin MAb labeled with HRP. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

Antigens, immunogens, polypeptides, proteins or protein fragments of the present invention elicit formation of specific binding partner antibodies. These antigens, immunogens, polypeptides, proteins or protein fragments of the present invention comprise immunogenic compositions of the present invention. Such immunogenic compositions may further comprise or include adjuvants, carriers, or other compositions that promote or enhance or stabilize the antigens, polypeptides, proteins or protein fragments of the present

- 36 -

invention. Such adjuvants and carriers will be readily apparent to those of ordinary skill in the art.

Pharmaceutical Compositions

5 Pharmaceutical compositions can include either polypeptides, antibodies, or nucleic acid of the invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

10 The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature, when given to a patient that is febrile. The precise effective amount for a subject will depend upon the subject's size and health, the
15 nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgment of the clinician.

20 For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

25 A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents.
30 The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

- 37 -

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's

5 Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid
10 solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods

15 Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the
20 interstitial space of a tissue. The compositions can also be administered into a lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal and transcutaneous applications, needles, and gene guns or hypodermic sprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.

25 Vaccines

Vaccines according to the invention may either be prophylactic (i.e., to prevent infection) or therapeutic (i.e., to treat disease after infection).

Such vaccines comprise immunizing antigen(s) or immunogen(s), immunogenic polypeptide, protein(s) or protein fragments, or nucleic acids (e.g., ribonucleic acid or
30 deoxyribonucleic acid), usually in combination with "pharmaceutically acceptable carriers," which include any carrier that does not itself induce the production of antibodies harmful to

- 38 -

the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the immunogen or antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, etc. pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DetoxTM); (3) saponin adjuvants, such as StimulonTM (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; (6) detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., WO 93/13302 and WO 92/19265; and (7) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59 are preferred.

- 39 -

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), *etc.*

5 The vaccine compositions comprising immunogenic compositions (e.g., which may include the antigen, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Alternatively, vaccine compositions comprising immunogenic compositions
10 may comprise an antigen, polypeptide, protein, protein fragment or nucleic acid in a pharmaceutically acceptable carrier.

More specifically, vaccines comprising immunogenic compositions comprise an immunologically effective amount of the immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is
15 meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, primate, *etc.*), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the
20 formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

Typically, the vaccine compositions or immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or
25 suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

The immunogenic compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Additional formulations suitable for
30 other modes of administration include oral and pulmonary formulations, suppositories, and transdermal and transcutaneous applications. Dosage treatment may be a single dose schedule

- 40 -

or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

As an alternative to protein-based vaccines, DNA vaccination may be employed (e.g., Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648).

Gene Delivery Vehicles

Gene therapy vehicles for delivery of constructs, including a coding sequence of a therapeutic of the invention, to be delivered to the mammal for expression in the mammal, can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches in *in vivo* or *ex vivo* modality. Expression of such coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constitutive or regulated.

The invention includes gene delivery vehicles capable of expressing the contemplated nucleic acid sequences. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, or togavirus viral vector. See generally, Jolly (1994) *Cancer Gene Therapy* 1:51-64; Kimura (1994) *Human Gene Therapy* 5:845-852; Connelly (1995) *Human Gene Therapy* 6:185-193; and Kaplitt (1994) *Nature Genetics* 6:148-153.

Retroviral vectors are well known in the art, including B, C and D type retroviruses, xenotropic retroviruses (for example, NZB-X1, NZB-X2 and NZB9-1 (see O'Neill (1985) *J. Virol.* 53:160) polytropic retroviruses e.g., MCF and MCF-MLV (see Kelly (1983) *J. Virol.* 45:291), spumaviruses and lentiviruses. See RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985.

Portions of the retroviral gene therapy vector may be derived from different retroviruses. For example, retrovector LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

- 41 -

These recombinant retroviral vectors may be used to generate transduction competent retroviral vector particles by introducing them into appropriate packaging cell lines (see US patent 5,591,624). Retrovirus vectors can be constructed for site-specific integration into host cell DNA by incorporation of a chimeric integrase enzyme into the retroviral particle (see
5 WO96/37626). It is preferable that the recombinant viral vector is a replication defective recombinant virus.

Packaging cell lines suitable for use with the above-described retrovirus vectors are well known in the art, are readily prepared (see WO95/30763 and WO92/05266), and can be used to create producer cell lines (also termed vector cell lines or "VCLs") for the production
10 of recombinant vector particles. Preferably, the packaging cell lines are made from human parent cells (e.g., HT1080 cells) or mink parent cell lines, which eliminates inactivation in human serum.

Preferred retroviruses for the construction of retroviral gene therapy vectors include Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus, Mink-Cell
15 Focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis Virus and Rous Sarcoma Virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley and Rowe (1976) *J Virol* 19:19-25), Abelson (ATCC No. VR-999), Friend (ATCC No. VR-245), Graffi, Gross (ATCC No. VR-590), Kirsten, Harvey Sarcoma Virus and Rauscher (ATCC No. VR-998) and Moloney Murine Leukemia Virus (ATCC No. VR-190).
20 Such retroviruses may be obtained from depositories or collections such as the American Type Culture Collection ("ATCC") in Rockville, Maryland or isolated from known sources using commonly available techniques.

Exemplary known retroviral gene therapy vectors employable in this invention include those described in patent applications GB2200651, EP0415731, EP0345242,
25 EP0334301, WO89/02468; WO89/05349, WO89/09271, WO90/02806, WO90/07936, WO94/03622, WO93/25698, WO93/25234, WO93/11230, WO93/10218, WO91/02805, WO91/02825, WO95/07994, US 5,219,740, US 4,405,712, US 4,861,719, US 4,980,289, US 4,777,127, US 5,591,624. See also Vile (1993) *Cancer Res* 53:3860-3864; Vile (1993) *Cancer Res* 53:962-967; Ram (1993) *Cancer Res* 53 (1993) 83-88; Takamiya (1992) *J Neurosci Res* 33:493-503; Baba (1993) *J Neurosurg* 79:729-735; Mann (1983) *Cell* 33:153;
30 Cane (1984) *Proc Natl Acad Sci* 81:6349; and Miller (1990) *Human Gene Therapy* 1.

- 42 -

Human adenoviral gene therapy vectors are also known in the art and employable in this invention. See, for example, Berkner (1988) *Biotechniques* 6:616 and Rosenfeld (1991) *Science* 252:431, and WO93/07283, WO93/06223, and WO93/07282. Exemplary known adenoviral gene therapy vectors employable in this invention include those described in the

5 above referenced documents and in WO94/12649, WO93/03769, WO93/19191, WO94/28938, WO95/11984, WO95/00655, WO95/27071, WO95/29993, WO95/34671, WO96/05320, WO94/08026, WO94/11506, WO93/06223, WO94/24299, WO95/14102, WO95/24297, WO95/02697, WO94/28152, WO94/24299, WO95/09241, WO95/25807, WO95/05835, WO94/18922 and WO95/09654. Alternatively, administration of DNA linked

10 to killed adenovirus as described in Curiel (1992) *Hum. Gene Ther.* 3:147-154 may be employed. The gene delivery vehicles of the invention also include adenovirus associated virus (AAV) vectors. Leading and preferred examples of such vectors for use in this invention are the AAV-2 based vectors disclosed in Srivastava, WO93/09239. Most preferred AAV vectors comprise the two AAV inverted terminal repeats in which the native

15 D-sequences are modified by substitution of nucleotides, such that at least 5 native nucleotides and up to 18 native nucleotides, preferably at least 10 native nucleotides up to 18 native nucleotides, most preferably 10 native nucleotides are retained and the remaining nucleotides of the D-sequence are deleted or replaced with non-native nucleotides. The native D-sequences of the AAV inverted terminal repeats are sequences of 20 consecutive

20 nucleotides in each AAV inverted terminal repeat (i.e., there is one sequence at each end) which are not involved in HP formation. The non-native replacement nucleotide may be any nucleotide other than the nucleotide found in the native D-sequence in the same position. Other employable exemplary AAV vectors are pWP-19, pWN-1, both of which are disclosed in Nahreini (1993) *Gene* 124:257-262. Another example of such an AAV vector is psub201

25 (see Samulski (1987) *J. Virol.* 61:3096). Another exemplary AAV vector is the Double-D ITR vector. Construction of the Double-D ITR vector is disclosed in US Patent 5,478,745. Still other vectors are those disclosed in Carter US Patent 4,797,368 and Muzyczka US Patent 5,139,941, Chartejee US Patent 5,474,935, and Kotin WO94/288157. Yet a further example

30 of an AAV vector employable in this invention is SSV9AFABTKneo, which contains the AFP enhancer and albumin promoter and directs expression predominantly in the liver. Its structure and construction are disclosed in Su (1996) *Human Gene Therapy* 7:463-470.

- 43 -

Additional AAV gene therapy vectors are described in US 5,354,678, US 5,173,414, US 5,139,941, and US 5,252,479.

The gene therapy vectors comprising sequences of the invention also include herpes vectors. Leading and preferred examples are herpes simplex virus vectors containing a
5 sequence encoding a thymidine kinase polypeptide such as those disclosed in US 5,288,641 and EP0176170 (Roizman). Additional exemplary herpes simplex virus vectors include HFEM/ICP6-LacZ disclosed in WO95/04139 (Wistar Institute), pHSVlac described in Geller (1988) *Science* 241:1667-1669 and in WO90/09441 and WO92/07945, HSV Us3::pgC-lacZ described in Fink (1992) *Human Gene Therapy* 3:11-19 and HSV 7134, 2 RH 105 and GAL4
10 described in EP 0453242 (Breakefield), and those deposited with the ATCC as accession numbers ATCC VR-977 and ATCC VR-260.

Also contemplated are alpha virus gene therapy vectors that can be employed in this invention. Preferred alpha virus vectors are Sindbis viruses vectors. Togaviruses, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Middleberg virus (ATCC VR-370), Ross
15 River virus (ATCC VR-373; ATCC VR-1246), Venezuelan equine encephalitis virus (ATCC VR923; ATCC VR-1250; ATCC VR-1249; ATCC VR-532), and those described in US patents 5,091,309, 5,217,879, and WO92/10578. More particularly, those alpha virus vectors described in U.S. Serial No. 08/405,627, filed March 15, 1995, WO94/21792, WO92/10578, WO95/07994, US 5,091,309 and US 5,217,879 are employable. Such alpha viruses may be
20 obtained from depositories or collections such as the ATCC in Rockville, Maryland or isolated from known sources using commonly available techniques. Preferably, alphavirus vectors with reduced cytotoxicity are used (see USSN 08/679640).

DNA vector systems such as eukaryotic layered expression systems are also useful for expressing the nucleic acids of the invention. See WO95/07994 for a detailed description of
25 eukaryotic layered expression systems. Preferably, the eukaryotic layered expression systems of the invention are derived from alphavirus vectors and most preferably from Sindbis viral vectors.

Other viral vectors suitable for use in the present invention include those derived from poliovirus, for example ATCC VR-58 and those described in Evans, *Nature* 339 (1989) 385
30 and Sabin (1973) *J. Biol. Standardization* 1:115; rhinovirus, for example ATCC VR-1110 and those described in Arnold (1990) *J Cell Biochem* L401; pox viruses such as canary pox

- 44 -

virus or vaccinia virus, for example ATCC VR-111 and ATCC VR-2010 and those described in Fisher-Hoch (1989) *Proc Natl Acad Sci* 86:317; Flexner (1989) *Ann NY Acad Sci* 569:86, Flexner (1990) *Vaccine* 8:17; in US 4,603,112 and US 4,769,330 and WO89/01973; SV40 virus, for example ATCC VR-305 and those described in Mulligan (1979) *Nature* 277:108 and Madzak (1992) *J Gen Virol* 73:1533; influenza virus, for example ATCC VR-797 and recombinant influenza viruses made employing reverse genetics techniques as described in US 5,166,057 and in Enami (1990) *Proc Natl Acad Sci* 87:3802-3805; Enami & Palese (1991) *J Virol* 65:2711-2713 and Luytjes (1989) *Cell* 59:110, (see also McMichael (1983) *NEJ Med* 309:13, and Yap (1978) *Nature* 273:238 and Nature (1979) 277:108); human immunodeficiency virus as described in EP-0386882 and in Buchschacher (1992) *J. Virol.* 66:2731; measles virus, for example ATCC VR-67 and VR-1247 and those described in EP-0440219; Aura virus, for example ATCC VR-368; Bebaru virus, for example ATCC VR-600 and ATCC VR-1240; Cabassou virus, for example ATCC VR-922; Chikungunya virus, for example ATCC VR-64 and ATCC VR-1241; Fort Morgan Virus, for example ATCC VR-924; Getah virus, for example ATCC VR-369 and ATCC VR-1243; Kyzylogach virus, for example ATCC VR-927; Mayaro virus, for example ATCC VR-66; Mucambo virus, for example ATCC VR-580 and ATCC VR-1244; Ndumu virus, for example ATCC VR-371; Pixuna virus, for example ATCC VR-372 and ATCC VR-1245; Tonate virus, for example ATCC VR-925; Trinita virus, for example ATCC VR-469; Una virus, for example ATCC VR-374; Whataroa virus, for example ATCC VR-926; Y-62-33 virus, for example ATCC VR-375; O'Nyong virus, Eastern encephalitis virus, for example ATCC VR-65 and ATCC VR-1242; Western encephalitis virus, for example ATCC VR-70, ATCC VR-1251, ATCC VR-622 and ATCC VR-1252; and coronavirus, for example ATCC VR-740 and those described in Hamre (1966) *Proc Soc Exp Biol Med* 121:190.

Delivery of the compositions of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example see US Serial No. 08/366,787, filed December 30, 1994 and Curiel (1992) *Hum Gene Ther* 3:147-154 ligand linked DNA, for example see Wu (1989) *J Biol Chem* 264:16985-16987, eucaryotic cell delivery vehicles cells, for example see US Serial No.08/240,030, filed May 9, 1994, and US Serial No. 08/404,796, deposition of

photopolymerized hydrogel materials, hand-held gene transfer particle gun, as described in US Patent 5,149,655, ionizing radiation as described in US5,206,152 and in WO92/11033, nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip (1994) *Mol Cell Biol* 14:2411-2418 and in Woffendin (1994) *Proc Natl Acad Sci* 91:1581-1585.

Particle mediated gene transfer may be employed, for example see US Serial No. 60/023,867. Briefly, the sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, as described in Wu & Wu (1987) *J. Biol. Chem.* 262:4429-4432, insulin as described in Hucked (1990) *Biochem Pharmacol* 40:253-263, galactose as described in Plank (1992) *Bioconjugate Chem* 3:533-539, lactose or transferrin.

Naked DNA may also be employed to transform a host cell. Exemplary naked DNA introduction methods are described in WO 90/11092 and US 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Liposomes that can act as gene delivery vehicles are described in U.S. 5,422,120, WO95/13796, WO94/23697, WO91/14445 and EP-524,968. As described in USSN. 60/023,867, on non-viral delivery, the nucleic acid sequences encoding a polypeptide can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose, or transferrin. Other delivery systems include the use of liposomes to encapsulate DNA comprising the gene under the control of a variety of tissue-specific or ubiquitously-active promoters. Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al* (1994) *Proc. Natl. Acad. Sci. USA* 91(24):11581-11585. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of

- 46 -

photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. 5,206,152 and WO92/11033

5 Exemplary liposome and polycationic gene delivery vehicles are those described in US 5,422,120 and 4,762,915; in WO 95/13796; WO94/23697; and WO91/14445; in EP-0524968; and in Stryer, *Biochemistry*, pages 236-240 (1975) W.H. Freeman, San Francisco; Szoka (1980) *Biochem Biophys Acta* 600:1; Bayer (1979) *Biochem Biophys Acta* 550:464; Rivnay (1987) *Meth Enzymol* 149:119; Wang (1987) *Proc Natl Acad Sci* 84:7851; Plant
10 (1989) *Anal Biochem* 176:420.

A polynucleotide composition can comprise a therapeutically effective amount of a gene therapy vehicle, as the term is defined above. For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

15

Delivery Methods

Once formulated, the polynucleotide compositions of the invention can be administered (1) directly to the subject; (2) delivered *ex vivo*, to cells derived from the subject; or (3) *in vitro* for expression of recombinant proteins. The subjects to be treated can
20 be mammals or birds. Also, human subjects can be treated.

Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, transdermally or transcutaneously, intravenously or intramuscularly or delivered to the interstitial space of a tissue. The compositions can also be administered into a tumor or lesion. Other modes of administration include oral and
25 pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hypodermic sprays. Dosage treatment may be a single dose schedule or a multiple dose schedule. See WO98/20734.

Methods for the *ex vivo* delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., WO93/14778. Examples of cells useful in *ex vivo*
30 applications include, for example, stem cells, particularly hematopoietic, lymph cells, macrophages, dendritic cells, or tumor cells.

- 47 -

Generally, delivery of nucleic acids for both *ex vivo* and *in vitro* applications can be accomplished by the following procedures, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct
5 microinjection of the DNA into nuclei, all well known in the art.

Polynucleotide and Polypeptide pharmaceutical compositions

In addition to the pharmaceutically acceptable carriers and salts described above, the following additional agents can be used with polynucleotide and/or polypeptide
10 compositions.

A. Polypeptides

One example are polypeptides which include, without limitation: asialoorosomucoid (ASOR); transferrin; asialoglycoproteins; antibodies; antibody fragments; ferritin;
15 interleukins; interferons, granulocyte, macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor and erythropoietin. Viral antigens, such as envelope proteins, can also be used. Also, proteins from other invasive organisms, such as the 17 amino acid peptide from the circumsporozoite protein of plasmodium falciparum known as RII.

B. Hormones, Vitamins, Etc.

Other groups that can be included in a pharmaceutical composition include, for example: hormones, steroids, androgens, estrogens, thyroid hormone, or vitamins, folic acid.

25 C. Polyalkylenes, Polysaccharides, etc.

Also, polyalkylene glycol can be included in a pharmaceutical compositions with the desired polynucleotides and/or polypeptides. In a preferred embodiment, the polyalkylene glycol is polyethylene glycol. In addition, mono-, di-, or polysaccharides can be included. In a preferred embodiment of this aspect, the polysaccharide is dextran or DEAE-dextran. Also,
30 chitosan and poly(lactide-co-glycolide) may be included in a pharmaceutical composition.

D. Lipids, and Liposomes

The desired polynucleotide or polypeptide can also be encapsulated in lipids or packaged in liposomes prior to delivery to the subject or to cells derived therefrom.

Lipid encapsulation is generally accomplished using liposomes which are able to stably bind or entrap and retain nucleic acid or polypeptide. The ratio of condensed polynucleotide to lipid preparation can vary but will generally be around 1:1 (mg DNA:micromoles lipid), or more of lipid. For a review of the use of liposomes as carriers for delivery of nucleic acids, see, Hug and Sleight (1991) *Biochim. Biophys. Acta.* 1097:1-17; Straubinger (1983) *Meth. Enzymol.* 101:512-527.

Liposomal preparations for use in the present invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner (1987) *Proc. Natl. Acad. Sci. USA* 84:7413-7416); mRNA (Malone (1989) *Proc. Natl. Acad. Sci. USA* 86:6077-6081); and purified transcription factors (Debs (1990) *J. Biol. Chem.* 265:10189-10192), in functional form.

Cationic liposomes are readily available. For example, N(1-2,3-dioleoyloxy)propyl)-N,N,N-triethylammonium (DOTMA) liposomes are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, NY. (See, also, Felgner *supra*). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer). Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g., Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198; WO90/11092 for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

The liposomes can comprise multilammellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs). The various liposome-nucleic acid complexes are prepared using methods known in the art. See e.g., Straubinger (1983) *Meth. Immunol.* 101:512-527; Szoka (1978) *Proc. Natl. Acad. Sci. USA* 75:4194-4198;

5 Papahadjopoulos (1975) *Biochim. Biophys. Acta* 394:483; Wilson (1979) *Cell* 17:77; Deamer & Bangham (1976) *Biochim. Biophys. Acta* 443:629; Ostro (1977) *Biochem. Biophys. Res. Commun.* 76:836; Fraley (1979) *Proc. Natl. Acad. Sci. USA* 76:3348; Enoch & Strittmatter (1979) *Proc. Natl. Acad. Sci. USA* 76:145; Fraley (1980) *J. Biol. Chem.* (1980) 255:10431; Szoka & Papahadjopoulos (1978) *Proc. Natl. Acad. Sci. USA* 75:145; and

10 Schaefer-Ridder (1982) *Science* 215:166.

E. Lipoproteins

In addition, lipoproteins can be included with the polynucleotide or polypeptide to be delivered. Examples of lipoproteins to be utilized include: chylomicrons, HDL, IDL, LDL,

15 and VLDL. Mutants, fragments, or fusions of these proteins can also be used. Also, modifications of naturally occurring lipoproteins can be used, such as acetylated LDL. These lipoproteins can target the delivery of polynucleotides to cells expressing lipoprotein receptors. Preferably, if lipoproteins are including with the polynucleotide to be delivered, no other targeting ligand is included in the composition.

20 Naturally occurring lipoproteins comprise a lipid and a protein portion. The protein portion are known as apoproteins. At the present, apoproteins A, B, C, D, and E have been isolated and identified. At least two of these contain several proteins, designated by Roman numerals, AI, AII, AIV; CI, CII, CIII.

A lipoprotein can comprise more than one apoprotein. For example, naturally

25 occurring chylomicrons comprises of A, B, C, and E, over time these lipoproteins lose A and acquire C and E apoproteins. VLDL comprises A, B, C, and E apoproteins, LDL comprises apoprotein B; and HDL comprises apoproteins A, C, and E.

The amino acid sequences of these apoproteins are known and are described in, for example, Breslow (1985) *Annu Rev. Biochem* 54:699; Law (1986) *Adv. Exp Med. Biol.*

30 151:162; Chen (1986) *J Biol Chem* 261:12918; Kane (1980) *Proc Natl Acad Sci USA* 77:2465; and Utermann (1984) *Hum Genet* 65:232.

- 50 -

Lipoproteins contain a variety of lipids including, triglycerides, cholesterol (free and esters), and phospholipids. The composition of the lipids varies in naturally occurring lipoproteins. For example, chylomicrons comprise mainly triglycerides. A more detailed description of the lipid content of naturally occurring lipoproteins can be found, for example, in *Meth. Enzymol.* 128 (1986). The composition of the lipids are chosen to aid in conformation of the apoprotein for receptor binding activity. The composition of lipids can also be chosen to facilitate hydrophobic interaction and association with the polynucleotide binding molecule.

Naturally occurring lipoproteins can be isolated from serum by ultracentrifugation, for instance. Such methods are described in *Meth. Enzymol. (supra)*; Pitas (1980) *J. Biochem.* 255:5454-5460 and Mahey (1979) *J Clin. Invest* 64:743-750.

Lipoproteins can also be produced by *in vitro* or recombinant methods by expression of the apoprotein genes in a desired host cell. See, for example, Atkinson (1986) *Annu Rev Biophys Chem* 15:403 and Radding (1958) *Biochim Biophys Acta* 30: 443.

Lipoproteins can also be purchased from commercial suppliers, such as Biomedical Technologies, Inc., Stoughton, Massachusetts, USA.

Further description of lipoproteins can be found in Zuckermann et al., PCT. Appln. No. US97/14465.

F. Polycationic Agents

Polycationic agents can be included, with or without lipoprotein, in a composition with the desired polynucleotide and/or polypeptide to be delivered.

Polycationic agents, typically, exhibit a net positive charge at physiological relevant pH and are capable of neutralizing the electrical charge of nucleic acids to facilitate delivery to a desired location. These agents have both *in vitro*, *ex vivo*, and *in vivo* applications. Polycationic agents can be used to deliver nucleic acids to a living subject either intramuscularly, subcutaneously, etc.

The following are examples of useful polypeptides as polycationic agents: polylysine, polyarginine, polyornithine, and protamine. Other examples of useful polypeptides include histones, protamines, human serum albumin, DNA binding proteins, non-histone chromosomal proteins, coat proteins from DNA viruses, such as Φ X174, transcriptional

- 51 -

factors also contain domains that bind DNA and therefore may be useful as nucleic acid condensing agents. Briefly, transcriptional factors such as C/CEBP, c-jun, c-fos, AP-1, AP-2, AP-3, CPF, Prot-1, Sp-1, Oct-1, Oct-2, CREP, and TFIID contain basic domains that bind DNA sequences.

5 Organic polycationic agents include: spermine, spermidine, and putrescine.

The dimensions and of the physical properties of a polycationic agent can be extrapolated from the list above, to construct other polypeptide polycationic agents or to produce synthetic polycationic agents.

10 G. Synthetic Polycationic Agents

Synthetic polycationic agents which are useful in pharmaceutical compositions include, for example, DEAE-dextran, polybrene. Lipofectin™, and lipofectAMINE™ are monomers that form polycationic complexes when combined with polynucleotides or polypeptides.

15

Immunodiagnostic Assays

Neisseria MenB antigens, or antigenic fragments thereof, of the invention can be used in immunoassays to detect antibody levels (or, conversely, anti-*Neisseria* MenB antibodies can be used to detect antigen levels). Immunoassays based on well defined, recombinant
20 antigens can be developed to replace invasive diagnostics methods. Antibodies to *Neisseria* MenB proteins or fragments thereof within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols
25 may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

30 Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the

invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, *etc.*) required for the conduct of the assay, as well as suitable set of assay instructions.

5 Nucleic Acid Hybridization

“Hybridization” refers to the association of two nucleic acid sequences to one another by hydrogen bonding. Typically, one sequence will be fixed to a solid support and the other will be free in solution. Then, the two sequences will be placed in contact with one another under conditions that favor hydrogen bonding. Factors that affect this bonding include: the
10 type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase sequence to the solid support (Denhardt's reagent or BLOTTO); concentration of the sequences; use of compounds to increase the rate of association of sequences (dextran sulfate or polyethylene glycol); and the stringency of the washing conditions following hybridization. See Sambrook *et al.* (*supra*)
15 Volume 2, chapter 9, pages 9.47 to 9.57.

“Stringency” refers to conditions in a hybridization reaction that favor association of very similar sequences over sequences that differ. For example, the combination of temperature and salt concentration should be chosen that is approximately 120 to 200°C below the calculated T_m of the hybrid under study. The temperature and salt conditions can
20 often be determined empirically in preliminary experiments in which samples of genomic DNA immobilized on filters are hybridized to the sequence of interest and then washed under conditions of different stringencies. See Sambrook *et al.* at page 9.50.

Variables to consider when performing, for example, a Southern blot are (1) the complexity of the DNA being blotted and (2) the homology between the probe and the
25 sequences being detected. The total amount of the fragment(s) to be studied can vary a magnitude of 10, from 0.1 to 1 µg for a plasmid or phage digest to 10^{-9} to 10^{-8} g for a single copy gene in a highly complex eukaryotic genome. For lower complexity polynucleotides, substantially shorter blotting, hybridization, and exposure times, a smaller amount of starting polynucleotides, and lower specific activity of probes can be used. For example, a
30 single-copy yeast gene can be detected with an exposure time of only 1 hour starting with 1 µg of yeast DNA, blotting for two hours, and hybridizing for 4-8 hours with a probe of 10^8

- 53 -

cpm/ μ g. For a single-copy mammalian gene a conservative approach would start with 10 μ g of DNA, blot overnight, and hybridize overnight in the presence of 10% dextran sulfate using a probe of greater than 10^8 cpm/ μ g, resulting in an exposure time of ~24 hours.

Several factors can affect the melting temperature (T_m) of a DNA-DNA hybrid
5 between the probe and the fragment of interest, and consequently, the appropriate conditions for hybridization and washing. In many cases the probe is not 100% homologous to the fragment. Other commonly encountered variables include the length and total G+C content of the hybridizing sequences and the ionic strength and formamide content of the hybridization buffer. The effects of all of these factors can be approximated by a single equation:
10 $T_m = 81 + 16.6(\log_{10} C_i) + 0.4\%(G + C) - 0.6\%(\text{formamide}) - 600/n - 1.5\%(\text{mismatch})$
where C_i is the salt concentration (monovalent ions) and n is the length of the hybrid in base pairs (slightly modified from Meinkoth & Wahl (1984) *Anal. Biochem.* 138:267-284).

In designing a hybridization experiment, some factors affecting nucleic acid hybridization can be conveniently altered. The temperature of the hybridization and washes
15 and the salt concentration during the washes are the simplest to adjust. As the temperature of the hybridization increases (i.e., stringency), it becomes less likely for hybridization to occur between strands that are nonhomologous, and as a result, background decreases. If the radiolabeled probe is not completely homologous with the immobilized fragment (as is frequently the case in gene family and interspecies hybridization experiments), the
20 hybridization temperature must be reduced, and background will increase. The temperature of the washes affects the intensity of the hybridizing band and the degree of background in a similar manner. The stringency of the washes is also increased with decreasing salt concentrations.

In general, convenient hybridization temperatures in the presence of 50% formamide
25 are 42°C for a probe with is 95% to 100% homologous to the target fragment, 37°C for 90% to 95% homology, and 32°C for 85% to 90% homology. For lower homologies, formamide content should be lowered and temperature adjusted accordingly, using the equation above. If the homology between the probe and the target fragment are not known, the simplest approach is to start with both hybridization and wash conditions which are nonstringent. If
30 non-specific bands or high background are observed after autoradiography, the filter can be washed at high stringency and reexposed. If the time required for exposure makes this

- 54 -

approach impractical, several hybridization and/or washing stringencies should be tested in parallel.

Nucleic Acid Probe Assays

5 Methods such as PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes according to the invention can determine the presence of cDNA or mRNA. A probe is said to "hybridize" with a sequence of the invention if it can form a duplex or double stranded complex, which is stable enough to be detected.

10 The nucleic acid probes will hybridize to the Neisserial nucleotide sequences of the invention (including both sense and antisense strands). Though many different nucleotide sequences will encode the amino acid sequence, the native Neisserial sequence is preferred because it is the actual sequence present in cells. mRNA represents a coding sequence and so a probe should be complementary to the coding sequence; single-stranded cDNA is complementary to mRNA, and so a cDNA probe should be complementary to the non-coding
15 sequence.

 The probe sequence need not be identical to the Neisserial sequence (or its complement) -- some variation in the sequence and length can lead to increased assay sensitivity if the nucleic acid probe can form a duplex with target nucleotides, which can be detected. Also, the nucleic acid probe can include additional nucleotides to stabilize the
20 formed duplex. Additional Neisserial sequence may also be helpful as a label to detect the formed duplex. For example, a non-complementary nucleotide sequence may be attached to the 5' end of the probe, with the remainder of the probe sequence being complementary to a Neisserial sequence. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity
25 with the a Neisserial sequence in order to hybridize therewith and thereby form a duplex which can be detected.

 The exact length and sequence of the probe will depend on the hybridization conditions, such as temperature, salt condition and the like. For example, for diagnostic applications, depending on the complexity of the analyte sequence, the nucleic acid probe
30 typically contains at least 10-20 nucleotides, preferably 15-25, and more preferably at least

- 55 -

30 nucleotides, although it may be shorter than this. Short primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.

Probes may be produced by synthetic procedures, such as the triester method of Matteucci *et al.* (*J. Am. Chem. Soc.* (1981) 103:3185), or according to Urdea *et al.* (*Proc. Natl. Acad. Sci. USA* (1983) 80: 7461), or using commercially available automated oligonucleotide synthesizers.

The chemical nature of the probe can be selected according to preference. For certain applications, DNA or RNA are appropriate. For other applications, modifications may be incorporated e.g., backbone modifications, such as phosphorothioates or methylphosphonates, can be used to increase *in vivo* half-life, alter RNA affinity, increase nuclease resistance *etc.* (e.g., see Agrawal & Iyer (1995) *Curr Opin Biotechnol* 6:12-19; Agrawal (1996) *TIBTECH* 14:376-387); analogues such as peptide nucleic acids may also be used (e.g., see Corey (1997) *TIBTECH* 15:224-229; Buchardt *et al.* (1993) *TIBTECH* 11:384-386).

One example of a nucleotide hybridization assay is described by Urdea *et al.* in international patent application WO92/02526 (see also U.S. Patent 5,124,246).

Alternatively, the polymerase chain reaction (PCR) is another well-known means for detecting small amounts of target nucleic acids. The assay is described in: Mullis *et al.* (*Meth. Enzymol.* (1987) 155: 335-350); US patent 4,683,195; and US patent 4,683,202. Two "primer" nucleotides hybridize with the target nucleic acids and are used to prime the reaction. The primers can comprise sequence that does not hybridize to the sequence of the amplification target (or its complement) to aid with duplex stability or, for example, to incorporate a convenient restriction site. Typically, such sequence will flank the desired Neisserial sequence.

A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a threshold amount of target nucleic acids are generated by the polymerase, they can be detected by more traditional methods, such as Southern blots. When using the Southern blot method, the labeled probe will hybridize to the Neisserial sequence (or its complement).

Also, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook *et al* (*supra*). mRNA, or cDNA generated from mRNA using a polymerase

- 56 -

enzyme, can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labeled with a radioactive moiety.

EXAMPLES

The invention is based on the 961 nucleotide sequences from the genome of *N. meningitidis* set out in Appendix C, SEQ ID NOs:1-961, which together represent substantially the complete genome of serotype B of *N. meningitidis*, as well as the full length genome sequence shown in Appendix D, SEQ ID NO 1068.

It will be self-evident to the skilled person how this sequence information can be utilized according to the invention, as above described.

The standard techniques and procedures which may be employed in order to perform the invention (*e.g.* to utilize the disclosed sequences to predict polypeptides useful for vaccination or diagnostic purposes) were summarized above. This summary is not a limitation on the invention but, rather, gives examples that may be used, but are not required.

These sequences are derived from contigs shown in Appendix C (SEQ ID NOs 1-961) and from the full length genome sequence shown in Appendix D (SEQ ID NO 1068), which were prepared during the sequencing of the genome of *N. meningitidis* (strain B). The full length sequence was assembled using the TIGR Assembler as described by G.S. Sutton et al., *TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects*, Genome Science and Technology, 1:9-19 (1995) [see also R. D. Fleischmann, et al., Science 269, 496-512 (1995); C. M. Fraser, et al., Science 270, 397-403 (1995); C. J. Bult, et al., Science 273, 1058-73 (1996); C. M. Fraser, et. al, Nature 390, 580-586 (1997); J.-F. Tomb, et. al., Nature 388, 539-547 (1997); H. P. Klenk, et al., Nature 390, 364-70 (1997); C. M. Fraser, et al., Science 281, 375-88 (1998); M. J. Gardner, et al., Science 282, 1126-1132 (1998); K. E. Nelson, et al., Nature 399, 323-9 (1999)]. Then, using the above-described methods, putative translation products of the sequences were determined. Computer analysis of the translation products were determined based on database comparisons. Corresponding gene and protein sequences, if any, were identified in *Neisseria meningitidis* (Strain A) and *Neisseria*

- 57 -

gonorrhoeae. Then the proteins were expressed, purified, and characterized to assess their antigenicity and immunogenicity.

In particular, the following methods were used to express, purify, and biochemically characterize the proteins of the invention.

5

Chromosomal DNA Preparation

N. meningitidis strain 2996 was grown to exponential phase in 100 ml of GC medium, harvested by centrifugation, and resuspended in 5 ml buffer (20% Sucrose, 50 mM Tris-HCl, 50 mM EDTA, adjusted to pH 8.0). After 10 minutes incubation on ice, the bacteria were
 10 lysed by adding 10 ml lysis solution (50 mM NaCl, 1% Na-Sarkosyl, 50 µg/ml Proteinase K), and the suspension was incubated at 37°C for 2 hours. Two phenol extractions (equilibrated to pH 8) and one ChCl_3 /isoamylalcohol (24:1) extraction were performed. DNA was precipitated by addition of 0.3M sodium acetate and 2 volumes ethanol, and was collected by centrifugation. The pellet was washed once with 70% ethanol and redissolved in 4 ml buffer
 15 (10 mM Tris-HCl, 1mM EDTA, pH 8). The DNA concentration was measured by reading the OD at 260 nm.

Oligonucleotide design

Synthetic oligonucleotide primers were designed on the basis of the coding sequence of each ORF, using (a) the meningococcus B sequence when available, or (b) the
 20 gonococcus/meningococcus A sequence, adapted to the codon preference usage of meningococcus. Any predicted signal peptides were omitted, by deducing the 5'-end amplification primer sequence immediately downstream from the predicted leader sequence.

For most ORFs, the 5' primers included two restriction enzyme recognition sites (*Bam*HI-*Nde*I, *Bam*HI-*Nhe*I, or *Eco*RI-*Nhe*I, depending on the gene's restriction pattern); the
 25 3' primers included a *Xho*I restriction site. This procedure was established in order to direct the cloning of each amplification product (corresponding to each ORF) into two different expression systems: pGEX-KG (using either *Bam*HI-*Xho*I or *Eco*RI-*Xho*I), and pET21b+ (using either *Nde*I-*Xho*I or *Nhe*I-*Xho*I).

5'-end primer tail: CGCGGATCCCATATG (*Bam*HI-*Nde*I)
 30 CGCGGATCCGCTAGC (*Bam*HI-*Nhe*I)

- 58 -

CCGGAATTCTAGCTAGC (EcoRI-NheI)
 3'-end primer tail: CCCGCTCGAG (XhoI)

For some ORFs, two different amplifications were performed to clone each ORF in the two expression systems. Two different 5' primers were used for each ORF; the same 3' XhoI primer was used as before:

5'-end primer tail: GGAATTCCATATGGCCATGG (NdeI)
 5'-end primer tail: CGGGATCC (BamHI)

Other ORFs were cloned in the pTRC expression vector and expressed as an amino-terminus His-tag fusion. The predicted signal peptide may be included in the final product. NheI-BamHI restriction sites were incorporated using primers:

5'-end primer tail: GATCAGCTAGCCATATG (NheI)
 3'-end primer tail: CGGGATCC (BamHI)

As well as containing the restriction enzyme recognition sequences, the primers included nucleotides which hybridized to the sequence to be amplified. The number of hybridizing nucleotides depended on the melting temperature of the whole primer, and was determined for each primer using the formulae:

$$T_m = 4 (G+C) + 2 (A+T) \quad (\text{tail excluded})$$

$$T_m = 64.9 + 0.41 (\% \text{ GC}) - 600/N \quad (\text{whole primer})$$

The average melting temperature of the selected oligos were 65-70°C for the whole oligo and 50-55°C for the hybridising region alone.

Oligos were synthesized by a Perkin Elmer 394 DNA/RNA Synthesizer, eluted from the columns in 2 ml NH₄-OH, and deprotected by 5 hours incubation at 56 °C. The oligos were precipitated by addition of 0.3M Na-Acetate and 2 volumes ethanol. The samples were then centrifuged and the pellets resuspended in either 100µl or 1ml of water. OD₂₆₀ was determined using a Perkin Elmer Lambda Bio spectrophotometer and the concentration was determined and adjusted to 2-10 pmol/µl.

Table 1 shows the forward and reverse primers used for each amplification. In certain cases, it might be noted that the sequence of the primer does not exactly match the sequence in the ORF. When initial amplifications are performed, the complete 5' and/or 3' sequence

- 59 -

may not be known for some meningococcal ORFs, although the corresponding sequences may have been identified in gonococcus. For amplification, the gonococcal sequences could thus be used as the basis for primer design, altered to take account of codon preference. In particular, the following codons may be changed: ATA→ATT; TCG→TCT; CAG→CAA;
 5 AAG→AAA; GAG→GAA; CGA and CGG→CGC; GGG→GGC.

Amplification

The standard PCR protocol was as follows: 50-200 ng of genomic DNA were used as a template in the presence of 20-40 µM of each oligo, 400-800 µM dNTPs solution, 1x PCR buffer (including 1.5 mM MgCl₂), 2.5 units *TaqI* DNA polymerase (using Perkin-Elmer
 10 AmpliTaq, GIBCO Platinum, Pwo DNA polymerase, or Tahara Shuzo Taq polymerase).

In some cases, PCR was optimised by the addition of 10µl DMSO or 50 µl 2M betaine.

After a hot start (adding the polymerase during a preliminary 3 minute incubation of the whole mix at 95°C), each sample underwent a double-step amplification: the first 5 cycles
 15 were performed using as the hybridization temperature the one of the oligos excluding the restriction enzymes tail, followed by 30 cycles performed according to the hybridization temperature of the whole length oligos. The cycles were followed by a final 10 minute extension step at 72°C.

The standard cycles were as follows:

	Denaturation	Hybridisation	Elongation
First 5 cycles	30 seconds 95°C	30 seconds 50-55°C	30-60 seconds 72°C
Last 30 cycles	30 seconds 95°C	30 seconds 65-70°C	30-60 seconds 72°C

20

The elongation time varied according to the length of the ORF to be amplified.

The amplifications were performed using either a 9600 or a 2400 Perkin Elmer GeneAmp PCR System. To check the results, 1/10 of the amplification volume was loaded onto a 1-1.5% agarose gel and the size of each amplified fragment compared with a DNA
 25 molecular weight marker.

The amplified DNA was either loaded directly on a 1% agarose gel or first precipitated with ethanol and resuspended in a suitable volume to be loaded on a 1% agarose

- 60 -

gel. The DNA fragment corresponding to the right size band was then eluted and purified from gel, using the Qiagen Gel Extraction Kit, following the instructions of the manufacturer. The final volume of the DNA fragment was 30µl or 50µl of either water or 10mM Tris, pH 8.5.

5 Digestion of PCR fragments

The purified DNA corresponding to the amplified fragment was split into 2 aliquots and double-digested with:

NdeI/XhoI or *NheI/XhoI* for cloning into pET-21b+ and further expression of the protein as a C-terminus His-tag fusion

10 BamHI/XhoI or *EcoRI/XhoI* for cloning into pGEX-KG and further expression of the protein as a GST N-terminus fusion.

For ORF 76, *NheI/BamHI* for cloning into pTRC-HisA vector and further expression of the protein as N-terminus His-tag fusion.

Each purified DNA fragment was incubated (37°C for 3 hours to overnight) with 20
15 units of each restriction enzyme (New England Biolabs) in a either 30 or 40 µl final volume in the presence of the appropriate buffer. The digestion product was then purified using the QIAquick PCR purification kit, following the manufacturer's instructions, and eluted in a final volume of 30 (or 50) µl of either water or 10mM Tris-HCl, pH 8.5. The final DNA concentration was determined by 1% agarose gel electrophoresis in the presence of titrated
20 molecular weight marker.

Digestion of the cloning vectors (pET22B, pGEX-KG and pTRC-His A)

10 µg plasmid was double-digested with 50 units of each restriction enzyme in 200 µl reaction volume in the presence of appropriate buffer by overnight incubation at 37°C. After loading the whole digestion on a 1% agarose gel, the band corresponding to the digested
25 vector was purified from the gel using the Qiagen QIAquick Gel Extraction Kit and the DNA was eluted in 50 µl of 10 mM Tris-HCl, pH 8.5. The DNA concentration was evaluated by measuring OD₂₆₀ of the sample, and adjusted to 50 µg/µl. 1 µl of plasmid was used for each cloning procedure.

- 61 -

Cloning

The fragments corresponding to each ORF, previously digested and purified, were ligated in both pET22b and pGEX-KG. In a final volume of 20 µl, a molar ratio of 3:1 fragment/vector was ligated using 0.5 µl of NEB T4 DNA ligase (400 units/µl), in the presence of the buffer supplied by the manufacturer. The reaction was incubated at room temperature for 3 hours. In some experiments, ligation was performed using the Boehringer “Rapid Ligation Kit”, following the manufacturer’s instructions.

In order to introduce the recombinant plasmid in a suitable strain, 100 µl *E. coli* DH5 competent cells were incubated with the ligase reaction solution for 40 minutes on ice, then at 37°C for 3 minutes, then, after adding 800 µl LB broth, again at 37°C for 20 minutes. The cells were then centrifuged at maximum speed in an Eppendorf microfuge and resuspended in approximately 200 µl of the supernatant. The suspension was then plated on LB ampicillin (100 mg/ml).

The screening of the recombinant clones was performed by growing 5 randomly-chosen colonies overnight at 37 °C in either 2 ml (pGEX or pTC clones) or 5ml (pET clones) LB broth + 100 µg/ml ampicillin. The cells were then pelleted and the DNA extracted using the Qiagen QIAprep Spin Miniprep Kit, following the manufacturer’s instructions, to a final volume of 30 µl. 5 µl of each individual miniprep (approximately 1g) were digested with either *NdeI/XhoI* or *BamHI/XhoI* and the whole digestion loaded onto a 1-1.5% agarose gel (depending on the expected insert size), in parallel with the molecular weight marker (1Kb DNA Ladder, GIBCO). The screening of the positive clones was made on the base of the correct insert size.

Cloning

Certain ORFs may be cloned into the pGEX-HIS vector using *EcoRI-PstI*, *EcoRI-SalI*, or *SalI-PstI* cloning sites. After cloning, the recombinant plasmids may be introduced in the *E. coli* host W3110.

Expression

Each ORF cloned into the expression vector may then be transformed into the strain suitable for expression of the recombinant protein product. 1 µl of each construct was used to

- 62 -

transform 30 µl of *E.coli* BL21 (pGEX vector), *E.coli* TOP 10 (pTRC vector) or *E.coli* BL21-DE3 (pET vector), as described above. In the case of the pGEX-His vector, the same *E.coli* strain (W3110) was used for initial cloning and expression. Single recombinant colonies were inoculated into 2ml LB+Amp (100 µg/ml), incubated at 37°C overnight, then diluted 1:30 in 20 ml of LB+Amp (100 µg/ml) in 100 ml flasks, making sure that the OD₆₀₀ ranged between 0.1 and 0.15. The flasks were incubated at 30°C into gyratory water bath shakers until OD indicated exponential growth suitable for induction of expression (0.4-0.8 OD for pET and pTRC vectors; 0.8-1 OD for pGEX and pGEX-His vectors). For the pET, pTRC and pGEX-His vectors, the protein expression was induced by addition of 1mM IPTG, whereas in the case of pGEX system the final concentration of IPTG was 0.2 mM. After 3 hours incubation at 30°C, the final concentration of the sample was checked by OD. In order to check expression, 1ml of each sample was removed, centrifuged in a microfuge, the pellet resuspended in PBS, and analysed by 12% SDS-PAGE with Coomassie Blue staining. The whole sample was centrifuged at 6000g and the pellet resuspended in PBS for further use.

15 **GST-fusion proteins large-scale purification.**

A single colony was grown overnight at 37°C on LB+Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight. Bacteria were diluted 1:30 into 600 ml of fresh medium and allowed to grow at the optimal temperature (20-37°C) to OD₅₅₀ 0.8-1. Protein expression was induced with 0.2mM IPTG followed by three hours incubation. The culture was centrifuged at 8000 rpm at 4°C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml cold PBS. The cells were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again. The supernatant was collected and mixed with 150µl Glutathione-Sepharose 4B resin (Pharmacia) (previously washed with PBS) and incubated at room temperature for 30 minutes. The sample was centrifuged at 700g for 5 minutes at 4°C. The resin was washed twice with 10 ml cold PBS for 10 minutes, resuspended in 1ml cold PBS, and loaded on a disposable column. The resin was washed twice with 2ml cold PBS until the flow-through reached OD₂₈₀ of 0.02-0.06. The GST-fusion protein was eluted by addition of 700µl cold Glutathione elution buffer 10mM reduced glutathione, 50mM Tris-HCl) and fractions collected until the OD₂₈₀ was 0.1.

- 63 -

21µl of each fraction were loaded on a 12% SDS gel using either Biorad SDS-PAGE Molecular weight standard broad range (M1) (200, 116.25, 97.4, 66.2, 45, 31, 21.5, 14.4, 6.5 kDa) or Amersham Rainbow Marker (M'') (220, 66, 46, 30, 21.5, 14.3 kDa) as standards. As the MW of GST is 26kDa, this value must be added to the MW of each GST-fusion protein.

5 **His-fusion soluble proteins large-scale purification.**

A single colony was grown overnight at 37°C on a LB + Amp agar plate. The bacteria were inoculated into 20ml of LB+Amp liquid culture and incubated overnight in a water bath shaker. Bacteria were diluted 1:30 into 600ml fresh medium and allowed to grow at the optimal temperature (20-37°C) to OD₅₅₀ 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours. The culture was centrifuged at 8000 rpm at 4°C, the supernatant was discarded and the bacterial pellet was resuspended in 7.5ml cold 10mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8). The cells were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed two times and centrifuged again. The supernatant was collected and mixed with 150µl Ni²⁺-resin (Pharmacia) (previously washed with 10mM imidazole buffer) and incubated at room temperature with gentle agitation for 30 minutes. The sample was centrifuged at 700g for 5 minutes at 4°C. The resin was washed twice with 10 ml cold 10mM imidazole buffer for 10 minutes, resuspended in 1ml cold 10mM imidazole buffer and loaded on a disposable column. The resin was washed at 4°C with 2ml cold 10mM imidazole buffer until the flow-through reached the O.D₂₈₀ of 0.02-0.06. The resin was washed with 2ml cold 20mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 20 mM imidazole, pH 8) until the flow-through reached the O.D₂₈₀ of 0.02-0.06. The His-fusion protein was eluted by addition of 700µl cold 250mM imidazole buffer (300 mM NaCl, 50 mM phosphate buffer, 250 mM imidazole, pH 8) and fractions collected until the O.D₂₈₀ was 0.1. 21µl of each fraction were loaded on a 12% SDS gel.

His-fusion insoluble proteins large-scale purification.

A single colony was grown overnight at 37 °C on a LB + Amp agar plate. The bacteria were inoculated into 20 ml of LB+Amp liquid culture in a water bath shaker and grown overnight. Bacteria were diluted 1:30 into 600ml fresh medium and let to grow at the

- 64 -

optimal temperature (37°C) to O.D₅₅₀ 0.6-0.8. Protein expression was induced by addition of 1 mM IPTG and the culture further incubated for three hours. The culture was centrifuged at 8000rpm at 4°C. The supernatant was discarded and the bacterial pellet was resuspended in 7.5 ml buffer B (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 8.8). The cells
5 were disrupted by sonication on ice for 30 sec at 40W using a Branson sonifier B-15, frozen and thawed twice and centrifuged again. The supernatant was stored at -20°C, while the pellets were resuspended in 2 ml guanidine buffer (6M guanidine hydrochloride, 100mM phosphate buffer, 10 mM Tris-HCl, pH 7.5) and treated in a homogenizer for 10 cycles. The product was centrifuged at 13000 rpm for 40 minutes. The supernatant was mixed with
10 150µl Ni²⁺-resin (Pharmacia) (previously washed with buffer B) and incubated at room temperature with gentle agitation for 30 minutes. The sample was centrifuged at 700 g for 5 minutes at 4°C. The resin was washed twice with 10 ml buffer B for 10 minutes, resuspended in 1ml buffer B, and loaded on a disposable column. The resin was washed at room temperature with 2ml buffer B until the flow-through reached the OD₂₈₀ of 0.02-0.06.
15 The resin was washed with 2ml buffer C (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 6.3) until the flow-through reached the O.D₂₈₀ of 0.02-0.06. The His-fusion protein was eluted by addition of 700µl elution buffer (urea 8M, 10mM Tris-HCl, 100mM phosphate buffer, pH 4.5) and fractions collected until the OD₂₈₀ was 0.1. 21µl of each fraction were loaded on a 12% SDS gel.

20 His-fusion proteins renaturation

10% glycerol was added to the denatured proteins. The proteins were then diluted to 20µg/ml using dialysis buffer I (10% glycerol, 0.5M arginine, 50mM phosphate buffer, 5mM reduced glutathione, 0.5mM oxidised glutathione, 2M urea, pH 8.8) and dialysed against the same buffer at 4°C for 12-14 hours. The protein was further dialysed against dialysis buffer
25 II (10% glycerol, 0.5M arginine, 50mM phosphate buffer, 5mM reduced glutathione, 0.5mM oxidised glutathione, pH 8.8) for 12-14 hours at 4°C. Protein concentration was evaluated using the formula:

$$\text{Protein (mg/ml)} = (1.55 \times \text{OD}_{280}) - (0.76 \times \text{OD}_{260})$$

- 65 -

Mice immunisations

20µg of each purified protein were used to immunise mice intraperitoneally. In the case of some ORFs, Balb-C mice were immunised with Al(OH)₃ as adjuvant on days 1, 21 and 42, and immune response was monitored in samples taken on day 56. For other ORFs, CD1 mice could be immunised using the same protocol. For other ORFs, CD1 mice could be immunised using Freund's adjuvant, and the same immunisation protocol was used, except that the immune response was measured on day 42, rather than 56. Similarly, for still other ORFs, CD1 mice could be immunised with Freund's adjuvant, but the immune response was measured on day 49.

10 ELISA assay (sera analysis)

The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37°C. Bacterial colonies were collected from the agar plates using a sterile dracon swab and inoculated into 7ml of Mueller-Hinton Broth (Difco) containing 0.25% Glucose. Bacterial growth was monitored every 30 minutes by following OD₆₂₀. The bacteria were let to grow until the OD reached the value of 0.3-0.4. The culture was centrifuged for 10 minutes at 10000 rpm. The supernatant was discarded and bacteria were washed once with PBS, resuspended in PBS containing 0.025% formaldehyde, and incubated for 2 hours at room temperature and then overnight at 4°C with stirring. 100µl bacterial cells were added to each well of a 96 well Greiner plate and incubated overnight at 4°C. The wells were then washed three times with PBT washing buffer (0.1% Tween-20 in PBS). 200 µl of saturation buffer (2.7% Polyvinylpyrrolidone 10 in water) was added to each well and the plates incubated for 2 hours at 37°C. Wells were washed three times with PBT. 200 µl of diluted sera (Dilution buffer: 1% BSA, 0.1% Tween-20, 0.1% NaN₃ in PBS) were added to each well and the plates incubated for 90 minutes at 37°C. Wells were washed three times with PBT. 100 µl of HRP-conjugated rabbit anti-mouse (Dako) serum diluted 1:2000 in dilution buffer were added to each well and the plates were incubated for 90 minutes at 37°C. Wells were washed three times with PBT buffer. 100 µl of substrate buffer for HRP (25 ml of citrate buffer pH5, 10 mg of O-phenildiamine and 10 µl of H₂O) were added to each well and the plates were left at room temperature for 20 minutes. 100 µl H₂SO₄ was added to each

- 66 -

well and OD₄₉₀ was followed. The ELISA was considered positive when OD₄₉₀ was 2.5 times the respective pre-immune sera.

FACScan bacteria Binding Assay procedure.

The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37°C. Bacterial colonies were collected from the agar plates using a sterile
5 dracon swab and inoculated into 4 tubes containing 8ml each Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD₆₂₀. The bacteria were let to grow until the OD reached the value of 0.35-0.5. The culture was centrifuged for 10 minutes at 4000 rpm. The supernatant was discarded and the pellet
10 was resuspended in blocking buffer (1% BSA, 0.4% NaN₃) and centrifuged for 5 minutes at 4000 rpm. Cells were resuspended in blocking buffer to reach OD₆₂₀ of 0.07. 100µl bacterial cells were added to each well of a Costar 96 well plate. 100µl of diluted (1:200) sera (in blocking buffer) were added to each well and plates incubated for 2 hours at 4°C. Cells were centrifuged for 5 minutes at 4000 rpm, the supernatant aspirated and cells washed by addition
15 of 200µl/well of blocking buffer in each well. 100µl of R-Phicoerytrin conjugated F(ab)₂ goat anti-mouse, diluted 1:100, was added to each well and plates incubated for 1 hour at 4°C. Cells were spun down by centrifugation at 4000rpm for 5 minutes and washed by addition of 200µl/well of blocking buffer. The supernatant was aspirated and cells resuspended in 200µl/well of PBS, 0.25% formaldehyde. Samples were transferred to
20 FACScan tubes and read. The condition for FACScan setting were: FL1 on, FL2 and FL3 off; FSC-H Threshold:92; FSC PMT Voltage: E 02; SSC PMT: 474; Amp. Gains 7.1; FL-2 PMT: 539. Compensation values: 0.

OMV preparations

Bacteria were grown overnight on 5 GC plates, harvested with a loop and resuspended
25 in 10 ml 20mM Tris-HCl. Heat inactivation was performed at 56°C for 30 minutes and the bacteria disrupted by sonication for 10' on ice (50% duty cycle, 50% output). Unbroken cells were removed by centrifugation at 5000g for 10 minutes and the total cell envelope fraction recovered by centrifugation at 50000g at 4°C for 75 minutes. To extract cytoplasmic membrane proteins from the crude outer membranes, the whole fraction was resuspended in

- 67 -

2% sarkosyl (Sigma) and incubated at room temperature for 20 minutes. The suspension was centrifuged at 10000g for 10 minutes to remove aggregates, and the supernatant further ultracentrifuged at 50000g for 75 minutes to pellet the outer membranes. The outer membranes were resuspended in 10mM Tris-HCl, pH8 and the protein concentration
5 measured by the Bio-Rad Protein assay, using BSA as a standard.

Whole Extracts preparation

Bacteria were grown overnight on a GC plate, harvested with a loop and resuspended in 1ml of 20mM Tris-HCl. Heat inactivation was performed at 56°C for 30' minutes.

Western blotting

10 Purified proteins (500ng/lane), outer membrane vesicles (5 µg) and total cell extracts (25µg) derived from MenB strain 2996 were loaded on 15% SDS-PAGE and transferred to a nitrocellulose membrane. The transfer was performed for 2 hours at 150mA at 4°C, in transferring buffer (0.3 % Tris base, 1.44 % glycine, 20% methanol). The membrane was saturated by overnight incubation at 4°C in saturation buffer (10% skimmed milk, 0.1%
15 Triton X100 in PBS). The membrane was washed twice with washing buffer (3% skimmed milk, 0.1% Triton X100 in PBS) and incubated for 2 hours at 37°C with 1:200 mice sera diluted in washing buffer. The membrane was washed twice and incubated for 90 minutes with a 1:2000 dilution of horseradish peroxidase labeled anti-mouse Ig. The membrane was washed twice with 0.1% Triton X100 in PBS and developed with the Opti-4CN Substrate Kit
20 (Bio-Rad). The reaction was stopped by adding water.

Bactericidal assay

MC58 strain was grown overnight at 37°C on chocolate agar plates. 5-7 colonies were collected and used to inoculate 7ml Mueller-Hinton broth. The suspension was incubated at 37°C on a nutator and let to grow until OD₆₂₀ was in between 0.5-0.8. The
25 culture was aliquoted into sterile 1.5ml Eppendorf tubes and centrifuged for 20 minutes at maximum speed in a microfuge. The pellet was washed once in Gey's buffer (Gibco) and resuspended in the same buffer to an OD₆₂₀ of 0.5, diluted 1:20000 in Gey's buffer and stored at 25°C.

- 68 -

50µl of Gey's buffer/1% BSA was added to each well of a 96-well tissue culture plate. 25µl of diluted (1:100) mice sera (dilution buffer: Gey's buffer/0.2% BSA) were added to each well and the plate incubated at 4°C. 25µl of the previously described bacterial suspension were added to each well. 25µl of either heat-inactivated (56°C waterbath for 30 minutes) or normal baby rabbit complement were added to each well. Immediately after the addition of the baby rabbit complement, 22µl of each sample/well were plated on Mueller-Hinton agar plates (time 0). The 96-well plate was incubated for 1 hour at 37°C with rotation and then 22µl of each sample/well were plated on Mueller-Hinton agar plates (time 1). After overnight incubation the colonies corresponding to time 0 and time 1h were counted.

The following DNA and amino acid sequences are identified by titles of the following form: [g, m, or a] [#].[seq or pep], where "g" means a sequence from *N. gonorrhoeae*, "m" means a sequence from *N. meningitidis B*, and "a" means a sequence from *N. meningitidis A*; "#" means the number of the sequence; "seq" means a DNA sequence, and "pep" means an amino acid sequence. For example, "g001.seq" refers to an *N. gonorrhoeae* DNA sequence, number 1. The presence of the suffix "-1" or "-2" to these sequences indicates an additional sequence found for the same ORF. Further, open reading frames are identified as ORF #, where "#" means the number of the ORF, corresponding to the number of the sequence which encodes the ORF, and the ORF designations may be suffixed with ".ng" or ".a", indicating that the ORF corresponds to a *N. gonorrhoeae* sequence or a *N. meningitidis A* sequence, respectively. Computer analysis was performed for the comparisons that follow between "g", "m", and "a" peptide sequences; and therein the "pep" suffix is implied where not expressly stated.

EXAMPLE 1

The following ORFs were predicted from the contig sequences and/or the full length sequence using the methods herein described.

Localization of the ORFs

ORF:	contig:
279	gnm4.seq

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 962>:

- 69 -

m279.seq

1 ATAACGCGGA TTTGCGGCTG CTTGATTTC ACGGTTTTCA GGGCTTCGGC
 51 AAGTTTGTCT GCGGCGGGTT TCATCAGGCT GCAATGGGAA GGTACGGACA
 101 CGGGCAGCGG CAGGGCGCGT TTGGCACCGG CTTCTTTGGC GGCAGCCATG
 5 151 GCGCGTCCGA CCGGCGCGGC GTTGCTTGCA ATCAGCATTT GTCCGGGTGA
 201 GTTGAAGTTG ACGGCTTCGA CCACTTCGCT TTGGGCGGCT TCGGCACAAA
 251 TGGCTTTAAC CTGCTCATCT TCCAAGCCGA GAATCGCCGC CATTGCGCCC
 301 ACGCCTTGCG GTACGGCGGA CTGCATCAGT TCGGCGCGCA GCGCACGAG
 351 TTTGACCGCG TCGGCAAAAT TCAATGCGCC GCGGCAACG AGTGCGGTGT
 10 401 ATTGCGCGAG GCTGTGTCCG GCAACGGCGG CAGGCGTTTT GCCGCCGCT
 451 TCTAAATAG

This corresponds to the amino acid sequence <SEQ ID 963; ORF 279>:

m279.pep

1 ITRICGCLIS TVFRASASLS AAGFIRLOWE GTDTGSGRAR LAPASLAAAM
 51 ARPTAAALPA ITICPGELKL TASTTSLWAA SAQMALTCSS SKPRIAAIAP
 101 TPCGTADCIS SARRRSLTA SAKFNAPAAT SAVYSPRLCP ATAAGVLPAP
 151 SK*

20 The following partial DNA sequence was identified in *N.gonorrhoeae* <SEQ ID 964>:

g279.seq

1 atgacgcgga tttgcggctg cttgatttca acggttttga gtgtttcggc
 51 aagtttgtcg gcggcggtt tcatcaggct gcaatgggaa ggaacggata
 101 ccggcagcgg cagggcgctg ttggctccgg cttctttggc ggcagccatg
 25 151 gtgcgtccga cggcgcgctg gttgcctgca atcacgactt gtccggcgga
 201 gttgaagttg acggttcgca ccacttcgcc ctgtgcggat tcggcacaaa
 251 tctgcctgac ctgttcatct tccaaaccca aaatggccgc cattgcgcct
 301 acgccttgcg gtacggcgga ctgcatcagt tcggcgcgca ggcggacgag
 351 tttgacggca tcggcaaaat ccaatgcttc ggcgcgaca agcgcggtgt
 30 401 attcgcgag gctgtgtccg gcaacggcgg caggcgtttt gccgccact
 451 tccaaatag

This corresponds to the amino acid sequence <SEQ ID 965; ORF 279.ng>:

g279.pep

1 MTRICGCLIS TVLSVSASLS AAGFIRLOWE GTDTGSGRAR LAPASLAAAM
 35 51 VRPTAAALPA ITICPGELKL TASTTSPCAD SAQICLTCS SKPKMAAIAP
 101 TPCGTADCIS SARRRSLTA SAKNSASAAT SAVYSPRLCP ATAAGVLPPT
 151 SK*

ORF 279 shows 89.5% identity over a 152 aa overlap with a predicted ORF (ORF 279.ng) from *N. gonorrhoeae*:

	10	20	30	40	50	60
m279.pep	ITRICGCLISTVFRASASLSAAGFIRLOWEGTDTGSGRARLAPASLAAAMARPTAAALPA					
	: : : : : : : :					
45 g279	MTRICGCLISTVLSVSASLSAAGFIRLOWEGTDTGSGRARLAPASLAAAMVRPTAAALPA					
	10	20	30	40	50	60
	70	80	90	100	110	120
m279.pep	ITICPGELKLTAATSLWAASAQMALTCSSSKPRIAAIAPTPCGTADCISSARRRSLTA					
	: : : : : :					
50 g279	ITICPGELKLTAATSPCADSAQICLTCS SKPKMAAIAPTPCGTADCISSARRRSLTA					
	70	80	90	100	110	120
	130	140	150			
m279.pep	SAKFNAPAATSAVYSPRLCPATAAGVLPASKX					
	: : : :					
55 g279	SAKNSASAATSAVYSPRLCPATAAGVLPPTSKX					
	130	140	150			

- 70 -

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 966>:

```

a279.seq
1   ATGACNCNGA TTTGCGGCTG CTTGATTTC ACGGTTTNA GGGCTTCGGC
5   51  GAGTTTGTCG GCGGCGGGT TCATGAGGCT GCAATGGGAA GGTACNGACA
    101  CNGGCAGCGG CAGGGCGCGT TTGCGCCGG CTTCTTTGGC GGCAAGCATA
    151  GCGCGCTCGA CGGCGGCGGC ATTGCCTGCA ATCACGACTT GTCCGGGCGA
    201  GTTGAAGTTG ACGGCTTCAA CCACTTCATC CTGTGCGGAT TCGGCGCAAA
    251  TTTGTTTTAC CTGTTCAICT TCCAAGCCGA GAATCGCCGC CATTGCGCCC
10  301  ACGCCTTGCG GTACGGCGGA CTGCATCAGT TCGGCGCGCA NGCGCACGAG
    351  TTTGACCGCG TCGGCAAAAT CCAATGCGCC GGCGGCAACN AGTGCGGTGT
    401  ATTCGCCGAN GCTGTGTCCG GCAACGGCGG CAGGCGTTTT GCCGCCCGCT
    451  TCCGAATAG

```

15 This corresponds to the amino acid sequence <SEQ ID 967; ORF 279.a>:

```

a279.pep
1   MTXICGCLIS TVXRASASLS AAGFMRLQWE GTDTGSGRAR LAPASLAASI
5   51  ARSTAAALPA ITTCPGELKL TASTTSSCAD SAQICFTCSS SKPRIAAIAP
    101  TPCGTADCIS SARXRTSLTA SAKSNAPAAT SAVYSPXLCP ATAAGVLPFA
20  151  SE*

```

m279/a279 ORFs 279 and 279.a showed a 88.2% identity in 152 aa overlap

```

25  m279.pep      10      20      30      40      50      60
    ITRICGCLISTVFRASASLSAAGFIRLOWEGTDTGSGRARLAPASLAAAMARPTAAALPA
    :| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279  MTXICGCLISTVXRASASLSAAGFMRLQWEGTDTGSGRARLAPASLAASIARSTAAALPA
      10      20      30      40      50      60

30  m279.pep      70      80      90     100     110     120
    ITICPGELKLTASTTSLWAASAQMALTCSSSKPRIAAIAPTPCGTADCISARRRTSLTA
    || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279  ITTCPGELKLTASTTSSCADSAQICFTCSSSKPRIAAIAPTPCGTADCISARXRTSLTA
      70      80      90     100     110     120

35  m279.pep      130     140     150
    SAKFNAPAATSAVYSPRLCPATAAGVLPAPASKX
    ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a279  SAKSNAPAATSAVYSPXLCPATAAGVLPAPASEX
      130     140     150
40

```

519 and 519-1 gnm7.seq

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 968>:

```

45  m519.seq (partial)
    1   ..TCCGTTATCG GCGTATGGA GTTGACAAA ACGTTTGAAG AACGCGACGA
    51  AATCAACAGT ACTGTTGTTG CGGCTTTGGA CGAGGCGGCC GGGgCTTgGG
    101  GTGTGAAGGT TTTGCGTTAT GAGATTAAAG ACTTGTTTCC GCCGCAAGAA
    151  ATCCTTCGCT CAATGCAGGC GCAAATTACT GCCGAACGCG AAAAACGCGC
50  201  CCGTATCGCC GAATCCGAAG GTCGTAAAAT CGAACAAATC AACCTTGCCA
    251  GTGGTCAGCG CGAAGCCGAA ATCCAACAAT CCGAAGGCGA GGCTCAGGCT
    301  GCGGTCAATG CGTCAAATGC CGAGAAAATC GCCCGCATCA ACCGCGCCAA
    351  AGGTGAAGCG GAATCCTTGC GCCTTGTGTC CGAAGCCAAT GCCGAAGCCA
    401  TCCGTCAAAT TGCCGCGGCC CTTCAAACCC AAGGCGGTGC GGATGCGGTC
55  451  AATCTGAAGA TTGCGGAACA ATACGTCGCT GCGTTCAACA ATCTTGCCAA
    501  AGAAAGCAAT ACGCTGATTA TGCCCGCCAA TGTGTCGAC ATCGGCAGCC
    551  TGATTTCTGC CGGTATGAAA ATTATCGACA GCAGCAAAAC CGCCAAaTAA

```

- 71 -

This corresponds to the amino acid sequence <SEQ ID 969; ORF 519>:

```

m519.pep      (partial)
      1  ..SVIGRMELDK TFEERDEINS TVVAALDEAA GAWGVKVLRY EIKDLVPPQE
      51  ILRSMQAQIT AEREKRARIA ESEGRKIEQI NLAGSQREAE IQQSEGEAAQ
5      101  AVNASNAEKI ARINRAKGEA ESLRLVAEAN AEAIRQIAAA LQTQGGADAV
      151  NLKIAEQYVA AFNNLAKESN TLIMPANVAD IGSLLISAGMK IIDSSKTAK*

```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 970>:

```

g519.seq
10      1  atggaatttt tcattatctt gttggcagcc gtcgccgttt tcggcttcaa
      51  atcctttgtc gtcattcccc agcaggaagt ccacgttgtc gaaaggctcg
      101  ggcgtttcca tcgcgccctg acggccggtt tgaatatttt gattcccttt
      151  atcgaccgcg tcgcctaccg ccattcgctg aaagaaatcc ctttagacgt
      201  acccagccag gtctgcatca cgcgcgataa tacgcaattg actgttgacg
15      251  gcatcatcta ttccaagta accgatccca aactcgctc atacggttcg
      301  agcaactaca ttatggcaat taccagctt gcccaaacga cgctgcgttc
      351  cgttatcggg cgtatggagt tggacaaaac gtttgaagaa cgcgacgaaa
      401  tcaacagtac cgtcgtctcc gccctcgatg aagccgcccg ggcttggggg
      451  gtgaaagtcc tcggttacga aatcaaggat ttggttcgcg cgcaagaaat
20      501  ccttcgcgca atgcaggcac aaattaccgc cgaacgcgaa aaacgcgccc
      551  gtattgccga atccgaaggc cgtaaaatcg acaaatcaa ccttgccagt
      601  ggtcagcgtg aagccgaaat ccaacaatcc gaagcgagg ctcaggctgc
      651  ggtcaatgcg tccaatgccg agaaaatcgc ccgcatcaac cgcgccaaag
      701  gcgaagcgga atccctgcgc cttgttgccg aagccaatgc cgaagccaac
25      751  cgtcaaattg ccgccgccct tcaaacccaa agcggggcgg atgcggtcaa
      801  tctgaagatt gcgggacaat acgttaccgc gttcaaaaat cttgccaaag
      851  aagacaatac gcggattaag cccgccaaag ttgccgaaat cggaaccct
      901  aattttcggc ggcattgaaa attttcgccg gaagcaaaaa cggccaaata
      951  a

```

30 This corresponds to the amino acid sequence <SEQ ID 971; ORF 519.ng>:

```

g519.pep
      1  MEFFIILLAA VAVFGKSFV VIPQQEVHVV ERLGRFHRAL TAGLNILIPF
      51  IDRVAYRHSI KEIPLDVPSQ VCITRDNTQL TVDGIIFYQV TDPKLASYGS
35      101  SNYIMAITQL AQTTLSRVIG RMELDKTFEE RDEINSTVVS ALDEAAGAWG
      151  VKVLRYEIKD LVPPQEILRA MQAQITAERE KRARIAESEG RKIEQINLAS
      201  GQREAEIQOS EGEAQAANA SNAEKIARIN RAKGEAESLR LVAEANAAN
      251  RQIAAALQTQ SGADAVNLKI AGQYVTAFKN LAKEDNTRIK PAKVAEIGNP
      301  NFRRHEKFSP EAKTAK*

```

40 ORF 519 shows 87.5% identity over a 200 aa overlap with a predicted ORF (ORF 519.ng) from *N. gonorrhoeae*:

```

m519/g519
45      m519.pep      10      20      30
                        SVIGRMELDKTFEERDEINSTVVAALDEAA
                        |||||
g519      YFQVTDPKLASYGSSNYIMAITQLAQTTLSRVIGRMELDKTFEERDEINSTVVSALDEAA
                        90      100      110      120      130      140

50      m519.pep      40      50      60      70      80      90
                        GAWGVKVLRYEIKDLVPPQEILRSMQAQITAEREKRARIAESEGRKIEQINLAGSQREAE
                        |||||
g519      GAWGVKVLRYEIKDLVPPQEILRAMQAQITAEREKRARIAESEGRKIEQINLAGSQREAE
                        150      160      170      180      190      200

55      m519.pep      100      110      120      130      140      150
                        IQQSEGEAAQAAVNASNAEKIARINRAKGEAESLRLVAEANAEAIRQIAAALQTQGGADAV

```

- 72 -

```

g519      |||||
          IQQSEGEAQAAVNASNAEKIARINRAKGEAESLRLVAEANAEANRQIAAALQTQSGADAV
          210      220      230      240      250      260

5
          160      170      180      190      200
m519.pep  NLKIAEQYVAAFNNLAKESNTLIMPANVADIGSL-ISAGMKIIDSSKTAK
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
g519      NLKIAEQYVTAFFKNLAKEDNTRIKPAKVAEIGNPNFRHEKFSPEAKTAK
          270      280      290      300      310

```

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 972>:

```

a519.seq
1  ATGGAATTTT TCATTATCTT GCTGGCAGCC GTCGTTGTTT TCGGCTTCAA
51  ATCCTTTGTT GTCATCCAC AGCAGGAAGT CCACGTTGTC GAAAGGCTCG
15 101  GCGGTTTCCA TCGCGCCCTG ACGGCCGGTT TGAATATTTT GATTCCCTTT
151  ATCGACCGCG TCGCCTACCG CCATTGCTG AAAGAAATCC CTTAGACGT
201  ACCCAGCCAG GTCTGCATCA CGCGCGACAA TACGCAGCTG ACTGTTGACG
251  GTATCATCTA TTCCAAGTA ACCGACCCCA AACTCGCCTC ATACGGTTCG
301  AGCAACTACA TTATGGCGAT TACCCAGCTT GCCCAAACGA CGCTGCGTTC
20 351  CGTTATCGGG CGTATGGAAT TGGACAAAAC GTTTGAAGAA CGCGACGAAA
401  TCAACAGCAC CGTCGTCTCC GCCCTCGATG AAGCCGCCGG AGCTTGGGGT
451  GTGAAGGTTT TCGGTTATGA GATTAAAGAC TTGGTTCCGC CGCAAGAAAT
501  CCTTCGCTCA ATGCAGGCGC AAATTACTGC TGAACGCGAA AAACGCGCCC
551  GTATCGCCGA ATCCGAAGGT CGTAAAATCG AACAAATCAA CCTTGCCAGT
25 601  GGTCAGCGCG AAGCCGAAAT CCAACAATCC GAAGGCGAGG CTCAGGCTGC
651  GGTCAATGCG TCAAATGCCG AGAAAATCGC CCGCATCAAC CGCGCCAAAG
701  GTGAAGCGGA ATCCTTGCGC CTTGTTGCCG AAGCCAATGC CGAAGCCATC
751  CGTCAAATTG CCGCCGCCCT TCAAACCCAA GGCGGTGCGG ATGCGGTCAA
801  TCTGAAGATT GCGGAACAAT ACGTCGCCGC GTTCAACAAT CTGCCAAAG
30 851  AAAGCAATAC GCTGATTATG CCCGCCAATG TTGCCGACAT CGGCAGCCTG
901  ATTTCTGCCG GTATGAAAAT TATCGACAGC AGCAAAACCG CCAAATAA

```

This corresponds to the amino acid sequence <SEQ ID 973; ORF 519.a>:

```

a519.pep
1  MEFFIILLAA VVVFQKSFV VIPQQEVHVV ERLGRFHRAL TAGLNILIPF
51  IDRVAIRHSL KEIPLDVPSQ VCITRDNTQL TVDGIIFYQV TDEKLASYGS
101  SNYIMAITQL AQTTLRSVIG RMELDKTFEE RDEINSTVVS ALDEAGAWG
151  VKVLRYEIKD LVPPQEILRS MQAQITAERE KRARIAESEGRKIEQINLAS
201  GQREAEIQQS EGEAQAAVNA SNAEKIARIN RAKGEAESLR LVAEANAEAI
40 251  RQIAAALQTQ GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL
301  ISAGMKIIDS SKTAK*

m519/a519  ORFs 519 and 519.a showed a 99.5% identity in 199 aa overlap

45
          10      20      30
m519.pep  SVIGRMELDKTFEERDEINSTVVAALDEAA
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a519      YFQVTDPKLASYGSSNYIMAITQLAQTTLRSVIGRMELDKTFEERDEINSTVVSALDEAA
          90      100      110      120      130      140

          40      50      60      70      80      90
m519.pep  GAWGVKVLRYEIKDLVPPQEILRSMAQITAEREKRARIAESEGRKIEQINLASGQREAE
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a519      GAWGVKVLRYEIKDLVPPQEILRSMAQITAEREKRARIAESEGRKIEQINLASGQREAE
          150      160      170      180      190      200

          100      110      120      130      140      150
m519.pep  IQQSEGEAQAAVNASNAEKIARINRAKGEAESLRLVAEANAEAIRQIAAALQTQGGADAV
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
a519      IQQSEGEAQAAVNASNAEKIARINRAKGEAESLRLVAEANAEAIRQIAAALQTQGGADAV
          210      220      230      240      250      260

```

- 73 -

160 170 180 190 200
 m519.pep NLKIAEQYVAAFNNLAKESNTLIMPANVADIGSLISAGMKIIDSSKTAKX
 5 a519 NLKIAEQYVAAFNNLAKESNTLIMPANVADIGSLISAGMKIIDSSKTAKX
 270 280 290 300 310

10 Further work revealed the following DNA sequence identified in *N. meningitidis* <SEQ ID 974>:

m519-1.seq

1	ATGGAATTTT	TCATTATCTT	GTTGGTAGCC	GTCGCCGTTT	TCGGTTTCAA
51	ATCCTTTGTT	GTCAATCCAC	AACAGGAAGT	CCACGTTGTC	GAAAGGCTGG
15	101	GGCGTTTCCA	TCGCGCCCTG	ACGGCCGGTT	TGAATATTTT
	151	ATCGACCGCG	TCGCCTACCG	CCATTGCGTG	AAAGAAATCC
	201	ACCCAGCCAG	GTCTGCATCA	CGCGCGACAA	TACGCAGCTG
	251	GCATCATCTA	TTTCCAAGTA	ACCGACCCCA	AACTCGCCTC
	301	AGCAACTACA	TTATGGCGAT	TACCCAGCTT	GCCCAAACGA
20	351	CGTTATCGGG	CGTATGGAGT	TGGACAAAAC	GTTTGAAGAA
	401	TCAACAGTAC	TGTTGTTGCG	GCTTTGGACG	AGGCGGCCGG
	451	GTGAAGGTTT	TGCGTTATGA	GATTAAAGAC	TTGGTTCCGC
	501	CCTTCGCTCA	ATGCAGGCGC	AAATTACTGC	CGAACGCGAA
	551	GTATCGCCGA	ATCCGAAGGT	CGTAAAATCG	AACAAATCAA
25	601	GGTCAGCGCG	AAGCCGAAAT	CCAACAATCC	GAAGGCGAGG
	651	GGTCAATGCG	TCAAATGCCG	AGAAAATCGC	CCGCATCAAC
	701	GTGAAGCGGA	ATCCTTGCGC	CTTGTGCGCG	AAGCCAATGC
	751	CGTCAAATTG	CCGCCGCCCT	TCAAACCCAA	GGCGGTGCGG
	801	TCTGAAGATT	GCGGAACAAT	ACGTCGCTGC	GTTCAACAAT
30	851	AAAGCAATAC	GCTGATTATG	CCCGCCAATG	TTGCCGACAT
	901	ATTTCTGCCG	GTATGAAAAT	TATCGACAGC	AGCAAAACCG

This corresponds to the amino acid sequence <SEQ ID 975; ORF 519-1>:

m519-1.

1	MEFFIILLVA	VAVEGFKSFV	VIPQQEVHV	ERLGRFHRAL	TAGLNILIPF
51	IDRVAYRHS	LKEIFLDVPS	QVCITRDNT	QLTVDGIIYF	QVTDPKLAS
15	101	SNYIMAITQL	AQTLRSVIG	RMELDKTFEE	RDEINSTVVA
	151	VKVLRYEIKD	LVPPQEILRS	MQAQITAERE	KRARIAESE
	201	GQREAEIQQS	EGEAQAAVNA	SNAEKIARIN	RAKGEAESLR
40	251	RQIAAALQTQ	GGADAVNLKI	AEQYVAAFNN	LAKESNTLIM
	301	ISAGMKIIDS	SKTAK*		

The following DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 976>:

g519-1.seq

45	1	ATGGAATTTT	TCATTATCTT	GTTGGCAGCC	GTCGCCGTTT	TCGGCTTCAA
	51	ATCCTTTGTC	GTCAATCCAC	AGCAGGAAGT	CCACGTTGTC	GAAAGGCTCG
	101	GGCGTTTCCA	TCGCGCCCTG	ACGGCCGGTT	TGAATATTTT	GATTCCCTTT
	151	ATCGACCGCG	TCGCCTACCG	CCATTGCGTG	AAAGAAATCC	CTTTAGACGT
	201	ACCCAGCCAG	GTCTGCATCA	CGCGCGATAA	TACGCAATTG	ACTGTTGACG
50	251	GCATCATCTA	TTTCCAAGTA	ACCGATCCCA	AACTCGCCTC	ATACGGTTTC
	301	AGCAACTACA	TTATGGCAAT	TACCCAGCTT	GCCCAAACGA	CGCTGCGTTC
	351	CGTTATCGGG	CGTATGGAGT	TGGACAAAAC	GTTTGAAGAA	CGCGACGAAA
	401	TCAACAGTAC	CGTCGTCTCC	GCCCTCGATG	AAGCCGCCGG	GGCTTGGGGT
	451	GTGAAAGTCC	TCCGTTACGA	AATCAAGGAT	TTGGTTCCGC	CGCAAGAAAT
55	501	CCTTCGCGCA	ATGCAGGCAC	AAATTACCGC	CGAACGCGAA	AAACGCGCCC
	551	GTATTGCCGA	ATCCGAAGGC	CGTAAAATCG	AACAAATCAA	CCTTGCCAGT
	601	GGTCAGCGTG	AAGCCGAAAT	CCAACAATCC	GAAGGCGAGG	CTCAGGCTGC
	651	GGTCAATGCG	TCCAATGCCG	AGAAAATCGC	CCGCATCAAC	CGCGCCAAAG
	701	GCGAAGCGGA	ATCCCTGCGC	CTTGTGCGCG	AAGCCAATGC	CGAAGCCATC
60	751	CGTCAAATTG	CCGCCGCCCT	TCAAACCCAA	GGCGGGGCGG	ATGCGGTCAA
	801	TCTGAAGATT	GCGGAACAAT	ACGTAGCCGC	GTTCAACAAT	CTTGCCAAAG

- 74 -

851 AAAGCAATAC GCTGATTATG CCCGCCAATG TTGCCGACAT CGGCAGCCTG
 901 ATTTCTGCCG GCATGAAAT TATCGACAGC AGCAAACCG CCAAATAA

This corresponds to the amino acid sequence <SEQ ID 977; ORF 519-1.ng>:

5 g519-1.pep
 1 MEFFIILLAA VAVFGFKSFV VIPQQEVHV V ERLGRFHRAL TAGLNILIPF
 51 IDRVAYRHSL KEIPLDVPSQ VCITRDNTQL TVDGIIFYQV TDPKLASYGS
 101 SNYIMAITQL AQTTLRSVIG RMELDKTFEE RDEINSTVVS ALDEAAGAWG
 151 VKVLRYEIKD LVPPQEILRA MQAQITAERE KRARIAESEG RKIEQINLAS
 10 201 GQREAEIQQS EGEEAQAANA SNAEKIARIN RAKGEAESLR LVAEANA EAI
 251 RQIAAALQTQ GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL
 301 ISAGMKIIDS SKTAK*

15 m519-1/g519-1 ORFs 519-1 and 519-1.ng showed a 99.0% identity in 315 aa overlap

		10	20	30	40	50	60
20	g519-1.pep	MEFFIILLAAVAVFGFKSFV	VIPQQEVHVVERLGRFHRAL	TAGLNILIPFIDRVAYRHSL			
	m519-1	MEFFIILLVAVAVFGFKSFV	VIPQQEVHVVERLGRFHRAL	TAGLNILIPFIDRVAYRHSL			
		10	20	30	40	50	60
25	g519-1.pep	KEIPLDVPSQVCITRDNTQL	TVDGIIFYQVTDPKLASYGSS	SNYIMAITQLAQTTLRSVIG			
	m519-1	KEIPLDVPSQVCITRDNTQL	TVDGIIFYQVTDPKLASYGSS	SNYIMAITQLAQTTLRSVIG			
		70	80	90	100	110	120
30	g519-1.pep	RMELDKTFEERDEINSTVVS	ALDEAAGAWGVKVLRYEIKD	LVPPQEILRAMAQITAERE			
	m519-1	RMELDKTFEERDEINSTVVA	ALDEAAGAWGVKVLRYEIKD	LVPPQEILRSMQAITAERE			
		130	140	150	160	170	180
35	g519-1.pep	KRARIAESEGRKIEQINLAS	GQREAEIQQSEGEAQAANAS	SNAEKIARINRAKGEAESLR			
	m519-1	KRARIAESEGRKIEQINLAS	GQREAEIQQSEGEAQAANAS	SNAEKIARINRAKGEAESLR			
		190	200	210	220	230	240
40	g519-1.pep	LVAEANA EAI RQIAAALQTQ	GGADAVNLKIAEQYVAAFNN	LAKESNTLIMPANVADIGSL			
	m519-1	LVAEANA EAI RQIAAALQTQ	GGADAVNLKIAEQYVAAFNN	LAKESNTLIMPANVADIGSL			
		250	260	270	280	290	300
45	g519-1.pep	ISAGMKIIDS	SKTAKX				
	m519-1	ISAGMKIIDS	SKTAKX				
		310					

The following DNA sequence was identified in *N. meningitidis* <SEQ ID 978>:

55 a519-1.seq
 1 ATGGAATTTT TCATTATCTT GCTGGCAGCC GTCGTTGTTT TCGGCTTCAA
 51 ATCCTTTGTT GTCATCCAC AGCAGGAAGT CCACGTTGTC GAAAGGCTCG
 101 GCGGTTTCCA TCGCGCCCTG ACGGCGGTT TGAATATTTT GATTCCCTTT
 151 ATCGACCGCG TCGCCTACCG CCATTCGCTG AAAGAAATCC CTTTAGACGT
 60 201 ACCCAGCCAG GTCTGCATCA CGCGCGACAA TACGCAGCTG ACTGTTGACG
 251 GTATCATCTA TTTCCAAGTA ACCGACCCCA AACTCGCCTC ATACGGTTCTG
 301 AGCAACTACA TTATGGCGAT TACCCAGCTT GCCCAAACGA CGCTGCGTTC

- 75 -

351 CGTTATCGGG CGTATGGAAT TGGACAAAAC GTTTGAAGAA CGCGACGAAA
 401 TCAACAGCAC CGTCGTCTCC GCCCTCGATG AAGCCGCCGG AGCTTGGGGT
 451 GTGAAGGTTT TGC GTTATGA GATTAAAGAC TTGGTTCCGC CGCAAGAAAT
 501 CTTTCGCTCA ATGCAGGCGC AAATTACTGC TGAACGCGAA AAACGCGCCC
 551 GTATCGCCGA ATCCGAAGGT CGTAAAATCG AACAAATCAA CCTTGCCAGT
 601 GGTCAGCGCG AAGCCGAAAT CCAACAATCC GAAGGCGAGG CTCAGGCTGC
 651 GGTCAATGCG TCAATGCCG AGAAAATCG CCGCATCAAC CGCGCCAAAG
 701 GTGAAGCGGA ATCCTTGCGC CTTGTTGCCG AAGCCAATGC CGAAGCCATC
 751 CGTCAAATTG CCGCGCCCT TCAAACCCAA GGCGGTGCGG ATGCGGTCAA
 801 TCTGAAGATT GCGGAACAAT ACGTCGCCGC GTTCAACAAT CTTGCCAAAG
 851 AAAGCAATAC GCTGATTATG CCCGCCAATG TTGCCGACAT CGGCAGCCTG
 901 ATTTCTGCCG GTATGAAAAT TATCGACAGC AGCAAAACCG CCAAATAA

This corresponds to the amino acid sequence <SEQ ID 979; ORF 519-1.a>:

15 a519-1.pep.
 1 MEFFIILLAA VVVFGEKSFV VIPQQEVHV ERLGRFHRAL TAGLNILIPF
 51 IDRVAYRHSL KEIPLDVPSQ VCITRDNTQL TVDGIIYFQV TDPKLSYGS
 101 SNYIMAITQL AQTTLRSVIG RMELDKTFEE RDEINSTVVS ALDEAAGAWG
 151 VKVLRYEIKD LVPPQEILRS MQAQITAERE KRARIAESEG RKIEQINLAS
 201 GQREAEIQQS EGEAQAAVNA SNAEKIARIN RAKGEAESLR LVAEANAELI
 251 RQIAAALQTQ GGADAVNLKI AEQYVAAFNN LAKESNTLIM PANVADIGSL
 301 ISAGMKIIDS SKTAK*
 25 m519-1/a519-1 ORFs 519-1 and 519-1.a showed a 99.0% identity in 315 aa overlap

		10	20	30	40	50	60
a519-1.pep		MEFFIILLAAVVVFGEKSFV	VIPQQEVHV	ERLGRFHRAL	TAGLNILIPF	IDRVAYRHSL	
		:					
30 m519-1		MEFFIILLVAVVFGEKSFV	VIPQQEVHV	ERLGRFHRAL	TAGLNILIPF	IDRVAYRHSL	
		10	20	30	40	50	60
		70	80	90	100	110	120
35 a519-1.pep		KEIPLDVPSQVCITRDNTQL	TDGIIYFQV	TDPKLSYGS	SNYIMAITQL	AQTTLRSVIG	
m519-1		KEIPLDVPSQVCITRDNTQL	TDGIIYFQV	TDPKLSYGS	SNYIMAITQL	AQTTLRSVIG	
		70	80	90	100	110	120
		130	140	150	160	170	180
40 a519-1.pep		RMELDKTFEERDEINSTVVS	ALDEAAGAWG	VKVLRYEIKD	LVPPQEILRS	MQAQITAERE	
m519-1		RMELDKTFEERDEINSTVVS	ALDEAAGAWG	VKVLRYEIKD	LVPPQEILRS	MQAQITAERE	
		130	140	150	160	170	180
		190	200	210	220	230	240
45 a519-1.pep		KRARIAESEGRKIEQINLAS	GQREAEIQS	EGEAQAAVNAS	SNAEKIARIN	RAKGEAESLR	
m519-1		KRARIAESEGRKIEQINLAS	GQREAEIQS	EGEAQAAVNAS	SNAEKIARIN	RAKGEAESLR	
		190	200	210	220	230	240
		250	260	270	280	290	300
50 a519-1.pep		LVAEANAELIRQIAAALQT	GGADAVNLK	IAEQYVAAFNN	LAKESNTLIM	PANVADIGSL	
55 m519-1		LVAEANAELIRQIAAALQT	GGADAVNLK	IAEQYVAAFNN	LAKESNTLIM	PANVADIGSL	
		250	260	270	280	290	300
		310					
a519-1.pep		ISAGMKIIDSSKTAKX					
60 m519-1		ISAGMKIIDSSKTAKX					
		310					

576 and 576-1 gnm22.seq

5 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 980>:

```

m576.seq.. (partial)
1  ..ATGCAGCAGG CAAGCTATGC GATGGGCGTG GACATCGGAC GCTCCCTGAA
51  GCAAATGAAG GAACAGGGCG CGGAAATCGA TTTGAAAGTC TTTACCGAAG
101 CCATGCAGGC AGTGTATGAC GGCAAAGAAA TCAAAATGAC CGAAGAGCAG
151 GCTCAGGAAG TCATGATGAA ATTCCTTCAG GAACAACAGG CTAAAGCCGT
201 AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GGCGAAGCCT
251 TTCTGAAAGA AAATGCCGCC AAAGACGGCG TGAAGACCAC TGCTTCCGGC
301 CTGCAATACA AAATCACCAA ACAGGGCGAA GGCAAACAGC CGACCAAAGA
351 CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACGGTAT
15 401 TCGACAGCAG CAAAGCCAAC GGCGGCCCGG TCACCTTCCC TTTGAGCCAA
451 GTGATTCCGG GTTGGACCGA AGCGGTACAG CTTCTGAAAG AAGGCGGCCA
501 AGCCACGTTC TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGGTCCGG
551 GCGACAAAAT CGGTCCGAAC GCCACTTTGG TATTTGATGT GAAACTGGTC
601 AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCCGG CTCAAGTCGA
20 651 CATCAAAAAA GTAAATTAA

```

This corresponds to the amino acid sequence <SEQ ID 981; ORF 576>:

```

m576.pep.. (partial)
1  ..MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ
25 51  AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG
101 LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
151 VIPGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVFVDKLV
201 KIGAPENAPA KQPAQVDIKK VN*

```

30 The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 982>:

```

g576.seq.. (partial)
1  ..atgggcggtg acatcgagcg ctccctgaaa caaatgaagg aacagggcgc
51  ggaaatcgat ttgaaagtct ttaccgatgc catgcaggca gtgtatgacg
101 gcaaagaaat caaaatgacc gaagagcagg cccaggaagt gatgatgaaa
35 151 ttctgcagg agcagcaggc taaagccgta gaaaaacaca aggcggatgc
201 gaaggccaac aaagaaaaag gcgaagcctt cctgaaggaa aatgccgcgc
251 aagacggcgt gaagaccact gcttcgggtc tgcagtacaa aatcaccaaa
301 caggggtgaag gcaaacagcc gacaaaagac gacatcgtaa cctgtggaata
351 cgaagggcgc ctgattgacg gtaccgtatt cgacagcagc aaagccaacg
40 401 gcggcccggc caccttcctt ttgagccaag tgattccggg ttggaccgaa
451 ggcgtaacgc ttctgaaaag aggcggcgaa gccacgttct acatcccgtc
501 caaccttgcc taccgcgaac aggggtgcgg cgaaaaaatc ggtccgaacg
551 ccactttggt atttgacgtg aaactggta aaatcggcgc acccgaaaac
45 601 gcgcccgcga agcagccgga tcaagtcgac atcaaaaaag taaattaa

```

This corresponds to the amino acid sequence <SEQ ID 983; ORF 576.ng>:

```

g576.pep.. (partial)
1  ..MGVDIGRSLK QMKEQGAEID LKVFTDAMQA VYDGKEIKMT EEQAQEVMMK
51  FLQEQQAKAV EKHKADAKAN KEKGEAFLKE NAAEDGVKTT ASGLQYKITK
50 101 QGEGKQPTKD DIVTVEYEGR LIDGTVFDSS KANGGPATFP LSQVIPGWTE
151 GVRLLKEGGE ATFYIPSNLA YREQGAGEKI GPNATLVFDV KLVKIGAPEN
201 APAKQPDQVD IKKVN*

```

55 Computer analysis of this amino acid sequence gave the following results:
Homology with a predicted ORF from *N. gonorrhoeae*

m576/g576 97.2% identity in 215 aa overlap

- 77 -

		10	20	30	40	50	60
	m576.pep	MQQASYAMGVDIGRSLKQMKEQGAEIDLKVFTEAMQAVYDGKEIKMTEEQAEVMMKFLQ					
5	g576	MGVDIGRSLKQMKEQGAEIDLKVFTEAMQAVYDGKEIKMTEEQAEVMMKFLQ					
		10	20	30	40	50	
		70	80	90	100	110	120
10	m576.pep	EQQAKAVEKHKADAKANKEKGEAFLKENAAKDGVKTTASGLQYKITKQGEKGKQPTKDDIV					
	g576	EQQAKAVEKHKADAKANKEKGEAFLKENAAEDGVKTTASGLQYKITKQGEKGKQPTKDDIV					
		60	70	80	90	100	110
		130	140	150	160	170	180
15	m576.pep	TVEYEGRLIDGTVFDDSSKANGGPVTFPLSQVIPGWTEGVQLLKEGGEATFYIPSNLAYRE					
	g576	TVEYEGRLIDGTVFDDSSKANGGPATFPLSQVIPGWTEGVRLLEKGEATFYIPSNLAYRE					
		120	130	140	150	160	170
20		190	200	210	220		
	m576.pep	QGAGDKIGPNATLVFDVKLVKIGAPENAPAKQPAQVDIKKVNK					
	g576	QGAGEKIGPNATLVFDVKLVKIGAPENAPAKQPDQVDIKKVNK					
25		180	190	200	210		

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 984>:

	a576.seq	
	1	ATGAACACCA TTTTCAAAT CAGCGCACTG ACCCTTTCCG CCGCTTTGGC
30	51	ACTTTCCGCC TCGGCAAAA AAGAAGCCGC CCCCGCATCT GCATCCGAAC
	101	CTGCCGCCG TCTTCCGCG CAGGCGACA CCTCTTCGAT CGGCAGCAG
	151	ATGCAGCAG CAAGCTATG CATTGGCGTG GACATCGGAC GCTCCCTGAA
	201	GCAAATGAAG GAACAGGCG CGGAAATCGA TTTGAAAGT TTTACCGAAG
	251	CCATGCAGGC AGTGTATGAC GGCAAAGAAA TCAAATGAC CGAAGAGCAG
35	301	GCTCAGGAAG TCATGATGAA ATTCTTCAG GAACAACAGG CTAAAGCCGT
	351	AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GGCGAAGCCT
	401	TTCTGAAAGA AAATGCCGCC AAAGACGGCG TGAAGACCAC TGCTTCCGGC
	451	CTGCAATACA AAATACCAA ACAGGGCGAA GGCAAACAGC CGACCAAGAC
	501	CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACGGTAT
40	551	TCGACAGCAG CAAAGCCAAC GGCGGCCCG TCACCTTCCC TTGAGCCAA
	601	GTGATTCTGG GTTGGACCGA AGGCGTACAG CTTCTGAAAG AAGGCGGCGA
	651	AGCCACGTTT TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGGTGGCG
	701	GCGACAAAAT CGGCCCGAAC GCCACTTTGG TATTTGATGT GAAACTGGTC
	751	AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCCGG CTCAAGTCGA
45	801	CATCAAAAAA GTAAATTAA

This corresponds to the amino acid sequence <SEQ ID 985; ORF 576.a>:

	a576.pep	
	1	MNTIFKISAL TLSAALALSA CGKKEAAPAS ASEPAASSA QGDTSSIGST
50	51	MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ
	101	AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG
	151	LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
	201	VILGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVFDVKLV
	251	KIGAPENAPA KQPAQVDIKK VN*
55	m576/a576	ORFs 576 and 576.a showed a 99.5% identity in 222 aa overlap
		10 20 30
	m576.pep	MQQASYAMGVDIGRSLKQMKEQGAEIDLKV
60	a576	CGKKEAAPASASEPAASSAQGDTSSIGSTMQQASYAMGVDIGRSLKQMKEQGAEIDLKV
		30 40 50 60 70 80

- 78 -

		40	50	60	70	80	90
	m576.pep	FTEAMQAVYDGKEIKMTEEQAQEVMMKFLQEQQAKAVEKHKADAKANKEKGEAFLKENAA					
	a576	FTEAMQAVYDGKEIKMTEEQAQEVMMKFLQEQQAKAVEKHKADAKANKEKGEAFLKENAA					
5		90	100	110	120	130	140
		100	110	120	130	140	150
	m576.pep	KDGVKTTASGLQYKITKQEGEKQPTKDDIVTVEYEGRLIDGTVFDSSKANGGPVTFPLSQ					
10	a576	KDGVKTTASGLQYKITKQEGEKQPTKDDIVTVEYEGRLIDGTVFDSSKANGGPVTFPLSQ					
		150	160	170	180	190	200
		160	170	180	190	200	210
	m576.pep	VIPGWTEGVQLLKEGGEATFYIPSNLAYREQGAGDKIGPNATLVFDVKLVKIGAPENAPA					
15	a576	VILGWTEGVQLLKEGGEATFYIPSNLAYREQGAGDKIGPNATLVFDVKLVKIGAPENAPA					
		210	220	230	240	250	260
		220					
20	m576.pep	KQPAQVDIKKVN					
	a576	KQPAQVDIKKVN					
		270					

Further work revealed the following DNA sequence identified in *N. meningitidis* <SEQ ID 986>:

	m576-1.seq	
30	1	ATGAACACCA TTTTCAAAT CAGCGCACTG ACCCTTTCCG CCGCTTTGGC
	51	ACTTTCCGCC TCGGGCAAAA AAGAAGCCGC CCCCGCATCT GCATCCGAAC
	101	CTGCCGCCGC TTCTTCCGCG CAGGCGCACA CCTCTTCGAT CGGCAGCAGC
	151	ATGCAGCAGG CAAGCTATGC GATGGGCGTG GACATCGGAC GCTCCCTGAA
	201	GCAAAATGAAG GAACAGGGCG CGGAAATCGA TTTGAAAGTC TTTACCGAAG
	251	CCATGCAGGC AGTGTATGAC GGCAAAGAAA TCAAATGAC CGAAGAGCAG
35	301	GCTCAGGAAG TCATGATGAA ATTCTTCAG GAACAACAGG CTAAGCCGT
	351	AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GGCGAAGCCT
	401	TTCTGAAAGA AAATGCCGCC AAAGACGGCG TGAAGACCAC TGCTTCCGGC
	451	CTGCAATACA AAATCACCAA ACAGGGCGAA GGCAAACAGC CGACCAAGAA
	501	CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACGGTAT
40	551	TCGACAGCAG CAAAGCCAAC GGCGGCCCG TCACCTTCCC TTGAGCCAA
	601	GTGATTCCGG GTTGGACCGA AGGCGTACAG CTTCTGAAAG AAGGCGGCCA
	651	AGCCACGTTT TACATCCCCT CCAACCTTGC CTACCGCGAA CAGGGTGCGC
	701	GCGACAAAAT CGGTCCGAAC GCCACTTTGG TATTTGATGT GAAACTGGTC
	751	AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCCGG CTCAAGTCGA
45	801	CATCAAAAAA GTAAATTAA

This corresponds to the amino acid sequence <SEQ ID 987; ORF 576-1>:

	m576-1.pep	
50	1	MNTIFKISAL TLSAALALSA CGKKEAAPAS ASEPAASSA QGDTSSIGST
	51	MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ
	101	AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG
	151	LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
	201	VIPGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVFDVKLV
55	251	KIGAPENAPA KQPAQVDIKK VN*

The following DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 988>:

	g576-1.seq	
60	1	ATGAACACCA TTTTCAAAT CAGCGCACTG ACCCTTTCCG CCGCTTTGGC
	51	ACTTTCCGCC TCGGGCAAAA AAGAAGCCGC CCCCGCATCT GCATCCGAAC
	101	CTGCCGCCGC TTCTGCCGCG CAGGCGCACA CCTCTTCAAT CGGCAGCAGC
	151	ATGCAGCAGG CAAGCTATGC AATGGGCGTG GACATCGGAC GCTCCCTGAA

- 79 -

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80

```

201 ACAAATGAAG GAACAGGGCG CGGAAATCGA TTTGAAAGTC TTTACCGATG
251 CCATGCAGGC AGTGTATGAC GGCAAAGAAA TCAAAATGAC CGAAGAGCAG
301 GCCCAGGAAG TGATGATGAA ATTCTGTCAG GAGCAGCAGG CTAAAGCCGT
351 AGAAAAACAC AAGGCGGATG CGAAGGCCAA CAAAGAAAAA GGCGAAGCCT
401 TCCTGAAGGA AAATGCCGCC AAAGACGGCG TGAAGACCAC TGCTTCCGGT
451 CTGCAGTACA AAATCACCAA ACAGGGTGAA GGCAAACAGC CGACAAAAGA
501 CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACCGTAT
551 TCGACAGCAG CAAAGCCAAC GGCGGCCCGG CCACCTTCCC TTTGAGCCAA
601 GTGATTCCGG GTTGGACCGA AGGCGTACGG CTTCTGAAAG AAGGCGGCCG
651 AGCCACGTC TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGGTGCGG
701 GCGAAAAAAT CGGTCCGAAC GCCACTTTGG TATTTGACGT GAAACTGGTC
751 AAAATCGGCG CACCCGAAAA CGCGCCCGCC AAGCAGCCGG ATCAAGTCGA
801 CATCAAAAAA GTAAATTAA

```

15 This corresponds to the amino acid sequence <SEQ ID 989; ORF 576-1.ng>:

g576-1.pep

```

1 MNTIFKISAL TLSAALALSA CGKKEAAPAS ASEPAAASAA QGDTSSIGST
51 MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTDAMQAVYD GKEIKMTEEQ
101 AQEVMMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG
151 LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPATFPLSQ
201 VIPGWTEGVR LLKEGGEATF YIPSNLAYRE QGAGEKIGPN ATLVFDVKLV
251 KIGAPENAPA KPDQVDIKK VN*

```

25 g576-1/m576-1 ORFs 576-1 and 576-1.ng showed a 97.8% identity in 272 aa overlap

30
35
40
45
50
55

```

g576-1.pep      10      20      30      40      50      60
MNTIFKISALTLSAALALSACGKKEAAPASASEPAAASAAQGDTSSIGSTMQQASYAMGV
|||||
m576-1          10      20      30      40      50      60
MNTIFKISALTLSAALALSACGKKEAAPASASEPAAASSAQGDTSSIGSTMQQASYAMGV
|||||

g576-1.pep      70      80      90      100     110     120
DIGRSLKQMKEQGAEIDLKVFTDAMQAVYDGKEIKMTEEQAQEVMMKFLQEQQAKAVEKH
|||||
m576-1          70      80      90      100     110     120
DIGRSLKQMKEQGAEIDLKVFTDAMQAVYDGKEIKMTEEQAQEVMMKFLQEQQAKAVEKH
|||||

g576-1.pep     130     140     150     160     170     180
KADAKANKEKGEAFLENAAKDGVKTTASGLQYKITKQGEKGKQPTKDDIVTVEYEGRLID
|||||
m576-1         130     140     150     160     170     180
KADAKANKEKGEAFLENAAKDGVKTTASGLQYKITKQGEKGKQPTKDDIVTVEYEGRLID
|||||

g576-1.pep     190     200     210     220     230     240
GTVFDSSKANGGPATFPLSQVIPGWTEGVRLLKEGGEATFYIPSNLAYREQGAGEKIGPN
|||||
m576-1         190     200     210     220     230     240
GTVFDSSKANGGPVTFPLSQVIPGWTEGVQLKEGGEATFYIPSNLAYREQAGDKIGPN
|||||

g576-1.pep     250     260     270
ATLVFDVKLVKIGAPENAPAKQPDQVDIKKVN*
|||||
m576-1         250     260     270
ATLVFDVKLVKIGAPENAPAKQPAQVDIKKVN*

```

The following DNA sequence was identified in *N. meningitidis* <SEQ ID 990>:

60 a576-1.seq

```

1 ATGAACACCA TTTTCAAAT CAGCGCACTG ACCCTTTCCG CCGCTTTGGC
51 ACTTTCCGCC TGCGGCAAAA AAGAAGCCGC CCCCGCATCT GCATCCGAAC
101 CTGCCGCCGC TTCTTCCGCG CAGGGCGACA CCTCTTCGAT CGGCAGCACG

```

- 80 -

5 151 ATGCAGCAGG CAAGCTATGC GATGGGCGTG GACATCGGAC GCTCCCTGAA
 201 GCAAATGAAG GAACAGGGCG CGGAAATCGA TTTGAAAGTC TTTACCGAAG
 251 CCATGCAGGC AGTGTATGAC GGCAAAGAAA TCAAAATGAC CGAAGAGCAG
 301 GCTCAGGAAG TCATGATGAA ATTCTTCAG GAACAACAGG CTAAGGCCGT
 351 AGAAAAACAC AAGGCGGACG CGAAGGCCAA TAAAGAAAAA GGCGAAGCCT
 401 TTCTGAAAGA AAATGCCGCC AAAGACGGCG TGAAGACCAC TGCTTCCGGC
 451 CTGCAATACA AAATACCAA ACAGGGCGAA GGCAAACAGC CGACCAAAGA
 501 CGACATCGTT ACCGTGGAAT ACGAAGGCCG CCTGATTGAC GGTACGGTAT
 551 TCGACAGCAG CAAAGCCAAC GGCGGCCCGG TCACCTTCCC TTTGAGCCAA
 10 601 GTGATTCTGG GTTGACCGA AGGCGTACAG CTTCTGAAAG AAGGCGGCGA
 651 AGCCACGTTC TACATCCCGT CCAACCTTGC CTACCGCGAA CAGGGTGCGG
 701 GCGACAAAAT CGGCCCGAAC GCCACTTGG TATTTGATGT GAAACTGGTC
 751 AAAATCGGCG CACCCGAAAA CGCGCCGCC AAGCAGCCGG CTCAAGTCGA
 801 CATCAAAAAA GTAAATTAA

This corresponds to the amino acid sequence <SEQ ID 991; ORF 576-1.a>:

a576-1.pep
 1 MNTIFKISAL TLSAALALSA CGKKEAPAS ASEPAASSA QGDTSSIGST
 51 MQQASYAMGV DIGRSLKQMK EQGAEIDLKV FTEAMQAVYD GKEIKMTEEQ
 20 101 AQEVMKFLQ EQQAKAVEKH KADAKANKEK GEAFLENAA KDGVKTTASG
 151 LQYKITKQGE GKQPTKDDIV TVEYEGRLID GTVFDSSKAN GGPVTFPLSQ
 201 VILGWTEGVQ LLKEGGEATF YIPSNLAYRE QGAGDKIGPN ATLVDVKLV
 251 KIGAPENAPA KQPAQVDIKK VN*

25 a576-1/m576-1 ORFs 576-1 and 576-1.a 99.6% identity in 272 aa overlap

	10	20	30	40	50	60
a576-1.pep	MNTIFKISAL	TLSAALALSA	CGKKEAPAS	ASEPAASSA	QGDTSSIGST	MQQASYAMGV
30 m576-1	MNTIFKISAL	TLSAALALSA	CGKKEAPAS	ASEPAASSA	QGDTSSIGST	MQQASYAMGV
	10	20	30	40	50	60
	70	80	90	100	110	120
35 a576-1.pep	DIGRSLKQMK	EQGAEIDLKV	FTEAMQAVYD	GKEIKMTEEQ	AQEVMKFLQ	EQQAKAVEKH
m576-1	DIGRSLKQMK	EQGAEIDLKV	FTEAMQAVYD	GKEIKMTEEQ	AQEVMKFLQ	EQQAKAVEKH
	70	80	90	100	110	120
	130	140	150	160	170	180
40 a576-1.pep	KADAKANKEK	GEAFLENAA	KDGVKTTASG	LQYKITKQGE	GKQPTKDDIV	TVEYEGRLID
m576-1	KADAKANKEK	GEAFLENAA	KDGVKTTASG	LQYKITKQGE	GKQPTKDDIV	TVEYEGRLID
	130	140	150	160	170	180
	190	200	210	220	230	240
45 a576-1.pep	GTVDSSKAN	GGPVTFPLS	QVILGWTEGV	QLKEGGEATF	YIPSNLAYRE	QGAGDKIGPN
m576-1	GTVDSSKAN	GGPVTFPLS	QVILGWTEGV	QLKEGGEATF	YIPSNLAYRE	QGAGDKIGPN
	190	200	210	220	230	240
	250	260	270			
a576-1.pep	ATLVFDVKLV	KIGAPENAPA	KQPAQVDIKK	VNX		
55 m576-1	ATLVFDVKLV	KIGAPENAPA	KQPAQVDIKK	VNX		
	250	260	270			

919 and 919-2 gnm43.seq

60

- 81 -

The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 992>:

```

m919.seq
1   ATGAAAAAAT ACCTATTCCG CGCCGCCCTG TACGGCATCG CCGCCGCCAT
5   51  CCTCGCCGCC TGCCAAAGCA AGAGCATCCA AACCTTTCCG CAACCCGACA
    101  CATCCGTCAT CAACGGCCCG GACCGGCCGG TCGGCATCCC CGACCCCGCC
    151  GGAACGACGG TCGGCGGCGG CGGGGCCGTC TATACCGTTG TACCGCACCT
    201  GTCCCTGCCC CACTGGGCGG CGCAGGATTT CGCCAAAAGC CTGCAATCCT
    251  TCCGCCTCGG CTGCGCCAAT TTGAAAAACC GCCAAGGCTG GCAGGATGTG
10  301  TCGGCCCAAG CCTTTCAAAC CCCCGTCCAT TCCTTTCAGG CAAAACAGTT
    351  TTTTGAACGC TATTTACAGC CGTGGCAGGT TGCAGGCAAC GGAAGCCTTG
    401  CCGGTACGGT TACCGGCTAT TACGAACCGG TGCTGAAGGG CGACGACAGG
    451  CGGACGGCAC AAGCCCCTTT CCCGATTTAC GGTATTCCCG ACGATTTTAT
    501  CTCCGTCCCC CTGCCTGCCG GTTTGCGGAG CGGAAAAGCC CTTGTCCGCA
15  551  TCAGGCAGAC GGGAAAAAAC AGCGGCACAA TCGACAATAC CGGCGGCACA
    601  CATACCGCCG ACCTCTCCcG ATTCCCCATC ACCGCGCGCA CAACAGCAAT
    651  CAAAGGCAGG TTTGAAGGAA GCCGCTTCCT CCCCTACCAC ACGCGCAACC
    701  AAATCAACGG CGGCGCGCTT GACGGCAAAG CCCCGATACT CGGTTACGCC
    751  GAAGACCTCG TCGAACTTTT TTTTATGCAC ATCCAAGGCT CGGGCCGTCT
20  801  GAAAACCCCG TCCGGCAAAT ACATCCGCAT CGGCTATGCC GACAAAAACG
    851  AACATCCyTA CGTTTCCATC GGACGCTATA TGGCGGATAA GGGCTACCTC
    901  AAACCTCGAC AAACCTCCAT GCAGGGCATT AAGTCTTATA TCGCGCAAAA
    951  TCCGCAACGC CTCGCCGAAG TTTTGGGTCA AAACCCAGC TATATCTTTT
    1001 TCCGCGAGCT TGCCGGAAGC AGCAATGACG GCCCTGTCGG CGCACTGGGC
25  1051 ACGCCGCTGA TGGGGGAATA TGCCGCGCGA GTCGACCGGC ACTACATTAC
    1101 CTTGGGTGCG CCCTTATTTG TCGCCACCGC CCATCCGGTT ACCCGCAAAG
    1151 CCCTCAACCG CCTGATTATG GCGCAGGATA CCGGCAGCGC GATTAAAGGC
    1201 GCGGTGCGCG TGGATTATTT TTGGGGATAC GGCGACGAAG CCGCGCAACT
    1251 TGCCGGCAAA CAGAAAACCA CGGGATATGT CTGGCAGCTC CTACCCAACG
30  1301 GTATGAAGCC CGAATACCGc CCGTAA

```

This corresponds to the amino acid sequence <SEQ ID 993; ORF 919>:

```

m919.pep
35  1   MKKYLFRAL YGIAAAILAA CQSKSIQTFP QPDTSVINGP DRPVGIPDPA
    51  GTTVGGGAV YTVVPHLSLP HWAAQDFAKS LQSFRLGCAN LKNRQGWQDV
    101  CAQAFQTPVH SFQAKQFFER YFTPWQVAGN GSLAGTVTGY YEPVLKGDDR
    151  RTAQARFPIY GIPDDFISVP LPAGLRSGKA LVRIRQTGKN SGTIDNTGGT
40  201  HTADLSRFPI TARTTAIKGR FEGRSFLPYH TRNQINGGAL DGKAPILGYA
    251  EDPVELFFMH IQGSGRLKTP SGKYIRIGYA DKNEHPYVSI GRYMADKGYL
    301  KLGQTSMQGI KSYMQRNPQR LAEVLGQNPS YIFFRELAYS SNDGPVGALG
    351  TPLMGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG
    401  AVRVDYFWGY GDEAGELAGK QKTTGYVWQL LPNGMKPEYR P*

```

45 The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 994>:

```

m919-2.seq
1   ATGAAAAAAT ACCTATTCCG CGCCGCCCTG TACGGCATCG CCGCCGCCAT
50  51  CCTCGCCGCC TGCCAAAGCA AGAGCATCCA AACCTTTCCG CAACCCGACA
    101  CATCCGTCAT CAACGGCCCG GACCGGCCGG TCGGCATCCC CGACCCCGCC
    151  GGAACGACGG TCGGCGGCGG CGGGGCCGTC TATACCGTTG TACCGCACCT
    201  GTCCCTGCCC CACTGGGCGG CGCAGGATTT CGCCAAAAGC CTGCAATCCT
    251  TCCGCCTCGG CTGCGCCAAT TTGAAAAACC GCCAAGGCTG GCAGGATGTG
    301  TCGGCCCAAG CCTTTCAAAC CCCCGTCCAT TCCTTTCAGG CAAAACAGTT
55  351  TTTTGAACGC TATTTACAGC CGTGGCAGGT TGCAGGCAAC GGAAGCCTTG
    401  CCGGTACGGT TACCGGCTAT TACGAACCGG TGCTGAAGGG CGACGACAGG
    451  CGGACGGCAC AAGCCCCTTT CCCGATTTAC GGTATTCCCG ACGATTTTAT
    501  CTCCGTCCCC CTGCCTGCCG GTTTGCGGAG CGGAAAAGCC CTTGTCCGCA
    551  TCAGGCAGAC GGGAAAAAAC AGCGGCACAA TCGACAATAC CGGCGGCACA

```

- 82 -

5
10
15

```

601 CATACCGCCG ACCTCTCCCG ATTCCCCATC ACCGCGCGCA CAACAGCAAT
651 CAAAGGCAGG TTTGAAGGAA GCCGCTTCCT CCCCTACCAC ACGCGCAACC
701 AAATCAACGG CGGCGCGCTT GACGGCAAAG CCCCGATACT CGGTACGCC
751 GAAGACCCTG TCGAACTTTT TTTTATGCAC ATCCAAGGCT CGGGCCGTCT
801 GAAAACCCCG TCCGGCAAAT ACATCCGCAT CGGCTATGCC GACAAAAACG
851 AACATCCCTA CGTTTCCATC GGACGCTATA TGGCGGATAA GGGCTACCTC
901 AAACCTCGGAC AAACCTCCAT GCAGGGCATT AAGTCTTATA TGCGGCAAAA
951 TCCGCAACGC CTCGCCGAAG TTTTGGGTCA AAACCCAGC TATATCTTTT
1001 TCCGCGAGCT TGCCGGAAGC AGCAATGACG GCCCTGTCGG CGCACTGGGC
1051 ACGCCGCTGA TGGGGGAATA TGCCGCGCA GTCGACCGGC ACTACATTAC
1101 CTGGGTGCG CCCTTATTG TCGCCACCGC CCATCCGGTT ACCCGCAAAG
1151 CCCTCAACCG CCTGATTATG GCGCAGGATA CCGGCAGCGC GATTAAAGGC
1201 GCGGTGCGCG TGGATTATTT TTGGGGATAC GGCGACGAAG CCGGCGAACT
1251 TGCCGGCAAA CAGAAAACCA CGGGATATGT CTGGCAGCTC CTACCCAACG
1301 GTATGAAGCC CGAATACCGC CCGTAA

```

This corresponds to the amino acid sequence <SEQ ID 995; ORF 919-2>:

20
25
30

```

m919-2.pep
1 MKKYLFRAL YGIAAAAILAA CQSKSIQTFP QPDTSVINGP DRPVGIPDPA
51 GTTVGGGGAV YTVVPHLSLP HWAAQDFAKS LQSFRLGCAN LKNRQGWQDV
101 CAQAFQTPVH SFQAKOFFER YFTPWQVAGN GSLAGTVTGY YEPVLKGDDE
151 RTAQARFPIY GIPDDFISVP LPAGLRSGKA LVRIRQTGKN SGTIDNTGGT
201 HTADLSRFPI TARTTAIKGR FEGRFLPYH TRNQINGGAL DGKAPILGYA
251 EDPVELFFMH IQGSRCLKTP SGKYIRIGYA DKNEHPYVSI GRYMADKGYL
301 KLGQTSMQGI KSYMQRNPQR LAEVLGQNPS YIFFRELAGS SNDGFPVAGL
351 TPLMGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG
401 AVRVDYFWGY GDEAGELAGK QKTTGYVWQL LPNGMKPEYR P*

```

The following partial DNA sequence was identified in *N.gonorrhoeae* <SEQ ID 996>:

35
40
45
50
55
60

```

g919.seq
1 ATGAAAAAAC ACCTGCTCCG CTCGCCCTG TACGGcatCG CCGCCgccAT
51 CctcgCCGCC TGCCAAAgca gGAGCATCCA AACCTTTCG CAACCCGACA
101 CATCCGTCAT CAACGGCCCC GACCGGCCG CCGGCATCCC CGACCCCGCC
151 GGAACGACGG TTGCCGGCGG CGGGGCGGTC TATACCGTTG TGCCGCACCT
201 GTCCATGCCC CACTGGGCGG CGCaggATTT TGCCAAAGC CTGCAATCCT
251 TCCGCCTCGG CTGCGCCAAT TTGAAAAACC GCCAAGGCTG GCAGGATGTG
301 TGCGCCCAAG CCTTCAAAC CCCCGTGCAT TCCTTTCAGG CAAAGcGgTT
351 TTTTGAACGC TATTTCACGC cgtGGCaggT tgcaggcaAC GGAAGcCTTG
401 CaggtaaggT TACCGGCTAT TACGAACCGG TGCTGAAGGG CGACGGCAGG
451 CGGACGGAAC GGGCCCGCTT CCCGATTAC GGTATTCCCG ACGATTTTAT
501 CTCGCTCCCG CTGCCTGCCG GTTTGCGGGG CGGAAAAAAC CTTGTCCGCA
451 TCAGGCAGac ggGGA AAAAC AGCGGCACGA TCGACAATGC CGGCGGCACG
601 CATACCGCCG ACCTCTCCCG ATTCCCCATC ACCGCGCGCA CAACGGcaat
651 caaaGGCAGG TTTGAaggAA GCCGCTTCCT CCCTTACCAC ACGCGCAACC
701 AAAtcaacGG CGGCgcgcTT GACGGCAAag cccCCATCCT CggttacgcC
751 GAagaccCcG tcgaacttTT TTTATGCAC AtccaaggCT CGGGCCGCCT
501 GAAAACCCcg tccggcaaat acatCCGcAt cggATacgcc gacAAAAAGC
851 AACAtccgTa tgtttccatc ggACGctaTA TGGCGGACAA AGGCTACCTC
901 AAGetcgggc agACCTCGAT GCAGGgcacC aaagcCTATA TGCGGCAAAA
951 TCCGCAACGC CTCGCCGAAG TTTTGGGTCA AAACCCAGC TATATCTTTT
1001 TCCGCGAGCT TGCCGGAAGC GGCAATGAGG GCCCCGTGCG CGCACTGGGC
55 1051 ACGCCACTGA TGGGGGAATA CGCCGGCGCA ATCGACCGGC ACTACATTAC
1101 CTTGGGCGCG CCCTTATTG TCGCCACCGC CCATCCGGTT ACCCGCAAAG
1151 CCCTCAACCG CTGATTATG GCGCAGGATA CAGGCAGCGC GATCAAAGGC
1201 GCGGTGCGCG TGGATTATTT TTGGGGTTAC GGCGACGAAG CCGGCGAACT
1251 TGCCGGCAAA CAGAAAACCA CGGGATACGT CTGGCAGCTC CTGCCCCAACG
60 1301 GCATGAAGCC CGAATACCGC CCGTGA

```


ORF 919 shows 95.9 % identity over a 441 aa overlap with a predicted ORF (ORF 919.ng) from *N. gonorrhoeae*:

		m919/g919											
20		10	20	30	40	50	60						
	m919.pep	MKKYLFRAALYGIAAAILAACQSKSIQTFPQPDTSVINGPDRPVGIPDPAGTTVGGGGAV											
	g919	MKKHLLRSALYGIAAAILAACQSRSIQTFPQPDTSVINGPDRPAGIPDPAGTTVAGGGAV											
25		70	80	90	100	110	120						
	m919.pep	YTVVPHLSLPHWAAQDFAKSLQSFRLGCANLKNRQGWQDVCAQAFQTPVHSFQAKQFFER											
	g919	YTVVPHLSMPHWAAQDFAKSLQSFRLGCANLKNRQGWQDVCAQAFQTPVHSFQAKRFFER											
30		130	140	150	160	170	180						
	m919.pep	YFTPQWVAGNGSLAGTVTGYIYEPVLKGGDDRRTAQARFPIYGI PDDFISVPLPAGLRSGKA											
	g919	YFTPQWVAGNGSLAGTVTGYIYEPVLKGGGRRTERARFPIYGI PDDFISVPLPAGLRGGKN											
35		190	200	210	220	230	240						
	m919.pep	LVRIRQTGKNSGTIDNTGGTHTADLSRFPITARTTAIKGRFEGSRFLPYHTRNQINGGAL											
	g919	LVRIRQTGKNSGTIDNAGGTHTADLSRFPITARTTAIKGRFEGSRFLPYHTRNQINGGAL											
40		250	260	270	280	290	300						
	m919.pep	DGKAPILGYAEDPVLEFFMHIIQSGSRLKTPSGKYIRIGYADKNEHPYVSI GRYMADKGYL											
	g919	DGKAPILGYAEDPVLEFFMHIIQSGSRLKTPSGKYIRIGYADKNEHPYVSI GRYMADKGYL											
45		310	320	330	340	350	360						
	m919.pep	KLGQTSMQGIKSYMQRNPQRLAEVLGQNPSYIFFRELAGSSNDGPVGALGTPLMGEYAGA											
	g919	KLGQTSMQGIKAYMRNPQRLAEVLGQNPSYIFFRELAGSGNEGPPVGALGTPLMGEYAGA											
50		370	380	390	400	410	420						
	m919.pep	VDRHYITLGAPLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDFYFWGYGDEAGELAGK											
	g919	IDRHYITLGAPLFVATAHPVTRKALNRLIMAQDTGSAIKGAVRVDFYFWGYGDEAGELAGK											

- 84 -

430 440
 m919.pep QKTTGYVWQLLPNGMKPEYRPX
 5 |||||
 g919 QKTTGYVWQLLPNGMKPEYRPX
 430 440

The following partial DNA sequence was identified in *N.meningitidis* <SEQ ID 998>:

10 a919.seq

1	ATGAAAAAAT	ACCTATTCCG	CGCCGCCCTG	TGCGGCATCG	CCGCCGCCAT
51	CCTCGCCGCC	TGCCAAAGCA	AGAGCATCCA	AACCTTTCCG	CAACCCGACA
101	CATCCGTCAT	CAACGGCCCG	GACCGGCCGG	TCGGCATCCC	CGACCCGCC
151	GGAACGACGG	TCGGCGGCGG	CGGGGCCGTT	TATACCGTTG	TGCCGCACCT
201	GTCCCTGCCC	CACTGGGCGG	CGCAGGATTT	CGCCAAAAGC	CTGCAATCCT
251	TCCGCCTCGG	CTGCGCCAAT	TTGAAAAACC	GCCAAGGCTG	GCAGGATGTG
301	TGCGCCCAAG	CCTTTCAAAC	CCCCGTCCAT	TCCGTTTCAGG	CAAAACAGTT
351	TTTGAACGC	TATTTCACGC	CGTGGCAGGT	TGCAGGCAAC	GGAAGCCTTG
401	CCGGTACGGT	TACCGGCTAT	TACGAGCCGG	TGCTGAAGGG	CGACGACAGG
451	CGGACGGCAC	AAGCCCGCTT	CCCGATTTC	GGTATTCCCG	ACGATTTTAT
501	TCCCGTCCCC	CTGCCTGCCG	GTTTGCGGAG	CGGAAAAGCC	CTTGTCGCA
551	TCAGGCAGAC	GGGAAAAAAC	AGCGGCACAA	TCGACAATAC	CGGCGGCACA
601	CATACGCGCG	ACCTCTCCCA	ATTCCCACATC	ACTGCGCGCA	CAACGGCAAT
651	CAAAGGCAGG	TTTGAAGGAA	GCCGCTTCCT	CCCCTACCAC	ACGCGCAACC
701	AAATCAACGG	CGGCGCGCTT	GACGGCAAAG	CCCCGATACT	CGGTTACGCC
751	GAGACCCCG	TCGAACTTTT	TTTTATGCAC	ATCCAAGGCT	CGGCGCGTCT
801	GAACACCCCG	TCCGGCAAAT	ACATCCGCAT	CGGCTATGCC	GACAAAAACG
851	AACATCCCTA	CGTTTCCATC	GGACGCTATA	TGGCGGACAA	AGGCTACCTC
901	AAGCTCGGGC	AGACCTCGAT	GCAGGGCATC	AAAGCCTATA	TGAGCAAAAA
951	CCCGCAACGC	CTCGCCGAAG	TTTTGGGGCA	AAACCCGAGC	TATATCTTTT
1001	TCCGAGAGCT	TACCGGAAGC	AGCAATGACG	GCCCTGTGCG	CGCACTGGGC
1051	ACGCCGCTGA	TGGGCGAGTA	CGCCGCGCGA	GTCGACCGGC	ACTACATTAC
1101	CTTGGGCGCG	CCCTTATTTG	TCGCCACCGC	CCATCCGTTT	ACCCGCAAAG
1151	CCCTCAACCG	CCTGATTATG	GCGCAGGATA	CCGGCAGCGC	GATTAAAGGC
1201	GCGGTGCGCG	TGGATTATTT	TTGGGGATAC	GGCGACGAAG	CCGGCGAACT
1251	TCCCGGCAAA	CAGAAAACCA	CGGGATATGT	CTGGCAGCTT	CTGCCCAACG
1301	GTATGAAGCC	CGAATACCGC	CCGTAA		

This corresponds to the amino acid sequence <SEQ ID 999; ORF 919.a>:

40 a919.pep

1	MKKYLFRAAL	CGIAAAILAA	CQSKSIQTFP	QPDTSVINGP	DRPVGIPDPA
51	GTTVGGGGAV	YTVVPHLSLP	HWAAQDFAKS	LQSFRLGCAN	LKNRQGWQDV
101	CAQAFQTPVH	SVQAKQFFER	YFTPWQVAGN	GSLAGTVTGY	YEPVLKGDDR
151	RTAQARFPIY	GIPDDFISVP	LPAGLRSGKA	LVRIRQTGKN	SGTIDNTGGT
201	HTADLSQFPI	TARTTAIKGR	FEGRFLPYH	TRNQINGGAL	DGKAPILGYA
251	EDPVELFFMH	IQSGRLKTP	SGKYIRIGYA	DKNEHPYVSI	GRYMADKGYL
301	KLQOTSMQGI	KAYMQNPQR	LAEVLGQNPS	YIFFRELTGS	SNDGPVGAIG
351	TPLMGEYAGA	VDRHYITLGA	PLFVATAHPV	TRKALNRLIM	AQDTGSAIKG
401	AVRVDYFWGY	GDEAGELAGK	QKTTGYVWQL	LPNGMKPEYR	P*

m919/a919 ORFs 919 and 919.a showed a 98.6% identity in 441 aa overlap

55

m919.pep	10	20	30	40	50	60
	MKKYLFRAALY	GIAAAILAAC	QSKSIQTFP	QPDTSVINGP	DRPVGIPDPA	GTTVGGGGAV
a919	MKKYLFRAAL	CGIAAAILAAC	QSKSIQTFP	QPDTSVINGP	DRPVGIPDPA	GTTVGGGGAV
	10	20	30	40	50	60
m919.pep	70	80	90	100	110	120
	YTVVPHLSLPH	WAAQDFAKS	LQSFRLGCAN	LKNRQGWQDV	CAQAFQTPVH	SFQAKQFFER
a919	YTVVPHLSLPH	WAAQDFAKS	LQSFRLGCAN	LKNRQGWQDV	CAQAFQTPVH	SFQAKQFFER

60

- 85 -

		70	80	90	100	110	120
		130	140	150	160	170	180
5	m919.pep	YFTPWQVAGNGSLAGT	VTGYEPEVLKGD	DRRTAQARFPIYG	IPDDFISVPLPAG	LRSGKA	
	a919	YFTPWQVAGNGSLAGT	VTGYEPEVLKGD	DRRTAQARFPIYG	IPDDFISVPLPAG	LRSGKA	
		130	140	150	160	170	180
10	m919.pep	LVRIRQTGKNSGTIDNT	GGTHTADLSRFPIT	ARTTAIKGRFEGSR	FLPYHTRNQINGGAL		
	a919	LVRIRQTGKNSGTIDNT	GGTHTADLSQFPIT	ARTTAIKGRFEGSR	FLPYHTRNQINGGAL		
		190	200	210	220	230	240
15	m919.pep	DGKAPILGYAEDPVEL	FFMHIQSGRLKTP	SGKYIRIGYADKNE	HPYVSIGRYMA	DKGYL	
	a919	DGKAPILGYAEDPVEL	FFMHIQSGRLKTP	SGKYIRIGYADKNE	HPYVSIGRYMA	DKGYL	
		250	260	270	280	290	300
20	m919.pep	KLQQTSMQGIKSYM	RQNPORLAEVLG	QNPYSYIFFREL	AGSSNDGPVGA	LGTPLMGEYAGA	
	a919	KLQQTSMQGIKAYM	QNPORLAEVLG	QNPYSYIFFREL	TGSSNDGPVGA	LGTPLMGEYAGA	
		310	320	330	340	350	360
25	m919.pep	VDRHYITLGAPLFV	ATAHPVTRKALN	RILMAQDTGSAI	KGAVRVDYFWG	YGDEAGELAGK	
	a919	VDRHYITLGAPLFV	ATAHPVTRKALN	RILMAQDTGSAI	KGAVRVDYFWG	YGDEAGELAGK	
		370	380	390	400	410	420
30	m919.pep	QKTTGYVWQLLP	NGMKPEYRPX				
	a919	QKTTGYVWQLLP	NGMKPEYRPX				
		430	440				
35	m919.pep	QKTTGYVWQLLP	NGMKPEYRPX				
	a919	QKTTGYVWQLLP	NGMKPEYRPX				
		430	440				
40	121 and 121-1						

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1000>:

45	m121.seq	1	ATGGAACAC	AGCTTTACAT	CGGCATCATG	TCGGGAACCA	GCATGGACGG
		51	GGCGGATGCC	GTACTGATAC	GGATGGACGG	CGGCAAATGG	CTGGGCGCGG
		101	AAGGGCACGC	CTTTACCCCC	TACCCCGGCA	GGTTACGCCG	CCAATTGCTG
		151	GATTTGCAGG	ACACAGGCGC	AGACGAACTG	CACCGCAGCA	GGATTTTGTC
		201	GCAAGAACTC	AGCCGCCTAT	ATGCGCAAAC	CGCCGCGGAA	CTGCTGTGCA
50		251	GTCAAACCT	CGCACCGTCC	GACATTACCG	CCCTCGGCTG	CCACGGGCAA
		301	ACCGTCCGAC	ACGCGCCGGA	ACACGGTTAC	AGCATACAGC	TTGCCGATT
		351	GCCGCTGCTG	GCGxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
		401	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
		451	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
55		501	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
		551	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx	xxxxxxxxxx
		601	xxxxxxCAGC	TTCTTACGA	CAAAAACGGT	GCAAAGTCGG	CACAAGGCAA
		651	CATATTGCCG	CAACTGCTCG	ACAGGCTGCT	CGCCACCCG	TATTTGCGAC
		701	AACGCCACCC	TAAAAGCACG	GGGCGCGAAC	TGTTTGCCAT	AAATTGGCTC
60		751	GAAACCTACC	TTGACGGCGG	CGAAAACCGA	TACGACGTAT	TGCGGACGCT
		801	TTCCCGTTTT	ACCGCGCAA	CCGTTTGCGA	CGCCGTCTCA	CACGCAGCGG

- 86 -

5
851 CAGATGCCCG TCAAATGTAC ATTTGCGACG GCGGCATCCG CAATCCTGTT
901 TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCCTGCACAG
951 CACCGCCGAC CTGAACCTCG ATCCGCAATG GGTGAAGCC GCCGnATTTC
1001 CGTGGTTGGC GGCGTGTGG ATTAATCGCA TTCCCGGTAG TCCGCACAAA
1051 GCAACCGGCG CATCCAAACC GTGTATTCTG AnCGCGGGAT ATTATTATTG
1101 A

This corresponds to the amino acid sequence <SEQ ID 1001; ORF 121>:

10 **m121.pep**
1 METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTP YPGRRLRRQLL
51 DLQDTGADEL HRSRILSQEL SRLYAQTAAE LLCSONLAPS DITALGCHGQ
101 TVRHAPHEGY SIQLADLPLL Axxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx
151 xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx
201 xxQLPYDKNG AKSAQGNILP QLLDRLLAHP YFAQRHPKST GRELFAINWL
15 251 ETYLDGGENR YDVLRTLRSF TAQTVCDAYS HAAADARQMY ICDGGIRNPV
301 LMADLAECFG TRVSLHSTAD LNLDPQWVEA AXFAWLAACW INRIPGSPHK
351 ATGASKPCIL XAGY^{YY}*

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1002>:

20 **g121.seq**
1 ATGGAACAC AGCTTTACAT CGGCATTATG TCGGGAACCA GTATGGACGG
51 GGCGGATGCC GTGCTGGTAC GGATGGACGG CGGCAAATGG CTGGGCGCGG
101 AAGGGACGC CTTTACCCCC TACCCTGACC GGTTCGCGCG CAAATTGCTG
25 151 GATTTGCAGG ACACAGGCAC AGACGAACTG CACCGCAGCA GGATGTTGTC
201 GCAAGAACTC AGCCGCCTGT ACGCGCAAAC CGCCGCCGAA CTGCTGTGCA
251 GTCAAAACCT CGCTCCGTGC GACATTACCG CCCTCGGCTG CCACGGGCAA
301 ACCGTCCGAC ACGCGCCGGA ACACGGTtac AGCATACAGC TTGCCGATTT
351 GCCGCTGCTG GCGGAACtGa cgcggatttT TACCGTCggc gacttcCGCA
401 GCCGCGACCT TGCTGCCGCG GGacaAGGTG CGCCGCTCGT CCCCgcCTTT
30 451 CACGAAGCCC TGTTCCGCGA TGACAGGGAA ACACGCGTGG TACTGAACAT
501 CGGCGGGATT GCCAACATCA GCGTACTCCC CCCCgCGCA CCGCCTTCG
551 GCTTCGACAC AGGGCCGGGC AATATGCTGA TGGAcgcgtg gacgcaggca
601 cactGGcagc TGCCTTACGA CAAAa^{ac}ggt gcAAAGg^{cg} cacAAGGCAA
651 catatTGCcg cAACTGCTCG gcaggetGCT CGCCcaccCG TATTTCTCAC
35 701 AACCcacc^c aaAAAGCACG GGgcGCGaac TgtttgcccT AAattg^gc^tc
751 gaaacctAcc ttgacggcgg cga^{aa}accga tacgacgtat tgcggacgct
801 ttccccgattc accgcgcaaA ccgTttggga cgcgctctca CACGCAGCGG
851 CAGATGCCCG TCAAATGTAC ATTTGCGCGC GCGGCATCCG CAATCCTGTT
901 TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCCTGCACAG
40 951 CACCGCCGAA CTGAACCTCG ATCCTCAATG GGTGGAGGCG gccgCATTtg
1001 cgtggttggC GGCGTGTGG ATTAACCGCA TTCCCGGTAG TCCGCACAAA
1051 GCGACCGGCG CATCCAAACC GTGTATTCTG GGCGCGGGAT ATTATTATTG
1101 A

45 This corresponds to the amino acid sequence <SEQ ID 1003; ORF 121.ng>:

g121.pep
1 METQLYIGIM SGTSMGDADA VLVRMDGGKW LGAEGHAFTP YPDRRLRRKLL
51 DLQDTGTDEL HRSRMLSQEL SRLYAQTAAE LLCSONLAPC DITALGCHGQ
101 TVRHAPHEGY SIQLADLPLL AELTRIFTVG DFRSRDLAAG GQGAPLVPFA
50 151 HEALFRDDRE TRVVLNIGI ANISVLPPGA PAFGFDTPGP NMLMDAWTQA
201 HWQLPYDKNG AKAAQGNILP QLLGRLLAHP YFSQPHPKST GRELFALNWL
251 ETYLDGGENR YDVLRTLRSF TAQTVWDAYS HAAADARQMY ICGGGIRNPV
301 LMADLAECFG TRVSLHSTAE LNLDPQWVEA AAFAWLAACW INRIPGSPHK
351 ATGASKPCIL GAGY^{YY}*

ORF 121 shows 73.5% identity over a 366 aa overlap with a predicted ORF (ORF121.ng) from *N. gonorrhoeae*:

m121/g121

60

- 87 -

		10	20	30	40	50	60
	m121.pep	METQLYIGIMSGTSMGDGADAVLIRMDGGKWLGAEGHAFTPYPGRLRRQLLDLQDTGADEL					
		: : : : :					
5	g121	METQLYIGIMSGTSMGDGADAVLVRMDGGKWLGAEGHAFTPYPDRLRRKLLDLQDTGTDEL					
		70	80	90	100	110	120
	m121.pep	HRSRILSQELSRLYAQTAELLCSQNLAPSDITALGCHGQTVRHAFEPHGYSIQLADLPLL					
		: : : : :					
10	g121	HRSRMLSQELSRLYAQTAELLCSQNLAPCDITALGCHGQTVRHAFEPHGYSIQLADLPLL					
		70	80	90	100	110	120
	m121.pep	AXXX					
		: : :					
15	g121	AELTRIFTVGDFRSRDLAAGGQGAFLVPAFHEALFRDDRETRVVLNIGGIANISVLPPGA					
		130	140	150	160	170	180
	m121.pep	XXXXXXXXXXXXXXXXXXXXXQLPYDKNGAKSAQGNILPQLLDRLLAHPYFAQRHPKST					
		:	:	: : : :			
20	g121	PAFGFDTGPGNMLMDAWTQAHWQLPYDKNGAKAAQGNILPQLLGRLLAHPYFSQPHPKST					
		190	200	210	220	230	240
	m121.pep	GRELFAINWLETYLDGGENRYDVLRTLSRFTAQTVCDVASHAAADARQMYICDGGIRNPV					
		250	260	270	280	290	300
25	g121	GRELFAINWLETYLDGGENRYDVLRTLSRFTAQTVWDVASHAAADARQMYICGGGIRNPV					
		250	260	270	280	290	300
	m121.pep	LMADLAECFGTRVSLHSTADLNLDPOWVEAAXFAWLAACWINRIPGSPHKATGASKPCIL					
		310	320	330	340	350	360
30	g121	LMADLAECFGTRVSLHSTAE LNLDPOWVEAAAFWLAACWINRIPGSPHKATGASKPCIL					
		310	320	330	340	350	360
	m121.pep	XAGYYYYX					
35	g121	GAGYYYYX					

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1004>:

	a121.seq	
40	1	ATGGAAACAC AGCTTTACAT CGGCATCATG TCGGGAACCA GCATGGACGG
	51	GGCGGATGCC GTACTGATAC GGATGGACGG CGGCAATGG CTGGGCGCGG
	101	AAGGGCACGC CTTTACCCCC TACCCCGGCA GGTTACGCCG CAAATTGCTG
	151	GATTTGCAGG ACACAGGCGC GGACGAACTG CACCGCAGCA GGATGTTGTC
	201	GCAAGAACTC AGCCGCCTGT ACGCGCAAAC CGCCGCCGAA CTGCTGTGCA
45	251	GTCAAAACCT CGCGCCGTCC GACATTACCG CCTCGGCTG CCACGGGCAA
	301	ACCGTCAGAC ACGCGCCGGA ACACAGTTAC AGCGTACAGC TTGCCGATTT
	351	GCCGCTGCTG GCGGAACGGA CTCAGATTTT TACCGTCGCG GACTTCCGCA
	401	GCCGCGACCT TGCGGCCGGC GGACAAGGCG CGCCGCTCGT CCCCGCCTTT
	451	CACGAAGCCC TGTTCGCGCA CGACAGGGAA ACACGCGCGG TACTGAACAT
50	501	CGGCGGGATT GCCAACATCA GCGTACTCCC CCCCAGCGCA CCCGCCTTCG
	551	GCTTCGACAC AGGACCGGGC AATATGCTGA TGGACGCGTG GATGCAGGCA
	601	CACTGGCAGC TTCCTTACGA CAAAACGGT GCAAAGGCGG CACAAGGCAA
	651	CATATTGCCG CAACTGCTCG ACAGGCTGCT CGCCCACCGG TATTTGCGAC
	701	AACCCACCC TAAAGCACG GGGCGCAAC TGTTTGCCCT AAATTGGCTC
55	751	GAAACCTACC TTGACGGCGG CGAAAACCGA TACGACGTAT TCGGACGCT
	801	TTCCCGATTC ACCGCGCAAA CCGTTTTCGA CGCCGTCTCA CACGCAGCGG
	851	CAGATGCCCG TCAAATGTAC ATTTGCGGCG GCGGCATCCG CAATCCTGTT
	901	TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCTGCACAG
	951	CACGCGCGAA CTGAACCTCG ATCCGCAATG GGTAGAAGCC GCCGCGTTCC
60	1001	CATGGATGCG GCGGTGTTGG GTCAACCGCA TTCCCGGTAG TCCGCACAAA
	1051	GCAACCGGCG CATCCAAACC GTGTATTCTG GGCGCGGGAT ATTATTATTG
	1101	A

- 88 -

This corresponds to the amino acid sequence <SEQ ID 1005; ORF 121.a>:

```

a121.pep
5      1  METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTP YPGRRLRRKLL
      51  DLQDTGADEL HRSRMLSQEL SRLYAQTAAE LLCSONLAPS DITALGCHGQ
     101  TVRHAPESY SVQLADLPLL AERTQIFTVG DFRSRDLAAG GQGAPLVPAP
     151  HEALFRDDRE TRAVLNIGGI ANISVLPPDA PAFGFDTGPG NMLMDAWMQA
     201  HWQLPYDKNG AKAQGNILP QLLDRLLAHP YFAQPHPKST GRELFALNWL
     251  ETYLDGGENR YDVLRTLSRF TAQTVFDAVS HAAADARQMY ICGGGIRNPV
    10  301  LMADLAECFG TRVSLHSTAE LNLDPQWVEA AAFAWMAACW VNRIPGSPHK
     351  ATGASKPCIL GAGYYY*

m121/a121  ORFs 121 and 121.a 74.0% identity in 366 aa overlap

15      10      20      30      40      50      60
m121.pep  METQLYIGIMSGTSMGDADAVLIRMDGGKWLGAEHHAFTYPGRRLRRQLLDLQDTGADEL
a121      METQLYIGIMSGTSMGDADAVLIRMDGGKWLGAEHHAFTYPGRRLRRQLLDLQDTGADEL
      10      20      30      40      50      60

20      70      80      90      100     110     120
m121.pep  HRSRILSQELSRLYAQTAAELLCSONLAPSDITALGCHGQTVRHAPHEGYSIQLADLPLL
a121      HRSRILSQELSRLYAQTAAELLCSONLAPSDITALGCHGQTVRHAPHEHSYVQLADLPLL
      70      80      90      100     110     120

25      130     140     150     160     170     180
m121.pep  AXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
a121      AERTQIFTVGDFRSRDIAAGGQGAPLVPAPHEALFRDDRETRAVLNIGGIANISVLPPDA
      130     140     150     160     170     180

30      190     200     210     220     230     240
m121.pep  XXXXXXXXXXXXXXXXXXXXXXXQLPYDKNGAKSAQGNILPQLLDRLLAHPYFAQRHPKST
a121      PAFGFDTGPGNMLMDAWMQAHWQLPYDKNGAKAAQGNILPQLLDRLLAHPYFAQPHPKST
      190     200     210     220     230     240

35      250     260     270     280     290     300
m121.pep  GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVCDVSHAAADARQMYICDGGIRNPV
a121      GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVFDAVSHAAADARQMYICGGGIRNPV
      250     260     270     280     290     300

40      310     320     330     340     350     360
m121.pep  LMADLAECFGTRVSLHSTADLNLDLPQWVEAAXFAWLAAACWINRIPGSPHKATGASKPCIL
a121      LMADLAECFGTRVSLHSTAE LNLDPQWVEAAAFAWMAACWVNRIPGSPHKATGASKPCIL
      310     320     330     340     350     360

45      310     320     330     340     350     360
m121.pep  LMADLAECFGTRVSLHSTADLNLDLPQWVEAAXFAWLAAACWINRIPGSPHKATGASKPCIL
a121      LMADLAECFGTRVSLHSTAE LNLDPQWVEAAAFAWMAACWVNRIPGSPHKATGASKPCIL
      310     320     330     340     350     360

50      310     320     330     340     350     360
m121.pep  XAGYYYX
a121      GAGYYYX

```

55 Further work revealed the DNA sequence identified in *N. meningitidis* <SEQ ID 1006>:

```

m121-1.seq
      1  ATGGAACAC AGCTTTACAT CGGCATCATG TCGGGAACCA GCATGGACGG
     51  GCGGATGCC GTACTGATAC GGATGGACGG CGGCAAATGG CTGGGCGCGG
    101  AAGGGCACGC CTTTACCCCC TACCCCGGCA GGTACGCCG CCAATTGCTG
    151  GATTTGCAGG ACACAGGCGC AGACGAACG CACCGCAGCA GGATTTTGTG
    201  GCAAGAACTC AGCCGCCTAT ATGCGCAAAC CGCCGCCGAA CTGCTGTGCA

```

- 89 -

251 GTCAAAACCT CGCACCGTCC GACATTACCG CCCTCGGCTG CCACGGGCAA
 301 ACCGTCCGAC ACGCGCCGGA ACACGGTTAC AGCATAACAGC TTGCCGATTT
 351 GCCGCTGCTG GCGGAACGGA CGCGGATTTT TACCGTCGGC GACTTCCGCA
 401 GCCGCGACCT TCGCGCCGCG GGACAAGGCG CGCCACTCGT CCCC GCCTTT
 451 CACGAAGCCC TGTTCCGCGA CAACAGGGAA ACACGCGCGG TACTGAACAT
 501 CGGCGGGATT GCCAACATCA GCGTACTCCC CCCC GACGCA CCGGCCTTCG
 551 GCTTCGACAC AGGGCCGGGC AATATGCTGA TGGACGCGTG GACGCAGGCA
 601 CACTGGCAGC TTCTTACGA CAAAACCGT GCAAAGGCGG CACAAGGCAA
 651 CATATTGCCG CAACTGCTCG ACAGGCTGCT CGCCCACCCG TATTTGCGAC
 701 AACCCACCC TAAAAGCACG GGGCGCGAAC TGTTTGCCCT AAATTGGCTC
 751 GAAACCTACC TTGACGGCGG CGAAAACCGA TACGACGTAT TCGCGACGCT
 801 TTCCCGTTTT ACCGCGCAAA CCGTTTGC GA CCGCTCTCA CACGCAGCGG
 851 CAGATGCCCG TCAAATGTAC ATTTGCGGCG GCGGCATCCG CAATCCTGTT
 901 TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCCTGCACAG
 951 CACCGCCGAC CTGAACCTCG ATCCGCAATG GGTGGAAGCC GCCGNATTTG
 1001 CGTGGTTGGC GCGGTGTTGG ATTAATCGCA TTCCCGGTAG TCCGCACAAA
 1051 GCAACCGGCG CATCCAAACC GTGTATTCTG ANCGCGGGAT ATTATTATTG
 1101 A

20 This corresponds to the amino acid sequence <SEQ ID 1007; ORF 121-1>:

m121-1.pep
 1 METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTP YPGRRLRQLL
 51 DLQDTGADEL HRSRILSQEL SRLYAQTAAE LLCSONLAPS DITALGCHGQ
 101 TVRHAPHEGY SIQLADLPLL AERTRIFTVG DFRSRDLAAG GQGAPLVPF
 151 HEALFRDNRE TRAVLNIGGI ANISVLPPDA PAFGFDTPG NMLMDAWTQA
 201 HWQLPYDKNG AKAAQGNILP QLLDRLLAHP YFAQPHPKST GRELFALNWL
 251 ETYLDGGENR YDVLRTLSRF TAQTVCDAYS HAAADAROMY ICGGGIRNPV
 301 LMADLAECFG TRVSLHSTAD LNLDPQWVEA AXFAWLAACW INRIPGSPHK
 351 ATGASKPCIL XAGYYY*

30 m121-1/g121 ORFs 121-1 and 121-1.ng showed a 95.6% identity in 366 aa overlap

35	m121-1.pep	10	20	30	40	50	60
		METQLYIGIMSGTSMGDADAVLIRMDGGKW	LGAEGHAFTPYPGRRLRQLLDLQDTGADEL				
	g121	METQLYIGIMSGTSMGDADAVLVRMDGGKW	LGAEGHAFTPYPDRRLRKLDDLQDTGTDDEL				
		10	20	30	40	50	60
40	m121-1.pep	70	80	90	100	110	120
		HRSRILSQELSRLYAQTAAELLCSONLAPSDITALGCHGQTVRHAPHEGYSIQLADLPLL					
	g121	HRSRMLSQELSRLYAQTAAELLCSONLAPCDITALGCHGQTVRHAPHEGYSIQLADLPLL					
		70	80	90	100	110	120
45	m121-1.pep	130	140	150	160	170	180
		AERTRIFTVGDFRSRDLAAGGQAPLVPFHEALFRDNRETRAVLNIGGIANISVLPPDA					
	g121	AELTRIFTVGDFRSRDLAAGGQAPLVPFHEALFRDDRETRVVLNIGGIANISVLPPGA					
50		130	140	150	160	170	180
55	m121-1.pep	190	200	210	220	230	240
		PAFGFDTPGPNMLMDAWTQAHWQLPYDKNGAKAAQGNILPQLLDRLLAHPYFAQPHPKST					
	g121	PAFGFDTPGPNMLMDAWTQAHWQLPYDKNGAKAAQGNILPQLLGRLLAHPYFQSQPHPKST					
		190	200	210	220	230	240
60	m121-1.pep	250	260	270	280	290	300
		GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVCDAYS HAAADAROMYICGGGIRNPV					
	g121	GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVWDAYS HAAADAROMYICGGGIRNPV					
		250	260	270	280	290	300

- 90 -

```

                    310      320      330      340      350      360
m121-1.pep  LMADLAECFGTRVSLHSTADLNLDPQWVEAAFXFAWLAACWINRIPGSPHKATGASKPCIL
5          g121  LMADLAECFGTRVSLHSTAE LNLDPQWVEAAAFWLAACWINRIPGSPHKATGASKPCIL
                    310      320      330      340      350      360

m121-1.pep  XAGYYYYX
10          g121  GAGYYYYX

```

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1008>:

```

a121-1.seq
15      1  ATGGAAACAC AGCTTTACAT CGGCATCATG TCGGGAACCA GCATGGACGG
      51  GGCGGATGCC GTACTGATAC GGAITGGACGG CGGCAAATGG CTGGGCGCGG
     101  AAGGGCACGC CTTTACCCCC TACCCCGGCA GGTTACGCCG CAAATTGCTG
     151  GATTTGCAGG ACACAGGCGC GGACGAACTG CACCGCAGCA GGATGTTGTC
     201  GCAAGAACTC AGCCGCCTGT ACGCGCAAAC CGCCGCGGAA CTGCTGTGCA
20      251  GTCAAAACCT CGCGCCGTCC GACATTACCG CCCTCGGCTG CCACGGGCAA
     301  ACCGTCAGAC ACGCGCCGGA ACACAGTTAC AGCGTACAGC TTGCCGATTT
     351  GCCGCTGCTG GCGGAACGGA CTCAGATTTT TACCGTCGGC GACTTCCGCA
     401  GCCGCGACCT TGCGCCCGGC GGACAAGGCG CGCCGCTCGT CCCCGCCTTT
     451  CACGAAGCCC TGTTCGCGCA CGACAGGGAA ACACGCGCGG TACTGAACAT
25      501  CGGCGGGATT GCCAACATCA GCGTACTCCC CCCCAGCGCA CCGCCTTCG
     551  GCTTCGACAC AGGACCGGGC AATATGCTGA TGGACGCGTG GATGCAGGCA
     601  CACTGGCAGC TTCCTTACGA CAAAACGGT GCAAAGGCGG CACAAGGCAA
     651  CATATTGCCG CAACTGCTCG ACAGGCTGCT CGCCCACCCG TATTTGCGAC
     701  AACCCACCCC TAAAAGCAGC GGGCGCGAAC TGTTTGCCCT AAATTGGCTC
30      751  GAAACCTACC TTGACGGCGG CGAAAACCGA TACGACGTAT TCGCGACGCT
     801  TTCCCGATT CCGCGCAAA CCGTTTTCGA CGCCGTCTCA CACGCAGCGG
     851  CAGATGCCCG TCAAATGTAC ATTTGCGGCG GCGGCATCCG CAATCCTGT
     901  TTAATGGCGG ATTTGGCAGA ATGTTTCGGC ACACGCGTTT CCCTGCACAG
     951  CACCGCCGAA CTGAACCTCG ATCCGCAATG GGTAGAAGCC GCCGCGTTCG
35      1001  CATGGATGGC GCGGTGTTGG GTCAACCGCA TTCCCGGTAG TCCGCACAAA
     1051  GCAACGGCG CATCCAAACC GTGTATTCTG GCGCGGGAT ATTATTATTG
     1101  A

```

This corresponds to the amino acid sequence <SEQ ID 1009; ORF 121-1.a>:

```

40      a121-1.pep
      1  METQLYIGIM SGTSMGDADA VLIRMDGGKW LGAEGHAFTP YPGRLLRRKLL
      51  DLQDTGADEL HRSRMLSQEL SRLYAQTAAE LLCQNLAAPS DITALGCHGQ
     101  TVRHAPESHSY SVQLADLPLL AERTQIFTVG DFRSRDLAAG GQGAPLVPAP
     151  HEALFRDDRE TRAVLNIGGI ANISVLPPDA PAFGFDTPGP NMLMDAWMOA
45      201  HWQLPYDKNG AKAAQGNILP QLLDRLLAHP YFAQPHPKST GRELFALNWL
     251  ETYLDGGENR YDVLRTLSRF TAQTVFDAVS HAAADARQMY ICGGGIRNPV
     301  LMADLAECFG TRVSLHSTAE LNLDPQWVEA AFAWMAACW VNRIPGSPHK
     351  ATGASKPCIL GAGYYY*

```

50 **m121-1/a121-1 ORFs 121-1 and 121-1.a showed a 96.4% identity in 366 aa overlap**

```

                    10      20      30      40      50      60
m121-1.pep  METQLYIGIMSGTSMGDADAVLIRMDGGKWLGAEGHAFTPYPGRLLRRQLLDLQDTGADEL
55          a121-1  METQLYIGIMSGTSMGDADAVLIRMDGGKWLGAEGHAFTPYPGRLLRRQLLDLQDTGADEL
                    10      20      30      40      50      60

                    70      80      90      100     110     120
m121-1.pep  HRSRILSQELSRLYAQTAAELLCQNLAAPSDITALGCHGQTVRHAPENHGYSIQLADLPLL
60          a121-1  HRSRILSQELSRLYAQTAAELLCQNLAAPSDITALGCHGQTVRHAPENHGYSVQLADLPLL
                    70      80      90      100     110     120

```


- 91 -

		130	140	150	160	170	180
	m121-1.pep	AERTRIFTVGDFRSRDLAAGGQGAPLVPAFHEALFRDNRETRAVLNIGGIANISVLPDPA					
5	a121-1	: :					
		130	140	150	160	170	180
	m121-1.pep	PAFGFDTGPGNMLMDAWTQAHWQLPYDKNGAKAAQGNILPQLLDRLLAHPYFAQPHPKST					
10	a121-1						
		190	200	210	220	230	240
	m121-1.pep	PAFGFDTGPGNMLMDAWTQAHWQLPYDKNGAKAAQGNILPQLLDRLLAHPYFAQPHPKST					
	a121-1						
		190	200	210	220	230	240
	m121-1.pep	GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVCDVSHAAADARQMYICGGGIRNPV					
15	a121-1						
		250	260	270	280	290	300
	m121-1.pep	GRELFALNWLETYLDGGENRYDVLRTLSRFTAQTVCDVSHAAADARQMYICGGGIRNPV					
	a121-1						
		250	260	270	280	290	300
20	m121-1.pep	LMADLAECFGTRVSLHSTADLNLDPOWVEAAXFAWLAACWINRIPGSPHKATGASKPCIL					
	a121	: : :					
		310	320	330	340	350	360
	m121-1.pep	LMADLAECFGTRVSLHSTADLNLDPOWVEAAXFAWLAACWINRIPGSPHKATGASKPCIL					
	a121	: : :					
25		310	320	330	340	350	360
	m121-1.pep	XAGYYYYX					
30	a121	GAGYYYYX					

128 and 128-1

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1010>:

35	m128.seq (partial)	
	1	ATGACTGACA ACGCACTGCT CCATTGGGC GAAGAACCCC GTTTTGATCA
	51	AATCAAAACC GAAGACATCA AACCCGCCCT GCAAACCGCC ATCGCCGAAG
	101	CGCGCGAACA AATCGCCGCC ATCAAAGCCC AAACGCACAC CGGCTGGGCA
40	151	AACACTGTCTG AACCCTGAC CGGCATCACC GAACGCGTCG GCAGGATTGT
	201	GGGCGTGGTG TCGCACCTCA ACTGCGTCGC CGACACGCCC GAACTGCGCG
	251	CCGTCTATAA CGAACTGATG CCCGAAATCA CCGTCTTCTT CACCGAAATC
	301	GGACAAGACA TCGAGCTGTA CAACCGCTTC AAAACCATCA AAAATTCCCC
	351	CGAATTCGAC ACCCTCTCCC CCGCACAAAA AACCAAATC AACCA
45	1	TACGCCAGCG AAAAATGCG CGAAGCCAAA TACGCGTTCA GCGAAACCGA
	51	wGTCAAAAA TAyTTCCCyG TCGGCAAwGT ATTAAACGGA CTGTTCCGCC
	101	AAmTCAAAAA ACTmTACGGC ATCGGATTTA CCGAAAAAAC yGTCCCCGTC
	151	TGGCACAAG ACGTGCGCTA TtkTGAATTG CAACAAAACG GCGAAmCCAT
	201	AGGCGGCGTT TATATGGATT TGTACGCACG CGAAGGCAA CGCGGCGGCG
	251	CGTGGATGAA CGACTACAAA GGCCGCCGCC GTTTTTCAGA CGGCACGCTG
50	301	CAAyTGCCCA CCGCCTACCT CGTCTGCAAC TTCGCCCCAC CCGTCGGCGG
	351	CAGGGAAGCC CGCyTGAGCC ACGACGAAAT CCTCATCTC TTCCACGAAA
	401	CCGGACACGG GCTGCACCAC CTGCTTACCC AAGTGGACGA ACTGGGCGTA
	451	TCCGGCATCA ACGGCGTAKA ATGGGACGCG GTCGAACTGC CCAGCCAGTT
	501	TATGGAATAT TTCGTTTGGG AATACAATGT CTTGGCACAA mTGTCAGCCC
55	551	ACGAAGAAAC CGGcgTTCCC yTGCCGAAAG AACTCTTsGA CAAAwTGCTC
	601	GCCGCCAAAA ACTTCCAAsG CGGCATGTTC yTsGTCCGGC AAwTGGAGTT
	651	CGCCCTCTTT GATATGATGA TTTACAGCGA AGACGACGAA GGCCGTCTGA
	701	AAAACCTGGCA ACAGGTTTGA GACAGCGTGC GCAAAAAGT CGCCGTCTATC
	751	CAGCCGCCCC AATACAACCG CTTGCGCTTG AGCTTCGGCC ACATCTTCGC
60	801	AGGCGGCTAT TCCGAGCTn ATTACAGCTA CGCGTGGGCG GAAGTATTGA

- 92 -

851 GCGCGGACGC ATACGCCGCC TTTGAAGAAA GCGACGATGT CGCCGCCACA
 901 GGCAAACGCT TTTGGCAGGA AATCCTCGCC GTCGGGGnAT CGCGCAGCGG
 951 nGCAGAAATCC TTCAAAGCCT TCCGCGGCCG CGAACCGAGC ATAGACGCAC
 1001 TCTTGCGCCA CAGCGGTTTC GACAACGCGG TCTGA

5 This corresponds to the amino acid sequence <SEQ ID 1011; ORF 128>:

m128.pep (partial)
 1 MTDNALLHLG EEPFRDQIKT EDIKPALQTA IAEAREQIAA IKAQTHTGWA
 51 NTVEPLTGIT ERVGRIWGVV SHLNCVADTP ELRAVYNELM PEITVFFTEI
 101 GQDIELYNRF KTIKNSPEFD TLSPAQKTKL NH
 //
 1 YASEKLREAK YAFSETXVKK YFPVGXVLNG LFAQXXKKLYG IGFTEKTVPV
 51 WHKDVRYXEL QQNGEXIGGV YMDLYAREGK RGGAWMNDYK GRRRFSFGTL
 101 QLPTAYLVCN FAPPVGGREA RLSHDEILIL FHETGHGLHH LLTQVDELGV
 151 SGINGVXWDA VELPSQFMEN FVWEYNVLAQ XSAHEETGVP LPKELXDKXL
 201 AAKNFQXGMF XVRQXEFALF DMMIYSEDDE GRLKNWQQVL DSVRKKVAVI
 251 QPPEYNRFAL SFGHIFAGGY SAAXYSYAWA EVLSADAYAA FEESDDVAAT
 301 GKRFWQEILA VGXSRSGAES FKAFRGREPS IDALLRHSGF DNAV*

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1012>:

20 g128.seq
 1 atgattgaca acgCActgct ccacttgggc gaagaaccCC GTTTTaatca
 51 aatccaaacc gaagACAtca AACCCGCCGT CCAAACCGCC ATCGCCGAAG
 101 CGCGCGGACA AATCGCCGCC GTCAAAGCGC AAACGCACAC CGGCTGGGCG
 25 151 AACACCGTCG AGCGTCTGAC CGGCATCACC GAACGCGTCG GCAGGATTG
 201 GGGCGTCGTG TCCCATCTCA ACTCCGTCGT CGACACGCCG GAACTGCCG
 251 CCGTCTATAA CGAACTGATG CCTGAAATCA CCGTCTTCTT CACCGAAATC
 301 GGACAAGACA TCGAACTGTA CAACCGCTTC AAAACCATCA AAAATTCCCC
 351 CGAATTGCA ACCTTTTCCC CCGCACAAAA AACCAAGCTC GATCACGACC
 401 TGCGCGATT TCGATTGAGC GCGCGGGAAC TGCCGCCCGA ACGGCAGGCA
 30 451 GAACCTGGCAA AACTGCAAAAC CGAAGGCGCG CAACCTTCCG CCAAATTCTC
 501 CCAAAACGTC CTAGACGCGA CCGACGCGTT CGGCATTAC TTTGACGATG
 551 CCGCACCGCT TGCCGGCATT CCGGAAGACG CGCTCGCCAT GTTTGCCGCC
 601 GCCGCGCAAA GCGAAGGCAA AACAGGTTAC AAAATCGGCT TGCAGATTCC
 651 GCACTACCTT GCGGTTATCC AATACGCCGG CAACCGCGAA CTGCGCGAAC
 35 701 AAATCTACCG CGCTACGTT ACCCGTGCCA GCGAACTTTC AAACGACGGC
 751 AAATTCGACA ACACCGCCAA CATCGACCGC ACGCTCGAAA ACGCATTGAA
 801 AACCgcaaa cTGCTCGGCT TTAAAAATTA CGCCGAATTG TCGTGGCAA
 851 CCAAAATGGC GGACACGCCG GAACAGGTTT TAAACTTCCT GCACGACCTC
 901 GCCCGCCGCG CCAAACCTTA CGCCGAAAAA GACCTCGCCG AAGTCAAAGC
 40 951 CTTCGCCCGC GAACACCTCG GTCTCGCCGA CCCGACGCCG TGGGACTTGA
 1001 GCTACGCCGG CGAAAACTG CGCGAAGCCA AATACGCATT CAGCGAAACC
 1051 GAAGTCAAAA AATACTTCCC CGTCGGCAAA GTTCTGGCAG GCCTGTTCCG
 1101 CCAAATCAAA AAACCTTACG GCATCGGATT CGCCGAAAAA ACCGTTCCCC
 1151 TCTGGCAGAA AGACGTGCGC TATTTTGAAT TGCAACAAAA CGGCAAAACC
 45 1201 ATCGGCGGCG TTTATATGGA TTTGTACGCA CGCGAAGGCA AACCGCGCGG
 1251 CGCGTGGATG AACGACTaca AAGGCCGCCG CCGCTTTGCC GACGgcacGC
 1301 TGCAACTGCC CACCGCCTAC CTCGTCTGCA ACTTCGCCCC GCCCGTCGGC
 1351 GGCAAAGAAG CGCGTTTAAG CCACGACGAA ATCCTCACCC TCTTCCACGA
 1401 AacCGGCCAC GGACTGCACC ACCTGCTTAC CCAAGTGGAC GAACTGGGCG
 50 1451 TGTCCGGCAT CAACggcgta GAATGGGACG CGGTGGAAT GCCAGCCAG
 1501 TTTATGAAAA ACTTCGTTTG GGAATACAAT GTATTGGCAC AAATGTCCGC
 1551 CCACGAAGAA AccgGCGAGC CCCTGCCGAA AGAACTCTTC GACAAAATGC
 1601 TcgCGCCAA AAACCTTCCAG CGCGGTATGT TCCTCGTCCG GCAAATGGAG
 1651 TTCGCCCTCT TCATATGAT GATTACAGT GAAAGCGACG AATGCCGTCT
 55 1701 GAAAAACTGG CAGCAGGTTT TAGACAGCGT GCGCAAAGAA GTcGCCGTCA
 1751 TCCAACCGCC CGAATACAAC CGCTTCGCCA ACAGCTTCGG CCacatctTC
 1801 CcgcgCGGCT ATTCGCGAGG CTATTACAGC TACGCATGGG CCGAAGTCTC
 1851 cAGCACCGAT GCCTACGCCG CCTTTGAAGA AAGcGACGac gtcGCCGCCA

- 93 -

1901 CAGGCAAACG CTTCTGGCAA GAAAtccttg ccgtcggcgg ctCCCGCAGC
 1951 gcgCGGGAAT CCTTCAAAGC CTTCCGCGGA CGCGAACCGA GCATAGACGC
 2001 ACTGCTGCGC CAaagcggT TCGACAACGC gGcttgA

5 This corresponds to the amino acid sequence <SEQ ID 1013; ORF 128.ng>:

g128.pep
 1 MIDNALLHLG EEPFRNQIQT EDIKPAVQTA IAEARGQIAA VKAQHTTGWA
 51 NTVERTLTGIT ERVGRIWGVV SHLNSVVDTP ELRAVYNELM PEITVFFTEI
 101 QODIELYNRF KTIKNSPEFA TLSPAQKTKL DHDLRDFVLS GAELPPERQA
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA
 201 AAQSEKGTGY KIGLQIPHYL AVIQYAGNRE LREQIYRAYV TRASELSNDG
 251 KFDNTANIDR TLENALKTAK LLGFKNYAEI SLATKMADTP EQVLNFLHDL
 301 ARRAKPYAEK DLAEVKAFAR EHLGLADPQP WDSYAGEKL REAKYAFSET
 351 EVKKYFPVGK VLAGLFAQIK KLYGIGFAEK TVPVVHKDVR YFELQQNGKT
 15 401 IGGVYMDLYA REGKRGGAWM NDYKGRRRFA DGTQLQPTAY LVCNFAPPVG
 451 GKEARLSHDE ILTLFHETGH GLHLLLTQVD ELGVSGINGV EWDDELPSQ
 501 FMENFVWEYN VLAQMSAHEE TGEPLPKELF DKMLAAKNFQ RGMFLVRQME
 551 FALFDMMIYS ESDECRLKNW QQVLDVRKE VAVIQPPEYN RFANSFGHIF
 601 AGGYSAGYYS YAWAEVLSTD AYAAFEESDD VAATGKRWFQ EILAVGGSRS
 20 651 AAESFKAERG REPSIDALLR QSGFDNAA*

ORF 128 shows 91.7% identity over a 475 aa overlap with a predicted ORF (ORF 128.ng)
 from *N. gonorrhoeae*:

25 m128/g128

g128.pep	10	20	30	40	50	60
	MIDNALLHLGEEPRFNQIQTEDIKPAVQTAIAEARGQIAAVKAQHTTGWANTVERLTGIT					
30 m128	MTDNALLHLGEEPRFDQIKTEDIKPAVQTAIAEAREQIAAIKAQHTTGWANTVEPLTGIT					
	10	20	30	40	50	60
g128.pep	70	80	90	100	110	120
	ERVGRIWGVVSHLNSVVDTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFA					
35 m128	ERVGRIWGVVSHLNCVADTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD					
	70	80	90	100	110	120
g128.pep	130	140	150	160	170	180
	TLSPAQKTKLDHDLRDFVLSGAELPPERQAEELAKLQTEGAQLSAKFSQNVLDATDAFGIY					
40 m128	TLSPAQKTKLNH					
	130					
45	//					
g128.pep	340	350	360			
	YAGEKLREAKYAFSETEVKKYFPVGKVLG					
m128	YASEKLREAKYAFSETXVKYFPVGXVLNG					
	10	20	30			
50	370	380	390	400	410	420
g128.pep	LFAQIKKLYGIGFAEKTVPVWHKDVRYPFELQQNGKTIGGVYMDLYAREGKRGGAWMNDYK					
m128	LFAQKKKLYGIGFTEKTVPVWHKDVRYPFELQQNGEXIGGVYMDLYAREGKRGGAWMNDYK					
55	40	50	60	70	80	90
g128.pep	430	440	450	460	470	480
	GRRRFADGTLQPTAYLVCNFAPPVGGKEARLSHDEILTLFHETGHGLHLLLTQVDELGV					

- 94 -

5

10

15

20

25

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1014>:

30

35

40

45

50

55

60

- 95 -

1551 CCACGAAGAA ACCGGCGTTC CCCTGCCGAA AGAACTCTTC GACAAAATGC
 1601 TCGCCGCCAA AACTTTCCAA CGCGGAATGT TCCTCGTCCG CCAAATGGAG
 1651 TTCGCCCTCT TTGATATGAT GATTACAGC GAAGACGACG AAGGCCGTCT
 1701 GAAAACTGG CAACAGGTTT TAGACAGCGT GCGCAAAGAA GTCGCCGTCT
 5 1751 TCCGACCGCC CGAATACAAC CGCTTCGCCA ACAGCTTCGG CCACATCTTC
 1801 GCAGGCGGCT ATTCGCGAGG CTATTACAGC TACGCGTGGG CGGAAGTATT
 1851 GAGCGCGGAC GCATACGCCG CCTTTGAAGA AAGCGACGAT GTCGCCGCCA
 1901 CAGGCAAACG CTTTGGCAG GAAATCCTCG CCGTCGGCGG ATCGCGCAGC
 1951 GCGGCAGAA CTTCAAAGC CTTCCGCGGA CGCGAACCGA GCATAGACGC
 10 2001 ACTCTTGCGC CACAGCGGCT TCGACAACGC GGCTTGA

This corresponds to the amino acid sequence <SEQ ID 1015; ORF 128.a>:

a128.pep
 1 MTDNALLHLG EEPRFDQIKT EDIKPALQTA IAEAREQIAA IKAQTHTGWA
 15 51 NTVEPLTGIT ERVGRIWGVV SHLNSVTDTP ELRAAYNEIM PEITVFFTEI
 101 GQDIELYNRF KTIKNSPEFD TLSHAQKTKL NHDLRDFVLS GAELPPEQQA
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA
 201 AAQSEGKTTY KIGLQIPHYL AVIQYADNRK LREQIYRAYV TRASELSDDG
 251 KFDNTANIDR TLENALQTAK LLGFKNYAEL SLATKMADTP EQVLNLFHDL
 20 301 ARRAKPYAEK DLAEVKAFAR ESLGLADLQP WDLGYAGEKL REAKYAFSET
 351 EVKKYFPVGK VLNGLFAQIK KLYGIGFTEK TVPVWHKDVR YFELQONGET
 401 IGGVYMDLYA REGKRGGAWM NDYKGRRRFS DGTLLQLPTAY LVCNFTPPVG
 451 GKEARLSHDE ILLTFHETGH GLHHLTQVD ELGVSGINGV EWDAVEPLSQ
 501 FMENFVWEYN VLAQMSAHEE TGVPLPKELF DKMLAAKNFQ RGMFLVRQME
 25 551 FALFDMMIYS EDDEGRLENW QQVLDSVRKE VAVVRPPEYN RFANSFGHIF
 601 AGGYSAGYYS YAWAEVLSAD AYAAFEESDD VAATGKRWFQ EILAVGGSRS
 651 AAESFKAFRG REPSIDALLR HSGFDNAA*

m128/a128 ORFs 128 and 128.a showed a 66.0% identity in 677 aa overlap

30 10 20 30 40 50 60
 m128.pep MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAA IKAQTHTGWANTVEPLTGIT
 a128 MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAA IKAQTHTGWANTVEPLTGIT
 35 10 20 30 40 50 60
 m128.pep ERVGRIWGVVSHLNCVADTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD
 a128 ERVGRIWGVVSHLNSVTDTPELRAAYNEIMPEITVFFTEIGQDIELYNRFKTIKNSPEFD
 40 70 80 90 100 110 120
 m128.pep TLSPAQKTKLNH-----
 a128 TLSHAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY
 45 130 140 150 160 170 180
 m128.pep -----
 a128 FDDAAPLAGIPEDALAMFAAAAQSEGKTYKIGLQIPHYLAVIQYADNRKLREQIYRAYV
 50 190 200 210 220 230 240
 m128.pep -----
 a128 TRASELSDDGKFDNTANIDRTLENALQTAKLLGFKNYAELSLATKMADTPEQVLNLFHDL
 55 250 260 270 280 290 300
 m128.pep -----YASEKLREAKYAFSETXVKKYFPVGX
 60 ||:||||||||| |||||

- 96 -

		a128	ARRAKPYAEKDLAEVKAFARESLGLADLQPWDLGYAGEKLREAKYAFSETEVKKYFPVVGK
			310 320 330 340 350 360
5	m128.pep	160 170 180 190 200 210	VLNGLFAQXKKLYGIGFTEKTVPVVHKDVRYXELQQNGEXIGGVYMDLYAREGKRGGAWM
	a128		VLNGLFAQIKKLYGIGFTEKTVPVVHKDVRYFELQQNGETIGGVYMDLYAREGKRGGAWM
			370 380 390 400 410 420
10	m128.pep	220 230 240 250 260 270	NDYKGRRRFS DGT LQLPTAYLVCNFAPPVGGREARLSHDEILILFHETGHGLHLLTQVD
	a128		NDYKGRRRFS DGT LQLPTAYLVCNFTPPVGGKEARLSHDEILTLEHETGHGLHLLTQVD
			430 440 450 460 470 480
15	m128.pep	280 290 300 310 320 330	ELGVSGINGVXWD AVELPSQFMENFVWEYNVLAQXSAHEETGVPLPKELXDKXLAAKNFQ
	a128		ELGVSGINGVEWD AVELPSQFMENFVWEYNVLAQMSAHEETGVPLPKELFDKMLAAKNFQ
			490 500 510 520 530 540
20	m128.pep	340 350 360 370 380 390	XGMFXVRQXEFALFDMMIYSEDDEGR LKNWQQV LDSVRKKVAVIQPPEYNRFALSFGHIF
	a128		RGMFLVRQMEFALFDMMIYSEDDEGR LKNWQQV LDSVRKEVAVVRPPEYNRFANSFGHIF
			550 560 570 580 590 600
25	m128.pep	400 410 420 430 440 450	AGGYSAA XYSYAWAEVLSADAYAAFEESDDVAATGKRFWQEILAVGXSRSGAESFKA FRG
	a128		AGGYSAGYYSYAWAEVLSADAYAAFEESDDVAATGKRFWQEILAVGGSRSAAESFKA FRG
			610 620 630 640 650 660
30	m128.pep	460 470	REPSIDALLRHSGFDNAVX
	a128		REPSIDALLRHSGFDNAAX
			670

Further work revealed the DNA sequence identified in *N. meningitidis* <SEQ ID 1016>:

		m128-1.seq					
45	1	ATGACTGACA	ACGCACTGCT	CCATTGGGC	GAAGAACCCC	GT'TT'GATCA	
	51	AATCAAAACC	GAAGACATCA	AACCCGCCCT	GCAAACCGCC	ATCGCCGAAG	
	101	CGCGCGAACA	AATCGCCGCC	ATCAAAGCCC	AAACGCACAC	CGGCTGGGCA	
	151	AACACTGTCTG	AACCCCTGAC	CGGCATCACC	GAACGCGTCG	GCAGGATTTG	
	201	GGGCGTGGTG	TCGCACCTCA	ACTCCGTCGC	CGACACGCCC	GAAGTGGCGG	
	251	CCGTCTATAA	CGAACTGATG	CCCGAAATCA	CCGTCTTCTT	CACCGAAATC	
50	301	GGACAAGACA	TCGAGCTGTA	CAACCGCTTC	AAAACCATCA	AAAATTCCCC	
	351	CGAATTCGAC	ACCTCTCTCC	CCGCACAAAA	AACCAAACTC	AACCACGATC	
	401	TGCGCGATT	CGTCTCAGC	GGCGCGGAAC	TGCCGCCCGA	ACAGCAGGCA	
	451	GAAGTGGCAA	AACTGCAAAC	CGAAGGCGCG	CAACTTTCCG	CCAAATTCTC	
	501	CCAAAACGTC	CTAGACGCGA	CCGACGCGTT	CGGCATTTAC	TTTGACGATG	
	551	CCGCACCGCT	TGCCCGCAT	CCCAGAGACG	CGCTCGCCAT	GT'TTGCCGCC	
55	601	CCGCGCAAAA	GCGAAAGCAA	AACAGGCTAC	AAAATCGGCT	TGCAGATTCC	
	651	ACACTACCTC	GCCGTCATCC	AATACGCCGA	CAACCGCGAA	CTGCGCGAAC	
	701	AAATCTACCG	CGCTACGTT	ACCCGCGCCA	GCGAACTTTC	AGACGACGGC	
	751	AAATTCGACA	ACACCGCCAA	CATCGACCGC	ACGCTCGCAA	ACGCCTTGCA	
60	801	AACCGCCAAA	CTGCTCGGCT	TCAAAACTA	CGCCGAATTG	TCGCTGGCAA	
	851	CCAAAATGGC	GGACACGCC	GAACAAGTTT	TAAACTTCCT	GCACGACCTC	

- 97 -

5
10
15
20

```

901  GCCCGCCGCG  CCAAACCTTA  CGCCGAAAAA  GACCTCGCCG  AAGTCAAAGC
951  CTTGCCCCGC  GAAAGCCTGA  ACCTCGCCGA  TTTGCAACCG  TGGGACTTGG
1001 GCTACGCCAG  CGAAAACTG  CGCGAAGCCA  AATACGCGTT  CAGCGAAACC
1051 GAAGTCAAAA  AATACTTCCC  CGTCGGCAAA  GTATTAAACG  GACTGTTCGC
1101 CCAAATCAAA  AAACCTCTACG  GCATCGGATT  TACCGAAAAA  ACCGTCCCCG
1151 TCTGGCACAA  AGACGTGCGC  TATTTTGAAT  TGCAACAAAA  CGGCGAAACC
1201 ATAGGCGGCG  TTTATATGGA  TTTGTACGCA  CGCGAAGGCA  AACGCGGCGG
1251 CGCGTGGATG  AACGACTACA  AAGGCCGCGC  CCGTTTTTCA  GACGGCACGC
1301 TGCAACTGCC  CACCGCCTAC  CTCGTCTGCA  ACTTCGCCCC  ACCGTGCGGC
1351 GGCAGGGAAG  CCCGCTGAG  CCACGACGAA  ATCCTCATCC  TCTTCCACGA
1401 AACCGGACAC  GGGCTGCACC  ACCTGCTTAC  CCAAGTGGAC  GAACTGGGCG
1451 TATCCGGCAT  CAACGGCGTA  GAATGGGACG  CGGTCGAACT  GCCAGCCAG
1501 TTTATGGAAG  ATTCGTTTG  GGAATACAAT  GTCTTGGCAC  AAATGTCAGC
1551 CCACGAAGAA  ACCGCGGTT  CCCTGCCGAA  AGAACTCTTC  GACAAAATGC
1601 TCGCCGCCAA  AAACCTCCAA  CGCGGCATGT  TCCTCGTCCG  GCAAATGGAG
1651 TTCGCCCTCT  TTGATATGAT  GATTTACAGC  GAAGACGACG  AAGGCCGTCT
1701 GAAAAACTGG  CAACAGGTTT  TAGACAGCGT  GCGCAAAAAA  GTCGCCGTCA
1751 TCCAGCCGCC  CGAATACAAC  CGCTTCGCCT  TGAGCTTCGG  CCACATCTTC
1801 GCAGGCGGCT  ATTCGCGAGG  CTATTACAGC  TACGCGTGGG  CGGAAGTATT
1851 GAGCGCGGAC  GCATACGCCG  CCTTTGAAGA  AAGCGACGAT  GTCGCCGCCA
1901 CAGGCAAAACG  CTTTGGCAG  GAAATCCTCG  CCGTCGGCGG  ATCGCGCAGC
1951 GCGGCAGAAT  CCTTCAAAGC  CTTCCGCGGC  CGCGAACCGA  GCATAGACGC
2001 ACTCTTGCGC  CACAGCGGTT  TCGACAACGC  GGTCTGA

```

25 This corresponds to the amino acid sequence <SEQ ID 1017; ORF 128-1>:

m128-1.pep.

```

1  MTDNALLHLG  EEPREFDIKT  EDIKPALQTA  IAEAREQIAA  IKAQHTTGWA
51  NTVPLTGTIT  ERVGRIWGVV  SHLNSVADTP  ELRAVYNELM  PEITVFFTEI
101  GDIELYNRF  KTIKNSPEFD  TLSPAQKTKL  NHDLRDFVLS  GAELPPEQQA
151  ELAKLQTEGA  QLSAKFSQNV  LDATDAFGIY  FDAAAPLAGI  PEDALAMFAA
201  AAQSESKTGY  KIGLQIPHYL  AVIQYADNRE  LREQIYRAYV  TRASELSDDG
251  KFDNTANIDR  TLANALQTAK  LLGFKNYAEL  SLATKMADTP  EQVLNFLHDL
301  ARRAKPYAEK  DLAEVKAFAR  ESLNLADLQP  WDLGYASEKL  REAKYAFSET
351  EVKKYFPVGK  VLNLFAQIK  KLYGIGFTEK  TVPVVHKDVR  YFELQONGET
401  IGGVYMDLYA  REGKRGGAWM  NDYKGRRRFS  DGTLLQLPTAY  LVCNFAPPVG
451  GREARLSHDE  ILILFHETGH  GLHHLLTOVD  ELGVSGINGV  EWDAVELPSQ
501  FMENFVWEYN  VLAQMSAHEE  TGVPLPKELF  DKMLAAKNFQ  RGMFLVRQME
551  FALFDMMIYS  EDDEGRLLKNW  QQVLDVSRKK  VAVIQPPEYN  RFALSFQGHIF
601  AGGYSAGYYS  YAWAEVLSAD  AYAAFEESDD  VAATGKRFWQ  EILAVGGSRS
651  AAESFKAFRG  REPSIDALLR  HSGFDNAV*

```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1018>:

g128-1.seq (partial)

```

1  ATGATTGACA  ACGCACTGCT  CCACTTGGGC  GAAGAACCCC  GTTTTAATCA
45  51  AATCAAAACC  GAAGACATCA  AATCCGCGGT  CCAAACCGCC  ATCGCCGAAG
101  CGCGCGGACA  AATCGCCGCC  GTCAAAGCGC  AAACGCACAC  CGGCTGGGCG
151  AACACCGTCG  AGCGTCTGAC  CGGCATCACC  GAACGCGTCG  GCAGGATTTG
201  GGGCGTCGTG  TCCCATCTCA  ACTCCGTCGT  CGACACGCCC  GAACTGCGCG
251  CCGTCTATAA  CGAACTGATG  CCTGAAATCA  CCGTCTTCTT  CACCGAAATC
50  301  GGACAAGACA  TCGAACTGTA  CAACCGCTTC  AAAACCATCA  AAAATTCCCC
351  CGAATTTGCA  ACGCTTTCCC  CCGCACAAAA  AACCAAGCTC  GATCACGACC
401  TGC CGCATTT  CGTATTGAGC  GGC GCGGAAC  TGCCGCCCGA  ACGGCAGGCA
451  GAACTGGCAA  AACTGCAAAC  CGAAGGCGCG  CAACTTTCCG  CCAAATTCTC
501  CCAAAACGTC  CTAGACGCGA  CCGACGCGTT  CGGCATTTAC  TTTGACGATG
55  551  CCGCACCGCT  TGCCGGCATT  CCCGAAGACG  CGCTCGCCAT  GTTTGCCGCC
601  GCCGCGCAAA  GCGAAGGCAA  AACAGGTTAC  AAAATCGGCT  TGCAGATTCC
651  GCACTACCTT  GCCGTTATCC  AATACGCCGG  CAACCGCGAA  CTGCGCGAAC
701  AAATCTACCG  CGCCTACGTT  ACCCGTGCCA  GCGAACTTTC  AAACGACGGC
751  AAATTCGACA  ACACGCGCAA  CATCGACCGC  ACGCTCGAAA  ACGCATTGAA
60  801  AACCGCCAAA  CTGCTCGGCT  TTAATAATTA  CGCCGAATTG  TCGCTGGCAA
851  CCAAAATGGC  GGACACGCCC  GAACAGGTTT  TAAACTTCCT  GCACGACCTC
901  GCCCGCCGCG  CCAAACCTTA  CGCCGAAAAA  GACCTCGCCG  AAGTCAAAGC

```

- 98 -

5 951 CTTTCGCCCGC GAACACCTCG GTCTCGCCGA CCCGCAGCCG TGGGACTTGA
 1001 GCTACGCCGG CGAAAACTG CGCGAAGCCA AATACGCATT CAGCGAAACC
 1051 GAAGTCAAAA AATACTTCCC CGTCGGCAAA GTTCTGGCAG GCCTGTTCCG
 1101 CCAAATCAAA AACTCTACG GCATCGGATT CGCCGAAAAA ACCGTTCCCG
 1151 TCTGGCACAA AGACGTGCGC TATTTTGAAT TGCAACAAAA CGGCAAAACC
 1201 ATCGGCGGCG TTTATATGGA TTTGTACGCA CGCGAAGGCA AACGCGGCGG
 1251 CGCGTGGATG AACGACTACA AAGGCCGCCG CCGCTTTGCC GACGGCACGC
 1301 TGCAACTGCC CACCGCCTAC CTCGTCTGCA ACTTCGCCCC GCCCGTCGGC
 1351 GGCAAAGAAG CGCGTTTAAAG CCACGACGAA ATCCTCACCC TCTTCCACGA
 10 1401 AACC GGCCAC GGACTGCACC ACCTGCTTAC CCAAGTGGAC GAACTGGGCG
 1451 TGTCCGCGCAT CAACGGCGTA AAA

This corresponds to the amino acid sequence <SEQ ID 1019; ORF 128-1.ng>:

15 g128-1.pep (partial)
 1 MIDNALLHLG EEPFRNQIKT EDIKPAVQTA IAEARGQIAA VKAQHTHTGWA
 51 NTVERLTGIT ERVGRIVGVV SHLNSVVDTP ELRAVYNELM PEITVFFTEI
 101 GQDIELYNRF KTIKNSPEFA TLSPAQKTKL DHDLRDFVLS GAELPPERQA
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA
 201 AAQSEGKTYG KIGLQIPHYL AVIQYAGNRE LREQIYRAYV TRASELSNDG
 20 251 KFDNTANIDR TLENALKTAK LLGFKNYAEI SLATKMADTP EQVLNFLHDL
 301 ARRAKPYAEK DLAEVKAFAR EHLGLADPQP WDSLAGEKL REAKYAFSET
 351 EVKKYFPVGK VLAGLFAQIK KLYGIGFAEK TYPVWHKDVR YFELQQNGKT
 401 IGGVYMDLYA RECKRGGAWM NDYKGRRRFA DGTQLQLEPTAY LVCNFAPPVG
 25 451 GKEARLSHDE ILTLFHETGH GLHLLTQVD ELGVSGINGV K

m128-1/g128-1 ORFs 128-1 and 128-1.ng showed a 94.5% identity in 491 aa overlap

30 g128-1.pep 10 20 30 40 50 60
 MIDNALLHLGEEPRFNQIKTEDIKPAVQTAIAEARGQIAAVKAQHTHTGWANTVERLTGIT
 m128-1 MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIIKAQHTHTGWANTVEPLTGIT
 35 10 20 30 40 50 60
 g128-1.pep 70 80 90 100 110 120
 ERVGRIVGVVSHLNSVVDTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFA
 m128-1 ERVGRIVGVVSHLNSVADTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD
 40 70 80 90 100 110 120
 g128-1.pep 130 140 150 160 170 180
 TLSPAQKTKLDHDLRDFVLSGAELPPERQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY
 45 m128-1 TLSPAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY
 130 140 150 160 170 180
 g128-1.pep 190 200 210 220 230 240
 FDDAAPLAGIPEDALAMFAAAAQSEGKTYGKIGLQIPHYLAVIQYAGNRELREQIYRAYV
 50 m128-1 FDDAAPLAGIPEDALAMFAAAAQSESKTYGKIGLQIPHYLAVIQYADNRELREQIYRAYV
 190 200 210 220 230 240
 g128-1.pep 250 260 270 280 290 300
 TRASELSNDGKFDNTANIDRTLENALKTAKLLGFKNYAEISLATKMADTPEQVLNFLHDL
 55 m128-1 TRASELSDDGKFDNTANIDRTLANALQTAKLLGFKNYAEISLATKMADTPEQVLNFLHDL
 250 260 270 280 290 300
 g128-1.pep 310 320 330 340 350 360
 ARRAKPYAEKDLAEVKAFAREHLGLADPQPWDSLAGEKLREAKYAFSETEVKKYFPVGK
 60 m128-1 ARRAKPYAEKDLAEVKAFAREHLGLADPQPWDSLAGEKLREAKYAFSETEVKKYFPVGK

- 99 -

m128-1		ARRAKPYAEKDIAEVKAFARESLNLADLPWDLGYASEKLREAKYAFSETEVKKYFPVVGK
		310 320 330 340 350 360
5	g128-1.pep	VLAGLFAQIKKLYGIGFAEKTVPVWHKDVRYFELQQNGKTIGGVYMDLYAREGKRGGAWM
	m128-1	VLNGLFAQIKKLYGIGFTEKTVPVWHKDVRYFELQQNGETIGGVYMDLYAREGKRGGAWM
		370 380 390 400 410 420
10	g128-1.pep	NDYKGRRRFADGTLQLPTAYLVCNFAPPVGGKEARLSHDEILTLFHETGHLHLLTQVD
	m128-1	NDYKGRRRFSDGTLQLPTAYLVCNFAPPVGGREARLSHDEILILFHETGHLHLLTQVD
		430 440 450 460 470 480
15	g128-1.pep	ELGVSGINGVK
	m128-1	ELGVSGINGVEWDAVELPSQFMENFVWEYNVLAQMSAHEETGVPLPKELFDKMLAANKFQ
		490 500 510 520 530 540

The following DNA sequence was identified in *N. meningitidis* <SEQ ID 1020>:

a128-1.seq	
25	1 ATGACTGACA ACGCACTGCT CCATTGGGC GAAGAACCCC GTTTTGATCA
	51 AATCAAAACC GAAGACATCA AACCCGCCCT GCAAACCGCC ATTGCCGAAG
30	101 CGCGCGAACA AATCGCCGCC ATCAAAGCCC AAACGCACAC CGGCTGGGCA
	151 AACACTGTGC AACCCCTGAC CGGCATCACC GAACGCGTCG GCAGGATTTG
35	201 GGGCGTGGTG TCGCACCTCA ACTCCGTCAC CGACACGCCC GAACTGCGCG
	251 CCGCCTACAA TGAATTAATG CCCGAAATTA CCGTCTTCTT CACCGAAATC
40	301 GGACAAGACA TCGAGCTGTA CAACCGCTTC AAAACCATCA AAAACTCCCC
	351 CGAGTTCGAC ACCCTCTCCC ACGCGCAAAA AACCAAATC AACACGATC
45	401 TCGCGGATTT CGTCCTCAGC GGCGCGGAAC TGCCGCGCGA ACAGCAGGCA
	451 GAATTGGCAA AACTGCAAAC CGAAGGCGCG CAACTTTCCG CCAAATTTCTC
50	501 CCAAACGTC CTAGACGCGA CCGACGCGTT CGGCATTAC TTTGACGATG
	551 CCGCACCGCT TGCCGGCATT CCCGAAGACG CGCTCGCCAT GTTTGCCGCT
55	601 GCCGCGCAAA GCGAAGGCAA AACAGGCTAC AAAATCGGTT TGCAGATTCC
	651 GCACTACCTC GCCGTCAATC AATACGCCGA CAACCGCAAA CTGCGCGAAC
60	701 AAATCTACCG CGCTACGTT ACCCGCGCCA GCGAGCTTTC AGACGACGGC
	751 AAATTCGACA ACACCGCCAA CATCGACCGC ACGCTCGAAA ACGCCCTGCA
65	801 AACC GCCCAA CTGCTCGGCT TCAAAACTA CGCCGAATTG TCGCTGGCAA
	851 CCAAATGGC GGACACCCCC GAACAAGTTT TAAACTTCCT GCACGACCTC
70	901 CCGCGCCGCG CCAAACCTTA CGCCGAAAAA GACCTCGCCG AAGTCAAAGC
	951 CTTCGCCCCG GAAAGCCTCG GCCTCGCCGA TTTGCAACCG TGGGACTTGG
75	1001 GCTACGCCGG CGAAAACTG CGCGAAGCCA AATACGCATT CAGCGAAACC
	1051 GAAGTCAAAA AATACTTCCC CGTCGGCAAA GTATTAAACG GACTGTTTCG
80	1101 CCAAATCAAA AAATCTACG GCATCGGATT TACCGAAAAA ACCGTCCCCG
	1151 TCTGGCACAA AGACGTGCGC TATTTTGAAT TGCAACAAAA CGGCGAAACC
85	1201 ATAGGCGGCG TTTATATGGA TTTGTACGCA CGCGAAGGCA AACGCGGCGG
	1251 CGCGTGGATG AACGACTACA AAGGCGGCCG CCGTTTTTCA GACGGCACGC
90	1301 TGCAACTGCC CACCGCCTAC CTCGTCTGCA ACTTCACCCC GCCCGTCGGC
	1351 GGCAAAGAAG CCCGCTTGAG CCATGACGAA ATCCTCACCC TCTTCCACGA
95	1401 AACC GGACAC GGCCTGCACC ACCTGCTTAC CCAAGTCGAC GAACTGGGCG
	1451 TATCCGGCAT CAACGGCGTA GAATGGGACG CAGTCGAAC TCCCACTCAG
100	1501 TTTATGGAAT ATTTGTTTTG GGAATACAAT GTCTTGCGCG AAATGTCCGC
	1551 CCACGAAGAA ACCGCGGTTT CCCTGCCGAA AGAACTCTTC GACAAAATGC
105	1601 TCGCCGCCAA AAATTTCCAA CGCGGAATGT TCCTCGTCCG CCAAATGGAG
	1651 TTCGCCCTCT TTGATATGAT GATTTACAGC GAAGACGACG AAGGCGCTCT
110	1701 GAAAACTGG CAACAGGTTT TAGACAGCGT GCGCAAAGAA GTCGCCGTCG
	1751 TCCGACCGCC CGAATACAAC CGCTTCGCCA ACAGCTTCGG CCACATCTTC
115	1801 GCAGGCGGCT ATTCCGCAGG CTATTACAGC TACGCGTGGG CGGAAGTATT
	1851 GAGCGCGGAC GCATACGCCG CCTTTGAAGA AAGCGACGAT GTCGCCGCCA
120	1901 CAGGCAAACG CTTTGGCAG GAAATCCTCG CCGTCGGCGG ATCGCGCAGC

- 100 -

1951 GCGGCAGAAAT CCTTCAAAGC CTTCCGCGGA CGCGAACCGA GCATAGACGC
 2001 ACTCTTGCGC CACAGCGGCT TCGACAACGC GGCTTGA

This corresponds to the amino acid sequence <SEQ ID 1021; ORF 128-1.a>:

5 a128-1.pep
 1 MTDNALLHLG EEPFRDQIKT EDIKPALQTA IAEAREQIAA IKAQHTGWA
 51 NTVEPLTGIT ERVGRIWGVV SHLNSVTDTP ELRAAYNELM PEITVFFTEI
 101 GQDIELYNRF KTIKNSPEFD TLSHAQKTKL NHDLRDFVLS GAELPPEQQA
 151 ELAKLQTEGA QLSAKFSQNV LDATDAFGIY FDDAAPLAGI PEDALAMFAA
 201 AAQSEGKTGY KIGLQIPHYL AVIQYADNRK LREQIYRAYV TRASELSDDG
 251 KFDNTANIDR TLENALQTAK LLGFKNYAEL SLATKMADTP EQVLNFLHDL
 301 ARRAKPYAEK DLAEVKAFAR ESLGLADLQP WDLGYAGEKL REAKYAFSET
 351 EVKKYFPVVGK VLNGLFAQIK KLYGIGFTEK TVPVVHKDVR YFELQONGET
 401 IGGVYMDLYA REGKRGGAWM NDYKGRRRFS DGTLLQLPTAY LVCNFTPPVG
 15 451 GKEARLSHDE ILLTFHETGH GLHHLLTQVD ELGVSGINGV EWDAVEPLSQ
 501 FMENFVWEYN VLAQMSAHEE TGVPLPKELF DKMLAAKNFQ RGMFLVRQME
 551 FALFDMMIYS EDDEGRKKNW QQVLDVSRKE VAVVRPPEYN RFANSFGHIF
 601 AGGYSAGYYS YAWAEVLSAD AYAAFEESDD VAATGKREWF EILAVGGSRS
 20 651 AAESFKAFRG REPSIDALLR HSGFDNAA*

m128-1/a128-1 ORFs 128-1 and 128-1.a showed a 97.8% identity in 677 aa overlap

25	a128-1.pep	10	20	30	40	50	60
		MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIIKAQHTGWTVEPLTGIT					
	m128-1	MTDNALLHLGEEPRFDQIKTEDIKPALQTAIAEAREQIAAIIKAQHTGWTVEPLTGIT					
		10	20	30	40	50	60
30	a128-1.pep	70	80	90	100	110	120
		ERVGRIWGVVSHLNSVTDTPELRAAYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD					
	m128-1	ERVGRIWGVVSHLNSVADTPELRAVYNELMPEITVFFTEIGQDIELYNRFKTIKNSPEFD					
		70	80	90	100	110	120
35	a128-1.pep	130	140	150	160	170	180
		TLSHAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY					
	m128-1	TLSPAQKTKLNHDLRDFVLSGAELPPEQQAELAKLQTEGAQLSAKFSQNVLDATDAFGIY					
		130	140	150	160	170	180
40	a128-1.pep	190	200	210	220	230	240
		FDDAAPLAGIPEDALAMFAAAAQSEGKTGYKIGLQIPHYLAVIQYADNRKLREQIYRAYV					
	m128-1	FDDAAPLAGIPEDALAMFAAAAQSESKTGYKIGLQIPHYLAVIQYADNRELREQIYRAYV					
45		190	200	210	220	230	240
50	a128-1.pep	250	260	270	280	290	300
		TRASELSDDGKFDNTANIDRTLENALQTAKLLGFKNYAELSLATKMADTPEQVLNFLHDL					
	m128-1	TRASELSDDGKFDNTANIDRTLANALQTAKLLGFKNYAELSLATKMADTPEQVLNFLHDL					
		250	260	270	280	290	300
55	a128-1.pep	310	320	330	340	350	360
		ARRAKPYAEKDLAEVKAFARESLGLADLQPWDLYAGEKLREAKYAFSETEVKKYFPVVGK					
	m128-1	ARRAKPYAEKDLAEVKAFARESLNLADLQPWDLYAGEKLREAKYAFSETEVKKYFPVVGK					
		310	320	330	340	350	360
60	a128-1.pep	370	380	390	400	410	420
		VLNGLFAQIKKLYGIGFTEKTPVPVHKDVRVYFELQONGETIGGVYMDLYAREGKRGGAWM					
	m128-1	VLNGLFAQIKKLYGIGFTEKTPVPVHKDVRVYFELQONGETIGGVYMDLYAREGKRGGAWM					

- 101 -

		370	380	390	400	410	420
		430	440	450	460	470	480
5	a128-1.pep	NDYKGRRRFSDGTLQLPTAYLVCNFTPPVGGKEARLSHDEILTLFHETGHGLHLLTQVD					
	m128-1	NDYKGRRRFSDGTLQLPTAYLVCNFAPPVGGREARLSHDEILILFHETGHGLHLLTQVD					
		430	440	450	460	470	480
10	a128-1.pep	ELGVSGINGVEWDAVELPSQFMENFVWEYNVLAQMSAHEETGVPLPKELFDKMLAAKNFQ					
	m128-1	ELGVSGINGVEWDAVELPSQFMENFVWEYNVLAQMSAHEETGVPLPKELFDKMLAAKNFQ					
		490	500	510	520	530	540
15	a128-1.pep	RGMFLVRQMEFALFDMMIYSEDDDEGRLLKNWQQVLDSSVRKEVAVVRPPEYNRFANSFGHIF					
	m128-1	RGMFLVRQMEFALFDMMIYSEDDDEGRLLKNWQQVLDSSVRKKVAVIQPEYNRFALSFGHIF					
		550	560	570	580	590	600
20	a128-1.pep	AGGYSAGYYSYAWAEVLSADAYAAFEESDDVAATGKRFWQEILAVGGSRSAAESFKAFRG					
	m128-1	AGGYSAGYYSYAWAEVLSADAYAAFEESDDVAATGKRFWQEILAVGGSRSAAESFKAFRG					
		610	620	630	640	650	660
25	a128-1.pep	REPSIDALLRHSGFDNAAX					
	m128-1	REPSIDALLRHSGFDNAVX					
		670	679				

206

35

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1022>:

	m206.seq						
	1	ATGTTTCCCC	CCGACAAAAC	CCTTTTCCTC	TGTCTCAGCG	CACTGCTCCT	
40	51	CGCCTCATGC	GGCACGACCT	CCGGCAAACA	CCGCCAACCG	AAACCCAAAC	
	101	AGACAGTCCG	GCAAATCCAA	GCCGTCCGCA	TCAGCCACAT	CGACCGCACA	
	151	CAAGGCTCGC	AGGAATCAT	GCTCCACAGC	CTCGGACTCA	TGGGCACGCC	
	201	CTACAAATGG	GGCGGCAGCA	GCACCGCAAC	CGGCTTCGAT	TGCAGCGGCA	
	251	TGATTCAATT	CGTTTACAAT	AACGCCCTCA	ACGTCAAGCT	GCCGCGCACC	
45	301	GCCCGCGACA	TGGCGGCGGC	AAGCCGSAAA	ATCCCCGAcA	GCCGCTCAA	
	351	GGCCGCGGAC	CTCGTATTCT	TCAACACCGG	CGGCGCACAC	CGCTACTCAC	
	401	ACGTCGGACT	CTACATCGGC	AACGGCGAAT	TCATCCATGC	CCCCAGCAGC	
	451	GGCAAAACCA	TCAAAACCGA	AAAACCTCTC	ACACCGTTTT	ACGCCAAAAA	
	501	CTACCTCGGC	GCACATACTT	TTTTTACAGA	ATGA		

50 This corresponds to the amino acid sequence <SEQ ID 1023; ORF 206>:

	m206.pep..						
	1	MFPPDKTLFL	CLSALLLASC	GTTSGKHRQP	KPKQTVRQIQ	AVRISHIDRT	
40	51	QGSQELMLHS	LGLIGTPYKW	GGSTATGFD	CSGMIQFVYK	NALNVKLPR	
	101	ARDMAAASRK	IPDSRXKAGD	LVFFNTGGAH	RYSHVGLYIG	NGEFIHAPSS	
55	151	GKTIKTEKLS	TPFYAKNYLG	AHTFFTE*			

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1024>:

	g206.seq						
	1	atgtttttccc	ccgacaaaac	ccttttcctc	tgtctcggcg	cactgctcct	

- 102 -

51 cgccctcatgc ggcacgacct ccggcaaaaca ccgccaaccg aaacccaaac
 101 agacagtccg gcaaattccaa gccgtccgca tcagccacat cgcccgacaca
 151 caaggctcgc aggaactcat gctccacagc ctccggactca tcggcagcgc
 201 ctacaaatgg ggccggcagca gcaccgcaac cggcttcgac tgcagcggca
 251 tgattcaatt ggtttacaaa aacgccctca acgtcaagct gccgcgcacc
 301 gcccgcgaca tggcggcggc aagccgcaaa atccccgaca gccgcctcaa
 351 ggccggcgac atcgtattct tcaacaccgg cggcgcacac cgctactcac
 401 acgtcggact ctacatcggc aacggcgaat tcattccatgc ccccggcagc
 451 ggcaaaacca tcaaaaccga aaaactctcc acaccgtttt acgcaaaaaa
 501 ctaccttgga gcgcatacgt tttttacaga atga

This corresponds to the amino acid sequence <SEQ ID 1025; ORF 206.ng>:

g206.pep
 1 MFSPDKTLFL CLGALLLASC GTTSGKHRQP KPKQTVRQIQ AVRISHIGRT
 51 QGSQELMLHS LGLIGTPYKW GGSSTATGFD CSGMIQLVYK NALNVKLPR
 101 ARDMAAASRK IPDSRLKAGD IVFFNTGGAH RYSHVGLYIG NGEFIHAPGS
 151 GKTIKTEKLS TPFYAKNYLG AHTFFTE*

20 ORF 206 shows 96.0% identity over a 177 aa overlap with a predicted ORF (ORF 206.ng) from *N. gonorrhoeae*:

m206/g206

25	m206.pep	10 20 30 40 50 60	MFPPDKTLFLCLLSALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIDRTQGSQELMLHS
	g206	10 20 30 40 50 60	MFSPDKTLFLCLGALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIGRTQGSQELMLHS
30	m206.pep	70 80 90 100 110 120	LGLIGTPYKWGGSSTATGFD CSGMIQFVYK NALNVKLPR TARDMAAASRK IPDSRXKAGD
	g206	70 80 90 100 110 120	LGLIGTPYKWGGSSTATGFD CSGMIQLVYK NALNVKLPR TARDMAAASRK IPDSRLKAGD
35	m206.pep	130 140 150 160 170	LVFFNTGGAHRYSHVGLYIGNGEFIHAPSSGKTIKTEKLSTPFYAKNYLGAHTFFTEX
40	g206	130 140 150 160 170	IVFFNTGGAHRYSHVGLYIGNGEFIHAPGSGKTIKTEKLSTPFYAKNYLGAHTFFTE

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1026>:

a206.seq
 45 1 ATGTTTCCCC CCGACAAAAC CCTTTTCCTC TGTCTCAGCG CACTGCTCCT
 51 CGCCTCATGC GGCACGACCT CCGGCAAAACA CCGCCAACCG AAACCCAAAC
 101 AGACAGTCCG GCAAATCCAA GCCGTCCGCA TCAGCCACAT CGACCGCACA
 151 CAAGGCTCGC AGGAATCAT GCTCCACAGC CTCGGACTCA TCGGCACGCC
 201 CTACAAATGG GGCCGGCAGCA GCACCGCAAC CCGCTTCGAT TGCAGCGGCA
 50 251 TGATTCAATT CGTTTACAAA AACGCCCTCA ACGTCAAGCT GCCGCGCACC
 301 GCCCGCGACA TGGCGGCGGC AAGCCGCAAA ATCCCCGACA GCCGCCTTAA
 351 GGCCGGCGAC CTCGTATTCT TCAACACCGG CGGCGCACAC CGCTACTCAC
 401 ACGTCGGACT CTATATCGGC AACGGCGAAT TCATCCATGC CCCCAGCAGC
 451 GGCAAAACCA TCAAAACCGA AAAACTCTCC ACACCGTTTT ACGCCAAAAA
 55 501 CTACCTCGGC GCACATACTT TCTTTACAGA ATGA

This corresponds to the amino acid sequence <SEQ ID 1027; ORF 206.a>:

a206.pep

- 103 -

1 MFPPDKTLFL CLSALLLASC GTTSGKHRQP KPKQTVRQIQ AVRISHIDRT
 51 QGSQELMLHS LGLIGTPYKW GGSSTATGFD CSGMIQFVYK NALNVKLPRT
 101 ARDMAAASRK IPDSRLKAGD LVFFNTGGAH RYSHVGLYIG NGEFIHAPSS
 151 GKTIKTEKLS TPFYAKNYLG AHTFFTE*

5

m206/a206 ORFs 206 and 206.a showed a 99.4% identity in 177 aa overlap

		10	20	30	40	50	60
	m206.pep	MFPPDKTLFLCLSALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIDRTQGSQELMLHS					
10	a206	MFPPDKTLFLCLSALLLASC GTTSGKHRQPKPKQTVRQIQAVRISHIDRTQGSQELMLHS					
		10	20	30	40	50	60
		70	80	90	100	110	120
	m206.pep	LGLIGTPYKWGGSSTATGFD CSGMIQFVYK NALNVKLPRTARDMAAASRKIPDSRXKAGD					
15	a206	LGLIGTPYKWGGSSTATGFD CSGMIQFVYK NALNVKLPRTARDMAAASRKIPDSRLKAGD					
		70	80	90	100	110	120
		130	140	150	160	170	
20	m206.pep	LVFFNTGGAHRYSHVGLYIGNGEFIHAPSSGKTIKTEKLSTPFYAKNYLGAHTFFTEX					
	a206	LVFFNTGGAHRYSHVGLYIGNGEFIHAPSSGKTIKTEKLSTPFYAKNYLGAHTFFTEX					
		130	140	150	160	170	

25

287

30 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1028>:

m287.seq

	1	ATGTTTAAAC	GCAGCGTAAT	CGCAATGGCT	TGTATTTTGG	CCCTTTCAGC
	51	CTGCGGGGGC	GGCGGTGGCG	GATCGCCCGA	TGTCAAGTCG	GCGGACACGC
35	101	TGTCAAAACC	TGCCGCCCTT	GTTGTTTCTG	AAAAAGAGAC	AGAGGCAAAAG
	151	GAAGATGCGC	CACAGGCAGG	TTCTCAAGGA	CAGGGCGCGC	CATCCGCACA
	201	AGGCAGTCAA	GATATGGCGG	CGSTTTCGGA	AGAAAATACA	GGCAATGGCG
	251	CTGCGGTAAAC	AGCGGATAAT	CCCCAAAATG	AAGACGAGGT	GGCACAAAAT
	301	GATATGCCGC	AAAATGCCGC	CGGTACAGAT	AGTTCGACAC	CGAATCACAC
	351	CCCGGATCCG	AATATGCTTG	CCGGAATAT	GGAAAATCAA	GCAACGGATG
40	401	CCGGGGAATC	GTCTCAGCCG	GCAAACCAAC	CGGATATGGC	AAATGCCGCG
	451	GACGGAATGC	AGGGGGACGA	TCCGTCGGCA	GGCGGGCAAA	ATGCCGGCAA
	501	TACGGCTGCC	CAAGGTGCAA	ATCAAGCCGG	AAACAATCAA	GCCGCCGGTT
	551	CTTCAGATCC	CATCCCCGCG	TCAAACCTTG	CACCTGCGAA	TGGCGGTAGC
	601	AATTTTGGAA	GGTTGATTT	GGCTAATGGC	GTTTTGATTG	ACGGGCCGTC
45	651	GCAAAATATA	ACGTGACCC	ACTGTAAAGG	CGATTCTTGT	AGTGGCAATA
	701	ATTTCTTGGA	TGAAGAAGTA	CAGCTAAAAT	CAGAATTGTA	AAAATTAAGT
	751	GATGCAGACA	AAATAAGTAA	TTACAAGAAA	GATGGGAAGA	ATGATAAATT
	801	TGTCGGTTTG	GTTGCCGATA	GTGTGCAGAT	GAAGGGAATC	AATCAATATA
	851	TTATCTTTTA	TAAACCTAAA	CCCACTTCAT	TTGCGCGATT	TAGGCGTTCT
50	901	GCACGGTCGA	GGCGGTCGCT	TCCGGCCGAG	ATGCCGCTGA	TTCCCGTCAA
	951	TCAGGCGGAT	ACGCTGATTG	TCGATGGGGA	AGCGGTCAGC	CTGACGGGGC
	1001	ATTCCGGCAA	TATCTTCGCG	CCCGAAGGGA	ATTACCGGTA	TCTGACTTAC
	1051	GGGGCGGAAA	AATTGCCCGG	CGGATCGTAT	GCCCTTCGTG	TTCAAGGCGA
	1101	ACCGGCAGAA	GGCGAAATGC	TTGCGGGCGC	GGCCGTGTAC	AACGGCGAAG
55	1151	TACTGCATTT	CCATACGGAA	AACGGCCGTC	CGTACCCGAC	CAGGGGCACG
	1201	TTTGCCGCAA	AAGTCGATTT	CGGCAGCAAA	TCTGTGGACG	GCATTATCGA
	1251	CAGCGGCGAT	GATTTGCATA	TGGGTACGCA	AAAATTCAAA	GCCGCCATCG
	1301	ATCGAAACGG	CTTTAAGGGG	ACTTGGACGG	AAAATGGCAG	CGGGGATGTT
	1351	TCCGGAAGT	TTTACGGCCC	GGCCGGCGAG	GAAGTGGCGG	GAAAATACAG
60	1401	CTATCGCCCG	ACAGATGCGG	AAAAGGGCGG	ATTCCGGCTG	TTTGCCGGCA

- 104 -

1451 AAAAAGAGCA GGATTGA

This corresponds to the amino acid sequence <SEQ ID 1029; ORF 287>:

5 m287.pep
 1 MFKRSVIAMA CIFALSACGG GGGGSPDVKS ADTLSKPAAP VVSEKETEAQ
 51 EDAPQAGSQG QGAPSAQGSQ DMAAVSEENT GNGGAVTADN PKNEDEVAQN
 101 DMPQNAAGTD SSTPNHTPDP NMLAGNMENQ ATDAGESSQP ANQPDMAANA
 151 DGMQGDDEPSA GGQNAGNTAA QGANQAGNNQ AAGSSDEIPA SNPAPANGGS
 201 NFGRVDLANG VLIDGPSQNI TLTHCKGDSC SGNNFLDEEV QLKSEFEKLS
 10 251 DADKISNYKK DGKNDKFVGL VADSVQMKGI NQYIIFYKPK PTSFARFRRS
 301 ARSRRSLPAE MPLIPVNQAD TLIVDGEAVS LTGHSGNIFA PEGNYRYLT
 351 GAEKLPGGSY ALRVQGEPAK GEMLAGAAVY NGEVLHFHTE NGRPYPTRGR
 401 FAAKVDFGSK SVDGIIDSGD DLHMGTOQFK AAIDGNGFKG TWTENGSGDV
 451 SGKFYGPAGE EVAGKYSYRP TDAEKGFGV FAGKKEQD*

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1030>:

g287.seq
 1 atgtttaaac gcagtgtgat tgcaatggct tgtatttttc ccctttcagc
 51 ctgtgggggc ggcgggtgcg gatcgcccg tgtcaagtcg gcggacacgc
 20 101 cgtcaaaacc ggcgcgcgcc gttgttgctg aaaaatgccg ggaaggggtg
 151 ctgccgaaag aaaagaaaga tgaggaggca gcgggcgggtg cgccgcaagc
 201 cgatacgagc gacgcaaccg ccggagaagg cagccaagat atggcggcag
 251 tttcggcaga aaatacaggc aatggcgggtg cggcaacaac ggacaacccc
 301 aaaaatgaag acgcgggggc gcaaaatgat atgccgcaaa atgcccgcca
 25 351 atccgcaaat caaacaggga acaaccaacc cgccggttct tcagattccg
 401 ccccccgcgc aaaccctgcc cctgcgaatg gcggtagcga ttttggaagg
 451 acgaacgtgg gcaattctgt tgtgattgac ggaccgtcgc aaaatataac
 501 gttgaccac tgtaaaggcg attcttgtaa tgggtgataat ttattggatg
 551 aagaagcacc gtcaaaatca gaatttgaaa aattaagtga tgaagaaaaa
 30 601 attaaagcat ataaaaaaga cgagcaacgg gagaattttg tcggtttggt
 651 tgctgacagg gtaaaaaagg atggaactaa caaatatata atcttctata
 701 cggacaaacc acctactcgt tctgcacggt cgaggaggtc gcttccggcc
 751 gagattccgc tgattcccgat caatcaggcc gatacgctga ttgtggatgg
 801 ggaagcggtc agcctgacgg gcattcccg caatatcttc gcgccgaag
 35 851 ggaattaccg gtatctgact tacggggcgg aaaaattgcc cggcggatcg
 901 tatgccctcc gtgtgcaagg cgaaccggca aaaggcgaaa tgcttggttg
 951 cacggccgtg tacaacggcg aagtgtgca tttccatatg gaaaacggcc
 1001 gtccgtaccc gtccggaggc aggtttgccg caaaagtcga tttcggcagc
 1051 aaatctgtgg acggcattat cgacagcggc gatgatttgc atatgggtac
 40 1101 gcaaaaattc aaagccgcca tcgatggaaa cggctttaag gggacttgga
 1151 cggaaaatgg cggcggggat gtttccgga ggttttacgg cccggccggc
 1201 gaggaagtgg cgggaaaata cagctatcgc ccgacagatg ctgaaaaggg
 1251 cggattcggc gtgtttgccg gcaaaaaaga tcgggattga

45 This corresponds to the amino acid sequence <SEQ ID 1031; ORF 287.ng>:

g287.pep
 1 MFKRSVIAMA CIFLSACGG GGGGSPDVKS ADTPSKPAAP VVAENAGEGV
 51 LPKEKKDEEA AGGAPQADTQ DATAGEGSQD MAAVSAENTG NGGAATTDNP
 101 KNEDAGAQND MPQNAAESAN QTGNNQPAGS SDSAPASNPA PANGGSDFGR
 50 151 TNVGNVVID GPSQNI TLTH CKGDSCNGDN LLDEEAPSKS EFEKLSDEEK
 201 IKRYKKDEQR ENFVGLVADR VKKDGTNKYI IFYTDKPTR SARSRSLPA
 251 EIPLIPVNQA DTLIVDGEAV SLTGHSGNIF APEGNYRYLT YGAEKLPGGS
 301 YALRVQGEPA KGEMLVGTAV YNGEVLHFHM ENGRPYPSG RFAAKVDFGS
 351 KSVDGIIDSG DDLHMGTOQF KAAIDGNGFK GTWTENGSGD VSGRFYGPAG
 55 401 EEVAGKYSYR PTDAEKGFG VFAGKKDRD*

m287/g287 ORFs 287 and 287.ng showed a 70.1% identity in 499 aa overlap

60

		10	20	30	40	49
	m287.pep	MFKRSVIAMACIFALSACGGGGGSPDVKSADTLSPKPAAPVSE-----KETE				A
5	g287	MFKRSVIAMACIFPLSACGGGGGSPDVKSADTPSKPAAPVVAENAGEGVLPEKKKDEEA				
		10	20	30	40	50
		60	70	80	90	100
	m287.pep	KEDAPQAGSQGQGAPSAQGSQDMAAVSEENTGNNGGAVTADNPKNEDQNDMPQNAAGT				
10	g287	AGGAPQADTQD--ATAGEGSQDMAAVSAENTGNNGGAATTDNPKNEDAGAQNNDMPQNAA--				
		70	80	90	100	110
		120	130	140	150	160
15	m287.pep	DSSTPNHTPDPNMLAGNMENQATDAGESSQPANQPDMANAADGMQGDDPSAGGQNAGNTA				
	g287	-----				
		170	180	190	200	210
20	m287.pep	AQQANQAGNNQAAGSSDPIPASNPAPANGGSNFGVRDLANGVLIDGPSQNITLTHCKGDS				
		::	::	::	::	::
	g287	-ESANQTNQNNQFAGSSDSAPASNPAPANGGSDFGRNTVGNSSVVIDGPSQNITLTHCKGDS				
		120	130	140	150	160
		170				
25		230	240	250	260	270
	m287.pep	CSGNNFLDEEVQLKSEFEKLSADAKISNYKKDGKNDKFVGLVADSVQMGKINQYIIFYKP				
		::	::	::	::	::
	g287	CNGDNLDEEAPSKSEFEKLSDEEKIKRYKKDEQRENFGVLVADRKKDGTNKYIIFYTD				
		180	190	200	210	220
30		230	240	250	260	270
	m287.pep	KPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSNIFAPEGNYRYLT				
			:	:	:	:
35	g287	KPPT-----RSARSRRSLPAEIPVQADTLIVDGEAVSLTGHSNIFAPEGNYRYLT				
		240	250	260	270	280
		290				
	m287.pep	YGAEKLPGGSYALRVQGEPAKGEMLAGAAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGS				
40	g287	YGAEKLPGGSYALRVQGEPAKGEMLVGTAVYNGEVLHFHMENGRPYPSGGRFAAKVDFGS				
		300	310	320	330	340
		350				
		410	420	430	440	450
45	m287.pep	KSVDDGIIDSGDDLHMGTKQFKAAIDGNFGKGTWTENGSGDVSGKFYGPAGEEVAGKYSYR				
	g287	KSVDDGIIDSGDDLHMGTKQFKAAIDGNFGKGTWTENGSGDVSGRFYGPAGEEVAGKYSYR				
		360	370	380	390	400
		410				
		470	480	489		
50	m287.pep	PTDAEKGGFVGFAGKKEQDX				
	g287	PTDAEKGGFVGFAGKKDRDX				
		420	430			

a287.seq

60

1	ATGTTTAAAC	GCAGTGTGAT	TGCAATGGCT	TGTATTGTTG	CCCTTTTCAGC
51	CTGTGGGGGC	GGCGGTGGCG	GATCGCCCGA	TGTTAAGTCG	GCGGACACGC
101	TGTCAAAACC	TGCCGCCCT	GTGTTACTG	AAGATGTCGG	GGAAGAGGTG
151	CTGCCGAAAG	AAAAGAAAGA	TGAGGAGGCG	GTGACTGGTG	CGCCGCAAGC
201	CATACGCAG	GACGCAACCG	CCGAAAAGG	CGGTCAAGAT	ATGGCGGCAG
251	TTTCGCGAGA	AAATACAGGC	AATGGCGGTG	CGGCAACAAC	GGATAATCCC

	a287.pep	1	MFKRSVIAMA	CIVALSACGG	GGGGSPDVKS	ADTLSPAP	VVTEDVGEEV	
30		51	LPKEKKDEEA	VSGAPQADTQ	DATAGKGGQD	MAAVSAENTG	NGGAATTNDP	
		101	ENKDEGPQND	MPQNAADTDS	STPNHTPAPN	MPTRDMGNQA	PDAGESAQPA	
		151	NQPDMANAAD	GMQGDDPSAG	ENAGNTADQA	ANQAENNVQV	GSONPASSTN	
		201	PNATNGGSD	GRINVANGIK	LDSGSENVTL	THCKDKVCDR	DFLDEEAPPK	
		251	SEFEKLSDEE	KINKYKKDEQ	RENFVGLVAD	RVEKNGTNKY	VIIYKDKSAS	
35		301	SSSARFRRSA	RSRRSLPAEM	PLIPVNQADT	LIVDGEAVSL	TGHSNIFAP	
		351	EGNYRYLTGY	AEKLSGGSYA	LSVQGEPAKG	EMLAGTAVYN	GEVLHFHMEN	
		401	GRSPSGGRF	AAKVDFGSKS	VDGIIDSGDD	LHMGTKQFKA	VIDGNGFKGT	
		451	WTENGGGDVS	GRFYGPAGEE	VAGKYSYRPT	DAEKGGFVVF	AGKKEQD*	
40	m287/a287		ORFs 287 and 287.a showed a 77.2% identity in 501 aa overlap					
			10	20	30	40	49	
	m287.pep		MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLSPAPV	VSE-----	KETEA			
45	a287		MFKRSVIAMACIVALSACGGGGGGSPDVKSADTLSPAPV	VTE	DV	GEEV	LPKEKKDEEA	
			10	20	30	40	50	60
		50	60	70	80	90	100	109
	m287.pep		KEDAPQAGSQGGGAPSAQGSQDMAAVSEENTGNGGAVTADNPKNEDEVAQN	DMPQNAAGT				
50	a287		VSGAPQADTQ--DATAGKGGQDMAAVSAENTGNGGAATTNDPENKDEGPQND	DMPQNAADT				
			70	80	90	100	110	
		110	120	130	140	150	160	169
	m287.pep		DSSTPNHTPDENMLAGNMENQATDAGESSQPANQPDMANAADGMQGGDDPSAGGQ	NAGNTA				
55	a287		DSSTPNHTPAPNMPTRDMGNQAPDAGESAQPANQPDMANAADGMQGGDDPSAG-ENAGNTA					
			120	130	140	150	160	170
		170	180	190	200	210	220	229
60	m287.pep		AQQANQAGNNQAAGSSDPIPASNPAPANGGSNFRGVDLANGVLIDGPSQNTILTHCKGDS					
	a287		DQAANQAENNVQGGSONPASSTNPNATNGGSDFGGRINVANGIKLDSGSENVTLTHCKDKY					

- 107 -

		180	190	200	210	220	230
5	m287.pep	230	240	250	260	270	280 289
		CSGNNFLDEEVQLKSEFEKLSADAKISNYKKDGKNDKFVGLVADSVQMKGINQYIIFYKP					
	a287	CD-RDFLDEEAPPKSEFEKLSDEEKINKYKKDEQRENFVGLVADRVEKNGTNKYVVIYKD					
		240	250	260	270	280	290
10	m287.pep	290	300	310	320	330	340
		KP--TSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSNIFAPEGNYRY					
	a287	KSASSSARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSNIFAPEGNYRY					
		300	310	320	330	340	350
15	m287.pep	350	360	370	380	390	400
		LTYGAEKLPGGSYALRVQGEPAKGEMLAGAAVYNGEVLHFHTENGRPYPTRGRFAAKVDF					
	a287	LTYGAEKLSGGSYALSVQGEPAKGEMLAGTAVYNGEVLHFHMENGRPSPSGGRFAAKVDF					
		360	370	380	390	400	410
20	m287.pep	410	420	430	440	450	460
		GSKSVDGIIDSGDDLHMGTOKEFKAAIDGNGFKGTWTENGSGDVSGKFYGPAGEEVAGKYS					
	a287	GSKSVDGIIDSGDDLHMGTOKEFKAAIDGNGFKGTWTENGSGDVSGRFGYPAGEEVAGKYS					
25		420	430	440	450	460	470
	m287.pep	470	480	489			
		YRPTDAEKGFGVFAGKKEQDX					
	a287	YRPTDAEKGFGVFAGKKEQDX					
		480	490				

406

35

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1034>:

m406.seq

40	1	ATGCAAGCAC	GGCTGCTGAT	ACCTATTCTT	TTTTCAGTTT	TTATTTTATC
	51	CGCCTGCGGG	ACACTGACAG	GTATTCCATC	GCATGGCGGA	GGTAAACGCT
	101	TTGCGGTCTGA	ACAAGAACTT	GTGGCCGCTT	CTGCCAGAGC	TGCCGTAAAT
	151	GACATGGATT	TACAGGCATT	ACACGGACGA	AAAGTTGCAT	TGTACATTGC
	201	CACTATGGGC	GACCAAGGTT	CAGGCAGTTT	GACAGGGGGT	CGCTACTCCA
	251	TTGATGCACT	GATTCGTGGC	GAATACATAA	ACAGCCCTGC	CGTCCGTACC
45	301	GATTACACCT	ATCCACGTTA	CGAAACCACC	GCTGAAACAA	CATCAGGCGG
	351	TTTGACAGGT	TTAACCACCT	CTTTATCTAC	ACTTAATGCC	CCTGCACTCT
	401	CTCGCACCCA	ATCAGACGGT	AGCGGAAGTA	AAAGCAGTCT	GGGCTTAAAT
	451	ATTGGCGGGA	TGGGGGATTA	TCGAAATGAA	ACCTTGACGA	CTAACCCGCG
	501	CGACACTGCC	TTTCTTTCCC	ACTTGGTACA	GACCGTATTT	TTCTGCGCG
50	551	GCATAGACGT	TGTTTCTCCT	GCCAATGCCG	ATACAGATGT	GTTTATTAAAC
	601	ATCGACGTAT	TCGGAACGAT	ACGCAACAGA	ACCGAAATGC	ACCTATACAA
	651	TGCCGAAACA	CTGAAAGCCC	AAACAAAAC	GGAATATTTC	GCAGTAGACA
	701	GAACCAATAA	AAAATTGCTC	ATCAAACCAA	AAACCAATGC	GTTTGAAGCT
	751	GCCTATAAAG	AAAATTACGC	ATTGTGGATG	GGGCCGTATA	AAGTAAGCAA
55	801	AGGAATTAAA	CCGACGGAAG	GATTAATGGT	CGATTTCTCC	GATATCCGAC
	851	CATACGGCAA	TCATACGGGT	AACTCCGCCC	CATCCGTAGA	GGCTGATAAC
	901	AGTCATGAGG	GGTATGGATA	CAGCGATGAA	GTAGTGCGAC	AACATAGACA
	951	AGGACAACCT	TGA			

- 108 -

This corresponds to the amino acid sequence <SEQ ID 1035; ORF 406>:

m406.pep

```

1  MQARLLIPIL FSVFILSACG TLTGIPSHGG GKRFQVEQEL VAASARAQVK
5  51  DMDLQALHGR KVALYIATMG DQSGSLTGG RYSIDALIRG EYINSPAVRT
   101  DYTYPYRQET AETTSGLTGG LTSLSTLNA PALSRTQSDG SGSSSLGLN
   151  IGGMGDYRNE TLTTNPRDTA FLSHLVQTVF FLRGIDVVSP ANADTDVFIN
   201  IDVFGTIRNR TEMHLYNAET LKAQTKLEYF AVDRTNKKLL IKPKTNAFEA
   251  AYKENYALWM GPYKVSQGIK PTEGLMVDPS DIRPYGNHTG NSAPSVEADN
   301  SHEGYGYSDE VVRQHRQGPQ *
```

The following partial DNA sequence was identified in *N. gonorrhoeae* <SEQ ID 1036>:

g406.seq

```

1  ATGCGGGCAC GGCTGCTGAT ACCTATTCTT TTTTCAGTTT TTATTTTATC
15  51  CGCTTGCAGG AACTGACAGG GTATTCCATC GCATGGCGGA GGCAAACGCT
   101  TCGCGGTCGA ACAAGAACTT GTGGCCGCTT CTGCCAGAGC TGCCGTTAAA
   151  GACATGGATT TACAGGCATT ACACGGACGA AAAGTTGCAT TGTACATTGC
   201  AACTATGGGC GACCAAGGTT CAGGCAGTTT GACAGGGGGT CGCTACTCCA
   251  TTGATGCACT GATTGCGGGC GAATACATAA ACAGCCCTGC CGTCCGCACC
   301  GATTACACCT ATCCGCGTTA CGAAACCACC GCTGAAACAA CATCAGGCGG
20  351  TTTGACGGGT TTAACCACTT CTTTATCTAC ACTTAATGCC CCTGCACTCT
   401  CGCGCACCCA ATCAGACGGT AGCGGAAGTA GGAGCAGTCT GGGCTTAAAT
   451  ATTGGCGGGA TGGGGGATTA TCGAAATGAA ACCTTGACGA CCAACCCGCG
   501  CGACACTGCC TTTCTTTCCC ACTTGGTGCA GACCGTATTT TTCCTGCGCG
   551  GCATAGACGT TGTCTTCTCT GCCAATGCCG ATACAGATGT GTTTATTAAC
25  601  ATCGACGTAT TCGGAACGAT ACGCAACAGA ACCGAAATGC ACCTATACAA
   651  TGCCGAAACA CTGAAAGCCC AAACAAACTT GGAATATTTT GCAGTAGACA
   701  GAACCAATAA AAAATTGCTC ATCAAACCCA AAACCAATGC GTTTGAAGCT
   751  GCCTATAAAG AAAATTACGC ATTGTGGATG GGGCCGTATA AAGTAAGCAA
   801  AGGAATCAAA CCGACGGAAG GATTGATGGT CGATTCTCTC GATATCCAAC
30  851  CATACGGCAA TCATACGGGT AACTCCGCCC CATCCGTAGA GGCTGATAAC
   901  AGTCATGAGG GGTATGGATA CAGCGATGAA GCAGTGCGAC AACATAGACA
   951  AGGGCAACCT TGA
```

This corresponds to the amino acid sequence <SEQ ID 1037; ORF 406.ng>:

g406.pep

```

1  MRARLLIPIL FSVFILSACG TLTGIPSHGG GKRFQVEQEL VAASARAQVK
35  51  DMDLQALHGR KVALYIATMG DQSGSLTGG RYSIDALIRG EYINSPAVRT
   101  DYTYPYRQET AETTSGLTGG LTSLSTLNA PALSRTQSDG SGSSSLGLN
   151  IGGMGDYRNE TLTTNPRDTA FLSHLVQTVF FLRGIDVVSP ANADTDVFIN
   201  IDVFGTIRNR TEMHLYNAET LKAQTKLEYF AVDRTNKKLL IKPKTNAFEA
   251  AYKENYALWM GPYKVSQGIK PTEGLMVDPS DIQPYGNHTG NSAPSVEADN
   301  SHEGYGYSDE AVRQHRQGPQ *
```

ORF 406.ng shows 98.8% identity over a 320 aa overlap with a predicted ORF (ORF406.a) from *N. gonorrhoeae*:

g406/m406

```

50  g406.pep      10      20      30      40      50      60
      MRARLLIPILFSVFILSACGTLTGIPSHGGGKRFQVEQELVAASARAQVKDMDLQALHGR
      |:|||||
m406    MQARLLIPILFSVFILSACGTLTGIPSHGGGKRFQVEQELVAASARAQVKDMDLQALHGR
      10      20      30      40      50      60

55  g406.pep      70      80      90     100     110     120
      KVALYIATMGDQSGSLTGGRYSIDALIRGEYINSPAVRTDYTYPRYETTAETTSGLTGG
      |||
```

- 109 -

m406	KVALYIATMGDQSGSLTGGRYSIDALIRGEYINSPAVRTDYTPRYETTAETTSGGTLG
	70 80 90 100 110 120
5	
g406.pep	LTTSLSTLNAPALSRTQSDGSGSRSSLGLNIGMGDYRNETLTTNPRDTAFLSHLVQTVF
m406	LTTSLSTLNAPALSRTQSDGSGSKSSLGLNIGMGDYRNETLTTNPRDTAFLSHLVQTVF
	130 140 150 160 170 180
10	
g406.pep	FLRGIDVVSPANADTDVFINIDVFGTIRNRTEMHLYNAETLKAQTKLEYFAVDRTNKKLL
m406	FLRGIDVVSPANADTDVFINIDVFGTIRNRTEMHLYNAETLKAQTKLEYFAVDRTNKKLL
	190 200 210 220 230 240
15	
g406.pep	IKPKTNAFEAAYKENYALWMGPYKVSIGIKPTEGLMVDIFSIDIQPYGNHTGNSAPSVEADN
m406	IKPKTNAFEAAYKENYALWMGPYKVSIGIKPTEGLMVDIFSIDIQPYGNHTGNSAPSVEADN
	250 260 270 280 290 300
20	
g406.pep	SHEGYGYSDEAVRQHRQGQPX
m406	SHEGYGYSDEVVRQHRQGQPX
	310 320

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1038>:

30	a406.seq	1	ATGCAAGCAC	GGCTGCTGAT	ACCTATTCTT	TTTTCAGTTT	TTATTTTATC
		51	CGCCTGCGGG	ACACTGACAG	GTATTCCATC	GCATGCGCGA	GGTAAACGCT
		101	TCGCGGTCTGA	ACAAGAACTT	GTGGCCGCTT	CTGCCAGAGC	TGCCGTTAAA
		151	GACATGGATT	TACAGGCATT	ACACGGACGA	AAAGTTGCAT	TGTACATTGC
35		201	AACTATGGGC	GACCAAGTTT	CAGGCAGTTT	GACAGGGGGT	CGCTACTCCA
		251	TTGATGCACT	GATTCGTGGC	GAATACATAA	ACAGCCCTGC	CGTCCGTACC
		301	GATTACACCT	ATCCACGTTA	CGAAACCACC	GCTGAAACAA	CATCAGGCGG
		351	TTTGACAGGT	TTAACCCTT	CTTATCTAC	ACTTAATGCC	CCTGCACTCT
		401	CGCGCACCCA	ATCAGACGGT	AGCGGAAGTA	AAAGCAGTCT	GGGCTTAAAT
40		451	ATTGGCGGGA	TGGGGGATTA	TCGAAATGAA	ACCTTGACGA	CTAACC CGC
		501	CGACACTGCC	TTTCTTTCCC	ACTTGGTACA	GACCGTATTT	TTCCTGCGCG
		551	GCATAGACGT	TGTTTCTCCT	GCCAATGCCG	ATACGGATGT	GTTTATTAAC
		601	ATCGACGTAT	TCGGAACGAT	ACGCAACAGA	ACCGAAATGC	ACCTATACAA
		651	TGCCGAAACA	CTGAAAGCCC	AAACAAAAC	GGAATATTTC	GCAGTAGACA
45		701	GAACCAATAA	AAAATTGCTC	ATCAAACCAA	AAACCAATGC	GTTTGAAGCT
		751	GCCTATAAAG	AAAATTACGC	ATTGTGGATG	GGACCGTATA	AAGTAAGCAA
		801	AGGAATTAAA	CCGACAGAAG	GATTAATGGT	CGATTCTCTC	GATATCCAAC
		851	CATACGGCAA	TCATATGGGT	AACTCTGCCC	CATCCGTAGA	GGCTGATAAC
		901	AGTCATGAGG	GGTATGGATA	CAGCGATGAA	GCAGTGCGAC	GACATAGACA
50		951	AGGGCAACCT	TGA			

This corresponds to the amino acid sequence <SEQ ID 1039; ORF 406.a>:

55	a406.pep	1	MQARLLIPIL	FSVFILSACG	TLTGIPSHGG	GKRFQVEQEL	VAASARAQVK
		51	DMDLQALHGR	KVALYIATMG	DQSGSGSLTGG	RYSIDALIRG	EYINSPAVRT
		101	DYTPRYETT	AETTSGGTLG	LTTSLSTLNA	PALSRTQSDG	SGSKSSLGLN
		151	IGMGDYRNE	TLTTNPRDTA	FLSHLVQTVF	FLRGIDVVSP	ANADTDVFIN
		201	IDVFGTIRNR	TEMHLYNAET	LKAQTKLEYF	AVDRTNKKLL	IKPKTNAFEA
		251	AYKENYALWM	GPYKVSIGIK	PTEGLMVDIFS	DIQPYGNHMG	NSAPSVEADN
60		301	SHEGYGYSDE	AVRRHRQGQP	*		

- 110 -

m406/a406 ORFs 406 and 406.a showed a 98.8% identity in 320 aa overlap

		10	20	30	40	50	60
5	m406.pep	MQARLLIPILFSVFILSACGTLTGIPSHGGGKRFAVEQELVAASARAAVKDMDLQALHGR					
	a406	MQARLLIPILFSVFILSACGTLTGIPSHGGGKRFAVEQELVAASARAAVKDMDLQALHGR					
		10	20	30	40	50	60
10	m406.pep	KVALYIATMGDQSGSLTGGRYSIDALIRGEYINSPAVRTDYTPRYETTAETTSGGLTG					
	a406	KVALYIATMGDQSGSLTGGRYSIDALIRGEYINSPAVRTDYTPRYETTAETTSGGLTG					
		70	80	90	100	110	120
15	m406.pep	LTTSLSLTLNAPALSRTQSDGSGSKSSLGLNIGGMGDYRNETLTNPRDTAFLSHLVQTVF					
	a406	LTTSLSLTLNAPALSRTQSDGSGSKSSLGLNIGGMGDYRNETLTNPRDTAFLSHLVQTVF					
		130	140	150	160	170	180
20	m406.pep	FLRGIDVVS PANADTDVFINIDVFGTIRNRTEMHLYNAETLKAQTKLEYFAVDRTNKKLL					
	a406	FLRGIDVVS PANADTDVFINIDVFGTIRNRTEMHLYNAETLKAQTKLEYFAVDRTNKKLL					
		190	200	210	220	230	240
25	m406.pep	IKPKTNAFEAAAYKENYALWMPYKVS KGIPKTEGLMVDFSDIRPYGNHTGNSAPSVEADN					
	a406	IKPKTNAFEAAAYKENYALWMPYKVS KGIPKTEGLMVDFSDIQPYGNHMGNSAPSVEADN					
		250	260	270	280	290	300
30	m406.pep	SHEGYGYSDEVVRQHRQGQPX					
	a406	SHEGYGYSDEAVRRHRQGQPX					
		310	320				
35	m406.pep	SHEGYGYSDEVVRQHRQGQPX					
	a406	SHEGYGYSDEAVRRHRQGQPX					
		310	320				

40 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1040>:

m726.seq

	1	ATGACCATCT	ATTTCAAAAA	CGGCTTTTAC	GACGACACAT	TGGGCGGCAT
	51	CCCCGAAGGC	GCGGTTGCCG	TCCGCGCCGA	AGAATACGCC	GCCCTTTTGG
45	101	CAGGACAGGC	GCAGGGCGGG	CAGATTGCCG	CAGATTCCGA	CGGCCGCCCC
	151	GTTTTAACCC	CGCCGCGCCC	GTCCGATTAC	CACGAATGGG	ACGGCAAAAA
	201	ATGGAATAATC	AGCAAAGCCG	CCGCCGCCGC	CCGTTTCGCC	AAACAAAAAA
	251	CCGCCTTGCC	ATTCCGCCTC	GCGGAAAAGG	CGGACGAACT	CAAAAACAGC
	301	CTCTTGCGCG	GCTATCCCCA	AGTGGAATC	GACAGCTTTT	ACAGGCAGGA
50	351	AAAAGAAGCC	CTCGCGCGGC	AGGCGGACAA	CAACGCCCCG	ACCCCGATGC
	401	TGGCGCAAAT	CGCCGCCGCA	AGGGCGGTGG	AATTGGACGT	TTTGATTGAA
	451	AAAGTTATCG	AAAAATCCGC	CCGCCTGGCT	GTTGCCGCCG	GCGCGATTAT
	501	CGGAAAGCGT	CAGCAGCTCG	AAGACAAATT	GAACACCATC	GAAACCGCGC
	551	CCGGATTGGA	CGCGCTGGAA	AAGGAAATCG	AAGAATGGAC	GCTAAACATC
55	601	GGCTGA				

This corresponds to the amino acid sequence <SEQ ID 1041; ORF 726>:

m726.pep

60	1	MTIYFKNGFY	DDTLGGIPEG	AVAVRAEYYA	ALLAQQAQGG	QIAADSDGRP
	51	VLTPPRPSDY	HEWDGKKWKI	SKAAAAARFA	KQKTALAFRL	AEKADELKNS

- 111 -

101 LLAGYPQVEI DSFYRQEKEA LARQADNNAP TPMLAQIAAA RGVELDLVIE
 151 KVIEKSARLA VAAGAIIGKR QQLEDKLNTI ETAPGLDALE KEIEEWTLNI
 201 G*

5

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1042>:

10 **m907-2.seq**
 1 ATGAGAAAAC CGACCGATAC CCTACCCGTT AATCTGCAAC GCCGCCGCCT
 51 GTTGTGTGCC GCCGGTGCCT TGTGCTCAG TCCTCTGGCG CACGCCGCGC
 101 CGCAACGTGA GGAACGCTT GCCGACGATG TGGCTTCCGT GATGAGGAGT
 151 TCTGTCGGCA GCGTCAATCC GCCGAGGCTG GTGTTTGACA ATCCGAAAGA
 201 GGGCGAGCGT TGGTTGTCTG CCATGTCGGC ACGTTTGGCA AGGTTCTGTC
 15 CCGAGGAGGA GGAGCGGCGC AGGCTGCTGG TCAATATCCA GTACGAAAGC
 301 AGCCGGGCCG GTTTGGATAC GCAGATTGTG TTGGGGCTGA TTGAGGTGGA
 351 AAGCGCGTTC CGCCAGTATG CAATCAGCGG TGTGGCGCGC CGCGGCCTGA
 401 TGCAGTTTAT GCCGTTTGG AAAAATACTA TCGGCAAAAC GGCGCACAAAC
 451 CTGTTTCGACA TCCGCACCAA CCTGCGTTAC GGCTGTACCA TCCTGCGCCA
 20 501 TTACCGGAAT CTTGAAAAAG GCAACATCGT CCGCGCGCTT GCCCGCTTTA
 551 ACGGCAGCTT GGGCAGCAAT AAATATCCGA ACGCCGTTTT GGGCGCGTGG
 601 CGCAACCGCT GGCAGTGGCG TTGA

25

This corresponds to the amino acid sequence <SEQ ID 1043; ORF 907-2>:

30 **m907-2.pep**
 1 MRKPTDTLPV NLQRRRLCA AGALLLSPLA HAGAQREETL ADDVASVMRS
 51 SVGSVNPPRL VFDNPKEGER WLSAMSARLA RFVPEEEERR RLLVNIQYES
 101 SRAGLDTQIV LGLIEVESAF RQYAISGVA RGLMQVMPFW KNYIGKPAHN
 151 LFDIRTNLRY GCTILRHYRN LEKGNIVRAL ARFNGSLGSN KYPNAVLGAW
 201 RNRWQWR*

35

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1044>:

40 **m953.seq**
 1 ATGAAAAAAA TCATCTTCGC CGCACTCGCA GCCGCCGCCA TCAGTACTGC
 51 CTCCGCCGCC ACCTACAAAG TGGACGAATA TCACGCCAAC GCCCGTTTCG
 101 CCATCGACCA TTTCAACACC AGCACCAACG TCGGCGGTTT TTACGGTCTG
 151 ACCGGTTCG TCGAGTTCCA CCAAGCAAAA CGCGACGTA AAATCGACAT
 201 CACCATCCCC ATTGCCAACC TGCAAAGCGG TTCGCAACAC TTTACCGACC
 251 ACCTGAAATC AGCCGACATC TTCGATGCCG CCCAATATCC GGACATCCGC
 301 TTTGTTTCCA CCAAATTCAA CTTCACGCGC AAAAACTGG TTTCCGTGTA
 351 CGGCAACCTG ACCATGCACG GCAAAACCGC CCCCCTCAA CTCAAAGCCG
 45 401 AAAAATTCAA CTGCTACCAA AGCCCGATGG AGAAAACCGA AGTTTGTGGC
 451 GCGCACTTCA GCACCACCAT CGACCGCACC AAATGGGGCA TGGACTACCT
 501 CGTTAACGTT GGTATGACCA AAAGCGTCCG CATCGACATC CAAATCGAGG
 551 CAGCCAAACA ATAA

50

This corresponds to the amino acid sequence <SEQ ID 1045; ORF 953>:

55 **m953.pep**
 1 MKKIIFAALA AAAISTASAA TYKVDEYHAN ARFAIDHFNT STNVGGFYGL
 51 TGSVEFDQAK RDGKIDITIP IANLQSGSQH FTDHLKSADI FDAAQYPDIR
 101 FVSTKFNENG KKLVSVDGNL TMHGKTAPVK LKAEKFNCYQ SPMEKTEVCG
 151 GDFSTTIDRT KWGMDYLVNV GMTKSVRIDI QIEAAKQ*

60

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1046>:

orf1-1.seq

- 112 -

1 ATGAAAAACAA CCGACAAACG GACAACCGAA ACACACCGCA AAGCCCCGAA
 51 AACCGGCCGC ATCCGCTTCT CGCCTGCTTA CTTAGCCATA TGCCTGTCGT
 101 TCGGCATTCT TCCCCAAGCC TGGGCGGGAC ACACCTATTT CCGCATCAAC
 151 TACCAATACT ATCGCGACTT TGCCGAAAT AAAGGCAAGT TTGCAGTCGG
 5 201 GCGCAAAGAT ATTGAGGTTT ACAACAAAA AGGGGAGTTG GTCGGCAAT
 251 CAATGACAAA AGCCCCGATG ATTGATTTT CTGTGGTGTC GCGTAACGGC
 301 GTGGCGGCAT TGGTGGGCGA TCAATATATT GTGAGCGTGG CACATAACGG
 351 CGGCTATAAC AACGTTGATT TTGGTGCGGA AGGAAGAAAT CCCGATCAAC
 401 ATCGTTTTAC TTATAAAATT GTGAAACGGA ATAATTATAA AGCAGGGACT
 10 451 AAAGGCCATC CTTATGGCGG CGATTATCAT ATGCCGCGTT TGCATAAATT
 501 TGTCACAGAT GCAGAACCTG TTGAAATGAC CAGTTATATG GATGGGCGGA
 551 AATATATCGA TCAAAATAAT TACCCTGACC GTGTTCTGAT TGGGGCAGGC
 601 AGGCAATATT GCGGATCTGA TGAAGATGAG CCCAATAACC GCGAAAGTTC
 651 ATATCATATT GCAAGTCCGT ATTCTTGGCT CGTTGGTGGC AATACCTTTG
 15 701 CACAAAATGG ATCAGGTGGT GGCACAGTCA ACTTAGGTAG TGA AAAAAT
 751 AAACATAGCC CATATGTTT TTTACCAACA GGAGGCTCAT TTGGCGACAG
 801 TGGCTACCA ATGTTTATCT ATGATGCCCA AAAGCAAAAG TGGTTAATTA
 851 ATGGGTATT GCAAACGGG AACCCCTATA TAGGAAAAAG CAATGGCTTC
 901 CAGCTGGTTC GTAAAGATTG GTTCTATGAT GAAATCTTTG CTGGAGATAC
 20 951 CCATTAGTA TTCTACGAAC CACGTCAAAA TGGGAAATAC TCTTTTAACG
 1001 ACGATAATAA TGGCAGGA AAAATCAATG CCAAAACATGA ACACAATTCT
 1051 CTGCCTAATA GATTAAAAAC ACGAACCGTT CAATTGTTTA ATGTTTCTTT
 1101 ATCCGAGACA GCAAGAGAAC CTGTTTATCA TGCTGCAGGT GGTGTCAACA
 1151 GTTATCGACC CAGACTGAAT AATGGAGAAA ATATTTCTCT TATTGACGAA
 25 1201 GGAAAAGGCG AATTGATACT TACCAGCAAC ATCAATCAAG GTGCTGGAGG
 1251 TTATATTTTC CAAGGAGATT TTACGGTCTC GCCTGAAAT AACGAACTT
 1301 GGCAAGGCGC GGGCGTTCAT ATCAGTGAAG ACAGTACCGT TACTTGGA
 1351 GTAAACGGCG TGGCAAACGA CCGCCTGTCC AAAATCGGCA AAGGCACGCT
 1401 GCACGTTCAA GCCAAAGGGG AAAACCAAGG CTCGATCAGC GTGGGCGACG
 30 1451 TGACAGTCAT TTTGGATCAG CAGGCAGACG ATAAAGGCAA AAAACAAGCC
 1501 TTTAGTGAAT TCGGCTTGGT CAGCGGCAGG GGTACGGTGC AACTGAATGC
 1551 CGATAATCAG TTCAACCCCG ACAAACTCTA TTTGGGCTTT CGCGGCGGAC
 1601 GTTTGGATTT AAACGGGCAT TCGCTTTCTG TCCACCGTAT TCAAAATACC
 1651 GATGAAGGGG CGATGATTGT CAACCACAAT CAAGACAAAG AATCCACCGT
 35 1701 TACCATTACA GGCAATAAAG ATATTGCTAC AACCGGCAAT AACACAGCT
 1751 TGGATAGCAA AAAAGAAATT GCCTACAACG GTTGGTTTGG CGAGAAAGAT
 1801 ACGACCAAAA CGAACGGGCG GCTCAACCTT GTTTACCAGC CCGCCGAGCA
 1851 AGACCGCACC CTGCTGCTTT CCGGCGGAAC AAATTTAAAC GGCAACATCA
 40 1901 CGCAAAACAA CGGCAAACTG TTTTTCAGCG GCAGACCAAC ACCGCACGCC
 1951 TACAATCATT TAAACGACCA TTGGTCGCAA AAAGAGGGCA TTCCTCGCGG
 2001 GGAATTCGTG TGGGACAAAC ACTGGATCAA CCGCACATTT AAAGCGGAAA
 2051 ACTTCCAAT TAAAGGCGGA CAGGCGGTGG TTTCCGCAA TGTGCCAAA
 2101 GTGAAAGGCG ATTGGCATT GAGCAATCAC GCCAAGCAG TTTTGGTGT
 2151 CGCACCGCAT CAAAGCCACA CAATCTGTAC ACGTTCGGAC TGGACGGGTC
 45 2201 TGACAAATTG TGTGAAAAA ACCATTACCG ACGATAAAGT GATTGCTTCA
 2251 TTGACTAAGA CCGACATCAG CGGCAATGTC GATCTTGCCG ATCACGCTCA
 2301 TTTAAATCTC ACAGGGCTTG CCACACTCAA CGGCAATCTT AGTGCAAATG
 2351 GCGATACACG TTATACAGTC AGCCACAACG CCACCCAAAA CGGCAACCTT
 2401 AGCCTCGTGG GCAATGCCCA AGCAACATTT AATCAAGCCA CATTAAACGG
 50 2451 CAACACATCG GCTTCGGGCA ATGCTTCATT TAATCTAAGC GACCACGCCG
 2501 TACAAAACGG CAGTCTGACG CTTTCCGGCA ACGCTAAGGC AAACGTAAGC
 2551 CATTCCGCAC TCAACGGTAA TGTCTCCCTA GCCGATAAGG CAGTATTCCA
 2601 TTTTGAAAGC AGCCGCTTTA CCGGACAAAT CAGCGGCGGC AAGGATACGG
 2651 CATTACACTT AAAAGACAGC GAATGGACGC TGCCGTCAGG CACGGAATTA
 55 2701 GGCAATTTAA ACCTTGACAA CGCCACCATT AACTCAATT CCGCTATCG
 2751 CCACGATGCG GCAGGGGCGC AAACCGGCAG TGGCAGAGAT GCGCCGCGCC
 2801 GCCGTTCCGCG CCGTTCGCGC CGTTCCTTAT TATCCGTTAC ACCGCCAACT
 2851 TCGGTAGAAT CCCGTTTCAA CACGCTGACG GTAAACGGCA AATTGAACGG
 2901 TCAGGGAACA TTCCGCTTTA TGTGGAACCT CTTCGGCTAC CGCAGCGACA
 60 2951 AATTGAAGCT GCGGAAAGT TCCGAAGGCA CTTACACCTT GCGGTCAAC
 3001 AATACCGGCA ACGAACCTGC AAGCCTCGAA CAATTGACGG TAGTGAAGG
 3051 AAAAGACAAC AAACCGCTGT CCGAAAACCT TAATTTACC CTGCAAAACG
 3101 AACACGTCGA TGCCGGCGCG TGGCGTTACC AACTCATCCG CAAAGACGGC

- 113 -

5 3151 GAGTTCCGCC TGCATAATCC GGTCAAAGAA CAAGAGCTTT CCGACAAACT
 3201 CGGCAAGGCA GAAGCCAAAA AACAGGCGGA AAAAGACAAC GCGCAAGGCC
 3251 TTGACGCGCT GATTGCGGCC GGGCGCGATG CCGTCGAAAA GACAGAAAGC
 3301 GTTGCCGAAC CGGCCCGGCA GGCAGGCGGG GAAAATGTCG GCATTATGCA
 3351 GGCAGAGGAA GAGAAAAAAC GGGTGCAGGC GGATAAAGAC ACCGCCCTTG
 3401 CGAAACAGCG CGAAGCGGAA ACCCGGCCGG CTACCACCGC CTTCCCCCGC
 3451 GCGCGCCGCG CCCGCCGGGA TTTGCCGCAA CTGCAACCCC AACCGCAGCC
 3501 CCAACCGCAG CGCGACCTGA TCAGCCGTTA TGCCAATAGC GGTTCGAGTG
 10 3551 AATTTTCCGC CACGCTCAAC AGCGTTTTTCG CCGTACAGGA CGAATTAGAC
 3601 CGCGTATTTG CCGAAGACCG CCGCAACGCC GTTTGGACAA GCGGCATCCG
 3651 GGACACCAAA CACTACCGTT CGCAAGATTT CCGCGCCTAC CGCCAACAAA
 3701 CCGACCTGCG CCAAATCGGT ATGCAGAAAA ACCTCGGCAG CGGGCGCGTC
 3751 GGCATCCTGT TTTCGCACAA CCGGACCGAA AACACCTTCG ACGACGGCAT
 3801 CGGCAACTCG GCACGCGTTG CCCACGGCGC CGTTTTCGGG CAATACGGCA
 15 3851 TCGACAGGTT CTACATCGGC ATCAGCGCGG GCGCGGGTTT TAGCAGCGGC
 3901 AGCCTTTTCAG ACGGCATCGG AGGCAAAATC CGCCGCCCGG TGCTGCATTA
 3951 CGGCATTTCAG GCACGATACC GCGCCGGTTT CCGCGGATTC GGCATCGAAC
 4001 CGCATATCGG CGCAACGCGC TATTTTCGTC AAAAAGCGGA TTACCGCTAC
 4051 GAAAACGTCA ATATCGCCAC CCCCGGCTT GCATTCAACC GCTACCGCGC
 20 4101 GGGCATTAAAG GCAGATTATT CATTCAAACC GCGCAACAC ATTTCCATCA
 4151 CGCCTTATTT GAGCCTGTCC TATACCGATG CCGCTTCGGG CAAAGTCCGA
 4201 ACACGCGTCA ATACCGCGT ATTGGCTCAG GATTTTCGGCA AAACCCGCAG
 4251 TGCGGAATGG GCGGTAAACG CCGAAATCAA AGTTTTCACG CTGTCCCTCC
 4301 ACGTGCCGCG CGCCAAGGC CCGCAACTGG AAGCGCAACA CAGCGCGGGC
 25 4351 ATCAAATTAG GCTACCGCTG GTAA

This corresponds to the amino acid sequence <SEQ ID 1047; ORF orf1-1>:

30 **orf1-1.pep**
 1 MKTTDKRTTE THRKAPKTGR IRFSPAYLAI CLSFGILPQA WAGHTYFGIN
 51 YQYYRDFEEN KGKFAVGAKD IEVYNKKGEL VGKSMTKAPM IDFSVVSRRNG
 101 VAALVGDQYI VSAHNGGYN NVDFGAEGRN PDQHRFTYKI VKRNNYKAGT
 151 KGHYPYGGDYH MPRLHKFVTD AEPVEMTSYM DGRKYIDQNN YPDRVRIGAG
 35 201 RQYWRSEDEE PNNRESSYHI ASAYSWLVG NTFQNGSGG GTVNLGSEKI
 251 KHSYPYGFLEPT GGSFGDSGSP MFIYDAQKQK WLVINGVLQTG NPYIGKSNFG
 301 QLVKRDWFYD EIFAGDTHSV FYEPRQNGKY SFNDNNGTG KINAKHEHNS
 351 LPNRLKTRTV QLFNVSLSET AREPVYHAAG GVNSYRPRLN NGENISFIDE
 40 401 GKGEILITSN INQAGGLYF QGDFTVSPEN NETWQAGVH ISEDSTVTWK
 451 VNGVANDRLS KIGKGLHVV AKGENQGSIS VGDGTVILDQ QADDKGKKQA
 501 FSEIGLVSGR GTVQLNADNQ FNPDKLYFGF RGGRLDLNGH SLSEFHRIQNT
 551 DEGAMIVNHN QDKESTVTIT GNKDIAATTGN NNSLDSKKEI AYNGWFGEKD
 601 TTKTNGRLNL VYQPAEDRT LLSGGTNLN GNITQTNGKL FFSGRPTPHA
 651 YNHLNDHWSQ KEGIPRGEIV WDNDWINRTF KAENFOIKGG QAVVSRNVAK
 45 701 VKGDWHLNSH AQAVFGVAPH QSHTICTRSD WTGLTNCVEK TITDDKVIAS
 751 LTKTDISGNV DLADHAHLNL TGLATLNGNL SANGDTRYTV SHNATQNGNL
 801 SLVGNAQATF NQATLNGNTS ASGNASFNLS DHAVQNGSLT LSGNAKANVS
 851 HSAIENGVS LADKAVHFES SRFTGQISGG KDTALHLKDS EWTLPSTEL
 901 GNLNLDNATI TLNSAYRHDA AGAQTGSATD APRRRSRRSR RSLLSVTPPT
 50 951 SVESRFNTLT VNGKLNQGT FREMSELFY RSDKLKLAES SEGTYTLAVN
 1001 NTGNEPASLE QLTVEGKDN KPLSENLFNT LQNEHVDAGA WRYQLIRKDG
 1051 EFRHLNPVKE QELSDKLGA EAKKQAEKDN AQSLDALIAA GRDAVEKTES
 1101 VAEPARQAGG ENVGIMQAE EKKRVQADKD TALAKQREAE TRPATTAFFPR
 1151 ARRARRDLPP LQPQPQPQPQ RDLISRYANS GLSEFSATLN SVFAVQDELD
 55 1201 RVFAEDRRNA VWTSGIRDTK HYRSQDFRAY RQQTDLRQIG MQKNLGSGRV
 1251 GILFSHNRTE NTFDDGIGNS ARLAHGAVEG QYGIDRFYIG ISAGAGFSSG
 1301 SLSDGIGGKI RRRVLHYGIQ ARYRAGFGGF GIEPHIGATR YFVQKADYRY
 1351 ENVNIATPGL AFNRYRAGIK ADYSFKPAQH ISITPYLSLS YTDAASGKVR
 1401 TRVNTAVLAQ DFGKTRSAEW GVNAEIKGFT LSLHAAAAGK PQLEAQHSAG
 60 1451 IKLGYRW*

- 114 -

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1048>:

```

orf46-2.seq
1   TTGGGCATTT CCGCAAAAT ATCCCTTATT CTGTCCATAC TGGCAGTGTG
5   51   CCTGCCGATG CATGCACACG CCTCAGATTT GGCAAACGAT TCTTTTATCC
    101   GGCAGGTTCT CGACCGTCAG CATTTCGAAC CCGACGGGAA ATACCACCTA
    151   TTCGGCAGCA GGGGGGAACT TGCCGAGCGC AGCGGCCATA TCGGATTGGG
    201   AAAAATACAA AGCCATCAGT TGGGCAACCT GATGATTCAA CAGGCGGCCA
    251   TTAAAGGAAA TATCGGCTAC ATTGTCCGCT TTTCCGATCA CGGGCACGAA
10   301   GTCCATTCCC CCTTCGACAA CCATGCCTCA CATTCCGATT CTGATGAAGC
    351   CGGTAGTCCC GTTGACGGAT TTAGCCTTTA CCGCATCCAT TGGGACGGAT
    401   ACGAACACCA TCCCGCCGAC GGCTATGACG GGCCACAGGG CGCGGGCTAT
    451   CCCGCTCCCA AAGGCGCGAG GGATATATAC AGCTACGACA TAAAAGGCGT
    501   TGCCCAAAAT ATCGCCTCA ACCTGACCGA CAACCGCAGC ACCGGACAAC
15   551   GGCTTGCCGA CCGTTTCCAC AATGCCGGTA GTATGCTGAC GCAAGGAGTA
    601   GGCACGGAT TCAAACGCGC CACCGGATAC AGCCCCGAGC TGGACAGATC
    651   GGGCAATGCC GCCGAAGCCT TCAACGGCAC TGCAGATATC GTTAAAAACA
    701   TCATCGGCGC GGCAGGAGAA ATTGTCGGCG CAGGCGATGC CGTGCAGGGC
    751   ATAAGCGAAG GCTCAAACAT TGCTGT'CATG CACGGCTTGG GTCTGCTTTC
20   801   CACCGAAAAC AAGATGGCGC GCATCAACGA TTTGGCAGAT ATGGCGCAAC
    851   TCAAAGACTA TGCCGCAGCA GCCATCCGCG ATTGGGCGAGT CCAAACCCC
    901   AATGCCGCAC AAGGCATAGA AGCCGTCAGC AATATCTTTA TGGCAGCCAT
    951   CCCCATCAAA GGGATTGGAG CTGTTCCGGG AAAATACGGC TTGGGCGGCA
25   1001  TCACGGCACA TCCTATCAAG CGGTCGCAGA TGGGCGCGAT CGCATTGCCG
    1051  AAAGGGAAAT CCGCCGTCAG CGACAATTTT GCCGATGCGG CATACGCCAA
    1101  ATACCCGTCC CTTTACCATT CCCGAAATAT CCGTTCAAAC TTGGAGCAGC
    1151  GTTACGGCAA AGAAAACATC ACCTCCTCAA CCGTGCCGCC GTCAAACGGC
    1201  AAAAATGTCA AACTGGCAGA CCAACGCCAC CCGAAGACAG GCGTACCGTT
    1251  TGACGGTAAA GGGTTTCCGA ATTTTGAGAA GCACGTGAAA TATGATACGA
30   1301  AGCTCGATAT TCAAGAATTA TCGGGGGGCG GTATACCTAA GGCTAAGCCT
    1351  GTGTTTGATG CGAAACCGAG ATGGGAGGTT GATAGGAAGC TTAATAAATT
    1401  GACAACCTCGT GAGCAGGTGG AGAAAAATGT TCAGGAAATA AGGAACGGTA
    1451  ATATAAACAG TAACTTTAGC CAACATGCTC AACTAGAGAG GGAAATTAAT
    1501  AAATAAAAT CTGCCGATGA AATTAATTTT GCAGATGGAA TGGGAAAATT
35   1551  TACCGATAGC ATGAATGACA AGGCTTTTAG TAGGCTTGTG AAATCAGTTA
    1601  AAGAGAATGG CTTACAAAAT CCAGTTGTGG AGTACGTTGA AATAAATGGA
    1651  AAAGCATATA TCGTAAGAGG AAATAATRGG GTTTTGTCTG CAGAATACCT
    1701  TGGCAGGATA CATGAATTAA AATTTAAAAA AGTTGACTTT CCTGTTCCTA
    1751  ATACTAGTTG GAAAAATCCT ACTGATGTCT TGAATGAATC AGGTAATGTT
40   1801  AAGAGACCTC GTTATAGGAG TAAATAA

```

This corresponds to the amino acid sequence <SEQ ID 1049; ORF orf46-2>:

```

orf46-2.pep
1   LGISRKISLI LSILAVCLPM HAHASDLAND SFIRQVLDLQ HFEPDGKYHL
51  FGSRGELAER SGHIGLGKIQ SHQLGNLMIQ QAAIKGNIGY IVRFSDHGHE
101 VHSPFDNHAS HSDSDEAGSP VDGFSLYRIH WDGYEHPAD GYDGPQGGGY
50  151  PAPKGARDIY SYDIKGVAQN IRLNLTNRS TGQRLADRFH NAGSMLTQVG
    201  GDGFKRATRY SPELDRSGNA AEAFTNGTADI VKNIIIGAAGE IVGAGDAVQG
    251  ISEGSNIAVM HGLGLLSTEN KMARINDLAD MAQLKDYAAA AIRDWAVQNP
    301  NAAQGIEAVS NIFMAAIPK GIGAVRGKYG LGGITAHPIK RSQMGAIALP
    351  KGKSAVSDNF ADAAYAKYPS PYHSRNIRSN LEQRYGKENI TSSTVPPSNG
55  401  KNVKLADQRH PKTGVFPDGK GFPNFEKHVK YDTKLDIQEL SGGGIPKAKP
    451  VFDAKPRWEV DRKLNKLT'TR EQVEKNVQEI RGNINSNFS QHAQLEREIN
    501  KLKSADEINF ADGMGKFTDS MNDKAFSRLV KSVKENGFTN PVVEYVEING
    551  KAYIVRGNNR VFAAEYLGRI HELKF'KKVDF PVPNTSWKNP TDVLNESGNV
60  601  KRPRYRSK*

```


Using the above-described procedures, the following oligonucleotide primers were employed in the polymerase chain reaction (PCR) assay in order to clone the ORFs as indicated:

5 Oligonucleotides used for PCR

Table 1

ORF	Primer	Sequence	Restriction sites
279	Forward	CGCGGATCCCATATG-TTGCCTGCAATCACGATT <SEQ ID 1050>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTTAGAAGCGGGCGGCAA <SEQ ID 1051>	XhoI
519	Forward	CGCGGATCCCATATG-TTCAAATCCTTTGTCGTCA <SEQ ID 1052>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTTGGCGGTTTTGCTGC <SEQ ID 1053>	XhoI
576	Forward	CGCGGATCCCATATG-GCCGCCCCCGCATCT <SEQ ID 1054>	BamHI-NdeI
	Reverse	CCCGCTCGAG-ATTTACTTTTTTGATGTCGAC <SEQ ID 1055>	XhoI
919	Forward	CGCGGATCCCATATG-TGCCAAAGCAAGAGCATC <SEQ ID 1056>	BamHI-NdeI
	Reverse	CCCGCTCGAG-CGGGCGGTATTCGGG <SEQ ID 1057>	XhoI
121	Forward	CGCGGATCCCATATG-GAAACACAGCTTTACAT <SEQ ID 1058>	BamHI-NdeI
	Reverse	CCCGCTCGAG-ATAATAATATCCCGCGCCC <SEQ ID 1059>	XhoI
128	Forward	CGCGGATCCCATATG-ACTGACAACGCACT <SEQ ID 1060>	BamHI-NdeI
	Reverse	CCCGCTCGAG-GACCGCGTTGTCGAAA <SEQ ID 1061>	XhoI
206	Forward	CGCGGATCCCATATG-AAACACCGCCAACCGA <SEQ ID 1062>	BamHI-NdeI
	Reverse	CCCGCTCGAG-TTCTGTAAAAAAGTATGTGC <SEQ ID 1063>	XhoI
287	Forward	CCGGAATTCTAGCTAGC-CTTTCAGCCTGCGGG <SEQ ID 1064>	EcoRI-NheI
	Reverse	CCCGCTCGAG-ATCCTGCTCTTTTTTGCC <SEQ ID 1065>	XhoI
406	Forward	CGCGGATCCCATATG-TGCGGGACACTGACAG <SEQ ID 1066>	BamHI-NdeI

- 116 -

	Reverse	CCCGCTCGAG-AGGTTGTCCTTGTCTATG <SEQ ID 1067>	XhoI
--	---------	---	------

EXAMPLE 2

Expression of ORF 919

5 The primer described in Table 1 for ORF 919 was used to locate and clone ORF 919. The predicted gene 919 was cloned in pET vector and expressed in *E. coli*. The product of protein expression and purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 919-His fusion protein purification. Mice were immunized with the purified 919-His and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal

10 assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; PP, purified protein, TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 919 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity

15 plots, antigenic index, and amphipatic regions of ORF 919 are provided in Figure 10. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 919 and the amino acid sequence encoded thereby is provided in Example 1.

20

EXAMPLE 3

Expression of ORF 279

 The primer described in Table 1 for ORF 279 was used to locate and clone ORF 279. The predicted gene 279 was cloned in pGex vector and expressed in *E. coli*. The product of protein expression and purification was analyzed by SDS-PAGE. In panel A) is shown the

25 analysis of 279-GST purification. Mice were immunized with the purified 279-GST and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle

30 preparation. Arrows indicate the position of the main recombinant protein product (A) and

- 117 -

the *N. meningitidis* immunoreactive band (B). These experiments confirm that 279 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 279 are provided in Figure 11. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 279 and the amino acid sequence encoded thereby is provided in Example 1.

10

EXAMPLE 4

Expression of ORF 576

The primer described in Table 1 for ORF 576 was used to locate and clone ORF 576. The predicted gene 576 was cloned in pGex vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 576-GST fusion protein purification. Mice were immunized with the purified 576-GST and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B).. These experiments confirm that ORF 576 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 576 are provided in Figure 12. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 576 and the amino acid sequence encoded thereby is provided in Example 1.

30

EXAMPLE 5

Expression of ORF 519

The primer described in Table 1 for ORF 519 was used to locate and clone ORF 519. The predicted gene 519 was cloned in pET vector and expressed in *E. coli*. The product of

- 118 -

protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 519-His fusion protein purification. Mice were immunized with the purified 519-His and sera were used for Western blot (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 519 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 519 are provided in Figure 13. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 519 and the amino acid sequence encoded thereby is provided in Example 1.

EXAMPLE 6

Expression of ORF 121

The primer described in Table 1 for ORF 121 was used to locate and clone ORF 121. The predicted gene *121* was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 121-His fusion protein purification. Mice were immunized with the purified 121-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Results show that 121 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 121 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 121 are provided in Figure 14. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 121 and the amino acid sequence encoded thereby is provided in Example 1.

EXAMPLE 7

Expression of ORF 128

The primer described in Table 1 for ORF 128 was used to locate and clone ORF 128. The predicted gene *128* was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 128-His purification. Mice were immunized with the purified 128-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D) and ELISA assay (panel E). Results show that 128 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 128 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipathic regions of ORF 128 are provided in Figure 15. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 128 and the amino acid sequence encoded thereby is provided in Example 1.

EXAMPLE 8

Expression of ORF 206

The primer described in Table 1 for ORF 206 was used to locate and clone ORF 206. The predicted gene *206* was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 206-His purification. Mice were immunized with the purified 206-His and sera were used for Western blot analysis (panel B). It is worth noting that the immunoreactive band in protein extracts from meningococcus is 38 kDa instead of 17 kDa (panel A). To gain information on the nature of this antibody staining we expressed ORF 206 in *E. coli* without the His-tag and including the predicted leader peptide. Western blot analysis on total protein extracts from *E. coli* expressing this native form of the 206 protein showed a reactive band at a position of 38 kDa, as observed in meningococcus. We conclude that the 38 kDa band in panel B) is

15

The primer described in Table 1 for ORF 287 was used to locate and clone ORF 287. The predicted gene 287 was cloned in pGex vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 287-GST fusion protein purification. Mice were immunized with the purified 287-GST and sera were used for FACS analysis (panel B), bactericidal assay (panel C), and ELISA assay (panel D). Results show that 287 is a surface-exposed protein. Symbols: M1, molecular weight marker. Arrow indicates the position of the main recombinant protein product (A). These experiments confirm that 287 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipathic regions of ORF 287 are provided in Figure 17. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 287 and the amino acid sequence encoded thereby is provided in Example 1.

- 121 -

EXAMPLE 10

Expression of ORF 406

The primer described in Table 1 for ORF 406 was used to locate and clone ORF 406. The predicted gene 406 was cloned in pET vector and expressed in *E. coli*. The product of protein purification was analyzed by SDS-PAGE. In panel A) is shown the analysis of 406-His fusion protein purification. Mice were immunized with the purified 406-His and sera were used for Western blot analysis (panel B), FACS analysis (panel C), bactericidal assay (panel D), and ELISA assay (panel E). Results show that 406 is a surface-exposed protein. Symbols: M1, molecular weight marker; TP, *N. meningitidis* total protein extract; OMV, *N. meningitidis* outer membrane vesicle preparation. Arrows indicate the position of the main recombinant protein product (A) and the *N. meningitidis* immunoreactive band (B). These experiments confirm that 406 is a surface-exposed protein and that it is a useful immunogen. The hydrophilicity plots, antigenic index, and amphipatic regions of ORF 406 are provided in Figure 18. The AMPHI program is used to predict putative T-cell epitopes (Gao et al 1989, *J. Immunol* 143:3007; Roberts et al. 1996, *AIDS Res Human Retroviruses* 12:593; Quakyi et al. 1992, *Scand J Immunol Suppl* 11:9). The nucleic acid sequence of ORF 406 and the amino acid sequence encoded thereby is provided in Example 1.

The foregoing examples are intended to illustrate but not to limit the invention.

- 122 -

Claims

1. A method for identifying an amino acid sequence, comprising the step of searching for putative open reading frames or protein-coding sequences within one or more
5 of *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.
2. A method according to claim 1, comprising the steps of searching a
N. meningitidis nucleotide sequence for an initiation codon and searching the upstream
10 sequence for an in-frame termination codon.
3. A method for producing a protein, comprising the step of expressing a protein comprising an amino acid sequence identified according to any one of claims 1-2.
- 15 4. A method for identifying a protein in *N. meningitidis*, comprising the steps of producing a protein according to claim 3, producing an antibody which binds to the protein, and determining whether the antibody recognises a protein produced by *N. meningitidis*.
5. Nucleic acid comprising an open reading frame or protein-coding sequence
20 identified by a method according to any one of claims 1-2.
6. A protein obtained by the method of claim 3.
7. Nucleic acid comprising one or more of the *N. meningitidis* nucleotide
25 sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID NO 962 to SEQ ID NO 1044.
8. Nucleic acid comprising a nucleotide sequence having greater than 50%
sequence identity to a nucleotide sequence disclosed in the sequence listing SEQ ID NOs 1-
30 961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

- 123 -

9. Nucleic acid comprising a fragment of a nucleotide sequence disclosed in the sequence listing SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

5 10. Nucleic acid according to claim 9, wherein the fragment is unique to the genome of *N. meningitidis*.

11. Nucleic acid complementary to the nucleic acid of any one of claims 7-10.

10 12. A protein comprising an amino acid sequence encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

15 13. A protein comprising an amino acid sequences having greater than 50% sequence identity to an amino acid sequence encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, or even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

20 14. A protein comprising a fragment of an amino acid sequence selected from the group consisting of one or more odd-numbered SEQ ID NOs 963-1037, amino acid sequences having greater than 50% identity with one or more odd-numbered SEQ ID NOs 963-1045, amino acid sequences encoded within one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961 and 1068, and amino acid sequences encoded by one or more even-numbered SEQ ID NOs from SEQ ID 962 to SEQ ID 1044.

25

15. Nucleic acid encoding a protein according to any one of claims 6-8.

30 16. A computer, a computer memory, a computer storage medium or a computer database containing the nucleotide sequence of a nucleic acid according to any one of claims 7-11.

- 124 -

17. A computer, a computer memory, a computer storage medium or a computer database containing one or more of the *N. meningitidis* nucleotide sequences SEQ ID NOs 1-961.

5 18. A polyclonal or monoclonal antibody which binds to a protein according to any one of claims 12-14 or 6.

19. A nucleic acid probe comprising nucleic acid according to any one of claims 5, 7-10, or 15.

10

20. An amplification primer comprising nucleic acid according to any one of claims 5, 7-10, or 15.

15 21. A composition comprising (a) nucleic acid according to any one of claims 5, 7-10, or 15; (b) protein according to any one of claims 12-14; and/or (c) an antibody according to claim 18.

22. The use of a composition according to claim 21 as a medicament or as a diagnostic reagent.

20

23. The use of a composition according to claim 21 in the manufacture of (a) a medicament for treating or preventing infection due to Neisserial bacteria and/or (b) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria.

25


24. A method of treating a patient, comprising administering to the patient a therapeutically effective amount of a composition according to claim 21.

FIG. 1A

919 (46 kDa)

PURIFICATION

M1 919

*FIG. 1B*

919 (46 kDa)


WESTERN BLOT

OMV TP PP

*FIG. 1C*


919 (46 kDa)

FACS

*FIG. 1D*

919 (46 kDa)

BACTERICIDAL ASSAY


*FIG. 1E*

919 (46 kDa)



ELISA assay: positive

FIG. 2A


279 (10.5 kDa)
PURIFICATION
M1 279

*FIG. 2B*

279 (10.5 kDa)
WESTERN BLOT
TP OMV

*FIG. 2C**FIG. 2D*

279 (10.5 kDa)
BACTERICIDAL ASSAY

*FIG. 2E*

279 (10.5 kDa)
ELISA assay: positive

FIG. 3A

576 (27.8 kDa)

PURIFICATION


M1 576

*FIG. 3B*

576 (27.8 kDa)


WESTERN BLOT

TP OMV

*FIG. 3C*



576 (27.8 kDa)

FACS

*FIG. 3D*

576 (27.8 kDa)

BACTERICIDAL ASSAY


*FIG. 3E*

576 (27.8 kDa)


ELISA assay: positive

FIG. 4A


519 (33 kDa)
PURIFICATION
M1 519

*FIG. 4B*


519 (33 kDa)
WESTERN BLOT
TP OMV

*FIG. 4C*

519 (33 kDa)
FACS

*FIG. 4D*

519 (33 kDa)
BACTERICIDAL ASSAY

*FIG. 4E*

519 (33 kDa)
ELISA assay: positive

FIG. 5A

121 (40 kDa)

PURIFICATION


M1 121

*FIG. 5B*

121 (40 kDa)


WESTERN BLOT

TP OMV

*FIG. 5C*


121 (40 kDa)

FACS

*FIG. 5D*

121 (40 kDa)

BACTERICIDAL ASSAY


*FIG. 5E*

121 (40 kDa)


ELISA assay: positive

FIG. 6A


128 (101 kDa)
PURIFICATION
M1 128

*FIG. 6B*


128 (101 kDa)
WESTERN BLOT
TP OMV

*FIG. 6C*

128 (101 kDa)
FACS

*FIG. 6D*

128 (101 kDa)
BACTERICIDAL ASSAY

*FIG. 6E*


128 (101 kDa)
ELISA assay: positive

FIG. 7A

206 (17 kDa)

PURIFICATION


M1 206

*FIG. 7B*

206 (17 kDa)


WESTERN BLOT

TP OMV

*FIG. 7C*



206 (17 kDa)

FACS

*FIG. 7D*

206 (17 kDa)

BACTERICIDAL ASSAY

*FIG. 7E*

206 (17 kDa)

ELISA assay: positive

FIG. 8A

287 (78 kDa)


PURIFICATION

M1 287

*FIG. 8B*



287 (78 kDa)

FACS

*FIG. 8C*

287 (78 kDa)

BACTERICIDAL ASSAY

*FIG. 8D*

287 (78 kDa)

ELISA assay: positive

FIG. 9A


406 (33 kDa)
PURIFICATION
M1 406

*FIG. 9B*



406 (33 kDa)
WESTERN BLOT
TP OMV

*FIG. 9C*

406 (33 kDa)
FACS

*FIG. 9D*

406 (33 kDa)
BACTERICIDAL ASSAY

*FIG. 9E*

406 (33 kDa)
ELISA assay: positive

10/18


919Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 10


279Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 11


576-1Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 12

519-1
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 13

121-1
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 14

128-1
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 15

206
Hydrophilicity Plot, Antigenic Index and AMPHI Regions




Fig. 16


287Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 17


Hydrophilicity Plot, Antigenic Index and AMPHI Regions

Fig. 18

APPENDIX A

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
1	GNMAA01R	9866	10311
1	GNMAA27F	10765	11284
1	GNMAA27R	11771	12130
1	GNMBA57F	5365	5930
1	GNMBA57R	6594	7118
1	GNMCD17F	9494	10035
1	GNMCD21F	14937	15512
1	GNMCD21R	16217	16700
1	GNMCD26F	27033	27561
1	GNMCD26R	25650	26101
1	GNMCD28F	27012	27561
1	GNMCD58F	27525	28047
1	GNMCD58R	26208	26582
1	GNMCF39F	25928	26411
1	GNMCF39R	24501	25188
1	GNMCK12F	18475	18966
1	GNMCK12R	16734	17175
1	GNMCL43F	31264	31793
1	GNMCL43R	32603	33038
1	GNMCL77F	7112	7681
1	GNMCL77R	8587	9143
1	GNMCO24R	8321	8920
1	GNMCP77F	24906	25412
1	GNMCP77R	26565	27107
1	GNMCQ74F	14937	15617
1	GNMCQ74R	13764	14477
1	GNMCS43F	3607	4278
1	GNMCS56F	21955	22578
1	GNMCS57F	7909	8608
1	GNMCV14F	5771	6272
1	GNMCV15R	7143	7800
1	GNMCV64F	23017	23484
1	GNMCV64R	21277	22018
1	GNMCV74F	16990	17305
1	GNMCV74R	18058	18796
1	GNMCV83F	4008	4503
1	GNMCV83R	2768	3286
1	GNMCY30F	7157	7897
1	GNMCY30R	8378	8912
1	GNMCZ78F	14192	14686
1	GNMCZ78R	15697	16234
1	GNMCZ93F	31337	31862
1	GNMCZ93R	30119	30639
2	GNMAA02F	27133	27648

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
2	GNMAA02R	26120	26546
2	GNMAA38F	16163	16379
2	GNMAA38R	14815	15335
2	GNMAA46F	2337	2704
2	GNMAA46R	3242	3746
2	GNMBA17F	15637	15798
2	GNMCD47F	11113	11453
2	GNMCD78F	13704	14196
2	GNMCD78R	15013	15380
2	GNMCK27F	4941	5490
2	GNMCK27R	3670	4086
2	GNMCL17F	23033	23527
2	GNMCL17R	21424	21995
2	GNMCL82F	24805	25200
2	GNMCL82R	26093	26659
2	GNMCN19F	5929	6601
2	GNMCP32F	18556	19103
2	GNMCP32R	19956	20403
2	GNMCQ84F	16351	17040
2	GNMCQ92F	3243	3692
2	GNMCQ92R	2022	2644
2	GNMCS51F	6645	7300
2	GNMCV24F	28139	28637
2	GNMCV25R	26839	27453
2	GNMCV77F	5149	5575
2	GNMCV77R	6008	6841
2	GNMCY52F	21892	22580
2	GNMCY52R	23157	23662
2	GNMCY74F	21900	22552
2	GNMCY74R	23519	24073
2	GNMCZ69F	1489	1999
2	GNMCZ70F	1489	1985
2	GNMCZ70R	2707	3232
3	GNMAA03F	16946	17459
3	GNMAA03R	18236	18447
3	GNMAA15F	3641	4156
3	GNMAA15R	4704	5176
3	GNMCA12F	8812	9427
3	GNMCB27F	19908	20403
3	GNMCB27R	21309	21630
3	GNMCB59F	22046	22554
3	GNMCB59R	20650	21230
3	GNMCD50F	8711	9229
3	GNMCF53F	15376	15861
3	GNMCF53R	16619	17312
3	GNMCF86F	22322	22760

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
3	GNMCL55F	12659	13194
3	GNMCL55R	13854	14380
3	GNMCM46R	11972	12662
3	GNMCM63F	7397	8071
3	GNMCM63R	8734	9381
3	GNMCP05F	2224	2964
3	GNMCV27F	10472	10969
3	GNMCV28R	11455	12172
4	GNMAA04R	21367	21727
4	GNMAA66F	9998	10514
4	GNMAA66R	9150	9669
4	GNMAA70F	19444	19961
4	GNMAA70R	20446	20841
4	GNMAB18F	34311	34576
4	GNMAB18R	32690	33102
4	GNMBA24F	21408	21950
4	GNMCA71F	35444	36106
4	GNMCA85F	14906	15535
4	GNMCB46F	27141	27652
4	GNMCB46R	28558	29138
4	GNMCD85F	25929	26447
4	GNMCF35F	37587	38065
4	GNMCF35R	36661	37327
4	GNMCK26F	23722	24268
4	GNMCK26R	25176	25751
4	GNMCK39F	26270	26836
4	GNMCK39R	27576	27934
4	GNMCK64F	37686	38053
4	GNMCK64R	36356	36915
4	GNMCL60F	2659	3206
4	GNMCL60R	4028	4520
4	GNMCM12F	21992	22465
4	GNMCM12R	23335	23919
4	GNMCM80F	15507	16171
4	GNMCM80R	16264	16990
4	GNMCN08R	33415	33739
4	GNMCO47F	23101	23700
4	GNMCO47R	24872	25344
4	GNMCP24F	34864	35552
4	GNMCP24R	33620	34225
4	GNMCP44F	24613	24976
4	GNMCP44R	25712	26279
4	GNMCQ80F	35274	35964
4	GNMCQ80R	34053	34632
4	GNMCS02F	37528	38035
4	GNMCV40F	33203	33632

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
4	GNMCX19F	37333	38076
4	GNMCX19R	36229	36871
4	GNMCX25F	28667	29362
4	GNMCX25R	27755	28398
4	GNMCX31F	1336	2085
4	GNMCX31R	1	640
4	GNMCX38F	15063	15774
4	GNMCX38R	14158	14836
4	GNMCY53F	8159	8846
4	GNMCY53R	6905	7405
4	GNMCZ25F	42411	42912
4	GNMCZ25R	40673	41229
4	GNMCZ27F	4786	5245
4	GNMCZ27R	3484	4030
5	GNMAA05F	5819	6334
5	GNMAA05R	6898	7190
5	GNMAA09F	15867	16369
5	GNMAA09R	15935	16368
5	GNMAA50R	17996	18383
5	GNMAA51F	44043	44409
5	GNMAA51R	43157	43679
5	GNMCA06F	43254	43764
5	GNMCA72F	7437	8102
5	GNMCA87F	36458	36899
5	GNMCB41F	44654	45224
5	GNMCB41R	45601	46039
5	GNMCD77F	46927	47437
5	GNMCD77R	48378	48761
5	GNMCF13F	18408	18911
5	GNMCF13R	16858	17553
5	GNMCF26F	44946	45450
5	GNMCF26R	46355	47018
5	GNMCF51F	31870	32355
5	GNMCK15F	34028	34591
5	GNMCK15R	33072	33560
5	GNMCK52F	13042	13587
5	GNMCK52R	11706	12267
5	GNMCK67F	16111	16399
5	GNMCK67R	14116	14459
5	GNMCL36F	26130	26644
5	GNMCL36R	24478	25038
5	GNMCL57F	46883	47459
5	GNMCL57R	48232	48759
5	GNMCL93F	6901	7404
5	GNMCL93R	5298	5897
5	GNMCN22F	4118	4792

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
5	GNMCN22R	5337	5969
5	GNMCN58F	17211	17798
5	GNMCN58R	15825	16436
5	GNMCN85F	38026	38698
5	GNMCN85R	39079	39669
5	GNMCP14F	47197	47893
5	GNMCP14R	47924	48597
5	GNMCP42F	23201	23701
5	GNMCP42R	24295	24875
5	GNMCP60F	31050	31537
5	GNMCP60R	29886	30442
5	GNMCQ39R	321	1003
5	GNMCS18F	39300	39713
5	GNMCS74F	41338	41970
5	GNMCS84F	47085	47801
5	GNMCS85R	48062	48687
5	GNMCV51F	33257	33720
5	GNMCV53F	35594	36106
5	GNMCV53R	36624	37232
5	GNMCV80F	3433	3924
5	GNMCV80R	2239	2949
5	GNMCX14F	15425	16088
5	GNMCX14R	14412	15041
5	GNMCY05F	26090	26786
5	GNMCY05R	25093	25665
5	GNMCY24F	45941	46684
5	GNMCY24R	47197	47748
5	GNMCY75F	9003	9618
5	GNMCY75R	9968	10503
5	GNMCZ74F	32693	33186
5	GNMCZ74R	31650	32179
6	GNMAA06F	43077	43280
6	GNMAA33F	21695	22061
6	GNMAA33R	22761	23120
6	GNMAA39F	11023	11390
6	GNMAA39R	12412	12870
6	GNMAB43F	13579	14098
6	GNMAB56F	20656	21079
6	GNMCA67F	37544	38219
6	GNMCB01F	34331	34902
6	GNMCB01R	35502	36050
6	GNMCD62F	6122	6648
6	GNMCD62R	4831	5183
6	GNMCD93F	1679	2157
6	GNMCD93R	3169	3495
6	GNMCK06F	20928	21478

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
6	GNMCK06R	19697	20289
6	GNMCL39F	24705	25251
6	GNMCL39R	23194	23548
6	GNMCM21F	32432	33056
6	GNMCM21R	33649	34334
6	GNMCN70R	14256	14926
6	GNMCO52F	13197	13922
6	GNMCO85F	26216	26827
6	GNMCO85R	25022	25686
6	GNMCS27F	16689	17300
6	GNMCS61F	3508	4184
6	GNMCS77F	40570	41276
6	GNMCS83F	32447	33093
6	GNMCS84R	30598	31235
6	GNMCV08F	42819	43260
6	GNMCV09R	44363	44932
6	GNMCV75F	14981	15479
6	GNMCX36F	38996	39738
6	GNMCX36R	39855	40528
6	GNMCX59F	39178	39574
6	GNMCX59R	40477	41178
6	GNMCY92F	24695	25185
6	GNMCZ42F	15656	16179
6	GNMCZ42R	17126	17641
6	GNMCZ59F	38912	39364
6	GNMCZ59R	37528	38062
7	GNMAA07F	8291	8808
7	GNMAA07R	9371	9793
7	GNMAA10F	39307	39822
7	GNMAA10R	37810	38060
7	GNMAA76F	289	796
7	GNMAA76R	1117	1517
7	GNMAB01F	33973	34541
7	GNMAB01R	34969	35306
7	GNMAB04F	53611	54157
7	GNMAB04R	52653	53059
7	GNMAB52F	37174	37740
7	GNMAB55F	52123	52618
7	GNMBA81F	28757	29327
7	GNMBA81R	27546	28097
7	GNMBB21F	40393	40959
7	GNMBB21R	39008	39449
7	GNMCA75F	31357	32032
7	GNMCB25F	33514	34085
7	GNMCB25R	34748	35431
7	GNMCB48F	14504	15191

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
7	GNMCB56F	36436	37114
7	GNMCB56R	35390	36079
7	GNMCB67F	42108	42771
7	GNMCB67R	41133	41740
7	GNMCB69F	27142	27807
7	GNMCB69R	25881	26530
7	GNMCD33R	50431	50757
7	GNMCD51F	6134	6629
7	GNMCF11F	35219	35727
7	GNMCF11R	36756	37229
7	GNMCF37F	51876	52358
7	GNMCF37R	49997	50607
7	GNMCF45F	40695	41177
7	GNMCF45R	41795	42403
7	GNMCF58F	6844	7311
7	GNMCF58R	5528	6208
7	GNMCF89F	52016	52469
7	GNMCF89R	53363	54002
7	GNMCH63F	39350	39770
7	GNMCH80F	20170	20607
7	GNMCK02F	43141	43483
7	GNMCK02R	41418	41852
7	GNMCK03F	41843	42407
7	GNMCK03R	40397	40952
7	GNMCK75F	29011	29346
7	GNMCK75R	27279	27840
7	GNMCL37F	37566	38097
7	GNMCL37R	38870	39442
7	GNMCL38F	38465	38990
7	GNMCL38R	37261	37843
7	GNMCL50F	52471	53006
7	GNMCL50R	51307	51879
7	GNMCM16R	43200	43943
7	GNMCM28F	31079	31677
7	GNMCM28R	29986	30699
7	GNMCM75F	29426	30002
7	GNMCM75R	28230	28947
7	GNMCN07R	31678	32296
7	GNMCN08F	30220	30908
7	GNMCN66F	49682	50383
7	GNMCN68R	48507	48702
7	GNMCP52F	53906	54238
7	GNMCP75F	3335	3631
7	GNMCP75R	2430	2916
7	GNMCP87F	19818	20336
7	GNMCP87R	21539	21853

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
7	GNMCQ05F	16992	17629
7	GNMCQ05R	15900	16596
7	GNMCQ06F	8173	8758
7	GNMCQ06R	6774	7461
7	GNMCQ11F	35268	35953
7	GNMCQ11R	36305	36981
7	GNMCQ13F	28320	29037
7	GNMCQ13R	29418	30079
7	GNMCQ24F	40176	40783
7	GNMCQ24R	40841	41510
7	GNMCQ37R	20188	20919
7	GNMCQ55F	40743	41309
7	GNMCQ55R	41980	42698
7	GNMCS30F	49344	49993
7	GNMCS53F	16879	17595
7	GNMCS95F	29469	29622
7	GNMCMV01R	30937	31651
7	GNMCMV17F	24334	24812
7	GNMCMV18R	25368	26100
7	GNMCMV28F	26427	26916
7	GNMCMV29R	24847	25211
7	GNMCMV69F	16647	17098
7	GNMCMV91F	10009	10521
7	GNMCMV91R	8630	9420
7	GNMCX23F	36634	37387
7	GNMCX23R	38318	38893
7	GNMCX24R	33857	34497
7	GNMCX67F	44537	45096
7	GNMCX67R	45763	46455
7	GNMCX77F	3423	4090
7	GNMCY56F	44117	44788
7	GNMCY56R	45883	46440
7	GNMCY79F	37394	38041
7	GNMCY79R	38954	39287
7	GNMCY84F	7387	8023
7	GNMCY84R	8749	9223
7	GNMCZ21F	28454	28986
7	GNMCZ21R	29774	30347
8	GNMAA08F	3883	4232
8	GNMAA08R	4930	5373
8	GNMAA17F	20102	20622
8	GNMAA17R	19135	19510
8	GNMAA18F	18255	18770
8	GNMAA69F	3985	4501
8	GNMAA69R	2840	3310
8	GNMBA02R	18827	19205

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
8	GNMBA38R	20196	20729
8	GNMBB17F	16245	16809
8	GNMBB17R	14789	15278
8	GNMCD01F	1726	2071
8	GNMCD01R	3032	3560
8	GNMCD57F	15533	16080
8	GNMCD57R	14017	14387
8	GNMCH21F	7735	8074
8	GNMCH58F	20193	20483
8	GNMCK17F	12025	12589
8	GNMCK17R	13519	14068
8	GNMCN37F	11716	12367
8	GNMCN37R	10459	10898
8	GNMCQ71F	15717	16394
8	GNMCQ71R	17082	17799
8	GNMCV56F	2818	3221
8	GNMCV56R	4184	4873
8	GNMCW18F	11443	12002
8	GNMCW19F	12243	12874
8	GNMCX44F	13230	13907
8	GNMCX44R	12093	12776
8	GNMCX81F	6904	7509
8	GNMCX81R	8613	9312
9	GNMAA11R	3820	4070
9	GNMCF10F	4237	4718
9	GNMCF10R	5381	6021
9	GNMCF16F	6231	6723
9	GNMCF16R	4976	5578
9	GNMCH10F	8003	8324
9	GNMCH10R	6412	6686
9	GNMCS36F	8057	8725
9	GNMCX89R	7787	8447
10	GNMAA12F	700	1214
11	GNMAA13F	48121	48639
11	GNMAA13R	49787	50045
11	GNMAA73F	9309	9827
11	GNMAA73R	10319	10725
11	GNMAA95F	5068	5583
11	GNMAA95R	4340	4731
11	GNMAB70F	44475	44906
11	GNMAB70R	45692	46213
11	GNMAB84F	34949	35517
11	GNMAB84R	35628	36115
11	GNMBA30F	35071	35637
11	GNMBA30R	34080	34618
11	GNMBA65F	46358	46779

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
11	GNMBA65R	48334	48629
11	GNMBA96F	25616	26168
11	GNMBA96R	27180	27576
11	GNMCA79F	12432	13093
11	GNMCA81F	64372	65033
11	GNMCB75F	12474	13003
11	GNMCB75R	11368	11898
11	GNMCB79F	12463	12998
11	GNMCB79R	11374	11879
11	GNMCB80F	12394	13044
11	GNMCB80R	11355	11761
11	GNMCB88F	26453	27107
11	GNMCB88R	25225	25878
11	GNMCD37R	1837	2210
11	GNMCD48F	36014	36541
11	GNMCD48R	37485	37833
11	GNMCD61F	33776	34331
11	GNMCD61R	32513	32886
11	GNMCF05F	61923	62430
11	GNMCF05R	63324	63994
11	GNMCF20F	64093	64548
11	GNMCF20R	62670	63312
11	GNMCF27F	7865	8322
11	GNMCF27R	6252	6941
11	GNMCF31F	2643	3144
11	GNMCF31R	3621	4255
11	GNMCF32F	34812	35310
11	GNMCF32R	33489	34167
11	GNMCF44F	7905	8323
11	GNMCF44R	6275	6806
11	GNMCF54F	4208	4682
11	GNMCF54R	5789	6419
11	GNMCH29F	4781	5137
11	GNMCH75F	60773	61203
11	GNMCH75R	62111	62403
11	GNMCK80F	40661	41202
11	GNMCK80R	39298	39847
11	GNMCL01F	59052	59569
11	GNMCL01R	57689	58283
11	GNMCL62F	36623	37174
11	GNMCL62R	38138	38721
11	GNMCL65F	11758	12282
11	GNMCL65R	13221	13807
11	GNMCM44R	3393	4077
11	GNMCM85R	60497	61118
11	GNMCN29F	75370	76048

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
11	GNMCN29R	76487	77001
11	GNMCN90F	53115	53836
11	GNMCN90R	51986	52525
11	GNMCP26F	38602	39106
11	GNMCP26R	37257	37549
11	GNMCQ58F	61396	62055
11	GNMCQ58R	62637	63355
11	GNMCS12F	7065	7598
11	GNMCV05F	4623	5085
11	GNMCV06R	3299	4083
11	GNMCV16F	51884	52341
11	GNMCV17R	53784	54354
11	GNMCV88F	70556	71043
11	GNMCV88R	69005	69740
11	GNMCW41F	39495	40133
11	GNMCX04F	26396	27141
11	GNMCX04R	25242	25882
11	GNMCX65F	43846	44360
11	GNMCX65R	45795	46258
11	GNMCY01F	42714	43318
11	GNMCY03F	16064	16747
11	GNMCY03R	17171	17665
11	GNMCY76F	36967	37624
11	GNMCY76R	38440	38999
11	GNMCZ26F	45695	46211
11	GNMCZ26R	46903	47445
11	GNMCZ30F	53419	53933
11	GNMCZ30R	54651	55202
11	GNMCZ86R	43568	43996
12	GNMAA14F	51035	51374
12	GNMAA62F	22307	22668
12	GNMAA62R	21211	21585
12	GNMAA84F	4132	4648
12	GNMAA84R	3028	3497
12	GNMAB19F	53197	53641
12	GNMAB19R	51715	51941
12	GNMAB34F	59820	60248
12	GNMAB75F	8230	8726
12	GNMAB75R	6772	7086
12	GNMBA16F	61880	62448
12	GNMBA16R	63397	63930
12	GNMBA55F	54894	55463
12	GNMBA55R	53249	53699
12	GNMBB07F	45401	45967
12	GNMBB07R	46474	46846
12	GNMBB23F	23330	23896

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
12	GNMBB23R	21762	22258
12	GNMBB28F	17524	18093
12	GNMBB28R	19255	19581
12	GNMCA08F	80267	80572
12	GNMCA26F	95492	95876
12	GNMCB71F	3761	4447
12	GNMCB71R	2760	3305
12	GNMCD40F	25822	26340
12	GNMCD40R	27392	27712
12	GNMCF14F	254	698
12	GNMCF23F	25032	25512
12	GNMCF23R	26296	26954
12	GNMCF59F	543	781
12	GNMCF59R	1909	2359
12	GNMCF75F	38537	38993
12	GNMCH09F	70027	70360
12	GNMCH09R	68764	69057
12	GNMCK63F	82010	82461
12	GNMCK63R	83284	83844
12	GNMCL27F	36594	37139
12	GNMCL27R	38339	38900
12	GNMCL83F	24969	25304
12	GNMCL83R	26594	27175
12	GNMCM24F	58035	58620
12	GNMCM24R	56788	57519
12	GNMCM26R	43862	44449
12	GNMCM33F	59354	60069
12	GNMCM33R	58194	58939
12	GNMCN23F	31658	32330
12	GNMCN23R	29999	30623
12	GNMCP07F	62762	63498
12	GNMCP07R	61716	62463
12	GNMCQ25F	29033	29713
12	GNMCQ25R	27952	28642
12	GNMCQ31F	33826	34489
12	GNMCQ31R	32628	33318
12	GNMCQ35F	99046	99645
12	GNMCQ35R	100151	100867
12	GNMCS06F	35210	35790
12	GNMCS07F	38327	38874
12	GNMCS37F	93209	93927
12	GNMCS45F	52207	52867
12	GNMCS59F	49955	50647
12	GNMCS63F	13556	14245
12	GNMCS75F	95191	95899
12	GNMCS94F	39007	39638

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
12	GNMCV02F	96642	97004
12	GNMCV03R	95290	96043
12	GNMCV19F	13169	13632
12	GNMCV20R	11334	12063
12	GNMCV67F	12472	12929
12	GNMCV67R	11158	11877
12	GNMCV95F	48011	48518
12	GNMCV95R	48642	49450
12	GNMCX03F	64105	64613
12	GNMCX03R	65502	66139
12	GNMCX62F	91416	91831
12	GNMCX68R	55716	56405
12	GNMCX82F	55372	56082
12	GNMCX82R	54147	54839
12	GNMCX90F	81959	82454
12	GNMCX90R	83099	83791
12	GNMCX91F	82087	82392
12	GNMCY47F	80254	80920
12	GNMCY47R	78886	79381
12	GNMCY81F	17736	18413
12	GNMCY81R	19180	19621
12	GNMCZ02F	24891	25412
12	GNMCZ02R	26406	26946
12	GNMCZ10F	34243	34706
12	GNMCZ10R	35555	36086
12	GNMCZ54F	59674	60174
12	GNMCZ54R	58180	58651
12	GNMCZ65F	70323	70828
12	GNMCZ65R	71871	72382
13	GNMAA19F	12931	13449
13	GNMAA19R	11822	12291
13	GNMAA55R	4581	5101
13	GNMAA63F	36862	37225
13	GNMAA63R	35706	36096
13	GNMAA77F	20561	20750
13	GNMAB20F	14416	14852
13	GNMBA41R	21126	21626
13	GNMCB15F	3423	3980
13	GNMCB15R	4343	4984
13	GNMCB38F	22717	23346
13	GNMCB38R	21451	22022
13	GNMCB57F	11695	12343
13	GNMCD23F	33967	34506
13	GNMCD23R	32498	32984
13	GNMCD27F	25756	26330
13	GNMCD27R	24266	24695

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
13	GNMCD30F	25823	26369
13	GNMCD30R	24703	25016
13	GNMCD91F	36457	36958
13	GNMCF77F	11321	11777
13	GNMCF77R	9878	10580
13	GNMCH04F	9222	9510
13	GNMCK07F	20658	21162
13	GNMCK07R	21983	22516
13	GNMCK24F	11029	11566
13	GNMCK24R	12531	12904
13	GNMCL26F	33412	33883
13	GNMCL26R	32004	32585
13	GNMCL42F	25017	25487
13	GNMCL42R	26410	26988
13	GNMCM18F	9081	9580
13	GNMCM18R	7774	8463
13	GNMCM79F	28296	28959
13	GNMCM79R	29623	30321
13	GNMCN57F	43959	44583
13	GNMCN57R	42560	43109
13	GNMCO81F	36053	36717
13	GNMCO81R	34853	35488
13	GNMCP18F	20932	21612
13	GNMCP18R	19724	20394
13	GNMCS73F	26639	27284
13	GNMCS76R	25539	26264
13	GNMCV09F	46801	47242
13	GNMCV10R	45342	46019
13	GNMCV48F	40436	40867
13	GNMCV81F	21352	21853
13	GNMCW37F	45183	45820
13	GNMCX11F	1628	2393
13	GNMCX11R	2983	3629
13	GNMCX76F	41236	41920
13	GNMCX76R	42308	42978
13	GNMCY20F	20524	21188
13	GNMCY20R	19350	19922
13	GNMCY46F	15097	15751
13	GNMCY46R	16501	17054
13	GNMCY87F	21699	22313
13	GNMCY87R	20274	20660
13	GNMCZ29F	46571	47106
14	GNMAA20F	2883	3399
15	GNMAA21F	12719	13236
15	GNMAA21R	11967	12439
15	GNMAA83F	2799	3318

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
15	GNMAA83R	3978	4448
15	GNMBA09F	4054	4621
15	GNMCB52F	15275	16007
15	GNMCB52R	16498	16827
15	GNMCB77F	18627	19229
15	GNMCB77R	20264	20766
15	GNMCB83F	18623	19271
15	GNMCB83R	20266	20777
15	GNMCL14F	3072	3593
15	GNMCL14R	1651	2228
15	GNMCL87R	9692	10245
15	GNMCN52F	5357	5991
15	GNMCN52R	6753	7339
15	GNMCP45F	11548	12079
15	GNMCP45R	13429	13801
15	GNMCQ09F	19788	20364
15	GNMCQ09R	18441	19134
15	GNMCQ40F	20922	21572
15	GNMCQ40R	22245	22939
15	GNMCV26F	13405	13894
15	GNMCV27R	12194	12828
15	GNMCW08F	23327	23910
15	GNMCX17F	4323	5048
15	GNMCX17R	3040	3690
16	GNMAA22F	54115	54632
16	GNMAA22R	55087	55557
16	GNMAA40R	44790	45219
16	GNMAA72F	58127	58639
16	GNMAA72R	57179	57650
16	GNMAB05F	47515	48081
16	GNMAB05R	46674	47004
16	GNMAB06F	65453	66020
16	GNMAB06R	66416	66833
16	GNMAB07F	65453	65772
16	GNMAB28F	70440	71008
16	GNMAB28R	71467	71806
16	GNMAB41F	21694	22260
16	GNMAB54F	45585	46150
16	GNMAB65F	18770	19084
16	GNMBA69F	9418	9986
16	GNMBA69R	8303	8848
16	GNMBA76F	39980	40549
16	GNMBA76R	41451	41944
16	GNMBA79R	1185	1359
16	GNMCA89F	63127	63781
16	GNMCB30F	5241	5748

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
16	GNMCB32R	3919	4495
16	GNMCD69F	20174	20609
16	GNMCD69R	21508	21899
16	GNMCD74F	20264	20751
16	GNMCF08F	25798	26287
16	GNMCF08R	24361	25036
16	GNMCF36R	42733	43371
16	GNMCF46R	4203	4663
16	GNMCF48F	40973	41398
16	GNMCF48R	39629	40232
16	GNMCF73F	27684	28143
16	GNMCF73R	26442	27127
16	GNMCF81F	67923	68332
16	GNMCH17F	68971	69291
16	GNMCH34R	22199	22496
16	GNMCK28F	17936	18486
16	GNMCK28R	16766	17104
16	GNMCK32F	20788	21317
16	GNMCK32R	21768	22345
16	GNMCK85F	4360	4910
16	GNMCK85R	5620	6191
16	GNMCL06F	5123	5624
16	GNMCL06R	3812	4383
16	GNMCL34F	28058	28532
16	GNMCL34R	26957	27535
16	GNMCL63F	31053	31621
16	GNMCL63R	32284	32700
16	GNMCL70F	26168	26684
16	GNMCM31F	50181	50817
16	GNMCM31R	48867	49582
16	GNMCN28F	69538	70215
16	GNMCN28R	68459	69068
16	GNMCN84F	68423	69040
16	GNMCN84R	66998	67589
16	GNMCO18F	2622	3166
16	GNMCO18R	1677	2332
16	GNMCO35F	70510	71084
16	GNMCO35R	69198	69780
16	GNMCP19F	46453	47147
16	GNMCP19R	48299	48962
16	GNMCP43F	14799	15124
16	GNMCQ02F	19223	19930
16	GNMCQ02R	20338	21001
16	GNMCQ22F	21355	22030
16	GNMCQ22R	19917	20600
16	GNMCQ53F	7175	7907

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
16	GNMCQ53R	8198	8928
16	GNMCQ96R	29546	30182
16	GNMCS41F	29075	29776
16	GNMCS68F	9040	9703
16	GNMCS75R	1277	1893
16	GNMCS76F	2498	3167
16	GNMCV38F	37452	37889
16	GNMCV55R	34048	34804
16	GNMCV60F	59043	59536
16	GNMCV60R	57614	58367
16	GNMCX12F	3746	4302
16	GNMCX12R	5111	5734
16	GNMCX21F	11333	11997
16	GNMCX21R	10200	10848
16	GNMCX63F	225	712
16	GNMCY14F	72030	72750
16	GNMCY14R	70731	71300
16	GNMCY23F	43229	43994
16	GNMCY23R	42063	42641
16	GNMCY41F	27768	28553
16	GNMCY41R	28801	29356
16	GNMCY50F	59253	60030
16	GNMCY50R	58094	58480
16	GNMCY59F	48831	49574
16	GNMCY59R	50018	50543
16	GNMCZ40F	12172	12645
16	GNMCZ40R	13578	14094
16	GNMCZ41F	60265	60795
16	GNMCZ41R	61535	62088
16	GNMCZ80F	29797	30278
16	GNMCZ80R	28542	29086
16	GNMCZ90R	34086	34573
17	GNMAA23F	31103	31553
17	GNMAA23R	32120	32558
17	GNMAA31F	20779	21295
17	GNMAA31R	21615	22086
17	GNMAA67F	32770	33282
17	GNMAA67R	33955	34310
17	GNMAB08F	35151	35717
17	GNMAB08R	33887	34310
17	GNMBA18F	51385	51952
17	GNMBA36F	8398	8967
17	GNMBA36R	9832	10331
17	GNMBA54F	57853	58426
17	GNMBA54R	56651	57182
17	GNMBA74F	22767	23336

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
17	GNMBA74R	21413	21911
17	GNMBA85F	33077	33648
17	GNMBA85R	31797	32251
17	GNMCA19F	36042	36621
17	GNMCB06F	26433	26953
17	GNMCB06R	28247	28714
17	GNMCB10F	38250	38813
17	GNMCB10R	36756	37384
17	GNMCB82F	31729	32377
17	GNMCB82R	32858	33235
17	GNMCF22F	37912	38405
17	GNMCF22R	36753	37421
17	GNMCK05F	7321	7797
17	GNMCK05R	5987	6514
17	GNMCK57F	39678	40046
17	GNMCK57R	40958	41325
17	GNMCM38F	10453	11189
17	GNMCM38R	11737	12393
17	GNMCM58F	22688	23288
17	GNMCM58R	23628	24315
17	GNMCN30F	55573	56235
17	GNMCN30R	56832	57420
17	GNMCO01F	27343	28038
17	GNMCO07F	12194	12723
17	GNMCO07R	13433	14166
17	GNMCO26R	5725	6371
17	GNMCO43F	35750	36434
17	GNMCO43R	37161	37681
17	GNMCO44F	32920	33658
17	GNMCO44R	31733	32327
17	GNMCO55F	10439	11147
17	GNMCO55R	12310	12961
17	GNMCO56F	54670	55322
17	GNMCO56R	55704	56309
17	GNMCP57F	10671	10932
17	GNMCP57R	8680	9034
17	GNMCP66F	57727	58211
17	GNMCP66R	58838	59416
17	GNMCQ42F	22050	22733
17	GNMCQ42R	23218	23942
17	GNMCQ81F	41410	42152
17	GNMCQ81R	42968	43610
17	GNMCS03F	707	1334
17	GNMCS35F	52431	53137
17	GNMCS44F	35071	35764
17	GNMCS70F	6806	7540

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
17	GNMCS89F	38449	39120
17	GNMCS90R	39272	39972
17	GNMCV42F	51980	52438
17	GNMCV92F	43715	44212
17	GNMCV92R	42381	43040
17	GNMCX53F	18076	18436
17	GNMCX53R	16632	17267
17	GNMCY21F	26276	26984
17	GNMCY21R	25220	25785
17	GNMCY43F	55511	56209
17	GNMCY58F	10946	11675
17	GNMCY58R	9574	10130
17	GNMCZ14F	4034	4557
17	GNMCZ14R	5449	5997
17	GNMCZ81F	12505	13016
17	GNMCZ81R	10929	11485
18	GNMAA24F	14784	15300
18	GNMAA24R	15822	16278
18	GNMAA91F	3107	3623
18	GNMAA93F	14115	14633
18	GNMAA93R	12779	13156
18	GNMAB47F	6436	7001
18	GNMCA24F	17599	18212
18	GNMCB51F	10483	11109
18	GNMCB51R	9080	9547
18	GNMCK79F	4421	4931
18	GNMCK79R	5949	6533
18	GNMCM27F	17624	18228
18	GNMCM27R	16432	17178
18	GNMCM56F	13615	14160
18	GNMCM56R	14770	15435
18	GNMCN40R	15893	16523
18	GNMCN44F	14468	15195
18	GNMCN44R	15922	16524
18	GNMCP83F	14201	14738
18	GNMCP83R	15673	16259
18	GNMCY13F	2490	3240
18	GNMCZ03F	14791	15109
18	GNMCZ03R	16087	16657
18	GNMCZ15F	6918	7405
18	GNMCZ15R	5483	6044
18	GNMCZ61F	15232	15736
18	GNMCZ61R	16804	17347
19	GNMAA25F	3689	4210
19	GNMAA25R	4679	5150
19	GNMAA53F	17218	17584

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
19	GNMAA53R	16131	16651
19	GNMAB22F	11317	11854
19	GNMBA56F	29237	29799
19	GNMBB20F	42956	43521
19	GNMBB20R	41743	42275
19	GNMCB08F	1626	2186
19	GNMCB08R	2749	3408
19	GNMCB49F	24542	25193
19	GNMCB49R	23154	23800
19	GNMCB50F	1442	2136
19	GNMCB50R	457	1122
19	GNMCB84F	25574	26173
19	GNMCB84R	24112	24577
19	GNMCD36F	32463	32986
19	GNMCF17F	11187	11695
19	GNMCF17R	9855	10520
19	GNMCF56F	43830	44301
19	GNMCF56R	42446	43137
19	GNMCF62F	46052	46506
19	GNMCH41R	48920	49204
19	GNMCK19F	5471	5977
19	GNMCK19R	6934	7451
19	GNMCK60F	19464	19828
19	GNMCK60R	20624	21189
19	GNMCL07F	29947	30379
19	GNMCL07R	31253	31828
19	GNMCL47F	13187	13681
19	GNMCL47R	11739	12309
19	GNMCL67R	10328	10861
19	GNMCM83F	7074	7667
19	GNMCM83R	5824	6505
19	GNMCM87R	6816	7475
19	GNMCN69F	21718	22367
19	GNMCN69R	23279	23896
19	GNMCO19F	7892	8641
19	GNMCO19R	6509	7230
19	GNMCQ23F	22847	23439
19	GNMCQ23R	24531	25070
19	GNMCQ63F	24578	25176
19	GNMCQ63R	23445	24129
19	GNMCS09F	31343	31944
19	GNMCS34F	32710	33397
19	GNMCV13F	11334	11854
19	GNMCV14R	10046	10690
19	GNMCX15F	8333	9060
19	GNMCX15R	10180	10827

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
19	GNMCX27F	8333	9060
19	GNMCX27R	10188	10827
19	GNMCX56F	40847	41206
19	GNMCX56R	41903	42589
19	GNMCX87F	33938	34084
19	GNMCX87R	31658	32349
19	GNMCY07F	37467	38035
19	GNMCZ04R	24360	24843
20	GNMAA26F	11314	11834
20	GNMAA34R	15825	16187
20	GNMBA46F	9402	9971
20	GNMBA83F	9481	10050
20	GNMBA83R	11039	11224
20	GNMBA92F	3716	4284
20	GNMBA92R	2437	2882
20	GNMCA93F	10570	11228
20	GNMCB42F	12316	12924
20	GNMCB42R	10720	11380
20	GNMCF68F	145	549
20	GNMCS13F	3147	3776
20	GNMCS19F	3135	3707
20	GNMCV43F	4932	5463
20	GNMCV43R	3493	4272
20	GNMCX01R	8929	9576
20	GNMCX32F	2827	3562
20	GNMCX32R	1753	2386
21	GNMAA29F	7970	8459
21	GNMAA29R	6973	7381
21	GNMAA79F	60518	61036
21	GNMAA79R	61382	61783
21	GNMAB13F	91199	91695
21	GNMAB13R	90065	90490
21	GNMAB15F	18098	18666
21	GNMAB15R	17086	17514
21	GNMAB38F	89228	89794
21	GNMAB49F	90018	90554
21	GNMAB53F	57858	58423
21	GNMAB76F	69791	70359
21	GNMAB76R	71099	71621
21	GNMBA08F	88398	88961
21	GNMBA08R	89946	90480
21	GNMBA62F	91149	91717
21	GNMBA62R	90149	90587
21	GNMBB08F	57329	57895
21	GNMBB08R	58629	59155
21	GNMCB36F	86172	86807

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCB36R	87700	88359
21	GNMCB40F	55242	55889
21	GNMCB40R	56581	57269
21	GNMCD13F	26267	26840
21	GNMCD13R	24739	25235
21	GNMCD14F	63282	63678
21	GNMCD22F	39214	39744
21	GNMCD89F	20621	21136
21	GNMCD89R	19243	19626
21	GNMCE04F	48264	48570
21	GNMCE16F	8955	9401
21	GNMCE16R	10419	10933
21	GNMCK72F	28120	28413
21	GNMCK72R	29725	30288
21	GNMCK82F	16224	16679
21	GNMCK82R	17910	18284
21	GNMCK92F	21493	21930
21	GNMCK92R	22899	23382
21	GNMCL15F	15475	16027
21	GNMCL15R	16323	16894
21	GNMCL18F	40761	41272
21	GNMCL18R	39414	39980
21	GNMCL35F	58131	58677
21	GNMCL35R	56683	57252
21	GNMCM02F	77632	78241
21	GNMCM02R	76049	76774
21	GNMCM42F	44749	45453
21	GNMCM51F	70991	71600
21	GNMCM51R	72059	72786
21	GNMCM59F	46177	46805
21	GNMCM59R	47628	48296
21	GNMCM67F	58893	59524
21	GNMCM67R	57080	57810
21	GNMCN01F	29541	30134
21	GNMCN03R	26156	26805
21	GNMCN04F	27776	28333
21	GNMCN07F	3923	4589
21	GNMCN20F	23898	24435
21	GNMCN20R	22616	23262
21	GNMCN38R	27178	27843
21	GNMCN42F	28721	29325
21	GNMCN42R	27182	27579
21	GNMCN48F	31545	32275
21	GNMCN48R	30254	30829
21	GNMCN56F	38871	39524
21	GNMCN56R	37891	38510

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCN74R	76122	76780
21	GNMCN76F	76705	77420
21	GNMCN87F	81602	82287
21	GNMCN87R	80523	81067
21	GNMCO27F	12120	12686
21	GNMCO27R	10881	11591
21	GNMCO37R	5718	6199
21	GNMCO40F	81181	81864
21	GNMCO40R	80087	80668
21	GNMCO41F	64583	65194
21	GNMCO41R	63303	63895
21	GNMCO62F	24786	25412
21	GNMCO62R	23316	23927
21	GNMCO69F	29872	30526
21	GNMCO69R	28732	29361
21	GNMCP53R	42566	43118
21	GNMCP68F	17274	17781
21	GNMCP68R	18590	19166
21	GNMCP78F	20880	21383
21	GNMCP78R	22662	23004
21	GNMCQ50F	52354	53060
21	GNMCQ50R	53094	53813
21	GNMCQ56F	24974	25298
21	GNMCQ56R	26318	26936
21	GNMCQ76F	26247	26921
21	GNMCQ76R	27401	28002
21	GNMCQ86F	45276	45978
21	GNMCQ86R	46636	47364
21	GNMCS08F	7772	7922
21	GNMCS22F	49814	50311
21	GNMCS62F	56147	56850
21	GNMCS82F	1052	1732
21	GNMCW22F	55865	56223
21	GNMCX02R	45344	45988
21	GNMCX09F	6251	6961
21	GNMCX09R	4718	5291
21	GNMCX16F	60624	61395
21	GNMCX16R	59855	60393
21	GNMCX60F	40043	40437
21	GNMCX60R	41031	41715
21	GNMCX74F	59663	60376
21	GNMCX74R	58460	59136
21	GNMCY45F	42419	43108
21	GNMCY45R	44124	44642
21	GNMCY64F	58336	59059
21	GNMCY64R	57045	57582

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
21	GNMCZ28F	82973	83440
21	GNMCZ28R	81697	82250
21	GNMCZ46F	28043	28521
21	GNMCZ46R	26632	27064
21	GNMCZ77F	22158	22671
21	GNMCZ77R	23472	24017
22	GNMAA30F	2165	2683
22	GNMAA30R	3510	3980
22	GNMBA03F	25307	25874
22	GNMCB39F	5720	6103
22	GNMCB39R	3638	3945
22	GNMCK48F	14049	14546
22	GNMCK48R	12667	13251
22	GNMCL28F	17498	18022
22	GNMCL28R	16124	16700
22	GNMCM15R	284	872
22	GNMCN47R	4247	4891
22	GNMCO22F	9932	10637
22	GNMCO22R	11087	11794
22	GNMCO23F	10489	11080
22	GNMCO23R	11662	12303
22	GNMCQ04F	25363	26023
22	GNMCQ04R	24009	24693
22	GNMCS17F	5636	6187
22	GNMCS20F	21715	22271
22	GNMCV45F	11101	11552
22	GNMCV45R	12185	12992
22	GNMCV65F	21938	22388
22	GNMCW11F	21268	21882
22	GNMCZ08F	9245	9752
22	GNMCZ56R	4001	4481
22	GNMCZ57F	92	610
22	GNMCZ57R	1391	1949
23	GNMAA32R	501	916
24	GNMAA32F	34126	34644
24	GNMAA78F	12905	13389
24	GNMAA78R	11993	12173
24	GNMAA92F	5430	5906
24	GNMAA92R	6781	6979
24	GNMBA28F	25580	26147
24	GNMBA28R	24581	24744
24	GNMBA64F	44750	45281
24	GNMBA64R	43715	43924
24	GNMCA03F	47978	48229
24	GNMCA11F	5227	5845
24	GNMCB53F	31273	31860

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
24	GNMCB53R	29940	30477
24	GNMCD60F	49318	49836
24	GNMCF28R	25897	26427
24	GNMCF33F	53794	54122
24	GNMCF33R	55250	55649
24	GNMCF55F	18332	18818
24	GNMCF55R	16670	17304
24	GNMCF88F	31085	31484
24	GNMCF88R	29803	30387
24	GNMCF94F	32330	32765
24	GNMCF94R	30474	31147
24	GNMCH39F	20653	21054
24	GNMCH71F	20501	20708
24	GNMCK74F	31152	31629
24	GNMCK74R	32456	33004
24	GNMCK94F	19578	20116
24	GNMCK94R	18366	18866
24	GNMCL74F	16135	16693
24	GNMCL74R	18346	18913
24	GNMCM07F	48543	49161
24	GNMCM07R	47427	48064
24	GNMCM72F	14897	15471
24	GNMCM72R	15789	16445
24	GNMCM86F	32288	32811
24	GNMCM86R	31171	31832
24	GNMCN14F	11430	12112
24	GNMCN14R	12286	12980
24	GNMCN59F	46864	47475
24	GNMCN59R	47935	48525
24	GNMCN60F	22771	23206
24	GNMCN60R	24286	24873
24	GNMCN91F	1694	2415
24	GNMCN91R	411	1022
24	GNMCO65F	4379	5044
24	GNMCO65R	5399	6070
24	GNMCO91F	54004	54574
24	GNMCO91R	55258	55836
24	GNMCP23F	21885	22586
24	GNMCP23R	20351	20912
24	GNMCP71F	53062	53612
24	GNMCP71R	54382	54958
24	GNMCQ33F	31360	32059
24	GNMCQ33R	30167	30816
24	GNMCS10F	52384	52999
24	GNMCS79R	9557	10245
24	GNMCV21F	13147	13602

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
24	GNMCV22R	14356	15028
24	GNMCV63F	11801	12250
24	GNMCV63R	12681	13494
24	GNMCV66F	53565	54040
24	GNMCV66R	52285	53073
24	GNMCV73R	42644	43443
24	GNMCV78F	23665	24161
24	GNMCV78R	24559	25362
24	GNMCX22F	8574	9293
24	GNMCX22R	9681	10320
24	GNMCX33F	23234	23994
24	GNMCX33R	21803	22176
24	GNMCX34F	23296	23994
24	GNMCX34R	21787	22355
24	GNMCX40F	28130	28866
24	GNMCX40R	29005	29697
24	GNMCX70F	10118	10635
24	GNMCX70R	11461	12043
24	GNMCX72F	27541	27741
24	GNMCY35F	32221	32765
24	GNMCY35R	31087	31546
24	GNMCY55F	45603	46359
24	GNMCY66R	2897	3449
24	GNMCY77F	29179	29866
24	GNMCY77R	27766	28254
24	GNMCY82F	9582	10184
24	GNMCY82R	11010	11421
24	GNMCY94F	6998	7520
24	GNMCY96F	22341	22994
24	GNMCY96R	23886	24294
24	GNMCZ37F	24346	24873
24	GNMCZ37R	23379	23953
25	GNMAA34F	450	701
25	GNMBA48F	4952	5519
25	GNMBA48R	4021	4222
25	GNMCA16F	14824	15438
25	GNMCB09F	22420	22990
25	GNMCB09R	23872	24453
25	GNMCD04F	2415	2961
25	GNMCD04R	1176	1633
25	GNMCK09F	3101	3667
25	GNMCK09R	4706	5009
25	GNMCK50F	8704	9235
25	GNMCK50R	10150	10511
25	GNMCM76R	3069	3807
25	GNMCM96F	13743	14447

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
25	GNMCM96R	12253	12967
25	GNMCN04R	15105	15705
25	GNMCN05F	13789	14465
25	GNMCP16F	9455	10151
25	GNMCP16R	8452	9076
25	GNMCP62R	9951	10498
25	GNMCX61F	2026	2420
25	GNMCX61R	3150	3850
25	GNMCY04F	10646	11249
25	GNMCY04R	12076	12645
25	GNMCZ20F	13438	13952
25	GNMCZ20R	12311	12861
26	GNMAA37F	45118	45485
26	GNMAA37R	46181	46702
26	GNMAA44F	38832	39198
26	GNMAA44R	37468	37990
26	GNMBB25F	2584	3149
26	GNMBB25R	4308	4852
26	GNMCA28F	34335	34909
26	GNMCB61F	37090	37496
26	GNMCE76F	146	542
26	GNMCE76R	1633	1980
26	GNMCF66F	27879	28279
26	GNMCF66R	29423	30059
26	GNMCL21F	39439	39981
26	GNMCL21R	37698	38064
26	GNMCL69F	3546	4121
26	GNMCL69R	4207	4797
26	GNMCM34R	3940	4653
26	GNMCM89F	5891	6343
26	GNMCM89R	7010	7718
26	GNMCM92R	30750	31399
26	GNMCN54F	28683	29364
26	GNMCN54R	27207	27807
26	GNMCN79F	51540	52223
26	GNMCN79R	50402	50941
26	GNMCO14F	33740	34469
26	GNMCO14R	35347	36067
26	GNMCQ26F	47379	47982
26	GNMCQ26R	48736	49406
26	GNMCS81F	36588	37281
26	GNMCS88F	19142	19409
26	GNMCS89R	17251	18014
26	GNMCV32F	18068	18514
26	GNMCV33F	30470	30781
26	GNMCV33R	28683	29309

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
26	GNMCV70F	41545	42025
26	GNMCV70R	42579	43282
26	GNMCV76F	30234	30720
26	GNMCV76R	31359	32063
26	GNMCV86R	42591	43300
26	GNMCV87F	41330	41805
26	GNMCV87R	42509	43300
26	GNMCX26R	42058	42510
26	GNMCY31R	1275	1860
26	GNMCY86F	27767	28402
26	GNMCY86R	26306	26736
26	GNMCZ13F	23798	24317
26	GNMCZ13R	24994	25572
26	GNMCZ64F	26763	27169
26	GNMCZ64R	27996	28534
26	GNMCZ71F	47451	47955
26	GNMCZ71R	46061	46606
26	GNMCZ95R	8013	8499
26	GNMCZ96R	8005	8483
27	GNMAA41F	3036	3402
27	GNMAA41R	2156	2677
27	GNMAA65F	58776	59296
27	GNMAA65R	60307	60457
27	GNMAB83F	38177	38746
27	GNMAB83R	36806	37326
27	GNMAB86F	20818	21390
27	GNMAB86R	21914	22429
27	GNMAB92F	21743	22226
27	GNMBA25F	28880	29408
27	GNMBA25R	27506	28043
27	GNMBA49F	40184	40752
27	GNMCB28F	15988	16497
27	GNMCB28R	14642	15180
27	GNMCB30R	14648	14996
27	GNMCB35F	33768	34099
27	GNMCB35R	32048	32548
27	GNMCB37F	31837	32567
27	GNMCB37R	30832	31421
27	GNMCB58F	30329	31041
27	GNMCB58R	31809	32460
27	GNMCD63F	15824	16290
27	GNMCD79F	63644	64156
27	GNMCD79R	62110	62364
27	GNMCF64F	41517	41871
27	GNMCF84F	518	956
27	GNMCF84R	1834	2533

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
27	GNMCF85F	6358	6815
27	GNMCF85R	7660	8383
27	GNMCH76F	22610	22966
27	GNMCH77F	22613	22953
27	GNMCK01F	62394	62733
27	GNMCK01R	60888	61415
27	GNMCK18F	66502	66997
27	GNMCK18R	65282	65724
27	GNMCK25F	27644	28213
27	GNMCK61F	32761	33107
27	GNMCK61R	30995	31329
27	GNMCK76F	19006	19542
27	GNMCK76R	17573	18122
27	GNMCK81F	61093	61511
27	GNMCK81R	59863	60445
27	GNMCK87F	36665	36996
27	GNMCK87R	34928	35498
27	GNMCL44F	38519	39001
27	GNMCL44R	37283	37863
27	GNMCL76F	49805	50300
27	GNMCL76R	48285	48854
27	GNMCM23F	27097	27789
27	GNMCM23R	25771	26483
27	GNMCN12F	8559	9239
27	GNMCN12R	7161	7752
27	GNMCN13F	68144	68833
27	GNMCN13R	66871	67394
27	GNMCN17F	36140	36815
27	GNMCN17R	35179	35753
27	GNMCN18F	55803	56468
27	GNMCN18R	54618	55229
27	GNMCN34F	59534	60268
27	GNMCN34R	19457	20056
27	GNMCN38F	17990	18719
27	GNMCN61F	18037	18594
27	GNMCN61R	19452	20056
27	GNMCN70F	32750	33421
27	GNMCN80R	37432	38115
27	GNMCN81F	38597	39329
27	GNMCN81R	37434	38096
27	GNMCO02R	59813	60549
27	GNMCO38F	51253	51930
27	GNMCO52R	33701	34400
27	GNMCO57F	37843	38469
27	GNMCO57R	36757	37320
27	GNMCP50F	7088	7522

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
27	GNMCP50R	5679	6058
27	GNMCQ93R	2933	3510
27	GNMCS49F	11768	12343
27	GNMCV50F	28795	29193
27	GNMCV50R	27644	28413
27	GNMCV85F	21568	22089
27	GNMCV85R	22559	23351
27	GNMCW02F	47088	47658
27	GNMCW24F	56091	56713
27	GNMCY27R	5455	5536
27	GNMCY33F	37884	38598
27	GNMCY33R	39134	39678
27	GNMCY62F	39794	40529
27	GNMCY62R	41156	41683
27	GNMCY63F	39843	40316
27	GNMCY72F	15711	16330
27	GNMCY72R	14681	15239
28	GNMAA45F	4450	4816
28	GNMAA54R	4273	4733
28	GNMCD82F	1790	2266
28	GNMCD82R	3389	3826
28	GNMCO78F	6645	7293
28	GNMCO86F	6688	7310
28	GNMCO86R	8039	8651
28	GNMCW05F	6711	7331
28	GNMCZ09F	13148	13623
28	GNMCZ09R	11925	12279
29	GNMAA47F	27107	27473
29	GNMAA47R	25852	26322
29	GNMAA71F	19984	20503
29	GNMAA71R	21408	21826
29	GNMAA80R	20918	21282
29	GNMAB31F	32769	33333
29	GNMAB31R	31525	31942
29	GNMAB77F	21439	22007
29	GNMAB77R	22335	22857
29	GNMCA22F	9411	10028
29	GNMCB74F	26713	27450
29	GNMCB74R	25839	26476
29	GNMCD08F	17015	17514
29	GNMCD31F	19776	20146
29	GNMCF43F	26320	26631
29	GNMCF43R	27361	28023
29	GNMCF87F	30819	31269
29	GNMCF87R	32125	32845
29	GNMCH41F	30939	31379

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
29	GNMCK20F	2703	3104
29	GNMCK20R	4020	4346
29	GNMCL02F	32166	32619
29	GNMCL02R	33533	33884
29	GNMCL12F	360	831
29	GNMCL12R	1490	2039
29	GNMCL73R	32923	33504
29	GNMCL85R	10861	11425
29	GNMCM77F	17717	18313
29	GNMCM77R	16440	17172
29	GNMCN64F	6192	6750
29	GNMCN64R	7430	8018
29	GNMCN68F	30002	30712
29	GNMCN83F	34059	34776
29	GNMCN83R	32873	33458
29	GNMCO28F	7197	7872
29	GNMCO28R	8396	9089
29	GNMCO53F	20633	21342
29	GNMCO53R	22061	22663
29	GNMCO67F	1523	2102
29	GNMCO67R	2871	3524
29	GNMCP82F	30881	31419
29	GNMCP82R	29550	30117
29	GNMCS26F	30683	31168
29	GNMCS90F	16067	16703
29	GNMCS91R	16949	17757
29	GNMCW09F	3770	4381
29	GNMCY19F	14037	14742
29	GNMCY89F	7491	8173
30	GNMAA48R	1027	1347
30	GNMAB21R	3808	4233
30	GNMCC90F	7658	8102
30	GNMCL10F	2942	3470
30	GNMCL10R	4319	4883
30	GNMCM64R	7645	8319
30	GNMCO63F	12259	12933
30	GNMCO63R	11104	11789
30	GNMCP58F	8513	9047
30	GNMCP58R	10322	10707
30	GNMCV03F	10383	10724
30	GNMCV04R	8992	9749
30	GNMCX06F	11346	12072
30	GNMCX06R	12784	13418
30	GNMCX18F	11968	12726
30	GNMCX18R	13547	14189
30	GNMCX71F	9073	9653

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
30	GNMCX71R	7669	8353
30	GNMCY15F	3214	3933
30	GNMCY15R	1508	2079
31	GNMAA49F	7079	7444
31	GNMAA49R	5736	6260
31	GNMBA38F	692	1262
31	GNMBA79F	7797	8367
31	GNMCL32F	3721	4184
31	GNMCL32R	2230	2815
31	GNMCN88F	1761	2482
31	GNMCN88R	3292	3892
31	GNMCQ51F	3265	3909
31	GNMCQ51R	4295	5012
31	GNMCX63R	7311	8010
31	GNMCY61R	4386	4868
31	GNMCY91F	2862	3456
32	GNMAA52F	1739	2107
32	GNMAA52R	2617	3138
32	GNMAA89F	13148	13666
32	GNMAB90F	5624	6192
32	GNMAB90R	6600	7118
32	GNMCF38F	3403	3878
32	GNMCF38R	4584	5237
32	GNMCK38F	6598	7143
32	GNMCK38R	5207	5792
32	GNMCP85F	6949	7473
32	GNMCP85R	5282	5869
32	GNMCQ07F	10995	11623
32	GNMCQ07R	12678	13358
32	GNMCV23F	5455	5912
32	GNMCV24R	4006	4751
32	GNMCX13F	9897	10671
32	GNMCX13R	8710	9345
32	GNMCX45F	3857	4557
32	GNMCX45R	2724	3424
32	GNMCX57F	6426	6642
32	GNMCX57R	6424	6642
32	GNMCY06F	10183	10812
32	GNMCY06R	9259	9808
33	GNMAA57F	2954	3324
33	GNMAA57R	1924	2445
33	GNMAB30F	5838	6402
33	GNMAB30R	4864	5193
33	GNMAB48F	8816	9381
33	GNMBA50F	7809	8374
33	GNMBA50R	6161	6686

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
33	GNMCA25F	18305	18918
33	GNMCA80F	3189	3849
33	GNMCL88F	12941	13492
33	GNMCL88R	11494	12068
33	GNMCM57F	6934	7569
33	GNMCM57R	7814	8548
33	GNMCN49F	18067	18780
33	GNMCN49R	16729	17352
33	GNMCO54F	17815	18524
33	GNMCO54R	16974	17598
33	GNMCP59F	13173	13661
33	GNMCP59R	14688	15102
33	GNMCQ29F	13338	14036
33	GNMCQ29R	11998	12686
33	GNMCQ87F	5967	6647
33	GNMCQ87R	7354	7981
33	GNMCS47F	7736	8461
33	GNMCV30F	18040	18529
33	GNMCV31F	1808	2296
33	GNMCV31R	16473	17092
33	GNMCV32R	2897	3643
33	GNMCY12F	13632	14327
33	GNMCY12R	14891	15465
33	GNMCZ12F	14374	14860
33	GNMCZ12R	12879	13414
34	GNMAA59R	20271	20600
34	GNMAB63F	21594	22082
34	GNMAB87F	4234	4656
34	GNMAB93F	8137	8678
34	GNMAB93R	7021	7543
34	GNMBA26F	17728	18076
34	GNMBA31R	20426	20952
34	GNMBA60F	2998	3562
34	GNMBA60R	4887	5305
34	GNMBA89F	12688	13184
34	GNMBA89R	11336	11869
34	GNMBA90F	1963	2532
34	GNMBA90R	3410	3918
34	GNMBB10F	18931	19469
34	GNMBB10R	20494	20791
34	GNMCA73F	10776	11434
34	GNMCD09F	1576	2151
34	GNMCD09R	202	580
34	GNMCL40F	6504	7032
34	GNMCL40R	7906	8476
34	GNMCM41F	15257	15722

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
34	GNMCM41R	13646	14279
34	GNMCM84F	10143	10755
34	GNMCM84R	11418	12090
34	GNMCP65R	13124	13566
34	GNMCQ57F	1107	1637
34	GNMCQ57R	2550	3230
34	GNMCV15F	10810	11260
34	GNMCV16R	9522	10243
34	GNMCX35F	24683	25380
34	GNMCX35R	25964	26651
34	GNMCX48F	27078	27683
34	GNMCX48R	25636	26324
34	GNMCZ82R	4431	4970
35	GNMAA60R	9724	9928
35	GNMAA81R	42064	42495
35	GNMAB09F	29605	30171
35	GNMBA37F	1865	2426
35	GNMBA37R	755	1265
35	GNMCA66F	14095	14490
35	GNMCB95F	29548	30210
35	GNMCB95R	28364	28994
35	GNMCD41F	4298	4824
35	GNMCD41R	2960	3326
35	GNMCD49F	47011	47510
35	GNMCD49R	45671	46032
35	GNMCD52F	46968	47374
35	GNMCE13F	44763	45068
35	GNMCE13R	43656	44020
35	GNMCK86F	32959	33472
35	GNMCL94F	45671	46185
35	GNMCL94R	44388	44948
35	GNMCM08F	32206	32865
35	GNMCM08R	33769	34324
35	GNMCN16F	11716	12326
35	GNMCN16R	10117	10693
35	GNMCN33F	2863	3568
35	GNMCN33R	4337	4927
35	GNMCO11F	117	667
35	GNMCO11R	1479	2220
35	GNMCO20F	41254	41858
35	GNMCO20R	42840	43385
35	GNMCP03R	15135	15820
35	GNMCP33F	33871	34386
35	GNMCP33R	31902	32446
35	GNMCS31F	25024	25611
35	GNMCS80F	26013	26719

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
35	GNMCV20F	11142	11598
35	GNMCV21R	9547	10242
35	GNMCV41F	1508	1764
35	GNMCV41R	2993	3375
35	GNMCV46F	19148	19638
35	GNMCX37F	10287	10978
35	GNMCX75F	16758	17496
35	GNMCX75R	17915	18615
35	GNMCY38F	35286	36002
35	GNMCY38R	36447	37009
35	GNMCZ63F	17628	18139
35	GNMCZ63R	16308	16866
36	GNMAA61F	17639	18003
36	GNMAA61R	19148	19669
36	GNMAB14F	9325	9894
36	GNMAB14R	10480	10900
36	GNMAB23F	5098	5510
36	GNMAB23R	5999	6420
36	GNMBA04F	7545	8114
36	GNMBA04R	8552	9087
36	GNMCB81F	1908	2616
36	GNMCB81R	1189	1739
36	GNMCD86F	266	753
36	GNMCD86R	1917	2276
36	GNMCL29F	19188	19732
36	GNMCL46F	5977	6459
36	GNMCL46R	6855	7431
36	GNMCL71R	2286	2862
36	GNMCN74F	8750	9460
36	GNMCN76R	7557	8138
36	GNMCP37R	5055	5645
36	GNMCS39F	3380	4120
36	GNMCV57F	6730	7217
36	GNMCV57R	7760	8463
36	GNMCX54F	7658	7977
36	GNMCX54R	6197	6884
36	GNMCY85R	6699	7077
36	GNMCZ06F	17782	18302
36	GNMCZ73F	15242	15755
37	GNMAA64F	11674	12041
37	GNMAA64R	10619	11088
37	GNMAB25F	25946	26508
37	GNMAB25R	27013	27437
37	GNMAB32R	446	844
37	GNMAB89F	2515	3085
37	GNMAB89R	3403	3923

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
37	GNMAB91F	19524	19900
37	GNMAB91R	18389	18909
37	GNMCA84F	8986	9651
37	GNMCA92F	10174	10831
37	GNMCB13F	28388	28959
37	GNMCB44F	17203	17885
37	GNMCB44R	16050	16676
37	GNMCB72F	15012	15708
37	GNMCB72R	16365	16857
37	GNMCD32F	4633	5112
37	GNMCD32R	2775	3142
37	GNMCD34F	21613	22123
37	GNMCD34R	23152	23452
37	GNMCD43F	23745	24277
37	GNMCF03F	23267	23766
37	GNMCF03R	21815	22457
37	GNMCK16F	12575	13127
37	GNMCK69R	981	1281
37	GNMCL41F	4846	5357
37	GNMCL41R	6380	6932
37	GNMCM06R	17272	17986
37	GNMCM82F	14731	15358
37	GNMCM82R	15814	16507
37	GNMCQ08F	20211	20740
37	GNMCQ08R	18866	19521
37	GNMCQ59F	16099	16826
37	GNMCQ59R	15132	15853
37	GNMCS58F	16358	17054
37	GNMCV94F	21841	22327
37	GNMCV94R	20477	21267
37	GNMCX07F	25522	26245
37	GNMCX07R	26310	26960
37	GNMCX69F	10320	10866
37	GNMCX69R	11842	12449
37	GNMCX93F	7947	8360
37	GNMCX93R	6445	6970
37	GNMCY18F	10778	11193
37	GNMCY18R	9630	10203
37	GNMCY67F	26216	26689
37	GNMCY67R	24586	24992
37	GNMCZ87F	28035	28543
37	GNMCZ87R	26386	26930
38	GNMAA74F	185	702
38	GNMAB59F	370	710
38	GNMCM68F	512	991
39	GNMBA35F	3187	3756

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
39	GNMCL49F	518	1006
39	GNMCM19F	3839	4413
39	GNMCM19R	2735	3480
39	GNMCM68R	3717	4374
39	GNMCN15F	11	695
39	GNMCN15R	1589	2036
39	GNMCS14F	2485	3018
39	GNMCV29F	4010	4481
39	GNMCV30R	2621	3321
39	GNMCZ91F	4347	4839
39	GNMCZ91R	3070	3594
40	GNMAA75F	1493	2009
40	GNMBA84F	14749	15315
40	GNMBA84R	13039	13401
40	GNMBB27F	7061	7629
40	GNMBB27R	5877	6280
40	GNMCA65F	10805	11468
40	GNMCF01F	9566	10068
40	GNMCF01R	7689	8249
40	GNMCF52F	13446	13800
40	GNMCF52R	14807	15448
40	GNMCK41F	1322	1894
40	GNMCK41R	1	549
40	GNMCN01R	8094	8669
40	GNMCN02F	6573	7152
40	GNMCY39F	12214	12932
40	GNMCY39R	11377	11773
40	GNMCZ75F	4573	5040
40	GNMCZ75R	3272	3824
41	GNMAA82F	1944	2123
41	GNMAA82R	540	848
41	GNMCA09F	4155	4769
41	GNMCL45F	5831	6382
41	GNMCL45R	7014	7592
41	GNMCX84F	6407	7029
41	GNMCX84R	4937	5630
41	GNMCZ07F	753	1256
41	GNMCZ07R	2139	2681
42	GNMAA85F	33488	34005
42	GNMAA85R	34461	34906
42	GNMAB11F	27021	27587
42	GNMAB16F	16195	16762
42	GNMAB16R	17262	17683
42	GNMAB51F	32336	32901
42	GNMAB64F	9048	9478
42	GNMBA52F	25714	26279

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
42	GNMBA52R	26930	27429
42	GNMBA63F	25856	26418
42	GNMCA10F	9199	9803
42	GNMCA90F	12306	12957
42	GNMCD76F	43170	43607
42	GNMCD80F	25485	25983
42	GNMCD80R	24100	24472
42	GNMCD81F	25467	25981
42	GNMCF21F	42792	43250
42	GNMCF21R	43820	44488
42	GNMCF79F	19953	20412
42	GNMCF79R	18429	19107
42	GNMCH08F	10638	10983
42	GNMCH61F	35608	36017
42	GNMCK58F	11541	12006
42	GNMCK58R	13419	13981
42	GNMCM03R	37448	38182
42	GNMCM48F	1	622
42	GNMCM48R	1215	1878
42	GNMCO34F	11655	12379
42	GNMCO34R	10537	11201
42	GNMCO70R	39192	39848
42	GNMCO84F	24768	25509
42	GNMCO84R	24098	24770
42	GNMCP29F	40509	41019
42	GNMCP29R	38958	39359
42	GNMCQ60F	38032	38565
42	GNMCQ69F	8563	9122
42	GNMCQ69R	6981	7666
42	GNMCS69F	3213	3921
42	GNMCV25F	17625	18095
42	GNMCV26R	16021	16633
42	GNMCX46F	4775	5450
42	GNMCX46R	3438	4125
42	GNMCX88R	17104	17778
42	GNMCY37F	7223	7838
42	GNMCY37R	5827	6323
42	GNMCY69F	22213	22853
42	GNMCY69R	21279	21796
42	GNMCZ85F	19300	19813
43	GNMAA86F	5244	5760
43	GNMAA86R	4311	4783
43	GNMCS54F	3163	3797
43	GNMCV84F	1109	1600
43	GNMCV84R	2002	2781
44	GNMAA87F	26931	27447

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
44	GNMAA87R	27952	28361
44	GNMAA90F	6714	7230
44	GNMAA90R	8124	8276
44	GNMAB27F	4036	4606
44	GNMAB27R	4904	5327
44	GNMCD11F	4246	4813
44	GNMCD11R	5623	6146
44	GNMCQ17F	6327	7009
44	GNMCQ17R	7631	8317
44	GNMCQ67F	1410	2013
44	GNMCQ67R	2571	3261
44	GNMCS92F	21392	22037
44	GNMCS94R	22779	23479
44	GNMCS96F	22613	22986
44	GNMCX79F	14815	15344
44	GNMCX79R	16086	16760
44	GNMCZ44F	19312	19820
44	GNMCZ44R	20486	21049
45	GNMAA88F	3827	4313
45	GNMBA05F	7835	8403
45	GNMBA05R	6395	6824
45	GNMCZ39F	143	619
45	GNMCZ39R	1545	2114
46	GNMAA94F	5740	6254
46	GNMAA94R	6575	7044
46	GNMAB29F	659	1225
46	GNMAB29R	1871	2298
46	GNMAB78F	16523	16951
46	GNMAB78R	15145	15666
46	GNMCA05F	4467	5137
46	GNMCD25F	11261	11830
46	GNMCD25R	10056	10529
46	GNMCD45F	4725	5273
46	GNMCD45R	3455	3826
46	GNMCD72F	12772	13251
46	GNMCD72R	14201	14542
46	GNMCK45F	6690	7258
46	GNMCK45R	5280	5857
46	GNMCK53F	9263	9636
46	GNMCK53R	10581	11122
46	GNMCN62R	20059	20606
46	GNMCO72F	11911	12654
46	GNMCO72R	10592	11291
46	GNMCS38F	8266	8953
46	GNMCS50F	9604	10313
46	GNMCY09F	18777	19443

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
46	GNMCY09R	20339	20885
46	GNMCY48F	13317	14054
46	GNMCY48R	12373	12900
47	GNMAB03F	39285	39849
47	GNMAB03R	40395	40825
47	GNMAB57F	8125	8631
47	GNMAB62F	5129	5697
47	GNMAB72F	25957	26522
47	GNMAB72R	26812	27332
47	GNMBA39F	10581	11112
47	GNMBA39R	9272	9805
47	GNMBA68F	33182	33747
47	GNMBA68R	32098	32634
47	GNMBB31F	46909	47485
47	GNMBB31R	45477	45996
47	GNMCB64F	8634	9225
47	GNMCB64R	9880	10466
47	GNMCD39F	26389	26882
47	GNMCF18F	42096	42592
47	GNMCF18R	40473	41111
47	GNMCF47F	46147	46634
47	GNMCF47R	44893	45560
47	GNMCK29F	14259	14820
47	GNMCK29R	12913	13476
47	GNMCK33F	11732	12246
47	GNMCK33R	10377	10759
47	GNMCK51F	19259	19619
47	GNMCK51R	17899	18248
47	GNMCL24F	21022	21491
47	GNMCL24R	19374	19922
47	GNMCL66F	34263	34768
47	GNMCL66R	35478	36049
47	GNMCM30R	35959	36642
47	GNMCM37R	18280	18787
47	GNMCN36F	28250	28958
47	GNMCN73F	29393	30074
47	GNMCN73R	28267	28921
47	GNMCN93F	1262	1971
47	GNMCN93R	2446	2878
47	GNMCO45F	14719	15397
47	GNMCO45R	15952	16635
47	GNMCO49F	38118	38828
47	GNMCO49R	39315	39845
47	GNMCO60F	21461	22152
47	GNMCO60R	19964	20648
47	GNMCO83R	16405	17063

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
47	GNMCP08F	4600	5318
47	GNMCP08R	5704	6436
47	GNMCP12F	44482	45180
47	GNMCP12R	43247	43929
47	GNMCQ70F	28264	28919
47	GNMCQ70R	27232	27902
47	GNMCS79F	28111	28860
47	GNMCX52F	44094	44441
47	GNMCX52R	45425	46100
47	GNMCX73F	8582	9157
47	GNMCX73R	7456	8141
47	GNMCY08F	22073	22785
47	GNMCY08R	20965	21539
47	GNMCY17F	13457	14071
47	GNMCY17R	12199	12710
47	GNMCY60F	4726	5396
47	GNMCY60R	3394	3937
47	GNMCZ72F	26112	26584
47	GNMCZ72R	27111	27642
48	GNMAB10F	45864	46429
48	GNMAB10R	46823	47246
48	GNMAB26F	18205	18771
48	GNMAB26R	17068	17496
48	GNMAB46F	39600	40166
48	GNMAB71F	36266	36835
48	GNMAB71R	35583	35981
48	GNMBA10F	24081	24641
48	GNMBA10R	25627	26158
48	GNMCA01F	2669	3310
48	GNMCA69F	24907	25573
48	GNMCA77F	44240	44904
48	GNMCB68F	48529	49183
48	GNMCB68R	49751	50229
48	GNMCD05F	61093	61524
48	GNMCD05R	47029	47548
48	GNMCD24F	41436	41982
48	GNMCD24R	42664	43161
48	GNMCD70F	43366	43798
48	GNMCE06F	45703	46081
48	GNMCE07R	46605	47129
48	GNMCE90F	6380	6925
48	GNMCE90R	5283	5799
48	GNMCF24F	56963	57448
48	GNMCF24R	55581	56243
48	GNMCF70R	50946	51263
48	GNMCF93F	46705	47157

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
48	GNMCF93R	48122	48692
48	GNMCH40F	24168	24458
48	GNMCH64F	60688	61022
48	GNMCK08F	12988	13530
48	GNMCK08R	11548	12144
48	GNMCK31F	48379	48939
48	GNMCK31R	47177	47731
48	GNMCK46F	13297	13814
48	GNMCK46R	12071	12654
48	GNMCK56F	29433	29963
48	GNMCK56R	27927	28487
48	GNMCK70F	41792	42156
48	GNMCK70R	43324	43888
48	GNMCL05F	22552	23041
48	GNMCL05R	21742	22293
48	GNMCL61F	15321	15724
48	GNMCL61R	14006	14449
48	GNMCL86F	23803	24358
48	GNMCL86R	22389	22965
48	GNMCM40F	60172	60784
48	GNMCM40R	43992	44623
48	GNMCM49R	63033	63741
48	GNMCM60F	28595	29249
48	GNMCM60R	27285	27929
48	GNMCN95F	21768	22424
48	GNMCN96F	52482	53159
48	GNMCO12F	49771	50550
48	GNMCO12R	49060	49698
48	GNMCO76F	26934	27624
48	GNMCO76R	25392	26062
48	GNMCO90F	10121	10652
48	GNMCO90R	8744	9318
48	GNMCP81F	26207	26575
48	GNMCP81R	27441	28017
48	GNMCQ16R	1	661
48	GNMCQ36R	13779	14476
48	GNMCQ48F	44157	44770
48	GNMCQ48R	43032	43754
48	GNMCQ64F	12475	13200
48	GNMCQ66F	12668	13370
48	GNMCQ66R	13747	14472
48	GNMCQ89F	16922	17619
48	GNMCV06F	48695	49152
48	GNMCV07R	47510	48231
48	GNMCV11F	26723	27238
48	GNMCV12R	27836	28452

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
48	GNMCV18F	35744	36244
48	GNMCV19R	34456	35205
48	GNMCV82F	8278	8644
48	GNMCV82R	8280	8645
48	GNMCV96F	45990	46492
48	GNMCV96R	44480	45162
48	GNMCX28F	42946	43632
48	GNMCX28R	44129	44767
48	GNMCX29F	59233	59998
48	GNMCX29R	58344	58984
48	GNMCX42F	22170	22862
48	GNMCX42R	23577	24264
48	GNMCX50F	29838	30232
48	GNMCX50R	30956	31633
48	GNMCX80F	30061	30735
48	GNMCX80R	31536	32224
48	GNMCY70F	13009	13629
48	GNMCY70R	11725	12281
48	GNMCZ84R	4001	4533
49	GNMAB32F	401	684
50	GNMAB35F	17857	18274
50	GNMBA70F	14615	15180
50	GNMBA70R	15849	16383
50	GNMCB20R	20852	21453
50	GNMCB89F	12569	13223
50	GNMCB89R	14045	14508
50	GNMCF67F	4524	4879
50	GNMCF67R	3257	3858
50	GNMCH89F	19690	20140
50	GNMCH89R	18248	18535
50	GNMCK49F	20201	20665
50	GNMCK49R	18771	19297
50	GNMCM01F	2158	2770
50	GNMCM01R	708	1314
50	GNMCN41F	21893	22570
50	GNMCN41R	23128	23476
50	GNMCO04F	2174	2638
50	GNMCO04R	837	1541
50	GNMCO82F	16481	17139
50	GNMCO82R	17538	18219
50	GNMCP61F	13046	13330
50	GNMCP61R	14605	15154
50	GNMCS33F	27679	28393
50	GNMCV22F	21920	22410
50	GNMCV23R	20644	21369
50	GNMCV47F	17147	17659

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
50	GNMCV47R	18206	18900
50	GNMCV58R	1132	1905
50	GNMCV59R	1242	1814
50	GNMCX41F	3977	4725
50	GNMCX41R	5212	5916
50	GNMCY22F	22454	23103
50	GNMCY29R	22461	23008
50	GNMCY71F	10076	10646
50	GNMCY71R	9041	9543
50	GNMCZ52F	20698	21140
50	GNMCZ52R	22156	22569
50	GNMCZ94F	3890	4317
50	GNMCZ94R	5230	5743
50	GNMCZ95F	3902	4346
50	GNMCZ96F	3902	4346
51	GNMAB39F	5946	6511
51	GNMBA51F	8613	9139
51	GNMBA51R	6844	7329
51	GNMCL84F	7136	7509
51	GNMCL84R	8501	9072
51	GNMCO08R	979	1711
51	GNMCY10F	1194	1921
51	GNMCY10R	50	610
51	GNMCZ33F	3405	3947
51	GNMCZ33R	4668	5244
52	GNMAB40F	15814	16385
52	GNMCB93F	7437	8109
52	GNMCB93R	8732	9304
52	GNMCF69F	9103	9470
52	GNMCF69R	7871	8573
52	GNMCF92F	2901	3235
52	GNMCF92R	1359	2018
52	GNMCL51F	16830	17360
52	GNMCL51R	18234	18580
52	GNMCM61R	12794	13378
52	GNMCN24F	1	676
52	GNMCN24R	1452	2016
52	GNMCO31F	17039	17664
52	GNMCO31R	18187	18861
52	GNMCS05F	11540	12169
52	GNMCX49F	10221	10402
52	GNMCX49R	8569	9260
52	GNMCX96R	4202	4835
52	GNMCZ83F	11839	12349
52	GNMCZ83R	13065	13609
53	GNMAB50F	81	306

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
54	GNMAB60F	4573	5141
54	GNMCD66F	258	750
55	GNMAB66F	1314	1623
55	GNMCB73F	3597	4316
55	GNMCB73R	5062	5644
55	GNMCM35F	3120	3883
55	GNMCM35R	2555	3288
55	GNMCX47F	5496	6201
55	GNMCX47R	4289	4982
55	GNMCY34F	5585	6305
56	GNMAB79R	1	246
57	GNMAB80F	19923	20432
57	GNMAB80R	21103	21624
57	GNMBA07F	14530	15093
57	GNMBA07R	15847	16378
57	GNMCB11R	30694	31243
57	GNMCB47F	29518	30234
57	GNMCB47R	28242	28881
57	GNMCD55F	32780	33171
57	GNMCE88F	13260	13679
57	GNMCE88R	14546	15067
57	GNMCF06F	16859	17358
57	GNMCF06R	15242	15921
57	GNMCF40F	18554	19027
57	GNMCF40R	19698	20365
57	GNMCF50F	20435	20910
57	GNMCF50R	21576	22262
57	GNMCF63F	30402	30884
57	GNMCF63R	28818	29412
57	GNMCF86R	32361	33020
57	GNMCK71F	8763	9100
57	GNMCK71R	10055	10613
57	GNMCL95F	3811	4223
57	GNMCL95R	2299	2901
57	GNMCN67F	20529	21206
57	GNMCN67R	19529	20102
57	GNMCP09F	2860	3520
57	GNMCP09R	1894	2615
57	GNMCP70F	17618	18104
57	GNMCP70R	18924	19511
57	GNMCP79F	8875	9372
57	GNMCP79R	10275	10855
57	GNMCQ41F	20359	21104
57	GNMCQ41R	19619	20345
57	GNMCQ44F	10270	10898
57	GNMCQ44R	11575	12244

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
57	GNMCS16F	20638	20868
57	GNMCS86F	30569	31246
57	GNMCV34F	21537	21988
57	GNMCY40F	20132	20855
57	GNMCY40R	19153	19716
57	GNMCY49R	26133	26607
57	GNMCY80F	8452	8787
57	GNMCY80R	6998	7416
57	GNMCY90F	19373	19946
57	GNMCZ43F	31206	31711
57	GNMCZ43R	32436	32921
58	GNMAB82F	9525	10095
58	GNMAB82R	8509	9029
58	GNMCO58R	15112	15768
58	GNMCY78R	3411	3857
58	GNMCY83F	11793	12472
58	GNMCY83R	10643	11053
59	GNMAB85F	2737	3302
59	GNMAB85R	1900	2305
59	GNMCO33F	2304	2941
59	GNMCO33R	1257	1881
59	GNMCX86F	2826	3461
59	GNMCX86R	1441	2128
59	GNMCZ32F	1619	2126
59	GNMCZ32R	2661	3195
60	GNMAB95F	13774	14279
60	GNMAB95R	15289	15810
60	GNMCA30F	937	1556
60	GNMCD44F	303	826
60	GNMCF04F	9775	10276
60	GNMCF04R	8305	8976
60	GNMCF90F	3862	4310
60	GNMCF90R	2510	3187
60	GNMCH28F	9435	9696
60	GNMCK30F	13554	14101
60	GNMCK30R	12158	12740
60	GNMCM05F	9295	9874
60	GNMCM05R	10879	11616
60	GNMCM55F	10074	10731
60	GNMCM55R	10796	11542
60	GNMCS87F	13103	13751
60	GNMCW39F	15206	15851
60	GNMCX55F	12701	12889
60	GNMCX55R	13822	14516
60	GNMCX62R	1554	2237
61	GNMBA06F	22890	23457

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
61	GNMBA06R	24229	24758
61	GNMCB04F	30158	30722
61	GNMCB04R	28612	29214
61	GNMCB21F	23862	24428
61	GNMCB21R	25186	25806
61	GNMCB63R	3796	4094
61	GNMCB86F	23284	23998
61	GNMCB86R	24021	24623
61	GNMCD18F	31187	31608
61	GNMCF95F	20692	21018
61	GNMCF95R	19232	19872
61	GNMCK40F	11307	11811
61	GNMCK65F	9007	9517
61	GNMCL04F	20077	20543
61	GNMCL04R	18687	19271
61	GNMCL20F	27968	28464
61	GNMCL20R	29257	29840
61	GNMCL22F	13417	13939
61	GNMCL22R	14872	15438
61	GNMCL29R	34192	34771
61	GNMCL53F	1518	2034
61	GNMCL53R	214	686
61	GNMCL90R	8315	8896
61	GNMCM65F	15441	16117
61	GNMCM65R	14289	14994
61	GNMCM71F	10516	11122
61	GNMCM71R	11703	12405
61	GNMCO61F	14512	15200
61	GNMCO61R	13255	13946
61	GNMCQ79F	15902	16644
61	GNMCQ79R	16726	17426
61	GNMCQ90F	2342	3073
61	GNMCQ90R	804	1426
61	GNMCQ95F	19198	19483
61	GNMCQ95R	20653	21277
61	GNMCS24F	19718	20379
61	GNMCS46F	18786	19366
61	GNMCV12F	30913	31415
61	GNMCV13R	31908	32632
61	GNMCY25F	25038	25729
61	GNMCY25R	26701	27270
62	GNMBA12F	7833	8334
62	GNMBA66F	8661	9232
62	GNMBA66R	9606	10138
62	GNMBB30F	3235	3799
62	GNMBB30R	4483	5016

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
62	GNMCB05F	4772	5096
62	GNMCB05R	6111	6717
62	GNMCD67F	7723	8233
62	GNMCF78F	3478	3931
62	GNMCM43F	12550	13285
62	GNMCM43R	11540	12127
62	GNMCP28F	3321	3756
62	GNMCP28R	1814	2235
62	GNMCP67F	2320	2824
62	GNMCP67R	3943	4497
62	GNMCV62F	8092	8582
62	GNMCV62R	9694	10487
62	GNMCX39F	7125	7796
62	GNMCX39R	5729	6265
62	GNMCZ55F	5209	5724
62	GNMCZ55R	3782	4320
62	GNMCZ76F	4455	4947
62	GNMCZ76R	3027	3553
63	GNMBA13F	14825	15391
63	GNMBA13R	13165	13703
63	GNMBA14F	12491	13059
63	GNMBA14R	13757	14281
63	GNMBA80F	12477	12855
63	GNMCB32F	472	756
63	GNMCD42F	20565	21089
63	GNMCF07F	13708	14215
63	GNMCF07R	12522	13201
63	GNMCK47F	10432	10931
63	GNMCK47R	9275	9813
63	GNMCK91R	9054	9617
63	GNMCN32F	16696	17346
63	GNMCN32R	17927	18521
63	GNMCS55F	1461	2208
63	GNMCX85R	14727	15427
63	GNMCZ11R	17115	17610
63	GNMCZ18F	1990	2479
63	GNMCZ18R	3109	3667
63	GNMCZ34F	13696	14216
63	GNMCZ34R	12451	13003
64	GNMBA27F	2420	2987
64	GNMBA27R	649	1182
64	GNMCK68F	8858	9142
64	GNMCN47F	8600	9323
64	GNMCQ47F	5300	5761
64	GNMCQ47R	3904	4632
64	GNMCZ45F	6005	6471

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
64	GNMCZ45R	7509	8073
64	GNMCZ89F	6722	7164
65	GNMBA40F	9256	9800
65	GNMBA40R	7884	8418
65	GNMCK42F	8125	8438
65	GNMCK42R	9146	9679
65	GNMCK43F	14839	15396
65	GNMCK43R	13196	13745
65	GNMCM11R	2515	3190
65	GNMCO03F	4056	4557
65	GNMCO03R	5332	6065
65	GNMCO32F	10209	10877
65	GNMCO32R	11348	11993
65	GNMCO78R	1107	1782
65	GNMCQ10F	9012	9752
65	GNMCQ10R	10149	10831
65	GNMCQ36F	19	522
65	GNMCZ17F	1839	2369
65	GNMCZ17R	3149	3711
65	GNMCZ24R	3485	4030
65	GNMCZ50R	2017	2356
65	GNMCZ51F	3684	4187
65	GNMCZ51R	5216	5657
66	GNMBA45F	5960	6527
66	GNMBA45R	4417	4948
66	GNMBB01F	3556	4094
66	GNMBB01R	2060	2598
66	GNMCA23F	4257	4873
66	GNMCN50F	6431	7098
66	GNMCN50R	5020	5625
66	GNMCO46F	1766	2443
66	GNMCO46R	706	1195
66	GNMCQ15F	1788	2506
66	GNMCQ15R	994	1686
66	GNMCZ67F	1099	1592
66	GNMCZ67R	2554	3093
66	GNMCZ68F	1130	1584
67	GNMBA56R	828	1363
67	GNMCZ01F	1176	1497
67	GNMCZ01R	2672	3147
68	GNMBA58F	11648	12214
68	GNMBA58R	10145	10680
68	GNMBB14F	7190	7758
68	GNMBB14R	8579	9037
68	GNMCD71F	502	959
68	GNMCL54F	10328	10882

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
68	GNMCL54R	11852	12293
68	GNMCN39F	13282	13967
68	GNMCN39R	11911	12477
68	GNMCP34F	12249	12751
68	GNMCP34R	10521	11087
68	GNMCP74F	9533	10032
68	GNMCP74R	8395	8982
68	GNMCV35F	11085	11475
68	GNMCV35R	12496	12972
69	GNMBA67F	10755	11332
69	GNMBA67R	9691	10167
69	GNMCA68F	138	798
69	GNMCA95F	7720	8389
69	GNMCB19F	7635	8181
69	GNMCB62F	4968	5465
69	GNMCB62R	6482	7170
69	GNMCD88F	6048	6546
69	GNMCD94F	10463	10960
69	GNMCD94R	12298	12546
70	GNMBA87F	8256	8675
70	GNMBA87R	6890	7365
70	GNMCA76F	9130	9792
70	GNMCB96F	10306	11006
70	GNMCB96R	11786	12359
70	GNMCD20F	2427	2973
70	GNMCD20R	3980	4417
70	GNMCE77F	10510	10866
70	GNMCF49F	13718	14204
70	GNMCF49R	11782	12414
70	GNMCF57F	24615	25081
70	GNMCF57R	23522	24203
70	GNMCF81R	14890	15469
70	GNMCK10F	32790	33342
70	GNMCL64F	2279	2735
70	GNMCL64R	1098	1594
70	GNMCM94F	15929	16589
70	GNMCM94R	16990	17708
70	GNMCO70F	6253	6962
70	GNMCP46F	28269	28572
70	GNMCP46R	29399	29799
70	GNMCP69R	14839	15383
70	GNMCQ60R	4262	4932
70	GNMCV71F	1570	2085
70	GNMCV71R	316	1151
70	GNMCV72F	29887	30336
70	GNMCV72R	28290	29022

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
70	GNMCV79F	9283	9798
70	GNMCV79R	8344	9079
70	GNMCV90F	15009	15476
70	GNMCV90R	16482	17299
70	GNMCX43F	15135	15898
70	GNMCX43R	14040	14726
70	GNMCY28F	27547	28277
70	GNMCY28R	26646	27207
70	GNMCZ35F	32742	33250
71	GNMBB05F	1960	2525
71	GNMBB05R	3344	3515
71	GNMCQ43F	7860	8357
71	GNMCQ43R	8617	9224
71	GNMCV39F	3444	3908
71	GNMCV39R	1967	2637
71	GNMCV40R	1959	2698
71	GNMCX05F	7245	7867
71	GNMCX05R	9020	9558
71	GNMCY02F	11233	11831
71	GNMCY02R	10519	11074
71	GNMCZ22F	12199	12719
71	GNMCZ22R	10978	11535
71	GNMCZ62F	5934	6428
71	GNMCZ62R	7330	7740
72	GNMBB26F	8760	9327
72	GNMBB26R	7556	8099
72	GNMCA20F	13469	14085
72	GNMCA70F	3932	4596
72	GNMCA83F	16236	16703
72	GNMCD73F	16569	17077
72	GNMCD73R	15204	15432
72	GNMCF25F	16016	16451
72	GNMCF25R	14647	15269
72	GNMCM14R	10622	11346
72	GNMCS42F	5706	6424
72	GNMCS67F	9325	10026
72	GNMCS91F	3912	4620
72	GNMCY88F	1473	2157
73	GNMCA21F	82	736
73	GNMCA82F	3679	3975
73	GNMCL92F	4664	5205
73	GNMCL92R	5485	5880
73	GNMCM22R	708	1428
73	GNMCM29R	1947	2683
73	GNMCO16R	1657	2311
73	GNMCV93F	347	830

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
73	GNMCV93R	1879	2561
74	GNMCA78F	5557	6224
74	GNMCB76F	5584	6225
74	GNMCB76R	4398	4946
74	GNMCF14R	1573	2079
74	GNMCF30F	9638	10051
74	GNMCF30R	8180	8703
74	GNMCL96F	16170	16676
74	GNMCL96R	14728	15294
74	GNMCN51F	7918	8654
74	GNMCN51R	6999	7601
74	GNMCN65F	14177	14895
74	GNMCN65R	12918	13517
74	GNMCN66R	12940	13557
74	GNMCO71F	2786	3525
74	GNMCO71R	3980	4683
74	GNMCP02F	9531	10254
74	GNMCP02R	10574	11268
74	GNMCQ12F	1447	2032
74	GNMCQ12R	416	1065
74	GNMCV61F	12114	12501
74	GNMCV61R	10643	11335
74	GNMCX30F	18292	19013
74	GNMCX30R	20178	20810
74	GNMCX94F	21616	22251
74	GNMCX94R	20632	21246
74	GNMCY73R	13205	13774
74	GNMCZ16F	14762	15283
74	GNMCZ16R	13378	13933
74	GNMCZ19F	23465	23941
75	GNMCA94F	3978	4349
75	GNMCB55F	2185	2819
75	GNMCB55R	3259	3917
75	GNMCL13F	4716	5241
75	GNMCL13R	2852	3443
75	GNMCL80F	4341	4845
75	GNMCL80R	2903	3473
75	GNMCM78R	2146	2889
75	GNMCV07F	1	479
75	GNMCV08R	1221	1918
75	GNMCV10F	5011	5503
75	GNMCV11R	3483	4212
75	GNMCV36F	4495	4971
75	GNMCV36R	3285	3527
75	GNMCV52F	3868	4351
75	GNMCV52R	2491	3098

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
75	GNMCX78F	3135	3788
75	GNMCX78R	4397	5087
76	GNMCB02F	2416	2977
76	GNMCB02R	3352	3966
76	GNMCB07F	2416	2984
76	GNMCB07R	3352	3954
76	GNMCB12F	2416	2974
76	GNMCB12R	3314	3966
76	GNMCY54R	5129	5668
77	GNMCB54R	4435	4640
77	GNMCB85R	2747	3439
77	GNMCF72F	4490	4924
77	GNMCF72R	5936	6649
77	GNMCK68R	568	1128
77	GNMCM47F	3316	3922
77	GNMCM47R	4346	4995
77	GNMCX10F	6886	7627
77	GNMCX10R	5801	6436
77	GNMCZ08R	3508	3954
78	GNMCB60F	1387	2047
78	GNMCB60R	2757	3429
79	GNMCB65F	287	954
79	GNMCB65R	1598	2122
79	GNMCY11F	3301	4016
79	GNMCY11R	2339	2911
81	GNMCD15F	1	519
82	GNMCO75R	2040	2712
83	GNMCD53F	466	1013
84	GNMCF02F	1638	2132
85	GNMCF15F	3019	3523
85	GNMCF15R	1257	1932
85	GNMCY26F	1834	2612
85	GNMCY26R	555	1120
86	GNMCF34F	1890	2365
86	GNMCF34R	259	918
86	GNMCS21F	1678	2392
87	GNMCF36F	274	748
88	GNMCF71R	10636	11160
88	GNMCL78F	2657	3153
88	GNMCL78R	4106	4665
88	GNMCN10F	7355	8034
88	GNMCQ46F	10928	11579
88	GNMCQ46R	9882	10586
88	GNMCQ88F	574	1196
88	GNMCQ88R	2017	2549
89	GNMCF76F	1981	2406

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
89	GNMCF76R	1	500
89	GNMCF80F	920	1305
89	GNMCF80R	2032	2709
89	GNMCL16F	247	763
89	GNMCL16R	1226	1784
89	GNMCN80F	788	1493
89	GNMCQ82F	1969	2554
89	GNMCQ82R	401	1093
89	GNMCZ19R	2292	2850
123	GNMCH27F	119	501
145	GNMCP17R	991	1517
152	GNMCP17F	81	776
153	GNMCK10R	756	1346
153	GNMCS01F	823	1344
153	GNMCX08F	332	1001
153	GNMCX08R	1513	2144
153	GNMCZ35R	695	1204
154	GNMCK14R	1	352
155	GNMCK59R	1	445
156	GNMCK78F	8693	9133
156	GNMCM20F	2049	2694
156	GNMCM20R	632	1335
156	GNMCS15F	3468	4033
156	GNMCS66F	4788	5488
156	GNMCV01F	1890	2231
156	GNMCV02R	166	894
156	GNMCV68F	2538	3032
156	GNMCV68R	3475	4231
157	GNMCL11F	295	834
157	GNMCL11R	1294	1846
158	GNMCL30F	1756	2276
158	GNMCL30R	448	1028
158	GNMCV49R	4317	5164
159	GNMCL48F	5961	6264
159	GNMCL48R	4706	5280
159	GNMCQ61R	922	1535
159	GNMCS71F	314	1024
159	GNMCY32F	8722	9407
159	GNMCY32R	10063	10584
159	GNMCY51F	8917	9628
159	GNMCY51R	10406	10895
160	GNMCL58R	4560	5111
160	GNMCN05R	9955	10528
160	GNMCO37F	8602	9262
160	GNMCV04F	951	1370
160	GNMCV05R	1971	2742

Coordinates of Sequences Released in Contigs			
Contig No.	Sequence Name	Coordinate	Coordinate
161	GNMCN26F	4880	5549
161	GNMCN26R	3911	4533
161	GNMCQ77F	6238	6857
161	GNMCQ77R	5035	5760
161	GNMCZ58F	3859	4357
161	GNMCZ58R	2375	2916
162	GNMCN45F	1676	2346
162	GNMCN45R	400	977
163	GNMCN92F	507	1223
163	GNMCN92R	1454	2112
163	GNMCY42F	1142	1860
163	GNMCY42R	2736	3290
163	GNMCZ36F	4711	5225
163	GNMCZ36R	6070	6592
164	GNMCN94F	3000	3708
164	GNMCN94R	1705	2265
165	GNMCQ54F	51	677
165	GNMCQ54R	936	1639
166	GNMCS72F	19	432
166	GNMCS74R	1	181
167	GNMCV58F	314	808
167	GNMCZ38F	6858	7329
167	GNMCZ38R	5443	5996
168	GNMCX26F	1	660
169	GNMCX92F	341	587
170	GNMCY65R	195	567

-1-

APPENDIX B**MenB ORFs****Number 1 ORF**

```

1  ..TTCGGCGA CATCGGCGGT TTGAAGGTCA ATGCCCCCGT CAAATCCGCA
51  GCGGTATTGG TCGGGCGCGT CGGCGCTATC GGACTTGACC CGAAATCCTA
101 TCAGGCGAGG GTGCGCCTCG ATTTGGACGG CAAGTATCAG TTCAGCAGCG
151 ACGTTTCCGC GCAAATCCTG ACTTCsGGAC TTTTGGGCGA GCAGTACATC
201 GGGCTGCAGC AGGGCGGCGA CACGGAAAAC CTTGCTGCCG GCGACACCAT
251 CTCGTAACC AGTTCTGCAA TGGTTCTGGA AAACCTTATC GGCAAATTCA
301 TGACGAGTTT TGCCGAGAAA AATGCCGACG GCGGCAATGC GGAAAAGCC
351 GCCGAATAA

```

Number 2 ORF

```

1  ..ATTTTGATAT ACCTCATCCG CAAGAATCTA GGTTCGCCCC TCTTCTTCTT
51  TCAGGAACGC CCCGGAAGG ACGGAAAACC TTTTAAAATG GTCAAATTCG
101 GTTCATGCG CGACGGCTTG TATTGAGACG GCATTCCGCT GCCCGACGGA
151 GAACGCCTGA CACCGTTCGG CAAAAAACTG CGTGCCGcCA GTWTGGACGA
201 ACTGCCTGAA TTATGGAATA TCTTAAAAGG CGAGATGAGC CTGGTCGGCC
251 CCCGCCCGCT GCTGATGCAA TATCTGCCGC TGTACGACAA CTTCAAAAAC
301 CGCCGCCACG AAATGAAACC CGGCATTACC GGCTGGGCGC AGGTCAACGG
351 GCGCAACGCg CTTTCGTGGG ACGAAAAATT CGCCTGCGAT GTTTGGGTATA
401 TCGACCACTT CAGCCTGTGC CTCGACATCA AAATCCTACT GCTGACGGTT
451 AAAAAAGTAT TAATCAAGGA AGGGATTTC GCACAGGGCG AACA.aCCAT
501 GCCCCCTTTC ACAGGAAAAC GCAAACCTCG CGTCGTCGGT GCGGGCGGAC
551 ACGGAAAAGT CGTTGCCGAC CTTGCCGCG CACTCGGCG GTACAGGGAA
601 ATCGTTTTC TGACGACCG CGCACAAGGC AGCGTCAACG GCTTTTCCGT
651 CATCGGCACG ACGCTGCTGC TTGAAAACAG TTTATCGCCC GAACAATACG
701 ACGTCGCCGT CGCGTCGGC AACAACCGCA TCCGCCGCCA AATCGCCGAA
751 AAAGCCGCCG CGCTCGGCTT CGCCCTGCCC GTACTGGTTC ATCCGGACGC
801 GACCGTCTCG CCTTCTGCAA CAGTCGGACA AGGCAGCGTC GTTATGGCGA
851 AAGCGGTCG..

```

Number 3 ORF

```

1  ..AACCATATGG CGATTGTCAT CGACGAATAC GCGGGCACAT CCGGCTTGGT
51  CACCTTTGAA GACATCATCG AGCAAATCGT CGGCGAAATC GAAGACGAGT
101 TTGACGAAGA CGATAGCGCC GACAATATCC ATGCCGTTTC TTCAGACACG
151 TGGCGCATCC ATGCAGCTAC CGAAATCGAA GACATCAACA CCTTCTTCGG
201 CACGGAATAC AGCATCGAAG AAGCCGACAC CATT.GGCGG CCTGGTCATT
251 CAAGAGTTGG GACATCTGCC CGTGCGCGGC GAAAAAGTCC TTATCGGCCG
301 TTTGCAGTTC ACCGTGCGAC GCGCCGACAA CCGCCGCGTG CATACGCTGA
351 TGGCGACCCG CGTGAAGTAA GC..... ACCGC CGTTTCTGCA
401 CAGTTTAG

```

Number 4 ORF

```

1  ATGCGCGGCG GCAGGCCGGA TTCCGTTACC GTGCAGATTA TCGAAGGTTT
51  GCGTTTTTCG CATATGAGGA AAGTCATCGA CGCAACGCCC GACATCGGAC
101 ACGACACCAA AGGCTGGAGC AATGAAAAAC TGATGGCGGA AGTTGCGCCC
151 GATGCCTTCA GCGGCAATCC TGAAGGGCAG TTTTCCCCG ACAGCTACGA
201 AATCGATGCG GCGGGCAGTG ATTTGCAGAT TTACCAAACC GCCTACAAgG
251 GCGATGCAAC GCCGCCTGAA TGAgGGCATG GGAAAGCAGG CAGGACGGGC
301 TGCCTTATAA AAACCCTTAT GAAATGCTGA TTATGGCGAr CCTGGTCGAA
351 AAGGAAACAG GGCATGAAGC CGAsCsCGAC CATGTcGCTT CCGTCTTCGT
401 CAACCGCCTG AAAATCGGTA TGCGCCTGCA AACCgAssCG TCCGTGATTT

```

-2-

```

451  ACGGCATGGG  TCGGGCATAC  AAGGGCAAAA  TCCGTAAAGC  CGACCTGCGC
501  CGCGACACGC  CGTACAACAC  CTACACGCGC  GCGGTCTGTC  CGCCAACCCC
551  GATTGCGCTG  CCC..

```

Number 5 ORF

```

1    CGTTTCAAAA  TGTTAACTGT  GTTGACGGCA  ACCTTGATTG  CCGGACAGGT
51   ATCTGCCGCC  GGAGGCGGTG  CGGGGGATAT  GAAACAGCCG  AAGGAAGTCG
101  GAAAGGTTTT  CAGAAAGCAG  CAGCGTTACA  GCGAGGAAGA  AATCAAAAAC
151  GAACGCGCAC  GGCTTGCGGC  AGTGGGCGAG  CGGGTTAATC  AGATATTTAC
201  GTTGCTGGGA  GGGGAAACCG  CCTTGCAAAA  GGGGCAGGCG  GGAACGGCTC
251  TGGCAACCTA  TATGCTGATG  TTGGAACGCA  CAAAATCCCC  CGAAGTCGCC
301  GAACGCGCCT  TGGAAATGGC  CGTGTGCGTG  AACGCGTTTG  AACAGGCGGA
351  AATGATTTAT  CAGAAATGGC  GGCAGATTGA  GCCTATACCG  GGTAAAGCGC
401  AAAACGSGGC  GGGGTGGCTG  CGGAACGTGC  TGAGGGAAAG  AGGAAATCAG
451  CATCTGGACG  GACGGGAAGA  AGTGTGGCT  CAGGCGGACG  AAGGACAG

```

Number 6 ORF

```

1    AACCTCTACG  CCGGCCCGCA  GACCACATCC  GTCATCGCAA  ACATCGCCGA
51   CAACCTGCAA  CTGGCCAAAG  ACTACGGCAA  AGTACACTGG  TTCGCCTCCC
101  CGCTCTTCTG  GCTCCTGAAC  CAACTGCACA  ACATCATCGG  CAACTGGGGC
151  TGGGCGATTA  TCGTTTTAAC  CATCATCGTC  AAAGCCGTAC  TGTATCCATT
201  GACCAACGCC  TCTTACCGCT  CTATGGCGAA  AATGCGTGCC  GCCGCACCCA
251  AACTGCAAGC  CATCAAAGAG  AAATACGGCG  ACGACCGTAT  GCGCAACAA
301  CAGGCGATGA  TGCAGCTTTA  CACAGACGAG  AAAATCAACC  CGaCTGGCG
351  GCTGCCTGCC  TATGCTGTG  CAAATCCCCG  TCTTCATCGG  ATTGTATTGG
401  GCATTGTTTC  CCTCCGTAGA  ATTGCGCCAG  GCACCTTGGC  TGGGTGGAT
451  TACCGACCTC  AGCCGCGCCG  ACCCCTACTA  CATCCTGCCC  ATCATTATGG
501  CGGCAACGAT  GTTCGCCCAA  ACTTATCTGA  ACCCGCCGCC  GAcCGACCCG
551  ATGCagGCGA  AAATGATGAA  AATCATGCCG  TTGGTTTTCT  CsGwCrTGTT
601  CTTCTTCTTC  CCTGCCGGks  TGGTATTGTA  CTGGGTAGTC  AACAACCTCC
651  TGACCATCGC  CCAGCAATGG  CACATCAACC  GCAGCATCGA  AAAACAACGC
701  GCCCAAGGCG  AAGTCGTTTC  CTAA

```

Number 7 ORF

```

1    ..GCCGTCTTAA  TCATCGAATT  ATTGACGGGA  ACGGTTTATC  TTTTGGTTGT
51   NAGCGCGGCT  TTGGCGGGTT  CGGGCATTGC  TTACGGGCTG  ACCGGCAGTA
101  CGCCTGCCGC  CGTCTTGACC  GNCGCTCTGC  TTTCCGCGCT  GGGTATTTNG
151  TTCGTACACG  CCAAAACCGC  CGTTAGAAAA  GTTGAAACGG  ATTATATCA
201  GGATTTGGAT  GCCGGACAAT  ATCTCGAAAT  CCTCCGNAC  ACAGGCGGCA
251  ACCGTTACGA  AGTT.TTTAT  CGCGGTACG.  ACTGGCAGGC  TCAAAATACG
301  GGGCAAGAAG  AGCTTGAACC  AGGAACTCGC  GCCCTCATTG  TCCGCAAGGA
351  AGGCAACCTT  CTTATTATCA  CACACCCTTA  A

```

Number 8 ORF

```

1    ATGTwTGATT  TCGGTTTrGG  CGArCTGGTT  TTTGTCGGCA  TTATCGCCCT
51   GATwGtCCTC  GGCCCCGAAC  GCsTGCCCGA  GGCCGCCCCG  AyCGCCGGAC
101  GGcTCATCGG  CAGGCTGCAA  CGCTTTGTCTG  GcAGCGTCAA  ACAGGAATTT
151  GACACTCAAA  TCGAACTGGA  AGAACTGAGG  AAGGCAAAGC  AGGAATTTGA
201  AGCTGCCGcC  GCTCAGGTTT  GAGACAGCCT  CAAAGAAACC  GGTACGGATA
251  TGGAAGGCAA  TCTGCACGAC  ATTTCCGACG  GTCTGAAGCC  TTGGGAAAAA
301  CTGCCCCAAC  AGCGGACACC  TGCCGATTTC  GGTGTCTGATG  AAAACGGCAA
351  TCCGCT.TCC  CGATGCGGCA  AACACCCTAT  CAGACGGCAT  TTCCGACGTT
401  ATGCCGTC..

```

Number 9 ORF

```

1  ATGCAAGCAC GGCTGCTGAT ACCTATTCTT TTTTCAGTTT TTATTTTATC
51  CGC.TGCGGG ACAC TGACAG GTATTCCATC GCATGGCGgA GkTAAACgCT
101 TTgCGGTCTGA ACAAGAACTT GTGGCCGCTT CTGCCAGAGC TGCCGT TAAA
151 GACATGGATT TACAGGCATT ACACGGACGA AAAGTTGCAT TGTACATTGC
201 CACTATGGGC GACCAAGGTT CAGGcAGTTT GACAGGGGGG TCGCTACTCC
251 ATTGATGCAC kGrTwCsTGG CGAATACATA AACAGCCCTG CCGTCCGTAC
301 CGATTACACC TATCCACGTT ACGAAACCAC CGCTGAAACA ACATCAGGCG
351 GTTTGACAGG TTTAACCCTT TCTTTATCTA CACTTAATGC CCCTGCACTC
401 TCTCGCACCC AATCAGACGG TAGCGGAAGT AAAAGCAGTC TGGGCTTAAA
451 TATTGGCGGG ATGGGGGATT ATCGAAATGA AACCTTGACG ACTAACCCGC
501 GCGACACTGC CTTTCTTTCC CACTTGGTAC AGACCGTATT TTTCTGCGC
551 GGCATAGACG TTGTTTCTCC TGCCAATGCC GATACAGATG TGTTTATTAA
601 CATCGACGTA TTCGGAACGA TACGCAACAG AACCGAAATG..

```

Number 10 ORF

```

1  ..GG.CAGCACA AAAAACAGGC GGTGGAACGG AAAAACCGTA TTTACGATGA
51  TGCCGGGTAT GATATTCGGC GTATTCACGG GCGCATTCTC CGCAAATAT
101 ATCCCCGCGT TCGGGCTTCA AATTTTCTTC ATCCTGTTTT TAACCGCCGT
151 CGCATTCAAA ACAC TGACATA CCGACCTCA GACGGCATCC CGCCGCTGC
201 CCGGACTGCC CrGACTGACT GCGGTTTCCA CACTGTTCCG CACAATGTCT
251 AGCTGGGTCG GCATAGGCGG CGGTTCACTT TCCGTCCCTT TCTTAATCCA
301 CTGCGGCTTC CCCGCCATA AAGCCATCGG CACATCATCC GGCCTTGCTT
351 GGCCGATTGC ACTCTCCGGC GCAATATCGT ATCTGCTCAA CGGCCTGAAT
401 ATTGCAGGAT TGCCGAAGG GTCAC TGGGC TTCCTTTACC TGCCCGCCGT
451 CGCCGTCTCT AGCGCGGCAA CCATTGCCTT TGCCCCGCTC GGTGTCAAAA
501 CCGCCACAA ACTTTCTTCT GCCAACTCA AAAAATC.TT CGGCATTATG
551 TTGCTTTTGA TTGCCGAAA AATGCTGTAC AACCTGCTTT AA

```

Number 11 ORF

```

1  ..GGAAACGGAT GGCAGGCAGA CCCC GAACAT CCGCTGCTCG GGCTTTTTCG
51  CGTCAGTAAT GTATCGATGA CGCTTGCTTT TGTGGAATA TGTGCGTTGG
101 TGCATTATTG CTTTTCGGGA ACGGTTCAAG TGTTTGTGTT TGCGGCACTG
151 CTCAAACTTT ATGCGCTGAA GCCGTTTATF TGGTTCGTGT TGCASTTTGT
201 GCTGATGGCG GTTGCCATATG TCCACCGCTG CCGTATAGAC CGGCAGCCGC
251 CGTCAACGTT CGGCGGCTCG CAGCTGCGAC TCGGCGGGTT GACGSCAGCG
301 TTGATGCAGG TCTCGGTACT GGTGCTGCTG CTTTCAGAAA TTGGAAGATA
351 A

```

Number 12 ORF

```

1  ATGAAAACCC CACTCCTCAA GCCTCTGCTN ATTACCTCGC TTCCCGTTTT
51  CGCCAGTGTT TTTACGCGCG CCTCCATCGT CTGGCAGCTA GGCGAACCCA
101 AGCTCGCCAT GCCCTTCGTA CTCGGCATCA TCGCCGGCGG CTTGTCTGAT
151 TTGGACAACC NCNTGACCGG ACGGCTNAAA AACATCATCA CCACCGTCGC
201 CCGTTTCAAC CTCTCCTCGC TCACGGCACA AAGCACCTC GGCACAGGGC
251 TGCCCTTCAT CCTCGCCATG ACCCTGATGA CTT.CG.CTT CACCATTTTA
301 GCGCGGNCG ...

```

Number 13 ORF

```

1  ATGAATATGC TGGGAGCTTT GGCAAAAGTC GGCAGCCTGA CGATGGTGTG
51  GCGCGTTTTG GGATTTGTGC GCGATACGGT CATTGCGCGG GCATTCGGCG
101 CGGGTATGGC GACGGATGCG TTTTTTGTCT CGTTCAAACCT GCCCAACCTG
151 CTTCGCGCGG TGTGTGCGGA GGGGGCGTTT GCCCAAGCGT TTGTGCGGAT
201 TTTGGCGGAA TACAAGGAAA CGCGTTCAA AAGAGCGG.C GAAGCCTTTA
251 TCCGCCATGT GCGGGGGATG CTGTCGTTTG TACTGGTTAT CGTTACCGCG
301 CTGGGCATAC TTGCCGCGCC TTGGGTGATT TATGTTTCCG CACCCGAGTT

```

-4-

```

351 TTGCCCAAGA TGCCGACAAA TTTCAGCTCT CCATCGATTT GCTGCGGATT
401 ACGTTTCCTT ATATATTATT GATTTCCCTG TCTTCATTTG TCGGCTCGGT
451 ACTCAATTCT TATCATAAGT TCGGCATTCC GCGGTTTACG CCAC.GTTTC
501 TGAACGTGTC GTTTATCGTA TTCGCGCTGT TTTTCGTGCC GTATTTTCGAT
551 CCGCCCGTTA CCGCGCyGGC GTGGGCGGTC TTTGTGCGCG GCATTTTGCA
601 ACTCGmTTC CAACTGCCCT GGCTGGCGAA ACTGGGCTTT TTGAACTGC
651 CCAAActGAG TTTCAAAGAT GCGGCGGTCA ACCGCGTGAT GAAACAGATG
701 GCGCCTGCgA TTTTgGGCGT GAgCGTGGCG CAGGTTTCTT TGGTGATCAA
751 CACGATTTTc GCGTCTTATC TGCAATCGGG CAGCGTTTCA TGGATGTATT
801 ACGCCGACCG CATGATGGAG CTGCCCAGCG GCGTGCTGGG GCGGCGACTC
851 GGTACGATTT TGCTGCCGAC TTTGTCCAAA CACTCGGCAA ACCaAGATAC
901 GGaACAGTTT TCCGCCCTGC TCGACTGGGG TTTGCGCCTG TGCATGCTgc
951 TGACGCTGCC GCGGgcGGTC GGA CTGGCGG TGTGTGCTT cCCgCtGGTG
1001 GCGACGCTGT TTATGTACCG CGwATTTACG CTGTTTGACG CGCAGATGAC
1051 GCAACACGCG CTGATTGCCT ATTCTTTCGG TTTAATCGGC TTAATCATGA
1101 TTAAAGTGTT GGCACCCGGC TTCTATGCGC GGCAAAACAT CAAwAmGCCC
1151 GTCAAAATCG CCATCTTCAC GCTCATCTGC mCGCAGTTGA TGAACCTTGs
1201 CTTTAyCGGC CCACTrrAAC rCaCTCGGAC TTTGCTTGC CATCGGTCTG
1251 GCGCGGTGTA TCAATGCCGG ATTGTTGTTT TACCTGTTGC GCAGACACGG
1301 TATTTACCAA CCTGG.CAAG GGTGGGCGAG CGTTCTT.AG CAAAAATGCT
1351 GcTCTCGCTC GCCGTGA

```

Number 14 ORF

```

1 atGATTAAAA TCAAAAAGG TCTAAACCTG CCCATCGCGG GCAGACCGGA
51 GCAAGCCGTT tACGACGGCC CGGCCaTTAC CGAAGtCGCG TTGCTTGCGG
101 AAGAATATGC CCGTATGCGC CCCTCGATGA AAGTCAAGGA AGGCGATGCC
151 GTcAAAAAAG GCCAAGTGCT GTTTGAAGAC AAAAAGAATC CGGGCGTGGT
201 GTTTACTGCG CCGGCTTCAG GcAAAATCGC CGCGATTAC CGTGCGGAAA
251 AGCGCGTACT TCAGTCAGTC GTGATTGCCG TTGAArGCAA CGACGAAATC
301 GAGTTTGAAC GCTACGCAAC TGAAGCGCTG GCAAActTAA CCGGCGAAGA
351 AGTGCGCCGC AACCTGATCC AATCCGTTT GTGGACTGCG CTGCGCACCC
401 GTCCGTTCAG CAAAATTCCT GCCGTCGATG CCGAGCCGTT CGCCATCTTC
451 GTCAATGCGA tGGACACCAA TCCG..

```

Number 15 ORF

```

1 ..GCGnCGnAAA TCATCCATCC CC..nACGTC GTAGGCCCTG AAGCCAActG
51 GTTTTTTATG GTAGCCAGTA CGTTTGTGAT TGCTTTGATT GGTATTTTGTG
101 TTA CTGAAAA AATCGTCGAA CCGCAATTGG GCCCTTATCA ATCAGATTTG
151 TCACAAGAAG AAAAAGACAT TCGGCATTCC AATGAAATCA CGCCTTTGGA
201 ATATAAAGGA TTAATTTGGG CTGGCGTGGT GTTTGTTGCC TTATCCGCC
251 TATTGGCTTG GAGCATCGTC CCTGCCGACG GTATTTTGCG TCATCCTGAA
301 ACAGGATTGG TTTCCGGTTC GCCGTTTTTA AAATCGATTG TTGTTTTTAT
351 TTTCTTGTG TTTGCACTGC CGGGCATTGT TTATGGCCG GTAACCCGAA
401 GTTTGCGCGG CGAACAGGAA GTCGTTAATG CGmyGGCCGA ATCGATGAGT
451 ACTCTGGsGC TTTmTTTGsw CAkcATCTTT TTTGCCGCAC AGTTTGTGCG
501 ATTTTTTAAT TGGACGAATA TTGGGCAATA TATTGCCGTT AAAGGGGCGA
551 CGTTCCTAAA AGAAGTCGGC TTGGGCGGCA GCGTGTGTT TATCGGTTTT
601 ATTTTAATTT GTGCTTTTAT CAATCTGATG ATAGGCTCCG CCTCCGCGCA
651 ATGGGCGGTA ACTGCGCCGA TTTTCGTCCC TATGCTGATG TTGGCCGGCT
701 ACGGCGCCGA AGTCATTCAA GCCGCTTACC GCATCGGTGA TTCCGTTACC
751 AATATATTA CGCCGATGAT GAGTTATTTT GGGCTGATTA TGGCGACGGT
801 GrkCmmunTAC AAAAAAGATG CGGGCGTGGG TaCGcTGATT wCTATGATGT
851 TGCCGTATTC CGCTTTCCTC TTGATTGCGT GGATTGCCTT ATCTGCAATT
901 TGGGTATTTg TTTTGGGCCT GCCCGTCGGT CCCGGCGCGC CCACATTCTA
951 TCCCGCACCT TAA

```

Number 16 ORF

```

1 ..ACAGCCGGCG CAGCAGGTTn CnCGGTCTTC GTTTTCGTAA CGGACAGTCA
51 GGTGGAGGTG TTCGGGAACA TCCAGACCGC AGTGAAACA GGTTTTTTTC

```

-5-

```

101 ATGGCATTTC GGTTCCTCT GTGTTTGGTG CGGCGGCACA AGACTCGGCA
151 ATgGCTTCGC GCAGTGCCTC TATACCGGTA TTTTCAGCAA CGGAAATGCG
201 GACGGcGgCA ATTTTCCCG CAGCGTCGCG CCATATGCCC GTGTTTgTT
251 CTTCAGACGG CAGCAGTCG GTTTTGTGT ACACCTTgAT GCACGGAAaTA
301 TCGCCGGCAT GGATTCTTG CAGTACGTT TCCACGTCTT CAATCTGCTG
351 TCCGCTGTTT GGAGCGGCGG CATCGACGAC GTGCAGCAGC ACATCgGcTT
401 gCGCGGTTTC TTCCAGCGTG GCgGAAAAGG CGGAAATCAG TTTgTGCGGC
451 agATyGCTnA CGAATCCGAC GGTATCGGTC AGGATAATGC TGCATTGCGG
501 ACT..

```

Number 17 ORF

```

1 ..GGCCATTACT CCGACCGCAC TTGGAAGCCG CGTTTGNCNG GCCGCCGTCT
51 GCCGTATCTG CTTTATGGCA CGCTGATTGC GGTATTGTG ATGATTTTGA
101 TGCCGAACCT GGGCAGCTTC GGTTCGGCT ATGCGTCGCT GCGCGCTTTG
151 TCGTTCGGCG CGCTGATGAT TCGCTGTTA GACGTGTCGT CAAATATGGC
201 GATGCAGCCG TTTAAGATGA TGGTCGGCGA CATGGTCAAC GAGGAGCAGA
251 AAA.NTACGC CTACGGGATT CAAAGTTTCT TAGCAAATAC GGGCGCGGTC
301 GTGGCGGCGA TTCTGCCGTT TGTGTTTGGC TATATCGGTT TGGCGAACAC
351 CGCCGANAAA GCGGTGTGTC CGCAGACCGT GGTGCTGGCG TTTTATGTGG
401 GTGCGGCGTT GCTGGTGATT ACCAGCGCGT TCACGATTTT CAAAGTGAAG
451 GAATACGANC CGGAAACCTA CGCCCGTTAC CACGGCATCG ATGTCGCCGC
501 GAATCAGGAA AAAGCCAACT GGATCGCACT CTTAAAA.CC GCGC..

```

Number 18 ORF

```

1 ATGTTGTTCC GTAAAACGAC CGCCGCCGTT TTGGCGCATA CCTTGATGCT
51 GAACGGCTGT ACGTTGATGT TGTGGGGAAT GAACAACCCG GTCAGCGAAA
101 CAATCACCCG NAAACAGTTC GNCAAAGACC AAATCCGNGN CTTGCGTGTG
151 GTTGCCGAAG ACAATGCCCA ATTGGAAGG GGCAGCCTGG TGATGATGGG
201 CGGAAAATAC TGGTTCGTCG TCAATCCCGA AGATTCGGCG AA.NTGACGG
251 GNATTTTGAN GGCAGGCTG GACAAACCTT TCCAAATAGT TNAGGATACC
301 CCGAGCTATG C.TGCCACCA AGCCCTGCCG GTCAAACTCG GATCGNCTGG
351 CAGCCAGAAT...

```

Number 19 ORF

```

1 ..GTCAGTCCTG TACTGCCTAT TACACACGAA CGGACAGGGT TTGAAGGTGT
51 TATCGGTTAT GAAACCCATT TTTCAGGGCA CGGACATGAA GTACACAGTC
101 CGTTCGATCA TCATGATTCA AAAAGCACTT CTGATTTTCA GCGCGGTGTA
151 GACGGCGGTT TTACTGTTTA CCAACTTCAT CGAACATGGT CGGAAATCCA
201 TCCGGAGGAT GAATATGACG GGCCGCAAGC AGCG.ATTAT CCGCCCCCG
251 GAGGAGCAAG GGATATATAC AGCTATTATG TCAAAGGAAC TTCAACAAA
301 ACAAAGACTA GTATTGTCCC TCAAGCCCCA TTTTCAGACC GTTGGCTAGA
351 AGAAAATGCC GGTGCCGCCT CTGGT..

```

Number 20 ORF

```

1 ATGAAAAAAC AAATCACCGC AGCCGTAATG ATGCTGTCTA TGATTGCCCC
51 CGCAATGGCA AACGGCTTGG ACAATCAGGC ATTTGAAGAC CAAATGTTCC
101 ACACGCGGCG AGATGCACCG ATGCAG...

```

Number 21 ORF

```

1 ATGAATAAAA CTCTCTATCG TGTAATTTTC AACCGCAAAC GTGGGGCTGT
51 GrTAGCCGTT GCTGAAACTA CCAAGCGCGA AGGTAAAGC TGTGCCGATA
101 GTGATTCAGG CAGCGCTCAT GTGAAATCTG TTCCTTTTGG TACTACTCAT
151 GCACCTGTTT GTg.CGTTaC AAATATCTTT TCTTTTCTT TATTGGCCTT
201 TTCTTTATGT TTGGCTGTAG GtacGGyCAA TATTGCTTTT GCTGATGGCA

```


-6-

251 TT..

Number 22 ORF

```

1 ATGAATACTC CTCCTTTTGT CTGTTGGATT TTTTGCAAGG TCATCGACAA
51 TTTCGGCGAC ATCGGCGTTT CGTGGCGGCT CGCCCGTGTT TTGCACCGCG
101 AACTCGGTTG GCAGGTGCAT TTGTGGACGG ACGATGTGTC CGCCTTGCGT
151 GCGCTTTGCC CTGATTTGCC CGATGTTCCC TCGGTTTCATC AGGATATTCA
201 TGTCCGCACT TGGCATCCG ATGCGGCAGA TATTGATACC GCG..

```

Number 23 ORF

```

1 ..TTGTTCTGCT GTGTNAAAGT GGGGCGTTTT TTCAGCAGTC CGGCGACGTG
51 GTTTCGGGNC AAAGACCCCTG TAAATCAGGC GGTGTTGCGG CTGTATNCGG
101 ACGAGTGGCG GCA.ACTTCG GTACGTTGGA AAATAGNCGC AACGTGCGAC
151 AGCCTGTGGC TCTGCACGCT GCTCGGAATG CTGGTGTGCG TATTGTTGCT
201 GCTTTTGGTG CGGCAATATA CGTTCAACTG GGAAAGCACG CTGTTGAGCA
251 ATGCCGCTTC GGTACGCGCG GTGGAATGT TGGCATGGCT GCCGTCGAAA
301 CTCGGTTTCC CTGTCCCCGA TCGCGGGTCG GTCATCGAAG GCCGTCTGAA
351 CGGCAATATT GCCGATGCGC GGGCTTGGTC GGGGCTGCTG GTCGNCAGTA
401 TCGCCTGCTA NGGCATCCTG CCGCGCCTG..

```

Number 24 ORF

```

1 ..CAGAAGAGTT TGTCGAGAAT TTCTTTATGG GGTITGGGCG GCGTGTTTTT
51 CGGGGTGTCC GGICTGGTAT GGTITTTCTTT GGGCGTTTCT TT.GAGTGCG
101 CCTGTTTTTC GGGTGTITCT TTTTCGGGTT CGGGACGGGG GACGTTTGTG
151 GGCAGTACGG GGGTTTCTTT GAGTGTGTTT TCAGCTTGTG TTCC.GGCGT
201 CGTCCGGCTG CCTGTGCGTT TGAGCTGTGT CGGCAGGTTG CG..GTTTGA
251 CCCGTTTTTT CTGGGTGCG GCAGGGGACG TCATTCTCCT GCCGCTTTTCG
301 TCTGTGCCGT CCGGCTGTGC GGGTTCGGAT GAGGCGGCGT GGTGGTGTTC
351 GGGTTGGGCG GCATCTTGTT CCGACTACGC CGTTTGGCAG CCAGAATTTCG
401 GTTTCGCGGG GGCTGTGCGT GTGTTGCGGT TCGGCTTGAA GGGTTTTGTC
451 GTCC..

```

Number 25 ORF

```

1 ATGAAAACCT TCTTCAAAC CCTTTCCGCC GCCGCACTCG CGCTCATCCT
51 CGCCGCCTGC GGATT.CAAA AAGACAGCGC GCCCGCCGCA TCCGCTTCTG
101 CCGCCGCCGA CAACGGCGCG GCGTAAAAAA GAAATCGTCT TCGGCACGAC
151 CGTCGGCGAC TTTCGGCGATA TGGTCAAAGA ACAAATCCAA GCCGAGCTGG
201 AGAAAAAAGG CTACACCGTC AAAGTGGTCG AGTTTACCGA CTATGTACGC
251 CCGAATCTGG CATTGGCTGA GGGCGAGTTG

```

Number 26 ORF

```

1 CCTCGTCGTC CTCGGCATGC TCCAGTTTCA AGGGGCGATT TACTCCAAGG
51 CGGTGGAACG TATGCTCGGC ACGGTCATCG GGCTGGGCGC GGGTTTGGGC
101 GTTTTATGGC TGAACAGCA TTATTTCCAC GGCAACCTCC TCTTCTACCT
151 CACCGTCGGC ACGCAAGCG CACTGGCCGG CTGGGCGGCG GTCGGCAAAA
201 ACGGCTACGT CCTmTGCTG GCAGGGCTGA CGATGTGTAT GCTCATCGGC
251 GACAACGGCA GCGAATGGCT CGACAGCGGA CTCATGCGCG CCATGAACGT
301 CCTCATCGGC GyGGCCATCG CCATCGCCGC CGCCAAACTG CTGCCGCTGA
351 AATCCACACT GATGTGGCGT TTCATGCTTG CCGACAACCT GGCCGACTGC
401 AGCAAAATGA TTGCCGAAAT CAGCAACGGC AGGCGCATGA CCCGCGAAGC
451 CCTCGAGGAG AACATGGCGA AAATGCGCCA AATCAACGCA CGCATGGTCA
501 AAAGCCGAG CCATCTCGCC GCCACATCGG GCGAAAGCTG CATCAGCCCC
551 GCCATGATGG AAGCCATGCA GCACGCCAC CGTAAAATCG TCAACACCAC
601 CGAGCTGCTC CTGACCACCG CCGCCAAGCT GCAATCTCCC AAATCAACG

```

-7-

```

651 GCAGCGAAAT CCGGCTGCTT GACCGCCACT TCACACTGCT CCAAAC....
701 ..... GC AGACACGCCC GCCGCATCCG
751 CATCGACACC GCCATCAACC CCGAACTGGA AGCCCTCGCC GAACACCTCC
801 ACTACCAATG GCAGGGCTTC CTCTGGCTCA GCACCGATAT GCGTCAGGAA
851 ATTTCCGCCC TCGTCATCCT GCTGCAACGC ACCCGCCGCA AATGGCTGGA
901 TGCCACGAA CGCCAACACC TCGCCAAAG CCTGCTTGA

```

Number 27 ORF

```

1 ..GAAATCAGCC TGGGTCCGA CNACAGGCCG GTTTCCTGN CGAAGCGGCG
51 GGATTCGGAA CGTTTCTGC TGTGGACGG CGGCAACAGC CGGCTCAAGT
101 GGGCGTGGGT GGAACGCGC ACGTTCGCA CCGTCGGTAG CGCGCCGTAC
151 CGCGATTGT CGCCTTGGG CGCGGAGTGG GCGGAAAAGG CGGATGGAAA
201 TGTCCGCATC GTCGGTTGCG CTGTGTGCGG AGAATTCAAA AAGGCACAAG
251 TGCAGGAACA GTCGCCCCA AAAATCGAGT GGCTGCCGTC TTCCGCACAG
301 GCTTT.GGCA TACGCAACCA CTACCGCCAC CCCGAAGAAC ACGTTCCGA
351 CCGCTGGTTC AACGCCTTGG GCAGCCGCCG CTTAGCCGC AACGCCTGCG
401 TCGTCGTCAG TTGCGGCACG GCGTAACGG TTGACGCGCT CACCGATGAC
451 GGACATTATC TCGGAGA.GG AACCATCATG CCCGTTTCC ACCTGATGAA
501 AGAATCGCTC GCCGTCCGAA CCGCCAACCT CAACCGGCAC GCCGTAAGC
551 GTTATCCTTT CCCGACCG..

```

Number 28 ORF

```

1 ATGTTTTACC AAATCCTTGC CCTGATTATC TGGAGCAGCT CGTTATTGCT
51 CGCCAAATAT GTCTATGGCG GCATCGATCC CGCATTGATG GTCGGCGTGC
101 GCCTGCTAAT TGCGCGCTG CCTGCACTGC CGGCCTGCCG CCGTCATGTC
151 GGCAAGATTC CGCGTGAGGA ATGGAAGCCG TTGCTGATTG TGTGTTCTGT
201 CAACTATGTG CTGACCCTGC TGCTTCAGTT TGTGGGTTG AAATACACTT
251 CGCGCGCCAG CGCATCGGTC ATTGTGGAC TCGAGCCGCT GTCGATGGTG
301 TTTGTGGAC ACTTTTCTT CAACGACAAA GCGCGTGCCT ACCACTGGAT
351 ATGCGGCGCG GCGGCATTTG CCGGTGTCGC GCTGCTGATG GCGGGCGGTG
401 CGGaAGAGGG CGGCGaAGTC GGCTGGTTCG GCTGCCTGCT GGTGTTGTTG
451 GCGGGCGCGG GCTTTGTGC CGCTATGCGT CCGACGCAA GGCTGATTGC
501 ACGCATCGGC GCACCGGCAT TCACATCTGT TTCCATTGCC GCCGCATCGT
551 TGATGTGCCT GCCGTTTTCG CTTGCTTTGG CGCAAAGTTA TACCGTGGAC
601 TGGAGCGTCG GGATGGTATT GTCGCTGCTG TATTGGGTT TGGGGTGC..

```

Number 29 ORF

```

1 ATGCGCCGTT TTCTACCGAT CGCAGCCATA TCGCGmGwms TCCTGkkGTA
51 sGGACTGACG GCGGCAACCG GCAGCACCAG TTCGCTGGCG GATTATTTCT
101 GGTGGATTGT TGCGTTCAGC GCAATGCTGC TGCTGGTGT GTCCGCCGTT
151 TTGGCACGTT ATGTCATATT GCTGTTGAAA GACAGGCGCG ACGGCGTATT
201 CGGTTCCGtA srTyGCCAAA gsGCCTgkks TGGG.ATGTT TACGCTGGTT
251 GCCGkACTGC CCGGCGTGT TCTGTTCCGC TTTCCCGCAC AGTTTCATCAA
301 CGGCACGATT AATTTCGTGGT TCGGCAACGA TACCCACGAG GCGCTTGAAC
351 GCAGCCTCAA TTTGAGCAAG TCCGATTGA ATTTGGCGGC AGACAACGCC
401 CTCGGCAACG CCGTCCCGT GCAGATAGAC CTCATCGGCG CGGCTTCCCT
451 GCGCGGGGAT ATGGGCAGGG TGCTGGAACA TTACGCGGC AGCGGTTTGT
501 CCCAGCTTGC CCGTACAAy ksCGCAAGCG GCAAAATCGA AAAAGCATC
551 AACCCGCACA AGCTCGATCA GCCGTTTCCA GGTAAGGCGC GTTGGGAAaAa
601 AATCCaACGG GCGGGTTCGG TCAGGGATT GGAAGCATA GGCGGCGTAT
651 TGTaCGCGCA GGGCTGGCTG TCGGCGGGTA CGCACwACGG GCGCAAGTAC
701 GCCTTGTTTT TCCGTCAGCC GGTTCCTAAA GGCGTGGCAG AGGATGCCGT
751 yTTAATCGAA AAGGCAAGGG CGAAATATGC TGAGTTGAGT TACAGCAAAA
801 AAGGTTTGCA GACCTTTTTC CTGGCAACCC TGCTGATTGC CTCGCTGCTG
851 TCGATTTTTT TGGCACTGGT CATGGCACTG TATTCGCCC GCCGTTTCGT
901 CGAACCCTGC CTATCGTTG CCGAGGGGCG GAAGGCGGTG GCGCAAGGCG
951 ATTTACAGCA GACGCGCCCC GTGTTGCGCA ACGACGAGTT CGGACGCTTG
1001 ACCArGTTGT TCAACCACAT GACCGAGCAG CTTTCCATCG CAAAGATGC
1051 AGACGAGCGC AACCGCCGGC GCGAGGAAGC CGCCAGGCAT TATCTTGAAT

```

-8-

1101 GCGTGTGGGA GGGGCTGACC ACGGGCGTGG TGGTGTGTTGA CGAACAAGGC
 1151 TGTCTGAAAA CCTTCAACAA AGCGGCGGGT ACC..

Number 30 ORF

1 ATGTACGCAT TTACCGCCGC ACAGCAACAG AAGGCACTCT TCCGGCTGGT
 51 GCTTTTTCAT ATCCTCATCA TCGCCGCCAG CAACTATCTG GTGCAGTTCC
 101 CTTTCCAAAT TTTCCGCATC CACACCACTT GGGGCGCATT TTCCTTTCCC
 151 TTCATCTTCC TTGCCACCGA CCTGACCGTC CGCATTTTCG GTTCTCACTT
 201 GGCACGGCGG ATTATCTTTT GGGTGATGTT CCCC GCCCTT TTGCTTTCCT
 251 ACGTCTTTTC CGTTTTGTTT CACAACGGCA GTTGGACAGG CTGGGCGCGG
 301 CTGTCCGAAT TCAACACCTT TGTCCGACGC ATCGCCTTAG CCAGCTTTGC
 351 CGCCTACGCG ATCGGACAAA TCCTTGATAT TTTTGTATT CACAAATTAC
 401 GCCGTCTGAA AGCGTGGTGG ATTGCACCGA ACGCATCAAC CGTCATCGGG
 451 CACGCGTTGG ATACG...

Number 31 ORF

1 ATGGTCATAA AATATACAAA TTTGAATTTT GCGAAATTGT CGATAATTGC
 51 AATTTTGATG ATGTATTTCGT TTGAAGCGAA TGCAAyGCA GTmwrAATAT
 101 CTGAAACTGT TTCAGTTGAT ACCGGACAAG GTGCGAAAAT TCATAAGTTT
 151 GTACCTAAAA ATAGTAAAC TTATTCATCT GATTTAATAA AAACGGTAGA
 201 TTTAACACAC AyyCCTACGG GCGCAAAAGC CCGAATCAAC GCCAAAATAA
 251 CCGCCAGCGT ATCCCCGCCG GCGGTATTGG CCGGGGTCGG CAAACTTGCC
 301 CGCTTAGGCG CGAAATTCAG CACAAGGGCG GTtCCCTATG TCGGAACAGC
 351 CcTTTTAGCC CACGACGTAT ACGAAAcTTT CAAAGAAGAC ATACAGGCAC
 401 GAGGCTACCA ATACGACCCC GAAACCGACA AATTTGTAAA AGGCTACGAA
 451 TATAGTAATT GCCTTTGGTA CGAAGACAAA AGACGTATTA ATAGAACCTA
 501 TGGCTGCTAC GCGGTTGAT..

Number 32 ORF

1 ATGAGATTTT TCGGTATCGG TTTTTTGGTG CTGCTGTTTT TGGAGATTAT
 51 GTCGATTGTG TGGGTTGCCG ATGGGCTGGG CGGCGGCTGG ACGTTGTTTT
 101 TGATGGCGGC AGGTTTTGCC GCCGGCGTGC TGATGCTCAG GCAAACCGGG
 151 GCTGACCGGT CTTTTATTGG CGGGCGCGGC AATGAGAAGC GGCGGGAAGG
 201 TATCCGTTTA TCAGATGTTG TGGCCTATC..

Number 33 ORF

1 ATGTTTGTGTT TTCAGACGGC ATTCTT.ATG TTTCAGAAAC ATTTGCAGAA
 51 AGCCTCCGAC AGCGTCGTCG GAGGGACATT ATACGTGGTT GCCACGCCCA
 101 TCGGCAATTT GCGGACATT ACCCTGCGCG CTTTGGCGGT ATTGCAAAAG
 151 GCG..... .GCGA AGACACGCGC GTTACCGCAC AGCTTTTGAG
 201 CGCGTACGGC ATTCAGGGCA AACTCGTCAG TGTGCGCGAA CACAACGAAC
 251 GGCAGATGGC GGACAAGATT GTCGGCTATC TTTCAGACGG CATGTTGTG
 301 GCACAGGTTT CCGATGCGGG TACGCCGGCC GTGTGCGACC CGGGCGCGAA
 351 ACTCGCCCGC CGCGTGCGTG AGGCCGGGTT TAAAGTCGTT CCCGTCCGTG
 401 GCGCAAC.GC GGTGATGGCG GCTTTGAGCG TGGCCGGTGT GGAAGGATCC
 451 GATTTTATTT TCAACGGTTT TGTACCGCCG AAATCGGGAG AACGCAGGAA
 501 ACTGTTTGCC AAATGGGTGC GGGCGGCGTT TCCTATCGTC ATGTTTGAAA
 551 CGCCGCACCG CATCGGTGCA GCGCTTGCCG ATATGGCGGA ACTGTTCCCC
 601 GAACGCCGAT TAATGCTGGC GCGCGAAATT ACGAAAACGT TTGAAACGTT
 651 CTTAAGCGGC ACGGTTGGGG AAATTCAGAC GGCATTGTCT GCCGACGGCG
 701 ACCAATCGCG CGGCGAGATG CTGTTGGTGC TTTATCCGGC GCAGGATGAA
 751 AAACACGAAG GCTTGTCCGA GTCCGCGCAA AACATCATGA AAATCCTCAC
 801 AGCCGAGCTG CCGACCAAAC AGGCGGCGGA GCTTGCTGCC AAAATCACGG
 851 GCGAGGGAAA GAAAGCTTTG TACGAT..

Number 34 ORF

```

1   ATGAAACAGA AAAAAACCGC TGCCGCAGTT ATTGCTGCAA TGTTGGCAGG
51  TTTTGCGGCA GC.AAAGCAC CCGAAATCGA CCCGGCTTTG .....
      //
651 ..... ...GAGTTGG TCAGAAACCA GTTGGAGCAG GGTTTGAGAC
701 AGGAAAAAGC CCGCTTGAAA ATCGATGCCC TTTTGGAAGA AAACGGTGTC
751 AAACCGTAA

```

Number 35 ORF

```

1   ATGAAAAAAT CTTTCCTTAC GCTTGTTCTG TATTCGTCTT TACTTACCGC
51  CAGCGAAATT GCCTTACCCC TTGGAATTGG GGATTGAAAC CTTACCGGCG
101 GCAAAAATTG CCGAAACGTT TCGCTGACA TTTGTGATTG CTGCGCTGTA
151 TCTGTTTGCG CGTAATAAGG TGACGCGTTT GTTGATTGCG GTGTTTTTTG
201 CGTTCAGCAT TATTGCCAAC AATGTGCATT ACGCGGATTA TCAAAGCTGG
251 ATGACG.... .....
      //
1201 ..... CAAACCGTAT TCGAGCAGCT GCAAAAGACT CCTGACGCGA
1251 ACTGGCTGTT TGCCTATACC TCCGATCATG GCCAGTATGT TCGCCAAGAT
1301 ATCTACAATC AAGGCACGGT GCAGCCCGAC AGCTATCTCG TGCCGCTAGT
1351 GTTGTTACAGC CCGGATAAGG CCGTGCAACA GGCTGCCAAC CAGGCTTTTG
1401 CGCCTTGCGA GATTGCCTTC CATCAGCAGC TTTCAACGTT CCTGATTAC
1451 ACGTTGGGCT ACGATATGCC GGTTCAGGT TGTGCGGAAG GCTCGGTAAC
1501 GGGCAACCTG ATTACGGGTG ATGCAGGCAG CTTGAACATT CGCGACGGCA
1551 AGGCGGAATA TGTTTATCCG CAATGA

```

Number 36 ORF

```

1   ...ACCCTGCTCC TCTTCATCCC CCTCGTCCTC ACAC.GTGCG GCACACTGAC
51  CGGCATACTC GCCCaCGGCG GCGGCAACG CTTTGCCGTC GAACAAGAAC
101 TCGTCGCCCGC ATCGTCCCGC GCCGCCGTCA AAGAAATGGA TTTGTCCGCC
151 yTAAAAGGAC GCAAAGCCGC CyTTTACGTC TCCGTTATGG GCGACCAAGG
201 TTCGGGCAAC ATAAGCGGCG GACGCTACTC TATCGACGCA CTGATACGCG
251 GCGGCTACCA CAACAACCCC GAAAGTGCCA CCCAATACAG CTACCCCGCC
301 TACGACACTA CCGCCACCAC CAAATCCGAC GCGCTCTCCA GCGTAACCAC
351 TTCCACATCG CTTTGAACG CCCC CGCGC CGyCyTGACG AAAACAGCG
401 GACGCAAGG CGAACGcTCC GCCGACTGT CCGTCAACGG CACGGGCGAC
451 TACCGCAACG AAACCTGCT CGCCAACCCC CGCGACGTTT CCTTCCTGAC
501 CAACCTCATC CAAACCGTCT TCTACCTGCG CCGCATCGAA GTCgTACCGC
551 CCGrATACGC CGACACCGAC GTATTCGTAA CCGTCGACGT A...

```

Number 37 ORF

```

1   ATGGCAGAGA TCTGTTGAT AACCGGCACG CCGGTTTCAG GGAAACATT
51  AAAAATGGTT TCCATGATGG CGAATGATGA AATGTTTAAG CCTGATGAAA
101 AAGCCATACG CCGTAAAGTA TTTACGAACA TAAAAGGCTT GAAAATACCG
151 CACACCTACA TAGAAACGGA CGCAAAAAG CTGCCGAAAT CGACAGATGA
201 GCAGCTTTTCG GCGCATGATA TGTACGAATG GATAAAGAAG CCCGAAAATA
251 TCGGGTCTAT TGTATTGTA GATGAAGCTC AAGACGTATG GCCGGCACGC
301 TCGGCAGGTT CAAAAATCCC TGAAATGTG CAATGGCTGA ATACGCACAG
351 ACATCAGGCG ATTGATATAT TTGTTTGAC TCAAGTCTCT AAGCTTCTAG
401 ATCAAAATCT TAGAACGCTT GTACGGAAAC ATTACCACAT CGCTTCAAAC
451 AAGATGGGTA TCGGTACGCT TTTAGAATGG AAAATATGCG CGGACGATCC
501 CGTAAAAATG GCATCAAGCG CATTCTCCAG TATCTATACA CTGGATAAAA
551 AAGTTTATGA CTTGTAYSrr TmmGCCGAAG TTCATACCGT AAATAAGGTC
601 AAGCGGTCAA AGTGGTTTCA CACTCTGCCa GTAATAGTAT TGCTGATTCC
651 CGTGTGTTGTC GGCCTGTCCT ATAAATGTT GagCaGTTAC GGAAAAAAC
701 aGGAAGAACC CGCAGCACA GAATCGGCGG CAACAGAACA GCAGGCAGTA
751 CTTCCGGATA AAACAGAAGG CGAGCCGGTA AATAACGGCA ACCTTACCGC
801 AGATATGTTT GTTCCGACAT TGTCCGAaa ACCCGrAAGC AAGCcgaTTT
851 ATAACGGTGT AAGGCAGGTA AGAACCTTTG AATATATAGC AGGCTGTATA

```

-10-

```

901 GAAGGCGGAA GAACCGGATG CGCCTGCTAT TCGCaTCAAG GGACGGCATT
951 gaAAGAAGTG ACGGaGTTGA TGTGcgaAgG aCTATGTaAA AAacGGCTTG
1001 CCGTTTTAACC CaTACAAAGA AGAAAGCCAA GGGCAGGAAG TTCAGCAAAG
1051 CGCGCAgCAA CATTCGGACA GGGCGgCAAG TTGCCACATT GGGCGGAAAA
1101 CCGTAGCAGA ACCTAATGTA CGATAATTGG GAAGAACGCG GGAACCGTT
1151 TGAAGGAATC GgCGGGGGC GTGGTCGGAT CGGCAAACTG A

```

Number 38 ORF

```

1 GTGGTTTTC TGAATGCCGA CAACGGGATA TTGGTTCAGG ACTGCTTTT
51 TGAAGTCAA CTGAAAAAAT TCCATATCGA TTTTACAAAT ACGGGTATGC
101 CGCGTGATT CGCCAGCGAT ATTGAAGTGA CGGACAAGGC AACCGGTGAG
151 AAACTCGAGC GCACCATCCG CGTGAACCAT CCTTTGACCT TGCACGGCAT
201 CACGATTAT CAGGCGAGTT TTGCCGACGG CGGTTCCGGT TTGACATTCA
251 AGGCGTGGAA TTTGGGTGAT GCTTCGCGCG AGCCTGTCGT GTTGAAGGCA
301 ACATCCATAC ACCAGTTTCC GTTGAAATTT GGCAAACACA AATATCGTCT
351 TGAGTTCGAT CAGTTCACCT CTATGAATGT GGAGGACATG AGCGAGGGCG
401 CGGAACGGGA AAAAAGCCTG AAATCCACGC TGCCCGATGT CCGCGCCGTT
451 ACTCAGGAAG GTCACAAATA CACCAAT... ..TACCG
501 TATCCGTGAT GCGCCAGGCC AGGCGGTCGA ATATAAAAAC TATATGCTGC
551 CGGTTTTGCA GGAACAGGAT TATTTTGGGA TTACCGGCAC GCGCAGCGC.
601 TTGCAGCAGC AATACCGCTG GCTGCGTATC CCCTTGGACA AGCAGTTGAA
651 AGCGGACACC TTTATGGCAT TGCGTGAGTT TTTGAAAGAT GGGGAAGGGC
701 GCAAACGTCT .GTTGCCGAC GCAACCAAAG GCGCACCTGC CGAAATCCGC
751 GAACAATTCA TGCTGGGCTG GGAACACACG CTGAACATCT TTGCACAAAA
801 AGGCTATTTG GGATTGGACG AATTTATTAC GTCCAATATC CCGAAAGAGC
851 AGCAGGATAA GATGCAGGGC TATTTCTACG AAATGCTTTA CGGCGTGATG
901 AACGCTGCTT TGGATGAAAC CAT.ACCCGG TACGGCTTGC CCGAATGGCA
951 GCAGGATGAA GCGCGGAATC GTTTCCTGCT GCACAGTATG GATGCGTACA
1001 CGGGTTTGAC CGAATATCCC GCGCCTATGC TGCTGCAACT TGATGGGTTT
1051 TCCGAGGTGC GTTCGTCGGG TTTGCAGATG ACCCGTTCCC C.GGTCCGCT
1101 TTTGTCTAT CTC...

```

Number 39 ORF

```

1 ATGATGAGTA ATAmAATGm ACAAAAAGGG TTTACATTGA TTGmTGAT
51 GATAGTCGTC GCGATACTCG GCATTATCAG CGTCATTGCC ATACCTTCTT
101 ATCmAAGTTA TATTGAAAAA GGCTATCAGT CCCAGCTTTA TACGGAGATG
151 GyCGGTATCA ACAATATTTT CAAACAGTTT ATTTTGAAAA ATCCCCTGGA
201 CGATAATCAG ACCATCGAGA ACAAACTGGA AATATTTGTC TCAGGCTATA
251 AGATGAATCC GAAAAATTGCC AAAAAaTATA GTGTTTCGGT AAAGTTTGTC
301 GATAAGGAAA AATCAAGGGC ATACAGGTTG GTCGGCGTTC CGAAGCGGGG
351 GACGGGTTAT ACTTTGTCGG TATGGATGAA CAGCGTGGGC GACGGATACA
401 AATGCCGTGA TGCCGCTTCT GCCCAAGCCC ATTTGGAGAC CTTGTCCTCA
451 GATGTCGGCT GTGAAGCCTT CTCTAATCGT AAAAAATAA

```

Number 40 ORF

```

1 ATGAAAAAAT CCTCCCTCAT CAGCGCATTG GGCATCGGTA TTTTGAGCAT
51 CGGCATGGCA TTTGCCGCC CTGCCGACGC GGTAAGCCAA ATCCGTCAA
101 ACGCCACTCA AGTATTGAGC ATCTTAAAAA ACGGCGATGC CAACACCGCT
151 CGCCAAAAAG CCGAAGCCTA TGCGATTCCC TATTTGATT TCCAACGTAT
201 GACCGCATTG GCGGTCGGCA ACCCTGGsG CACCG.GTCC GACG.GCAA
251 AACAGCGTT GGCCn.AGAA TTTCAACCC...

```

Number 41 ORF

```

1 ATGAAACACA TACTCCCCCT GATTGCCGCA TCCGCACTCT GCATTTCAAC
51 CGCTTCGGCA CATCCTGCCA GCGAACCGTC CACTCAAAAC GAAACCGCTA
101 TGATCACGCA TACCCTCATC TCAAAATACA GTTTTGnnn nnnnnnnnn
151 nnnnnnnnnn nnGCCATAAA AAGCAAAGGG ATGGACATTT TTGCCGTCAT

```

-11-

```

201 CGACCATCAG GAAGCCGCAC GCCGAAACGG CTTAACGATG CAGCCGGCAA
251 AAGTCATCGT CTTGCGCACG CCCAAAGCCG GCACGCCGCT GATGGTCAAA
301 GACCCCGCCT TCGCCCTGCA ACTGCCCTTA CGCGTCTCTG TTACCGAAAC
351 GGACGGCAAA GTACGCGCCG CCTATACCGA TACGCGCGCC CTCATCGCCG
401 GCAGCCGCAT CGGTTTCGAC GAAGTGGCAA ACACTTTGGC AAACGCCGAA
451 AAACTGATAC AAAAAACCGT AGCGGAATAA

```

Number 42 ORF

```

1 ATGGCTTTTA TTACGCGCTT ATTCAAAGC AGTAAATGGC TGATTGTGCC
51 GCTGATGCTC CCCGCCTTTC AGAATGTGGC GCGGAGGGG ATAGATGTGA
101 GCCGTGCCGA AGCGAGGATA ACCGACGGCG GCGAGCTTTC CATCAGCAGC
151 CGCTTCCAAA CCGAGCTGCC CGACCAAGCTC CAACAGGCGT TCGCCCGGGg
201 CGTGCCGCTC AACTTTACCT TAAGCTGGCA GCTTTCCGCC CCGATAATCG
251 CTTCTTATCG GTTTAAATTG GGGCAACTGA TTGGCGATGA CGACaATATT
301 GACTACAAAC TGAGTTTCCA TCCGCTGACc AaACGCTACC GCGTTACCgT
351 CGgCGCGTTT TCGACAGACT ACGACACCTT GATGCGGCA TTGCGCGCGA
401 CCGGCGCGGT TGCCAACCTG AAAGTCCTGA ACAAAGGCGC GCTGTCCGGT
451 GCGGAAGCAG GGGAAACCAA GGCGGAAATC CGCTGACGC TGTCCACTTC
501 AAAACTGCCC AAGCCTTTTC AAATCAATGC ATTGACTTCT CAAAACTGGC
551 ATTTGGATTTC GGGTTGGAAA CCTCTAAACA TCATCGGGAA CAAATAA

```

Number 43 ORF

```

1 ATGGACACAA AAGAAATCCT CGG.TACGCG GcAGGcTCGA TCGGCAGCGC
51 GGTTTTAGCC GTCATCATCc TGCCGCTGCT GTCGTGGTAT TTCCCCCGCG
101 ACGACATCGG GCGCATCGTG CTGATGCAGA CGGCGGCGGG GCTgACGGTG
151 TCGGTGTGTG GCCTCGGGCT GGATCAGGCA TACGTCCGCG AATACTATGC
201 CACCGCCGAC AAAGACAcCT TGTTCAAAC CCGTTCCTG CCGCCGCTGC
251 TGTCTGCCG CGCGATAGCC GCCCTGCTGC TTTCCCGCCC GTCCCTGCCG
301 TCTGAAATCC TGTTTTCACT CGACGATGCC gCCGCCGGCa TCGGGCTGGT
351 GCTGTTTGAA CtGAGCTTCC TGCCCATCCG cTTTCTCTTA CTGGTTTTGC
401 GTATGGAAGG ACGCGCCcTT GCCTTTTCGT CCGCGCAACT CGTGCCcAAG
451 CTCGCCATCC TGCTGCTG.T GCCGCTGACG CTCGGGCTGC TGCACTTTC
501 AGCGAACACC GCCGTCTGTA CCGCCGTTA CCGCTGGCA AACCTTGCCG
551 CCGCCGCTT TTTGCTGTTT CAAAACCGAT GCGCTCTGAA GGCCGTCCCG
601 CACGACCCGT TTTCCGCCG CGTCCTGCAC CGGGGg.TGC GCTACGGCAT
651 ACCGATCGCA CTGAGCAGCA TCGCCTATTG GGGGCTGGCA TCCGCCGACC
701 GTTTGTTCCT GAAAAAATAT GCCGGCCTGG ACAGCTCGG CGTTTATTCG
751 ATGGGTATTT CGTTCGGCGG GGCGGCATTA TTGTTCCAAA GCATCTTTTC
801 AACGCTCTGG ACACCGTATA TTTCCGCGC AATCGAAGAA AACGCCCCGC
851 CCGCTCGCCT CTCGGCAACG GCAGAATCCG CCGCCGCCCT GCTTGCTTCC
901 GCCCTCTGC. TGACCGGCAT TTTCTCGCCC CTGCTCTCC TCCTGCTGCC
951 GGAAGCTAC GCCGCGCTCC GGTTTATCGT CGTATCGTGT ATG.TGCCGC
1001 CGCTGTTTTG CACGCTGGCG GAAATCAGCG GCATCGGTTT GAACGTCGTT
1051 CGCAAAACGC GCCGATCGC GCTCGCCACC TTGGGCGCGC TGGCGGCAAA
1101 CCTGCTGCTG CTGGGGCTTG ACCGTGCCGT ACCGGCGAGG CCGCC.GGCG
1151 CGGCGGTTGC CTGTGCCGCC TCATTCTGGC TSTTTTTTGC CTTCAAGACC
1201 GAAAGCTCyT GCCGCCTGTG GCAGCCGCTC AAACGCCCTG CGCTTTATCT
1251 GCACACATTG TTCTGCCTGA CCTCCTCGGC GGCCTACACC TGCTTCGGCA
1301 CGCCGGCAAA CTATCCCTG TTTGCCGGCG TATGGGCGGC ATATCTGGCA
1351 GGCTGCATCC TCGCCACCG GAAAGATTG CACAACTGT TTCATTATTT
1401 GAAAAACAA GGTTCCCAT TATGA

```

Number 44 ORF

```

1 .ATCCTGAAAC CGCATAACCA GCTTAAGGAA GACATCCAAC CTGATCCGGC
51 CGATCAAAAC GCCTTGTCGG AACCGATGC TCGACAGAG CGAGAGCAGT
101 CGGATGCGGA AAATGCTGCC GACAAGCAGC CCGTTGCCGA TAAAGCCGAC
151 GAGGTGGAAG AAAAGGCGGG CGAGCCGGA CGGGAAGAGC CGGACGGACA
201 GGCAGTGCGT AAGAAAGCGC TGACGGAAGA GCGTGAACAA ACCGTCAGGG
251 AAAAAGCGCA GAAGAAAGAT GCCGAAACGG TAAAATACA AGCGGTAAAA

```

-12-

```

301 CCGTCTAAAG AAACAGAGAA AAAAGCTTCA AAAGAAGAGA AAAAGGCGGC
351 GAAGGAAAAA GTTGCACCCA AACCAACCCC GGAACAAATC CTCAACAGCG
401 GCAGCATCGA AAAGmGCGCGC AgTGCCGCCG CCAAAGAAGT GCAGAAAATG
451 AA.AACGTCC GACAAGGCGG AAGC.AACGC ATTATCTGCA AATGGGCGCG
501 TATGCCGACC GTCAGAGCGC GGAAGGGCAG CGTGCCAAAC TGGCAATCTT
551 GGGCATATCT TCCAAGGTGG TCGTTATCA GCGGGGACAT AAAACGCTTT
601 ACCGGGTGCA AAGCGGCAAT ATGTCTGCCG ATGCGGTGA

```

Number 45 ORF

```

1 ATGAACCACG ACATCACTTT CCTCACCTTG TTCCTACTCG GTkTCTTCGG
51 CGGAACGCAC TGCATCGGTA TGTGCGGCGG ATTAAGCAGC GcGTTTgs.s
101 TCCAATCCC CCCGCATATC AACCGCTTTT GGCTGATCCT GCTGCTTAAC
151 ACAGGACGGG TAAGCAGCTA TACGGCAATc GGCCTGATAC TCGGATTAAT
201 CGGACAGGTC GGCGTTTCAC TCGAcCAaAC CCGCGTCCTG CAGAATATTT
251 TATACACGGC CGCCAACCTC CTGCTGCTCT TTTTAGGCTT ATACTTGAGC
301 GGTATTTCTT CCTTGGCGGC AAAAATCGAG AAaATCGGCA AACCGATATG
351 GCGGAACCTG AACCCGATAC TCAACCGGCT GTTACCCATA AAATCCATAC
401 CCGCCTGCCT tGCGgTCGGA ATATTATGGG GCTGGCTGCC GTGCGGACTG
451 GTTTACAGCG CGTCGCTTTA CGCGCTGGGA AgCGGTAGTG CGGCAACGGG
501 CGGGTTATAT ATGCTTGCCCT TTGCACTGGG TACGCTGCCC AATCTTtTAG
551 CAATCGGCAT TTTtTCCCTG CAACTGAAwA AAATCATGCA AAACCGATAT
601 ATCCGCCTGT GTACGGGATT ATCCGTATCA TTATGGGCAT TATGGAACT
651 TGCCGTCTCG TGGCTGTAA

```

Number 46 ORF

```

1 ATGGAAAACC AAAGGCCGCT CCTAGGCTTT CGCTTGGCAC TTTTGGCGGC
51 GATGACGTGG GGAACGCTGC CGAT.TCCGT GCGGCAGGTA TTGAAGTTG
101 TCGATGCGCC GACGCTGGTG TGGTGCGTT TTACCGTGGC GGCGGCGGTA
151 TTGTTTGTTT TGCTGGCACT GGGCGGGCGG CTGcGAAGC GGCGaGGATT
201 TTTCTTGTTG CTATTTCAGG CTGCTGCTGC TCGGCGTGGC GGGCATTTCG
251 GCAAACCTTG TGCTGATTGC CCAAGGGCTG CATTATATTT CGCCGACCAC
301 GACGCAGGTT TTGTGGCAGA TTTGCGCGTT TACGATGATT GTwGTCGGTG
351 TGTTGGTGTT TAAAGACCGG ATGACTGCCG CTCAGAAAAT CGGCTTGTTT
401 TTGCTGCTTG CCGGTTTGCT TATGTATTTT AACGATAAAT TCGGCGAGTT
451 GTCGGGTTTG GCGCGCTATG C.AAGGGCGT GTTGCTGTGT GCGGCAGGCA
501 GTATGGCATG GGTGTGTAAT GCCGTGGCGC AAAAGCTGCT TCGGCGCAA
551 TTCGGGCGGC AACAGATTCT GCTGTTGATT TATGCGGCAA GTGCCGCCGT
601 GTTCCTGCCG TTTGCCGAAC CGGCACACAT CGGAAGTATG GACGGTACGT
651 TGGCGTGGGT ATGTATTGCG TATTGCTGCT TGAATACGTT AATCGGTTAC
701 GGCTCGTTCT GCGAGGCGTT GAAACATTGG GAGGCTTCCA AAGTCAGCGC
751 GGTAAACAAC TTGCTCCCCG TGTTTACCGT AATAAATACT TTGCTCGGGC
801 ATTATGTGAT GCCTGAAACT TTTGCCGCGC CGGA..

```

Number 47 ORF

```

1 ATGGTAGCTC GTCGGGCTCA TAACCCGAAG GTCGTAGGTT CGAATCCTGT
51 .CCCACAACC TAATTTCAAA CCCCTCGGTT CAATGCCGAG GG.GTTTTGT
101 T.TTGCTGT TCCCTGTTTC CTGTTTCCTG CCGCTCCGT TTTTGGCCG
151 ATTTTCCTTC CGGCCGCAAT ATCGGAACGG CAGACGCGC TCTGTTTGCG
201 GTTGCAAATT CAGGCAGTTT GGCTACAATC TTCCGATTG TCTTCAAGAA
251 AGCCAACCAT GCCGACGTC CGTTTTACCG AATCCGTCAG CAAACAAGAC
301 CTTGATGCTC TGTTTCAGTG GGCAAAAGCA AGTTACGGTG CAGAAAGTTG
351 CTGAAAACG CTGTATCTGA ACGGTCysCC TTTGGGCAAC CTGTCGCCG
401 AATGGGTGGA ACGCGTsmmA AAAGACTGGG AGGCAGGCTG CyCGGAGTCT
451 TCAGACGGCA TTTTTCGAA TgCGGACGgc TGgCctGATA TGGgCGGAcg
501 cTTACAGCAC CTCGCCCTCG GTTGGCACTG TGCGGGGCTG TTGGACGgst
551 GGCGCAACGA GTGTTTCGAC CTGACCGACG GCGGCGGCAA CCCCTTGTTC
601 ACGCTCGaAc GCGCCGyTTT mCGTCCTkTC GGACTGCTCA GCCGCGCCGT
651 CCATCTCAAC GGTCTGACCG AATCGGACGG CCGATGGCAT TTCTGATAG
701 GCAGGCGCAG TCCGCACAAA GCAGTCGATC CCAACAACT CGACAATACT

```

-13-

```

751 rCCGCCGGCG GTGTTTCCGG CGGCGAAATG CCGTCTGAAG CCGTGTGTCC
801 CGAAAGCAGC GAAGAAGCCG GTTTGGATAA AACGCTGcTT CCGCTCATCC
851 GCCCGGTATC GCAGCTGCAC AGCCTGCGCT CCGTCAGCCG GGGTGTACAC
901 AATGAAATCC TGTATGTATT CGATGCCGTC CTGCCG...

```

Number 48 ORF

```

1 ATGAATAGAC CCAAGCAACC CTTCTTCCGT CCCGAAGTCG CCGTTGCCCG
51 CCAAACCAGC CTGACGGGTA AAGTGATTCT GACACGACCG TTGTCATTTT
101 CCCTATGGAC GACATTTGCA TCGATATCTG CGTTATTGAT TATCCTGTTT
151 TTGATATTGG GTAACATAAC GCGAAAGACA ACAGTGGAGG GACAAATTTT
201 ACCTGCATCG GCGTAATCA GGGTGTATGC ACCGgATACG rKACAATTA
251 CAGCGAAATT CGTGAAGAT GGmsAAAAGG TTAAGGCTGG CGACAAGCTA
301 TTTGCGCTTT CGACCTCACG TTTCGGCGCA GGAGGTAGCG TGCAGCAGCA
351 GTTGAAAACG GAGGCAGTTT TGAAGAAAAC GTTGGCAGAA CAGGAACTGG
401 GTCGTCTGAA GCTGATACAC GGGAAATGAAA CGCGCAGCcT TAAAGCAACT
451 GTCGAACGTT TGGAAAACCA GGAACCTCAT ATTTGCAAC AGATAGACGG
501 TCAGAAAAGG CGCATTAGAC TTGCGGAAGA AATGTTGCAG AAATATCGTT
551 TCCTATCCGC .CAATGA

```

Number 49 ORF

```

1 ATGCTGAATA CTTTTTTTGC CGTATTGGGC GGCTGCCTGC TGCT.TTGCC
51 GTGCCGCAA TCCGTAAATA CGGCGGTACA GCCGCAAAAC GCGGTACAAA
101 GCGCGCCGAA ACCGTTTTTC AAAGTCATAT ATATCGACAA TACGGCGATT
151 GCCGTTTGG ATTTGGGACA AAGCAGCGAA GGCAAAACCA ACGACGGCAA
201 AAAACAAATC AGTTATCCGA TTAAAGGCTT GCCGGAACAA AATGTTATCC
251 GACTGATCGG CAAGCATCCC GGCGACTTGG AAGCCGTCAG CGGCAAATGT
301 ATGGAAACCG ATGATAAGGA CAGTCCGGCA GGTGGGCGAG AAAACGGCGT
351 GTGCCATACC TTGTTTGCCA AACTGGTGGG CAATATCGCC GAAGACGGCG
401 GCAAACAGAC GGATTACCTA GTTTCGCATG CCGCCCTGCA ACCCTATCAG
451 GCAGGCAAAA GCGGCTATGC CGCCGTGCAG AACGGACGCT ATGTGCTGGA
501 AATCGACAGC GAAGGGGCGT TTTATTTCCG CCGCCGCCAT TATTGA

```

Number 50 ORF

```

1 ATGGAAGATT TATATATAAT ACTCGCTTTG GGTTTGGTTG CGATGATTGC
51 CGgATTATC GATgcatTg cGgCGGGG TGTTTGGATT ACGTGCCCG
101 CACTCTGTGTT GGCAGGTATT CCTCCGTGT CCGCAATTGC CACCAACAG
151 CTGCAAgCAG CCGCTGCTAC GTTTTCAGCT ACGGTTTCTT TTGCACGCAA
201 AGGTTTGATT GATTGGAAGA AAGGTCTCCC GATTGCCGCA GCATCGTTTG
251 TAGGCGGCGT GGcCGGTGCA TTATCGGTCA GCTTGGTTTC CAAAGATATT
301 CTgCTgCGG TCGTGCCGGT TTTGTTGATA TTTGTGCGAC TGTATTTTGT
351 GTTTTCGCCC AAGCTCGACG GCAGTAAGGA AGGCAAAGCC AGAATGTCTT
401 TTTTCTGTGTT cGGGCTGACG GTCGC.ACCG CTTTGGGTT TTTACGACGG
451 TGTGTTGCGA CCGGTGTGCG GCTCGTTTTT TCTGATTGCC TTTATTGTTT
501 TGCTCGGCTG CAAgCTGTTG AACGCGATGT CTTACACCAA ATTGGCGAAC
551 GTTGCCTGCA ATCTTGTTTC GCTATCGGTA TTCCTGCTGC ACGGTTTCGAT
601 TATTTTCCCG ATTGCGGCAA CGaTGCGGT CCGTGCGTTT GTCGGtCGCA
651 ATTTAgGTGC GAGATTTGCC GTaCgctTCG GTTCGAAGCT GATTAA

```

Number 51 ORF

```

1 ..CTGCTAGGGT ATTGCATCGG TTATCGGTAC GgCTGTTGCA GCAAAACCAG
51 CCGCAGACGG ATTATTTGGT CAAATTCGGA TCGTTTTGGG CGAG.ATTTT
101 TGGTTTTCTG GGAATGTATG ACGTCTATGC TTCGGCATGG TTTGTCGTTA
151 TCATGATGTT TTTGGTGGTT TCTACCAGTT TGTGCCTGAT TCGCAATGTG
201 CCGCCGTTCT GCGCGGAAAT GAAGTCTTTT CGGGAAAAGG TTAAAGAAAA
251 ATCTCTGGCG GCGATGCGCC ATTCTTCGCT GTTGGATGTA AAAATTGCGC
301 CCGAGGTTGC CAAACGTTAT CTGGAAGTAC AAGGTTTTCA GGGGAAACC
351 ATTAACCGTG AAGACGGGTC GGTTCGTATT GCCGCCAAA AAGGCACAAT

```


-14-

```

401  GAACAAATGG GGCTATATCT TTGCCCATGT TGCTTTGATT GTCATTTGCC
451  TGGGCGGGTT GATAGACAGT AACCTGCTGT TGAAACTGGG TATGCTGACC
501  GGTCCGATTG TTCCGGACAA TCAGGCGGTT TATGCCAAGG ATTTT.AAGC
551  CCGAAAGTAT .TTTGGGTGC gTCCAATCTC TCATTTAGGG GCAACGTCAA
601  TATTTCCG.A GGGGCAGAgT GCGGATGTGG TTTTCCTGA

```

Number 52 ORF

```

1  ATGCCGTCCTG AAACACGCCT GCCGAACTTT ATCCGCGTCT TGATATTTGC
51  CCTGGGTTTC ATCTTCCTGA ACGCCTGTTC GGAACAAACC GCGCAAACCG
101 TTACCCTGCA AGGCGAAACG ATGGGCACGA CCTATACCGT CAAATACCTT
151 TCAAATAATC GGGACAAACT CCCCTCACCT GCCGAAATAC AAAAACGCAT
201 CGATGACGCG CTAAAGAAG TCAACGGCA GATGTCCACC TATCAGCCCG
251 ACTCCGAAAT CAGCCGGTTC AACCAACACA CAGCCGGCAA GCCCTCCCG
301 ATTTCAAGCG ACTTCGCACA CGTTACTGCC GAAGCCGTCC GCCTGAACCG
351 CCTGACACAC GGC GCGCTGG ACGTAACCGT CGGCCCTTG GTCAACTTT
401 GGGGATTCGG CCCCACAAA TCCGTTACCC GTGAACCGTC GCCGGAACAA
451 ATCAAACAGG CGGCATCTTA TACGGGCATA GACAAAATCA TTTTGAAACA
501 AGGCAAAGAT TACGCTTCCT TGAGCAAAAC CCACCCCAAG GCCTATTTGG
551 ATTTATCTTC GATTGCCAAA GGCTTCGGCG TTGATAAAGT TCGGGCGGAA
601 CTGGAAAAAT ACGGCATTCA AAATTATCTG GTCGAAATCG GCGGCGAGTT
651 GCACGGCAAA GGCAAAACG CGCGCGGCGA ACCGTGGCGC ATCGGTATCG
701 AGCAGCCCAA TATCGTCCAA GGCGGCAATA CGCAGATTAT CGTCCCGCTG
751 AACAAACGTT CGTTGCCAC TTCCGGCGAT TACCGTATTT TCCACGTCGA
801 TAAAAACGGC AAACGCCTCT CCCATATCAT CAACCCGAAC AACAAACGAC
851 CCATCAGCCA CAACCTCGCC TCCATCAGCG TGGTCGCAGA CAGTCGATG
901 ACGGCGGACG GCTTGTCCAC AGGATTATTC GTATTGGGCG AAACCGAAGC
951 CTTAAAGCTG GCAGAGCGCG AAAAATCTCG TGTTCCTG ATTGTCAGGG
1001 ATAAAGGCGG CTACCGCACC GCCATGTCTT CCGAATTGA AAACTGCTC
1051 CGCTAA

```

Number 53 ORF

```

1  . .CCGTGCCGCC GACAGGGCGA CGACGTGTAT GCGGCGCAGC CGTCCCCTCA
51  AAAATTGTGG CTGCGCTTCA TCGGCGGCCG GTCGCATCAA AATATACGGG
101 GCGGCGCGGC TCGGACGGG TGGCGCAAAG GCGTGCAAAT CGGCGCGGAG
151 GTGTTGTAC GGCAAAATGA AGGAGCCKA yTGGCAATCG GCGTGATGGG
201 CGGCAGGGCC GGCCAGCACG CwTCAGTCAA CGGCAAAGC GGTGCGGCAG
251 gCAGTGATT GTATGGTTAT GgCGGGGgTG TTTATGCTgC GTGGCATCAG
301 TTGCGCGATA AACAAACGGG TgCGTATTTG GACGGCTGGT TGCAATACCA
351 ACGTTTCAA CACCGCATCA ATGATGAAAA CCGTGCGGAA CgCTACAAAA
401 CCAAAGTTG GACGGCTTCT GTCGAAGGCG GCTACAACGC GCTTGTGGCG
451 CAAGGCATTG TCGGAAAAGG CAATAATGTG CGGTTTACC TACAACCGCA
501 GgCGCAGTTT ACCTACTTGG GCGTAAACGG CGGCTTACC GACAGCGAGG
551 GGACGCGGGT CGGACTGCTC GGCAGCGGTC AGTGGCAAAG CCGCGCCGGC
601 AtTCGGGCAA AAACCCGTTT TGCTTTGCGT AACGGTGTCA ATCTTCAGCC
651 TTTTGCCGCT TTTAATGTt TGCACAGGTC AAAATCTTTC GGCGTGAAA
701 TGGACGGCGA AAAACAGACG CTGGCAGGCA GGACGCGACT CGAAGGGCGG
751 TTCGGTATTG AAGCCGTTG GAAAGGCCAT ATGTCCGCA. .

```

Number 54 ORF

```

1  . .GCGGAATATG TTCAGTTCTC TATAGATTG TTCAGTGTGG GTAAATCGGG
51  GGGCGGTATA CCTAAGGCTA AGCCTGTGTT TGATGCGAAA CCGAGATGGG
101 AGGTTGATAG GAAGCTTAAT AAATTGACAA CTCGTGAGCA GGTGGAGAAA
151 AATGTTCAGG AAACGAGAAG AAGGAGTCAG AGTAGTCAGT TTAAAGCCCA
201 TGCGCAACGA GAATGGGAAA ATAAAACAGG GTTAGATTTT AATCATTTTA
251 TAGGTGGTGA TATCAATAAA AAAGGCACAG TAACAGGAGG GCATAGTCTA
301 ACCCGTGGTG ATGTACGGGT GATACAACAA ACCTCGGCAC CTGATAAACA
351 TGGGGT.TTA TCAAGCGACA GTGGAAATTN A

```

-15-

Number 55 ORF

```

1   ATGAATATTC ACACCCTGCT CTCCAAACAA TGGACGCTGC CGCCATTTCCT
51  GCCGAAACGG CTGCTGCTGT CCCTGCTGAT ACTGCTTGCC CCCAATGCGG
101 TGT TTTGGGT TTTGGCACTG CTGACCGCCA CCGCCCGCCC GATTGTCAAT
151 TTGGACTATC TTCCCGCCGC GCTGCTGATC GGCCTGCCTT GGCCTTTCGT
201 CAAAATTGCC GGCCTATTGG CGTTTTGGCT GGCCTTTTTG TTTGACGGGC
251 TGATGATGGT GATCCAATC TTCCCTTTTA TGGATCTCAT CGGCGCCATC
301 AACCTCGTCC CCTTCATCCT GACCGCCCCC GGCCTTATC AGATAATGAC
351 CGGGCTG...

```

Number 56 ORF

```

1   ..GTGAGCGGAC GTTACCGCGC TTTGGATCGC GTTTCCAAAA TCATCATCGT
51  TACTTTGAGT ATCGCCACGC TTGCCGCCGC CGGCATCGCT ATGTCGCGCG
101 GTATGCAGAT GCAGTCCGAT TTTATCGAGC CGACACCGTG GACGCTTGCC
151 GGT TTTGGGT TCCTGATCGC GCTGATGGGC TGGATGCCCG CGCCGATTGA
201 AATTTCCGCC ATCAATTCTT TGTGGGTAAC CGAAAAACAA CGCATCAATC
251 CTTCCGAATA CCGCGACGGG ATTTTGAAT TCAACGTCGG TTATATCGCC
301 AGTGCGGTTT TGGCTTTGGT TTTCCTTGCA CTGGGCGC.G TAGCGCCGAA
351 CGGCAACGGC GA.ACAGTGC AGATGGCGGG CGGCAAATAT AACGGGCAAT
401 TGATCAATAT GTACGCC..

```

Number 57 ORF

```

1   ..TTGCGGGAAA CGGCATATGT TTTGGATAGT TTTGATCGTT ATTTTGTGT
51  TCGCTTGCC GGCTTGTTTT TTGTCCGCGC ACAATCCGAA CGCGAGTGGA
101 TCGCGAGGT TTCTGCGTGG CAGGAAAAGA AAGGGGAAAA ACAGGCGGAG
151 CTGCCTGAAA TCAAAGACGG TATGCCCGAT TTTCCGAAC TTGCCCTGAT
201 GCTTTTCCAC GCCGTCAAAA CGGCAGTGTA TTGGCTGTTT GTCGGTGTCTG
251 TCCGTTTCTG CCGAACTAT CTGGCGCAGC AATCCGAACC GGACAGGCC
301 GTTCCGCCT..

```

Number 58 ORF

```

1   ATGATTTATC AAAGAAACCT CATCAAAGAA CTCTCTTTTA CCGCCGTGCG
51  CATTTTCGTC GTCCTCTTGG CGGTATTGGT CTCCACGCAG GCAATCAACC
101 TGCTCGGCCG TGCCGCCGAC GGGC..GTGA TCGCCATCGA TGCCGTGTG
151 GCATTGGTCG GCTTCTGGGT C..... //
901 .....A TTGCCATCGG TTTGTTTTTA ATTTACCAA ACGGGCTGAC
951 CCTGCTTTTT GAAGCCGTGG AAGACGGCAA AATCCATTTT TGGCTCGGAC
1001 TGCTGCCTAT GCACATTATC ATGTTTGTC TTGCACTCAT CCTGTTGCGC
1051 GTCCGCAGTA TGCCAGCCA GCCCTTCTGG CAGGCGGTTG GCAAAAGTCT
1101 GACATTGAAA GCGGAAAAAT GA

```

Number 59 ORF

```

1   ..GGTGGTGGTT TTATCAATGC TTCCTGTGCC ACTTTGACGA CAGCCAAACC
51  GCAATATCAA GCAGGAGACC TTAGCGCTTT TAAGATAAGG CAAGGCAATG
101 TTGTAATCGC CGGACACGGT TTGGATGCAC GTGATACCGA TTACACACGT
151 ATTCTCAGTT ATCATTCCAA AATCGATGCA CCCGTATGGG GACAAGATGT
201 TCGTGTCTGC GCGGGACAAA ACGATGTGGC CGCAACAGGT GATGCACATT
251 CGCCTATTCT CAATAATGCT GCTGCCAATA CGTCAAACAA TACAGCCAAC
301 AACGGCACAC ATATCCCTTT ATTTGCGATT GATACAGGCA AATTAGGAGG
351 TAT.GTATGC CAACAAAATC ACCTTGATCA GTACGGTCTG GCAAGCAGGC
401 ATTCGTAA

```

Number 60 ORF

```

1  ..TCAACGGGAC ATAGCGAACA AAATTACACT TTGCCGCGAG AAATCACACG
51  CAACATTTCA CTGGGTTTCAT TTGCCTATGA ATCGCATCGC AAAGCATTA
101 GCCATCATGC GCCAGGCCAA GGCACTGAGT TGCCGCAAAG CAACGGTATT
151 TCGCTACCTT ATACGTCCAA TTCTTTTACC CCATTACCCA GCAGCAGCTT
201 ATACATTATC AATCCTGTCA ATAAAGGCTA TCTTGTGAA ACCGATCCAC
251 GCTTTGCCAA CTACCGTCAA TGGTTGGGTA GTGACTATAT GCTGGACAGC
301 CTCAACTAG ACCCAAACAA TTTACATAAA CGTTTGGGTG ATGGTTATTA
351 CGAGCAACGT TTAATCAATG AACAAATCGC AGAGCTGACA GGGCATCGTC
401 GTTTAGACGG TTATCAAAAC GACGAAGAAC AATTTAAAGC CTTAATGGAT
451 AATGGCGCGA CTGCGGCACG TTcGATGAAT CTAGCGTTG GCATTGCATT
501 AAGTGCCGAG CAAGTAGCGC AACTGACCAG CGATATTGTT TGGTTGGTAC
551 AAAAAGAAGT TAAGTTCCTT GATGGCGGCA CACAAACCGT ATTGGTGCCA
601 CAGGTTTATG TACGCGTTAA AAATGGCGAC ATAGACGGTA AAGGTGCATT
651 GTTGTCAAGC AGCAATACAC AAATCAATGT TTCAGGCAGC CTGAAAAACT
701 CAGGCACGAT TGCAGGgCGC AATGCGCTTA TTATCAATAC CGATAGCCTA
751 GACAATATCG GTGGGCGTAT TCATGCGCAA AAATCAGCGG TTACGGCCAC
801 ACAAGACATC AATAATATTG GCGGCATGCT TTCTGCCGAA CAGACATTAT
851 TGCTCAACGC AGGCAACAAC ATCAACAGCC AAAGCACCAAC CGCCAGCAGT
901 CAAAATACAC AAGGCAGCAG CACCTACCTA GACCGAATGG CAGGTATTTA
951 TATCACAGGC AAAGAAAAAG GTGTTT..

```

Number 61 ORF

```

1  ..TCAGGGAATA ACCTCAATGC CAAAGCTGCC GAAGTCAGCA GCGCAAACGG
51  TACACTCGCT GTGTCTGCCA ATAATGACAT CAACATCAGC GCAGGCATCA
101 ACACGACCCA TGTGTATGAT GCGTCCAAAC ACACAGGCAG AAGCGGTGGT
151 GGCAATAAAT TAGTCATTAC CGATAAAGCC CAAAGTCATC ACCGAAACCGC
201 CCAAAGCAGC ACCTTTGAAG GCAAGCAAGT TGTATTGCAG GCAGGAAACG
251 ATGCCAACAT CCTTGGCAGC AATGTTATTT CCGATAATGG CACCAGATT
301 CAAGCAGGCA ATCATGTTCC CATTGGTACA ACCCAAATC AAAGCCAAAG
351 CGAAACCTAT CATCAAACCC AGAAATCAGG ATTGATGAGT GCAGGTATCG
401 GCTTCACTAT TGGCAGCAAG ACAAAACACAC AAGAAAACCA ATCCCAAGAC
451 AACGAACATA CAGGCAGTAC CGTAGGCAGC TTGAAAGGCG ATACCACCAT
501 TGTTGCAGGC AAACACTACG AACAAATCGG CAGTACCGTT TCCAGCCCGG
551 AAGGCAACAA TACCATCTAT GCCCAAAGCA TAGACATTCA AGCGGCACAC
601 AACAAATTAA ACAGTAATAC CACCCAAACC TATGAACAAA AAGG.CTAA
651 GGTGGCATTC AGTTCGCCCG TTACCGATTG GGCACAACAA ...

```

Number 62 ORF

```

1  ATGATTTACA TCGTACTGTT TCTAGCTGTC GTCCTCGCCG TTGTCGCCTA
51  CAACATGTAT CAGGAAAACC AATACCGCAA AAAAGTGCGC GACCAAGTTCG
101 GACACTCCGA CAAAGATGCC CTGCTCAACA GCAwAACCAG CCATGTCCGC
151 GACGGCAAAC CGTCCGGCGG GTCAGTCATG ATGCCGAAAC CCCAACCGGC
201 GGTCAAAAAA ACGGCAAAAC CCCAAGACCC CGyCATGCGC AACCTGCAAG
251 AACAGGATGC CGTCTACATC GCCAAGCAGA AACAGGCAAA AGCCTCCCG
301 TTCAAAACCG AAATCGAAAC CGCCTTGGA GAAAGCGGCA TTATCGGCAA
351 CTCCGCCAC ACCGTTTCCG AACCCCAAAC CGGACATTCC GCAACGAAAC
401 CTGCCGACGC GTCGGCAAAA CCTGCACCCG TTCCGCAAAC ACCTGCAAAA
451 CCGCTGATTA CGCTCAAAGA ACTGTCAAAA GTCGAATTAT CCTGGTTTGA
501 CGTGCGCATC GACTTCATCT CCTAT...

```

Number 63 ORF

```

1  ..GCGCGGCACG GCACGGAAGA TTTCTTCATG AACAAAGCG ACAC.ATCAG
51  GCAGATAGTC GAAAGCACCA CCGGTACGAT GAAGCTGCTG ATTTCTCCA
101 TCGCCCTGAT TTCATTGGTA GTCGGCGGCA TCGGCGTGAT GAACATCATG
151 CTGGTGTCG TTACCGAGCG CACCAAAGAA ATCGGCATAC GGATGGCAAT
201 CGGCGCGCGG CGCGGCAATA TTTyGCAGCA GTTTTGTATT GAGGCGGTGT
251 TAATCTGCGT CATCGCGGT TTGGTCGGCG TGGTTTGTG CGCCGCCGTC

```

-17-

```

301   AGCCTCGTGT TCAATCATTT TGTAACCGAC TTCCGGATGG ACATTTCCGC
351   CATGTCCGTC ATCGGCGCGG TCGCCTGTTC GACCGGAATC GGCATCGCGT
401   TCGGCTTTAT GCGTGCCAAT AAAGCAGCCA AACTCAATCC GATAGACGCA
451   TTGGCACAGG ATTGA

```

Number 64 ORF

```

1   ..GGGACGGGAG CGATGCTGCT GCTGTTTTAC GCGGTAACGA T.CTGCCTTT
51  GGCCACTGGC GTTACCCTGA GTTACACCTC GTCGATTTTT TTGGCGGTAT
101 TTTCTTCCTT GATTTTGAAA GAACGGATTT CCGTTTACAC GCAGGCGGTG
151 CTGCTCCTTG GTTTTGCCGG CGTGGTATTG CTGCTTAATC CCTCGTTCCG
201 CAGCGGTCAG GAAACGGCGG CACTCGCCGG GCTGGCGGGC GGCGCGATGT
251 CCGGCTGGGC GTATTTGAAA GTGCGCGAAC TGTCTTTGGC GGGCGAACCC
301 GGCTGGCGCG TCGTGTTTTA CCTTCCGTG ACAGGTGTGG CGATGTCGTC
351 GGTTCGGCGG ACGCTGACCG GCTGGCACAC CCTGTCTTT CCATCGGCAG
401 TTTATCTGTC GTGCATCGGC GTGTCCGCGC TGATTGCCCA ACTGTCGATG
451 ACGCGCGCCT ACAAAGTCGG CGACAAATTC ACGGTTGCCT CGCTTTCCTA
501 TATGACCGTC GTTTTTTCCG CTCTGTCTGC CGCATTTTT CTGGGCGAAG
551 AGCTTTTCTG GCAGGAAATA CTCGGTATGT GCATCATCAT CQTACGCGT
601 ATTTTGA

```

Number 65 ORF

```

1   ATGAAGCGGC GTATAGCCGT CTTCGTCCTG TTCCCGCAGA TAATCCGAGT
51  TTTGGGACAA CTGTTGCCGA AAATCGTCAA TACAGTTCCG GCACATCGGA
101 TGCTCTTCCA GATTTTCGGG ATGTTCTTTT TCTTCATACA CCAGCAATAT
151 CTGCCCGGGA TCGCCGAAAT CGATTCCCA TGCGGCATCG TGTTCGGTGC
201 GCTCCTCTTC CGTCATCTGC CCGCGCATTG CCTGTATGGT AAAGCCGCCG
251 TAGGGGATGC CgTTGCACAC GAACATCCAG TCGCTGATGT CGTCAACCGG
301 AACGCAAACG cTTTCGCCTT GTTCGACATT GSTCAGTTCC CcsGGTTCAT
351 TGTTCAGCAC ACCGTAAATA TAAAGACCGT CAAAATAAAT ATCGTCGATC
401 CACATATGTT CGCAAATTTT GCGTCTTCG CCGTCTTGA AAAAAGGGAC
451 TTTGACCATG GCAAAATCCA AGGCGGAAAT AATGCGGCGG CGTTCCCAAA
501 AAAGcTCGCG CCAAAATAT TTGAATGTTT TACGGGCGCG TTCGTCGGCA
551 CGGTTTACCG GTTCGTCTGC CTGTTCTACA TAATAAATGA CGGAATCGCC
601 CATCATATCT GCTCCTCAAC GTGTACGGTA TCTGTTTGCA CCTTACTGCG
651 GCTTTCTgcC kTCGGCATCC GATTCGGATT TGAAAAGTTC mmrwyATTCG
701 GAATAG

```

Number 66 ORF

```

1   ATGGAAAATA TGGTAACGTT TTCAAAAATC AGACCGCTTT TGGCAATCGC
51  CGCCGCGCGG TTGCTTGCCG CC.TGCGGAC GGCGGGAAAT AATGCTGTCC
101 GCAAGCCGGT GCAAAACGCC AAACCCGCGC CAGTGGTCGG TTTGGCACTC
151 GGTGGCGGCG CATCTAAAGG ATTTGCCCAT GTAGGTATTA TTAAGTTTTT
201 GAAAGAAAAC GGTATTCTCTG TGAAGGTGGT TACCGGCACC TCCGCAGGTT
251 CGATTGTCCG CAACCTTTTT GCATCGGGTA TGTGCCCCGA CCGCCTCGAA
301 TTGGAAGCCG AAATTTTAGG CAAAACCGAT TTGGTCGATT TAACCTTGTC
351 CACCAATGGG TTTATCAAAG GCGCAAAGCT GCAAAATTAC ATCAACCGAA
401 AACTCCGCGG CATGCAGATT CAGCAGTTTC CCATCAAATT TGCCGCC..

```

Number 67 ORF

```

1   ATGTTTCGTT TACAATTCAG GCTGTTTCCC CCTTTGCGAA CCGCCATGCA
51  CATCTGTGTG ACCGCCCTGC TCAAATGCCT CTCCCTGcTG CCGCTTTCCT
101 GTCTGCACAC GCTGGGAAAC CGGCTCGGAC ATCTGGCGTT TTACCTTTTA
151 AAGGAAGACC GCGCGCGCAT CGTCGCCmAT ATGCGGCAGG CGGGTTTGAA
201 CCCCGACCCC AAAACGGTCA AAGCCGTTTT TGCGGAAACG GCAAAAGGCG
251 GTTTGGAAC TCCCCCGCG TTTTTCAGAA AACCAGGAAGA CATAGAAACA
301 ATGTTCAAAG CGGTACACGG CTGGGAACAT GTGCAGCAGG CTTTGACAA
351 ACACGAAGGG CTGCTATTC..

```

-18-

Number 68 ORF

```

1  ..GCGTGGTCGG CCGGCGAATC GTGGCGTGTG TTAATGGAAA GTGAAACGTG
51  GCATGCGGTG TGGAATACTT TGCCTTCTC GCGGCGGCG GTGTATGCGG
101 CAGCGGTTTT GGGTGTGGTG TATGCGGCGC CGGCGCGCG GTCCGCGTGG
151 ATGCGCGGGC TGATGTTTTA GCCGTTTATG GTGTCGCCGG TTTGTGTTTC
201 GCGGCGCGTG CTGCTGCTTT ATCCGCAGTG GACGGCTTCG TTGCCGTTGC
251 TGCTGGCGAT GTATGCGCTG CTGGCGTATC CGTTTGTGGC AAAAGATGTT
301 TTATCAGCCT GGAATGCACT GCCGCCGAT TACGGCAGGG CGGCGGCGGG
351 TTTGGGTGCA AACGGCTTTC AGACGGCATG CCGCATCAG TTCCCCCTCT
401 TGAACCGGCG GTTGCGGCGC GGTCTGACTT TGGCGGCGGC AACCTGCGTG
451 GGCGAATTTG CGGCGACATT GTTTCTGTCT CGTCCGGAAT GGCAGACGCT
501 GACGACTTTG ATTTATGCCT ATTTGGGACG CGCGGGTGAG GATAATTACG
551 CCGGGGCGAT GGTGCTG..

```

Number 69 ORF

```

1  ATGGACGGCT GGACACAGAC GCTGTCCGCG CAAACCCTGT TGGGCATTTT
51  GGCGGCGGCA ATCATCCTCA TTCTGATTTT AATCGTCAGA TTCCGCATCC
101 ACGCGCTGCT GACACTGGTC ATCGTCAGCC TGCTGACGGC TTTGGCAACC
151 GGTTCGCCC CAGGCAGCAT TGTCAAAGAC ATACTGGTCA AAAACTTCGG
201 CGGCACGCTC GCGGCGGTGG CGCTTCTGGT CGGCCTGGGC GCGATGCTCG
251 AACGTTTGGT C...

```

Number 70 ORF

```

1  ..GATTTCCGCA TATCGCCCGT GTATCTTTGG GTTGCCGCGG CGTTCAAACA
51  TTTGCTGTG CCGTGGGCTG CCGACTCATA CGATGTCGCA CGCTTTGCGG
101 GCGTATTTTT TGCCGTTATC GGA CTGACTT CCTGCGGCTT TGCCGGTTTC
151 AACTTTTTGG GCAGACACCA CGGGCGCAC. GTCGTCTGA TTCTCATCGG
201 CTGTATCGGG CTGATTCCAG TTGCCCATTT CCTCAACCCC GCTGCCGCGG
251 CCTTTGCCGC CGCCGACTG GTGCTGCACG GTTATTCTTT GGCTCGCCGG
301 CGCGTGATTG CCGCCTCTTT TCTGCTCGGT ACGGGCTGGA CGCTGATGTC
351 GTTGGCAGCA GCTTATCCGG CAGCATTTGC CCTGATGCTG CCCTTGCCCG
401 TACTGATGTT TTTCCGTCCG ..

```

Number 71 ORF

```

1  ..CAATCCGCCA AATGGTTATC GGGCCAAACT CTAGTCGGCA CAGCAATTGG
51  GATACGCGGG CAGATAAAGC TTGGCGGCAA CCTGCATTAC GATATATTTA
101 CCGGCCGCGC ATTGAAAAAG CCCGAATTTT TCCAATCAAG GAAATGGGCA
151 AGCGGTTTTT AGGTAGGCTA TACGTTTTAA

```

Number 72 ORF

```

1  ATGCGGACGA AATGGTCAGC AGTGAGAAGC TGCTTACTTG GCGGACACC
51  GCCGACATCG ATACCGCTTT GAACCTGTTG TACCGTTTGC AAAAAGTCGA
101 ATTCCTCTAT GGCGATGAAA ACGGTCATTG AGACGGCATC AATTTGwCGG
151 ACGAGCAATT GCCGTTGCTG ATGGAACAAT TGTCCGGCAG CGGTAAGGCG
201 TTATTGGTCG ATCGGAACGG TCTGTATCTT GCCAACGCCA ATTTCCATCA
251 TGAGGCGGCG GAAGAGTTGG GGTGTTGGC GGCAGAAGTC GCACAGATGG
301 AAAAGAAATA CCGGCTGCTG ATTAAGAACA AC..

```

Number 73 ORF

```

1  ATGACCTTTT TACAACGTTT GCAAGGTTTG GCAGACAATA AAATCTGTGC
51  GTTTGCATGG TTCGTCTCC GCCGCTTTGA TGAAGAACGC GTACCGCAGr

```

-19-

```

101  CGGCGGCAAG CATGACGTTT ACGACGCTGC TGGCACTCGT CCCCGTGCTG
151  ACCGTGATGG TGGCGGTGCG TTCGATTTC CCCGTGTTG ACCGCTGGTC
201  GGATTGTTT GTCTCCTTCG TCAACCAAAC CATTGTGCCG CA.GGCGCGG
251  ACATGGTGTT CGACTATATC AATGCGTTCC GCGAGCAGGC GAACCGGCTG
301  ACGGCAATCG GCAGCGTGAT GCTGGTCGTT ACCTCGCTGA TGCTGATTCG
351  GACGATAGAC AATACGTTCA ACCGCATCTG GaCGGGTCAA wTyCCAGCGT
401  CCGTGGATG..

```

Number 74 ORF

```

1  ..AGACACGCCC GCCGCATCCG CATCGACACC GCCATCAACC CCGAACTGGA
51  AGCCCTCGCC GAACACCTCC ACTACCAATG GCAGGGCTTC CTCTGGCTCA
101 GCACCGATAT GCGTCAGGAA ATTTCCGCCC TCGTCATCCT GCTGCAACGC
151 ACCCGCCGCA AATGGCTGGA TGCCACAGAA CGCCAACACC TGCGCCAAAG
201 CCTGCTTGAA ACACGGGAAC ACGGCTGA

```

Number 75 ORF

```

1  ..GCCGAAGACA CGCGCGTTAC CGCACAGCTT TTGAGCGCGT ACGGCATTCA
51  GGGCAAATC GTCACTGTGC GCGAACACAA CGAACGGCAG ATGGCGGACA
101 AGATTGTCGG CTATCTTTCA GACGGCATGG TTGTGGCACA GGTTCGGAT
151 GCGGTACGC CGGCCGTGTG CGACCCGGGC GCGAAACTCG CCCGCCGCGT
201 GCGTGAGGCC GGGTTTAAAG TCGTTCCCGT CGTGGGCGCA AC.GCGGTGA
251 TGGCGGCTTT GAGCGTGGCC GGTGTGGAAG GATCCGATTT TTATTTCAAC
301 GGTTTGTAC CGCCGAAATC GGGAGAACGC AGGAAACTGT TTGCCAAATG
351 GGTGCGGGCG GCGTTTCCTA TCGTCATGTT TGAAACGCCG CACCGCATCG
401 GTGCAGCGCT TGCCGATATG GCGGAACTGT TCCCCGAACG CCGATTAATG
451 CTGGCGCGCG AAATTACGAA AACGTTTGAA ACGTTCTTAA GCGGCACGGT
501 TGGGGAAATT CAGACGGCAT TGTCTGCCGA CGGCGACCAA TCGCGCGGCG
551 AGATGGTGTT GGTGCTTTAT CCGCGCAGG ATGAAAAACA CGAAGGCTTG
601 TCCGAGTCCG CGCAAAACAT CATGAAAATC CTCACAGCCG AGCTGCCGAC
651 CAAACAGGCG GCGGAGCTTG CTGCCAAAAT CACGGGCGAG GGAAAGAAAG
701 CTTTGTACGA T..

```

Number 76 ORF

```

1  ATGAAAAACA CCGACAAACG GACAACCGAA ACACACCGCA AAGCCCCGAA
51  AACCGGTGCG ATCCGCTTCT C.GCTGCTTA CTTAGCCATA TGCTGTGCT
101 TCGGCATTCT TCCCCAAGCC TGGGCGGGAC ACACTTATTT CGGCATCAAC
151 TACCAATACT ATCGCGACTT TGCCGAAAAT AAAGGCAAGT TTGCATTCGG
201 GGCGAAAGAT ATTGAGTTT ACAACAAAAA AGGGGAGTTG GTCGGCAAAT
251 CAATGACAAA AGCCCCGATG ATTGATTTTT CTGTGGTGTC GCGTAACGCG
301 GTGGCGGcAT TGGTGGGCGt ATCAATATAT TGTGAGCGTG GCACATAACG
351 GCGGCTATAA CAACGTTGAT TTTGGTGCGG AAGGAAK.AA tATCCC.GAT
401 CAACAwCGww TACTTTATAA AATTGTGAAA CGGAATAATT ATAAAGCAGG
451 GACTAAAGGC CATCCTTATG GCGGCGATTA TCATATGCCG CGTTTGcATA
501 AATWTGTCAC AGATGCAGAA CCTGTTGAAA TGACCAGTTA TATGGATGGG
551 CGGAAATATA TCGATCAAAA TAATTACCCT GACCGTGTTT GTATTGGGGC
601 AGGCAGGCAA TATTGGCGAT CTGATGAAGA TGAGCCCAAT AACCGCGAAA
651 GTTCATATCA TATTGCAAGT .....
701 ..... GGCTC ACCAATGTTT ATCTATGATG CCCAAAAGCA
751 AAAGTGTTA ATTAATGGGG TATTGCAAAC GGGCAACCCC TATATAGGAA
801 AAAGCAATGG CTTCCAGCTG GTTCGTAAAG ATTGGTTCTA TGATGAAATC
851 TTTGCTGGAG ATACCCATTC AGTATTCTAC GAACCACGTC AAAATGGGAA
901 ATACTCTTTT AACGACGATA ATAATGGCAC AGGAAAAATC AATGCCAAAC
951 ATGAACACAA TTCTCTGCCT AATAGATTAA AAACACGAAC CGTTCaATTG
1001 TTTAATGTTT CTTTATCCGA GACAGCAAGA GAACCTGTTT ATCATGCTGC
1051 AGGTGGTGTC AACAGTTATC GACCCAGACT GAATAATGGA GAAAATATTT
1101 CTTTATTGA CGAAGGAAAA GGCGAATTGA TACTTACCAG CAACATCAAT
1151 CAAGGTGCTG GAGGATTATA TTTCCAAGGA GATTTTACGG TCTCGCCTGA
1201 AAATAACGAA ACTTGGCAAG GCGCGGGCGT TCATATCAGT GAAGACAGTA
1251 CCGTTACTTG GAAAGTAAAC GCGTGGCAA ACGACCGCCT GTCCAAAATC

```

-20-

```

1301 GGCAAAGGCA CGCTG..... //
2101 ..... ..GATAAAG
2151 TGA CTGCTTC ATTGACTAAG ACCGACATCA GCGGCAATGT CGATCTTGCC
2201 GATCACGCTC ATTTAAATCT CACAGGGCTT GCCACACTCA ACGGCAATCT
2251 TAGTGCAAAT GGCGATACAC GTTATACAGT CAGCCACAAC GCCACCCAAA
2301 ACGGCAACCK TAqCCTcGtG G.sAATGcCC AAGCAACATT TAATCAAGCC
2351 ACATTAAACG GCAACACATC GGCTTCgGGC AATGCTTCAT TTAATCTAAG
2401 CGACCACGCC GTACAAAACG GCAGTCTGAC GCTTTCCGGC AACGCTAAGG
2451 CAAACGTAAG CCATTCCGCA CTCAACGGTA ATGTCTCCCT AGCCGATAAG
2501 GCAGTATTCC ATTTTGAAAG CAGCCGCTTT ACCGGACAAA TCAGCGGCGG
2551 CAagGATACG GCATTACACT TAAAAGACAG CGAATGGACG CTGCCGTCaG
2601 GarCGGAATT AGGCAATTTA AACCTTGACA ACGCCACCAT TACaCTCAAT
2651 TCCGCCTATC GCCACGATGC GGCAGGGGCG CAAACCGGCA GTGCGACAGA
2701 TCGCGCGCGC GCGCGTTCGC GCCGTTCGCG CCGTTCCTTA TTATmCGTTA
2751 CACCGCCAAC TTCGGTAGAA TCCCGTTTCA ACACGCTGAC GGTAAACGGC
2801 AAATTGAACG GTCAGGGAAC ATTCCGCTTT ATGTCGGAAC TCTTCGGCTA
2851 CCGCAGCGAC AAATTGAAGC TGGCGGAAAG TTCCGAAGGC ACTTACACCT
2901 TGGCGGTCAA CAATACCGGC AACGAACCTG CAAGCCTCGA ACAATTGACG
2951 GTAGTGGAAG GAAAAGACAA CAAACCGCTG TCCGAAAACC TTAATTTAC
3001 CCTGCAAAAC GAACACGTCG ATGCAGGCGC GTGG..... //
3551 ..... ..TTAGAC CCGGTATTTG CCGAAGACCG
3601 CCGCAACGCC GTTTGGACAA GCGGCATCCG GGACACCAAA CACTACCGTT
3651 CGCAAGATTT CCGCGCCTAC CGCCAACAAA CCGACCTGCG CCAAATCGGT
3701 ATGCAGAAAA ACCTCGGCAG CGGGCGCGTC GGCATCCTGT TTTCGCACAA
3751 CCGGACCGAA AACACCTTCG ACGACGGCAT CGGCAACTCG GCACGGCTTG
3801 CCCACGCGC CGTTTTCGGG CAATACGGCA TCGACAGGTT CTACATCGGC
3851 ATCAGnCGCG GCGCGGGGTT TTAGCAGCGG CAGCCTTTcA GACGGCATCG
3901 GAGsmAAAwT CCGCCGCCGC GTGctGCATT ACGGCATTCA GGCACGAtAC
3951 CGCGCCGgtt tCgqCGgATt CGGCATCGAA CCGCACATCG GCGCAACGcG
4001 ctATTTCTGTC CAAAAGCGG ATTACCGCTA CGAAAACGTC AATATCGCCA
4051 CCCCCGGCCT TGCATTCAAC CGcTACCGCG CGGGCATTaA GGCAGATTAT
4101 TCATTCAAAC CGGCGCAACA CATTTCATC ACGCCTTATT TGAGCCTGTC
4151 CTATACCGAT GCCGCTTCGG GCAAAGTCCG AACACGCGTC AATACCGCG
4201 TATTGGCTCA GGATTTCGGC AAAACCCGCA GTGCGGAATG GGqCGTAAAC
4251 GCCGAAATCA AAGGTTTCAC GCTGTCCCTC CACGTGCCG CCGCAAAGG
4301 CCCGCAACTG GAAGCGCAAC ACAGCGCGG CATCAAATTA GGCTACCGCT
4351 GGTA...

```

Number 77 ORF

```

1 ..AAGGTGTGGC AATTGTGCGA AGA.CCGCTG CGTGCCGTCG TGCCTGCCGA
51 CAGTTTTGAA CCGACGCGC AAAAATTGAA CCTGTTTAA GCGGGTGCGG
101 CAACCATTTT GTTTATGAA GATCAAAATG TCGTCAAAGG TTTGCAGGAG
151 CAGTTCCTG CTTATGCCG TAACTTCCCC GTTTGGGCGg ATCAGGCAAA
201 CGCGATGGTG CAGTATGCCG TTTGGACGAC ACTTGCCGCG GTCGGCGTAG
251 GTGCAAACCT GCAACATTAC AATCCCTTGC CCGATGCGGC GATTGCCAAA
301 GCGTGGAATA TCCCCGAAAA CTGGTTGTTG CGCGCACAAA TGGTTATCGG
351 CGGTATTGAA GGGGCGGCAG GTGAAAAGAC CTTTGAACCC GTTGAGAAGC
401 GTTTGAAAGT GTTCGGCGCA TAA

```

Number 78 ORF

```

1 ..GGCTACAAC ACCTGTTTCG CCGCGGCAGC CGCATCGCCA ACTACCAAAT
51 CAACGGCATC CCCGTTGCCG ACGCGCTGGC CGATACGGGt CAATGCCAAC
101 ACCGCCGCT ATGAGCGCGT AGAAGTCGTG CGCGGCGTGG CGGGGCTGCT
151 GGACGGCACG GCGGAGCCTT CCGCCACCGT CAATCTGGTG CGCAAACGCC
201 TGACCCGCAA GCCATTGTTT GAAGTCCGCG CCGAAGCgGG CAACCGcAAA
251 CATTTCGGGC TGGACGCGGA CGTATCGGGC AGCCTGAACA CCGAAG.crc
301 rCTGCGCgGC CGCCTGGTTT CCAcCTTCG ACGCGGCGAC TCGTGGCGGC
351 GGCGCGAACG CAGCCGsKAT GCCGAACCTC ACGGCATTTT GGAATACGAC
401 ATCGCACCGC AAACCGCGT CCACGCArGC ATGGACTACC AGCAGGCGAA

```

-21-

```

451  AGAAACCGCC GACGCGCCGC TCAGcTACGC CGTGACGAC AGCCAAGGTT
501  ATGCCACCGC CTTGGGCCCG AAAGACAACC CCGCCACAAA TTGGGCGAAC
551  AGCCACCACC GTGCGCTCAA CCTGTTCGCC GGCATCGAAC ACCGCTTCAA
601  CCAAGACTGG AACTCAAAG CCGAATACGA CTAC..

```

Number 79 ORF

```

1  ATGCGCACGG CAGTGGTTTT GCTGTTGATC ATGCCGATGG CGGCTTCGTC
51  GGCAATGATG CCGGAAATGG TGTGCGCGGG CGTGTCGCCG GGAACGGCAA
101 TCATATCCAA GCCGACCGAA CAAACGGCGG TCATGGCTTC GAGTTTGTCC
151 AGCGTCAGcA CGCCTGCTTC GCGGgcGgCa ATCATACTT CGTCTTCGGA
201 AACGGGGATA AACGcGCCAC TCAAACCCCC GACCGCGCTG GAAGCCATCA
251 TGCCGCCTTT TTTCACGGCA TCGTTCAGCA ATGCCAAAGC TGCTGTTGTG
301 CCGTGCGTAC CGCAGACGCT CAAGCCATT TATTCAAGAA TGCGTGCCAC
351 TnAGTCGCCG ACGGGG..

```

Number 80 ORF

```

1  ..ACCGACGTGC AAAAAGAGTT GGTGGCGGAA CAACGCAAGT GGGCGCAGGA
51  AAAAATCAGC AACTGCCGAC AAGCCGCCGC GCAGGCAGAC CGGCAGGAAT
101 ACGCCGAATA CCTCAAGCTG CAATGCGACA CGCGGATGAC GCGCGAACGG
151 ATACAGTATC TTCGCGGCTA TTCCATCGAT TAG

```

Number 81 ORF

```

1  ATGCAGCTGA TCGACTATTC ACATTCATTT TTCTCGGTTG TGCCACCCTT
51  TTTGGCACTG GCACTTGCCG TCATTACCCG CCGCGTACTG CTGTCTTTAG
101 GCATCGGTAT TCTGGWysGC GTTGCCTTTT TGGTCGGCGG CAACCCCGTC
151 GACGSTCTGA CACACCTGAA AGACATGGTC GTCGGCTTGG CTTGGTCAGA
201 CGsyGATTGG TCGCTGGGCA AACC AAAAAT CTTGGTTTTT CkGATACTTT
251 TGGGTATTTT TACTTCCCTG CTGACCTACT CCGGCAGCAA T.....
//
851 .....AC TTGCTGGTA
901 TTCGGCGGCA CTTGCGGCGT CTTGCCGTC GTTCTCTGCA CGCTCGGCAC
951 GATTAAACC GCCGACTATC CCAAAGCCGT TTGGCAGGGT GCGAAATCTA
1001 TGTTCCGCGC AATCGCCATT TTAATCCTCG CTTGGCTCAT CAGTACGGTT
1051 GTCGGCGAAA TGCACACCGG CGATTACCTC TCCACACTGG TTGCGGGCAA
1101 CATCCATCCC GGCTTCCTGC CCGTCATCCT CTTCCTGCTC GCCAGCGTGA
1151 TGGCGTTTGC CACAGGCACA AGCTGGGGGA CTTTCGGCAT TATGCTGCCG
1201 ATTGCCCGCG CCATGGCGGT CAAAGTCGAA CCGCGCTGA TTATCCCGTG
1251 TATGTCCGCA GTAATGGCGG GGGCGGTATG CCGCGACCAC TGCTCGCCCA
1301 TTTCCGACAC GACCATCCTG TCGTCCACCG GCGCGCGCTG CAACCACATC
1351 GACCACGTTA CCTCGCAACT GCCTTACGCC TTAACCGTTG CCGCCGCCGC
1401 CGCATCGGGC TACCTCGCAT TGGGTCTGAC AAAATCCGCG CTGTTGGGCT
1451 TTGGCACGAC AGGCATTGTA TTGGCGGTGC TGATTTTCT GTTGAAAGAT
1501 AAAAAA..

```

Number 82 ORF

```

1  ..AAGCAATGGT ATGCCGACGN .AGTATCAAG ACGGAAATGG TTATGGTCAA
51  CGATGAGCCT GCCAAAATTC TGAATTGGGA TGAAAGCGGC CGATTACTCT
101 CGGAACGTGC TATCCGCCAC CATCAACGCA ACGGGGTGGT TTTGGAGTGG
151 TATGAAGATG GTTCTAAAAA GAGCGAAGT GTTTATCAGG ATGACAAGTT
201 GGTCAAGAAA ACCCAGTGGG ATAAGGATGG TTATTTAATC GAACCTGA

```

Number 83 ORF

```

1  ATGAAACAGA CAGTCAA.AT GCTTGCCGCC GCCCTGATTG CTTGGGCTT
51  GAACCGACCG GTGTGGNCGG ATGACGTATC GGATTTTCGG GAAACTTGC

```


-22-

```

101 A.GCGGCAGC ACAGGGAAT GCAGCAGCCC AATACAATTT GGGCGCAATG
151 TAT.TACAAA GGACGCGCGT GCGCCGGGAT GATGCTGAAG CGGTCAGATG
201 GTATCGGCAG CCGGCGGAAC AGGGGTTAGC CCAAGCCCAA TACAATTTGG
251 GCTGGATGTA TGCCACGCGG CGCGC.GTGC GCCAAGATGA TACCGAAGCG
301 GTCAGATGGT ATCGGCAGGC GGCAGCGCAG GGGGTTGTCC AAGCCCAATA
351 CAATTTGGGC GTGATATATG CCGAAGGACG TGGAGTGCGC CAAGACGATG
401 TCGAAGCGGT CAGATGGTTT CCGCAGGCGG CAGCGCAGGG GGTAGCCCAA
451 GCCCCAAACA ATTTGGGCGT GATGTATGCC GAAAGANCGC GCGTGCGCCA
501 AGACCG...

```

Number 84 ORF

```

1 ATGAAATTTA CCAAGCACCC CGTCTGGGCA ATGGCGTTCC GCCCATTTTA
51 TTCGCTGGCG GCTCTGTACG GCGCATGTGC CGTATTGCTG TGGGGTTTCG
101 GCTACACGGG AACGCACKAG CTGTCCGGTT TCTATTGGCA CGCGCATGAG
151 ATGATTTGGG GTTATGCCGG ACTGGTCGTC ATCGCCTTCC TGCTGACCGC
201 CGTCGCCACT TGGACGGGGC AGCCGCCAC GCGGGGCGGC GTaTCTGGTC
251 GGCTTGAATA TCTTTTGGCT GGCTGCGCGG ATTGCCGCCT TTATCCCGGG
301 TTGGGGTGCG TCGCAACGCG GCATACTCGG TACGCTGTTT TTCTGGTACG
351 GCGCGGTGTG CATGGCTTTG CCCGTTATCC GTTCGCAGAA TCAACGCAAC
401 TATGTTgCCG TGTTCGCGCT GTTCGTCTTG GCGGCGACGC ATGCGGCGTT
451 CCACGTCCAG CTGCACAACG GCAACCTAGG CCGACTCTTG AGCGGATTGC
501 AGTCGGGCTT GGTGATG

```

Number 85 ORF

```

1 ..ATGCCGTCTG AAGGTTTCAGA CGGCmTCGGT GyCGGGGAAY CAGAAGyGGT
51 AGCGCATGCC CAATGAGACT TCGTGGGTTT TGAAGCGGGT GTTTTCCAAG
101 CGTCCCAGT TGTGGTAACG GTATCCGGTG TCyAArGTCA GCTTGGGyGT
151 GATGTCGAaA CCGACCCGG CGATGACACC AAGACCyAmG CTGCTGATrC
201 TGTrkGCTTTC GTGATAGGsA GGTtTGyTGG kmksAsyTTG TAyrATwkkG
251 CCTssCwsTG kAGmGCCkTk CkyTGGTkKA swGrwArTAG TCGTGGTTTy
301 TkTtyyCACC GAATGAACyT GATGTTTAAC GTGTCCGTAG GCGACGCGCG
351 CGCCGATATA GGGTTTGAAT TTATCGTTGA GTTTGAAATC GTAAATGGCG
401 GACAAGCCGA GAGAAGAAAC GGCGTGGAAG CTGCCGTTTC CCTGATGTTT
451 TGTTTGGGTT TCTTTGTAGT TGTGTTTAT CTCTTCAGTA ACTTTTTTAG
501 TAGAAGAATT ACTTTCTTTC CATTTTCTGT AACTGGCATA ATCTGCCGCT
551 ATTCTCCAGC CGCCGAAATC ..

```

Number 86 ORF

```

1 ATGTTTGCTT TTTTAGAAGC CTTTTTTGTC GAATACGGTT ATGCGGCTGT
51 TTTTTTTGTA TTGGTCATCT GCGGTTTCGG CGTGCCGATT CCCGAGGATT
101 TGACCTTGGT AACAGGCGGC GTGATTTCCG GTATGGGTGA TACCAATCCG
151 CATATTATGT TTGCAGTCGG TATGCTCGGC GTATTGGTCC GGGACGGCAT
201 CATGTTCCGC GCCGGACGAA TTTGGGGGCA GArArTCCTA rGGTTCArAC
251 CTATTGCGsG CATCATGACG CCGrAACGTT ATGAGCAGGT TCAGGAAAAA
301 TTCGACAAAT ACGGTAACGT GGTCTTATTT GTCGCCCGTT TCCTGCCCGG
351 TTTGAGAACG GCCGTATTG TTACAGCCGG TATCAGCCCG AAGGTTTCAT
401 ACTTGCGTTT TATCATTATG GATGGACTGG CCGCA...

```

Number 87 ORF

```

1 ATGAAAAAAT TATTGGCGGC CGTGATGATG GCAGGTTTGG CAGGCGCGGT
51 TTCCGCCGCC GGAGTCCACG TTGAGGACGG CTGGGCGCGC ACCACCGTCG
101 AAGGTATGAA AATAGGCGGC GCGTTTCATGA AAATCCACAA CGACGAAGCC
151 AAACAAGACT TTTTGCTCGG CGGAAGCAGC CCCGTTGCCG ACCGCGTCGA
201 AGTGATACC CACATCAACG ACAACGGCGT GATGCGGATG CGCGAAGTCG
251 AAGGCGGCGT GCCTTTGGAA GCGAAATCCG TTACCGAACT CAAACCCGGC
301 AGCTATCATG TGATGTTTAT GGGTTTGAAA AAACAATTAA AAGAGGGCGA
351 TAAAATTCCC GTTACCCTGA AATTTAAAAA CGCCAAAGCG CAAACCGTCC

```

-23-

401 AACTGGAAGT CAAAATCGCG CCGATGCCGG CAATGAACCA C...

Number 88 ORF

```

1  ATGACGGTAA CTGCGGCCGA AGGCGGCAAA GCTGCCAAGG CGTTAAAAAA
51  ATATCTGATT ACGGGCATT TGGTCTGGCT GCCGATTGCG GTAACGGTTT
101 GGGTGGTTTC CTATATCGTT TCCGCGTCCG ATCAGCTCGT CAACCTGCTG
151 CCGAAGCAAT GCGCGCCGCA ATATGTTTTG GGGTTTAATA TCCCGGGGCT
201 GGGCGTTATC GTTGCCATTG CCGTATTGTT TGTAACCGGA TTGTTTGCCG
251 CCAACGTATT GGGTCGCGAG ATCCTCGCCG CGTGGGACAG CCTGTTGGGG
301 CGGATTCCGG TTGTGAAAtC CATCTATTCT AGTGTGAAAA AAGTATCCGA
351 ATAcgTGCTG TCCGACAGCA GCCGTTCTGT TAAACGCGG GTACTCGTGC
401 CGTTTCCCA GCCCGGTATT TGGACGATyG CTTTCGTGTC AGGGCAGGTG
451 TCGAATGCCG TTAAGGCCGC ATTGCCGAAs GACGGCGATT ATCTTTCCGT
501 GTATGTTCCG ACCACGCCGA ATCCGACCGG CGGTACTAT ATTTATGGTAA
551 AGAAAAGCGA TGTGCGCGAA CTCGATATGA GCGTGGACGA AsCATTGAAA
601 TATGTGATTT CGTGGGTAT GGTCACTCCT GACGACCTGC CCGTCAAAAC
651 ATTGGCAsGA CCTATGCCGT CTGAAAAGGC GGATTTGCCC GAACAACAAT
701 AA

```

Number 89 ORF

```

1  ATgAAAACGG TAGTCTGGAT TGTCGTCCTG TTTGCCGCGG CCGTCCGACT
51  GCGCTGGCT TCGGGCATT ACACCGGCGA CGTGTATATC GTACTCGGAC
101 AGACCATGCT CAGAATCAAC CTGCACGCCT TTGTGTTAGG TTCGCTGATT
151 GCCGTCTGGG TGTGGTATTT CTTGTTTAAA TTCATTATCG GgGgTACTCA
201 ATATCCCCGA AAAGATGCAG CGTTTCGGTT CGGCnCGTAA AGGCCkCAAG
251 ssCGsGCTTG CCTTGAACAA GGCGGGTTTG GCGTATTTTG AAGGGCGTTT
301 TGAAAAGGCG GAACTAGAAG CCTCACGCGT GTTGGTCAAC AAAGtAGGCC
351 GaGAGACAAC CGGACTTTGG CATTGATGCT GrGCGCGCAC GCCGCCGAC
401 AGATGGAAAA CATCGAsTG CGCGACCGTT ATCTTGCGGA AATCGCCAAA
451 CTGCCGAAA AACAGCAGCT TTCCCGTTAT CTTTTGTTGG CGGAATCGGC
501 GTTGAACCGG CGCGATTACG AAGCGGCGGA AGCCAATCTT CATGCGGCGG
551 CGAAGATGAA TGCCAACCTT ACGCGCCTCG TGCGTCTGCA .ATTCTGTAC
601 GCTTTCGACA GGGGCGACGC GTTGcAGGTT CTGGCAAAAA CCGAAAACT
651 TTCCAAGGCG GCGCGTTGG GCAAATCGGA AATGGAACGG TATCAAAATT
701 GGGCATATCC GTGCCAGCT GCGGATGCT GCCGATGCCG CCGCTTTGAA
751 AACCTGCCTG AAGCGGATTC CCGACAGCCT CAAAAACGGG GAATTGAGCG
801 TATCGGTTGC GGAAAAGTAC GAACGTTTGG GACTGTATGC CGATGCGGTC
851 AAATGGGTCA AACAGCATT TCCGCAsAAC CGCCGCCCG AGCTTTTGA
901 AGCCTTTGTC GAAAGCGTGC GCTTTTGGG CGAGCGCGAA CAGCAGAAAG
951 CCATCGATTT TGCCGATGCT TGGCTGAAAG AACAGCCGA TAACGCGCTT
1001 CTGCTGATGT ATCTCGGTCT GCTCGCCTTC GGCCGCAAC TTTGGGGCAA
1051 GGCAAAAGGC TACCTTGAAG CGAGCATTGC ATTAAGCCG AGTATTCCG
1101 CCGGTTTGGT TCTAACAAAG GTTTTCGACG AAATCGGAGA ACCGCAGAAG
1151 GCGGAGGCGC AC...

```

Number 90 ORF

```

1  ATGATGTTTT CTGGTTCAA GCTGTTTAC TTTTTTTTG TCATTTCTGTG
51  GTTTGCAGGG CTGTTTTACC TGCCGAGGAT TTTCTCAAT ATGGCGATGA
101 TTGATGTGCC GCGCGGCAAT CCCGAGTATG TGCGTCTGTC GGGCATGGCG
151 GTGCGGCTGT ACCGTTTTAT GTCGCGCTTG GGCTTCGGCG CGGTCTGTGT
201 CCGCGCGGCG ATACCGTTG CCGCGGCTG GTGGGCGAGC GGCTGGGTAC
251 ACGTCAAACT GTGTTTGGGC TTGATGCTCT TGGCTTACCA GTTGATTTGC
301 GCGGTGCTGC TGCGCGTTT TCAGGATTAC AGCAATGCTT TTTACACCG
351 CTGGTACCGC GTGTTCAACG AAATCCCCGT GCTGCTGATG GTTGCCGCGC
401 TGTATsTGGT CGTGTTCAAA CCGTTTTGA

```

Number 91 ORF

```

1  ATGGCAAAAA TGATGAAATG GCGGCTGTT GCGGCGGTCTG CGGCGGCAGC
51  GGTTCGGGGC GGATGGTCTT AACTGAAGCC CGAGCCGCAC GTGCTTGATA
101 TTACGGAAAC GGTACGGCGC GGC // .....
//.. ATTCGTTTA CGATTTTGTC CGAACCGGAT ACGCCGATTA AGGCGAAGCT
51  CGACAGCGTC GACCCCGGGC TGACCACGAT GTCGTCGGGC GGTTACAACA
101 GCAGTACGGA TACGGCTTCC AATGCGGTCT ACTATTATGC CCGTTCGTTT
151 GTGCCGAATC CGGACGGCAA ACTCGCCACG GGGATGACGA CGCAGAATAC
201 GGTTGAAATC GACGGCGTGA AAAATGTGCT GATTATTCCG TCGCTGACCG
251 TGAAAAATCG CGGCGGCAAG GCGTTTGTGC GCGTGTGGG TCGCGACGGC
301 AAGGCGGCGG AACGCGAAAT CCGGACCGGT ATGAGAGACA GTATGAATAC
351 CGAAGTAAAA AGCGGGTTGA AAGAGGGGGA CAAAGTGGTC ATCTCCGAAA
401 TAACCGCCGC CGAGCAACAG GAAAGCGGCG AACGCGCCCT AGGCGGCCCG
451 CCGCGCCGAT AA

```

Number 92 ORF

```

1  ..ATTCCCGCCA CGATGACATT TGAACGCAGC GGCAATGCTT AAAAAATCGT
51  TTCGACGATT AAAGTGCCGC TATACAATAT CCGTTTCGAG TCCGGCGGTA
101 CCGTTGTCCG CAATACCCTG CACCCTACCT ACTATAGAGA CATACGCAGG
151 GGCAAACGTG ATGCGGAAGc CAAATTCGCC GACgGcAGCG TAACCTACGG
201 CAAAGCGGGC GAGAGCAAAA CCGAGCAAAG CCCCAAGGCT ATGGATTTGT
251 TCACGCTTGC CTGGCAGTTG GCGGCAATG ACGCGAACT CCCCCGGGG
301 CTGAAAATCA CCAACGGCAA AAAACTTTAT TCCGTCGGCG GTTTGAATAA
351 GCGGGGTACA GGAAAATACA GCATAGGCGG CGTGGAACC GAAGTCGTCA
401 AATATCGGGT GCGGCGCGGC GACGATGCGG TAATGTATTT cTTCGCACCG
451 TCCCTGAACA ATATTCCGGC ACAAATCGGC TATACCGACG ACGGCAAAAC
501 CTATACGCTG AAATCAAAT CCGTGCAGAT CAACGGCCAG GCAGCCAAAC
551 CGTAA

```

Number 93 ORF

```

1  ATGTATCGGA GGAAAGGGCG GGGCATCAAG CCGTGGATGG GTGCCGGTGC
51  .GCGTTTGCC GCCTTGGTCT GGCTGGTTTT CCGCTCGGC GATACTTTGA
101 CTCGTTTGC GGTTCGGCG GTGCTGGCGT ATGTATTGGA CCCTTTGGTC
151 GAATGGTTGC AGAAAAAGGG TTTGAACCGT GCATCCGCTT CGATGTCTGT
201 GATGGTGTTC TCCTTGATT TGTGTTGGC ATTATTGTT ATTATCGTCC
251 CTATGCTSGT CCGGCGAGTT AACAATTGG CATCGCGCCT GCCCAATTA
301 ATCGGTTTTA TGCAGAACAC GCTGCTGCCG TGTTGAAAA ATACAATCGG
351 CGGATATGTG GAAATCGATC AGGCATCTAT TATTGCGTGG CTTCAGGCGC
401 ATACGGGAGA GTTGAGCAAC GCGCTTAAGG CGTGGTTTCC CGTTTGTATG
451 AGGCAGGGCG GCAATATT..

```

Number 94 ORF

```

1  ..ACTGCTTTTT CCGCGGCGCT GCGCTTGAGT CCATCATGAC TCGTCATATT
51  TTTGTCTTTT GGGAAACCGT ATCAACAAAC AGCCGCCATC TTAACATTTT
101 TTTGCACGTC CTGCCCAGCG CGTTCAAATG CGTACCAGCA ATACCGCCGC
151 CTGCGCTCT ATGCCTTCCA TCCGCCGAG ATAGCCGAGT TTTTCGTTGG
201 TTTTGCCTTT GATGTTGACG CACGAAATGT CTATGCCCAA ATCGGCGGCG
251 ATGTTGGCAC GCATTTCGGG AATGTGCGGC GCGAGTGTGG GTTTCTGTGC
301 AATCACGGTC GTATCGACAT TGACCGCCTG CCAACCTGCG GCCTGAACGC
351 TTTGATACGC CGCACGCAA AGGACGCGGC TGTCCGCATC TTTGAACCTC
401 GCGGCGGTGT CCGGGAAATG GCTGCCGATA TCGCCCAAAC CTGCCGACC
451 GAGCAGCGCG TCGGTAACGG CGTGCAGCAG CGCATCGGCA TCGGAGTGTC
501 CGAGCAGCCC TTTTCAAAT GGGATTTCAT CTCCGCCAAG TATCAG..

```

Number 95 ORF

```

1  ..GCCGGCGCGA GTGCGAACAA CATTTCCGCG CGTTTTGCGG AAACACCCGT

```

-25-

```

51      CGCTGTCAGC GTTACCCTGA TCGGCACGGT ACTTGCCGTC ATGCTGCCCG
101     TTACCGAATA TGAAAACTTC CTGCTGCTTA TCGGCTCGGT ATTTGCCCGC
151     ATGGGGCGGA TTTTGATTGC CGACTTTTTC GTCTTGAAAC GGCCTGA

```

Number 96 ORF

```

1      ATGACCCGTA TCGCCATCCT CGGCGGCGGC CTCTCGGGAA GGCTGACCGC
51     GTTGCACTT GCAGAACAAAG GTTATCAGAT TGCACTTTTC GATAAAAGCT
101    GCCGCCGGGG CGAACACGCC GCCGCCTATG TAGCCGCCGC CATGCTCGCG
151    CCTGCAGCGG A.ACGGTGCA AGCCACGCCG GAAGTGGTCA GGCTGGGCAG
201    GCAGAGCATC CCGCTTTGGC GCGGCATCCG ATGCCGTCTG AACACGCACA
251    CGATGATGCA GGAAACGGC AGCCTGATTG TATGGCACGG GCAGGACAAG
301    CCATTATCCA GCGAGTTCTG CCGCCATCTC AAACGCGCGG CGCT.ACGBA
351    TGACGAAATC GTCGGTTGGC GCGCCGACGA CATCGCCGAA CGCGAACCGC
401    AACTCGGCGG ACGTTTTTAA GACGGCATCT ACCTGCCGAC CGAAGC.CAG
451    CTCGACGGGC GGCAATTATA GTCTGCACTT GCCGACGCTT TGGACGAACT
501    GAACGTCCCC TGCCATTGGG AACACGAATG CGTCCCCGAA GCCTGCAAG..

```

Number 97 ORF

```

1      ATGACTGATA ATCGGGGGTT TACGCTGGTT GAATTAATAT CAGTGGTCTT
51     GATATTGTCT GTACTTGCTT TAATTGTTTA TCCGAGCTAT CGCAATTATG
101    TTGAGAAAGC AAAGATAAAT CCACTGCGGG CAGCCTTGTT AGAAATGCA
151    CATTTTATGG AAAAGTTTTA TCTGCAGAAT GGGAGGTTTA AACAAACATC
201    TACCAAGTGG CCAAGTTTGC CGATTAAAGA GGCAGAAGGC TTTTGTATCC
251    GTTTGAATGG AATCGTCGCG CGGG..GCTT TAGACAGTAA ATTCATGTTG
301    AAGGCGGTAG CCATAGATAA AGATAAAAAAT CCTTTTATTA TTAAGATGAA
351    TGAAAATCTA GTAACCTTTA aTTTGCAAGA AGTCCGCCAG TTCGTGTAGT
401    GACGGGCTGG ATTATTTTAA AGGAAATGAT AAGGACTGCA AGTTACTTAA
451    GTAG

```

Number 98 ORF

```

1      ..GTGTCGCTGG CTTCGGTGAT TGCCTCTCAA ATCTTCCTTT ACGAAGATTT
51     CAACCAAATG CGGAAAACCG GTGGAGCTAT CTGCGGTTTT CTGTCCAAT
101    ATTTATCTGG GGTTCAGCA GGGGTATTTT GATTTGAGTG CCGACGAGAA
151    CCCCCTACTG CATATCTGGT CTTTGGCAGT AGAGGAACAG TATTACCTCC
201    TGTATCCCTT TTTGCTGATA TTTTGTGCA AAAAAACCAA ATCGCTACGG
251    GTGCTGCGTA ACATCAGCAT CATCCTGTTT TTGATTTTGA CTGCCTCATC
301    GTTTTTGCCA AGCGGGTTTT ATACCGACAT CCTCAACCAA CCAATACTT
351    ATTACCTTTC GACACTGAGG TTTCCCGAGC TGTTGGCAGG TTCGCTGCTG
401    GCGGTTTACG GGCAAACGCA AAACGGCAGA CGGCAAACAG CAAATGGAAA
451    ACGGCAGTTG CTTTCATCAC TCTGCTTCGG CGCATTGCTT GCCTGCCTGT
501    TCGTGATTGA CAAACACAAT CCGTTTATCC CGGGAATGAC CCTGCTCCTT
551    CCCTGCCTGC TGACGGCACT GCTTATCCGG AGTATGCAAT ACGGGCACT
601    TCCGACCCGC ATCCTGTCGG CAAGCCCCAT CGTATTTGTC GGCAAAATCT
651    CTTATTCCTT ATACCTGTAC CATTGGATTT TTATTGCTTT CGCTCCGCTC
701    ATTAGAGCGG GGAAACAGCT CGGACTGCCT GCCG..

```

Number 99 ORF

```

1      ..ATTATTTACG AATACCGCTG GATGTTTCTT TACGGCGCAC TGACGACCTT
51     GGGGCTGACG GTCGTGGCAA C.GCGGGCGG TTCGGTATTG GGTCTGTTGT
101    TGGCGTTGGC GCGCCTGATT CACTTGGAAG AAGCCGGTGC GCCGATGCGC
151    GTGCTGGCGT GGGCGTTGCG TAAAGTTTCG CTGCTGTATG TTACGCTGTT
201    CCGGGGTACG CCGCTGTTTG TGCAGATTGT GATTTGGGCG TATGTGTGGT
251    TTCCGTTTTT CGTC..

```

Number 100 ORF

```

1  ..CTGAAAGAAT GCCGTCTGAA AGACCCTGTT TTTATTCCAA ATATCGTTTA
51  TAAGAACATC GCCATTACTT TCCTGCTCTT GCACGCCGCC GCCGAACCTT
101 GGCTGCCCGC GCAAACCGCC GGTTTTACCG CGCTCGCCGT CGGCTTCATC
151 CTGCTCGCCA AGCTGCGTGA gCTTCACCAT CACGAACTCT TACGTAAACA
201 cTACGTCCGC ACTTATTACy TGCTCCAAC TTTTGCCGCC GCAGgcTAgT
251 TTGTGGACAG GCGCGCGwA ATTACAAAAC CTGCCCGCyT CCGCGCCCTT
301 GCACCTGATT ACCCTCGGCG GCATGATGGG CGGCGTGATG ATGGTGTGGc
351 TGACCGCCGG ACTGTGGCAC AGCGGCTTTA CCAAACCTCGA CTACCCCAAA
401 CTCTGCCGCA TTGCCGTCCC CATCCTTTTC GCCGCCGCCG TCTCGCGCGC
451 TTTCTTGrTG AACGTGAACC CGrTATTTTT CATTACCGTT CCTGCGATTC
501 TGACCGCCGC CGTATTCGTA CTGTATCTTT TCrCGTTTAT ACCGATATTT
551 CGGGCGAATG CGTTTACAGA CGATCCGGAr TAR

```

Number 101 ORF

```

1  ATGGAATTC GGGCAATAAA ATATACGGCA ATGGCTGCGT TGCTTGCAAT
51  TACGGTTGCA GGCTGCCCGC TGGCGGGGTG GTATGAGTGT TCGTCCCTCA
101 CCGGCTGGTG TAAGCCGAGA AAACCGGCTG CCATCGATTT TTGGGATATT
151 GCGCGCGAGA GTCCGCCGTC TTAGGGGAC TACGAGATAC CGCTTTCAGA
201 CGGCAATAGT TCCGTCAGGG CAAACGAATA TGAATCCGCA CAACAATCTT
251 ACTTTTACAG GAAATAGGG AAGTTTGAAG C.TGCGGGCT GGATTGGCGT
301 ACGCGTCACG GCAAACCTTT GATTGAGACG TTCAAACAGG GAGGATTGA
351 CTGCTTGAA AAG..

```

Number 102 ORF

```

1  ATGAAACACA TCCATATTAT CGGTATCGGC GGCACGTTTA TGGGCGGGCT
51  TGCCGCCATT GCCAAAGAAG CGGGGTTTGA AGTCAGCGGT TGCGACCGCA
101 AGATGTATCC GCCGATGAGC ACCAGCTCG AAGCCTTGGG TATAGACGTG
151 TATGAAGGCT TCGATGCCGC TCAGTTGGAC GAATTTAAAG CCGACGTTTA
201 CGTTATCGGC AATGTCGCCA AGCGCGGGAT GGATGTGGTT GAAGCGATTT
251 TGAACCTCGG CCTGCCTAT AtTtCGGCC CGCAATGGCT GTCGGAAAAC
301 GTGCTGCACC ATCATTGGGT ACTCGGTGTG GCGGGGACgC ACGGCAAAAC
351 GACCACCGCC TCCATGCTCG CATGGGTCTT GGAATATgCC GGCTTCGCGC
401 CGGGCTTCTT TATtGGCGGC GTACC.GGAA AATtCGGCC TTTCCGCCCG
451 CCTGCCGCAA ACGCCGCGCC AAGACCGGAA CAGCCAATCG CCGTTTTTcG
501 TCATCGAAGC CGACGAATAC GACACCGCCT TtTCGACAA ACGTTCTAAA
551 TtCGTGCAAT ACCGTCCGCG TACCGCGTG TTGAACAATC TGGAATTCGA
601 CCACGCCGAC ATCTTTGCCG ACTTGGGCGC GATACAGAc CAGTTCCACT
651 ACCTCGTGCG TACCGTGCCG TCTGAAGGCT TAATCGTCTG CAACGGACGG
701 CAGCAAAGCC TGCAAGATAC TTTGGACAAA GGCTGCTGGA CGCCGGTGA
751 AAAATTCGGC ACGGAACACG GCTGGCA..

```

Number 103 ORF

```

1  ..CCGGGCTATT ACGGCTCGGA TGACGAATTT AAGCGGGCAT TCGGAGAAAA
51  CTCGCCGACA TmCAAGAAAC ATTGCAACCG GAGCTGCGGG ATTTATGAAC
101 CCGTATTGAA AAAATACGGC AAAAAGCGCG CCAACAACCA TTCGGTCAGC
151 ATTAGTGCGG ACTTCGGCGA TTATTTTCATG CCGTTTCGCC GCTATTCGGG
201 CACACACCGT ATGCCCAACA TCCAAGAAAT GTATTTTTC CAAATCGGGC
251 ACTCCGGCGT TCACACCGCC TTAACCAG AGCGCGCAA CACTTGGCAA
301 TTTGGCTTCr ATACCTATAA AAAAGGATTG TTAACAAG ATGATACATT
351 AGGATTAAAA CTGGTCGGCT ACCCGAGCCG CATCGACAAC TACATCCACA
401 ACGTTTACGG GAAATGGTGG GATTGAACG GGGATATTCC GAGCTGGGTC
451 AGCAGCACCG GGCTTGCCCTA CACCATCCAA CATCGCrATT TCaWAGACAA
501 AGTGCAATCAA nnnnnnnnnn nnnnnnnnnn nnnnTACGAT TATGGGCGTT
551 TTTTCACCAA CCTTCTTAC GCCTATCAAA AAAGCACGCA ACCGACCAAC
601 TTCAGCGATG CGAGCGAATC GCCCAACAAT GCGTCCAAAG AAGACCAACT
651 CAAACAAGGT TATGGGTTGA GCAGGGTTTC CGCCCTGCCG CGAGATTACG
701 GACGTTTGA AGTCGGTACG CGCTGGTTGG GCAACAAACT GACTTTGGGC

```

-27-

```

751  GGCGCGATGC GCTATTTCGG CAAGAGCATC CGCGCGACGG CTGAAGAACG
801  CTATATCGAC GGCACCAACG GGGGAAATAC CAGCAATTCG CCGCAACTGG
851  GCAAGCGTTC CATCAAACAA ACCGAAACTC TTGCCCAGCA GCCTTTGATT
901  TTWGATTTTa ACGCCGCTTA CGAGCCGAAG AAAAACCTTA TTTTCCGCGC
951  CGAAGTCAAA AATCTGTTTC ACAGGCGTTA TATCGATCCG CTCGATGCGG
1001 GCAATGATGC GGCAAC.GAG CGTTATTACA GCTCGTTCTGA CCCGAAAGAC
1051 AAGGACrrAG ACGTAACGTG TAATGCTGAT AAAACGTTGT GCaACGGCAA
1101 ATACGGCGGC ACAAGCAAAA GCGTATTGAC CAATTTTGCA CGCGGACGCA
1151 CCTTTTgAT GACGATGAGC TACAAGTTTT AA

```

Number 104 ORF

```

1  ATGAACCTGA TTTACAGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT
51  TTACGCGCTC CTTGCCTTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT
101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GGAATGCTG
151 GGCTACACCG CCCTCAAAAT GCGCGCCGCG GCCTACGAAC TGATTCCCTT
201 CGCGTCCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCGCGCGGCA
251 GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG
301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT
351 CGGCGAATGG GTTGGCGCCA CACTGAGCCA AAAAGCGGAA AACATCAAAG
401 CCGCGCCCAT CAACGGCAA ATCAGCACCG GCAATACCGG CCTTGGCTG
451 AAAGAAAAAA ACAGCGTGAT CAATGTGCGC GAAATGTTGC CCGACCAT..

```

Number 105 ORF

```

1  ATGAAACTTC TGACCACCGC AATCCTGTCT TCCGCAATCG CGCTCAGCAG
51  TATGGCTGCC GCCGCTGGCA CGGACAACCC CACTGTTGCA AAAAAACCG
101 TCAGCTACGT CTGCCAGCAA GGTAAAAAAG TCAAAGTAAC CTACGGCTTC
151 AACAAACAGG GTCTGACCAC ATACGCTTCC GCCGTCATCA ACGGCAAACG
201 CGTGCAAATG CCTGTCAATT TGGACAAATC CGACAATGTG GAAACATTCT
251 ACGGCAAAGA AGGCGGTTAT GTTTTGGGTA CCGGCGTGAT GGATGGCAA
301 TCCTACCGCA AACAGCCCAT TATGATTACC GCACCTGACA ACCAAATCGT
351 CTTCAAAGAC TGTCCCCAC GTTAA

```

Number 106 ORF

```

1  ..ACACTGTTGT TTGCAACGGT TCAGGCAAGT GCTAACCAAT GAAGAGCAAG
51  AAGAAGATTT ATATTAGAC CCCGTACAAC GCACTGTTGC CGTGTGATA
101 GTCAATTCCG ATAAAGAAGG CACGGGAGAA AAAGAAAAAG TAGAAGAAAA
151 TTCAGATTGG GCAGTATATT TCAACGAGAA AGGAGTACTA ACAGCCAGAG
201 AAATCACCyT CAAAGCCGGC GACAACCTGA AAATCAAACA AAACGGCACA
251 AACTTCACCT ACTCGCTGAA AAAAGACCTC AcAGATCTGA CCAGTGTG
301 AACTGAAAAA TTATCGTTTA GCGCAAACGG CAATAAAGTC AACATcACAA
351 GCGACACCAA AGGCTTGAAT TTGCGAAAG AAACGGCTGG sACGAACgC
401 GACACCACGG TTCATCTGAA CGGTATTGGT TCGACTTTGA CCGATACGCT
451 GCTGAATACC GGAGCGACCA CAAACGTAAC CAACGACAAC GTTACCGATG
501 ACGAGAAAAA ACGTGCGGCA AGCGTTAAAG ACGTATTAAA CGCTGGCTGG
551 AACATTAAAG GCGTTAAACC CGGTACAACA GCTTCCGATA ACGTTGATTT
601 CGTCCGCACT TACGACACAG TCGAGTTCTT GAGCGCAGAT ACGAAAACAA
651 CCACTGTAA TGTGGAAAGC AAAGACAACG GCAAGAAAAC CGAAGTTAA
701 ATCGGTGCGA AGACTTCTGT TATTAAAGAA AAAGAC...

```

Number 107 ORF

```

1  ..GGCACCGAAT TCAAAACCAC CCTTTCGGGA GCCGACATAC AGGCAGGGGT
51  GGGTGAAAAA GCCCGAGCCG ATGCGAAAAT TATCCTAAAA GGCATCGTTA
101 ACCGCATCCA AACCAGAGAA AAGCTGGAAT CCAACTCGAC CGTATGGCAA
151 AAGCAGGCCG GAAGCGGCAG CACGGTTGAA ACGCTGAAGC TACCGAGCTT
201 TGAAGGGCCG GCACTGCCTA AGCTGACCGC TCCCGGCGGC TATATCGCCG
251 ACATCCCCAA AGGCAACCTC AAAACCGAAA TCGAAAAGCT GGCCAAACAG
301 CCCGAATATG CCTATCTGAA ACAGCTTCAG ACGGTCAAGG ACGTGAACCTG

```

-28-

```

351  GAACCAAGTA CAGCTCGCTT ACGACAAATG GGAATAATAA CAGGAAGGCC
401  TAACCGGAGC CGGAGCCGCA ATTANCGCAC TGGCCGTAC CGTGGTCACC
451  TCAGGCGCAG GAACCGGAGC CGTATTGGGA TTAANACGNG TGGCCCGCGC
501  CGCAACCGAT GCAGCATTT...

```

Number 108 ORF

```

1  ..CGGATCGTTG TAGGTTTGGC GATTTCTTGC GCCGTAGTCA CCGTAGTCCC
51  AAGTATAACC CAAGGCTTTG TCTTCGCCTT TCATTCCGAT AAGGGATATG
101 ACGCTTTGGT CGGTATAGCC GTCTTGGGAA CCTTGTCCA CCCAACGCAT
151 ATCTGCCTGC GGATTCTCAT TGCCGCTTCT TGGCTGCTGA TTTTCTGCC
201 TTCGCGTTTT TCAACTTCGC GCTTGAGGGC TTCGGCATAT TTGTCGGCCA
251 ACGCCATTTC TTTCGGATGC AGCTGCCTAT TGTCCAATC TACATTGCGA
301 CCCACCACAG CACCACCACT ACCACCAGT GCATAG

```

Number 109 ORF

```

1  ..AAGTTTACT TTACCTGGTT TATTCCGGCG GTAATCAAAT ACCGCCGGTT
51  GTTTTTTGAA GTATTGGTGG TGTGCGTGGT GTGACAGTG TTTGCGCTGA
101 TTACGCCTCT GTTTTCCAA GTGGTGATGG ACAAGGTGCT GGTACATCGG
151 GGATTCTCTA CTTTGGATGT GGTGTCGGTG GCTTTGTTGG TGGTGTCGCT
201 GTTTGAGATT GTGTGGGCG GTTTGCGGAC GTATCTGTT GCACATACGA
251 CTTACGTAT TGATGTGGAA TTGGGCGCGC GTTTGTTCCG GCATCTGCTT
301 TCCCTGCCTT TATCCTATTT CGAGCACAGA CGAGTGGGTG ATACGGTGCG
351 TCGGGTGCGG GAATTGGAGC AGATTGCAA TTTCTTGACC GGTCAGGCGC
401 TGACTTCGGT GTTGATTG GCGTTTTCGT TTATCTTTCT GGCGGTGATG
451 TGGTATTACA GCTCCACTCT GACTTGGGTG GTATTGGCTT CGTTG.....
//
1451 .....
1501 ..... ..ATTGCGC
1551 CAACCGGACG GTGCTGATTA TCGCCACCG TCTGTCCACT GTTAAACGG
1601 CACACCGGAT CATTGCCATG GATAAAGGCA GGATTGTGGA AGCGGAACA
1651 CAGCAGGAAT TGCTGGCGAA CG..AACGGA TATTACCGCT ATCTGTATGA
1701 TTACAGAAC GGTAG

```

Number 110 ORF

```

1  ATGAAATACT TGATCCGCAC CGCCTTACTC GCAGTCGCAG CCGCCGGCAT
51  CTACGCCTGC CAACCGCAAT CCGAAGCCGC AGTGCAAGTC AAGGCTGAAA
101 ACAGCCTGAC CGCTATGCGC TTAGCCGTCG CCGACAAACA GGCAGAGATT
151 GACGGGTGA ACGCCAAAK sGACGCCGAA ATCAGA...

```

Number 111 ORF

```

1  ATGTTATCG GAATATTACT CGCATCAAGC AAGCATGCTC TTGTATTAC
51  TCTATTGTTA AATCCCGTCT TCCATGCATC CAGTTGCGTA TCGCGTTsGG
101 CAATACGGAA TAAAAtCTGC TGTTCGCTT TGGCTAAAT TGCCAAATTG
151 TTTATTGTTT CTTTAGGAGC AGCTTGCTTA GCCGCCTCG CTTTCGACAA
201 CGCCCCACA GCGCTTCCC AAGCgTTGCC TACCGTTACC GCACCCGTGG
251 CGATTCCCGC GCCCGCTTCG GCAGCCTGA

```

Number 112 ORF

```

1  ATGTTACAGTA TTTTAAATGT GTTCTTCAT TGTATTCTGG CTTGTGTAGT
51  CTCTGGTGAG ACGCCTACTA TATTTGGTAT CCTTGCTCTT TTTTACTTAT
101 TGTATCTTTC TTATCTTGCT GTTTTAAAGA TTTTCTTTC TTTTCTTAA
151 GACAGAGTTT CACTCCGGTC TCCCAGGCTG GAGTGCAAAT GGCATGACCC
201 TTTGGCTCAC TGGCTCACGG CCACTTCTGC TATTCTGCCG CCTCAGCCTC
251 CAGGG...

```

Number 113 ORF

```

1  ..GTGCGGACGT GGTGGGTTTT TTGGTTGCAG CGTTTGAAAT ACCCGTTGTT
51  GCTTTTGATT GCGGATATGT TGCTGTACCG GTTGTGGGC GGCGCGGAAA
101 TCGAATGCGG CCGTTGCCCT GTGCCGCCGA TGACGGATTG GCAGCATTTT
151 TTGCCGGCGA TGGGAACGGT GTCGGCTTGG GTGGCGGTGA TTTGGGCATA
201 CCTGATGATT GAAAGTGAAA AAAACGGAAG ATATTGA

```

Number 114 ORF

```

1  ATGTTTCAAA ATTTTGATT GGGCGTGTTT CTGCTTGCCG TCCTCCCCGT
51  GCTGCCCTCC ATTACCGTCT CGCAGGTGGC GCGCGGCTAT ACGGCGCGCT
101 ACTGGGGAGA CAACACTGCC GAACAATACG GCAGGCTGAC ACTGAACCCC
151 CTGCCCCATA TCGATTTGGT CGGCACAATC ATCgTACCGC TGCTTACTTT
201 GATGTTACAG CCCTTCCTGT TCGGCTGGGC GCGTCCGATT CCTATCGATT
251 CGCGCAACTT CCGCAACCCG cGCCTGCCT GCGGTTGCGT TGCCGCGTCC
301 GGCCCGCTGT CGAATCTAGC GATGGCTGTW CTGTGGGGCG TGGTTTTGGT
351 GCTGACTCCG TATGTCGGCG GGGCGTATCA GATGCCGTTG GCTCAAATGG
401 CAAACTACGG TATTCTGATC AATGCGATTG TGTTCGCGCT CAACATCATC
451 CCCATCCTGC CTGGGACGG CGGCATTTTC ATCGACACCT TCCTGTCGGC
501 GAAATATTTC CAAGCGTTCC GCAAAATCGA ACCTTATGGG ACGTGGATTA
551 TCCTACTGCT GATGCTGACC sGGGTTTTGG GTGCGTTTAT wGCACCGATT
601 sTGCGGmTGc GTGATTGCrT TTGTGCAGAT GTwCGTCTGA CTGGCTTTCA
651 GACGGCATAA

```

Number 115 ORF

```

1  ATGAACCTGA TTTCACGTTA CATCATCCGT CAAATGGCGG TTATGGCGGT
51  TTACGCGCTC CTTGCCCTCC TCGCTTTGTA CAGCTTTTTT GAAATCCTGT
101 ACGAAACCGG CAACCTCGGC AAAGGCAGTT ACGGCATATG GAAATGCTG
151 GGCTACACCG CCCTCAAAAT GCGCGCCCGC GCCTACGAAC TGATTCCCTT
201 CGCGTCCCTT ATCGGCGGAC TGGTCTCCCT CAGCCAGCTT GCCGCCGGCA
251 GCGAACTGAC CGTCATCAAA GCCAGCGGCA TGAGCACCAA AAAGCTGCTG
301 TTGATTCTGT CGCAGTTCGG TTTTATTTTT GCTATTGCCA CCGTCGCGCT
351 CGGCGAATGG GTTGCGCCCA CACTGAGCCA AAGAGCCGAA AACATCAAAG
401 CCGCCGCCAT CAACGGCAAA ATCAGCACCG GCAATACCGG CCTTTGGCTG
451 AAAGAAAAAA ACAGCGTGAT CAATGTCCGC GAATGTTGC CCGACCAT..

```

Number 116 ORF

```

1  ..GCAGTAGCCG AAAC TGCCAA CAGCCAGGGC AAAGGTAAAC AGGCAGGCAG
51  TTCGGTTTCT GTTTCACCTGA AAAC TTCAGG CGACCTTTGC GGCAAACTCA
101 AAACCACCCT TAAAACTTTG GTCTGCTCTT TGGTTTCCCT GAGTATGGTA
151 TTGCCTGCCC ATGCCCAAAT TACCACCGAC AAATCAGCAC CTAAAAACCA
201 GCAGGTCGTT ATCCTTAAAA CCAACACTGG TGCCCCCTTG GTGAATATCC
251 AAAC TCCGAA TGGACGCGGA TTGAGCCACA ACCGCTA.TA CGCATTTGAT
301 GTTGACAACA AAGGGGCAGT GTTAAACAAC GACCGTAACA ATAATCCGTT
351 TGTGGTCAAA GGCAGTGCGC AATTGATTTT GAACGAGGTA CGCGGTACGG
401 CTAGCAAACT CAACGGCATC GTTACCGTAG GCGGTCAAAA GGCCGACGTG
451 ATTATTGCCA ACCCAACGG CATTACCGTT AATGGCGGCG GCTTTAAAAA
501 TGTCGGTCGG GGCATCTTAA CTACCGGTGC GCCCCAAATC GGCAAAGACG
551 GTGCACTGAC AGGATTTGAT GTGGGTCAAG GCACATTGgA CCGTAGrAGC
601 AGCAGGTTGG AATGATAAAG GCGGAGCmrm yTACACCGGG GTACTTGCTC
651 GTGCAATTGC TTTGCAGGGG AAATTwmGG GTAAA.AACT GCGGTTTCT
701 ACCGGTCCTC AGAAAGTAGA TTACGCCAGC GCGGAAATCA GTGCAAGTAC
751 GGCAGCGGGT ACGAAACCGA CTATTGCCCT TGATACTGCC GCACTGGGCG
801 GTATGTACGC CGACAGCATC AACTGTATTG CCAATGAAAA AGGCGTAGGC
851 GTCTAA

```


Number 117 ORF

```

1  ..CGCTTCATTG ATGATGAAGC AGTCGGCAGC AACATCGGCG GCGGCAAAAT
51  GATTGTTGCA GCCGGGCAGG ATATCAATGT ACGCGGCAnA AGCCTTATTT
101 CTGATAAGGG CATTGTTTTA AAAGCAGGAC ACGACATCGA TATTTCTACT
151 GCCCATAATC GCTATACCGG CAATGAATAC CACGAGAGCA WAAAwTCAGG
201 CGTCATGGGT ACTGGCGGAT TGGGCTTTAC TATCGGTAAC CGGAAACTA
251 CCGATGACAC TGATCGTACC AATATTGTsC ATACAGGCAG CATTATAGGC
301 AGCCTGAaTG GAGACACCGT TACAGTTGCA GGAAACCGCT ACCGACAAAC
351 CCGCAGTACC GTCTCCAGCC CCGAGGGGCG CAATACCGTC ACAGCCAAAw
401 GCATAGATGT AGAGTTTCGA AACAACCGGT ATGCCACTGA CTACGcCCAT
451 ACCCAgCGAA CAAAAAGGCC TTACCGTCGC CCTCAATGTC CCGGTTGTCC
501 AAGCTGCACA AAACCTTCATA CAAGCAGCCC AAAATGTGGG CAAAAGTAAA
551 AATAAACGCG TTAATGCCAT GGCTGCAGCC AATGCTGCAT CATCGGCTTA
601 TCAAGCAACC CAACAATGC AACAATTTGC TCCAAGCAGC AGTGCGGGAC
651 AAGGTCAAAA CTACAATCAA AGCCCCAGTA TCAGTGTGTC CATTAC .TAC
701 GGCGAACAGA AAAGTCGTAA CGAGCAAAA AGACATTACA CCGAaGCGGC
751 AgCAAGTCAA ATTATCGGCA AAGGGCAAAC CACACTTGCG GCAACAGGAA
801 GTGGGGAGCA GTCGAATATC AATATTACAG GTTCCGATGT CATCGGCCAT
851 GCAGGTACTC C .CTCATTGC CGACAACCAT ATCAGACTCC AATCTGCCAA
901 ACAGGACGGC AGCGAGCAAA GCAAAAACAA AAGCAGTGGT TGGaATGCAG
951 GCGTACGTnn CAAAATAGGC AACGGCATCA GGTTTGGAAT TACCGCCGGA
1001 GGAAATATCG GTAAAGGTAA AGAGCAAGGG GGAAGTACTA CCCACCGCCA
1051 CACCCATGTC GGCAGACAA CCGGCAAAAC TACCATCCGA AGCGCGGGg
1101 GATACCAACC TCAAAGGTGT GCAGCTCATC GGCAAAGGCA TACAGGCAGA
1151 TACGCGCAAC CTGCATATAG AAAGTGTTCa AGATACTGAA ACCTATCAGA
1201 GCAAACAGCA AAACGGCAAT GTCCAAGTTt ACTGTCGGTT ACGGATTTCAG
1251 TGCAAGCGGC AGTTACCGCC AAAGCAAAGT CAAAGCAGAC CATGCCCTCCG
1301 TAACCGGGCA AAgCGGTATT TATGCCGGAG AAGACGGCTA TCAAATyAAA
1351 GTyAGAGACA ACACAGACCT yAAGGGCGGT ATCATCACGT CTAGCCAAAG
1401 CGCAGAAGAT AAGGGCAAAA ACCTTTTTTCa GACGGCCACC CTTACTGCCA
1451 GCGACATTCA AAACCACAGC CGCTACGAAG GCAGAAGCTT CGGCATAGGC
1501 GGCAGTTTCG ACCTGAACGG CGGCTGGGAC GGCACGGTTA GGCACAAACa
1551 AGGCAGGCCT ACCGACAGGA TAAGCCCGGC AGCCGGCTAC GGCAGCGACG
1601 GAGACAGCAA AAACAGCACC ACCCGCAGCG GCGTCAACAC CCACAACATA
1651 CACATCACCG ACGAAGCGGG ACAACTTGCC CGAACAGGCA GGACTGCAAA
1701 AGAAACCGAA GCGCGTATCT ACACCGGCAT CGACACCGAA ACTGCGGATC
1751 AACACTCAGG CCATCTGAAA AACAGCTTCG AC...

```

Number 118 ORF

```

1  ..ACGACCGGCA GCCTCGGCGG CATACTGGCC GGCGGGCGGCA CTTCCCTTGC
51  CGCACCGTAT TTGGACAAAG CGGCGGAAAA CCTCGGTCCG GCGGGCAAAAG
101 CCGCGGTCAA CGCACTGGGC GGTGCGGCCA TCGGCTATGC AACTGGTGGT
151 AGTGGTGGTG CTGTGGTGGG TGCGAATGTA GATTGGAACA ATAGGCAGCT
201 GCATCCGAAA GAAATGGCGT TGGCCGACAA ATATGCCGAA GCCCTCAAGC
251 GCGAAGTTGA AAAACGCGAA GGCAGAAAA TCAGCAGCCA AGAAGCGGCA
301 ATGAGAATCC CGAGGCAGAT ATGCGTTGGG TGGACAAAGG TTCCCAAGAC
351 GGCTATACCG ACCAAAGCGT CATATCCCTT ATCGGAATGA

```

Number 119 ORF

```

1  ..CAATGCCGTC TGAAAAGCTC ACAATTTTAC AGACGGCATT TGTTATGCAA
51  GTACATATAC AGATTCCCTA TATACTGCCC AGrkGCGTGC GTgGCTGAAG
101 ACACCCCTTA CGCTTGCTAT TTGrAACAGC TCCAAGTCAC CAAAGACGTC
151 AACTGGAACC AGGTACwACT GGCGTACGAC AAATGGGACT ATAAACAGGA
201 AGGCTTAACC GGAGCCGGAG CAGCGATTAT TCGGCTGGCT GTTACCSTGG
251 TTACTGCGGG CGCGGGAgCC GGAGCCGCAC TGGGcTTAAA CGGCGCGGcc
301 GCAGCGGCAA CCGATGCCGC ATTGCCTCG CTGGCCAGCC AGGcTTCCGT
351 ATCGCTCATC AaCAACAAAG GCAATATCGG TAaCACCCTG AAAGAGCTGG
401 GCAGAAGCAG CACGGTGAAA AATCTGATGG TTGCCGTGc tACCGCAgGC
451 GTaGcGaCA AAATCGGTGC TTCGGCACTG AACAATGTCA CCGATAAGCA
501 GTGGATCAAC AACCTGACCG TCAACCTGGC CAATGCGGGC AGTGCCGCAC

```

-31-

```

551   TGATTAATAC CGCTGTCAAC GGCGGCAGCc tgAAAGACAA TCTGGAAGCG
601   AATATCCTTG CGGCTTTGGT GAATACTGCG CATGGAGAAG CAGCCAGTAA
651   AATCAAACAG TTGGATCAGC ACTACATTAC CCACAAGATT GCCCaTGCCA
701   TAGCGGGCTG TGCGGcTGCG GCGGCgAATA AGGGCAAGTG TCAGGATGGT
751   GCGATAgGTG CGGCTGTGGG CGAGATAGTC GGGGAgGCTT TGACAAACGG
801   CAAAAATCCT GACACTTTGA CAGCTAAAgA ACGCGaACAG ATTTTGGCAT
851   ACAGCAAAct GGTtGCCGGT ACGGTAAAGC GTGTGGTcGG CGGCGATGTA
901   AATGCGGCGG CGAATGCGGC TGAGGTAGCG GTGAAAATA ATCAGCTTAG
951   CGACAAAtGA

```

Number 120 ORF

```

1   ATGGCAATCA TTACATTGTA TTATTCTGTC AATGGTATTT TAAATGTATG
51  TGCAAAAGCA AAAAATATTC AAGTAGTTGC CAATAATAAG AATATGGTTC
101 TTTTtGGGTT TTTGGsmrGC ATCATCGGCG GTTCAACCAA TGCCATGTCT
151 CCCATATTGT TAATATTTTT GCTTAGCGAA ACAGAAAATA AAAATcgTAT
201 CGTAAATCA AGCAATCTAT GCTATCTTTT GCGAAAATT GTTCAAATAT
251 ATATGCTAAG AGACCAGTAT TGgTTATTAA ATAAGAGTGA ATACGdTTA
301 ATATTTTTAC TGTCCGTATT GTCTGTtATT GGATTGTATG TTGGAATTCG
351 GTTAAGGACT AAGATTAGCC CAaATTTTTT TAAATGTTA ATTTTtATTG
401 tTTTATTGGT ATTGGCtCTG AAAATCGGGC AttCGGGTTT AAtCAAACCT
451 TAA

```

Number 121 ORF

```

1   ATGTTACGtT TGACTGctTT AGCCGTATGC ACCGCCCTCG CTTTGGGCGC
51  GTGTTcGCCG CAAAATtCCG ACTCTGCCCC ACAAGCCAAA GaACAGGCGG
101 TTTCCGCCGC ACAAAcCGAA GgCGCGTCCG TTACCGTCAA AACCgCGCGC
151 GGCGACGTTT AAATACCGCA AAACCCCGAA CGCATCGCCG TTTACGATT
201 GGGTATGCTC GACACCTTGA GCAAACTGGG CGTGAAAACC GGTtTGTCCG
251 TCGATAAAAA CCGCCTGCCG TATTTAGAGG AATATTTCAA AACGACAAAA
301 CCTGCCGGCA CTTTGTTCGA GCCGGATTAC GAAACGCTCA ACGCTTACAA
351 ACCGCAGCTC ATCATCATCG GCAGCCGCGC CgCCAAGGCG TTTGACAAAT
401 TGAAcGAAAT CGCGCCGACC ATCGrmwTGA CCGCCGATAC CGCCAACCTC
451 AAAGAAAGTG CCAArGAGGC ATCGACGCTG GCGCAATCT TC..

```

Number 122 ORF

```

1   ATGAGACATA TGAAAATACA AAATTATTTA CTAGTATTTA TAGTTTACa
51  TATAGCCTTG ATAGTAATTA ATATAGTGTT TGgTTATTTT GTTTTtCTAT
101 TTGATTTTTT TGCGTTTTTG TTTTTTGCAA ACGTCTTtCT TGCTGTAAAT
151 TTATTATTTT TAGAAAAAAA CATAAAAAC AAATTATtGT TTTTATTGCC
201 GATTtCTATT ATTATATGGA TGGTAATTCA TATTAGTATG ATAAATATAA
251 AATTTTATAA ATTTGAGCAT CAAATAAAGG AACAAAATAT ATCCTCGATT
301 ACTGGGGTGA TAAaACCACA TGATAGTTAT AATTATGTTT ATGACTCAAA
351 TGGATATGCT AAATTAAAAG ATAATCATAG ATATGGTAGG GTAATTAGAG
401 AAACACCTTA TATTGATGTA GTTGcATCTG ATGTTAAAAA TAAATCCATA
451 AGATTAAgCT TGgTTTGTGG TATTCATtCA TATGCTCCAT GTGCCAATTT
501 TATAAAATTT GTCAGG..

```

Number 123 ORF

```

1   ..ACCCcCAACA GCGTGACCGT CTTGCCGTCT TTCGGCGGAT TCGGGCGTAC
51  CGGCGCGACC ATCAATGCAG CAGGCGGGGT CGGCATGACT GCCTTTTtCGA
101 CAACCTTAAT TTCCGTAGCC GAGGGCGCGG TTGTAGAGCT GCAGGCCGTG
151 AGAGCCAAAG CCGTCAATGC AACCgCCGCT TGcATTTTtA CGGTCTTGAG
201 TAAGGACATT TTCGATTtCC TTTTATTTT CCGTTTTcAG ACGGCTGACT
251 TCCGCCTGTA TTTTCGCCAA AGCCATGCCG ACAGCGTGCG CCTTGACTTC
301 ATATTTAAAA GCTTCGCCGC GTGCCAGTTC CAGTTCGCGC GCATAGTTTT
351 GAGCCGACAA CAGCAGGGCT TGCGCCTTGT CGCGCTCCAT CTGTGcGATG
401 ACCGCCTGCA GCTTCGCAAA TGCCGACTTG TAGCCTTGAT GGTGCGACAC

```

```
451  AGCCAAGCCC GTGCCGACAA GCGCGATAAT GGCAATCGGT TGCCAGTAAT
501  TCGCCAGCAG TTTCACGAGA TTCATTCTCG ACCTCCTGAC GCTTCACGCT
551  GA
```

APPENDIX C

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 1>:

gnm_1

```
5  GAAAAATTCAGCAGCAGCAGGAAGATTGCCAGCATTTCGCGGGCGGTTTTAAACTTACCGA
   CGGTGGCGACGGCAACGCTGTTCTTTTGCCATTTCGCGCATCCATTTCGCGCAATGCGG
   AAATGGTAATTTCCCTGCCGATGATGATCATGGCAAACAAAACATAGGTCCGGTCGAGTT
   TGACCAGTAAAGCAAAGAGACGGCGACCATCAGCTTGTCGGCAACGGGATCGAGGAAGG
   CGCCGAAATCCGAGGTCTGTTCCACAACCTTGCCAAAAATCCGTCAAACCAAGTCGGTCA
10  AGGCGGCAACGGCAAAAATGACGGCGGGCGGTGAGATTAATCGTTTCCCTCCGCGAACCACG
   GAAAAGGCAGGTAAAAAGGGCTGTGAGGACAGGAATGAGCAAGACCCTCAACCATGTGA
   GGAAGATGGGAGATTCCAAGGCATCGGTTTTCTCTGTGCAGACTGTAAAGTTGTGATTA
   TAACGGTTATCCTCATAACCCAAAACGTAAAATTGCTGCATGGGCATCCCCCGCCCCGC
   CAATCTGTTTTACATTTCTTTCAAACGCAGGAAAATGGCGGGCAATAAAAGCAAAATAC
15  CCAGTTTCAGGCTGAAAACGGCAGGTTGTGCCAACACTTCGACAAGGCGGTCTTCCGTGC
   GGGCAAAATCTTTATTGCTTATAGACACTGCCACTGTTGCGGTATTCCAACAGAACGCCG
   TTTAAAAAACCTTTGCCGACGGTTTCGCTTAAAACGGCTCTAACCTGCTCCGCCCTGATG
   GTTCTGCCGATATTGCCGCTGTGCACAACTGTGCAACCCATAGCAGGAAAGCCGGTAA
   TGCTGCCCGTCTGCATCCAGTTTGATTGCCCGTCCGCTGCGGTTGAGGGCGGTAACGGTC
20  AATTCGCGCATATTCGAATGTTTTTCTTGTTCGTGAAATGCCGTGAGGTGCAATA
   AAAACGGCGGACAACAGCAGACAGCTTATGGCGGCAACCATACCCAGCGATAATATAGT
   GGATTAAATTTAAACCAAGTACAGCGTTGCCCTCGCCTTAGCTCAAAGAGAACGATTCTCTA
   AGGTGCTGAAGCACCAAGTGAATCGGTTCCGTACTATTTGTAAGTGTCTGCGGCTTCGTCTG
   CCTTGTCTGATTTAAATTTAATCCACTATATTTACGCTTACCCCTTGTTTCTCAAATG
25  CCGTCTGAAATAAGCGGCTTAATATATTGTTTACAGTATTGGGAAGCATAACAGACAAAA
   TGCCGTCTGAAATATTTTCAGACGGCATTCTTATCCGAAACGGATTATTTTTCGCTTTC
   AACCGCTTCCAATGCACGCAGGGCATAAGTGAAGCGGCACCCGCATTACAGGGCAATGGC
   GGTGTCGAATGCACCTGCGATTTCGCTGTGCGTGCACCGGCTTTGGTGGCGGCGGCGGC
   GTGAACACTGATGCAGCTCTCACACGTGTAGTAATGGCAACGGCGATGGCAATCAGTTC
30  GCGTGTTTTAGCATCAAGTGCCTCTGCAGCTGCCGCTTGTTCCAATGCGCCGTAGGCCTG
   CAGCATTTTATGATGCGCCTTACCCAGCTCGCCGAACGATTTTTTAACCAATGCGGTATG
   TTCTTTCCAATCTTTAAACATTTTCTTTTCTTTCTCTTGCGTTTTAACCTTGATACGCGC
   TTGCGTATCTGTTTTCGATGTGCGTATTATTGCAATTATTCAGTTGTGTTTCTCGTTTAA
   TCATCTCATTTTATGGTTCAAAAAGATTTATGGACATTCTGGACAACTGGTCGATTTTCG
35  CCAATTGACGGGCAGTGTGGATGTGCAGTGCCTTTTGGGCGGACAATGGTCGGTACGGC
   ATGAAACCTTGCAACGCGAAGGATTGGTACACATTGTTACATCGGGCAGCGGCTATCTCT
   GCATCGACGGCGAAACTTCCCCGCGTCCGGTCAGTACAGGGGATATTGTATTTTTCCCGC
   GCGGCTTGGGTATGTGTTGAGCCACGACGGAAAAATGCGGAGAAAGTTTACAACCGGATA
   TGCGGCAGCACGGTGCCTTTACGGTCAAGCAGTGCGGCAACGGACAGGATATGAGCCTGT
40  TTTGCGCCCGTTTCCGCTACGACACCCACGCGGATTGATGAACGGGCTGCCTGAAACCG
   TTTTTCTGAACATGCCCCATCCGAGTTTACAGTATGTGGTTTCAATGCTGCAACTGGAAA
   GCAAAAACCTTTGACGGGGACGGTTTCCATGGTCAACGCATTGTCGTCCGTCTCTGCTGG
   TGCTTATCCTGCGCGCCTATCTCGAACAGGATAAGGATGTCGAACTCTCGGGCGTATTGA
   AAGGTTGGCAGGACAAACGTTTGGGACATTTAATCCAAAAGGTGATAGACAAACCGGAAG
45  ACGAATGGAATGTCGACAAAATGGTGGCGGCTGCCAATATGTCGCGCGCGCAACTGATGC
   GCCGTTTCAAAGCCGGGTCGGACTCAGCCCGCACGCCTTTGTGAACCATATCCGCCTGC
   AAAAAGCGCGTTGCTGCTGAAAAAAACCCGGATTTCGGTTTTGTGCGTGCACGTGTCGG
   TAGGCTTTTCAGTCGAAACGCACCTTCGGCAAGGCGTTCAAACGGCAATATCACGTTTCGC
   CGGGTCAATACCGGAAAAGAAGCGGGCAAAAATAAATCGGGGCTTCAAACGCAAAATGCCGT
50  CTGAAAAGGCTTTATACAGCATTGCGTACCGCGTCATTTCAAGGGCTGCATCTTCATC
   ACTTCCATCAAAAAGTTGGTAAATGCGGGGTTGTTGGGTTTGACATCCATATTTTTCCAA
   CGCTGCTGCCAGCCGCGCAAGGCATTCTGGATATACAGCTTGGACTGTTCCGTATTGATT
   GCGCCCCGCTGGCTGTCTATCGCCGAACGCAGGTAGATTTATACATACTGTCATCGACG
   GCATTGCGTCCGACCAGGCGTTTTCTGAAGTTGTTTACAGATATTGCGCCGCGCTGAACCTTG
```

5 GTCATTTTACCGATAACCCACCTGATAGCCCAAGCGCGTCGCTTCATCGCTGATTTTGGCA
ACATCCGTCCAATGCGAAGAGGCAAGGCGGAAACCTTTTGAGGTGCTTCCGTTTTGACG
GTATTGATAGGATTACGGGGATTTCGCTCAATGTGGGCACATAAATAGACTGGCAGCCG
GAAAGAACTGCCGCAATGGAAAGAGGGATAAGGTATTTTTTCATGCCCCCATTATAATCA
10 AGTTTGCCTTGAGAAAACAAATTGTTTCGGCAAGAAAAATAAAATTTTCGGCATCAGAAGCA
GGCAAAAACACATTCCACAAGCCTTGCCGCAAGGTTTACAATCCGACCGTCCTTATCGCA
ACGACCGTTTTATGGATAACCGCAAAAAAAGACATTTTAGGATCGGGCTGGATGCTGGTGGC
GGCGGCCTGCTTTACCATTTATGAACGTATTGATTAAAGAGGCATCGGCAAAATTTGCCCT
CGGCAGCGGCGAATTGGTCTTTTGGCGCATGCTGTTTTCAACCGTTGCGCTCGGGGCTGC
15 CGCCGTATTGCGTCGGGACAmCTTCCGCACGCCCCATTGGAAAAACCACTTAAACCGCAG
TATGGTCGGGACGGGGCGATGCTGCTGCTGTTTTACGCGGTAACGCATCTGCCTTTGGC
CACTGGCGTTACCCTGAGTTACACCTCGTCGATTTTTTGGCGGTATTTTCCTTCCTGAT
TTTGAAAGAACGGATTTCCGTTTACACGCAGGCGGTGCTGCTCCTTGGTTTTGCCGGCGT
GGTATTGCTGCTTAATCCCTCGTTCGCGAGCGGTGAGGAAACGGCGGCACTCGCCGGGCT
20 GGCAGGGCGGCGCATGTCGGGCTGGGCGTATTTGAAAGTGCAGCAACTGTCTTTGGCGGG
CGAACC CGGCTGGCGCGTGTGTTTTACCTTTCCGTGACAGGTGTGGCGATGTGTCGGT
TTGGGCGACGTGACCGGCTGGCACACCCTGTCCTTTCCATCGGCAGTTTATCTGTGCTG
CATCGGCGGTGTCGCGCTGATTGCCCACTGTGCGATGACGCGCGCTTACAAAGTCGGCGA
CAAAATTCAGGTTGCTCGCTTTCTATATGACCGTCGTTTTTTCCGCTCTGTCTGCGCG
25 ATTTTTTCTGGGCGAAGAGCTTTTCTGGCAGGAAATACTCGGTATGTGCATCATCATCCT
CAGCGGTATTTTGGCAGCATCCGCCCCACTGCCTTCAAACAGCGGCTGCAATCCCTGTT
CCGCCAAAGATAAAAAATGCCGTCCGAACATCCTTCAGACGGCATATCGGGCTTTATTTT
CCCGCCTTCACATCCTGCCACTGGCGCACCATAACTTCAATGCCGCCGGCTGGATAGGC
ACCATGATAAAGCTGTTTTTCAAATCCTCCTCGGTTGGGAAAAATCGTATTGTGCTTTTTTA
30 AATTCGTCTTCCATCAGCTCACGCGCAGGCTTGCTCGAAGGCGCGTAAGTAACGAAATTG
CCGTTTTTCCGCGACACTTCCGGGTCGAGGAAGTCGTTGATGTATTGTGCGCGTTGGCG
ACGTTTTTTCGCATCTTTTCGGAATCACGAAAGAATCCACCCAAATCCCCACGCCCTCTTTG
GGCATCATCACGCGGATTTTTTTCCTTGGCGCCCGCTTCTTCGGCACGGCGTTTGGCGATG
TTCAAATCGCCGCGGAAACCGATTGTTACGCAGGTATCGCCGCGCGCCAAATCATCGATA
35 AAGCCGGACGAAGTAAAGCGTTTGATATTGGGGCGGTTTTTCTTGAGTAGGGCGGTTGCC
TCCCTGATGCTTCCGTATTGCTGCTGTTCGGGTTTTTACCCAAATAGTTCAACACCATA
GGATAGATTTCCGCCGCGCTGTCCAAATAGCTGATGCCGCATTGCTTGAGTTTGGACGTG
TATTCGGGGTCGAACACCAAATCCCACTGGTTGTCCGGCAGCTTGTCCTGACCCAAAGCC
TTTTTCACGCGTTTCGGTATTGATGGCGAAGGTATTTGTCCCCCAATAAAACGGCACGGCG
40 TATTCGTGGCGGGGATCGACCCCGTCCATCAGCCTCATCATTTCCGGGTTGAGGTGTTTA
TAATTGGGAATCAGCGACTTATCGATTTTCTGATACGCACCTGCCTTAATCTGCCTGCC
ACAAACGCATTGGACGGCGCGACAATGTGTAACCGGACTTGCCTGTGAGCACCTTGCTT
TCCAGCGTTTCATCGCTGTGCTACACATCATAAGTAACCTTGATGCCGTTTTTCTTTTCA
AAATCGGCAACGGTTTTCCGGATCGACATATTCCGACCAGTTGTAAATTTTCAATACGTTT
45 TGGTTTTCCGCCGGTGCCGGTTTTTCGGCAGGCGGTTTGTCCGAACCGCCGCACGCTGCA
AGCAGCAAAGCAGTCAGGACGGCCAGGGGAGATGTTTGGTCATTATCATTCCTTGCATA
TCGGGTTGGAGAAAGCGGCCATTATAGCCGATATTGGCAACAGGGCTTCAGACGGCATTC
AAAATCCCGCCACACTCTTCCGAAACCGCCGCTTCCATAGCTAGAAACAGGGATTTGCG
GTAAGATACCGCCGTTCTGTTTTCCCTGCTTTTACCATGACAAGACATTTGAGAGACATTG
50 AAAAAATTATGAAAACCTCCGAATGCGCCAAAAATTCCTAAAAATTTTTTGAAACCAAAG
GCCACACCGTCGTCCGCTCTTCCAGCCTCGTGCCGCACGACGACCCGACCCTGCTGTTTA
CCAACGCGGGCATGAACAGTTTAAAGACGTATTCTTAGGTTTCGACAAACGCCCCGTACA
GCCGCGCCACCACCGCGCAAAATGCGTACGCGCAGGCGGCAACACAACGACTTGAAAA
ACGTCCGGCTACACCGCCCGCCACCACACCTTCTTTGAAATGATGGGCAACTTCTCCTTCG
55 GCGACTACTTCAAACGCGACGCCATCCACTTCGCTTGGGAATTTCTGACTTCCCCGAAT
GGCTCAACATCCCTAAAGACAACTGTTGGCGACCGTTTACGCGGAAGACGACGAAGCCT
ACAACATCTGGTTGAACGAAATCGGTATGCCGTCCGAGCGCATCGTCCGCATCGGCGACA
ACAAAGGCGCGAATAACGCATCCGACAACCTTCTGGCAATGGGCGACACCGGCCCTTGGC
GCCCTGCTCCGAAATTTTCTACGACCACGGCGAAGAAATCTGGGGCGGCATTCCCGGCA
GTCCCGAAGAAGACGGCGACCGCTGGATCGAAATTTGGAAGTGCATTTTATGCAGTTCA
ACCGCGACGAACAAGGCAATATGAACCGCTTCCCAAACCTTCGTCGATACCGGTATGG
GCTTGAACGCATAGCCGCCGTGATGCAGCATGTTACAGCAACTACGAAATCGACTTGT

TCCAAGACCTGCTCAAAGCCGTTGCCCGCGAAACCGGCGCGCCGTTCAGAATGGAAGAAC
CCAGCCTGAAAGTCATCGCCGACCACATCCGCTCCTGCTCGTTCCCTGATTGCAGACGGCG
TCTTGCCCTTCCAACGAAGGCCGCGGCTACGTATTGCGCCGCAITATCCGCCGCGCCGTGC
GCCACGGTTACAACTGGGTCAAAGCAAACCGTTCTTCCACAACTCGTTGCCGATTTGG
5 TCAAAGAGATGGGCGGTGCCTACCCTGAATTGAAAGAAAAACAAGCCCAATCGAAGAAG
CATTGAAAAACGAAGAAAGCCGTTTTGCCCAAACGCTGGAAACCGGTATGGCTTTGTTGG
AAAACGCGCTGGTyAAAGGCGGCAAAACACTCGGCGGCGAAATCATCTTCAAACCTCTACG
ATACCTACGTTTTCCCATACGACTTGACTGCCGACATCTGCCGCGAACGCAATATCGAAC
CGGACGAAGCAGGCTTCGAGCGCGAAATGGAAGCCCAACGCGCACGCGCACGCGCCGCC
10 AAAGCTTCAAAGCCAACGCCCACTGCCTTATGACGGTCAAGACACCGAGTTTAAAGGTT
ATAGCGAACGCCAAACCGAATCCAAAGTCCTCGCCCTCTACAAAGACGGCGAGCAAGTCA
ACGAATTGAACGAAGGCGACAGCGGCGCAGTCGTCTACGACTTTACCCCGTTCTATGCAG
AATCCGGCGGCCAAGTCGGCGATGTCCGCTATATCTTCTCAGGCGAAAACCGCTTTGAAG
TACGCGATACCCAAAAAATCAAAGCGGCCGTATTCGGTCAATTCGGCGTACAACTTCAG
15 GCCGTCTGAAAGTCGGCGACAGCGTTACCGCCAAAGTGGACGACGAAATCCGCAATGCCA
ATATGCGCAACCACAGCGCAACCCACTTGATGCACAAAGCCCTGCGCGATGTATTGGGCA
GACACGTCGAACAAAAAGGCTCTTTGGTTACCGCCGAATCCACCCGTTTCGACATTTCCC
ATCCCCAAGCGGTAATGCCGAAGAAATTGCCGAAGTAGAACGCCCGCTCAACGAAGCCA
TTTTGGCGAACGTTGCCGTCAATGCAGCATTATGAGCATGGAAGACGGCGCAAAAAACCG
20 GCGCGATGATGCTCTTCGGCGAAAAATACGGCGAAGAAGTGC GCGTACTGCAAAATGGGCG
GTTTCTCTACCGAATTGTGCGGCGGCACACACGTTTCACGCACCGGCGACATCGGCCTCT
TCAAATCATCAGCGAAGGCGGTATTCGCCGAGGCGTGC GCGTATCGAAGCCATCACCG
GCCTGAACGCACTCAAATGGGCGCAAGAGCAAGAGCGTTTGGTGAAAGACATTATTGCCG
AAACCAAAGCCCAACCGAAAAAGACGTAAGTGGCAAAATCCAAGCAGGCGCGGCACACG
25 CCAAAGCATTGGAAAAAGAATTGGCACGCGCCAAAGCCGAATCGCCGTCACGCAGGCG
CCAACTCTTGACGATGCAAAAGACTTGGGCGCAGCCAACTCGTTGCCGCCCAATCG
AAGCCGACGCGCCGCCCTGCGCGAAATCGTTACCGATTAAACCGGTAATCCGACAACG
CCGTGATTCCTTTAGCGGCAGTAAACGACGGCAAGTCTCCCTGTGCGCCGGCGTATCCA
AACC GTTGACCGGCAAGTGAAAGCAGGCGATCTGGTTAAATTTGAGCCGAACAAGTCG
30 GCGGCAAGGCGGCGGCAGACCAGATTTGGCGCAAGCCGCGGCACGGATGCCGACAAAT
TGCCCGCGGTGTTGGATAGCGTGAAAGACTGGGTGCGCGCAAGCTGGTTTGATGTGGGA
AAGGCAGCTGAAAGGTTTCAGGCTGCCTTTTGTGCAAGAGGCGCTCTGAAAGGTCTCG
TTTGCCGTAGGTTGGGTGCGGACCCAACAAATTTTGTGAAGTATAAAAATGTTGGTCATG
ACCCAACCTACCTGCCTTTTTGTACAAAGAGGCTATCTGAAAGGCCTTGTTTGCCGTATG
35 GTGGGTGCGACCCAGCAGATTTTTATTAGGGTATGACCCAAGCTACTTGCTACGATAAA
AAAGATTTTAAATGAGCATTAGCCTTATTGGACTACACATTACCATAGCAATCATTTT
GTTTTTACTACAAATTTTATGGGAAAAAATCATCTATATTGGCTATTACCAACTGTC
TTTTAGCGAAGAAATCACTCTCCGGCATTTAATATTTTTTACAGAGCATTACCCCTAT
ATTATTTATCGTTATTTTTCTTGGGTGTTACTAGTCTTGAAATTCCCATTTCTCTTGA
40 AAAGATAAACTATGTAGTAATTTATTATTTTATAATTAGATTGTTATCTGTATTTGTTTT
TGAGAAAACACACATAGTTAACTGGTTTAATCAACTAACAATACCCATACCTATCCATAAC
ATTATCATTTATAGTATATAACAAATGATTTTGCCCAAAAGTTTTCTACTTCCATCCCTC
ACAAGAAGTAGCTACTACTTTTTGAATAGCGCTTGGTGGTTACATATATAATATATTTAAA
TAATGAATCAGGGCATTAAAACTTATAAAGAAAGAGTAAATTATGTAAACACAT
45 GCACAAAAAATTTGAAAGTTATTTGGTAAAATTATAGATAAAATAATCAAAGAGGATAG
TTATAATAATGATGATTTTTTAACCGATAAGAAAAAAGCACTAATATATTCAGTTTAAAT
TTATGAGAATTTTAATAGGGGACTAGTTTATAGATATTTGAAAAAATTTATTTGTACT
GGTAGAATAAAAAACATTTGGAATAATGCAAGTAACCTCAGCAGAGTACCTTTCCAATGAG
GAAAGTATAAAAAAAGGCGGAAATATTCTTATGAAAAATACAATGAAAAATATAATGAA
50 TCTATTGATGGCAATAAACTCTCTATAAATCATATTATGAATCAAGAAGAGAGATATT
AAAACTACAACCCAGATGCAAAATACATTAATGAAATTGAATCAATTTACATGATGCTT
GGAGAAATCTATCAAATGCACCAGACTTCATGTCACCACATTTTGAGGGGACTGCTCT
GAGGGGAATAAAATCATTATTTATTTAGTTATTAGCAGGATTTGTCGGGCATA
AATGCCCCACCTACAAATTCATTTTTCAAACCTCTGCCAAATATTTTCATCTTTGCAA
55 GGCTGTCTGAAACCCAAACCCCATTTTCAGACGGCTTTTTTCGCTAAAATCCCCATAC
CGTTCAATCCGAAACACAGGAGAATCATCATGGAAGTTACCATCTCCGCCATCATCAAT
GGCGAATTTGCCGACCAATACGGCAAGCGCGGTAGTCAGTTTAAATGAAACGGGATGCTG

ATTTAATTCTATTTCTTTGAAACTACCAATAACCTGCCTCCATCATAAACTAAAAGCA
 AGCCGTAGCCTGCATTCCCACAAACCGCGTGCCTGCCATGTACACACCCTACCTGCGG
 GCGACGCAACACCTTAAGAGACCTTTGCAAAATCCCCAAATCCCCTAAATTCCCACCA
 GACATTTAGGGGATTTCTCATGAGCACCTTCTTTCAACAAACCGCCCAAGCCATGATTGC
 5 CAAACACATCGACCGCTTCCCGCTATTGAAGTTGGACCGGGTGATTGATTGGCAGCTGAT
 CGAACAATACCTGAACCGTCAAAAAACCCGTTACCTTAGAGACCACCGCGGCCGTCTGC
 CTATCCCCTGCTGTCCATGTTCAAAGCCGTCTCTGCTCGGACAATGGCACAGCCTCTCCGA
 TCCCGAACTCGAACACAGCCTCATTACCCGCATCGATTTCACCTGTTTTGCCGTTTTGA
 10 CGAACTGAGCATCCCCGATTACAGCACCTTATGCCGCTACCGCAACCGGCTGGCGCAAGA
 CAATACCCTGTCTGAACTGTTGGAAGTGATTAACCGCCAACCTGACCGAAAAAGGTTTAA
 AATAGAGAAAGCATCCGCTGCCGTGCTTGACGCCACCATTATTCAGACCGCCGGCAGCAA
 ACAGCGTCAGGCCATAGAAGTTGACGAAGAAGGACAAATCAGCGGTCAAACACACCGAG
 TAAGGACAGCGATGCCCGTTGGATAAAGAAAAACGGCCTCTACAAACTCGGTTACAAACA
 ACATACCCGTACCGATGCAGAAGGCTATATCGAGAACTGCACATTACCCCCGCCAATGC
 15 CCATGAGTGCAAACACCTGTGCCGTTGTTGGAAGGTCTGCCCAAAGGTACGACCGTCTA
 TGCCGACAAAGGCTATGACAGTGCGGAAAACCGGCAACATCTGGAAGAACATCAGTTGCA
 GGACGGCATTATGCGCAAGCCTGCCGCAACCGCCCGCTGTGGAAGTGCAAACCAAGCG
 TAACCGATATTTGTCGAAGACCCGTTATGTGGTGAACAAAGCTTCGGTACGCTGCACCG
 TAAATTCGCCATGCCCGGGCAGCCTATTTGCGACTGATTAAGTGAGTGCGCAAAGCCA
 20 TCTGAAGGAGATGTTGTTGAACCTGTTGAAAGCCGCCAACAGGCTAAGTGCGCCCGCTGC
 CGCCTAAAAGGCAGCCCGGATGCCTGATTATCGGGTGTCCGGGGAGGATTAAGGGGGTGT
 TTGGGTAATAATTAGGCGGTATTTGGGGCGAAAACAGCCGAAAACCTGTGTTGGGATTTG
 GTTGTGCTGAGGGAAAGGAATTTGCAAAGGTCTCCAGCAGTTTGCGCATACATGCCGTA
 ACGGCAACCTTATACGGCTTACCCTCGGACAGCGGGCGTTGGTGGAATCCCGAATAAGC
 25 GGTTCAAACGTGTGCTGCCACGGTAGCCATATACAGTGCCCTAAGCACCGCAGACCTT
 CCGCCAAAGCAGCGGCTTTTGAATTTGGCTTCCCCGCTCTTCCCTCGGGTGCGGGGCAATG
 CCGACCAAACCTCGCTATCCGTTTGTGCGACAGCCGCCCAATTACGGTAGCATCGCCATC
 AGCGTAGCCGTGTTATCGAACCGATGCCTTTGATTTGCTCCGCCACTTGGGCTTTGCCG
 TCAAAATGCGTGTGGGTGTGGTCTGATTTGTTTGTCCGATTGTCATCAGCCGGTCA
 30 AAATGGGCAATCAGTTGTTTGACGCTTCCGACTTGCGTTTCTGTAACCTGATGCAGACGG
 TTTTCTCGGCAGTCCGCATATCCGCCGATTGGTTGCGGCGGTTAACCAAGGCTTCCAAC
 ACTTCTTCCGCTTCTGTGGGCGGGTGGTAGGGCATGGTTTGCCAATCTTCTTTCTGTGCC
 TTCATCTGTGCGAAGAAGGCAGGCATTTTGGCATCTTTGGCGTCGGTTTTGGTCAGCGAC
 TGCGATTGCGCAAACTGATGCGTCTGACGCGGGTTGGCGATAATCACGGCTATGCCTGCT
 35 CGGTGGATGGCTTTGGCGGCGGGGATTTGAGACCTCCGGTACTTTCCGTCACGACGAGG
 GCGACCTTGTGTTTTTAAGGTATTCGATAGTATGGGCGATACCTTTGGGGTGTGTGGTT
 TCGGTTTTGTTTTAGACAAAGACGAAACGGCGATGACGAAGTTTCGTTTGGCGAIGTCG
 ATATAGTAATTAACAAAATCAGGACAAGGCGGCGAGCCGAGACAGTACGGATAGTAC
 GGAACCGATTCACTTGGTGCTTCAACACCTTAGAGAATCGTTCTTTCGAGCTAAGGCGA
 40 GGCAACGTCGTAAGTTTTGTTAATTCATATATCTGTGCGTTACGACGGCATGCCGT
 CTGAAGGGTGTATGTCTGCATCTAAGAAATTTCCGATTCCTTTGAGCTATTTACGCAT
 CGCGCTGGGCTTGTGTTGCCCTTGGGGCTGTGCTGGCGTTACGGCGCGTCTGTGCGGCTGCT
 GCCCGCCTTGGCCGCCGAATCGCTGCTTGGCGCGGCTTCGGTCTGCTGGCTCTTGCTGGT
 GCGGCGATACCTGATCAAAATGTTTGGCTACCGAAACGATTTTTTGTCTGATTTACGCGA
 45 CTTGGTGCAATGCTGCTTATCAGCGCGATTCCGATTACCGCTATGCTGGAGGGACTCGC
 GCTGAAGCCCTATCAGGCAGGCGCGGCGGCGAGTCTGATTTATGTGCGCGTTGCCGGACA
 GTTGGCTTTTTCGATGTATCGGGCGGCGGCTGTGTCGCGCGGCTGCATTCTTTGGAGGC
 GACGACGCCGATTATTTATCTGCCTACGGTTGCGACAACTTTGTGACGCGCTCATCTCT
 GCGGCGGCTTGGGGCATCATGATTATGCAGCTTTGTTTTTCGGCGCGGGTATGTTTTCTG
 50 GCTGAGCTTGGAAGCCTCCATCTTGGGCAGGCTGCGCACGGCGGCACCGGTGCGCACGGC
 GCGCGCGGCGTGGTCCGCATCCAGCTTGGCGCCCGCTTTGTGCGCTGCGGCGCGTATTT
 TGCCGTGCGCGGTAAAGTCGACGGTTTGGCTTGGCATTAATCGGCTACGGCTGCCTGCA
 GCTTTTGTCTTGTGCGCCTGACCCGCTGGTTTTGGGAAGGTGGTTTTACGATGAGCTT
 TTGGGATTTTCACTCGGTTTCGCGGCAATGGCAGGATGCGGTCTGCATCTGGCGGCTTC
 55 CGGCGTATTTGTCGGGCTTGGGGCTGACGCTTGCCACCGCCGATCGGCAGGCGTGGCGCT
 GCTGCTTGTGCGTACGCTGCACCGGATAGCGACGGGGCGTTTCTTGGTACGCAGCTGATG
 CGTTTTGCCGCTTGTCAAAATGCCGCTGTAACGCTGGGATTACAGACGGCATTTTTTA

TTTCACACCCTTACAGGTAGAATTTTTCGATGACTTTCAAATTGTCGTCCAATTTGTACA
CCAACGGCTGACCGGTGCGGATTTCCAAGCCCATAATGTCTTCGTGCGAAATGCCCTCGA
TGTGTTTTGCCAGCGCGCGCAGGGAGTTGCCGTGCGCCGCCACCAAGACGCGTTTGCCGC
TCAAAATCGCGGGGGCGATTGGTCTTCCCAAACGGCAATACGCGCTCCAGCGTTACTT
5 TCAGGTTTTCGCCGTGCGGTACGACATCGGCAGGCAGATGGGCATAGCGGCGGTCTTTGT
GTGCGGAAAACATCATCGTCTTTGTCCAAAAGCGCGGCAGGGTGTCTAGCTGCGCCGCC
AGATGCGGACTTGCTCGTCGCGCTATTGTTGCGCGGTTTGTTTTTGTCCAGGCCTTGCA
GTTGGCCGTAGTGGCGTTCGTTTCAGCCGCCACGTTTTGATTGCGGTACGAACAGTTGGT
CGGATTCTTCCAAAACGATGTTGCAGGTCTTAATCGCGCGGGTCAGGACGGATGTGAAGG
10 CGATGTCGAACTCATAGCCGTTTTCTTTCAGTTTCTTGCCGCGGCGGCAGCCTCGGCAA
GCCCCTGCTCGCTCAGCTTCACGTGCGGCCAGCCTGTAAACAGGTTTTTCGCGTTCCATT
CGCTTTGTCCGTGGCGGATAAATACCAGTTCCATATCGTCTCCAATGTGTGAAAGTGGGA
AAGCCTTATTTATAACATATTTTACATTTCCCGTATTTGATTTCAGATTTCAGACACGCGC
CCACTATCGTTTGCCGTTTTGATTACATAATGTCCTTGCTTTACATTCCGCATACAC
15 AATGAATACGCAAGCGCACGCCCCACATACCGATTCCAATACGCTGATGCTCGGCCGATA
CGCCGAACGCGCCTATCTCGAATACGCCATGAGCGTGGTCAAAGGCCGCGCGCTGCCTGA
AGTTTCAGACGGCCAGAAGCCCGTGCAGCGGCGCATTTTGTGTTGCCATGCGCGATATGGG
TTTGACGGCGGGGGCGAAGCCGTTGAAATCGGCGCGCGTGGTTCGGCGAGATTTTGGGTAA
ATACCACCCGCACGGCGACAGTTCCGCCTATGAGGCGATGGTTCGGGATGGCGCAGGATTT
20 TACCTTGCGCTATCCCTTAATCGACGGCATCGGCAACTTCGGCTCGCGCGACGGCGACGG
GGCGGCGCGATGCGGTTACACGAAGCGCGGTGACGCGGATTGCGGAATTGCTGTTGTC
CGAAATCAATCAGGGGACGGTGGATTTTGTGCCGAACACGACGGCGCGTTTGACGAACC
GCTGCACCTGCCCGCCGCTGCCTATGGTGTGCTCAACGGCGCGTCAGGCATTGCGGT
GGGCATGGCGACCGAGATTCCGCCGCACAATTTGAACGAAGTGACGCAGGCGGCGATTGC
25 GTTGTGAAAAAGCCGACGCTGGAACCGCCGACCTGATGCAATATATTCCTGCCCCGA
TTTGCCGGCGGCGGTCAAATCATCACGCCGGCGGACGAATTGCGCCGATTTATGAAAC
CGGCAAGGGCAGCGTGCGCGTGCGTGCGGTTATGAAATCGAAAAATTGGCGCGCGGACA
GTGGCGCGTCATCGTAACCGAGCTGCCGCCGAACGCCAATTCGCCAAAATCCTTGCCGA
AATCGAAGACGAAACCAACCCGAAACCGAAGCGGGTAAGAAACAGCTCAACCAAGACCA
30 GCTCAATACCAAAAAGCTGATGCTGGATTTAATCGACCGCGTGCGCGACGAGTCCGACGG
CGAACATCCCGTGCGACTGGTATTCGAGCCGAAATCCAGCCGCATCGATACCGATACCTT
CATCAACACGCTGATGGCGCAAACCTTCGCTGGAAGGCAATGTGTGATGAACCTGGTGAT
GATGGGTTTGGACAACCGCCCCGCGCAGAAAAACCTGAAAACGATTTTGCAGGAATGGCT
GGATTTCCGCACCGTAACCGTAACACGCCGTCTGAAATTCCGTTTGAACCAAGTGAAAA
35 ACGGCTGCACATCCTCGAAGGCCGTCTGAAAGTCTTCTGCACATCGACGAAGTGATTAA
AGTCATCCGCGAATCAGACGACCCGAAAGCCGATTTGATGGCGGCGTTCCGGCTGACCGA
AATCCAAGCCGAAGACATTTTGGAAATCCGCCTGCGCCAGTTGGCGCGTTTGGAGGGTTT
CAAACCTGAAAAAGAATTGAACGAGTTGCGCGAGGAACAAGCCGTCTGAACATCCTTTT
GAGCGACGAAAAACGAAACGCAAGCTGATTGTCAAAGAGATGCAGGCGGATATGAAACA
40 ATACGGCGACGCGCGACGCACGCTGGTGGAAAGAGCCGGACGCGCCGTGCTGACGCAGAC
CACCGCCGACGAACCCATCACGCTGATCCTGTGCGAAAAAGGCTGGATACGCAGCCGCGC
CGGACACAATCTCGATTTGAGCCAAACCGCGTTCAAAGAAGGCGACTGCCTCAAACAAAC
CCTCGAAGGCAGAACGGTTTTACCCGTGCTCATCCTCGATTTCATCGGGCAGAACCTACAC
GCTCGATGCCGCCGAAATCCCCGAGGGCGCGGCGACGGCGTACCGGTTTTCTCCTTAAT
45 CGAGCTGCAAAACGGCGCGAAACCCGTTGCGATGTTGACAGGATTGCCGGAACAACATTA
TTTATTATCAAGCAGCAGCGGCTATGGCTTCATACCAAGCTGGGCGATATGGTCGGGCG
CGTGAAAGCGGGCAAAGTGGTGATGACCGCAGACAGCGGCGAAACCGTTTTGCGCCCGGT
TGCCGTCTATGCCTCCTCGTTCATCAACCCCGACTGCAAAATCATTGCCGCCACAGTCA
AAACCGCGCCCTCGCCTTCCCCATCGGCGAATTGAAAATTATGGCGAAAGGCAAAGGGCT
50 GCAATCATCGGATTAAACGCCGGCGAATCGATGACGCATACCGCGTTTCTTCCGAGCT
GGAAATCCTGATTGAAAGCGAAGGCAGGCGCGGCGCGCACAAAGACCGCATCCCCAT
CTCCCTGCTTGAGGCAAAACGCGGCAAAAAGGCGAGCTATTGCCCATATCGGGCAGCCT
GAAACAGCTTTCTTCCCTAAATAAACCCGGTTCCGCACATATTATGGTGATTTCCAACC
CCCAGCACTTGAAAACTCAAAGACCGGATTCCCAATCTGATCAACATCATCCGCGTCG
55 CCATCGTTTTTCCGCTGATGATTATGCACATCCTCGGGCTGAAACCGGCGAGCCGTGCGA
ACCTGCACGCTTCGTGGACGGCGTGGGCGTTTTATGTTTGGCTCGCCATTGCCTGCTGGC
TGATTTTCTTTCCATTATCCATCCGCATTGGCAATGGCAGTCGCTGAAAAATGCCGCGTT

TCAGCGCGGTAGCGGACATCACGATGATCGGCGTGCTGACCTACCTGTTTCGGCGGCATCG
 ATTCGGGCTTCGGGCATCCTGATCCTGCCCTTCGTGCTGCTCCTGCTCAGCTACG
 GCGGCTACCCCTGCTCTATTCCAGCTACGCCGCCATCCTGCTGATATTCAACGCCATTG
 5 CCGACGGCGATATCGGCAAATACCCGCTCATATCGGATGCCCGAACC3CCTCGGCAACCT
 TCATCCTTGTCGCGCCTCCTATCTTTCCGCCATCTTACCTCACTGTCGGTCAAATACA
 TCGACCGTGCCGGAAAACCTCGCCTACGACAGCCATATCGCCTACCACCGCATCAAAGGCT
 TGAGCCAAACCGTACTCGAACGCGTTCAGGAAGCTGTCGTGCTCATCAATGCCGAAGGGC
 TGGCGGTGCTGTTCAACCGGAAGGCGAAAGACCTTTTCCCGCGCTCGAAATCGGACGGC
 GCGCGGTGCTGTCCGATTCTGCCCGGAACTGTGGGATCAAGCCTCTCCGCACACTTTCG
 10 AATACGTCTCCTCGGCACACCCGGCCTGAACGCCGGCATCCGCGCCGTTCCGGTCAACAAAG
 GGTCCGACAAGCTGCTCATCTCTACATCCGCCCGCAAAGCGAAATT CAGGCAGAAGCCC
 TGTCCTGCAAACCTTGCCGCGCTCGGACAACCTGACCGCCAACCTCGCCCACGAAATCCGCA
 ACCCGATGTCCGCCATCCGCCACGCCAACGACCTGCTGCGCGAAAATATGGAAGCGGGGG
 CGGCAGATCCGTTCAACGCCAAATTGTGCAAAATCATCGACGGCAACATCTGCCGCATCG
 15 ACAAATGCTCGAAGACATTTCTCGCTCAACAAGCGCAACAAAACCGAACGCGAAACCA
 TCGGCTGATACCGTTTGGGAAGAATTCAAACAAGAGTTCTGCTCGGCCATCCCGATG
 CCGCGACTGCATCCGTCCGGACATTCAAGGCGGCAGCCCGACCGCCTATTTTCGATCCCG
 CCCACCTGCGGCAAATTATGTGAACCTCGCCAACAACGCGTGGCGGCACAGCCGCAAAC
 AGCCCGGCTCGATTTCCGTCACCATCCGCCCGCGCAAAAAACACCGTCTGTATCCTCT
 20 TTGCCGACCGCCGAAGTGCAGGAACACCTGTTGCAACCTTTTACACCGCGCGGAAAA
 CGGCACCGGCTCGGGCTGTATGTGCGCCGCGAAGTGGCGCACGCCAATTCGGCGATT
 GACCTACCTACCGGAAGCCAAATGTTTCGAACCTACATTACCGGAAAAACCAATGACTG
 AACTGCAACACCCCGTCTCGTCTGATGACGAAACCGACATTCTCGACCTGATGGAAA
 TGACCTGATGAAAATGGGCTTGCGCGTCCATACCGCGTCAGGCGTTGCCGAAGCCAAAA
 25 ACAAGCTCGACAGCCAACGCTATTGCTCGTCTGACCGATATGCGTATGCCGGACGGCT
 CGGGGCTGGAAGTCTGTCACACATCAACAGCCGCTGCTCGATACGCCGTTGCCGTCA
 TCACCGCCTTCGGCAACGCGGATCAGGCACAGGAAGCGTTGCGTTGCGGCGCGTTCCGACC
 CCGATACCATGCAGATACAGGACTATCTCGACCAAATCGAACGCGACATCATCGAACAAA
 CCTCAAACAAACCGAAGGCAACCGCACGCGCCGCAAAACGCTTGGGCATCAGCTTCC
 30 GTTCCATGCGCTACCGTATGGAACGCTCAACATCGGCTGACGACAAAACGGCATCCGCA
 CCATCTCCGCCCCACCGAAAAAATGCCGTCTGAAACGGCACGGGAAAGCGGTTCCGCCCC
 ACGCCCGAACGGACACAAAACACCATGACCGACATCCTTATTGACAACACCGCCACCGAA
 ACCGTCCGCACCTGATACGGGCATTCCCCCTTGTCGCCGTTTCCCAACCGCCCGAACAA
 GGCAGTTACCTCCTTGCCGAACACGATACCGTCAGCCTCAGGCTTGTCGGGGAAAAAAGC
 35 AGCGTCATCGTCGATTTTGCTCCGGCGCGGCACAATACCGGCGCACAAAAGCGGGGGC
 GAACTCATCGCCAAAGCCGTCAACCACACCGCGCACCCACCGTTTGGGACGCAACCGCA
 GGATTGGGGCGCGACAGCTTCGTCTCGCTCGCTCGGGCTGGCCGTTACCGCCTTCGAG
 CAACATCCCGCCCTCGCCTGCCTGCTTTCAGACGGCATCCGCCGCGCCCTCCTCAATCCC
 40 GAAACGCAAAACACCGCCGCGCACATCAACCTCCATTTTCGGCAACGCGCGGAACAAATG
 CCCGCACTTGTCCAAACACAAGGCAACCCGACATCGTCTATCTCGACCCCATGTATCCC
 GAACGCCGCAAAAGTGCCGCCGTTAAAAAAGAAATGACCTACTTCCACCGGCTCGTCGGC
 GAAGCGCAAGATGAAGCGGCACTCCTGCATACCGCACGCCAAACAGCAAAAAACGCGTC
 GTCGTCAAACGCCCCCGCCTCGGCGAACACCTTGCCGGACAAGACCCTGCCTACCAATAC
 45 ACAGGCAAAAGCACCCGCTTCGACGTTTACCTGCCCTACGGGACGGACAAGGGATAACGC
 CCATAAAACAAGACACCGAAAAATTGCGGTTCTTATGCAACGAGAAACCGGTTTTTGC
 GTTTCGACTGTTTTGGATAAGTCATCACACCTTAAAGTTTGTCAATCCACAGAAGTGGG
 AATCCGATTCATTGAGTTTTATAGTGGTTTAAATTTAAACCACTATAGTTGTTTTGAGT
 50 TTCAGGCAACTTCCAAACCGTCATTTCCACGGAAGTGGGAATCTAGAAATGAAAGGCAAC
 AGGAATTTATCGTAAATGACTGAAACCGAACGGAAGTAGATTCCCGCTACGCGGGAATGA
 CGGGGCGGGCAGATGCCGTCTGAAATTCGGTCATTCCCGTGAAAAACGGGAATCTAGAAT
 TCTGATTTTTTCAGACGACTTTTGAACATTGCCGCCACCCAATGATCTGGATTCCCACCTG
 CGCGGGAATGACGAGGTTTCAGGTTGCTGTTTTTAAGTTGCTGTTTCGGGTTGCTGTTTT
 TTATGGAATGACAAGGTTTTAGATTGCGAGAATTTATCCGCTCCTCCGTCAATCCCACG
 55 GAAGTGGGAATCCAGAAATGAAAAGCAACAGGAATTTATCATAAATGACCGAAACCGAAC
 GGACTCAGATTTCCGACTGCGCGGGAATGACGGGGCGGGAGGATGCCGTCTGAAATCCGT
 CATTCGGTGAAAACGGGAATCTAGAATCTGATTTTTTCAGACGACTTTTGAACATTGCG
 CGCTACCCAATGATTTGGATTCCCGCCTCGCGGGGAATGACGATGTAAAATTATCCGGGA

TTCAAAAAGACAGGCTTTACATCCGTGGGAATGACTGCGGAAAGATGATTTTTATAGTG
GATTAACAAAAATCAGGACAAGGCGACGAAGCCGCAGACACTACAAATAGTACGGCAAGG
CGAGGCAACGCCGTACTGGTTTTTGTAAATCCACTATATTTTGTCAAAAAATCCGCACC
5 TTAATCAGTTGGCGGTTAAATCAAACCTTTAGGGTGCAGATTACTTTTTATGATTTCAGA
CAGCATTTTGACAGGCGGCAGCCTATTTTCGGCAATACCAAAAACTTAATCAGCAGTTCTT
TGAATACAAAACCGAACACGCCCAAGCCCAAAACCAAAAACAAATGGCGATGCCGAATT
TGCTGCTTTGGACTCCTTGCCCAAATTCCAAACGATAAAACCCAAAAAATAATCAAGC
CGGTACGGCAGATTTTCAACGCCCAATCGGCAAAAACCGCTTCATCCATATTTTTTTCCT
10 ATTGTGTATGTGTATGCCATATAAGATAAGGGTTTCAGACGGCATCTGCTGTCCAATGCC
GTCTGAAACACGCAATCAGCGTGCAGTGCCTGTTTCAAATCGTCAATCAAATCGCCAAC
ATATTCCAAACCGACCGACAGGCGCACCAATCCGGGGCGGATGTTGGCGGCGAGTTTTTC
TTCGGGCTGCATCTTCCGTGCGTGGTTGTCCACGGGTGGGTAATGGTCGAGCGCACGTC
ACCGAGGTTGGCGGTGCGGGAAGAGTTCCACGCCCTCCACAACCTTTCCACGCCGCTTC
15 TTGATCGGCAACTTCAAAGCCGATGACGATGCCGCCGCGTTTGTCTGTTTGCGGATAAG
CGCCGCTGAGGATGGTCGGACAATCCGGTGTAGTACACGGCTTGAACCTGCGGCTGCGC
TTGCAGCCATTGTGCGATTTTCAGGGCGTTGTGCAACTGTTTTTCCATACGCAGCGACAG
GGTTTCCACGCCGCTCAACAACCTGCCACGCATTAAACGGCGACATCGCCAGCCCGCAAGA
GTTGCAATACATGGCGACCTGCGCCAACAACCTCTTCGAACCCGCCAACACGCCGCCCAT
CACACGCCCGTGTCCGTCTATGGCTTTGGTCGCGGAGGAAACGGAAATATCCGCACCGTG
20 TTTCAAAGGCTGCGAGCCGACGGGCGACAGCAGGCTGTTGTCCACCACCAAGAGCGCGCC
GATGCCGTGCGCAATTCCGCCAAGGCTTCCAAGTCGGCCACTTCGCCTAAGGGGTTGGA
CGGCGTTTCCAAAAACAGCAGTTTGGTATTGGCTTTGACGGCGGCTTTCCATTGCTTTAT
ATCAGTCGGCGACACGTGGCTCACTTCGATGCCGAATTTGGCAACGATGTTATTGATAAA
GCCGACGGTCTGTCGGAACAGGCTGCGGCTGGAAATCACATGGTCGCCCCGCTGCAAAAA
25 GGTGAAAAACGCCGCTGAATCGCAGACATACCCGCCGAAGTGGCGACCGCGCGTTCCGC
ACCTTCCAAAGCGGCGATGCGTTTTTCAAAGGCGGCTGTGGTCGGGTTGGCGGTACGGGT
ATAAGTGAACCCTTTGATTTTTTTTGAACAACATCGGCAGCGTGTGGGCGTTGTCCCA
CATGAAGCTGCTGGTCAGAAACAATGCCTGATTGTGTTGCGGTTATTCGGTTTGTCTTT
GCCGCCGCTATGGCGAGCGTTTGCAGATGGAGTTTTTGTCTCATCGGTGATTCTCTCGGT
30 TTTGTCCGTTTCGGCAACGAGCGTGCGCCCGTTGTTTAATTTGTTAAATATTTGCGCCTG
TTCTATGATGCTTCAAGTCGGATGAGAATGCAATGCCGTCTGAAACGGCTTTCAGACG
GCATGGCAATCAGCGTTTGTATTTTAACTCGTACTTGATGTCGTTGAGGATTTTGCGGAC
ATCGTGTTCCAACACGTCTTCGACTACCGCCCCGCTGCTCGTGCAGCATCTGCTGGAG
CTGATAGGTGAAAACCGCCATCTGCTTTTGCACCGCCGTTCCGGATGATGCCGTTGACGGT
35 ATCGGTGATGCGGGCGCAGGCGTTTGATCAGCCGTTCCGGTCAGCTCCTGTTCCGACAG
GCAGAACACTTCGCGCCGTTGACGGCTTTCCGGTTCAGGATATTGATTGGACGGGCAT
CAACGTTCTTCCGCATCGTTTTTCCCGTTTTTCCGAAACCGCCGGCTCATTCGTGCCGGA
TTCTGCTCTCGGCGTTTCCCGCTTTCAATCTGTCCGTTTTCAAATTCGACACTGTC
TTTTTTGGTATCAAACCGGATTCTCCGCCGATTTCGATGTGTTTTTCCGAAACCGACAT
40 TTGCAGGGAAGCCTGCGCGTTGAGCCAGTTTTCTGAAGGACGATCATCGGGTCGGTTTC
GACTTCCTCGCCGCAATCGGCAACGGCGGCATTGTGTTCTCCTGCCATTTTTTCAGATA
CGCCTTCAACACAGGGCTCGGCTCTCATCGTCCAGTTTCGGCACAGGCGCGTCCGTTCC
GGTTTCAGAGGGGCGGGACAGCGGCGCTAAGTCGGCACTGCCTTCATACGGCGCGTCTG
ACGCAGGTTTTCCAAACGTTTTTCCCAATTCCGGCTCTTATTTCGCATCCATTTTCGGCTT
45 CCGGTTCTTAATCTTTGCAAGCAGACAAACCCGCGCCAAAGCGCGGTTTGATATAATGG
CGCATTTTAACAGATTGCGGAGGATACATCATGGGCAGCATCGAACAGCGTTTGAATAT
CTGGAAGAGGCGAACGACGTGCTGCGTATGCAGAACCACGTCTGTCCACCGCATTCAA
GCCTTAATCCGCGCCCTTCCGCGGAAACCGCGGAAATCGCGGTGAGTTCGATTACGCTT
GCTTTTGAGGACGCCCTTGGCAGAATTGAGCTATGAGGACAGCCCGCATACGGATTTGTTT
50 CACGACGTTACTTATGCGTTTTTCCGTGAAAAAGAACGTTAATTTATGTTAACTGATT
TTTTTAGGCTTTTGATTACCGAAAGGAATTTTGATGAATATGAAAAATGGATTGCCGCC
GCCCTTGCTGTTCCGCGCTCGCGCTGTCTGCCTGCGGCGGTGAGGGCAAAGATACCGCC
GCGCCTGCCGCCAACCCGACAAAGTGTACCGCGTGGCTTCCAACGCCGAGTTTGCCCC
TTTGAATCTTTAGACTCGAAAGGCAATGTGCAAGGTTTCGATGTGGATTGATGAACGCG
55 ATGGCGAAGGCGGGCAATTTTAAATCGAATTCAAACACCGCGTGGGACAGCCTTTTC
CCCGCTTAAACAACGGCGATGCGGACGTTGTGATGTGCGGCGTAACCATACCGACGAC
CGCAACAGTCTATGGACTTCAGCGACCCGTATTTTGAATCACCCAAGTCGTCTCGTT

CCGAAAGGCCAAAAAGTATCTTCTTCCGAAGATTTGAAAAACATGAACAAAGTCGGCGTG
GTAACCGGCTACACGGGCGATTTCTCCGTATCCAAACTCTTGGGCAACGACAATCCGAAA
ATCGCGCGCTTTGAAAAAGTTCCTGATTATCAAAGAACTGGAAAAACGGCGGCTTGGAT
TCCGTGGTCAGCGACAGCGCGGTTCATCGCCAATTATGTGAAAAACAATCCGGCCAAAGGG
5 ATGGACTTCGTTACCTTCCCCGACTTCACCACCGAACACTACGGCATCGCGGTACGCAA
GGCGACGAAGCAACCGTCAAAATGCTGAACGATGCGTTGGAAAAAGTACGCGAAAGCGGC
GAATACGACAAGATTTACGCCAAATATTTTGCAAAAGAAGACGGACAGGCCGCAAAATAA
GCCCCCGCTCCGAACACAATGCCGTCTGAAGCCCTTTTACAGCGGCATTGTTTCATCAATC
GGCCTACAATGAAGTGCCTGCTGATTTCTCCCTACCGCAAAGCAACAGGCAAAGATTACA
10 AATATCAAAATCCGAGTAAACAGTATTTTATTAACAAATGATAATCAAGAGATTAG
AATTATGTATTGCTTTTACCGTACAAACGCTGGCACTATTTCAACCTGATAAAAAACAGC
CTTCAAAAGGTTGTTTAAACAGCAGCAGACACTTACCGCCACAACCTTGAAAAGGAAC
ACAATCATGACCGTCATCAACAGGAAGACTTTATCCAAAGCATTTCGATGCCTTCCAA
TTCATCAGCTACTATCATCCAAAGACTACATCGACGCGCTTTATAAGGCGTGGCAGAAG
15 GAAGAAAATCCTGCCGCCAAAGACGCGATGACGCAGATTTTGGTCAACAGCCGTATGTGT
GCGGAAAACAACCGCCCCATCTGCCAAGACACAGGTATCGCAACCGTCTTCTCAAAGTC
GGTATGAACGTCCAATGGGATGCGGACATGAGCGTGGAAGAGATGGTTAACGAAGGCGTA
GCGCGCGCTTACCTTGGGAAGGCAATACGCTGCGCGCTTCCGTCTCGCCGATCCGGCC
GGCAAAACGCCAAAAACACAAAGACAACACCCCGCGCTCATCCATATGAGCATCGTGCCG
20 GCGGTAAGTTCGAAGTAACCTGCGCGGCAAAAGGCGGCGCTCTGAAAACAAATCCAAA
CTCGCCATGCTCAATCCTTCCGACAACATCGTCGATTGGGTATTGAAAACCATCCCGACC
ATGGGCGCGGCTGGTGTCTTCCCGCATCTTGGGTATCGGCATCGGCGGCACGCCCCGAA
AAAGCCGTGCTGATGGCAAAAGAGTCCCTGATGAGCCACATCGACATTCAAGAATTGCAG
GAAAAGGCCGCTCCGGCGCGGAATTGTCCACCACCGAAGCCCTGCGCCTCGAATCTTT
25 GAAAAAGTCAACGCGCTGGGCATCGGCGCACAAAGGCTTGGGCGGACTGACCACCGTGTTG
GACGTGAAAAATCCTCGATTATCCGACCCACGCGCCTCCAAACCGATTGCCATGATTCCG
AAGTCCCGCCGCGCGCTCGAAGACTGGCCGATTTGACTTACAGCCCCGACAACGGCAACGC
ACGCGCGCGCGCTCGAAGACTGGCCGATTTGACTTACAGCCCCGACAACGGCAACGC
GTGATGTGACGAAGCTGACCAAGAAGAGTGGCAAGCTGGAAAACCGGCGACGTATTG
30 CTGTTGAACGGCAAAATCCTCACCGCGCGATGCCGCACACAAACGCTCGTCGATATG
CTCAACAAAGGCGAAGAATTGCCCGTCGATTTACCAACCGCCTGATTTACTACGTGCGC
CCCGTCGATCCGGTCCGGCATGAAGTCGTGCGTCCGGCAGGTCCGACCACAGCCACCCGC
ATGGACAAATTACCCGCCAAATGCTCGAACAACCGACCTCTTGGGCATGATCGGCAAA
TCCGAGCGCGGCGTGGCCACCTGCGAAGCCATCGCCGACAACAAAGCCGTGTACCTCATG
35 CGAGTCGGCGGCGCGGCTATCTCGTGGCAAAAGCCATCAAATCTTCAAAGTCTTGGCG
TTCCCGGAATTGGGCATGGAAGCCATTTACGAATTTGAAGTCAAAGACATGCCCGTAACC
GTCGCGGTAGATAGCAAAGGCGAATCCATCCACGCCACCGCCCCGCGCAAAATGGCAGGCG
AAAATCGGCATCATCCCCGTCGAATCTTGAGGCGCCATGCCGTCTGAACACAAAATCTGC
CTTCAGACGGCATTTCGCCCCCGGTTGCGGTACAATCCACCATTTTCATCACTCGGCGAC
40 CCACACCGTGAAAATCCTCATTTTAGGCAACGGACAGGTAGGTTCTACCGTCGCACAAAA
CCTTGCCGCCATACCCAACACGACGTAACCGTTATCGACATCGACGAAAAGCATTGCA
GGAAACAGGCAGCCGCTCGATGTCAAACCGTTTTCGGCAACGGCGCATCCCCCTTCAC
ATTAGAACGCGCGCGCGGGAAGATGCCGACTTGCTGCTCGCGCTCTCCCGCAGCGACGA
AACCACATCGTCGCTGCAAAGTTGCCGCGACCTGTTCAACATCCCCGGCGCATCGC
45 GCGCGTCCGTTCCAGCGAATACCTCGAATACCTCAGCCCCAAGCTCGAAAACAACGAAAA
CGGCAGCCTTTCCATATTCCGCATAACCGAAACCATCAGCCCCGAACAGCTCGTTACCGA
ACAGCTTGCCGGCTGATAGACTGCCCGGCGCATTCAGGTTTTACGTTTTGACGACGA
CCGCGTGGCGATGGTCATCATACAGGCGCGGCGGCGGACTGCTTGTGCGACGCAGCAT
TGCCGACATCGCCCCAAGATTTGCCGACGGGGCGGACTGCCAAATCTGCGCCGTTTACCG
50 CAACAACCGCCTCATCGTCCCCGCGCGCAAAACCGTCATCATCGAAGGCGACGAAATCCT
ATTTGCCGCGCGCGCGGAAAACATCGGCGCGGTACATCCCGAATTGCGCCCCAAAGAAAC
CAGCACCAGCGCATCATGATTGCCGCGGCGGCAACATCGGCTACCGTCTCGCCAAGCA
GCTCGAACACGCATACACGTCAAATCATGAATGCCGCGCGCGGTGCCGAATGGAT
AGCCGAAAACCTCGACAACACCTCGTCTGCAAGGTTTCGGCAACCGACGAAACCTGCT
55 CGACAACGAATACATCGACGAAATCGACGTATTCTGCGCCCTGACCAACGACGACGAAAG
CAACATTATGTCCGCCCTTTTGGCGAAAAACCTCGGCGCGAAGCGGTTCATCGGCATCGT
CAACCGCTCAAGTACGTGATTTGCTCGAAGGCAACAAATCGACATCGTCTCTCCCC

CCACCTCATCACCATCGGCTCGATACTCGCCACATCCGGCGCGGCGACATCGTTGCCGT
CCACCCCATCCGGCGCGGCACGGCGGAAGCCATCGAAGTCGTCGCACACGGCGACAAAA
AACTTCCGCCATCATCGGCAGGCGCATCAGCGGCATCAAATGGCCGAAGGCTGCCACAT
TGCCGCCGTGTCGTCGCGCCGGAACCGGCGAAACCATTATGGGACACCATAACCGAAACCGT
5 CATCCAAGACGGCGACCACATCATCTTTTTCGTCTCGCGCCGGCGCATCCTGAACGAACT
GGAAAACTCATCCAGGTCAAATGGGCTTTTTCGGATAAACCGCCCCATTCCGGACATA
TTGCCGCCAAGCGGTATGGAAGCGGAAATAATGGTAGGTGGGCTTCAGACGGCATCCGCC
CTCCCCGTCAATCCCGCGTAAGCGGGCATCCAGACCTTGGGATAGCGGCAATATTCAAAG
GTTATAAAAGACCCGTCAATCCCGCGCAGGCGGGAATCCAGACCTTGGGATAGCGGCAAT
10 ATTCAAAGGTTATCTGAAAATTTAGAGGTTCTAGATTCCCGCTTTTCGCGGGAATGACGAA
AAGTTGCGGGAATCCAGAACGTGCGGCAACGGCAATATTCAAAGCCGTCTGAAAATTTA
AAAGTTCTAGATTCCCGCTTTTCGCGGGAATGACGAAGTTTCAGACGGCATCGCCCGCCTG
TTTTGATATAGCGGCACCCCCCGACAAAAAACAATCCGGAACGCATCTGACCGTTCCG
GCTTGTTTTTCAGGCGAATCCGCCGCATCAGAACATACTGCGCACGCCCATATTGACCTGC
15 CAAGTCTAGCGCATCGTGTGCATCGAAGACCTTTGCGCCTCAAAATAAAGCTGCCTTCCG
TTGTCCGGCATTACCACGCAAAAAATGAATTGCTTGATATTCCAATGTTTTTATATGTT
TTTATATTGTGATGCGATCAGACAAACGCCCCCTGACATTTGTTTAGACGGCATCGTAT
TGCTAAATTTCTATAAGTATGTATAATGTCCGTTTCCACGCGCCCATCGTCTAGAGGCCT
AGGACACTGCCCTTTTCAGGCGGCAACCGGGGTTTCAATCCCCGTGGGCGTGCCAATTCA
20 AAAACCTGCTTGTTCAGCAGGTTTTTTTATTATGAGTCGTCATTCCCGCAATTTTTTCGT
CATTTCCCGCAAAAGCGGGAATCTAGAGCGTAGGGTTGAAGAAACCGTTTTATCCGATAAG
TTTCCGTGCCGACAGGTCTGGATTmCCGCTGCGCGGAAGGACGGCAGAGGTGGACGA
TGCCGTCTGAAGCTGACAAAGCATTTGATGCCGTCTGAACTTCGTCATTCCCGCAAAA
GCGGGAATCTAGAGCGTAGGGTTGAAGAAACCGTTTTATCCGATAAGTTTCCGTGCCGAC
25 AGGTCTGGATTCCCGCTTTTCGTAGGAATGACGGAATTTTAGGTTTCTGTTTTTGTGGA
TGACGAATAAAGCGTGCCGGTTTATGCTCGCCGCAACACGCGGTTTCAGACGGCATTGCTC
TCTTTTTTCATTATCAGTGGGTGTAGCAACTGTATTTTTACCCCGTCGGGCAAAAATAC
AGTTGCTACGATGCACCCCGCCCTGCCCTGTGCCTTGCTCTGCAATACGGCATATAA
TGCACCACAAACCCCGCGCTGCGGTTTTTCAGACGGCATCGCCGTGCTTTTTTACAGGCA
30 TTAGCCCTTTTTATCGGACGCAATATTAAGGAGGAACAAATGAAAAGCTCTTTTGTGCAA
ACGCTTACCATCGCCGGTTTCGGATTTCGGGCGGCGGTGCGGGCATTTCAGGCGGATTTGAAA
ACATTTACGATGCGCGGCGTGTTCGGAACGTGCGTCATCACCGCGTTACCGCGCAAAAT
ACCTTGGGCGTGTCGGCGGTTTCATCTCGTCCCGACCGAAACCATCACCGCACAAATCCAA
GCAATCAGGGAAGACTTCGACATCCGCGCCTACAAAATCCGTATGCTCGGCACGGCGGAA
35 ATCATCGAATGCGTTGCCGACAAGCTGAAACACTGCAGCTTTGGCAGGCGCGTACTCGAC
CTGTGATGATTGCCAAAGGCGGTGCGCCGCTGTTGCAGGATTCCGCCGTTGCGGCACTG
ACGCGCCTGCTGCTTCCCGATACGGATGTATTGACCCCAACCTGCCCGAAGCGGAAGCT
CTGACCGGCGTGATATTGAAAACCGTAAAGATGCGGAACGTGCGGCAAAAATCCTGCTT
GATTACGGTGTCAAAAATGTCTTATCAAAGGCGGACATTTGAACGGCAGCACAGCGGA
40 CGCTGCACGGATTGGCTGTTTACACAAAATGAAACGTGGAATTCGACAGCCCGCGCTTT
CCGACCGCCACACGCACGGCACGGGCTGCACGTTTTCCGCCTGCATCACCGCCGAGTTG
GCAAAAGGCTCGGACGTTTGCGAAGCCGTACAGACTGCCAAGGCCTACATCACGGCGGCA
ATCTCAAACCCCTTTGGAAATCGGCGCAGGACACGGCCCGGTCAATCATTTGGGCGTATCGG
GACTAACCGTA AAAATGCCGTCTGAAACAAAATGTTTCAGACGGCATTTTTGAGGATTATT
45 CAGGCTTTTTTCGCCAGCATCGTTACAAATTTAAACCGTATCGGATTGCCGTTTTCGTCTT
TGGCATGCATAGAACCAATTCTTCTTTATATTTCGACCAGTTCCCAATCCCGATAATAAT
CCTTCAGCTCGCCCTCTTTAAATTTAAAGGGAACGGCATCGGACAGGGGAAATCCGCCG
TATCCATTGCCGATACAATCAAGTTGTACCCGCCCGCCGCGTATGCGCCTGCATATCGG
CAATCACGTCCGGTACGCGTGCGGCATCAGGAACATCAGCACCAGTGTGCCACAATAT
50 AATCAAACCTCGCCCTGCAAGGCGGCGGCGTTCAAATCATATTCCAGCGTGCGGACGTTCA
AACCCTCCGCCTCTGCCAGCTCCGCCAGTTTGCCAAGGCGGCGGGATTGTGATCGACTG
CAGTAACCTTCAAACCCCTTCAAACCGAGAAACAGCGCGTTGCGCCCTGTCCGCAGCCCA
TATCCAACGCCCTGCCCGCGGTACGGTATCCCGTGCCGCGCGGACCGCAGAATGCGTGG
CACTCATCCCGTATTTTTTGTGAAAATAGTCTGCCGCGCGCAATACAGCGACAAACGGA
55 TTTCCGCATCGTCCGTTTTTCGGTTTGACAGAAAACACCTGCTGCGGCGCAAAACACAAT
CGCCGCCGTCTGCCGACCAAACCTTCTGCCGACCCGTCCGGTGCACGAACCTTCGACATCGC
CCTGCAACACATTCAGGCAGACCCACTCCCTTCTCTAGACGAATAGCCGACAACAAA

CTTCCGGCAGGTTTTTCCACTTTCCATACAGGCATCTGTCCGAAACAAAACAACTCGCCAC
TTTGACCCACTATCCGCTCCTTCaWATTCAAAAATAAAGTTGCACATTATATGCCTATTT
TAATCCGCCGCAATCTTTAGACGGCACGGCGCGCAAACCGCTTATAATCACGCCGGACA
CCACACAAAGGCACAATAATGAACCAAACCGTTTACCTTTACACCGACGGCGCGTGCAAA
5 GGCAATCCCGGCGCGGGCGGGTGGGGCGTGTTAATGCGCTACGGTAGCCACGAAAAAGAA
CTTTTCGGCGGGCAAGCGCAAACCACCAACAACCGCATGGAAGTGAAGTGCCTCATCGAA
GGACTGAAATCGCTCAAACGCCGCTGCACCGTCATCATCTGCACCGACTCGCAATACGTC
AAAAATGGCATGGAAAACCTGGATACACGGTTGGAAGCGCAACGGCTGGAAAACCGCCTCC
AAACAGCCCGTCAAAAACGACGACTTGTGGAAAGAACTCGACGCTCTAGTCGGACGGCAT
10 CAAGTCAGTTGGACTTGGGTGAAAGGACACGCGGGACACGCGGAAACGAACGCGCCGAC
GATTTGGCAAACCGTGGCGCAGCGCAGTTTTCCTGACTGCCGCTCCGGCAAAAATGCCGT
CTGAAAACCGCTAATGGGCTTCAGACGGCATCGTCCCTCCACCGTCATTCCCGCGCAAGCGG
GAATCCAAACCGTCGGGCAACGGCAATATTCAAAGATTATCTGAAAGTTTGAAGTTCTAG
ATTCCCGTTTTTCACGGGAATGACGAAAAGTTGCAAGAATGACGGAGTTTCAGGCGGCATC
15 CGACCGCCCCGTCAATCCCGCAAAGCGGGAATCTAAAACCCCAACGCTGCAAGATTTAT
CAGAAACAACCTGAAACCGAACGGACTGGATTCCCGCCTGCGCGGGAATGACGGGATTTTA
GTAACCGTAGCAACCGCCTGCGCGACGGCTAAGGGGCTTCAGCAACCGTAGCAACTGCCT
GTGTGGGAATGACGGACAATGGGCTTCAGACGGCATCTCTTGCTGCCGCTAAAACAGTT
TGCCGCACAACCTGTTCAAACGCGTCCGATATGTTTCAACACACAGGACGACACATAAAGC
20 ACCTCCCTATGTGTGCTGCTCTGATTTGGAAGGGGTACACCCCTCCCAAATAAAGTCTGA
TCCTGCCGCCCTAAAGGGCGGGTTCACCCGAAAAGGAAATACGATGAAGTGGTACAAT
TAGCGGCAATGCGGACAGACAAATTAACTATAGTGGATTAAATTTAAACAGTACGGCG
TTGCCTCGCCTTAGCTCAAAGAGAACGATTCTCTAAGGTGCTGAAGCACCAGTGAATCG
GTTCTGTACTATTTGTACTGTCTGCGGCTTCGTTGCCTTGTCTGATTTTGTTAATCCG
25 CTATATCAGAAATTACCCTACCGTTTTTTAAACACTTTTCAGGAATAAGGAAAAATGACCG
CCCAACCCCTGCCCATCTGCACGGCGCAAATGAAGACGTTTTGCTGCAAAACCCCAACC
TCCGCGTCATCGCGTCCATAACGACAGCGGTTGCGCTGCATTCTGCCGCGTCATTTGGC
GTAAGCATATTGCCGAAATGACCGACCTTTCGGCAGCGGAACGCGCGCAATTGATGGAAA
TGGTGTACAAAGTCGAAGCCGCTATGCGCCAAGTGTTCCGGCCGGCAAAAATCAACCTCG
30 CCAGCTTGGGCAATGTCGTGCGCACCTGCATTGGCATATTATCGCCCGCTTTGAAAACG
ATGCGTCTTTCCCGCGCGGATTTGGGCAACCCCGTCCGGAACACGGTATGACCCTGC
CGCAAGATTGGACGGAACAGCTTAAAAAGCTGCTTTAAGCCCGCCGATGCCGTCTGAAC
CGTATGAAAGGGAAATTATGACCGAACCGACCTCCCGCCGCGGTTTTCTGAAAACCTGCA
CCGCGCTGCCGCGCGGGGCTGCTTCAGGCTTGCGGCACATCCGCCACATCCGTTCCGC
35 CCCTTCCCTCTTCCCATTCGTTGTGAAAGCCCGAACCGTGCCTCTCCAAACGCCACGCC
GTCAAAGTTGCGACGGCAACCTTCTGCGCTTGTGCTTCTGCTCAGGATTTGCCGAAGACA
CCAACCGCGTCAACACAGCCTTAACCCGCTTTACAATGTGCGTTTTACCGTAACCAACC
AACAGGCGGGCAGCCCGCTTTCCAACGGTTTGCCGGCACGGACACGCAACGTGCCGCCG
ATTTCCAAGAGGTCGCTTCCGGCCGCTGCCACGCCTAAAGTGTGATGGGTTTGCGCG
40 GCGGTTACGGTGGCGCGCGGATTCTGCCGCATATCGATTTTGCTTCGCTCGGCGCAAGGA
TGCGCGAACACGGCACGCTCTTTTTCGGATTACAGCGACGTATGCGCCGTCCAGCTGGCAT
TGTTGGCAAAAGGCAATATGATGAGTTTTGCCGGCCCGATGGCTTATAGCGATTTTGGCA
AACCCGCCCCCGGTGCGTTTACGATGGATGCCTTTATCAAGGGTGCAACCCAAAACCGCC
TGACCGTTGATGTTCTTATATCCAACGCGCGGATGTGAAACCGAAGGCATATTGTGGG
45 GCGGCAACTTAAGCGTCTCGCTCGCTCGCCGGCACGCCTTATATGCCCGACATCGACG
GCGGCATTTTGTCTCGAAGATGTGCGGCAACAGCCCTACCGCATCGAACGTATGCTCA
ATACGCTGTATCTTTCGGGTATTTTGAAGAAACAGCGCGCCATCGTGTTCGGCAATTTCC
GTATGGAAAAAATTCGAGATGTCTATGATCCGTCTTATGATTTTTCTGCCGTTGCCAACC
ATGTTTCGCGCACGGCGAAAATCCCGTGCTGACGGGCTTCCCGTTCCGACACATTGCCG
50 ACAAATCACTTTCCCTCTAGGCGCGCACGCCCCGAATCCGTATGAACGGAAACAGCGGTT
ATTCCGGTCGCGTTTGAAGGCTACCCACACTCGATGCGTCCGCCCTGACTTTGGATACCC
TGCTCCACCGCCGGATTTGCCATCTTCCCGGAAAGCGGTGTTGCCGATATTTCCGAAT
AAACCGCAACCGGACAAATGCCGTCTGAAGCCTTCAGACGGCATTTCCCAAGACGGCGG
CAGATTACAGCAATGCCGAATATCGGCTTCGATTTCTTCGGGCGTAACACTAGGCGCAA
55 AACGCTCGACCACTTCGCCGTCGCGGTTGACGAGGAATTTGGTAAAGTTCCATTTGATGT
CGCCTTCGTGCGCTTCTCTCCAAAGCTGCGAGCTTCAACACGAAATCTTTAAACAGAT
GATTGCCCTTATCTTGCGGTTTGACGGATTTTCAGGTAGGCATACAAGGGCGCGGTATTTG

-11-

CTCCATTGACTTCGATTTTGTGCGAAAATCTTAACTTCGTGCCAAACTTCATCATACACA
 CTTGGGCAATTTCTCCGCTGCTTTCGGGAGCCTGTTTCGCGGAACTGGTTGCACGGAAAAAT
 CCAAAATCTCCAAGCCTTCTGCGGTATATTGTGCATACAGCTTCTGCAAAGCCTCGTATT
 GCGGGGTCTAGACCGCAACGCGTTGCCGTGTTGACAATCAGCAGAACCTTGCCGCGATAGC
 5 CTGACAAAATCAACCGCATTGCCCTTCTGCATCTTTCATTGAAAATCGTAAATACCCATTT
 TTATCCTTATCTGATGTAAACCGATGCCATCTGAAACGTGCTTCAGACGGCATGAAAGCA
 GCAATTGTATAGCCGATTAAAAATAAAAAATCCACATCCTTTTCCATTCCCCTCCCAATCC
 GCAATAAAAAAATGCACCCGAAAACGGGTGCAGTTGCTCATTTTCATACCGCAAACTTAT
 TTGTCGCGGCCGAATACGATTTTAGTGGCTTGGATGCGGACACAGATTGCACCGCCGATA
 10 AAGACCAAGTCAGCTGCCGTACGTACCCAACGCAAGGTATCGAGGATTTCCATTTCGAGG
 AACTCTTCGCTGCGGGCATAACACAGACCGTGCGTGATGGAGGCGTATGCCGTAATCGCG
 CCGACAGGCAGCAGGCTGATGGCAATCATACCGGCCAAGCCGCGTTGAGCAGCCAGAAG
 CCCCCAAGTCATCAGTTTGTGCTCAAACGCGCGTTTCGGTTTCAAATAACGGGCAACCGAGC
 AATACGAAGCCCAATGCCAAGAAACCGTACACACCAAAACAAGGCGGCGTGCGCGTGAAACG
 15 GCAGAAGTGTTCAAACCTTGGATATAGAACAGGGAAATCGGCGGATTGATCAGGAAGCCG
 AATACGCCCGGCACCGATCATATTCCAAAAGGCGACTGCCACGAAGCACATCAGCGGCCAA
 CGCAGGCGTTTCGCCCCAGTCGGACAGGTGTTGGTAAGACAGTGTTCTGTATGCTTCACGG
 CCCAGCAACACCAGCGGCACGACTTCCAAAGCGGAGAAGCAGGCACCGATTGCCATAGAG
 GCGGAGGTAGAGCCGGAGAAGTACAGGTGGTGACGCGTGCCCGGAACGCCGCCCAACATA
 20 AAGATGGCGGCAGCGGCCAAAGTGGAGGCACTGGCGGTACTGCGGCGGACAAAGCCCAT
 TTGTAGAAGACAAAGGCAAGGCGGCAAGTGGCAAAATACTTCGAAGAAGCCTTCTACCCAC
 AGGTGAACCAACCCACCAACGCCAGTATTCATAACGCGCAATCGGGGATTTTTCGCCATAG
 AACAGGCCTGGTGCGTAGAATACGCCACACCGACCATAGAAGCTACGAAGATAGCCAAC
 AGGTTTTTGTCCACGCCCTTTTCTTTAAAGGCGGAAACCGTGCAACGCAACATCAGGAAC
 25 AGCCATAACAGCAGACCGACCATCAAAAGGAGTTGCCAGAAACGTCCCAAATCGAGGTAT
 TCGTAACCTTGGTGTCCGAACCAAGTTAAATTCGGGGGAAGGATGTGCGTCAACGCG
 AAGAAGTTGCCCGGTAAGAACCGCCGACCACGATGAAGAGGGCGATATAGAGGAAGTTT
 ACGCCGGCACGTTGGAACCTTGGGATCTTTACCGCCGTTGACAATCGGCGCGAGGAACAAA
 CCTGCCGTCAAAAAGCCGCTTGCAATCCAGAAGATGGCGGATTGGATGTGCCAAGTACGG
 30 GTCAGGGCGTAGGGGAACCAAGTCCGACATTTCAAAGCCCAACGCCTCGTCAATGCCGTAG
 AAACCCTGGCCTTCGACGGTGTAGTGCGCGGTGAGTCCGCCCAGCAATACTTGTACCACA
 AACAGGGCGACCGTCAGGAAGACGTATTTGCCCAATGCTTTTTGCGAAGGGGTGAGTTGG
 ATTTTGGAAATCGGGTCTTCAGACGGCACTTCCACTTCCTCGTGTTTGGTCAGGAAGGAA
 TAACCCACATCAGCAAACCGATGCCCATCAGCAGAAGAACAACGCTGGTGAATGACCAC
 35 ATATAGTTTTTCAGTGGTTCGGTACGTTGTTGATCAAAGGTTTCGTGCGGCCAGTTGTTGGTG
 TAAGTAAATTTCTCGTCAGGACGGTTGGTTCGAAGCAGACCAAGAAGTCCAGAAGAAGAAG
 TTGAACAGTTTTTTCACGCGCTTCTTGGCTTGGCAATGTATTGTTTTTCATTGCAAAGTGT
 TCGCGAGTGGTTTGGAACTTAGGATCGTCCGTGTACACACCGTGGTAGTAAGGCAGGATG
 CTTTTCGATGGCTTTCACGCGCGTATCGCTGATGACGACGCTGCCGTCTTCTTTCACGCGG
 40 CTTTGATTGCGGTATTTCGTGCGCCAGGCGTGTTTTCAAGACGGCTTGTTCTCGGGGGAA
 ACCTCGTCGAATTTTTTTCGCGTAAGTCTGTTGCGCGGTCAAATCCAACAGGCAACCAAC
 TCACGATGCAGCCAGTCCGCCGTCCAGTCCGGAGCCTGATATGCACCGTGACCCAAAATC
 GAACCGACTTCCATACCGCCGGTAGTCTGCCATGCAGACTGACCTGCCAAAATATCGTCT
 45 TTCGTATCAAGACCTTGCCGGATGCGGAAACGACCTGTTCCGGGGTAAGGCGGGGCTTTT
 TTGTAAACCTCGCTGCCCATATAGCCAAGAATGGTAAAGCATAcCGGGTAC

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 2>:

50 **gnm_2**

CGAGGCGCAGATACAGGTTTTGGAAGATGTGCACGTCAAGGCGAAGCGCGTACCGAAAGA
 CAAAAAGTGTTTACCGATGCGCGTGCCGTATCGACCGTCAGGATATATTCAAATCCAG
 CGAAAACCTCGACAACATCGTACGACGATCCCCGGTGCGTTTACACAGCAAGATAAAAG

CTCGGGCATTGTGTCTTTGAATATTTCGCGGCAGACGGGTTTCGGGCGGGTCAATACGAT
GGTGGACGGCATCACGCAGACCTTTTATTTCGACTTCTACCGATGCGGGCAGGGCAGGCGG
TTCATCTCAATTTCGGTGCATCTGTGACAGCAATTTTATTGCGGACTGGATGTCGTCAA
AGGCAGCTTCAGCGGCTCGGCAGGCATCAACAGCCTTGCCGGTTCGGCGAATCTGCGGAC
5 TTTAGGCGTGGATGACGTCGTTCAAGGGCAATAATACCTACGGCCTGCTGCTAAAAGGTCT
GACCGGCACCAATTCAACCAAAGGTAATGCGATGGCGGCGATAGGTGCGCGCAAAATGGCT
GGAAAGCGGAGCATCTGTCTGGTGTGCTTTACGGGCACAGCA_gGCGCAGCGTGGCGCAAAA
TTACCGCGTGGGCGGCGGGCAGCACATCGGAAATTTTGGCGCGGAATATTTGGAACG
GCGCAAGCAGCGATATTTTGTACAAGAGGGTGCTTTGAAATTCATTCCGACAGCGGAAA
10 ATGGGAGCGGGATTACAAAGGCAACAGTGGAATACAAGCCGTATAAAAAATTACAACAA
CCAAGAATAACAAAAATACATCCAAGAGCATGACAAAAGCTGGCGGGAAAACCTGGCAAC
CGCAATACGACATTACCCCATCGATCCGTCCAGCCTGAAGCAGCAGTGGCAGGCAATC
TGTTTAAATTTGGAATACGACGGCGTATTCAATAAATACACGGCGCAATTTTCGCGATTAA
ACACCAAAATCGGCAGCCGCAAAATCATCAACCGCAATTATCAGTTCAATTACGGTTTGT
15 CTTTGAACCCGTATACCAACCTCAATCTGACCGCAGCCTACAATTCGGGCGAGCGAGAAAT
ATCCGAAAGGGTCGAAGTTTACAGGCTGGGGGCTTTTAAAGGATTTTGAACCTACAACA
ACGCGAAAATCCTCGACCTCAACAACACCGCCACCTTCCGGCTGCCCGCGAAACCGAGT
TGCAAAACCACTTTGGGCTTCAATTATTTCCACAACGAATACGGCAAAAACCGCTTTCTCTG
AAGAATTGGGGCTGTTTTTCGACGGTCTGATCAGGACAACGGGCTTTATTCCTATTTGG
20 GCGGTTTTAAGGGCGATAAAGGGCTGCTGCCCCAAAAATCAACCATTGTCCAACCGGCCG
GCAGCCAATATTTCAACACGTTCTACTTCGATGCCGCGCTCAAAAAGACATTTACCGCT
TAAACTACAGCACCAATACCGTCGGCTACCGTTTCGGCGGCGAATATACGGGCTATTACG
GCTCGGATGACGAATTTAAGCGGGCATTCGGAGAAAACTCGCCGACATACAAGAAACATT
GCAACCGGAGCTGCGGGATTATGAACCCGTATTGAAAAAATACGGCAAAAAGCGCGCCA
25 ACAACCATTCGGTCAGCATTAGTGGGACTTCGGCGATTATTTTCATGCCGTTCCGCCAGCT
ATTTCGCGCACACACCGTATGCCCAACATCCAAGAAATGTATTTTCCCAAATCGGCGACT
CCGGCGTTTACACCGCCTTAAACCAGAGCGCGCAAAACACTTGGCAATTTGGCTTCAATA
CCTATAAAAAAGGATTGTTAAACAAGATGATACATTAGGATTAAAACCTGGTCGGCTACC
GCAGCCGCATCGACAATACTACATCCACAACGTTTACGGGAAATGGTGGGATTGTAACGGGG
30 ATATTCGAGCTGGGTTCAGCAGCACCGGGCTTGCTTACACCATCCAACATCGCAATTTCA
AAGACAAAGTGACAAACACGGTTTTTGAGTTGGAGCTGAATTACGATTATGGGCGTTTTT
TCACCAACCTTTCTTACGCCTATCAAAAAAGCACGCAACCGACCAACTTCAGCGATGCGA
GCGAATCGCCCAACAATGCGTCCAAGAAGACCAACTCAACAAGGTTATGGGTTGAGCA
GGGTTTCCGCCCTGCCGCGAGATTACGGACGTTTGAAGTTCGGTACGCGCTGGTTGGGCA
35 ACAAAGTACTTTGGGCGGCGGATGCGCTATTTTCGGCAAGAGCATCCGCGCGACGGCTG
AAGAACGCTATATCGACGGCACCAACGGGGGAAATACCAGCAATTTCCGGCAACTGGGCA
AGCGTTCCATCAAAACAAACCGAACTCTTGCCCGCCAGCCTTTGATTTTTGATTTTTACG
CCGCTTACGAGCCGAAGAAAAACCTTATTTCCGCGCCGAAGTCAAAAATCTGTTTCGACA
GGCGTTATATCGATCCGCTCGATGCGGCAATGATGCGGCAACGACGCTTATTACAGCT
40 CGTTCGACCCGAAAGACAAGGACGAAGACGTAACGTGTAATGCTGATAAAACGTTGTGCA
ACGGCAAAATACGGCGGCACAAGCAAAAGCGTATTGACCAATTTTGACGCGGACGCACCT
TTTTGATGACGATGAGCTACAAGTTTTAAAGGCAGCCCGCATTTTGTAGAAAACCGCAAT
GCCGTCTGAAAGCCCTTCAGACGGCATTTGTTTTCCCAAACGCATCATCCTGCCGCAAGC
CTATGCCAATCCGTTTTATCGCATCGGCAACTCAAAGAAAAATCCATTTTCATTTCCACGC
45 AGGGAAGCCGGTTTTTGATTTTCGGTTATTTTGGTTGTTTCGGGTAATTTATGAGTCGTC
ATTCCCGCAAAAGCGGGAATCAGTTTTTTTAAAGTTTCAGCCATTTCCGATAAATTCCTGT
GGCTTTAGCTTTCCGGATTCCCACTTTTCGTGAGAATGACGTGGTGCAGGTTTCCGTACGG
ATGGATTTCGTCAATTCGCGCGCAGCGGGAATCTAGACCGTTTCGGTTTCGGTTTTTTTGGT
TAGTGCCGCAACATTAAATTTCTAGATTTCCCACTTTTCGTGGGAATGACGGCGGAGCGGTT
50 TCTGCTTTTTCCAATAAATGCCCCAACCTAAAATCCGTCATTTCCGCGCAGGCGGGAAT
CTAGCATTTCAATGCTAAGGCAATTTATCGGAAATGACTGAAACTCAAAAACCTAGATTC
CCACTTTTCGTGGGAATGACGTGGTGCAGGTTTTCCGTATGGATGGATTTCGTCAATTCGCGC
CAGGCGGGAATCTAGTCCGTTTCGGTTTTTCGGTTTTTTTGGCTAATGCCGCAACATTAAAT
TCTAGATTCCCACTTTTCGTGGGAATGACGGCGGAGCGGTTGCTGTTTTTCCCAATAAATG
55 CCCCCAACCTAAAATCCGTCATTTCCGCGCAGGCGGGAATCTAGTCCGTTTCGGTTTCGG
TTTTTTTGGCTAGTGCCGCAACATTAAATTTCTAGATTCCCACTTTTCGTGGGAATGACGG
CGGAGCGGTTTTCTGCTTTTCCCAATAAATGCCCCAACCTAAAATCCGTCATTTCCGCGC

AGGCGGGAATTTAGACATTCAACGCTAAGGCAATTTATCGGAAATGACTGAAACTCAAAA
AACTGGATTCCCTCTTTTCGTGGGAATGACGTAGTGCAGGTTTCCGTACGGATGGATTTCGT
CATTCCCGCGCAGGCGGGAATCTAGACATTCAATGCTAAGGCAATTTATCGGAAATGACT
GAAACTCAAAAACTGGATTCCCGCTTTTCGTGGGAATGACGCGATTAGAGTTTCAAAATT
5 TATTCTAAATAGCTGAAACTCAACGCACTGGATTCCCGCCTGAGCGGGAATGACGAAGTG
GAAGTTACCCGAAACTTAAACAAGCGAAACCGAACGAACCTGGATTCCCACTTTTCGTGGG
AATGACGGAATGTAGGTTTCGTGGGAATGACGGGATGCAGGTTTCCGATGGATGGATTTCGT
CATTCCCGCGCAGGCGGGAATCTAGACATTCAACGCTAAGGCAATTTATCGGAAATGACT
GAAACTCAAAAACTGGATTCCCACTTTTGTGGGAATGACGCGATTAGAGTTTCAAAATT
10 TATTCTAAATAGCTGAAACTCAACGCACTGGATTCCCGCCTGAGCGGGAATGACGAATTT
CAGGTTGCTGTTTTTGGTTTTCTGTTTTTGTGAAAATAATGGGATTTTAGCTTGTGGGTA
TTTACCGGAAAAACAGAAACCGCTCCGCCGTCAATCCCGCGCAGGCGGGAATCTAGTCC
GTTCCGTTTTCCGTTTTTTTGGCTAGTGCCGCAACATTAAATTTCTAGATTCCCACTTTTCG
TGGGAATGACGGGATGTATAGTGGATTAACAAAAACCACTACGGCGTTGCCTCGCCTTAG
15 CTCAAAGAGAACGATTGTCTAAGGTGCTGAAGCACCAAGTGAATCGGTTCCGTACTATTT
GTACTGTCTGCGGCTTCGTCCGCTTGTCTGATTTTTTGTGTAATCCACTATAAATTTAATC
CACTATATTTTTTGTTCCAAAGTCAAAATATGCCGTCCGAACATTCTGGGCGGCAGACAAA
ACGGCACTGCCCGATAAAGGCACTGCCGTTGTCCGTTTCAAACCGTGAAACATCAGCCCA
AATTAAAGGCTTTATGCAATACCCTGGTTGCCAGTTCCATGTATTTTTTCATCAATCAATA
20 CGGAAACTTTGATTTTCGGAGGTGGAATCATTGATGTTGATACCCTCTTCGGCGAGCG
TGCGGAAGATTTTGGCGGCTACACCGACGTGCGAACGCATACCAAACCGACTGCGGAGA
CTTTGCATACGGTGTCTGTCGCCATCAATAGAAGCCGCGCGGATACTGTCTTGGCGTTCCG
ACAGGATTTCCAAAGTCTGCTTGTAAATCGCCGCGCGGTACGGTAAAGGAAAAATCGGTTG
TGCCTTCGCTGCCGACATTTTGGATAATCATATCGACTTCGATGTTGGCATCGGCAACCG
25 CGCCTAAATCTGATAGGCGACGCCAGGTTTGTCCGGTACGCCGCGCACGTTGATGCGGG
CTTGGTTTTTTTGAATGCGATACCGGTTACGGCAGCTCTTTCCATGTTGTCTGCTCCTCTT
CAAAGGTAATTAAGGTGCCATTGCCCGGCTCTTGCAGGCTGCTCAGTACGCGCAGGCGCA
CTTTGTATTTTCCGGCGAATTCTACTGAACGGATTGCAAAACTTTTGAACCGAGGCTTG
CCAGTTCGATCATTTCTTCAAATGTAACCGTATCCATGCGGCGCGCTTCGGGTACGACGC
30 GGGGGTCGGTTGTGTAAACGCCGTCTACGTCCGTATAGATTTGGCACTCGTCCGCTTTGA
GCGCGGCGGCAAGCGCGACGGCGGAAGTGTGGAACCGCCGCGTCCGAGCGTGAAATAT
CGCCTTCACTGCTGATGCCCTTGAAGCCGGCAACGATGACGACTTTGCCGCGCGTAAGGT
CGGCACGCATTTTTTCGTCAATGCTTTTCGATGCGGGCTTTGGTGTGGGCGGTATCGG
TTTTGAGGCGACCTGCCAGCCTGTGTAGCTTTTGGCATCCACGCCGATGTCTTTCAATG
35 CCATCGCCAAAAGGCCGATGTTTGTTCGCCGCTAGCTAAGACGACGTCCAGCTCGC
GCGGATCGGGATGCTCTTGCATTTTCGTGCGCCAGTGCGACCAAGTTCGGTTTTCGCCG
TCATGGCGGATACGACGACTACGATGTCTGTCCTTCGGCGCGGGCTTTGGCGACACGTT
TGGCTACGTTTTTGTGCGTTTCGGGCGAGCCTACTGATGTGCCGCCGTATTTATGTACGA
TTAACGCCATGTTTCGTGCTTTCTTGTGGGGTGTGTCGGGCGAGCTTGGTTTGTGAAAA
40 AGGGTTATTATTACTATTTTTTACATGGAATTCAAGAACGACTGCGCTTTCCCGCCTGC
CGTTTGACAGCGGTACCGGAAAAACCTGTTCTTTTCAGATTGTTGACAAAATGCCGTCTGA
ACGGTTTTTCAGACGGCATCCGGACGACAATCAGGCGGCGGACAACGCATTTTGTGTTGT
TGCAGAGTTTCGCTATGCCTTTTTTGCGCCAGTGCAACCAAGTTTGCCCAATTTCGTCCAAA
45 CTGAACGGCGCGTCTTCCGCCGTCCCTGTATTTTCGATGATTTTCCCGATGCGGTCATG
ACGATATTCACATCACTGTGCAACCGGAGTCTTCGGGATAATCCAAATCCAAAAGCGGC
ACGCCGTTCACTACGCCCTACTGACACAGCGGCAACGGCTTCGCGGATGGGGTTTTCACTC
AAAATGCCGTCTGAAACCAAGTTTGGCGACGGCGATTGTCAGCGGACAAAACGCACCGGTA
ATCGAAGCCGTGCGCGTACCGCCGTCTGCCTGAATCACATCGCAGTCAATCAAGATTTGT
CGTTACCGAGTTTTTCCATATCCACGACCGCGCGCAGGGAACGCCCGATCAAACGTTGG
50 ATTTCTTGTGTGCGCCCGGACTGTTTGGCCGCCGAAGCTTCGCGGAGCATCCGGGAAGCA
GTTGAGGAGGCGAGCATCCCGTATTCGCCCGTTACCCAGCCTTGGTTTTTACCGCGCAGA
AACGGCGGAGCTTTTTCATCTATGGAAGCGGTACAAATCACTTTGGTATTGCCGCATTCA
ATAAGGCACGAACCGTCCGTATGCGGCAGGAAATGAGGGTGATTTTGATATCGCGCAGG
CTGTGCGGCGCGCGGAGATGCGGATGTAATCAGGCATACTGCCCTCCCGTTAAAAACAG
55 ATAAATTAAGCCCTTAAATATGAAAAATCACATTTAAGGCCCTCAAACGAAATTTTC
TACGCCTCTTCGGCTTTGCTGCGGATAATCAAAGCGGCAGGTGGCTTTGGCGCATTACC
GTTTCGGCAAACTGCCATTAAAGGTGCATCAGCCCGGTACGTCCGTGCGTACCCAAC

ACCAGCAGGTCGGCACCGTTTTTCATCGGCATAATCAACCAAATCCTGCGCCATTTTCACGC
GCACCCCTTATTTGGCAACCAGCAGGTGTTTGACGGTATTTTCCACACCCAGTTCCTGGGCG
GTGCGCTCGGCGGCATCCAAACTTCGTTGCCTTGCGCGACGGCGGCGGCTTCGTAGCTT
TCGTGTTGCAAAAATTCGGGGGCGAGTGCCATATATTCGGCAGGATTGGCAACGTGCACC
5 AAAGTCAGGCGCGCACCGTTGACCCCGGCAAGCTCGGCGGCATGTTTCAGGGCATTGATG
GACGTTTTCTACTGCCGTCAACGGCAACAACCAAATGTTTGTACATATCTATTCTCCTTTT
GCACCGCCTCGCGGTGCCCTCTTGTCGGATGGGCGCAGGGACAGTTTTCGCTGTTTCATT
ATAGACCCGCGCTCGGGCTTTATACAACAGCCGAACAGCCGACCGCTTTCCAGTATAAT
ATGCCGCTTCCGTGCAGTCAGGCATTTTTTGCCGGCTTTCGTTCACTTTTTGATTGACG
10 CAATCTTGACGATTTCGACCATGTCCGACAACGCTTTGACCTCTTCGCGACGCTTCGGCG
GCATCGCCAGACTCTACGGAGACTCTGCCTTGCGCGACTTTTCACAGGCACACGTCTGCG
TAGTCGGCGTGGGCGGTGTGCGCTCGTGGGCGGTGAGGCTTTGGCGCGGACGGGCATCG
GACGTTTGACTTTGATTGATTGGACAACGTTGCCGAATCGAATGTCAACCGCCAGCTGC
ACGCCCTGACCGGCGACTTCGGCAAAGCAAAAGTTACCGCCTTGCGCGAACGCATTACAC
15 AAATTAATCCGCAATGCGAAGTGTGAAATTGAAGATTTCGTTACCGAAGACAATTTGC
CGGAATACTTCGGAAAAGGTTTTGATTTCGTATCGACGCGATCGACCAAGTGCGCGTCA
AAGCAGCAATGGCGGCTTATTTTGTGGAACGCAACAACCGTTTGTCTCAGCGGCGGCG
CGGGCGGACAAAAAATCCGGCTTAATCCAAACCGCGGATTGAGCCGCGTAACCCACG
ACCCGCTGCTTGCCAACTGCGCTACACCTTGCGGAAACGCTACGGATTTCAGCCGCGATA
20 CGAAAGCAATATGCGCGTGCCTTGCGTGTATTGACCGAAAAATATCGTGCCGCGCGAGT
CTAGGGAGGCTTGTTCCGCGAGATGCCGCTCCGCAAGGCTTGTGTCGCGCGGCTACGGTG
CAAGCATGCTCGTTACCGCTTCGTTCCGGCTATATTGCGCACAGGCGGCGGTGGAACACA
TCGAGACAAAAAATAAGCAATGCCGTCTGAAACAGGATTTCAGACGGCATTGAAACAAAC
TATGGTTATGATTTAAGACAACAAAGGATACGGATAAAAAATAACATAAAATATATGATT
25 CCTAATAATATACCAAGTATCGGAGAGCTATTTAATGGAATTCGTTAATAATTTAGTTAT
TTTTTCATTTTTATTACTAATGCTTATTCGATATTTTTGTAGTATATGGTATATACCA
TAAGATACGTTATCGCAAAATATGTATCCTAAGAACAGTTTTATATTATTAGTGGTAAT
ACTTTGCAGTATGTATTACATATATTGCCGTTATCTTGACCAACAAAAAGTAGCTTATTA
TTGCATAGATGAACAATGTATTTCTATTGTTTCATCTATACAAAGATTATGGTATAAACTC
30 TCCCACATATGCGAGAATTTACGCAGGAAAAATATTGTTTAGATTTCAAGTAAGAGCTAA
AAATTACGCTGAATTACTTATGGAAGATGATATATCAATTAGTAAAAAATTTTGGGGAA
TAAATTTATCATTTATGGTTCGCTACCTGTAATATACGGTAATGTAGATAATATTGAAGT
AAAAGAAGCTACTGGTTATATAGATAGATCCAGTACTGATTATATTGCTCAAGAACTT
AAAATTCAGACATTTATATTAATTAAGAGGTTTTAGCAAGAGTGCCGTCAAAATATAGGG
35 CGCATCATCGAATTCGCGAAAGACAAACGCTACGATGAACGTTTCAAGGATTGAAAAAA
GAATCCATAGGCTATCTGAACCGGCATCCCGGTTTGGTGTCCGACTACCTGAAGCGGCA
ATCAAGCTGTGCGTTTCAGAAAAACCAACATCAGCACGCCTAAAACCGTATTCACAACCTG
CTCCTTTTCAAAACATTTGCATTTAAAAGCCGTTATAATGCCGTCTGAACATCTGCCCGA
CCACATTATACGTGAATGTGCGCAGATTGTTTTCTTTGTAACTTATATTAATCCAC
40 TTACCGATTACGCGCATGCCGCCCATCCCTGCCCCATCTGCACCATCCGAGCACACTGTC
GCATGGGTATTCGGCCAACCCGTTACCGATTTGCCCCAGGATTTGTTTATTCCGCCCCGAT
GCATTGAAAGTCGTATTGGGCAGCTTCCAAGGCCCTTTGGATCTACTGCTGTATCTGATC
CGCAAACAGAATATCGACGTACTGGATATTCGATGGTGAAGATTACCGAGCAGTATCTG
CACTACATCGCCCAAATAGAAACCTATCAGTTTGATTGCGCGCGGAATATCTTTTGATG
45 GCAGCAATGCTGATTGAAATCAAATCGCGCCTGCTGCTGCCGCGTACCGAAACCGTCGAA
GACGAAGAAGCCGACCCGCGTGCCGAGTTGGTGCGCGCCTGCTGGCTTACGAACAGATG
AAGCTGGCGGCGCAGGGTTTGGACGCGCTGCCCGAGCCGGACGGGATTTGCGGTGGGCT
TACCTGCCGCTGGAAATTGCCGTGCAAGCCAAGCTGCCCGAAGTCTATATTACCGACTTG
ACGCAAGCGTGCGTGGGTATTTTGTCTCGGGCAAAACACACGCGCAGCCACGAAGTAATC
50 AAAGAAACCATCTCCGTGCGCGCGCAATGACGGCAATCCTGCGCCGTTTGAACGGACAC
GGAATATGCAGTTTCACGACCTGTTCAATCCCAAACAGGGCGCGGCTTACGTGGTCTGTC
AACTTCATCGCACTGTTGGAGCTTGCCAAAGAAGGATTGGTCAGAATCGTGCAGGAAGAC
GGTTTTCGGAGAAATCCGAATCAGCCTCAATCATGAGGGGGCGCATTCAGACGGCATTTC
GGCACACGAGGCGGGCGGATGTGTTCTAATACGCCCAAGCCGCCACCAAAAATCGGGA
55 GACACGCCATATGACCGGCATCATACATTGCTGCTTGACACCGACCTCTACAAATTCAC
TATGCTGCAAGTGGTTCTGACACAGTTTCCGCGAGACGCACAGCCTTTACGAATTCGCGT
CCGCAACGCCTCGACCGTCTATCCGCTTGCCGACATCAGGAAGACTTGGAAGCCGAAC

CGACGCGCTCTGCCAACTACGCTTCACCCACGACGAACTCGGCTATCTGCGCTCCCTGCG
TTTCATTAAAGCGACTTTGTGATTATCTCGAACTCTTCCAGCTCCAACGCCGCTTTGT
CGAAATCGGCACAGACGATAAAGACCGTCTGAACATCCGCATCGAAGGTCCGATGATACA
GGCGATGTTTTTTGAAATCTTCATCCTCGCCATTGTCAACGAACTTTACTTCCGCCGCCCT
5 GGAAACCCCTGCAGTCATAGAAGAAGGCGAACGCCGGCTTCAAGCCAAAGCCGCGCGCCT
CAAAGAAATCGCCGCCGACAAAACCCCGACGAACGCCCTTCCTGATTTCCGACTTCGG
CACGCGCCGCCGCTACAAGCTCGCGTGGCAGGAACACGTCATCCGCACCCTGCTTGAAGC
CGCCCCCGGCATCGTACGCGGCACCAGCAATGTCTTTCTCGCCAAAAAATCGGCATCAC
10 CCCCATCGGCACCATGGCGCACGAGTTCCTGCAGGCATTCCAGGCCCTCGACGTACGCCT
GCGGAATTTCCAAAAGGCCGCGCTCGAAAGCTGGGTGCACGAATACCGGGGCGATTTGGG
CGTTGCCCTGACCGACGTGGTTCGGTATGGATGCCTTCTGCGCGATTTGACCTCTATTT
CGCCAAACTTTTCGACGGGCTGCGCCACGACAGCGGCGACCCTTACGTTTGGGGCGACAA
AGCCTACGCCCACTATCAAAGCTCAAATCGACAGCCGACCCAAAATGCTGACCTTCTC
CGACGGGCTGGACATCGAACGCTCTTGGGCATTGCACCAATATTTCAAAGACCGCTTCAA
15 AACCGGCTTCGGCATCGGCACCAACCTCACCACGATATGGGGCATAACGCCCTTGAATAT
CGTCTTGAACTGGTGAATGCAACGGGCAGTCCGTGCGCAAGCTGTCCGACTCTCCGGG
CAAACCATGACCAACAACAGCACCTTCCTCGCCTACCTGCGCCAAGTGTTGACGTACC
CGAACCCGAAACGCCGTAAACGGGCAGAAAAAGCGCACAAATTCCTGTTTCTGCCGCATAA
AATCTTTTAAATACCGCCTGATTTGAATTTAACCGAAAGACCGAACTTCATGAACCTAC
20 ATCAAACCGTCGAACACGAAGCCGCCCGCCTTTGCCGCCGAGGCATCGCCGACAGCC
CTATTTGTTTTGCAGCCGACCAAAAACGCCGAACACGGCGATTTCCAAATCAACGGCGTGA
TGGGTGCGGCGAAAAAGCCAAACAAAACCCGCGCGAGTTGGCGCAAAGGTGCGCCGAG
CATTTGGCGGACAACGCCGTGATTGAAAGCGCGGAAGTCCGCCGTCCGGGCTTCATCAACC
TGCGCCTCGCCCCGAATTTCTCGCGCAAAACATTGACAGCGCCTTGAACGACGCTCGTT
25 TCGGCGTGGCAAAAACCGACAAAACCGCAAAACCGTTCGTTATCGACTATTCTTCGCCCAATC
TGGCGAAGGAAATGCACGTGCGCCACCTGCGTTCCAGCATCATCGGCGACAGCATTTCCGC
GCGTGTGGCATTATATGGGCAATACCGTTATCCGTCAAACACAGTCGCGGACTGGGGTA
CGCAGTTCGGTATGTTGGTCGCTTATTTGGTTCGAGCAGCAAAAAGACAATGCCGCGTTCG
AGTGGCGGATTTTGGAGCAGTTTACCGCGCCGCCAAAGTGCGCTTTGACGAAGACCCGTG
30 CTTTGGCGACACCGCACGCGAATACGTTGTGAAGCTGCAAGGCGGCGATGAAACCGTTT
TGGCATTGTGGAAACAGTTTGTGATATTTGCTCTCGCACGCCCCAAGCCGTTTACGACA
CGCTGGGCTTGAAGCTGCGTCTGAAGACGTGGCAGGCGAATCGAAATACAACGACGATT
TGACGCCCGTGGTTCGATGATTGGTTCAAAGAGGTCTGGCGGTTGAGGACGACGGCGCGA
AAGTCGTGTTCTTGGACGAATTTAAAAACAAGAAGGCGAACC CGCCGATTTATCGTGC
35 AAAAAACAAGGCGGCGGCTTCCTCTACGCCTCCACCGATTTGGCGTGCTGCGTACCGCA
TAGGCCGTCTGAAGCCGACCGCCTGCTGTACGTGTCGACCACCGCCAAGCCCTGCACT
TCGAACAACCTTTTCACCACTTCCCGCAAAAGCAGGCTATCTGCCGAAAACGTCGGCGCGG
CATTTATCGGCTTCGGCACCATGATGGGCAAAGACGGCAAGCCGTTCAAACGCGCAGCG
GCGACACCGTGAAACTGGTCGATCTGCTGACCGAAGCCGTGAGCGCGCCACCGCTTTGG
40 TGAAAGAAAAAATCCCGAATGGGTGCGGACGAAGCCGCTAAAATCGGTAAAACCGTCG
GCATCGGCGCAGTCAAATACGCCGACTTGAGCAAAAACCGCACCGACTATGTGTTTCG
ACTGGGATGCCATGCTCTCGTTTGAAGGCAACACCGCCCCCTATCTGCAATACGCCTACA
CCCGCGTGCAAAGCGTGTTCCGCAAAGCAGGCGAATGGGATGCAATGCGCCAACCGTTT
TGACCGAACCGCTGGAAAAACAGCTTGC CGCCGAGCTGCTGAAATTTGAAGACGTACTGC
45 AAAGCGTGGCGGACACGGCGTATCCGCACTACCTCGCCGCTACCTCTATCAAATTGCGA
CCCTGTTTCAGCCGCTTCTACGAAGCCTGTCCGATACTCAAAGCCGAAGGCGCAAGCCGCA
ACAGCCGCTGCAACTGGCAAAACTCACCGGCGACACGCTGAAACAAGGCTTGGATTTGC
TGGGCATCGATGTGTTGGACGTAATGTAAAACCGCACCGCCCGATTGCGGACAACAGCCT
CGCCATCCTTATCCGAATCTGAAAAAGCGGCGCGATACACCGTATCCGCCGCCCTCCC
50 AAAATGCGAAACAAACAAACGCCAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA
AGCAAGCAAAAAATTATAACCCCTTCTGCGGACGACGCACTTTCCGCGCGGCGCATT
CCCCTTTTCCCGCCCCCTCAAATCCGCCTTTTCTTCAGGCAGGGTTTCAGCCCGCCTCTTT
TCCCTGTTTTCTTTCCCGACACGCGTGCCTCCCCCTGCCGCACTGTGCTGCACTTTTC
GCGCCGCGACGCGATCGTTCCGCCATCCGGTTCTCTGTTTTACATACCCCTGTTTCAGAA
55 AGAAATGCAGATGTTTCAACACACAGGACGACACATAAAGCACCGCCCTATGTGTTGCC
TGATTTGGAAGGGGTTACGCCTCCCAAATAAAGTCTGATCCTGCCGCCCCGAAGGACAGA
TGTCCGAGTGGCGAAGTTTCAACCGAAAAGGAAATACGATGAATATTCACACCCTGCTCT

5 CCAAACAATGGACGCTGCCGCCATTCTGCGGAAACGGCTGCTGCTGTCCCTGCTGATAC
TGCTTGCCCCCAATGCGGTGTTTTGGGTTTTTGGCACTGCTGACCGCCACCGCCCGCCCGA
TTGTCAATTTGGACTATCTTCCCGCCGCGTCTGATCGCCCTGCCTTGGCGTTTCGTCA
AAATTGCCGCGGTATTGGCGTTTTGGCTGGCGGTTTTGTTTGACGGGCTGATGATGGTGA
10 TCCAACCTCTTCCCTTTTATGGATCTCATCGGCGCCATCAACCTCGTCCCCTTCATCCTGA
CCGCCCCCGCCCTTATCAGATAATGACCGGGCTGTTGCTGCTGATATGCTGGCGATGC
CGTTTTGTGTTGCAGAAAGCCGCCGCAAAACCGACTTCCGGCACATTGCCGTCTGCGCCG
CCGTTGTGGCGGCAGCCGGCTATTTACCGGCCATTGAGTTACTACGACCGGGGTCCGA
15 TGGCCAATATCTTCGGCGCAAACAACTTCTACTACGCCAAAAGTCAGGCGATGCTCTACA
CCGTCAGCCAGAATGCCGACTTTATTACCGCCGGCCTGGTCGATCCCGTCTTCCCTCCCT
TGGGCAATCAACAGCGTGCCGCCACGCATCTGAACGAGCGGAAATCTCAAAAAATCCTCT
TTATCGTCGCCGAATCTTGGGGGTGCCGGCAATCCCGAACTTCAAAACGCCACTTTTG
CCAACTGCTGGCGCAAAAGACCGTTTTTTCGGTTTGGGAAAGCGGCAGTTTTCCCTTCA
20 TCGGCGCGACGGTGAAGGCGAAATGCGCGAACTGTGTGCCTACGGCGGTTTGGCGGGGT
TCGCACTGCGCCGCGCGCCCGACGAAAAATTTGCCCGCTGCCTCCCCAACCGTTTGAAAC
AAGAAGGTACGCCACCTTTGCGATGCACGGCGCGGGCAGTTCGCTTTACGACCGCTTCA
GCTGGTATCCGAGGGCGGGCTTTCAAGAAATCAAACCGCCGAAAACCTGATCGGTAAAA
AAACCTGCGCCATTTTCGGCGGCGTGTGCGACAGCGAGCTGTTCGGCGAAGTGTGCGCAT
25 TTTTCAAAAAACGACACAAGGACTGTTTTACTGGATGACGCTGACCAGCCACGCCGACT
ATCCCGAATCCGACATTTTCAACCACAGGCTCAAATGCACCGAATATGGCTGCCCGCCG
AAACCGACCTCTGCCGCAATTTACGCTGCACACCCAATTCTTCGACCAACTGGCGGATT
TGATCCAACGCCCCGAAATGAAAGGCACGGAAGTCATCATCGTCGGCGACCATCCGCCGC
CCGTCGGCAACCTCAATGAAACCTTCGCTACCTCAAACAGGGGCACGTCGCCTGGCTGA
30 ACTTCAAAATCAAATAACAACATGCCGTCTGAACGCACCAACAGCCTTCAGACGGCATT
TTGCAGACAGACCGACCTTCAAGCCCACTTTTTTTCATCATCTCCGATAAATTGCTTTGT
ATAGTGGATTAAACAAAACAGTACGGCGTTGCCTCGCTTAGCTCAAAGAGAACGATTC
TCTAAGGTACTGAAGCACCAGTGAATCGGTTCCGTACTATTTGTACTGTCTGCGGCTTC
GTCCCTTGTCCCTGATTTTTTGTAAATCCGCCATAAAGACCGTCGGGCATCTGCAGCCGTC
35 ATTCGCCGCGCAGGCGGGAATCCAGAACGTGGAATCTAAAGAAACCGTTTTACCCGATAAG
TTTCCGCACCGACAGACCTAGATTCCCGCCTGCGCGGGAATGACGGGATTTTAGGTTTCT
GATTTTGGTTTTCTGTCTTGTGGGAATGACGGGATGTAGGTTTCATAGGAATGACGTGGT
GCAGGTTTCCGTATGGATGGATTGTCGTTCCCGCGAAAGCGGGAATCCGGAAACCCAAA
GCCACGGGAATTTATCGGAAAAACCGAAACCGCTCCGCCGTCAATCCCGCGCAGGCGGGA
40 ATCTAGGTCTGTGCGTGGGAAACTTATCGGATAAAACGGTTTTCTTCAGATTTTACGTTT
TGGATTCCCACTTTTCGTGGGAATGACGGGATGTAGGTTTCGTAGGAATGACGTGGTGCAGG
TTTCCGTATGGATGGATTCCCTCTTGCCTGAGGCTGACAGATGCCGTCTGAAAGACTTT
CAGACGGCATAGCTTTTTCTCTTTGAATTTATAGTGGATTAAACAAAATCAGGACAAGGC
GGCGAGCCGACAGACGTACAGATAGTACGGAACCGATTCACTCGGTGCTTCAGCACCTTA
45 GAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCCGTACTGGTTTTTGTAAATCCACG
ATAAATTTGCCACAAAAAGCTGCCTCAAATGAATACCCGGGCAGCTTTTTGTTGATATG
ACTCCAATCAGCGGTGTTGCGGATTGTAACGTTTTTCCAAACGCAGGAATATCCAGCCTA
AGAAAGTCGTATCAACAGATAAATCAGGGCGACGGTGTAAGCGGTTCTTCATAAACCG
AATACCGGCCCCGTAATCGTATCTGAACATACGCCAACTCCGCCACAGCAATGACCGACA
50 GCAGCGAGCTGTCTTCAAGAGCGTGATGAACTCGCTCGCCAAAGCGGCAGCATGCGGC
GCAATGCCTGCGGCAGAAATCACATAGCGCATCGCTGCGGATAGGTACGCCCCAAAGAAC
GCGCCGCTCCATCTGTCTTGTCTATAGACTGGATGCCCGCGCGGAAAATCTCACAGA
TATACGCCCCCGAGTTGGCGATCAGTGCCAAAGAACCGCAATCAGCGGCCCGTATCCGC
GACGCAGCGCGATTGCCGCTCGCCGCTGACCAAAATGCCGTCTGAAGGATGGACGAAAA
ACGGAACACACATACGCCCAAATCACAATCTGCACAAACAGCGGCGTACCCCGGAACA
55 CGGTAACATACAGCAGCGAAACTTTACGCAACGCCACGCCAGCAGCGCATCGGCGCAC
CGGCTTTTTTCAAGTGAATCAGGCGCGCAACGCCAACAACAGACCCAATACCGAACCGC
CCGCCGTTGCCACGACCGTCAGCCCCAAGTTCGTGAGTGCAGCGTAAAGAAACATCCAGC
GGTATTGTAATAATGTCAAAACGAAATCCATAAACCGTCCGTATCAAAACCGGCGG
AACTGCCGCGGTTGCAAAATAATCCGCCATTTTACCGTAAACCGCGCCGCTGAACTTTT
60 TTATCGCGGCAGACGGCGGTTGCGCGTCTCCGCAAAATGCAGGGCGCGCGGTTTTCAGA
CGGCATTTGCCGTTCAAAGCCGTGCGGTGTCTTTACCAATGCCCAACCATTCGCCACG
GCATCCATCCAATCTTATTGCCCCCGCGCTCCTGCCTGCTCGGCGGTACGCCACGGC

GCTTGGCGATTTTTGTAGCTTTCCACAATCCTTTGCGTTCCTTTCCGCTGAATTTGAGCG
TCGGCATAATCGGCCAAATCCGCTTATCCTGCTGTTCTTTAGCATAACTTTTATAATGC
CACGCCGCCCCGTCTGACCTGCATCAGGTTCAAATCGGTTTTGCCGACAGAAACCTGC
GCCACTTCGCGCTGGTAGCGGTGCGTATCGAACACGCGCAGCTGACTTTCCTGCCTTCC
5 GCGCGCGCGCGCAGGTTGTGCGCGGAACGCGTGCCGTAAGCCTGTTTCATCTCCGGCGCG
TCGATATACGCCATCCGGATTTTGTGTTTCGCGCCGTGCGCGTCGATAACGTGAAGGGTG
TCGCCGTACATAGACTTTGGACACCGTGCTGTGTAGCGGTGGCCGGATTTCGCCGATGCT
CGGCGGCGGGCGGGCGCGTCGGAACCCGCGTCCCCTGCCGCGCGGAGTACGTCGAGTACG
GCAACCGCGCTCCGACCGCCTCGCTGCCGTACCCCGTATAACCCAAACGCACCCAAAAGC
10 GACAGGGCGACGGGAAGCCATTTTCATGATTTTTTTTAACTGTCATATTTTCAAATGCCGA
TGCCGTCTGAACATATCGGAATCGGATTTTCAGACGGCATCTTAACGTGAGGATTACCCCTT
GGCAGGGATAGATGACTTTCGCACCCCTCTTCCGTCCCCAAAATCAACACATCGGCGGCAT
CGCGGGCGAATATGCCGTTTTTCGAGCACGCGGTGATTTTGTGATTTTCGTCTTCCATCG
TCAGCGGCTGATCGATATTCAAGCGTGGACATCGACGATTTGGTTGCCGTAAAACGTGG
15 TGTAGCCGATACGCAGTTCCGGCTGTCCGCCATAGCGAGCAGTTTGCGCGAAACAGAG
AGCGCGCGCTTTCGACGACTTCCACAGGCAGAGGGAATTTGCCCAAACGTGAAACATATT
TGCTTTCATCCGCAATGCAGATGAATTTTTCGGACGCGCTGGCGACGATTTTTTCGTTGA
GGTGCGCGCGCGCCACCGCTTTTAACTATTTCAGGGCGTGTTCACTTCATCCGCACCGT
CGATATAGACCGCAACCCCGTACTTTCGTTCAAAGAAACGACGGGAATATCGTACTGGG
20 CAAGCAGTTTCGCCGATTTTTTGGAAAGTAGATACCGCGCCTTTGATTTTTTTCGCCGTCT
TACCCAAGGCTTCGATGAAAAAGTTGATGGTCGAGCCGGTACCGATGCCGATATATTCAT
TTTCGGGTACGAATTCGACTGCTTTTTTCGGCGCGATGCGCTTGAGTTCGTCTTGTGTCG
TCATATTTTTTGTCTTTGGGAAACCGTATCAACAAACAGCCGCATCTTAACATTTTTTT
GCACGTCTGCGCGCGGTTCAAATGCGTACCAGCAATACCGCGCGCTGCGCTCTATG
25 CCTTCCATCCGCCCGAGATAGCCGAGTTTTTCGTTGGTTTTGCCTTTGATGTTGACGCAC
GAAATGTCTATGCCCAAATCGCGGCGATGTTGGCACGCATTTGCGGAATGTGCGGCGCG
AGTTTGGGTTTTCTGTGCAATCACGGTCGTATCGACATTGACCGCTGCCAACCTGCGCC
TGAACGCTTTGATACGCCGCACGCAAAAGGACGCGGCTGTCCGCATCTTTGAACTCTGCG
GCGGTGTGCGGGAAATGGCTGCCGATATCGCCCAAACCTGCCGCACCGAGCAGCGCTCG
30 GTAACGGCGTGCAGCAGCGCATCGGCATCGGAGTGTCCGAGCAGCCCTTTTTCAAATGGG
ATTTCAAATCCGCCAAGTATCAGCTTCTGCTTCGGTCAGTTGGTGGACATCGTAGCCC
TGTCGATACGGATGTTTCGTATCGTTTGTGTTTCTGATGTTTTGAATTGAAGTTCAGAC
GGCATCGAGCAGCAGCTGACGATGTATGCGTCTGCGGCTGCGTCAGTTTCAAATTGCG
CAGCTGCGCTGTATCAGTAGCGGACGCACACCCAATTTTTCCACGGCGGACGCTTCATC
35 GGTAATGCCGTCCAAGTTTTCCGACGCAATGCGCGGTGCAGCAGCCGCGCGGAAAAG
CTGCGGCGTTTTCGCGCTGCCAAAGGCTCGTCCGCTCGACGGTTGCACTAATGTTCCACC
GTCCGCGCACTTGAGCGTATCGGCAATGGGAATTGCCAAAATCCCGCCTTCGGCGGCGTT
GCCCCCTGTTCTATCAACCGCGTCAAAGCTTCAGACGGCAGGCAGCAACGCGCGGCATC
GTGTACCAGAATATTGTGCGTTTCCGCCGCCAAACCGGTTTCCAACAGTTTGGCACACC
40 GTTGCGGACGGTTTCGCGCGGGTCTGTCCGCGTTTTTCCACACCCGAACCTGTGGAAA
TGCCGTCTGAACCTTATCGGCAACGTGTCTTCGGGCGAGACGACAACGACGGTCAAATC
GACGGCCTCATGCCGTTCAAAAATCCCAATCGTATGTTCTAAAACGGTTTTGCTTCCGAT
TTCGACATATTGCTTGGGTTTGTCCGCACCGAAACGCGCCCGATGCCGGCGGCGGGAAT
CAGCGCGATATTTTTGCGCTTCATGCGTCCGTCCCGCGTTTTTCAGACGGCACGGCTTCC
45 TTGCGCCAGATACAGGCTTCGCCCAAGCCGTCCAAATATTGCCCGTGGCGCGCAACTCG
TTTTCGTCCGCCCTGATGACTTTCAGTTTGGCGCTGCGTTTGGTTTCCGTATGACCACG
GGTTTGGTTTTCCATTTTTCTCTGCGGCCGACCCATCAGGTCGAACCTGCCGCCGCTC
ATAGCAAGATAGACTTCGCCCAAAGTTTCGAGTCGATCAATGCGCCSTGCAGGACGCGC
TTGCTGCGGTGACGGAAAAACGGTTGCACAAGGCATCCAGGCTGGCTTCTGCCCGGGG
50 AACATTTCCGCGGCCATCGCCAGGGTATCGGTAACGGTACAGCCGAGTTCTCAACGGTC
GGCAACCCCATCCGGCGGAACTCCATATTGAGGAAGCCACGTCGAATTTGGCATTGTGG
ATAATCAGTTCCGCAACCGCGCAGGAAATCGGCAATCTGCCTGCCGACCTCTGCAACGGC
GGCGCGTTTTTCCCTTCCAAAACCTGTATCGTCAAGCCGTGGACGCGTGCCGCTCTTCG
GGCATATCGCGCTCGGGGTGGACATAGAGGTGCAGGTTTTTGTGCGTCAATTGGCGGTTG
55 ACCATTTCCAAACCGGCAAACTCGACCAAGCGGTGCGCGCGCTCGGCATACAGACCGGTG
GTTTTCGGTATCGAGGATGATTTGGCGTGTGTCATATCGGTGTCTTCTTCTATCTTCGT
AAATTGCTTATTTTTTAAGCAATGTATTTTTCTGTTTTCAATTCACAAACCCACT

TATTCACAGTGTGTTTCAACATTGGGCAGGCGGATTGTGTATTTTGGGGACAATTTTTT
CAGACGGCATTCAAGGTTTTTCTGATTGCCGCCGCGCCTAAAAACCGCTTTTCGCGCT
TAATCAAAAATACCGACAACGGAATATTGCCCAAAGCGACAATCAGATACAACAAGGAAA
TGCTGTCAAACAAAACAGCAACACCGCGCTCAAAACGGCAGCGGAAACCATAAAAATAC
5 CGTTAACGATATTGTTGGCGGCAACGGCGCGGGCGCGGAAAGTCTCGCTACTGGCGGTTT
GCAGCCAGGTATAGAGCGGAACGGAGAAAAATCCGCCGAAAAAGCCGATCAGCGTCATCA
CCGCCATCACGGGATATGCCCATCCTTGCGATAAAAAACAAAAATGCCGTTTCAGCCCTT
CAAAACGGTGTCCGTGCGTCAGCCACACCAAAACCAAGCCGCAACCGTCAAACCCAACG
CACCAACCGTTACCCAAGCCAACATCAGGCGTTCCTGCTGAACTTGGCACACAGTACCG
10 AACCGGCGGCAATACCGATGGAAAACAGAGCAAGCATCAGGTTGAAAACATTGTCGTTGC
CGCCAGATGGATTGCGGTAAAGGTCGGCAGTTGCGTGGTATAAAACCGCGCCGACAAACC
AAAACCACGAAATACCGATAATGGCGGTAAAAACGGGCTTGTCGCCGACCGTTTTACGCA
GCAGGGATTTTGTGCCACGGACAATATCCACTCAATTTGTGTATCGGCAGCCTTGCGCG
GTACGGACGGCATAAACAGGCTGCCGACCGTGCTCCGACGGCGACCAGCAAAACAGTA
15 TCCCGACAATATAAGCGGGTACACCTGCCACCGCGCTTCCAAAAATCTGACCGAACAGGA
TGGCGACAAACGTACCCGATTCAATCAGGCTGTGCCCATCATCAACTCTTTGTCTGTCGA
GATAATCGGGCAGGATGGCGTATTTACGCGGCCCGAACAGCGTCGATTGCGCGCCCATGC
AAAACAGACAGCCAAAAGCAGCGGGGACAGCCGATATAAAACCGGTATGCCGCCACCG
CCATAATGATCATTTCCAGCACCTTGACCCAACGCGCCAAAACGGCCTTGTCGAATTTGT
20 TACCCAACCTGCCCGACAGCGAGGAAAACAGGAAATACGGCAAAATAAACAGCAACGCGC
CCAAGTTCAACATCTGTCCGGCAGGCAGGAAGCCGTTTTGCCCAAACCGTAAAACCCAA
TCATCACAACAGCGCGGTTTTGAACACATTGTCGTTGAACGCGCCGAGAACTGCGTAG
CGAAAAGAGGTGCGAAACGGCGGCTTTTAACAGTCCCAAACCGCCTTTTTTAGCGTACA
TCGTTTTCCCTCTCTTTTTCAATCAGTTTACTTGTCTGAATCATCATCCATCAGGATGCGG
25 TGCGCCGGCCCTTCCAAGTCGTCAAACGCGCTTTTTGCCCGACCAACAAAAAACAG
CCGATGACAAACGCCAAAATAATGCTGATGGGCACCAATATAAACATGCTTTCCATCACA
TATTCCCTGTCAAATCGTTCAAACAAAAGTCTGCCCGACACGGTCAGATATTGTTTGC
GCAAAGTTCGACGGGAGCTTCGTCAAAAAACAGCTCGATACGGTCTTTGACCACGCGCC
AATATTGGGGGATTTCCGTCTGACCGAACGGCGACAGGACATGATTTTCCATTCCGCCTT
30 CAAGTTTGACGGCAAAACGCCCGCTTTGCGGCCGTGCTTCCGATTGTCGTCGGCAAGCA
GGATGAAAAAGCCTATATGCCGTCCCGATTGGTCATGAATACTGAAATAATGCATAAATT
TCCACCCCGCCTTTTTTTCAGACGACACCAACTAAAAACAGGGCGAATGTACCAGTTTGG
CGGGAAGAATGCAAAGAAATTCTCCCTCCCCCAGCCGAAAAACACCGGCAACCCGCATATC
CCCTTTTTTCCGTCAAATGCCTGACTTCCGCCATTTTCACGCAACGCCCGATTAAAGC
35 CAAGCAATTGCAAAGATTTTTGCTAGAATAGCCTGCTTCTTTATCAACCTTTTCAGAC
GGCCCCACTACTTTCCCGCCAGGAAGGCAAAACGGATTTCGCGACGAATCCGGTTAGTAT
CCGTGTCCGATTCCAATGCCGTCTGAAACTTTCCGGAGTAAGAAAATGTCCCAAAAATTG
ATCTTGGTTTTGAACTGCGGCAGCTCGTCCCTCAAAGGCGCGGTCTGGATAACGGCAGC
GGCGAAGTCTGCTCAGCTGCCTTGCCGAAAAACTCAACCTGCCCGATGCCTACATCACA
40 TTCAAAGTAAACGGCGAAAAACACAAAGTCGATCTGTCCGCACATCCCGACCACACCGGC
GCGGTGGAAGCCCTGATGGAAGAACTCAAAGCCACGGCTCGACAGCCGCATCGGCGCC
ATCGGCCACCGCGTCGTACGCGCGGCGAACTGTACAGCGAATCCATCCTCGTTGACGAC
GAAGTCATTGCCGGCATCGAAAAATGCATCCCGCTCGCCCCCTGCACAACCCCGCCAC
CTCTTGGGCCTGCGTGCCGCGCAAAGCATTTTCAAAGGCCTGCCCCAACGTCGTCGTATT
45 GATACCTCCTTCCACCAACCATGCCCCGAAGTCGCTACAAATACGCCGTTCCGCAAGGAG
TTGTATGAAAAATACGGCCTGCGCCGTACGGCGCGCACGGTACCAGCTACCGCTTCGTC
GCCGACGAAACCGCGCGCTTCTCGGCAAAAGACAAAAAGACCTGCGTATGGTCATTGCC
CACTTGGGCAACGGCGCGTCCATTACCGCCGTGCGCAACGGCGAATCGCGCGACACAGT
ATGGGCCTGACCCCGCTGGAAGGCTGGTAATGGGTACGCGCAGCGGCGACATCGATCCT
50 TCCGTATTGCGCTTCTCGCCGAAAAACGCCAATATGACCATCGCCCAATCACTGAAATG
CTGAACAAAAATCCGGTCTGCTCGGCATTTCCGGCCTGTCCAACGACTGCCGACCATTT
GAAGAAGAAGCCCAAGGGGCATAAAGGCGCGAAATGGCCTTGGATATGTTTATCTAC
CGCCTTGCCAAATACATCGGCAGTATGGCGGTTGCCGAGCGGTTTGGACGCACTGGTC
TTTACC GGCGCATCGGCGAAAACTCCGACATCATCCGCGAACGCGTGATCGGCTACTTG
55 GGCTTCTCGGTCTGAACATCGACCAAGAAGCCAACCTGAAAGCCCGCTTCGGCAACGCC
GGCGTGATTACCACTGCCGACAGCAAAGCCGTTGCCGTGGTCATTCCGACCAACGAAGAG
CTGATGATTGCCACGACACTGCCCGTTTTGAGCGGTCTGTAAGGTTTTATCCGCACACGA

ACTGCCTCCGGAAATGGAGGCAGTTTTTTTTATCCGGCTTCCATGCTTAAACAGCACTGC
CTCTTTTCAGACATTGACGGTTGCAGCCGCTTACCTGAACCTTATAGTGGATTAAATTTA
AATCAGTACGGCGTTGCCTCGCCTTGCCGTACTATCTGTACTGCTGCGGCTTCGTGCGC
TTGTCTTGATTTAAATTTAATCCACTATAATGATTAACATTTTTTAAATCATGTTATTAT
5 TTTCCATAAAATACATGACATTAAGATGTTTTTCCACAAAAGATACACACACCGGCAAAAC
ACCGGCTGTGTTTATCTTTTCTATGCCTATTTTTTAAATCATCGTATTTTTTATCTTTTAA
TTTCAATACGCAAACTAACTTATACACACGGTTTTTACATCTTTAGACTGCTTCCGTGTG
TATAGTGGATATTGCCGTTTTCTTTCTGACAAAAATGCCGTCTGAGAACTTCAGACGGC
ATTTGAAACATCGGAATCAGCGGTTTTGTTTCATACCACTCGATAAACTTGTCTGCTTTGA
10 CAAAACCCAGCAGCGGCTCGCTGCGGCTGCCGTGCGAGCGGACGACAAACACGCCCGGCG
GCCGAACAGACCGTATTCCTTCAACAACGCCGTGATGTTGCGGCGTGTGGCGGTTACGT
CGATTTGGAAAAAGCGTTCCATATCGACTGCCTGATGCACTTCCGGCTGATTGAGCGTGT
AAGCCGCCATTTCTTTGCAGGAAATGCACCAGTCGGCATAAAAATCCAAAACGACGGGTT
TGTCGGGATGTTCTTTCAACGCCGTATCCATCGCTGCCTTCAGCGCGGCAGTATCGGCAA
15 ACATTTTGCCGTGTTCCGAAGATTTGCCTGCTTCGGCTGGTGGATTGAGGGTCAGGAAAT
GGTGCAGCGCGGTGCTTTTTGCCGTTTGCGCCCTGCCAGCCGAACCACGCGCCGCTATCA
GCAATATACCGCCCAATGCGAATGCCACAGCTTTCGGACGGCGTTTTCTGCCTGCGTCCGT
TGACCAGCAGCATAAAGGCAGGAACAGCATCAGCAGCGTGTACAGCGCGACGACGAGAT
AATAGGGCAAGTCCGGCGTGGCGAGGTAAACGGCGACGGCTAGCAGGATGAAGCCGAATG
20 CGTATTTGACGGCATTCATCCAATCGCCTGCCTTAGGCAGGATATGCCCGCCGAACGTGC
CGATGGCAATCAGCGGAACGCCGGTGCCCAACGCCAAAGTGTAAGTGCCAAACCGCCTA
AAACCGCATCGCCCGTCTGACCGATGTAGCCCAAAGCAAATGCCAGCGCGGGGCGACGC
ACGGCCCGACAATCAGCGCGGACAATATGCCCATAATAAAGACGGAAACGATTTTACCGC
CTGAAAGCCTGCTGCTTTGATTCTGAAATACGACTGCACGGCGTTGGGAAGCTGGATGT
25 TGAACAGCCCGAACATAGACAGTGCCAAGACGACCATTAAAGCCGATGCCGCCAATACCA
CCCAAGCCTGCTGCAACCATACGGTCAGCAGTGCGCCCGTCAGTCCGGCAACAATGCCGA
CCAGCGTATAAGTCAGAGCCAAACCTGAACATAAACGACGGACAGCACAAACGCCCGCG
CCTTGCCCGCCTTTTTGTGCGCCGACCACAATACTGGAAACAATCGGCAACAGGGGATACA
TACAGGCGGTAAACTCAGGCCCAAACCAGCGAGAAAAAACGCCAAAAGATTGGCGTTGA
30 GCGTATCCCAAGACAGCTTGAAACGGCTGTGCGCCGCCCTCATCCCCCTTCGGGGGCGGCA
GCGCCCCGCTGCCGTTTTGAGAGGAAGGCTGCAAAAAGCGGTCTTTGGCGGATGCCGTT
CGTCGGTTTGCGGATGGTAAGTGCCGTTGCCGAAAATATCAAACTCGGTATCCACGGGCG
GATAGCACACGCCGGCTTCGGCACAGCCCTGATAGGTCAAACCAATTTATACGGTTTCGC
CGACAGCCTTTGCATAAGGAAAGGCAACCTGCGCCTCGTGATGGTAAACCGTCTGCCTGC
35 CGAAAAATCGTCTTCTCTCTTCGCCCTTGCTGAAAGAAGGCTGTCCCAACAAATCCG
CCGGATCGGTCTGCCGACGATTTTCGCTGATACATATAGTATCCGTCCGCAATCCTGA
AACGGACGTTACACCGTCTGTCGGCAACGGCAAGCTCCGGCACGAATGCCCTTTTCCGGCG
GCAGCAGATCGTTCGCATCCAGCGCGAAAGCTCGTCCGCACAACATCAAAAATACGGCGA
ACAGGCAAATCAGTTTTTTCATAATCGAATCCGTTTCAGACAAATAATTTGTCTGCATTA
40 TAAATGGTAAGGTTGACGGTGGGATTTAATTTATGTAAAACCCGCCATTATCCGAACCTA
TTTCCATAAACATCTTATCGAACCCGCCATGTACGATGTCAATACCCACGATGTCCGCCG
CTTTTTCGCCCGCGTGTGGCAGCAGCGGCTCAATCCGCTGCAACTGAGCGCACTGGAACA
GAAAGCCCTCCGCATTTGTCGAAGCCCATCCCGAATACCACCGTTATCTCGAACGCATCGA
AGACCATCTGGACACCGACTGGCTGCCGAAAAACGGCGAAAGCAACCCCTTCTTGCATAT
45 GTCGCTGCATCTGTCCGTCCAAGAACAGGCGGGCATAGACCAGCCGACGGCATAACGCGC
AATCCACGACACCCTGTGCGCAAACGCGGCTGGCTGGAAGCCGAACACGAAATGATGGA
GGCACTGGCGGAAACACTGTGGACGGCGCAACGCTACGGCACCGGTTTGGATGTCAATTT
CTACATGACCCGACTGCGCAAACATCGGCTTGGGTGCAGAAGATCAAGCCAGATTGAA
CCCGCATGAAATCGCCTGACCATAACCAACCGCCTGCAAAATGCCGTCTGAAGCGGAACAA
50 CCCCTTTTACAGCGGCATTCATTTTCCCCCAATCATTTCCACAACGCCTTTTTTACGCATAA
TCAACCAATCCTTCTTATCCAAAACGGGGCGTTGTGCAAACACATCGTATCGGCACGCGT
CCAGTTTCTGCAAAATCAACTGCGCCCCCAACACAATCATACGGAGTTCCAAACCGATAC
GCCATTACGTTCCCTTGCCAAAGGCGAACC CGCCTTCAGCATACGGAACGCACGCGGAC
ACTCATACGCCATCAGCCGCTGAAACGCCGCATCCGCCCGTCTGCGCGATCTGTTCTCT
55 CAGAAACACCGAATTTCAACAATCGTCCTGCGGAATATAAACCCCTGCCTTTTTGCCAAT
CCACAGCCACATCCTGCCAAAATTCACCAGTTGCAAAGCCGTACAGATGCCGTGCGTTT
GCGCCACGCACACCGCATCCGTTTTCCCGTACAAAGCCAGCATAATGCGTCCGACAGGGT

TGGCGGAACGCCGACAATAATCGGCCAGCTCGCCGAAATTTCCATACCTTGTTTTAACCA
CATCCTGAGAAAAATGCAGAAAGCAAAATCATAAAACGGCTGCAAATCCAAACCGAACGGCA
CAACCGCCTCGGCATCCAATCGTGCAATCAAAGGATGCGCCGACCGGCCGCCGATGCCA
ACACGTCCAACCTCGCGCTGCAAACCCCTCAACCCCGCCAACCTGGCTTCAGACGGCATAAC
5 TGCCCTCGTCCGCCATATCGTCCGCCGTCCGTGCAAACGGGTACACCGCGTGAACCGGCT
TCCTCAACCTGCGCGGCAAAATCAGCGAACCGACGGGAAAATTTCTCATAATGCCCAACCG
ACATACCTTCTCCATCCATCAAACAAAATGCCGTCTGAAACGGAACAAACCTTTTTCAGA
CGGCATCAGATACCTCCAAGCTGCCGGCAATCAGTGGTGGTGATGACCGTGCGGGGCCGTG
GACATGACCGTGTGCGATTTCTTCATCGGATGCATCGCGCACGCTTTCAACTGTAGCCTT
10 AAAGCGGATTTTCATGCCCTGCCAAAGGATGGTTGCCGTCCACCACCGCCTTGCCGTCCGC
AATCATCGGTTACACGATAGACGACAACATCGCCGGTTTCAGGATCGTCCGGCTTCAAACAT
CATGCCGACTTCGACTTCAACAGGGAACACGCCCCGATCTTCGATACGGACCAACTCCGG
ATCCTGCTCGCCGAACGCATCGTCCGGCGACAGCGCCACATCGACCGTATCGCCGGCATC
CTTACCGTGCAACGCCTCTTCCACCAAAGGGAAAATGCCGTGTAACCGCCGTGCAGATA
15 CGCAATCGGTTCTTCGGTTTTGTCCAAAAGCTGATTGTTGGCATCATACTCTCATAATG
CAGCGAAACCACGGAATTTTTACGATAGCCATATTTGTCTTTTCAGGAACAGCAGATTA
ATTACAGGCGCATTTCTAACACAACCGCCGCGCCGGCGGATTACCGTTAACCTGTTCTATAA
ACTGTACAGCACATATTTCAATGTAAATCTTTGTTATTTTATGCGGTGTAACTTTTTTA
CAACATTTCTTAAACCATTCCGACCTGTCTGCCGACTTTCCCAATCCGCCTTAATAAATC
20 ATACAAGATACTGAAATTATATTAATCTCTATAATATTTATCCCTATCGAATTTTTTAACA
GCAAAACCGTTTTACAGGATTTATCAATCCGCCCGCCAGAAAACCTTTTCATTCAAACCTT
TTTCCCATCTGTACGACATTGCAATCCCTTATTCCATAGTGCATAATTACGCAAATTCAG
CGATGAATTTCCAACCCGGTTTTGTAGTATGGTCGATAAAGACCTATTTGTTTCAATAATT
TAAATTGGTTCTTAAAGGTTACTAAAATGAAAAAATCCCTGTTTGCCGCTGCTTTGTGTG
25 TTTGGTTCTGGCAGCCTGCGCGGTGAAAAAGCCGCTGAAGCTCCCGCTGCTGAAGCACC
TGCCGCCGAAGCTCCCGCTACTGAAGCACCTGCCGCCGAAGCTCCCGCTGCTGAAGCACC
TGCCGCCGAAGCTCCTGCTGCTGAAGCTGCCGCTACCGAAGCACCTGCCGCTGAAGCTGC
CGCTACCGAAGCACCTGCCGCTGAAGCTGCCGCTACCGAAGCACCTGCCGCTGAAGCTCC
TGCTGCCGAAGCTGCAAAATAAGCATTTTCCGCTTGCAAAAAAGCAGGATACGTTTCAGTA
30 TCCTGCTTTTTTTGATTTTTTCAGACGGCATCAGATTCCCTTCTCTCAATCTTCTCCCTACCC
TTCCGACAAACATGCTTGACCTTCATACCGAATTTTCCCGACTCCTACCGGCAGATGAAA
TTGCCGAACCTTCTCCGACGCTTTTAAAGACCAGCGCAACCGCTTTACGTTCTGCACCAG
ACATCATTTTGCAGCCGCTCAGCGTTAAAAGCGTGCAAACCATTTATGCGTTTTCTGCCACC
AACACCGTATTCCGGTTACGCCGCAAGGCGGCAATACTGGTTTGTGCGGCGCGGCAGTAT
35 CGGAAAACGGCGTATTGCTGAACCTTTCCAAACTCAACCGCATCCGACGATCAATTTGT
CAGACAACCTGCATAACCGTTCGAAGCAGGTTCCGTACTCCAAACCGTCCAACAGGCAGCG
AAGCCTCAAACAGGCTGTTCCCACTCAGTCTCGCCAGCGAAGGCTCGTGCCAAATCGGCG
GCAACATCGCCTGCAATGCCGGAGGTTTGAACGTATTGCGTTACGGCACGATGCGCGACC
TGTTTATCGGTTTGGAAAGTCGTCTTCCCCAACGGCGAACTGGTTTCCCATCTCCATCCCC
40 TGCATAAAACACCACCGGTACGACCTGCGCCATCTGTTTATCGGTAGCGAAGGTACAT
TGGGCATTATCACTGCCGCCACGCTCAAGCTGTTTGCCAACCCCTTAGACAAAGCAACCG
CATGGGTCCGCATACCCGACATCGAATCCGCCGTCCGCCTGCTGACCGAAACCCAAGCAC
ACTTTGCCGAACGCCTATGCAGTTTTGAGCTGATCGGCCGTTTTTGCCGCCGAATGTCTT
CCGAATTCAGCAAACCTCCCTGCCGACACATTCAGAATGGCATATTTTACTTGAGTTGA
45 CCGACTCATTACCCGACAGCAATCTTGATGATCGGCTTGTCGAATTTCTTTATAAAAAAG
GCTTTACCGACAGCGTGTGGCGCAAAGCGAACAAGAAGTATCCATATGTGGGCGTTGC
GCGAAAACATCTCCGCATCGCAACGCAAACTGGGCACCAGCATCAAACACGATATTGCCG
TTCCTATCGGGCGCGTTGCCGACTTTGTCCGCCGGTGCGCCAAAGATTTGGAACAGAATT
TCAAAGGCATACAAATCGTCTGCTTCGGACATCTGGGCGACGGCAGCCTGCACTACAATA
50 CTTTCTGCCCCGAAATCCTCAGCAATGAAGTCTATCGTTACGAAAACGACATCAACAGCA
CAGTCTATCGCAACGTCTTGCCTGCAACGGCACGATTGCCGCCGAACACGGCATAGGTA
TCATCAAAAACAGTGGCTGGACAAAGTACGCACGCCTGCCGAAATCGCCCTGATGAAAA
GCATCAAAACAACCTTGATCCATATAACATATGAATCCGGGGCAAACTGCTTCGGTAAC
CGGCATTTCTGATTTGCATACACAACAAAGAAAGGGACAATAGATCCGATTGTTCGGTTTA
55 GCGCGAGCTCGTGAGTGCGGTTAAAAATTGGTGGAATTACACGAAAAATGACCGCACTT
TTAAATAAAAAAATCGGCAGTGAATTTCCCTGCCGATTTTATTTTGTACAACTTAACT
TAAACGCTCCACTGTAAATTCAACGCACCTTGTTTAGCTTGATGATGTTGCCTGTTTGG

CGGTTGAATGTGGCTTGTAAAGTTAAGTGAGATTTGATTTTCACTGCTACACCTAATTGG
CTCTCAATTGCCGCTCTTATTGTTTATCACTCGACGCTCTCCGTCCTATTTCCACACCGAAA
GGTTTGTGTGGTAAAGCGCGTTTACAGCGGCGAAAGGTTCAATAGCGATATTTTATAG
AGTGAAATTTGAGCTTTAGCTTGAACGCCAACCCGAGTTTGTAAATTGGCGGGAGCCAAAGT
5 AAATTCACGTGGGCATTTTCGCTATCGCTGAATTTCCGTTTACCCCCAAATAAGTCAAT
TGTGCCCTGTGGTTGTAGGTAAACACGAAGGCTGTTGCCCTTTTAGTGAAGTGTTCGGCC
AATAACGCATTGTAACCTGCTTCAATTGAGGCAGTAATACCTTTTGAAGTAAAACGTTCT
GTACCATCTTCAGTGTGATACGGTGGCGGAAGCGTTGATATTGCATCCAGCTATCCGCA
TACGCACCTGTCTGTTTGTCTGAAGTTGGTGCCAAGTGGCGTAAACGCCTGCACCAAAG
10 CCTTTCACATTTCCCGTTGTAAGATTGTCTGTATCTGGGTTGTGGAAAGTGCTACGTTGT
TCTGCTTGTCCGCCCATTAAAGCCAATAGAAAGTTGATTACTTTTCCGTTTGGCATGTGAAT
ACTTCGCCCGCGAGTTGCACACCTTTACGATAGCCTTCTACAGGTGCTGTTTTCCTTGC
ACCCATTGGTTGGAATGTCCGTCAATCACACGCAACCACAAGCCTTTGCGTGGTAAAGTG
CGGTCGAAAATATCGCTGTTTTTGTGTTCAAACGCAAGGCGAATAAGGTATTGGCGGCT
15 TGAGCCTGTTGTGCATAAATCGCCATATCATCGCTTCTTGCCTTTGGTAAAAAGCCC
TCTGGGCGTGTGTGTAAGAAAGCGTATAAATCCCTTTTGGTGTGGCCAGAAAGACGG
AATGCGTGTATCTGCTGTGCCATTTACTTTGATAATTTGATGCCCATCGAGGCTTTTT
AAATCGTCTATTGGATTTTCGAAGATGATGTCGGAAGTGCCAGTAACATTTTCTCAAAA
ATTAATGCAGTATTTTTCGCTTCTTTAGGATCGTAAGCAAAACGAAAACGAGCTCCGCCA
20 GCATAATCTTCTTTACGAGTAACTTTTCACTTTTACTATTAAACCGGATGTCTGCATT
GTTGTTTTTAAATTTCCCAACATTAGAATCCCAACGGGGCTCCAGAGAGAATTTTCTAAG
CGGAATTCATCCAACTAATCGTTTGGCCGATAACGTGCGAGTTGTCTGTAACCTCAATA
TAGTGAATGGATCTAAACCAGAATATAGATGTGCTGCAAAAGAAACATAATTTCAATA
TGATGAATTACTTGTATTAGCCATTCTGTATAATTTCCGACAGATAAAATTTGCTGTTG
25 ATATGACTATTTTTTATTTTTTGACCTAAGGAGAAATATATGACTTTTTTACTATAAGAGGA
TGGGATCCAAATTTTTCAGCTTGGCAAGTACTATAATCACGTATCTTAGTGTTAGAATTA
AAACATTCTTAAATATTTCCGTATTTGTTCTTCTGTGTCCCCATTTCTTTTTGCAACC
CCTAAACCTCGGGCGAAGCCAACTAGGTAACCTTCGGTATATTCTTGATCATAAAAGAA
ATCTTTTTTGAGTTATTGATGTTTTTCAATTTGGTATGTTCTAGGGTATAGTGCGGGAAAG
30 GGTGGAACTTTGGATTATCTCGGTTATAAGATAAGTTTCTTTTTTCCAATATTTCACTC
GTTTTATCGCGGAGTTTTTTAAGCGGGTAATTTCAATAGTGAGCTTGGTTTTGTGCG
TAAACGTAATCAACAGCCAAAAGCGGAGAGGTATAAAGAATAGAAAAAATAGACTTACA
ATAAATGATTTTTTAACTTCTGCTTGCTTGCTTGCTTGCTTCGAGTTTCAATAAAAT
TTCCTTTGTCAAGTAAAAATAAATGGGGCGTGGATTTTAGCATAAACTGAACAAAAAAT
35 GTCATTTATCTCACATTTTCTCTATTTATTTCTTGTATTATAAAGTAAACGTTTGCTT
TTTGCTATTTTGTCAAGCCAGTTTGAATATGTGATAATTGCCCTCGTTATTTACAAAAA
TTTCAGGAAAAATGACCGCACTTTACCCTTGGCTAATGCCAATTTATCATCAAATTGCTC
AAACCTTTGACGAAAGCTTGGGGCATCATGCCGTGCTGATTAAAGCGGATGCTGGTTAG
GTGTAGAACGTTTACACATCAGGCGGCAGCCTTGCCCATACCGTCTGAAGCACTGTTTCC
40 ACAATCAGCGCGTATGCTTAATCAACCGCTGTTTCTCGCGTTTCCAATCCGCTCTTTCA
TACTCTGGCGTTTGTGCTGCTGTTTCTTACCTTTTGCCAAACCGATTTCCATCTTGATTT
TTCCGCGTGAAAAATGCAATCCAGCGGCACGATGGTGTAGCCGGCACGTTCCGTTTTGC
CGATTAATTTGTTGATTTCCGACTGGTTCAACAAGAGCTTGGCGGGACGTACGGCATCTG
GTTTAATGTGTGTCGAGGCTGTGGGCAAAGCCGTAATATGGCAGCCGACCAGATAAAACG
45 CGTCTTTTTTCCAATAGATATAACTCTCTTTAAGCTGTACGCGCGCGGCGGATTGCTT
TGACTTCCCGAGCCTTCCAAGACCAACCGGCTTCAATCCGGTCTTCAATGAAAAAATCGT
GAAATGCTTTTTTATTGTTTCGCAATAGCCATAAACATCCTATCAATATCCGCCGTGAGC
GGCATAAACCCGAAAACAGAACCCATCATACCGCCTCTTCAACCGCCTGCACAATCTTCT
CGGGATACAGCCTGTTGAGGCAGTCGGTATGCCCCAGCGGACATTCCCGCTTAAACACG
50 GCGAACATTCCAAGTGACGGCTGACGATTTTCCGCTATCGCTCAAAGCGGGCGTATGCG
TCGGGCTGGAAGAACCGTAAACCGCCACCCTTCTGCCCAAAGCTGCCGCCAAATGCA
TCAATCCGCTGTCGTTACACACGACCGTGTCCGCCAACGACAGCAATCCATTGCCTGCG
ACAAATCGGTTTTTGGCGCAAAATTGACACACATACCGTCTGAAAGGCGGTTGATTTCT
CGGCAATTTTCATCATCTTTTTTGGCAACCGAACAGCCAAACCTGCCAACCCGCGCCAGAT
55 AATGTTTGGCCAACTCGGCAAAATGCCTTGTGCGGCAACGCTTTGCCGGCCCGAATTCCG
CACCCGGACAAAAAGCCAGAACAGGCTTTCCAATATCCAAGCCAAAGGTTTCGACAGAAA
TTTCCCGCCCGCGTTTCATCAATGGAAACTCGGGGAATCCCGAATGCCCGTCAAAATCTT

CCTGACTCGGATGCGCGAGAGCCGTATATCGATCCACCATCAAAGGCAGACGTTCCCTTAT
 CCAGCCTGCGTATATCGTTCAACAGAAAAATAACGGCTTTCACCGACATAACCCGTCCTTT
 TACCGATACCTGTCGCCAGCGCGATGATTGCCGATTTCAAAGAACCAGGCAACACGATAA
 5 CCTGATCGTATCCGCGCGCCGCCAAATCCCTACCGACCGCCAAACGGCGTTTCAACTCCA
 ACGCACCATGTCCGAACGAATTCTCAAGAATTTCACTTCCGGCATAACGCTCGAACA
 CCGCCATCGACCACTTCGGTGCGAACACATCAATCGTGCAACCGGGGTGAAGTTCCTTCA
 AACGGCGGAACAAGGGCTGGGTCAACGCAGTCGCCTATCCAATGGGGGAAATAATCA
 GGATTTTGATGGACATAACAAGAAACCGAAATCAGACAGGCAGAATTTTACCGCGAAACC
 GTTGAAAACCTATCTTGCCGCATTCCGAACGCCGGACGTGCAAATATGAAAAGCCCCGA
 10 ACATTCAAGTTCGGGCTTCAAAATCTGGCTCCCCGACCTGGGCTCGAACCAGGGACCTG
 CGGATTAACAGTCCGTCGCTCTACCGACTGAGCTATCGGGGAATGGGGCGTATTATAGCG
 TC

15 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 3>:

gnm_3

GCGGGGGCTTCCATCGCAGTCATGCACAACATCTGCATCAAATGGTTTTGCACCATATCG
 CGCAACGCGCCGGTAATGTCTGTAACAACTACCGCGCTCTCCACACCGAGCTGTTCCGGCG
 ATGGTCAACTGCACGCTTTCGATATATTTATTGTTCCACAGCGGCTCGAACATTACATTG
 20 GCAAAACGCAGCGCAAGCAGGTTTTGCAAGGCTTCTTTGCCAAGGTAGTGGTCGATGCGG
 TAAATTTGCCCTTCTTTGAAATAACGCGCAACATCGGTATTGATTGCTGGGAAGAAGCC
 AAATCCGTACCCAACGGTTTTTCCAAACTACGCGCACATTGTCGGCATTCAAACCGATC
 GCAGCAAGGTTTTACAGGCTTGCGCGAAGAATTTGGGCGCGGTGGACAGATAGATGACG
 ACGTGTGCGGTTTTCTTTGCGCGCTTTGACCAATCGCCCAAGCGGCAAAATCGTCCGGC
 25 TCGGTAACATCGACTTTGAGATATGCGAAACGTTGACAAACGATGCCCAAGCCTCATCG
 GAAAAATTTCTTTACATGGATTTTGGAACTGGTTTCCACCTTCGCCAGAAAACCTTCG
 GTATCCAACCTCGCTGCGGCTGACCCCAAAATACGCCCTTCGGGATGAAGCAGACCGGCA
 ACATGCGCCTGGTACAGACAGGGCAACAGCTTGCGCATCGCCAAATCGCCGGTCGCACCG
 AACAAACACCAAAATCAAAATTTGTTTGTGTACTCATCGTATTATCTCGTCAGGAAAGAATT
 30 TTTTCGATGCCGCTCTGAAACCTGTTTCCCCCATCACGCTGCATCGCAATATCGGAAACAAA
 GGCAGGCGGCATAATGAGTAGTAATACTACACACCGCTACACTTTTTGTCTATTCCCATT
 TTTACAATTTATTTGACCTAGTCCAAAAATCGGGCAGGTTTCCCCTATTCCGTTACAACA
 ATCGAAAGATTCTGCGATTTAAATCAAATTTCTTTCAATGCCTGATTTTTTTGTAACAA
 AATTACAAATTTGTACTATAATAACACCCGCTTCCCACTTTCAGACGGCATACTTTTA
 35 AAATATAGTGGATTAACAAAAATCAGGACAAGGCGACGAAGCCGACAGTACAGATAA
 TACGGAACCGGATTACCTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGG
 CGAGGCAACGCCGTACTGGTTTTTGTAAATCCACTATACTTACCGTCTGAATACCCGATA
 CAAAAATCAGAAACGCACAAACAAATCCCCAATACCCCCCGTTCCGACAGGAGACCGA
 CCGTGAACACTACTCTATCCACTCCAACTCGCCGAAATCACCGGGCGCATTATTGAAC
 40 GCAGCCGTCCGACGCGTGAATAATATCTGGCGAAGATCCGCAGTGCCAAACAAATGGGAC
 GCTTAGAGCGCAACCAGCTCGGCTGCAGCAACTTGGCACACGGCTATGCTGCCATGCCTA
 AAAGTATCAAATCGAAATGCTTCAGGAAACCGTCCCCAATTAGGCATCATCACCGCCT
 ACAACGACATGTTTTCCGCACACACCGCTTTAAAGACTTCCCTGACCAATCAAAGACG
 AAGCGCAGAAAAACGGCGCGACCGCCCAAGTCGCGGCGGCGACGCCCCCATGTGCGACG
 45 GCATCACGCAAGGCTACGCCGGCATGGAATTGTCGCTGTTCTCCCGCGACGTGATTGCCA
 TGAGTACCGCCATCGGGCTGTGCGATCAAATGTTTGACGGCAGCCTGTTTATGGGCGTAT
 GCGACAAAATCGTTCCAGGTTTGATGATAGGCGCGCTTTCGTTCCGGTCATATTCCGGGTA
 TCTTCGTCCCCGAGGCCCGATGTCCAGCGGTATCGGCAACAAAGAAAAAGCCCGCACCC
 GCCAGCTTTTCGCCGAAGGCAAGGTCGGACGCAACGAACTTTTGAAAAGCGAAATGGGTT
 50 CTTACCACAGCCCGGCACCTGCACTTTCTACGGCACGGCAAACCTCCAAACCAATGATGA
 TGGAAATGATGGGCGTGACCTGCCTGCCGCCGCTTCGTCCACCCTTACACCGACCTGC
 GCGAAGCGCTGACCCGCTACGCCGCCGGACACCTCGCGCGCGCATCAAAAACGGCACGA
 TTAAACCTTTGGGCGAAATGTTGACCGAAAAATCCTTTATCAACGCCTTGATTGGCCTGA

TGGCAACCGGCGGTTCGACCAACCACACCATGCACCTCGTCGCTATGGCGCGTGCGGCCG
GCGTGATTTTGAAGTGGGACGACTTCGACGAAATTTCTCCATCATCCCGCTGCTCATCC
GCGTTTATCCGAACGGCAAGGCCGACGTGAATCACTTTACCGCAGCGGGCGGACTGCCTT
TCGTTATCCGCGAATTGCTGAATGCAGGCCTGTTGCACGACGATGTCGATACCGTCGTCG
5 GACACGGTATGCGCCACTACACCAAAGAGCCTTTCTTATCGACGGCAAACCTCGAATGGC
GCGAAGCCCCGAAACCAGCGGCAACGACGACATCCTGCGCAAAGCTGACAACCCGTTCT
CCCCCGACGCGGTCTGCGCCTGATGAAAGGCAACATCGGACGCGGCGTGATTAAAGTGT
CCGCCGTGCGCGAAGGCTGCCGCATTATTGAAGCGCCTGCCATCGTGTTCAACGACCAAC
10 GCGAAGTGTGGCTGCGTTTGAACGCGGCGAGTTGGAACGCGATTTTGTGTGCGTCGTCC
GCTACCAAGGCCCGCGTGCCAACGGTATGCCCGAATTGCACAACTGACCCCGCCTTTGG
GCATCCTGCAAGACCGCGGCTTCAAAGTGGCGCTGCTGACCGACGGCCGTATGTCCGGCG
CGTCCCGCAAAGTTCCAGCCTCCATCCACATGACACCCGAAGCCCTGATGGGCGGCAACA
TCGCCAAAATCCGTACCGGCGACCTGATCCGCTTCGACTCCGTTAGCGGCGAACTCAACG
TCCTGATTAACGAAACCGAATGGAATGCCCGCGAAGTCGAAAGCATCGACTTGGGCGCGA
15 ACCAACAAGGCTGCGGCCGCGAACTCTTCGCCAACTTCGCGAGCATGACCAGCAGCGCGG
AAACCGGTGCCATGAGTTTCGGCGGCGAATTTGCCTGATGCGCGTTTCAGACGGCCTTTT
CAGACCGAAGGCCGTCTGAAAAATATTCAAGCGTTTAAAGATAGACGTAGGTTGGATT
TCGAATCCGACACAGCCGTCCAAGATGTGGTTTCTTGAATCCGACCTACAACCTGTCCC
ATCTTAATAAAATACCCATTCCACCCGGGAGAACCGAAATGTCCAACTGACCCCCCGCG
20 AAATTTTGACCGCCGGCGCAGTTGTGCGGTAATGGCGATTGACGACTTAAGCACCGCCA
TCGATTTGTCCCACGCCCTTGTCGAAGGCGGCATCCCTACCCTCGAAATCACCTGCGCA
CCCCGTGTCGGCTCGATGCCATCCGCTGATTGCCAAAGAAGTGCCCAACGCCATCGTCG
GCGCAGGTACGGTAACCAATCCCGAACAGCTCAAAGCCGTGGAAGACGCGAGGCGCGTTT
TCGCCATCAGCCCGGGGCTGCATGAATCCCTCGCCAAAGCCGGCCACAACAGCGGCATCC
25 CCCTGATTCCCGGTGTTGCCACCCCGGGCGAAATCCAATGGCTTTGGAACAGCGCATCG
ACACCTCAAACCTCTCCCCCGCGAAGTCGTGCGCGGCAAAGCCATGCTCAAAGCCCTGT
ACGGCCCTTACGCCGATGTTGCTTCTGCCCGACAGGCGGCATCAGCCTCGCCACCGCGC
CCGAGTACTTGGCACTGCCAACGTCCTGTGCGTCGGCGGCTCTTGGCTGACACCGAAAG
AAGCCGTGAAAAACAAAGACTGGGACACCATCACCCGCCCTCGCCAAAGAAGCGCGGCGT
30 TGAAACCCAAAGCCTGATTGCGATCGTAAAAATGCCGTCTGAAAAACCTTTCCCGTTTCA
GACGGCATTTTGCCGATTGAGGGCACAGTCGGCATAACGGCAGCACTGATCAGACATAC
CGCCCCATAAATGCCCATCCGCCTTCGCGATAATAAAAAATAACGTTCACTTCATTGACA
GCAGCCGGACAGCCCATCTACGCGGCTGAAAAATGCCGTCTGAAACGCATTGAGACGG
CATCCACTTAAAAAAAACAACGATTCAACGCCGATTAATCCGCTTCCAAAACCACTTTC
35 ATCACTTGGTTTTTCGGCGGCGTGTGTTGAACACGTCGTAGGCTTTTTCCAATTCAGTGAAT
TTGAAATGATGGTTCAGCATTTTGGTGTATCGACGGAGCTGCTGGAAATCGCCTTCATC
AGCATTTTCGGTGGTATTGGCGTTTACCAGACCGGTAGTGATGGCAAGCTTTTAAATCCAG
AGTTTTTTCAGTTTGAATCAACGGATTGACCATGTACACCAACCACAGCGATATGGCCG
CCGGGTTTACAATGTCTTGGCACATATCCATGTAGCAGGGATACCGACGGCTTCGATG
40 GCGCAATCCACGCCGTCTTCGCCGACGATGGCAAAGACTTGTGTTGGATACTTCGCCGAA
GCAGGGTTAATGGTATGGGTGCGACCCAATTCTTTCGCCAGTTTCAAACGGTTTTCTGTC
ATATCGCAAACGATGATGGCGGCGGGACTGTACAGTTGGGCGGTCAACAGGGCGGACATA
CCGACAGGGCCTGCCCCAGCGATGAATACGGTGTGCGCGGGTTTGACATCGCCGTATTGC
ACGCCGATTTCTGGGCGGTGCGCAAAGCGTCGCTCAACAACAGGGCGGATTTCTTCGTTG
45 ACATTATCGGGCAGCGGAACGAGGCTGTTGTCGGCATAAGGCGTACGGACGTATTCGGCC
TGAGTACCGTCAATCATGTAACCCAAAATCCAACCGCCGTTACGGCAGTGTGAATAGAGT
TGGGTTTTGCAGTTGTGCGAAGTGCAACATTTGCTGACGCATGAAATAATGACTTTATCG
CCGACTTTGATGTTTTTACAGCCTCGCCGACTTCTTCTACAATACCGATGCCCTCATGA
CCGAGAATACGGCCGTGCGCAACTTCGGGGTTTTTGCCTTTCCAAATACCCAAATCGGTA
50 CCGCAAATCGTGGTTTTGACGATTTTACCACCGCATCGGTGCGATCGATAATCTGCGGA
CGGGGTTTTTCTTCAAACGGATGTCGTTTGCGCCGTGATAAACCATTGCTTTTCATGCTG
ATACTCCTTGCTTGTGATAAATAATTTCAATACCGCAATAAAGTTTCTTTATATGAGTT
ATATGCCCTACAAAAAATAAGTCAATAAGAATTATTTTCAATGTTATACAATAACAT
ACGTTTTTAAATATAAATAAAACCACCGATTGATATTAATGAACACCCCATCCCCTTCT
55 CCGAACGGCTCATCCGCTGGCAAAAACAACACGGTCGCCACCACCTCCCTTGGCAGGTCA
AAAACCTTTATTGCGTCTGGCTTTCCGAAATCATGCTCCAGCAAACGCAAGTCGCCACCG
TGTTGGACTACTATCCGCGCTTCTTAGAAAAATCCCGACCGTTCAGACGCTTGCCGCCG

CGCCGCAAGACGAAAGTGTGTGCTTGTGGGCGGGCTTGGGCTATTACAGCCGCGCGCGCA
ACCTGCACAAAGCCGCGCAACAAGTCGTACGGCAATTCGGCGGCACGTTTCCGTCCGAGC
GCAAAGACTTGGAACCCCTCTGCGCGTAGGCAGAAGCACCGCCGCCGCAATTTGCGCCT
TCTCCTTCAACCGCCGCGAAACCTTTTGGACGGCAACGTCAAACGCGTACTCTGCCGCG
5 TGTTCCGCGCGACGGCAATCCGCAGGACAAAAATTTGAAAACCTCGCTCTGGACACTTG
CCGAAAGCCTGCTGCCGTCTGAAACGCGCATATGCCTGCCTATACACAAGGTTTGATGG
ATTTGGGCGCGACCGTGTGCAACCGGACGAAACCCCTGTGCCACCAATGCCCGATGGCGG
ACATCTGCGAAGCGAAAAAGCAACACCGCACCGCGAGCTGCCGCGCAAAAAACCGCCG
CCGAAGTACCGACCCCTGCCGCTTACTGGCTGATTGTCCGCAACCGGGACGGCGCGATTT
10 TGCTGGAAAAACGCCCGCCAAAGGCATTTGGGGCGGGCTGTATTGCGTGCCGTGTTT
AAAGTTTGAACGGGCTTTCCGACTTTGCCGCCAAATTTCTCCCTGACCATGGCAGATATGG
ACGAACAAACCGCCCTGACCCACCGCTGACGCACCGGCTGCTATTGATTACGCCCTTTG
AAGCACAATGCCGTCTGAAAGCCCTTCAGACGGCATTTGGATAAAGCCGGCGCATTTGA
AAGATTACGGTTTGGCCAAGCCTTTGGAAATTTATTTAAACGGTAATAGGTTAGAATAAA
15 CAAAATAAACCCATTGAACTGTTGTTTGCAGGTATCGCAGCAAGAACAACCGATGAATTT
GGGTCGTATTTTAGGCGGCGGGATAATGTTCAAATGGGACATTTGGAACGGGAAGTCTG
GCAATTTAAAGGATTTAAAAAGCAAAGAAGGTCAAAAACATGAACACAACTTAAATG
ACAAAGACAAAAGCCATGGATACCGCAATCAGGTTTCAGAAAAGGATGAGGATTCGAAAT
TTTTCTTTTAAATTTCTCGGAATCACAATGGTTTGGCATTATTCAGACGTGATAACGG
20 GTTCTAATTTTCTGCAATAACAATTAATGTAAATTTTCGTAAAAATTTATCGGCTTTT
AAAACAAAATTGACTAAAATAGTCGCGAGTTTTTACTGCAATAAAGGAGATTGCAATGAA
TATGAAAACCTTATTAGCACTAGCGGTTAGTGCAGTATGTTCAAGTTGGTGTTCGCGAAGC
ACACGAGCATAATACGATACCTAAAGGTGCTTCTATTGAAGTGAAAGTGCAACAACCTGA
TCCAGTAAACGGTAACAAAGATGTGGGTACAGTACTATTACTGAATCTAACTATGGTCT
25 TGTGTTTACCCCTGATTACAAGGATTAAGCGAAGGCTTACATGGTTTCCACATCCATGA
AAACCCAAAGCTGTGAGCCAAAAGAAAAGAAGGTAAATTGACAGCTGGTTTAGGCGCAGG
CGGTCACTGGGATCTTAAAGGTGCAAAACAACATGGTTACCCATGGCAAGATGATGCACA
CTTAGGTGATTTACCTGCATTAACTGTATTGCATGATGGCACAGCAACAATCCTGTTTT
AGCACACGCTCTTAAACATTTAGATGATGTTTCGCGGTCACTCTATTATGATCCACACGGG
30 TGGTGATAATCACTCCGATCATCCAGCTCCACTTGGCGGTGGCGGCCACGATGGCATG
TGGCGTGATTAATAAATTCGATTGTTTCGAAACGAAAAGTGCAGTGAATTTGACCGCACT
TTTTTGCTAGATATTTAGCATTGAGACCTTTGCAATAACATAGGTTACTAAAATTTTATG
CTCAATCTCATTTTCAAATGCAAACTTTTCTGATTTTTCCTACTTTTGTCTCAATATT
AGGAAGGTTTTTAGGCAATTGAAAATTTTTTGGCGCATTTTATGCGTCAAAATTCGTAA
35 CAGACTATTTTGCAAGGTTTCTATTGATAAGTTTCCCGAAATTCACATAACCGAAA
CCTGACAATAACCGTAGCAACTGAACCGTCAATTCGCGCAAGCGGGAATCTAGACCTTA
GAACAACAGCAATATTCAAAGATTATCTGAAAGTCCGAGATTCTAGATTTCCCGCTTTCGC
GGGAATGACGAAAAGAGACCTTTGCAAAATTCCTTTTCCCGACAGCCGAAACCCCAACA
CAGGTTTTTCGGCTGTTTTGCCCCAAATACCGCCTAATTCTACCCAAATATCCCTTAAT
40 CCTCCCCGGATACCCGATAATCAGGCATCCGTGCTGCCTTTTAGGCGGCAGCGGGCGCAC
TTAGCCTGTGGCGGCTTTCAACAGGTTCAAACACATCGCCTTCAGGTGGCTTTGCGCAC
TCACTTTAACCAGTCCGAAATAGGCTGCCCGGGCGTAGCGGAATTTACGGTGCAGCGTAC
CGAAGCTCTGTTCAACCACATAACGGGTCTTCGACAAATATCGGTTGCGTTTGGTTTGCA
CTTCCGTGACGGGACGGTTGCGGTGGGCTTTGCGCATAATGCCGTCCAGCAACTGATGTT
45 CTTCCAGATGTTGCCGTTTTTCCGCACTGTCGTAGCCTTTGTGCGCATAGACGGTCGTAC
CTTTGGGCAGTCTTCCAACAACGGCGACAGGTGTTTGCACTCATGGGCATTGGCGGGGG
TAATGTGCAGTTTCTCGATATAGCCTTCTGCATCGGTACGGGTATGTTGTTTGTAACCGA
GTTTGTAGAGGCCGTTTTTCTTTATCCAACGGGCATCGCTGTCCTTACTCGGTGTGGTTT
GACCGCTGATTTGCTTCTTCTGTCACCTTCTATGGCCTGACGCTGTTTGTGCGCGCGG
50 TCTGAATAATGGTGGCGTCAACGACGGCAGCGGATGCTTTCTCTATTTTTAAACCTTTTT
CGGTCAAGTTGGCGGTTAATCAGTTCCAACAGTTTCAGACAGGGTATTGCTTGGCGCCAGCC
GGTTGCGGTAGCGGCATAAGGTGCTGTAATCGGGGATGCTCAGTTCGTCAAACCGGCAAA
ACAGGTTGAAATCGATGCGGGTAATGAGGCTGTGTTTCAGAGTTCGGGATCGGAGAGGCTGT
GCCATTGTCCGAGCAGGACGGCTTTGAACATGGACAGCAGGGGATAGGCAGGACGGCCGC
55 GGTGGTCTCTAAGGTAACGGGTTTTTTGACGGTTCAGGTATTGTTTCGATCAGCTGCCAAT
CAATCACCCGGTCCAACCTTCAATAGCGGGAAGCGGTGATGTGTTTGGCAATCATGGCTT
GGGCGGTTTTGCTGGAAGAAGGTGCTCTTGAGAAATCCCCTAAATGTCTTGGTGGGAATTT

AGGGGATTTTGGGGAATTTTGCAAAGGTCTCTAGATGAGTGAAAAAGAAGTGCAGGCTGC
CTAAAAAGACAGAAAAAGTCTTTCCGGCAGCCTGCACTTTGGTTTCATTTTCAGTCAGTAA
ACCCAGTAAACGACGGTCTGAAAACGCAGAACGTTACGAAAAAGCAGCCTACACGCCCA
TCCCCCGCCTTCTACCCGTTCTGTAAATCATACAGATAGCGGTAATATCCGTTTCGGCTTC
5 GCCAGCAATTCCTGCTGTGTTCCCGCTTCCACAATCCTGCCTTTATCCATGGCAATGATC
CGGTGTGCCGTTTAAACAGTGGACAGACGGTGGGCGATAATCAGCACCGTCCGGTTGGCG
CAAATGGCCTGCATGTTCTGCATAATCGCTCGTTCACTTTCATAATCCAGCGCGCTGGTG
GCTTCATCAAAAATCAGAATGCGCGGATTGGTGATTAACGCGCGGGCAATCGCAATACGC
TGCCGCTGTCCGCCCGACAAGCCGGGCCCTTGTTCGCCACCACGGTGCCGTAGCCTTCC
10 GGCAGCTCCATAATAAACTCGTGTGCGCCCGCCAGTTTGGCTGCTTCGATAATGCGTTCC
AGCGGCATACCCGTATCCGTACGCGGATATTGTGCGGTATGCTGCGGTTGAGCAGCACA
TTCTCCTGCAAGACCACGCCGACCTGCGCGCAGCCAGGCAGGAGCGGCCAAAGCCAAA
TCGTTGCCGTCCACCAACACCCGTCCTGTCTCCGTACATACAGACGCTGCACCAATTTG
GTGAGTGTGGATTTGCCCGACCCCGAACGTCCCACAATCCCCAGCACTTCCCCCGCCCGA
15 ATCCGCAGGTTCAAATCCTGCAAAATCAGCCTGCCGTCCGCTTATAGCGGAAATCGACA
TGTTTCGAACGTAATCTCCCCCGGATATCGGGCAAAGCCAAATGCGAAGACGCATTCTCG
GTCCGGCATTGAGAATATCCCCCAAACGCGCCACCGAAATCCCCACCTGCTGGAAATCC
TGCCACAATGCGCCAAACGGATAACAGGCGCGCCACCTGTCCCGAGAGCATATTAAC
GCAATCAGCTGCCCCACCGTCAGCTTGCTCTCAATTACCAGCCGTGCGCCAATCCACAAC
20 GTCCGACCGTCACCGCTTCTGAATCAGCTGCACCCCTGCTGGCCGACCACCGCCAAC
TTGCTTACCCGAAATCCCGAAGCCACATAAGCCGCCAACTGATTGTCCCAACGCTGCGTC
ATCTGCGGCTCCACCGCCATCGCCTTTACCGTACCCACCGCAGTGATGCTTTCTACTAAA
AACGACTGGTTGTCTGCATTGCGCGCAACTTATCGTTCAGACGCGTCCGCAGTATCGGA
CTGATAAATGCCGACCAAAACGCATAGGCAGGCAACGAAGCCAATACCACCCAAGTCAGA
25 GTGGAGCTGTAATACCACATACCGCCAGAAAGATAAACGAAAACGCCAAATCCAACACC
GAAGTCAGCGCCTGACCGGTCAAGAAATTGCGAATCTGCTCCAATTCCCCGACCCGAGCC
ACCGTATCACCCACTCGTCTGTGCTCGAAATAGGATAAAGGCAGGGAAGCAGATGCCGG
AACAAACGCGCGCCCAATTCCACATCAATACGTGAAGTCGTATGTGCAACAGATACGTC
CGCAAACCGCCCAACACAATCTCAAACAGCGACACCACCAACAAAGCCACCGACACCACA
30 TCCAAAGTAGAGAATCCCCGATGTACCAGCACCTTGTCATCACCCTTGAAAAACAGA
GGCGTAATCAGCGCAAACAGCTGCAACACCACCGACACCACCAATACTTCAAAAAACAAC
CGGCGGTATTTGATTACCGCCGGAATAAACCAGGTAAAGTCAAACCTTTGCCAACTGCC
AATACCGAAGCGCGGAAGCAACCAATATCAGTTTGCCCGAATATCTGTTAGAAAATTG
GCAAAAGACAATACCGCAGACTTATTGTAACCAATCCTGTATCAAAAATTGGGCATGC
35 TCACCCTCACCGTCTGTTTTGGCCAAAATGAAATGGTTGCCGTATCACACCATAACCAAT
GCGGGTAAAGTCGCCATAGCCAAACGTTTAAATAGGCTGGCGGACTACCTTTGCCTTCAAT
CCCAAAGATTTGGCGGCTAACAGCATTGCGTTTTCAATTAATCGCTCTGTGCGGAAGTA
CAAAATTCATGCTGTATATCGGCAGGATTGGCGGCAATGCCGTGGTAATGGGCGAGGATG
ATGAGGGCGGAAGGGCGGGGAGCGGTGCGGATACGATAGACATAAATAAAATATAGTTA
40 GATTGGATGTGGATAACGGCTGGCTGGAAAAGGAATATATTAAGTAGAAAGAAATATATA
AATAAAACAGCAGAACGCATTGTAAGGATATATATGGGAATTGTAAAGAGAAAGTATGGA
AAAGTTCTCGTTTCAGGAAGGTAAAACGGCTTAGGAATCGAGTTAGATGAGGATGCCTCG
CACCTCTCGTGCCCTCTGCATACCGTTAAGGCACAGGGTTAAGGTGCAGGCTGCTCCGAA
CTCTGTTGCGGTCCGGTAATGTTATTTTTGTGTTTCAGGCAGCCTGAAATATCTGTATA
45 TTTTGTTTTTAAATAGATTTTAAAGATTGATAACTGTTCTTGACGATTTTCAAGAAAG
AGTAAATTTCAAGAAAGGAGTAAAGTGACTTATTATCAATGACAAGCAACGCGCGAAGTG
ACAAGGAAAATCTACTTAAATTTCTAAGGAGGCTTCGAATATCATAAACCAATCAGAA
ACATAGAGATAAAAATTATGTACAAATATAATCCTCTTATACAATTTATTGCACAGTTGA
TTATGTCTTATGGAGCAAGCGTAGGGTGGGCACTTGCTGCCCCACGCGTTTCATATTTCA
50 AGGCAGCCTGAAACCGTGTGGGCATAAATGCCACCTACATCCCCAAAACAAGCGCAG
CCTGCGTGTGTAGGGTGCGAACTTTCGGCAGGTAGACACGCAGTTTTATATTTTCAAGCT
GAGGGATGCTTAAGAAAAGTACAAAACATTAATAAAGGGGCTGTACTAGATTAGCCC
TAAATCCACCAATCCCGCAAGATTTTGTAGCTGTGCGGACGGTGTGCCGAAGTTAAATC
GAAATTCGATTTCTTCAAGAACAGCGGGAAGATTGTGCGATCAATTCGGTTCTATTTGC
55 GCAAGACGCGTTTTGCGCTGATTCCAAAAGTTCTCAATGCCGTTTATGTGTTCTGACGGT
CAGCAAATTCCTTGGAAATGGTTGATGCGGTAATGGATAAACCGCTTACGTCCAATCTGT
CGTAACTGCTCAGGCTGTCGGTATAAACAATGCTGTCCGGCATGATTTCTGTTTGATAA

CAGGCATTAAAGTATCGGACTTGGCATTATCTACGACAACGGTATAGACCCGTCGGTTAC
GTTTCAGAATGCCGAAGACAACCACTTTTCCTGCCGCACCGCGACACGTTTGCCTTTAC
GCCGTCCGCCGAAATAGCTTTTCGTCCAACCTCGACAGAGCCCTCGAAAACCTCATTGGCAG
CCAAGGCCAGATAATGGCTGATGACCATACGGATTTTTCGGTAGAACAGGACTGCCGAAT
5 TGGGATGGATACCCAAATATCGGCAGCAGAACGGGCGGTAACTTCGAGTACAAAAAAC
GGAGCAGCTCTTTCTGTACTTTTTCTTTAATTTGCAGTGTGTTATCTTCATATTTCCGGG
GGTAACATATCTGCTAATCTAGTACAGCCTCAAACAAAAAGAGAAATTTTAATTTTCGCT
AAATCGCATAAAGATTAATCAAGAGTATCATTAAATGATATGAGTGAGCATCTATAATGC
CAAGAAGAGTTGTTAAGACATAACGATTATTGAAATAGATTGTAAAATAGATACTTAGAT
10 AGTCTGAAAAACGGATTTGTGAACTTTTTATTACGCGCCATCATTTGAAATGAACTT
AAAAACACTTATCATAATAAATATTTCTTTACGTTGTTTGCTAATAAACTCAGTGCAA
TATCAGCGCAATATTTTATGGAAATTTTATGGATAACAAAAAGAATTTATTAATAATTT
AACAAATAGGTATATGTGGATCTATCCATTGGTCTTAAATATTCTATTTCTACCTTTT
CCAGTCCCTACCAATCTTTTTTATTGCGCTTGGTTGTTTGTGTTGCACTGGTTAGAAAAAT
15 GCAAAGCTTAGATTTTAAATTACAAAATCATATTGTATTGTTAAATATAAAAAAGTGCTTG
GGCAGATAAAAAAGTATTTTTGATTAGGATAGTAGTCTCATGGTTGGCAGTAATGGAAAT
ATGGATGTGTTTTATTTCCGAATCATCAACGTGGGTATGCGGTGCTTTTTGTTTAAATAG
TGAAATATTGAAAAAATTTTCGTGGCTTTGGTTATTCTGGTAGTTTTATTTTTTTATT
TATATTGATGATTGATCTCAATAAGTTAAGAGAGAGTATTGAATTTCATTTTTGTGTTG
20 ACTTAAACTCAAGGAGAGTAACAATGATTGGTAGTGGTGATACTAAACAATGCAAAAAAT
TTTCTGCGTGTGATGGAAAAATACCACGCTACGATCCCTCGCCCTAGACTTGGACGGCG
ACGGCATAGAAACAGTCACCGCCAAAGGCTTTTCAGGCAGCCTGAAGACTGAGAGAGTGA
ATACGATGAGTATACACTCTATGCCACTAAATTGATATTCATAAATCATACCAGCTATA
TTTTATTTAATGAGACATATGAAAAATAAAATTTATTTACTAGTATTTATAGTTTACAT
25 ATAGCCTTGATAGTAATTAATATAGTGTTGGTTATTTGTTTTCTATTTGATTTTTTT
GCGTTTTTGTTTTTTGCAAACGTCTTTCTTGCTGTAAATTTATTATTTTAGAAAAAAC
ATAAAAAACAAATTTATGTTTTATTGCCGATTTCTATTATTATATGGATGGTAATTCAT
ATTAGTATGATAAATATAAAATTTTATAAATTGAGCATCAAATAAAGGAACAAAATATA
TCCTCGATTACTGGGTGATAAAACCACATGATAGTTATAATTATGTTTATGACTCAAAT
30 GGATATGCTAAATTAAGATAATCATAGATATGGTAGGTAATTAGAGAAACACCTTAT
ATTGATGTAGTTGCATCTGATGTTAAAAATAAATCCATAAGATTAAGCTTGGTTGTGGT
ATTCATTATCATATGCTCCATGTGCCAATTTTATAAAATTTGCAAAAAACCTGTAAAATT
TATTTTTATAATCAACCTCAAGGAGATTTTATAGATAATGTAATATTTGAAATTAATGAT
GGAAACAAAAGTTTTGTACTTGTAGATAAGTATAAACATTTTTTCTTATTGAAAACAGT
35 GTTTGTATCGTATTAATTATTTTATATTTAAATTTAATTTGCTTTTATATAGGACTTAC
TTCAATGAGTTGGAATAGTTTTGGTAATTTTATGAGCGCACGCTCATCCGCGTTAGCAGA
ATTTGGAAATATGGTTGCTAATTTAGTTTCTGCAAAAAATGAGAAAGATATCTCGAAACG
TAATGAATATTACAAACAAGCTGGTTATAGTGCATTATTAGCATTGTTAATTTGGCTAG
TAATATTGCACCAGGTAGTACGTCATCGCATATTGTAAACGGAACAAATGCCCTCTGTGAT
40 TGCAAGCCGCTCTCTCTGGAATATATCTTCAGCTATTGAGGAGCATAAAGATGGTAAAGT
TAATATCAACCGTTTTCAAATATTTTAGCGGATTTATATTCAATTGGGAGGGTTAGGAAG
TACATTAATAGAGAAGAATGGAATATGCAGAGTTGGGGGATTCCATTAGCAATTGCTGG
AGATATAATTGCAGCAACGGCTATTGCCACAGGAGATACTGGTACGATATCTACAGAGGA
ATTTTATAATTTTGACAACTGGAAAGGTTTTGGGTATGAGCTATTTGAAGACTGGTCTCG
45 TTGGGTATACGACTGGCTGCCCCAGCGCTGGAATCTGTGGAAGAATTTGGACAGAAACCG
TTCAGGCCAATACCACATCTACGACCCCTCGCCCTAGACCTAGACGCGGACGGCATAGA
AACAGTCGCCCGCCAAAGGCTTTTCAGGCAGCCTCTTCGACCATAACGGCAACGGCATCCG
CACCGCCACTGGCTGGGTTTTCTGCCGATGACGGTTTTACTCGTCCGCGATTTGAACGGCAA
CGGCATCATCGACAACGGCGCGGAATCTTCGGCGACAACACCAAATGGCAGACGGTTC
50 TTTTGCCAAACACGGCTATGCAGCTTTGGCCGAATTGGATTCAAACGGCGACAACATCAT
CAACGCGGCAGACGCCGCATTCCAATCCCTGCGTGTATGGCAGGATCTCAACCAGGACGG
CATTTCCCAAGCTAATGAATTGCGTACCCTTGAAGAATTGGGTATCCAATCTTTGGATCT
CGCCTATAAAGATGTAAATAAAAAATCTCGGTAACGGTAACACTTTGGCTCAGCAAGGCAG
CTATACCAAAACAGACGGGTACAACCGCAAAAATGGGGGATTTACTTTTAGCAGCCGACAA
55 TCTGCACAGCCGCTTCACGAACAAAATGCTATCCATTAGCCATGTTTCGGGAAAAACAGCAT
TTCCCGGTTTTGTTTTAGGCTGTCTAAACAAATAACCATAAATGTATATCATTATTTAAAA
TAAATAAAGTATTTAACTATTATTGACGAAATTTTAGAGAAAGAGTAGACTGTGATTA

5 AATGACAAACAATAGTGAGAAAGGAAATATTTACTATCCGAGCACAGAGCATATTTTAGG
TAGCCTGTAACGTGTTCTGCTGGCGGAAGAGGATGAAGGTTGACTTACCCGAGAATAAAT
GTCTGTGTTGTGTGATATGGATGCCATGCCGCGAAGCAATTGATGCAATCACGGCAGTCCT
ACTTGAATGAAACCTGTCGTTGCAGAATTTGAAAACGCTATTTTTAAGAAAGGATAAAGG
10 GAGAAAGAATTTTTGGTTTTTAAGCTGCATGAAACCGTGTGGAAATAAATGCACACCTAC
GATAATTAATAATTTTCGTTTTTTATTCTACAAGCTATTTATATATGATTGCTAAAAGTT
TATTTTTTTAGATGCCAAAAATATATTTTATATACTTCATATTGTTTATATGTCITTTATT
TGAATATATCTTACGATGGGGAAATATTTATATATTTTATAATAAATTTTACTCATTTC
TAATATGTCATGGAATATTACTTGTATTTTGTAGAATTTTCCCATATGAAAATATTCCAT
15 TTACTATTTTTCTGAACCTTATTAGTTTTATTTTAAATTTTTTACCTCTTATATTTACCA
TAAGAGAGCTAATTGATTCATATTATATGAGTCGATAATTAATTTATTCTTAATTTTAA
TTCCTCACGTTATTTTTTAAATTTTACTTGAAAGGAAAGCAGATATGACATCTGCAAATTT
TAATATTAACGGTTTTGGAGATGTGAAATTAACACCCTATTACCCTCTTGGGATATAA
AGCTTGGGATTCAATTTATTGGTCTATTCAATCCTTATCTGATTTAATCTATAATGTGGA
20 TAACAATAGAAATAAATGGAATTACTGTTAATAATGCTATTCAAGCTGCAGATAGCTT
TTTAAGCAGTAATTGGAAGAGATAACAAAATAACAAAATAACAAAATAACAAATACGCT
TCTTTACTTGCATCCTTCGATAACATTTTTTAAATTTAAGAAATGTATCTCGAGATATAC
GAGAAACAGGAAAATTTAAACCTAATGATATTCAACAAGCAATTGGTGATATATTCATTG
CTGCTGGTGATGGATTACAATATATAAAACAACAACAGAGGCGATGGCTCAAAGCAAAT
25 TCTTACCAACTAAATTAATAAAGCTGGTTTTAAATGATGTCTTAAATCTAGAATGCTAAAA
CCTCTACTGTTTTACAGCATGAATTGAATTAATAAGGATTATGGAAACGAGAGGCTTGG
CGAATCTATAATGAATATAGATGATTTTACACCAAGTAAGATAGCAAACCTTTTTTGC
TCCTGATACATACAGCAATGTATTAGAAGAAGTATCTAGGTTTATATATTCCTTAGTCC
TGATGATGCAAACCTTGGAAAGGGGCGAAGATTATTTGGACGAGGGATAAGTGAATG
30 GGGAGAGTTACTGGAAAAATGGTATAAACAAGATTTTCTCCCTTATCTTGAAAAGAAATGG
GACCAATTTCCGAAATTTGAAGATTGGCTGCCTGAATTCCTTGAATGGGCAAGAGAGTGG
TTGAAATTAGCTCTCAAACGTTACGGCAAATATAACGTTTACGATCCCCTCGCCCTAGAT
TTGGACGGCGACGGTATAGAAACCGTTGCCACCAAGGCTTTTCAGGCAGCTTATTTGAT
CACACCAACAACGGCATCCGCACCGCCACGGGCTGGATTGCTGCATATGACGGTTTTCT
35 GTGCGCAAATTAACAGTAACGGGGCATTATTAGCACGACAGATACCATATTTCCAATCT
TTGCATACATGGCTTGATCATCAACCAAGATGATATTTCCAAGCACAGCATGATGCATG
CCATTGAAAAATATAGAAAATTAATTGAAAGCTTAAATGGATATTGAAATGAATGATCAC
ATAGTACAAATATAAGAAGGTTCCGGGCTAGGTAGGATATTTTTTTATTTCGTATAGCAA
TCATCTATAATAATTTTTTCTTCGTATGTTGTTTTATTATATAATTTACAATTATCAATTT
40 AATTACCTTTTCGCTTTTAAATTTATTATTACCAATATTGTGCAGTATATATATGTTTATA
TTTTTTTTTAGGAAAACTAAGGATACATTAACGACAGAGCGAAGAAAAAATTTTTTAAT
TCTATTTTTTCCACTTAGAATTTCTAATGATAAATAGGTTCTGAGAAAAAGAGGTTAGGCATC
GGTAGTTTTTATTGCTAAACCTACTATGGATTATTTGGTGTCTTATGATTCATAGAGAA
CAAGTCCCATTAATAAATTAACCTCCTATTATCCTTCATATTTTCATTATTTTTTTTA
45 TTATGTGATTTTGTGTTTTATTATGAATGTTTATGTTTATTTTTTAAATTAAGAGAGGCT
TAATATGGTTAATCAAATCAAATCTGATAAATAATTCAGTTTCTATTGAATTTATATAAGA
TTTTATAACTGCAAGTACGGATGTAATTAATCTGAGTTACGAAAATTTTCGTAAAAATTT
TTATACACAAATGTCAACTGATTTACCAATTATGCAGCCAAACATGAAAGTTTAGGAAA
ATCGGTACAACGTGAATTACAAAAAACACAAAGTCAGTTGAGACAAGTTGTAAGAAAAAT
50 GCAGAGTAAATATAATATAAATAAAGACGAGTAGCAGAAATATCTTTGTTAAGGCA
AATGCAAAGCCAATTTTTCTCGAAAAATATGTAACAAAAATCTTGGTAACAGCAACACTTT
GGCTCAACAAGGCAGCTACACCAAAAAAGACGGCACAACCGCGCAAGCAGGCGATTGCT
GTTGGCTGCTGACAACCTGCACAGCCGCCTCACGGACAAAATGCTATCCATTAGCCATGT
TCGGGAAAACACGATTTCCCGSTTTGTTTTAGGCTGTCTAAAACAAATAACCATAAATGC
55 ATATCATTATTTAAATAAATAAAGTATTTAACTATTTTTGACAAAATTTAGAAATAG
AGCTAGAGTTTTAGTTAAGTAGAAATTGATAGTGCTTCAAGGGAAGTATTTCTCTATGTTT
GCATTAAAGGGGGTCTGATAAAGCTATTATTCATTACTATGGACTTTTATTTTCAATTATTT
TCAGGCGGAAATCTCATAGCCGTTTTGAATTTTTCTCTCCTTATTAAATTATACAAATAA
TTAGTATATTCTGATATGGATTTTTTGGAAATTTTTATATGTCTGCATTTAGAAAAATA
TTATTAATAATATCTTGCTATTGATTGCTAGCTGCAGTTTTGTTGAAACTATTTTTTAT
ATGGCTATTAGCCAGAACCTGTTGTGGTAGACTTTCCTCTTGGTAAAAAAACAAAAAGA
TCTATTGAACTCAAACAGAAAATTTGGTAAACCTTATGCAATATCGTTAGGAATAATTTT

ATACATTATGATCCAAAACAGGGGGAGAGGTGGATTGATGATAAGTTAACTATCCATAT
AATATATCGGTTAAATATTTAAAGTGAAGAAGATGGTAAAAAACTTATTATAGATGAG
TTGCTTACAGAGAGAAGTAGAAAATTAGGAGGCGGAGTATTTGGAGCTGGGGGAAAATAC
AGTATGCATATTTATGATTTTTATTGCCGGAAGGGGAATATTTATTTGAGATTTCTGAT
5 AATAGTGAATATATTCCACTTTACGATGAAATAAATAATTCTATAAGAATAGTAGTTAAT
GCACGAATTCAGTAAATTTTTCTAGAAATGTGGGGTTACTTATGGCTGATTATTATGCGA
TAACTGTAAAATTTGCGAAGCAGGGTACGCCACTGAAACAAGAGGGGGTGTATCCAAGAC
GGGTACGTTTGGGTGAACTGTATTCGGCTAGAGATAAAAAAATCGGGGCTGTACTAGAT
10 TAGCCCTAAATCCACACCAATCCCGCAGGATTTTAAGCTGTTGAGACGGTGTGCCGAAG
TTAAATCGAAATTCGCATTCTTTCAAGAACAGCGGGGAAAGATTTACGATCGATTCCGTTG
TATTTTCGCAAGACGCGTTTTGCCTGATTCCAAAAATCTCAATGCCGTTAATGTGGTTC
TGACGGTCTGCAAATTCCTTGAATGGTTGATGCGGTAATGGATAAAACCGCTCACGTCC
AACTTGTGCGCAGCTGCTCAGACTATCGGTATAACAATACTGTCCGGCATGATTTTCTTT
15 TTGATGACAGGGAGTAACGTTTCAGACTTGGCATTATCTACGACAACGGTATAGCCCGT
CCGTTGCGTTTTAGAATGCCGAAGACAACCACTTTTCTGCGCACCGCGACCACTCTG
CCTTTACGCCGTCGCCGAAATCGCTTTCTGTCGGCTCGACAGGGCCCTCAAAAACCTCA
TCGGCAGCCAAAGGCCAAATGATGGTTGATAACCGTGCGGATTTTACGGTAGAACAGTACT
GCCGAATTTGGGATGGATACCCAAATATCGGCGGAGAACGGGCGGTAACCTCCAGCACA
AAAAAACGGAGCAGTTCTTTCTGTACTTTTTCTTTAATTTGCAGTGCGTTATCTTCATA
20 TTTTCGAGGGTAACATATCTGCTAATCTAGTACAGCCCCAAAAATATACCAAAAACAGCAA
AACAAATTGTAAGGATAGGTATAGGCTTTGTAAAGGTAAATTGTGAAAAAAGCAGTTTTT
TAAACGAATGAAACGGCTTCGGGCTGAAATATATGCTGATGCCCTGTCTTCCCGTATAT
CTTGTGTGTTGTCAAAGTGCAGGCTGCTTTGAAATCGGTATTGCCATCTATGAACCACCA
CTTTGTTTTATTTACGCGGGCTTGAGATGTGTATAAGAATATTGTTTTGAATAAAATTTAA
25 AAAAATGATAATCGTTATTGACGATTTTTAAAGGAAAGCGTAGAGTGCCAAATCTATGAA
GCAATACGGTAAGTAACAATGAAAAATATCTACTGCTTGGGTATAGGCATATTTCAACA
CCGTAACCTATTCTTGCGGAAACAGAGAAAAAGTTTCTCTTCTATCTTGGATAAAATATAT
TTACCTCAGTTTAGTTAAGTATTGGAATTTATACCTAAGTAGTAAAAGTTAGTAAATTA
TTTTTAACATAAGAGTTAGTATCTACCATAATATATTCTTTAACTAATTTCTAGGCTTGA
30 AATTATGAGACCATATGCTACTACTATTTATCAACTTTTTATTTTGTATTATGGGAGTGT
TTTTACTATGACCTCATGTGAACCTGTGAATGAAAAGACAGATCAAAAAGCAGTAAGTGC
GCAACAGGCTAAAGAACAACCAAGTTTCAACAATCCCGAGCCAATGACAGGATTTGAACA
TACGGTTACATTTGATTTTCAGGGCACCAAAATGGTTATCCCTATGGCTATCTTGCACG
GTATAACGTAAGACAATGCCACAAATGGCTTTCCGACACGCCAGGGCAGGATGCTTACTC
35 CATTAATTTGATAGAGATTAGCGTCTATTACAAAAAAACCGACCAAGGCTGGGTGCTCGA
ACCATAACAACAGCAAAACAAAGCGCACTTTATCCAATTTCTACGCGACGGTTTGGATAG
CGTGGACGATATTGTTATCCGAAAAGATGCGTGTAGTTAAGCACGACTATGGGAGAAAG
ATTGCTTACTTACGGGGTTAAAAAATGCCATCTGCCTATCCTGAATACGAGGCTTATGA
AGATAAAAGACATATTCCTGAAAATCCATATTTTCATGAATTTTACTATATTA AAAAAGG
40 AGAAAATCCGGCGATTATTACTCATCGGAATCATAGGIATGGAGAGAACGATTACAG
CACTAGCGTAGGTTCCCTGTATTAACGGTTTCACGGTACGGTATTACCCGTTTATTCGGGA
AAAGCAGCAGCTCACACAGCAGGAGTTGGTAGGTTATCACCACAAGTAGAGCAATTGGT
ACAGAGTTTTGTAAACAATCCAAGTAAAAATAATGGGGCTGTCTTAGATAACTAGGATA
AACTCGATTTTACTAATTGTTTTAAATGGAACAAGAACTTTTATCTCACTGTTGTTAAA
45 ACGCCATTGCGCACTCCTTTAAATACAGCTCAAAATGCGCTTTGGGAATGCCGTTAACTT
GCGTAAATGACGTTTTGCCTGGTTCCAAAAGTTCTCAATTCATTAATATGGTTTTGTGCG
TTCAGCAAAATGTGTGCTGTGATTGATACGAAAACGAAGTTTCAGCGAAGCTAAAATGGC
TAAATTCGCGCACATCTAATACATCATAGCTACGATAACAATCCGTATAAATAATGCTGT
CAGGTTTCACTTGTTCACGGATAATAGGAAATAAAGTAGCGGTTTGAGTATTCGGTACTG
50 TAACCGTATAAACCTTACCATTTGCTTCAAAAGACCGAATACGGCGACTTTACCGGCAG
CACCCGACCGCGTTTGCCCTTTGCGTTGTCGCCAAAATAACTTTCATCTGCTTCTACTT
CGCCATCAAAACATTTCCAAATGCGGACTGTTTTGATAAATAAGTAATCGTAAACGATGAA
AATAATAGGCTGCGGTATTTTTATTAAACGCTACTAACTCTGCTGCCGTTCTTGCAGTTA
CACCTGTGACAAAATAGCTCAATGAGTTTATTTGTTTATACTGGCTTAGACGACTTTTTTC
55 TCATAGGGATAATTCTAACTTAATTTGAATTTCCCTAGTTATCTAGGACAGCCCTATTC
TTTAACTAATTTCTAAGCTTGAAATATGAGACCATATGCTACTACCATTTATCAACTTT
TTATTTTGTATTATGGGAGTGTTTTTACTATGACCTCATGTGAACCTGTTAATGAACAAA

CCAGTTTCAACAATCCCGAGCCAATGACAGGATTTGAACATACGGTTACATTTGATTTTC
 AGGGCACCAAAATGGTTATCCCCTATGGCTATCTTGACGGTATACGCAAGACAATGCCA
 CAAATGGCTTTCCGACACGCCAGGGCAGGATGCTTACTCCATTAATTTGATAGAGATTA
 5 GCGTCTATTACAAAAAACCGACCAAGGCTGGGTGCTCGAACCATAACAACCAGCAGAACA
 AAGCACACTTTATTCAATTTCTACGCGATGGTTTGGATAGCGTGGACGATATTGTTATCC
 GAAAAGATGCGTGTAGTTTAAAGCACGACTATGGGAGAAAGATTGCTTACTTACGGGGTTA
 AAAAAATGCCATCTGCCTATCCTGAATACGAGGCTTATGAAGATAAAAGACATATTCCTG
 AAAATCCATATTTTCATGAATTTTACTATATTAAAAAGGAGAAAATCCGGCGATTATTA
 10 CTCATTGGAATAATCGAGTAAACCAGGCTGAAGAAGATAATTATAGCACTAGCGTAGGTT
 CCTGTATTAAACGGTTTCACGGTACAGTATTACCCGTTTATTCGGGAAAAGCAGCAGCTCA
 CACAGCAGGAGTTGGTAGGTTATCACCAACAAGTAGAGCAATTGGTACAGAGTTTGTAA
 ACAATTCAAGTAAAAATAATTTAAAGGATCTTATTATGAATGAGGGTGAAGTTGTTTTA
 ACACCAGAACAAATCCAAACCTTGCCTGGTTATGCTTCCCGTgCGGATACCTATGGCGGT
 15 TGGTATCCGAGCT

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 4>:

gnm_4

CGGGGCTTACAACATCGGGCGCAATCGACAAAAAGACCATGCGCGACTTTGACAAGTCCTG
 20 CCTGACCGAAATCAAACCGTTGAGCGCGGAGACATCAAGGCAATCAGGGAGAAGGAGGC
 ACTATCGCAAGCCGCTTTTCGCCATCTATCTCAACGTGGGAAAAAATCACGTTTCGGCTTG
 GGAGCGGGCGTTAAAAAGCCGAGCGGCGCGCGCTTGAAGCTGCTGACCATCGTCAAAAA
 CAAGGGCATCGAAGCCATTGCGTAGCCGACTTGGCAAACGGCAAAATCAGCAAGTTCACA
 ATAGACGCGCTGCTGAATATGCTGCCAAGACAGGCAAGACCGCCGAATGAATATCAGG
 25 GCGTAGCCGCATAAATGCCCGACCGCATCAAACCAAGCCGAAACGGCGGCGGTGCAGACG
 ACATAGCCCGACAGCAAGGCACGGCGCAGACGGGCGCGAAACCCGAAACATCACCGACCG
 CGAGGTACGGGATTTTTTGCGCCCGTTGCAGGGGGGATTGGATTTAAGCGGCGCGGGC
 TTGAAGGCAAAACGGGTGGGGCACAGAATGTTTAAATGCAGTCTGAATCTCAAACGATT
 TCAGACGGCATTTTTGAACAATGGCTCAAATTTCTCGATCCCTTCCCTTAACGCCGACGT
 30 TTTTATTAAACGCGCCCTTATTCTGACACTTTGCTCATAAACCGGCATAACGGTCGGC
 AACAAACCGTTTTAGATTTTCTATACGGGCATTGTTTGTGCGGATGAGTAGAGGTAATAGCA
 TAAATAAAGCCGTTTTGGTCGTTTTCTGATTCATTTTTCCCAAACCTGACAGCGGCC
 GCCGATGATAGCCTGCCTGCGCCATCAACATCATCCCCCTCATCGGCTTCTCTCTCC
 AAGCTGCGGCTATAAGGCAAGGTAAGACCGTACGTCCCCAAAATATCCATACCCAATCCG
 35 ACCAATTCGGATTAGTATCCGGTTTTTGTCTAATATAATCTGCGTGCCTATCTGCGCC
 GCCGTATTGGTCAAGATTTGCTGCCCCGACCTATTTTTTACCGTGTTTCATGCAGGGCGTGC
 GTCATTTTCATGCCCCATAATGGCGGCAATTTTCGTCAATCGGTCAGCTTGAGTTTGTGACT
 ATCCCCGTATAAAACGCCATTTTTCCACCGGGCATTGCCACGCGTTTCAGCTCATCGTTT
 TTGAAAACCGTCATTTTCCAGTCAAACCTATGGCTGGTATTATTTGCCGCATCGGCATAA
 40 GGCAGCATACGTCGAAATACTGCCTGCACCCTGCGGGCTGTTCTGGATGTGGTATCGACA
 TTGCCGGCAGACTTGTTTAACTCAACCGTTTTTCATATAATCTTTGGCAGCCGACGCGTTC
 ATTGTGGCGGAATCATGACCGTAAACATCAGCAACGACCGCACAGCCCCCAATACCGAG
 ATTACTGCCGACAGGCAGAGTATCCGTTTAAAGGAAGGAAGGAAGGAATTTTCATATTTA
 GGTTTACTCCTTAAAAAATTAAATTTCAAAAAAATGCCGTCTGAATCCAAAACGGATTTT
 45 GGACGGCATCTTAACATTGTTAATGTTTTTAAAAAGATTTACACCACGATGTTCTCCAG
 TCTGCCCCGGTACGGCGATGATTTTCTTGGCAGGCTTGCCCTCTATGAATTTACCGCGCC
 TTCAGCGGCGTATTCGGCAGCTTCTTCAGCCGGTTTGTGCGAAATCACGCATAAATTGCCA
 ATAATTCTCCAACTTTTTACGGCTGCTGCTGCCTTTTGCGGCAATATTGCGCTGAACTT
 CAACTGTTTTTCAAAATGGCAGAAGAATAAATATCCCTTGTGAATTCAGTATCATGATTTG
 50 AAATCAAAATACCTTGGGAGTTGGGCGCAATTTATTGATTTTTTGTAAAGTCCGCGACCA
 ATGAATTCGATCGTATTTTGGTCGCGCAGAATTTGCAACTGTTGGCGGATTTTGTCTCTG
 ATATGGTTGTTTTGGGGAAATGGATGGATAGTTTGTTTTCAAATTCATACATTTGCGAC

AATGTGAATTCTTCGGGGAGTTGGTCGATACATTTTCATAACAGCCAGAAGCCAGCCTTTG
CGCTCCGCATTTTTGGTTGCGTAAAAACAAATTGGATTGCCATTTTTTCAGAACGGTTTCG
GGTTCGATAATGCGGGAATTGTCTATTAAGAATAATTTGCCGCTTCAGGCAAAGGGGCG
AGATTGATAGAACACATAATGTGGTTCGGCCGGTTTTTAATGCCTTTATTTCTGGGAATA
5 ATCATATCCGGCGTGATGAAATGTTTGGGTACAAGCACC AATTGCCGTATGGAGTAATCC
GCTTTTTTATATGCAAGAAAGAAAAAGTTGGGGTGGTATCTGACCGGATGCGCTCCAAC
ATGGTGTGATATGCACCGTCAGGCACGCTGTTGCCTATGGTTTTTGATTTTTACTCTTT
AATTCATATTGCTCGTGGCAATTTGGGCAAAAGAGGTCTGCAACAGGTTTGTTATTGGCA
AATCTCTGCATCGGCTTGCTTCCGCAACAGGGGCGAGTAGCCGTTTTTTCCAACCAAGCC
10 TCGCTCATACACGATTTTATGGGTGCTTTATTTTGTGCTTCCCAATTCGGTATCG
AAAAATAAATTCATGTTTTGGATTTTGAGATTTTCAGTTATTCGGGGTTCGTATGCAGAC
AACACAATCCACCTTAAAAAGGCCGTCTGAAACCCTGTTTCCAAGTTTCAGACGGCCTTT
ATCCGTGTGGCTAAACCTTAAAAGCGGTTAGACGACGATGTTACCAGTCTGCCCGGTAC
GACGATGATTTTCTTCGCCGGTTTGCTTCCATGAATTTACCGCGCCTTCGGTGGCGAG
15 TGCGGCGGCTTCGAGGTGCGCTTTGGATGCGTCGGCGGCAACAGTGATTTTGCCGCGCAG
TTTGCCGTTGACTTGAACCATCACTTCGATTTTCGGATTTGACCAAGGCGGCTTCGTGCGAC
TGTCGGCCAGCCTGCTTCCCACAGTTTCGCGCCGTTCAATTGCGTCCACAGGGTTTCGCA
GATGTGCGGCACGATGGGCCACAACAGGCGTACGGCGGTTTCCAATACTTCTTGGGCGAC
GGCGCGTCCCTTTGCTTCGCCGCGGTTGTCGCTTTTGTGCTATTGGTTGAGCAATTCATCAC
20 GGCGGCGATGCGCGGTGTTGAAGTCTGGCGGCGGCGTAGTCGTGCTGACTTTGGCAGT
GGTCGCGTGCAGTTTGTGGCGCAGGTCTTTGAGTTCTTTAGACAAACCGTCTTGGCTGCC
TGCGAACGCTTTGACCGCTTCGCTTCAAGTATTCGTAAACGGTACGCCACAGGCG
GCGCAGGAAGCGGTGTGCGCCTTCGACGCGGCTGTGCTCCATTCGAGGGACTGTTCCGG
CGGTGCGCGCAACATCATAAACAGCGGGCGGTGTCCGCGCCGTAGGCGTTAATCAGTTC
25 TTGCGGATCGACGCCGTTGTTTTGGACTTGGACATTTTTTCCGTGCCGCTGATGACGAC
GGGACGCCGTCGGCTTTGAGGACGGCGGAAATGGGGCGGCTTTGTCGTGCAACGTCAG
CTCGACATCGGCGGGGTTGATCCAATCTTTGCCGCTTTGTCGTTTTTCGCGGTAGTAGGT
TTCGCAACGACCATGCTTTGCGTCAGCAGGCGTTCAAACGGTTTCGTCAACATTGACTAG
ACCTTCGTGCGCATCAGTTTGGTGAAGAAACGCGCGTACAAGAGGTGCAAAATCGCGTG
30 TTCGATGCCGCCGATGTATTGGTCGACCGCGCCCGAGTATTTGCGGCGGCGAGGATCGAC
CATGCCGTCTGAAAATTTTGGCGACATGTAGCGGAAGAAATACCAGCTCGATTCCATGAA
GGTGTCATGGTGTGCGTTTTGCGTTTTGCGCGCGCCGCGCAGCATGGGCAGGCAGTTTC
GTAAACTCGGGCATTTTTGCCAGCGGCGAACCATGCCGTGCGGTACGACGTTTTTCAGG
CAAAACGACCGGCAATTGGTCGGCAGGGACGGGTACGTGCGCGCATTGTTGCGCAATGGAC
35 GATGGGAATCGGGCAGCCCACTAGCGTTGGCGCGAAATGCCCACTCGCGCAGGCGGTA
TTGGGTTTTTCGTTTTGCGCCGCGCTTGCTTTGCGAGCTTGCGCGGCGACGGCGTCGAATGC
CGTCTGAAAATCCAAGCGGTCCAAGTGCCTGCTGTTGACCAATACGCCGTTTTCTTTGTC
GCCGTACCATTTCTTGCCATTGGTTTTTCGTCAAATGCGTTGTGCGCGACGGCAATGACTTG
TTTTTTCGGCAGATTGTATTGGTGGCGAACTCAAATCGCGTTCGTGTCGCGCGGAAC
40 CGCCATCACCGCGCCGTGCGCGTAGCCCCACAATACATAGTTGGCAATCCACACTTCCAG
CTTGTCGCGGTTGAGCGGGTTGACGACGTAGCGGCGGTCGGCACGCCTTTTTCTCCAT
CGTCGCCATATCGGCTTCGGCAACCGAACCAGGCTTTGCATTGGCAATAAATGCCTGCAA
TTCGGGTTTTGTCGGCGGCTGCGGCGGCTGCCAGCGGATGCTCGGCGGCAACGGCAACATA
45 AGTCGCACCCATCAGCGTGTGCGGGCGGGTGGTATAAACTGCAGGAATTCGCGTAATC
GCCTTCCAAGCCTTGTTTTGCTGTGCTGTGAAACGCGGAAGCGCACGGTCAACCGCGCGA
TTTGCCGATCCAGTTGCGCTGCATGGTTTTGACTTGTTCGGCCAGTGTTCAGCTTGTC
CAAGTCGTTGAGCAGCTCTTCGGCGTAATCCGTGATTTTGAAGTAATACATCGGGATTTTC
GCGTTTTTCGATCAATGCGCGGAACGCCAGCGCGTCCGTGATGACTTGCTCGTTGGC
AAGGACGGTTTTGGTCGACAGGGTCCAGTTTACCGTGCCGTTTTTTCGATAAACGATGCC
50 TTTTTCAAACAGCTTGGTAAACAGCCATTGTTCCAGCGGTAGTATTCGGGTTTGAGGT
TGCGGTTTTGCGCGCGCCAGTCAATCGCAAAACCTAGGCTTTTGAGCTGGGTTTTTCATGTA
TTCGATGTTATCTAGTCCAAGCGGCGAGGGCGACGTTGTTTTTCATCGCCGCGTTTTTC
CGCCGGCATGCCGAACGCGTCCCAACCATAGGCTGCATGACGTTGAAGCGGTTTTAAAG
TTTGAAGCGGCTCAATACATCGCCGATGGTGTAGTTGCGCACATGCCCCATGTGCAGCTT
55 GCCGCTGGGATAGGGGAACATGGAGAGGCAATAATTTGGGTTTGGAGCGCTTTCGGA
GACGTTGAAAATACGGGCGTCTCCCATTTTTTCTGCGCGCAGGCTCAATGGCGGCGGG
CCGGTATTGTTCTTGCAATAGTCATTCTGTTTTGCTTAAAAACGTTGAAAAATAAAGTC

GGCATCAATTATAACAGGTTGCCGGAAGCGGCGAATCGGCAGATTGCCGGCAGGATGCGT
AAATTCGCACGCGCATTATTCCGTATGCCGTACAAATACACCGCGTTTATTGATACGCAC
GTTTTTTATGCTAATATTACAAACCAAAATCAAATGTTTAAAACTCTCCTGATGCGGCTC
TTCCGAACAAAAGGCAGACGCGCATCGGGTAAAAGAGGATTCTGCATATGAAAATCAAAC
5 AAATCGTCAAACCGGGCTTGGCAGTATTGGCGGCGGGCGTTCTGTCTGCCTGCGCAACCA
AAAGCAACGTCAAAGCCGACGGCAGCACCACAATCCGGTTTTCCCGAAACCCCTATTCCG
TAACGCTCGACAACAAGCGCGGCACATTCCCGACTTATGACGAACTGGATCAGATGCGCC
CCGGCCTGACCAAAGACGACATCTACAAAATCCTGGGCCGCCCGCATTACGACGAAAGTA
10 TGTACGGCGTGCGCAATGGGATTACCTGTTCCACTTCCATACCCCGGGCGTAGGTATCG
ACCCTGAAAACACTTCCGGCGTAGAAGATGTTACTACCTGCCAATACAAAGTGATTTTCG
ATAAAGACAAATTTGCCCGCAGCTTCTACTGGAACCCCGTCTTCCCGAAAGATGCCGCT
GTCCGCGCGCCGACCCCAAAGCCGAGCCGCAAGTCATCATCCGCGAAATCGTGCCGGCAA
AACCGAAACGTATCCGCCAATAATCCGACATGCCGTTCCGCTGTTTTTAGGGATATTAT
GCGGCCTGTCAATGGTTGCCCCGTATATGCACAGGGGCAGCCGGATACGGTCGGCGACT
15 TTATCCAAAAGAAAAAGTCATCGTCGATACATCAAAGCGGAACTCTGTTTCGCTGACG
ACCGTCAGTGCCACCCCGTCTCATCGGTGTTGCCACGCCCAAGGGGACGTTCCGGCTGA
CGCTGAACAGTACCGACAAGCCCGGATACGGCGGCGAAGTCATCGGTTTCAAGCAGGAGG
GTGATTTTCTTTTCGCCCTGCACCGCGTTTGGAAATCAGATACCGTCGGAAAGCGGAAACG
AACGCATCGCCTCCCGTCCGTGTCCGACAGGATTATGACCAACGGCTGCATCAACGTCA
20 GCGATGCGGTGTACGAAAACTGCGTCATTATTTGTGTTGGAAGTGATTGAAACAGAC
GGATACCGCAGCGCGCGGTATCTGTTTTACATTGCCCGCATGCCTGAAACAGACTGTCC
GCCACGTATGCCGTCTGAAACCGGCGCAGATGCCGCCAAGCCTTCAGACGGCATTGCCT
GCCCCGTCCGACCGAACAACAACCATCTTTGGGAGAACCTTATGCCCGAACAAAACCGCA
TCCTCTGCCGCGAACTGAGCTTGCTGGCATTCAACCGCCGCGTGTGGCGCAGGCGGAAG
25 ACCAAAACGTCCCCCTTTTGGAAACGCTGCGCTTCTGTGCATCGTTTCATCCAACCTCG
ACGAGTTTTTCGAAGTCCGTATGGCGTGGCTGAAGCGCGAACAACAACGCTGCCCGCAGC
GCAGGCTGGACAACGGCAAAATGCCGTCTGAAACCATCGCCGACGTTACCGAAGCGGGCG
GCTCCCTGATACGGCACCAGTACGACCTGTCAACAACGTCTTTCAGCCCGAGCTGGCAC
AAGAAGGCATCCATTTTACC CGCCGCGAAATTGGACAGACACACAGAAAAAATGGATTG
30 AAGACTATTTTCGACCGCAATTGCTGCCGATCCTGACCCCCATCGGACTCGACCCTTCCC
ACCCCTTCCCGCGCCCGCTGAACAAATCGCTCAACTTCGCCGTGAACTCGACGGCACAG
ACGCGTTCCGGCAGGCCTTCGGGGATGGCGATTGTGCAGGCACCACGCATCTGCCGCGCG
TTGTTCCCTGCGCGTCCGAACTGTGTGGCGCGGACACGGCTTCGTCTCTCTCTCTCCA
TCCTGCACGCCACGTCGGAAAACTCTTCCCGGGCATGAACGTCAAAGGCTGCCACCAGT
35 TCCGCTGACGCGCGACAGCGACTTGACCGTTGACGAAGAAGACCTGCAAAACCTCCGCG
CCGCCATTCAAACGAGTTGCACGACCGCAATACGGCGACGGCGTGCGGCTCGAAGTCG
CCGACACCTGTCTACCGCTACATCCGCACTTCTGTGCGCAATTCAAACCTGACCGCGC
CCGAACCTCTATCAGTCAAAGGCCGGTCAACCTCGTGCGCCTCAACGCGCTCCCGACC
TAGTCAACCGCCCCGATTTGAAATTTCCACACACACGCGGGCAGACTGAAAGCCTTGG
40 GCAAAACCGCGTCCATATTGATTGGTGCGCAATCGCCATCTGCTGCACACCCCT
ACCAATCGTTTCGACCCCGTTGTGCAATGATGCGCGAAGCCCGCCCGACCCCGCGTGC
TTGCCGTCAAATGACGATTTACCGCACCGGCACGCGTTCCGAACTCGTCCGCGCCCTGA
TGAAGGCGGCACTCGCCGGCAAACAAGTAACCGTCGTGCTGAACTGATGGCGCGTTTTG
ACGAAGCCAACAACGTCAACTGGGCGAAGCAGCTCGAAGAGGCGGGCGGCACGTCGTGT
45 ACGGCGTGTTCGGCTACAAAGTCCACGCCAAAATGGCACTGGTCATCCGCGCGAAGACC
GCGTGCTCAAACGTTACGCCCATCTCGGCACGGGCAACTACCACCAAGGCACATCGCGCA
TCTACACCGACTTCGGCCTCATTACCGCCGACGAACAATCACCGCCGATGTGAACATAT
TGTTTTATGGAAATCACAGGTTTGGGCAAACCCGGGCGGCTGAACAACTCTACCAAAGTC
CGTTTACCTTGCAAAAATGGTTATCGACCGCATCGCACGCGAAACCGAACGCAAAAG
50 CCGGCAAACCGGCGCGGATTACCGCCAAGATGAATTCGCTCATCGAACCGACCGTCATCG
AAGCCCTGTATCGGGCAAGCGCGGACGCGTACAAATCGATTTGATTGTGCGCGGTATGT
GCACCTTGCGCCCGGGTGTAAGGCTTGTCCGAAAACATCCGCGTCCGCTCCATCGTCG
GCAGGCAGCTCGAACACGCGCGCGTGATTACTTCCATAACAACGGCACGGACGATACCT
TTATCTCTCAGCGCGGATTGGATGGGGCGCAACTTCTTCCGCGCATCGAAACCGCCACGC
55 CGATTACCGCGCCCGAACTCAAAGCGCGTTATACATGAAGGACTGACCATGGCACTGG
ACGACAACACCCACGCGTGGCTGATGCAGCCCGACGGCGGCTATATCCGCGCCGACCTG
CCGAGGGCGAATCCGAAGCCGACCTGCAAAACGATTGTGGACACTGCTCGGAGGCTGAC

CCGCACCGCCCCAATCAAAAACCATGCCGCTCTGAAACCTTTCGGTTTCAGACGGCATGGT
TTTACAGCAATCTAAACAGGGCGGACCGAGTCAAAAACACACCTTCGCCATTCCCTGCAC
AAGCACTTCCCCATACGCTCCCAACCCCAAGCCGCGCATTCCAGACGGCATTATAGTG
GATTAAATTTTAGGGGCTGTACTAGATTAGCAGATATGTTACCCCTCGAAATATGAAGATA
5 ACGCACTGCAAAATTAAGAAAAAAGTACAGAAAGAACTGCTCCGTTTTTTGTGCTGGAAG
TTACCGCCCGTTCTGCCGCGGATATTTGGGTATCCATCCCAATTCCGGCAGCACTGTTCT
ACCGTAAATCCGCACGGTTATCAACCATCATTTAGCCTTGCGTGGCGATGAGGTTTTTG
AGGGCCCTGTGAGCCGGACGAAAGCGATTTCCGGCGACGGCGTAAAGGCAGACGTGGTC
GCGGTGCGGCAGGAAAAGTGGTTGTCTTCGGCATTCTGAAACGCAACGGACGGGGCTATA
10 CCGTTGTCTAGATAATGCCAAGTCTGAAACGTTACTCCCTGTCATCAAGAAGAAAATCA
TGCCCGGACAGCATTGTTTTATACCGATAGTCTGAGCAGCTGCGACAAGTTGGACGTGAGCG
GTTTTATCCATTACCGCATCAACCATTCCAAGGAGTTTGACAGCCGTGAGAACCACATTA
ACGGCATTGAGAATTTTTGGAATCAGGCAAAACGCGTCTTGCGAAAATTATAGTGGATTA
ACAAAAATCAGGACAAGGCGACGAAGCCGACAGACAGTACAAATAGTACGAAACCGATTCA
15 CTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCCGTA
CTGGTTTTTGTTCATCCACTATACCTTTCCGACAGCCGAACAAAACCCCGAATCCGTCTG
CACGGTTCCGGGTATATCTCCAATACGGGCATCGTGTTCGGGAAAACCGTCAAATCCGCA
TCGGCATCACAAATATTTGAAATTCGGATTGTTCCGGCAGGTAAACAGCGTCGAGCGGT
TGCGATCGCCGAAGGCAAGCTGCATATCGTCGGAATGGATGTTGCGCAACACGTCCATCA
20 GATAGCCGATATTGAAACCGACTTCGAGTTTCGCCGCCCTGATAGGCGATTTGATTTCTT
CGCGCGCTTCTCTGCTCGTTGTTGCTGCACACAACGCTCAACAGGCCGGGTGCAAAA
ACAAATCGCGCACCGCGGAATTTTTTATTGGCAAGAATCGATGCACGTTCCAACGCGCCCA
ACAAATCTGCCCTCGACAACACGAAAATCTTGTCTGTTGCCAAAGGAATCACGCGTTGA
AATCGGGGAATTTGCCGTCGATGACCTTGCTGACGATGGTCTGCCGTTGCATTGGAAAC
25 GCACCTGTTTGTCCAGCAGCTCGATTTGAATCGGATCGTCGGGGTGTTCACAGTTTGA
ACAGTTCAGCACCGTTTTTCCGCGGCAAAATCACTTCGGCGCGCGGCAATCCGCATCAA
TCGGCAGGCTGCATAGGCAAGGCGGTGTCGGTCGGTCGCCACAAGGCGCAACTGGCTGC
CCTCAACCTGCATCAGCAGACCGTTGAGATAATAGCGGATGTCTGCACCGCCATGCTGT
ACTGCACCTTGCGACAGCATGGTTTTTGAACGCTCCTGCTCCAGCGAGAAAGTCGCGCTGA
30 TGTCCTCGCCGACATTATCATCGGAAAATCGGCGGCAGGCAGGGTCTGCAGGGCAAAAC
GCGATTTGCCCGCCTTCAGCGTCAGACGGCTGTCTGCCAATCCAGCGACACCAGCGCAC
CGGCAGGCAGCGCGCGCAAAATATCCTGAAATTTCTTGGCATTGGTGGTGATGCGGAAGT
CGCCCGCGCGCCCTCGGGACCCGAGTGTGATTTGGATTTCCAAATCGGTTGCCAAGA
GTTTGGTCTGACCGCCTTTTCCCTCAATCAGGACGTTGGACAGGATGGGCAGGGTGTGGC
35 GCGGTCGAGATGCGGTAACGGCTTGCAACGGCTTGAGCAGGCTGTCCGCTCGGCTCGGCTT
GTAAAATCAACATGTTTCGCTCCTTTAAATCGGTTTGATAGTGGAATTAATTTAAATCAG
GACAAGGCGACGAAGCCGACAGCGGTACAAATAGTACGGAACCGATTCACTTGGTGCTTC
AGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCCGTACTGGTTTAAAG
TTAATCCGCTATATCTTTACCTTCGGACGGCATGGGCAATATCATGTCGTCTGAAAACG
40 TTTTCCATCAGTTTTGAATCAGAATCAGCAGCTTTTCATAATCCTGAGCCAATTCGGAT
CTTCTTCGCGCAGTTTCGCCACTGCCCTGATGCCGTGCATAACGGTTCGTATGGTCGCGCC
CACCAAACGAATCGCCGATAGACGGCAGGCTCAAAGTAGTCAGTTCTTTGGTCAGGCTCA
TCGCCACCTGGCGCGGACGGGCAATGTTTCGTGTCCGTTTCTTACCGAGCACATCGCTGA
TTTGTATGCGGTAATATTTTCGCCACCGCATCGATGATGTCGGCGGTGATGACTTTGT
45 GCTTCTCGGCAATAATGTCTGCAAAGCGGTACGCGCCAAATCGATGTGATGACGGGAC
GGTTCATAAAGCGGCTGCTCGCTCCGACACGATTAACGCGCCTTCAAGCTCGCGCACGT
TGGAACGGATCAGATTGGCAATGAACAGCGCGGCTTCGTCTTCGATACTGATGCCCGCCG
CTTCCGCTTTTTCTGCAAAATGGCGATGCGCATTTCCAATTCGGGCGGCTCGAGTTCCA
AAGTCAGTCCCCATGAAAAACGGGATTTGAGGCGGTTCGTCCATGCCTTCGATTTTCGCAG
50 GCAACACATCGCAAGTGAGGATGAGCTGTTTTTCTCGTTGTGGAATGGTTGTACAGAT
AGAAAAATCTTCCATCGTACGGTCTTTGCCCTTGATGAACTGGATGTCGTCGATAATCA
GCAGGTCGTATTGCTTGTATTGCTGCTTGAACACGTGTAAGTGTGTTGCGAACCCTT
TCATAAAGCTGCGGATATAGTCATCCGAATGCATATAGCGCACTTTGGCATCGGGACGGT
TTTTTCAGCAGCTCGTTGCCGACCGCTGCACAAGGTGGGTTTTGCCCAAACCCGTGCTGC
55 CATAGAGGAAGAACGGGTGTAACCTTGCCCCGGGCTTTCCGCAATCGCCTGCGCCGACG
CCGCCGCAAGGCGGTGCCCCTTACCTTCTACCAACGTATCAAACGTGTAATCCGGAGACA
GGTTGGTCTGCTCGTAACGCGCCTCTTCGCATCGCGCTGCACGTCGGTCCGTGCTTTGG

CAACTGCCACCGATTCCGGCCGGGAAGCAGACCCGGCAGCCTGACGCGGCTCGTGCGGCA
GGTTTTTCATACGTTCCGCCAAAATATCCGCCGCCGTTTTTCGACGCAGCGGGTTTGACAG
GCTCTTCAGACGGCAGCTCGTCCAACAGAACCTCCTGCACGGGCATTCCCTCCGACACCG
CATGCAAGGACGGCTCGGCAGGTTTCGACAGCACCTTCAACCGCCGCCATCTCATAACGCA
5 CGCCTTCTCCCGGTTTTGAATACGAAGGCGGAACGGCCGGCAGCCAACTCTTCCCTCACCG
CTTCTATTTTTCCGGCAAACCTGGCTCTTGAGCATATTGCAGGCAAACCTGGTTCTTGCCGT
ACACCACCCATACGCCACCTCCTCACCAACGGTAAGGGGCGCAATCCATTGCGCAAACCT
GCCCTTGAGGCAACATATCGTGAAGACGGCGGAGGCACAGCGGCCAAAACCTCTGCTAATG
TCATGGATAGGCTCGAATCGGTAAAAATGAAATCGAAAACAAAGAAAATATAATATTTTC
10 AAAAGGAAAACAAATCTGTGTAACGCACATCGGTTCAAACGCGACTGCCCGATTATACC
GACTCACGAATATTTTTATCCACAACCCGTGCAAAAATTTATCCACAGAAAGCGGCGGAA
ATCCGCAGGCAATCGGGCAATCTTCTGCAAAGTTTCTATATTGATTGACAAAAGCGGCA
AATTGGAGTGTAATTCACGGTTTAATTATCTACCCATTCTATTTTAGGAAACATCATGAA
ACGCACTTATCAACCTTCCGTTACCAAACGCAACGCACCCACGGCTTCCCTGGTGCGCT
15 CCAAAACGCGCGGCGGCGCAGTATTGGCCGCACGCCGTGCCAAAGGCCGCAACGCC
TGGCGGTATAATTTTGGACTACCGCTTCGGAAGGCAGTACCGCTTGTGAAAACGGATGA
TTTTTCATCCGTTTTTGCATTAGAAAACCGCCGAGCCGCGACCTGCTGCAAGTTTCGCG
CTCAAACGGCAACGGGCTGGGCCATCCCCGCATCGGTCTGGTGGTCGGCAAAAAAACCGC
CAAACGCGCCAAACGAAACGAAATATATGAAGCGGCTTATCCGCGACTGGTTTAGATTGAA
20 CAAAAACGGGCTGCCGCCGAGGATTTCTGTCGTGCGCGTCCACCGTAAATTGACAGGGC
TACCGCAAAACAGGCAAGGGCGGAACCTGGCACAACCTCATGTTCCGGCAACCCGCAACCGG
ATGCAGGAAACAGGCATGATCAGAACGGTACTCTGCAGGCAAGGTTGACAGGCAACGGG
TTTCCCATACAAGGAACATCCCGATGAACCTCCTATTGTCCAAACCTGCTGGGACTGA
TACGGTTCTACCAATATTGCATCAGCCCGCTGATTCCGCCGCGCTGCCGTATACGCCGA
25 CCTGTTCCGAATACGCGGTGCAAGCGGTCAAAAAATACGGCGCATTCAAAGGCGGCGGCG
TCGCCATCAAGCGCATTCGACGCTGCCACCCTTTCGGCGGACACGGACACGACCCCGTTT
CCTGACCCGACGCAATATTCAAATTGCACGCTTTCCTTTTATTTCCCATCGGTTTCTATA
TAATGCCGTCTGAAGCTTCGGGCAGGCGGCAACGACCGCGGGTATGAAGCCCGCCCTTAT
TCCCCGTCTATCGGAACACGCAACCTGCGGCATTTCCGACCATTCAKGAACCTCTTATGG
30 ATTTTAAAAGACTCACGGCGTTTTTCGCCATCGCGCTGGTGATTATGATCGGCTGGGAA
AGATGTTCCCACTCCGAAGCCCGTCCCGCGCCCCAACAGGCAGCACAACAACAGGCCG
TAACCGCTTCCGCCGAAGCCGCGCTCGCGCCCGCAACGCCGATTACCGTAACGACCGACA
CGGTTCAAGCCGTCATTGATGAAAAAGCGGCGACCTGCGCCGCTGACCCTGCTCAAAT
ACAAAGCAACCGCGACGAAAATAAACCGTTCATCCTGTTTGGCGACGGCAAAGAATACA
35 CCTACGTCGCCCAATCCGAACCTTTTGGACGCGCAGGGCAACAACATTCTAAAAGGCATCG
GCTTTAGCGCACCGAAGAAACAGTACAGCTTGGAAAGGCGACAAAGTTGAAGTCCGCCTGA
GCGCGCCTGAAACACGCGGTCTGAAAATCGACAAAGTTTATACTTTACCAAAGGCAGCT
ATCTGGTCAACGTCGCTTCGACATCGCCAACGGCAGCGGTCAAACCGCCAACCTGAGCG
CGGACTACCGCATCGTCCGCGACCACAGCGAACCCGAGGGTCAAGGTTACTTTACCCACT
40 CTTACGTCGGCCCTGTTGTTTATACCCCTGAAGGCAACTTCCAAAAAGTCAGCTTTTCCG
ACTTGGACGACGATGCCAAATCCGGCAAATCCGAGGCCGAATACATCCGCAAAACCCCGA
CCGGCTGGCTCGGCATGATTGAACACCACTTCATGTCCACCTGGATTCTCCAACCTAAAG
GCAGACAAAGCGTTTGGCCCGCAGGCGAGTGCAACATCGACATCAAACGCCGCAACGACA
AGCTGTACAGCACCAGCTCAGCGTGCCCTTAGCCGCCATCCAAAACGGCGCGAAAGCCG
45 AAGCCTCCATCAACCTCTACGCCGCGCCGACAGACCATCCGTCATCGCAAACATCGCCG
ACAACCTGCAACTGGCCAAAGACTACGGCAAAGTACACTGGTTTCGCCTCCCCGCTCTTCT
GGCTCCTGAACCAACTGCACAACATCATCGGCAACTGGGGCTGGGCGATTATCGTTTTAA
CCATCATCGTCAAAGCCGTACTGTATCCATTGACCAACGCCTCTTACCGCTCTATGGCGA
AAATGCGTCCCGCCGACCCAACTGCAAGCCATCAAAGAGAAATACGGCGACGACCGTA
50 TGGCGCAACAACAGGCGATGATGCAGCTTTACACAGACGAGAAAATCAACCCGCTGGGCG
GCTGCCGTGCTATGCTGTTGCAATCCCCGTCTTCATCGGATTGTATTGGGCATTGTTCC
CCTCCGTAGAATTGCGCCAGGCACCTTGGCTGGGTTGGATTACCGACCTCAGCCGCGCCG
ACCCCTACTACATCCTGCCCATCATTTATGGCGGCAACGATGTTTCGCCAAACTTATCTGA
ACCCGCCCGGACCGACCCGATGCAGGCGAAAATGATGAAAATCATGCCGTTGGTTTTCT
55 CCGTCATGTTCTTCTTCTTCCCTGCCGGTCTGGTATTGTACTGGGTAGTCAACAACCTCC
TGACCATCGCCAGCAATGGCACATCAACCGCAGCATCGAAAAACAACGCGCCCAAGGCG
AAGTCGTTTCTCAAATGCCGCGAGCATGAAAAATGCCGTCTGAAACCTGTTTACAGCGGCAT

TTTTATTGCCACCCCCTATCGGGGCGGAAATCTTCAACCCGCATACATCACAAAAATCG
TCGGGCGTTTTTTTTCAGATTGGGCATTTCTTTTCTTTTTCGCCACTGCACGATTGTTTGAC
TGATGATTTTCTGTGTGCGCAAGGTCAAATCCGTAGCCGTGCATAAACGCGTTTCAGGAT
GCAGGTTTTCCACCGCATCGGCAAGCAGCGCATCATTCGCGTAAGGCGTTTCAATAAAAA
5 TCTGCGTCTCGCCGCACTGGCGCGAACGCTGTTCCAAAGCCCGAAAAGCCTGAATCCGCT
CGTTTTTTTTCAGACGGCAGATAGCCTTTAAACGCAAACTCTGCCCGTTTCGCACCCGAAG
CCATCAAAGCCAGCAGCAGGCTGGAAGGCCCGACACGCGGACGCACTTCAAAACCGTGTT
TATGCGCCAATGCCACCAAATTCGCACCCGGATCGGCCACAGCCGGGCAACCCGCTCAC
TGACAATGCCCATACTGCGCCCTTCTTGCAAAGGTTTCAGCAATTCGGGCAAAGTCTTCA
10 AATCCGTATGTTTCATTCAACGTTTGCAGATTTCAGCTCGCGGATAGGCGTAGTCACGCCCA
AATGTTTTCAAATGCGCACGCGCCGTTTTTTCCGCCCTCCACGACAAAATCCGTACGCCCGA
CAATCGCCTGTTGTTTCATGCGGCAACAGGCACGCGGTGTCAGGCGTACCCAAAGGCGTAG
GAATCAAATACAAAACAGGAGACATCATTCCTCACTCATCGGTTAAAAATGCCGTCTGA
GCCTTTTCAGACGGCATAAACGGGCAGTTACAGAACCTCCACGCCCTCATTTTTCAAGAAA
15 TCGACCAGACGGAACCCGCAACCGATTAAAGCATTTCGGATCGGTACTCTCAATCCTT
TCAATCAGCAATGCACCCAAATCCTCACTCTTCAGCGCACACGAACAATAAACCGCATCA
GGCTCGCGCTCCAAATAGCGGAGGATATGCAACTCGTCCAACTGCCTCATCACGACCACC
GTCTTATCGATATGCGCCCGCATCTGCCCCGTAACCGTATTCAACAGCAGATCGCGCTG
TAAACTCAATCTCCCTGCCGCTCAAGTGCATCAGCATCTTTTTCGCGATTGGCAAGGTTT
20 ATCGGCTTGCACCCACTGCGCTGCCGTTCGCACACGCCACCTGGTCCGCACCGACAATCAAC
GCCTCTGGGAAACGCGCGGTCAACGACCGCGCCTTACCCTCGGCAAGGCGCAATGCCGTC
TGAGGGGCGGATTCCCCAACATCGGCGTTTCGTCAAAATCGGGGGACGCCGCTGAAAG
GCAATGCCGAGCCTTTCCATCTGTTTCGCGGCGGAAAACCGAACTCGTACCCAAAATCAAA
GGCAGTTCCAAACCCATCCCATCCTCCTTACCCTTGAAAACACGCCCGAAGGGGCAGTAA
25 AATCCAGCCATGCGCCGAAACACGGATACCCGCTTCGGCGTACCGCAACATTTTTCTTA
AAAATATTGACGTTAGAATCTAAATTATATCATATCCCGTTTATGTCAGACCCTAATT
TGATTGACTTGGAAATTTTTGCCGCCGAAGGGCAGAACCTGCAAGGCAGTTTCTGTCTGG
AAGAATTGGATGAACGCGTCAGTTTCGCACGATTATCCCGCCGACAGGCAGACCAAAATAT
CGTTTACACTGACCGCGGTTCGCGACCGGCTGCAACGCCTGTTCTCGACCTGAACGTCA
30 AAGCCGATATGCCCCGATTTGCCAGAGATGTATCAAACCCATGCCGTTTCATGCTTGATG
AAAGCAGCCGTATCGTCCTGTTTTTCCAACGAAGAGTCTTGGACGAATCCATGCTTGCCG
ACGAAGAATCGAAGGCATACTGATTGAAAAGAAGTTCGACGTGCGCACATTGGTAGAAG
ACCAATCCTGATGTCCCTGCCCTTTTTCGCCGCGACACGAAGACTGCGGCGACAATGGGA
CACTGGAAGAAGTCAATCGGGACAAACCCAAACCCCTTTGCTGTTTTTGGCAGGTTTGAAAA
35 GCAATTGATTAGGACACAGTTTATTTATCTAGGAGCTTGAAATGGCCGTTCAACAAAACA
AAAATCCCTTCCAAACGCGGTATGCACCGTTTCGCACGACGCGTACCGCGCCTGTCAC
TGTCTGTGACAGCACAAACCGGCGAAGTACACCGCCGACACACATCTCCCCAACGGTA
TGTACCGCGGCGGCAAGTGGTCAAAGCCAAAGGCGAATAATCCCTATTTCGACTGACTGA
AAAAGCCAGAACATTGCCATGCAATTACTGGCTTTTTTTTGCATTGGACGCACCATCCGTC
40 CAACTTTTCGCCATACGTCAACACACAGGGGCAAAGCGTTCCGTATAATACCCCGTGAAA
ATATTCCAAAAGCCCCAACCAAGGAAATTCGGATGAAACAGAAAATCTGGTACACCT
ACGATGACATCCACCGCGTCATCAAAGCATTGGCAGAAAAATCCGGAACGCCGACATCA
AATACGATGCCATGATTGCCATCGGCGCGGCGGCTTTATTCGGGCACGTATGCTGCGCT
GTTTTCTGGAATTCGATTTATGCCGTAACCAACCGCCTATTACGACAGCGACAACGAAG
45 GACAGGTTACCGAAGAAGTCAAAAAAGTCCAATGGCTCGACCCCGTTCCCGAAGCCCTGC
GGGGCAAAAACGTACTCGTCGTGATGAAGTGGACGACAGCCGCTAACCATGGAGTTCT
GCCTGAAAGAACTGCTCAAGGAAGACTTCGGTACGATCGGAGTCGCCGTAAGTGCACGAAA
AAATCAAAGCCAAAGCAGGCAAAATCCCCGAAGGCATTCCCTATTTAGCGGCATCACCG
TAGAAGACTGGTGGATCAACTATCCGTGGGACGCACTCGACATCGACGAACACAACCGCC
50 TTGCCGAGGCGCGCGAGGCTGACCTTTTCAGACGGCATATTTTCCGAACCGATGCCGTC
TGAAGCCCGCACGACCCCTGCCGACAGCCGAAAACCTACCGGAGAAACCCCTATGATTACA
TTGGCGGTAGATGCCATGGGCGGCGACCAAGGACTTGCCGTTACCGTACCGGGCGCAACC
GCAATTCCTCCAAGCACACCCCGATGTCCGCTGATTATGACCGGCGACGAAACGCAACTG
CGCCAAGCCCTGACCGCGGCGAGGCGACCGATGGAACGCATCGACATCTGCCATACCACC
55 CAAGTCGTGCGCATGGACGAAGCCCCGCAATCCGCCCTGAAAAACAAAAAGACTCCTCC
ATGCGCGTCGCCATCAACCAGGTTAAAGAAGGCAAAGCCCAAGCCGCGTATCCGCAGGC
AACACGGGTGCGCTCATGGCAACCGCACGTTTCGTCTCTCAAACCATTCGGGCATCGAA

CGCCCCGCCATCGCCAAATTCCTTCCTTCGGACACCGACCACGTTACCCCTTGCACTCGAC
CTTGCGCGGAACGTCGACTGCACGTCCGAACAGCTCGCCCAATTTGCCGTTATCGGCAGC
GAACTCGTCCACGCACTCCATCCTCAAAAAGGACAGCCGCGCTCGGGCTGGTCAACGTC
GGCACGGAAGACATCAAAGGTACGGACACCGTCAAACAAACCTACAAACTGCTGCAAAAC
5 AGCAAACCTCAACTTTATCGGCAACATCGAAAGCAACGGCATCCTCTACGGCGAAGCAGAT
GTCGTCGTCGCGGACGGCTTTGTGCGCAACGTCATGCTCAAAACCATCGAAGGCGCGGTC
AAATTCATGAGCGGAGCCATCCGCCGGAATTCCAAAGCAACCTGTTCAACAAACTTGCC
GCCGTTGCCGCCCTACCCGCCCTCAAAGGGCTGAAAAACAACTCGACCCGCGCAAAATC
AACGGGGCCATCCTGCTCGGGCTGCGCGGCATCGTGATTAAAAGCCACGGCGGCACAGAC
10 GAAACCGCTTTCCGCTATGCCCTCGAAGAAGCCTACCACGAAGCCAAGTCCGCCGGCCTT
TCCAAAATCGAACAGGGCGTAGCCGAACAACTCGCCGCACTCGAAACTGCCAAAGCCGTC
CAAAACGAAAATGTGCGCGGTCTGTAACACACACGATGCCGTCTGAACGCCCCCGCCCT
TTCAGACGGCATCCGCCCGCACCAACCTGCGGGCGCGGACGGCGATGCGCCTGTCCGGC
ACTTCCCAAATATCGCCTTGTAAAATAAGGAGTATTTGAAAAATGAAGACATTAGAAAAA
15 CGGATGAAAGCTCTAGACAAACGGATTATGAAGTTCGGAATAATCCCTTGAAGGCAGGCTT
GATGCCCGTCTGATTGAATCCGCATTGGATTATATTCATTATTCGGAACGTTTTTTGGCT
TTTGAAATCCTGTGTACTTATATCGAAGATTTTCGATGTCCGGCTGACGGAACAAGATCC
CGGGAATTTCTTTTATCAACAAGGAATTTGAGATAGAAAGCACGTCCGATTAACCAATA
AAGCCAATGGGTTGATAAACATGAAAACATCGACGGTCGTTTTTTGGCGGATTTTTATGG
20 CAGACAACGGAGAGCGAATCCAAATCCCCGTTTTTGAAAAATCCTGACATTAGGGAAATCA
ATCACTTTTTTCCGTATCAATTTTGAGAAAAAACCGGCGTCCTTGTTCAGAAATCA
TCCCCGAGCCGGAATTTGGCAATACCGAATTAAGTGTCTATTTTAAAAAAGGATATTATA
GTGGATTAACAAAACAGTACGGCGTTGCCTCGCCTTGCCTGACTGGTTTTTGTAAATC
CACTATATCAGACGAAAACAAACACCCGCGCCAATAGCCTGACGGCAACCCGGCAATCAA
25 AATGCCGTCTGAAGCAGCTTGGGCTTTTCAGACGGCATTTCCCTTCGCTTAAACAGCGTAT
CGGCAACCCCGCCCTGCCTGTCCACGGCAATCTGCATCTGAAAACCATCTGTATCCCAAA
CCACACCCCATCCCTGTTTCCATCATGTGCACCCCTGTCCGTATTGGGCAATCATCTGTT
TTTCGCTTACAATAGCCGAATCTGAACCAACTCTCTAAAAAGGCCGTTCCTATGCAGTAT
GCAAAAATTTCCGGCACAGGCAGCTATCTTCCCGCCAACCGCGTCAGCAATGACGACCTT
30 GCCCAAAGGTAGATACCTCTGACGAGTGGATTACCGCGCGCACGGGCATCAAATTCGCG
CATATTGCAGCCGAAAACGAAAAACAGCGATCTTGCCGCCGAAGCGGCGCACCGCGCG
CTGGATGCAGCCGGATTAGACAGCGGCGAAATCGATTTGATTATCGTGGCAACGGCAACG
CCGGATATGCAGTTTCCGCTACTGCGACCATCGTGCAACAAAATTTGGGCATCACCAC
GGCTGCCCGCGTTTTGACGTACAGGCGGTGTGCGCCGGCTTTATGTACGCGCTGACCACG
35 GCAAACGCCTACATTAAGAGCGGTATGGCGAAAAACGCGCTGGTCATCGGCGCGGAAAC
TTCAGCCGCTATTGAGACTGGAACGACCGCACAACTGCGTATTGTTCCGGCAGCGCGCG
GGCGCGGTGGTTTTTAAGCGCGTCGGACACGCGGGGCATCATCCACAGCAAACCTCAAGGCC
GACGGCAATTATCTGAAACTCTTAAACGTCCCCGGGCAATCGCCTGCGGCAAGTTTCC
GGTTCGCCGTACATTTTCGATGGACGGTCCCGCGGTGTTCAAGTTTGCCGTCAAATGCTG
40 TCCAAAATCGCGATGACGTTATCGAAGAAGCAGGTTACACCGCCGCTCAAATCGACTGG
ATTGTTCCCATCAGGCAAACCGCCGATTATCGAATCGACCGCGAAACATTTAGGTTTG
AGTATGGACAAAGTCGTCTGACCGTCCAAGACCACGGCAACACATCCGCCGCATCGATT
CCGCTGGCTTTGGATACGGGCATCCGCAGCGGACAAATCAAACGCGGTCAAACCTGCTG
CTCGAAGGCATCGGCGCGGTTTTCGCGTGGGGCGCGGTGCTGTTGCAATATTGAACCCGA
45 TGCCGTCTGAAACAGGCTTTTCAGACGGCATTTCCCATATCATGAAGCGGCAGGCTTTCTT
CAAACCTGATGGCGTGTGCGGCATTTCTGTCTGCCGTTTTCGCTGCGCCTCCCCGTATTGG
CGCGTGTACGCAATATTGTCCCTCTATGCGTTTTGCACTTTACGGCATCGACAAACGGTG
CGCCATACGGGGCAACGCCGATTCCCGAACACCGCCTGCTGCTGCCTGCATTGCTCGG
CGGCTGGGTGGGCGCGTATTTCCGGCAGCATGACATTCAAACATAAGACAGCGAAAAAGCG
50 TTTTGTGTGCTGTTCCGTCTGACTGTTTCAGGTAATGTCTTGGCGACCCTCATCCTGAT
TTATAGTGGATTAAATTTAAACAGTACGGCGTTGCCTCGCCTTGCCGTACTATTTGTAC
TGTCTGCGGCTTCGTCGCTTGTCTGATTTTTGTAAATCCACTATATATTTTGTCCCG
CCTGAATTTTTTCGTAACAACTCGGGCAGAATACCTGATTATCCAACCAACAAAGGAATAC
TATGTCTTTTCCGTTCTTTTTTCCCGACAAGGTTCCAAAGCCTCGGTATGATGAACGG
55 CTTTGCCGAACACGCCATCGTCAAAAACACCTTTGCCGAAGCCTCCGCCATATTGGGGCA
GGACTTGTGGGCGATGATAACGGCAGCGATGCCGAAATCATCGGTCAAACCGTCAACAC
CCAGCCCATTATGCTCGCGCCGGCGTTGCCGTTTACCGCGCCTATTTAGAAGCGGGCGG

CAAAACGCCTGCCGCCGTTGCCGGACACAGCCTCGGCGAATACACCGCACTCGTTGCCGC
CGGCGCATGAATTTTGGCCGACGCGGTCAAACCTCGTGCGCCTGCGCGCCGAACATGATGCA
GTCCGCGGTACCGCAAGGCGTGGGCGCAATGGCGGCGATTCTCGGCTTGGAAGATGAGCA
GGTTAAAGCCATTTGTGCCGAAGCCGCCAAAGCGAAGTGGTGAAGCCGTCAACTTCAA
5 CTCACCCGGACAAATCGTGATTGCAGGCAACGCCGCCGCGTGGACGCGCCATGGCTGC
CGCCAAAGAAGCCGGTGCCAAACGCGCCCTGCCGCTGCCGCTGTCCGTACCTTCCCATTG
CAGCCTGATGAAACCCGCCGCCGACAACTTGCCGAAGCCCTGAAAACCGTTGAAATCAA
GCAGCCGCAAATCCGCGTTATCCACAACGCCGACGTTGCCGCTACGATGATGCCGACAA
AATCAAAGACGCGCTCGTCCGCCAGCTTTACAGCCCCGTACGCTGGACGGAAAACCGTCAA
10 CGCCCTCGTTTCAGACGGCATTGCCGAATCCGCCGAATGCGGCCCGGGCAAAGTGTGGC
GGGCTTGCCAAAACGCATCAACAAAGCCGCCGCGTGCAGCGCACTGACCGATGCCGGACA
GGTTGCCGCTTTATCGAAGCGCACTGACTTCGTTCTGCAAAAAGCAGCCTGCCCTCTTC
AGGCTGCTTTTATGTCCGAACGACGGCAGCCCCATATTTACGCTATAATCCATCCCGAC
CAAACACCGACAGCGGCTGCCGTTGCAGTTCGCCGCCCTACCGATATGATAGAAAACTG
15 ACTTTCGGACTGTTTAAAAAAGAAGACGCGCGCAGCTTTATGCGCCTGATGGCGTACGTC
CGCCCCACAAAATCCGCATCGTTGCCGCCCTGATTGCCATTTTCGGCGTTGCCGCCACC
GAAAGCTACCTTGCCGCCCTTCATCGCCCCCTGATTAACCACGGCTTTTCCGCACCTGCC
GCGCGCCCCGAGCTGTCTGCCGCCGCCGGCATCATTTCCACCCTGCAAAACTGGCGCGAA
CAGTTTACCTATATGGTTTGGGGGACGGAAAACAAAATCTGGACCGTCCCGCTCTTCCTC
20 ATCATCTCGTCGTCTCGTGGCATCTGCCGCTTTACCAGCACCTATCTGATGACTTGG
GTCTCCGTGATGACCATCAGCAAAATCCGCAAGATATGTTTGCCAAAATGCTGACCCTT
TCCTCCCGCTACCATCAGGAAACGCCGTCCGGCACCGTACTGATGAATATGCTCAACCTG
ACCGAACAGTCGGTCAGCAACGCCAGCGACATCTTACCGTCTTCACGCGGACACGATG
ATCGTTACCGGCTGACCATCGTCCTGCTTTACCTCAACTGGCAGCTCAGCCTCATCGTC
25 GTCTGATGTTCCCCCTGCTCTCCCTGCTCTCGCGCTACTACCGCGACCGTCTGAAACAC
GTCATTTCCGACTCGCAAAAAGCATAGGCACGATGAACAACGTGATTGCCGAAACCCAT
CAGGGACACCGCGTCGTCAAGCTGTTCAACGGGCAGGCGCAGGCGGCAACCCGGTTTCGAC
CGGTCACCCGACCATCGTCCGCCCTCAGCAAAAAATCAGCAGGCAACGGCGGCACAT
TCCCGGTTTCAGCGAACTGATCGCCTCGATCGCCCTCGCGTCTCATCTTCATCGCCCTG
30 TGGCAAAGCCAAAACGGCTACACCACCATCGGCGAATTTATGGCATTTCATCGTCGCGATG
CTGCAAATGTACGCCCCCATCAAAGCCTTGCCAACATCAGCATCCCTATGCAGACGATG
TTCCTCGCCGCCGACGGTGTATGTGCATTTCTCGACACCCCGCCGAACAGGACAAGGGC
ACGCTCGCACCGCAGCGTGTGAAGGGCGCATCAGCTTCCGCAACGTCGATGTGAATAC
CGTTTCAGACGGCATCAAAGCCCTCGACAACCTTCAACCTCGACATCAGACAAGGCGAACGC
35 GTCGCCCTGGTCGGACGTTCCGGCAGCGGCAAATCCACCGTCGTCAACCTGCTGCCCGC
TTTGTGAACCGTCTGCCGGCAACATCTGCATAGACGGTATCGACATCGCCGACATCAAA
CTCCGATGCTCGCGGCCCAATTCCGCCCTCGTCTCCCAAGACGTATTCCTGTTTGACGAC
ACCCGTGTTTGAAGACGTCCGATACAGCCGTCCCGACGCGGGCGAAGCCGAAGTCTGTT
GCCCTCCAAACCGCCAACCTGCAAAGCCTGATTGACAGCTCCCGCTCGGACTGCACCAG
40 CCCATCGGATCGAACGGCAGCAACTTATCCGGCGGACAGCGGCAACGCGTCGCCATTGCC
CGCGCCATTTTGAAGACGCGCGGATATTATTATTGGACGAAGCCACCAGCGCATTAGAC
AACGAATCCGAACGCCTCGTCCAACAGGCGCTCGAACGCCTGATGAAAACCGCACCGGC
ATCATCGTCGCCCACCGCTGACCACCATCGAAGGGGCGACCGCATCATCGTGATGGAC
GACGGCAAAATCATCGAACAAGGCACACACGAACAACCTGATGTCCAAAACGGTTACTAC
45 ACGATGTTACGCAATATCTCAAACAAGATGCCGCCGTCCGGACGGCATAAACAACATGC
CGTCCGAAATGGTACAATCGCCCCGACCTTTTCAGACGGCATCATATCCGCGGACCCATC
CGATTATCTTCAATCACTGTAAAACCCATTATGACCCAAGACAAAATCCTCATCCTTGAC
TTCGGTTTCGAAGTTACCCAGCTCATCGCCCGCGCGTGCAGCAAGCCACGTTTACTGC
GAGCTGCATTCTTTCGATATGCCTTTTGACGAAATCAAAGCCTTCAACCCCAAAGGCATC
50 ATCCTCTCCGGCGGCCCAATTCCGTTTACGAATCCGACTATCAAGCCGATACCGGTATT
TTTGATTTGGGCATTCCGGTTTGGGCACTGTGTACGGCATGCAGTTTATGGCGCACCCAC
TTGGGCGGCGAAGTGCAGCCCGGCAACCAGCGCGAATTCGGTTATGCGCAAGTTAAAACC
ATAGACGCGAGCTGACACGCGGCATTCAAGATGGTGAGCCAAACACACTCGACGTATGG
ATGAGCCACGGCGACAAAGTGTCCAACCTGCCCGACGGTTTCGCGGTGATCGGCAACACC
55 CCGTCTGCCCGATTGCCATGATGAAAACGCCGAAAACAAATCTACGGCATCCAGTTC
CACCCCGAAGTTACCCACACCAACAAGGCCGCGCCCTGTTGAACCGCTTTGTCTGGAT
ATTTGCGGCGCACAACCGGGCTGGACGATGCCGAACATCATGAAGAAGCGTTGCCAAA

ATCCGCGAACAGGTCCGGCAGCGACGAAAGTGATTTTAGGTCTGTCCGGCGGGCGTGGACTCT
TCCGTAGCCGCGCGCTGATTACCCGCGCCATCGGCGACCAACTGACCTGCGTGTTTCGT
GATCACGGTTTGGTTGCGCCTGAACGAAAGCAAATGGTGATGGATATGTTGCCCCGCAAC
TTGGGTGTGAAAGTGATACACGTCGATGCCGAAGGGCAGTTTATGGCGAAACTCGCCGGC
5 GTAACCGACCCCCGAGAAAAACGCAAATCATCGGTGCGGAATTTATCGAAGTATTTGAT
GCCGAAGAAAAAAACTTACCAACGCCAAATGGTTGGCACAAGGCACGATTTACCCTGAC
GTAATCGAATCCGCAGGTGCAAAAACCAAAAAGCCACGCCATCAAATCGCACCACAAC
GTCGGCGGGCTGCCTGAAAACATGAAGCTCAAATTGCTTGAGCCTTTGCGCGATTTGTTT
10 AAAGACGAAGTACGCGAATTGGGTGTGGCTTTGGGCCTGCCGCGCGAAATGGTGTACCGT
CATCCGTTCCCGGGTCCGGGTTTGGGCGTGCGTATTTTGGGCGAAGTGAAAAAGAATAT
GCCGACCTGCTTCGTGAGGACGACGATATTTTCATTCAAGAATTGCGCAATACTACCGAT
GAAAACGGTACATCTTGGTACGACCTGACCAGCCAGGCATTGCGCGTGTTCTTCCGCGGTC
AAATCTGTGCGCGTAATGGGCGACGGCCGCACATACGATTACGTCATTGCCTTGCGTGCC
15 GTGATTACCAGCGACTTTATGACCGCGCATTTGGGCGGAAGTCCGCTATTCCTTGTGGGC
AAAGTGTCCAACCGCATCATCAACGAAGTCAAAGGCATCAACCGCGTGGTTTATGATGTG
AGCGGCAAACCGCTGCCACCATCGAGTGGGAATAAACAGCAAACATGGCTGCCCCGTCC
GGCGCAGTCCTTCGATTATCGGAAAAAAGGAAAAAATATGAGCACACAAGATTTAAACGG
CAAAATCGCTTTGGTAACAGGCGCATCGCGCGGTATCGGTGCAGCAATTGCCGACACGCT
GGCGGCAGCGGTGCCAAAGTCATCGGTACGGCGACCGAGTGAGAGCGGTGCGGCGGGCAT
20 TAGCGAGCGGTGGCGCAATGGGCGGGCGAAGGCCGCGTATTAAATCCGCGGAACCTGA
AACCATCGAAAGCCTGATTGCCGACATCGAAAAAGCGTTGCGCAAACTCGATATTCTGGT
CAACAACGCCGGCATCACCCGCGACAACCTCCTGATGCGCATGAAAGAAGAAGAGTGGGA
CGACATCATGCAGGTCAACCTCAAATCCGTGTTCCGCGCTTCTAAAGCCGTTTTCGCGCG
TATGATGAAACAACGTTCCGGCCGCATCATCAACATCACATCCGTGCTGCGCGTGATGGG
25 CAATGCCGGTCAAACCAACTATGCCGCGGCAAAAGCAGGCTTAATCGGTTTCTCCAAATC
CATGGCGCGCGAAGTCGGCAGCCGGGGCATTACCGTCAACTGCGTCGCCCTTGCTTTAT
CGATACCGACATGACACGCGCCCTGCCGGAAGAAACCCGCCAAACCTTTACCGCCCAAAC
CGCCTTGGGCAGATTCCGGCGACGCGCAAGACATCGCCGATGCGGTTCTGTTCTCTGCTTC
CGACCAAGCAAAATACATCAACGGCCAAACGCTGCACGTCAACGGCGGTATGCTGATGCC
30 TTAACAGACAACCTTTTCAACCATGCCGTCTGAAGCCCTTTTACAGCGGCATTTGCATTCT
CAGGCAAAATGAACACACACCACACCCCGCCCTGCCCATGCGGCTCAGGCACAAGCTGAG
ACCTTTGCAAAATTCCTTTCCCTCCCGACAGCCGAAACCCCAACACAGGTTTTCAGCTGT
TTTCAGCTGTTTTGCCCCAAATACCGCCTAATTCTACCCAAATACCCCTTAATCCTCC
CCGGACACCTGATAATCAGGCATCCGGGTACCTTTTAGGCGGCAGCGGGCGCACTTAGC
35 CTGTTGGCGGCTTTCAAAGGTTCAAACACATCGCCTTCAGATGGCTTTGCGCACTCACT
TTAATCAGTCCGAAATAGGCTGCCGGGCGTAGCGGAATTTATGGTGCAGCGTACCGAAG
CTCTGTTGACCATATAGTGGATTAAACAAAACAGTACGGCGTTGCCTCGCCTTAGC
TCAAAGAGACGATTTCTTAAGGTGCTGAAGCACCGAGTGAATCGGTTCCGTACTATTTG
TACTGTCTTCGGCTTCGTGCGCTTGCTGATTTTGTAAATCCACTATACATCATCGCT
40 ACTACCGTTCCGGCGCAACAGGCATTCCTCGATGCCGCCGAAGTATGCAATGGAGTATA
GAAACCGAAGGGCTGGGCTTGAACGTCATCTCGCACAAGATACTCGGCAAAGACCACGCC
CAAGTCGAATTTGAAGCCTACTTCCGAGACGGACAACACCGATCCGCGCATCACGAACGT
TCCGGCTTCGTCAACATCGGCGGACAATGGTATTTTATCGATCCCACCGTTCCGCATCCT
GCGATGAAACAACCTGCATTTGCGGATCAGGCAAAAATTCAAAGCCTGCTGCGGCAAA
45 TATCTGAAACCTGTCGCATAAAAATGCCGTCTGAACGTTTACAGCGGCATTTTCAACGTGC
AAAAAAAACCATTCATACCAAGGGTAAGTATGAATGGTCAATACATTGCGGGAAACGTC
TTACTTGCTGCACTGCCGAAAAGGGAGAAACGGCAGCGGTAATCAGCGGAAAGGATTGTA
CCCGAATTAATATTAAGAAACGTTAATCGCGAAAATATATTAACAAACCTGTTGAAACCT
ATTGGTTTTTCCGATATCCACCCGACCCAGCGTTCAAACAGCTTCGGTTCGAGCGCGGCAA
50 CGACCGAGCGTTTGAACACGTGTTACCACTCCAAAACCCGTGCCTTCCAAAGTCGTCA
GCCTGCCGCCCCGCTCCTCGAAAATCAACGCGCCGGCGGCAATAATCCACAGCTTCTGCC
CGCGTGAAACATAAACATCATAACGCCCCGACGCCAGATAACACCAATCCAACGTACTGC
TGCCCATACTCCGTATCGTTCCAAAAGGCGCGAGCGTACTCATACGGCTGGAAAGTTTGC
CCGAACGCAGATATTTGATTTCCACGCCGCAATCGCCTCATGAGTTTTTTATCCACGA
55 GGCGCAGGGGCGAGCGCTCCCGTTTAAAAACGCCCCCTGCCCGCGTTTCGGCATAAAAAAC
ATTCGCCGTGACTGGGTGTAGATTACGCCCAACTCGGCGCGCCGTTGCGGACAAACG
CCACCGATACCGCAAAATGCGGCGACCCGTTGACAAAATGTTTCGTCCCGTCTATCGGAT

CGACAATCCACAGCCCCCTTTTCCCCGAATATTGTTCCACAAAAGCCGACTGTTCCCTGCC
GCGACATTTCTCACCACATCGGACTGTGATTAAAGCGGCAACGCGGCGGCAAAAG
CCGTCTGCGCGGCAATGTCCGCCTCGCTCAACATCGAACCGTCTTCCTTGCAGTGAGACG
5 GCGTATTCAAAAAACGCGGCATAATTTGCGTTTGCAGGATATGGCGCACGACTTTCTGCA
AACGGTGTAAACACTTCTACTGTCTCATATTTTGAACCTTGCAGGCGCGCAACGTATAAT
GTCCGCTTCCATCACGCCGCTGCGACGGATTATAACCGTCCGAACCGCCAAAACTATGC
CCCCATTCCACCTGCCCGAAAACCTTTCCGTGCGACAAAACCGTGCCTTCCCGGACAAAC
TCGTCCGCCACCTCAACGTCTTGCAGTCCGCCCAACGAAAACATCACCTCTTCGACG
10 GCAAAGGCAAGGCACACGCCGCGACGGCTGACCGTTTTGGAAAAACGCCGCGCCGAAGCCG
AAATCCTGCACGAAGACACAACCGACAACGAGTCCCGCTCAACATCACACTGATACAAT
CCATCTCCTCCGGCGATCGCATGGATTTACCCTGCAAAAAAGCGTCGAACCTCGGCGTAA
CCGCCATACAGCCCGTCATCAGCGAACGCTGCATCGTCCGCTCGATGGGGAACGCGCCG
CCAAACGCCCTCGCACGCTGGCAGGAAATCGTCATCTCCGCTGCGAACAAAGCGGCAGGA
ACACCGTTCCCCCGTACTGCCATCATCGGCTACCGTGAAGCACTCGACAAAAATGCCGT
15 CTGAAAGCACCAAGCTGATTATGAGCATCAACCGCGCCCGCAAACTCGGCGACATACGCC
AACCGTCCGGCGCAATCGTCTTATGGTGGGCCCCGAAGGCGGCTGGACAGAACAGGAAG
AACACAGGCATTTGAAGCTGGCTTTCAGGCGGTTACACTCGGCAACGGATTTTACGCA
CAGAAACGCCCCACTCGCCGCCCTCGCCGCCATGCAGACGCTTTGGGGCGATTTGCGCAT
AAACAGAAATGCCGTCTGAAACCCGTTAGACGGCATTTTGCAGCCGATTAAGATAGTAG
20 GTTCAAATAAGATTTCCCGTGTGCTCATTTCCGCGAAAAGCGGGAATCTAGAAACGAAAA
CTACAGAGATTTATCCGAAACAACAACCTCTCCGCGTCAATTCGCGCAAAAGCGGGAAT
CTAGAAACGAAAACTACAGGGATTTATCCGAAACAACAACCTCTCCGCGCTCATTTCC
CGCGCAGGCGGGAATCTAGAAACGAAAACTACAGGGATTTATCCGAAACAACAACCTCT
CTCCGCGTCAATTCGCGCGCAGGCGGGAATCTAGAAATTTAACGTTGCGGTGATTTATCG
25 GAAATGACTGAACTCAACGACTGGATTCCCGCTGCGCGGGAATGACGAGATTTTAGG
TTTCTGTTTTTGGTTTTCTGTCTCGCGGGAATAACGGAATTTTAAGTTTTAGGAATTTG
TCGGAACAAACAGAAATCCCCCGCGCTCATTTCCGCAAAAGCGGGAATCTAGAAACGAAA
AACTACAGGGATTTATCCGAAACAACAACCTCTCCGCGTCAATTCGCGGAAAGCGGG
AATCTAGAAATTTAACGTTGCGGTGATTTATCGGAAATGACTGAACTCAACGACTGGA
30 TTCCCGCTGCGCGGGAATGACGAATTTTAGGTTTCTGTTTTTGGTTTTCTGTTCTCGCG
GGAATAACGGAATTTTAAGTTTTAGGAATTTATCGGAAACAGAAATCCCCCGCGCTC
ATTCCGCGGAAAGCGGGAATCTAGAAATTTAACGTTGCGGTGATTTATCGGAAATGACTG
AAACTCAACGACTGGATTCCCGCTGCGCGGGAATGACGAATTTTAGGTTGCTGTTTTT
TGGTTTTCTGTTTTTGCAGGAATGACGAATTTTAGGTTTCTGTTTTTGGTTTTCTGTTCT
35 CGCGGGAATAACGGAATTTTAAGTTTTAGGAATTTGTCGGAACAAACAGAAATCCCCCAC
CGTCATTTCCGCAAAAGCGGGAATCTAGAAATTTAACGTTGCGGTGATTTATCGGAAATG
ACTGAAACTCAACGACTGGATTCCCGCTGCGCGGGAATGACGAAGTGAAGTTACCCG
AAACTTAAACCAAGCAACCGAACGACTAGATTCCCGCTGCGCGGGAATGACAGTGT
ATCCATTTCTAATTTTAAATCCGCTATATTTTACACAACTATTTGAACGATATGACCGC
40 CTGCCGTAAGCTTTCTCAAGCTCCGCTGCCTTTGACGCTCCATTCTTTCTTTCTTTCC
CTACCGAATTTACCCAAAGCACGCTTCAAGTCAAACATCACCTTCAACGAACGGCGGTGT
CTTCTTTCTTGTTCCTATCTTTTTCCAAATCGCTACCCAACATACTGTTTTTACTGAGG
AATTGGCATAATGCAATTCTTGGGTACATAAGGCGGGATTAACCTGATAAACAGGCATC
CCCTCCTTATCAAAGAAATAAGTAAACATCATCAATCTACCGCTTTAATCCACTCTGCC
45 GGCAAAACGGCAACCTTTCCAAGAAAAACCGCATCGCCTCACGCGAAATGATATAGCCA
GCCGTCCTCCCAATGTTGCTCTCCAGCAAGGAAATGACCGATTCTCATAATTCAGGACT
TTATCCGCTCTGACAATAACTTTTCGCAACATCGTTTTCCAAACGAACGATAAAGGCAGAA
TCCTTATCAAACGCTCTTCCAACCAAGTATCTTCGCAAGGAACTTTTCTGCGTCTTTG
CCAAGCAGGACATCATCCTCAAATACGGCAACATAGGGCAGACCTTCATCAATGCCTGT
50 TTCCACAATACGGCGTGGCTCATAAAGCAGGCTTTTTCCACTTCGCTCAACAGGTGCTGT
TTTGCCAATCCCGGCACCAATTCGCCATCATCCGATTGATTCTTCAGACGGCATCAGT
GCGTCGAAAACTGAAACGGGATGCCGCGCACGCCGAAGGTTGCGGCAATGTGCGCCCTG
CGTTCTGCGCGGAAGCTAAGCTGATAACATGGTTTTGCATAATTTATCCTGTTTTTGT
CTGTTGGATAAAGCGGCTTTTTCAACGGTTTTTCAGCAATCGGCGCAAAATGCCGAAGT
55 ATTGCTCAAGGTAAACAGCGCGCATCCTGCCGTCTGCTGCAAAATACGATGTCCATCT
CTCCTCCTTTTATTTGAAAGGCACAACTGAAGTGTTCGCGCCTTTGCCGGCGTTTTTCCCT
TTCCCTGCTGATTTTGGTCAAGGCGCGGATCAGGCGGTGTTTGAATGTGTTGGCGGGGA

ATCGCGCCTTTGCTGTTTGCGGTTTCAGGAGGCGGTCTGTTCGATCAGGCTGCCCAATGC
GCTGTTTTGGTTCGTGAAACTTGGCATAATGCAGCTCTTGGGCGCACAAAGGCGGGATTGAG
CTGGCAAACCGGCATTCTTCCCTGTGAAAAAATCGCTGAACATCATCAGATCGACGGG
GTGCAGCCCTTCGGGCGGCAGGGCGCAACCTGTCCAGGAAAAACCGCATCGCTTTTCG
5 GGAAATGATATAGCCCCCGCTCCCCAGTGTTCGCTTTCCAACAGCGGAAAGGCGCGCCC
GCAGTAATCCGCCACGCCGAGGGCGAGGTTCAGGACGTGCATAAACATCGTTTCCAAGCG
GACGATAAAGGCGGTATCCGGGTCAAAGCGTTCTTGCAGCCAAGCGTCTTCGGCAAGGAA
TTTTTCCGCACCTTCGCCGAGTAAACGTCTCTCAAATACGGTGATATACGGCAGACC
TTCGTCCAATGCCTGCTTCCACAATACGGCGTGGCTCATAAAGCAGGCTTTTTCCACTCC
10 GCTCAAATAGGGGTGCGCCGACAAGCGGGGACGAGTTCGCCCATTCCTGCTGTCCAGCCT
TTCAGACGGCATCAGTGCCTCGAAAACTGAAACGGGATGCCGTGCCTGCCGAAGGTATC
GGCAATGTGCGCCCTCGCTTCTGCGGCGGAAGCTAAGCTGATAACGTGGTTTTGCATAAT
TTATCCTGTTTTTTGTCTGTTGGATAAAGCGGCGTTTTTCAACGGTTTTTTCAGCAATCGG
TGCAAAATGCCGAAGTATTGCCTCAAGGTAAACAGCCGCCGCATCCTGCCGTCTGCCGCA
15 AAATCCAGCCACGCGCCGCGGGCAGCGTGTCCGTCCGTTTGAAGCATTGGTACAAAAAC
CGGCGGGCGCGTTCAAATCTTCTCCGGCAAATGTTTCTCCAGCAATTCATACGCTACT
GCTTTTATTTGGCGGTATTCAAGGCTGTGCAACCGGTTTTTAAACCCATAGACTGCAAA
AAATCGTTTTCTGGCGGTTTTTTGGATGCCTTGC CGGATTTCTGTGTTGGCGGATGCTGTAT
TTGGATGAAACCTGATTGGCGTGAAGGCGGTATTGACCAAGGCTTCGGGATAATAAGCC
20 AGCCTGCCCAATTTGCTGACATCGTACCAAAATTGGTAATCTTCCGCCCAATCCCGCTCG
GTGTTGTAACGCAAAACCGCGTCAATGACGCTGCGCCTCATAATCATCGTGTGTTGTGT
ATGGGGTTGCCGAAAGGGAAAAAGTCGGCAATGTCTCGTGTGCGGGTCGGTTTTTTCCAA
ATTTTGCCGTGTTCTGTGGTGC CGCGCCAGCCGTTGCCGTCTTTTCTTCCGACAAAAC
TCCAGCCACGCACCCATCGCGATGATGCTGCGGTCTTTTCCATCTCACCCACGATTTTC
25 TCAATCCAGTCGGGGGCGGCAATATCGTCTGCATCGGTGCGCGCAATATATCCCCCCCC
CCCCCGGACTTTGCCAATTCATCCAGCCCGATGTTTAAAGAGGGAATCAGACCGGAATTG
CGCGGCTGCGCGAGGATGCGGATGCGGCCGTCTGTCTTGGAACGCTGGGCAATGGCA
AGCGTACCGTCCGTGAGCCGTATCGACAATCAAATATCCAAGTTGCGCCAAGTTTGA
TTCACGACGGCGGCTAATGATTGGGCGAAATATTTTCTACGTTGTAGGCGCAAATCAAT
30 ACGCTGACATAAAGGCTGCAATTTATTCTCCGATAGGCACGATGCCGTCTGAAGGCTTCA
GACGGCATTTGGA CTGTACAACGGTTACTCGCCCAAAAGCGCGATATCCGCTACCGCGTT
CATTTGTTCTGCCAAGCGGTTTCAGCAGGTTTCAGGCGTTTTGTTTACGGCGGCATCTTC
CGCCATCACCATCACGCCGTGGAAGAAGGCATCGACTTGC GGTTTTGACGGAAGCCAGTTC
GGACAAGGCGGTCTGGAATTTGCCTTCGGCAACGGCGGCGGCAATTTTCGGCTGCAAGCC
35 TTGTGCGGCGGCAAAAGAGGGCTTTTTCTTCGTCTGTGTCAGCAAGCTTTCGTTAACCGC
GCCCAACTCGGCATCGGCTTTTTTCAGCAGTTTTGACGCGTTTTGTTGGCAGCGGCGAG
CGCGGCGGCTTCGGGCACTGTTTGAACGCGGCGACAGCCTGCAGTTTGGCGGTCAAATC
GTCCAAACGGCGCGGCTGCTTGGCAAGTACGGCGGCAACGATGTCTTGGCGATAATCGTT
TTGCAGCAATACGGCAAGCGCGCCTGCATGAAGTCGGCGGTTTCAGACGGCGTTTTTTTC
40 GTTGAGCAAACCTTGGGGAAGCTGTTGAAGGCCGTCTGAATCAGTTCGTTTACGTCCAA
ACCGTACTGCATCAGCATACGCAAAATACCCAATGCGGCGCGGCGCAGGGCGTATGGGTC
TTTGTGCGCGGTTCGGAATCAGGCCGATACCCCAAATGCCGACCAAGGTTTCCAGTTTGT
GGCAAGCGCAACGGCGGCGGCAATTTTGCCCTCAGGCAGGTTGTGCGCGCAAAACGCGG
TTGGTAGTGTGCTCGACGGCTTCGGTAATTTCTTCGGTTTTCGCCGTCCAAGCGGGCGTA
45 GTATTTGCCCATCGTGCCTTGCA GTTCGGGGAACCTCGCCGACCATTTCGGTTACTAAGTC
GGCTTTTGGCAAACGCGCGGCGGCTTCGGCTGCGGCGGCATCCGCGCCAAAGCCTTGGC
GATATGGGCGGCGATGCTTTGCAAGCGTTTCGATGCGTTTCGGCTTGC GAACCGATTTTGT
GTGATAAACACGTTTCGT CAGTTTGGGCAGGCGGCTTTCCAAAGTCGCTTTTTGGTCTTG
TTTGTAGAAGAACTCGGCATCAGACAGGCGCGCGCAAGACACGTTTCATTGCCTTGAT
50 GATGTGTGACGGATCTTCGGTTTGCAGATTGGACACCAGCAGGAAGCGGTTTCATCAGCTT
GCCGTTTTTGGTCGAGCAGCGGGAAGTATTTTGGTTTTGCTGCATCGTCAGAATCAGGCA
TTCTTGCGGTACGGCGAGGAAGTGTCTTCAAAACCGGCTTCCAATACCACAGGCCATT
GACCAGCGCGGTTACTTCGTCCAACAAGGCTTCATCGGCGGCGGCGGTGCGGTTACAGAC
GCGTGCCTGCCCTTCCAATACCGTCTGAATCGCGGCTTTGCGCTCGGCAAACGAAGCGAC
55 GACTTTGCCTTGCTCGCGCATTTGTGCGGCGTAGCTGTGCGGCTTTTCAATGGTAATTT
GCCGTGCGAGAGGAAGCGGTGTCCCAAGGTTTTGTTGCCGCTTTGCAGACCCAAAACGCT
GACGTTACAATGTCGCCGCCGTGCAGTACA ACTAGCCGTGAACGGGGCGCACAAAGGT

AAACGTGCTGCTGCCCCAACGCATTACTTTGGGAATCGGCAGCTTCTTAACCGCTTGATT
GATAATGTCTTCCAAAAGTCCGCCAACGGTTTGCCGATTTGGACGTATTCGTAGGCGTA
CACGTCCTGCTTGCCGTGCTGGACGATGGTCAAGTCTTCGATTTTCGCGCCCCGACCGCG
TGCGAAACCTTCCAAAGCCTTGTTGGCGCACCGTCTTTTCATGGCATTTCGCTACGGCAGG
5 GCCTTTTTTACAAATTTTTTATCAGCCTGAACGGCTTTGACGTTTTTGACTTGAACCGC
CAAACGGCGCGGCGAGGCATAAGCCGTAAATTCGGCTGCGCCGTCAACCAGTTGCGCTTT
TTCCAAGCCTTCGGCAACGGAAGCGGCGAAATGGTTGCCAGATTATTAGGGCTTTGGG
CGGGAGTTCTTCGGTAAGGAGTTCGATTAAAAGGGTTTGGGTTCATCATTTCGGCTTTCTTT
10 GAATTTGCTTAATCTGCCTGTTTATAGGTTTCGCTGTAATTTCCCAGCCGTATCCCCA
TAAAAACCGTCAACCAGCGGGGTGGCGTACAAAGTGGCAACATCTTCGCGGTCTGCCAGC
CAAGAGATAATGGCTTTTTTCTCGGTTTCTCCCAAGCTTCGGGCACCGGATTTTTTGAAAC
AGGCACGAAAAATCGCCGCAATCGCCCCCGCCATTTCAAAGCCGTTTGCCGCAAGATA
CGCAATCAGCTCGTCCATAAAGCGGTGCAACGCTTCGGCATCGTCTCAGCTTGGTGCAA
ACTGCCTTGAACGCCGAAATCAATGTTTGAAACTCGCCCAAATGCAGCTTTTTATGCTG
15 GCGGCGGTTTCATTTTGTGCAGGCGTTTCTGCTTGGGGTGCGGAAATAGACAGGCATGAT
TTTCTTAAAAATATAATGGCTTCCGGACGGCTGCCTTATCGTGCCGCCCGAACGTAATA
AATCGTCGCCCCCTTAGGCGGCGTTTGCTTCATTAAAGGGAAGCCAGTTTTTCGCGGC
TTTCAACATATTTTGGCGCCACGGCGCGGCTCAATGCACGAATACGTCCAATATAAGTTG
CCCGCTCAGTTACGGAATCGCGCGCGTCTAAAAGGTTGAACGTATGCCCCGCTT
20 TGAGGACAAGCTCGTAGGCAGGCAGGGCGAGGGCGGCGTTTTCTTCGGCAAGCAGGCGTT
TGGCTTGCCTTCGTAGTCGTTGAACTGGCGCAGCAGCCAGTCGGCATCGCTGTATTGCA
AGTTGTAGGTGGATTGCTCGACTTCGTTTTGGTGGTACACGTCGCCGTAGGTGACGGTGT
TGCCGTCGAGCGTTTTTGCCCAAACGAGGTCGTAGACGTTTTCTACACCTTGCAAGTACA
TCGCCAAGCGTTCGATGCCGTAGGTGATTTCCGCCAGTACGGGCGTGCAGTCGATGCCGC
25 CGACTTGTTGGAAATAGGTAAACTGGGTACTTCCATGCCGTTGAGCCAGACTTCCCAGC
CCAAACCCACGCGCCGAGGGTGGGGTTTTCCAGTCGTCTTCGACAAAGCGGATGTGCT
GGACTTTGGGATCGATGCCCAATTTCGCGCAGAGAGTCGAGATAGAGGTCTTGATATTGG
CGGGAGCGGGCTTGAGGGCGACTTGGAATTGGTAATAGTGTTCGAGGCGGTTGGGTTGT
CGCCGTAGCGGCCGTCTTTGGGGCGGCGGCTGGGTGGACGTAGGCGGCAAACCAAGGCT
30 CGGGGCCGAGTGCGCGCAGGCAGGTGGCGGGATGGGATGTGCCGGCACCGACTTCCATGT
CGAAGGGTTGGATGACGGTGCAGCCTTTGTCTGCCAGAATGTTTGAGTTTGAAGATGA
TTTGTGGAAGGTAAGCATGGCTTATGATTCGATAAAATAAAGGGTTTTATTTACTGTTT
CCATTGCTGTTTGGATAGGTTTATCTCAAAGACAGACTGATTTGAAACACGGCATAACAT
GATATAGTGGATTAAATTTAAACAGTACAGCGTTGCCTCGCCTTAGCTCAAAGAGAACG
35 ATTCTCTAAGGTGCTCAAGCACAAGTGAATCGGTTCCGTACTATTTGTACTGTCTGCGG
CTTCGTGCGCTTGCTGATTTTTGTTAATCCGCTATATGTTTCGGTTAGGCGCGAGGCT
GCCCTATTGAATACCTTAAAGCAGGCTATGCCTGCCAACGCCATATCCAAACACAGTCTT
TAATTTAAATCCGGAATAAAGCAGCACGACCAACGGTTCGTGCTTTTCCAAACCAAACA
AGTTTATTTCTTGTGCGAACGGATATAGTCCAAAGTTTTGAGCTGTGCAATCGCAGCAGC
40 CAATACTTTATGCGCTTCCGCCAAAGCCTTATCGTCTTTAGCTTGGGAAATGCCGCTTC
TGCGGCTTTTTTCGCTCTTCCGCACGTGCCCGATCCATCTCCGCACTGCGGACGGCAAC
ATCCGCCAAGACAGTTACTTTATCAGGCTGTACTTCCAAACACCGCCGGAAACAGCAAC
CAAAACCTCTTTATCCTCGCCCGAACGGTCAAACGCAAAGCCCCCGCCGACCAAACT
CATAATCGGCTCGTGTGCGGATAAATACCGAGTTGCGCCTGTACAGTCGGAACAACGAT
45 AAATGTTGCCTCGCTGAATAGATTTTCTGCTCGCTACTTACCACCTCAACTTGCATGAT
GCTCATGCCGACCTCCTTAGTTTAAAGGTTTTCGCTTTCTCTACTGCTTCTTCAATGCTGC
CGACCATATAGAATGCCTGCTCGGGCAGATGATCGTATTGCCGTTCAAGATGGCTTTGA
AGCCGGCAATGGTATCGCGCAGGGCGACATATTTACCCGGAGAACCTGTAAACACTTCGG
CAACGTGGAACGTTGGGACAGGAAGCGTTGGATTTTACGCGCACGCATTACGGTCAGTT
50 TGTCTTCATCAGACAATTCGTCCATACCCAAGATGGCGATGATGTGCGCAATTTCTTTGT
ATTTTTCAGGGTGGACTGCACACCGCGCGCCACGTCGTAGTGCTCTTGACCCAATACCA
TCGGATCCAGTTGGCGCGAAGTAGAATCAAGCGGATCGACTGCCGGGTAAATACCCAAAG
AGGCAATATCGCGGCTCAATACGACGTTGCGTCCAAGTGGGCGAACGTTGTTGCCGGAG
ACGGGTGCGTCAAGTCGTCCGACGTTACATATACGGCTTGGATGGAAGTAATAGAACCGG
55 TTTGGGTAGAGGTAATACGCTCCTGCAAACGACCCATTTCTTCTGCCAATGTGGTTGGT
AGCCCACTGCAGACGGCATAACGACCAACAATGCGGATACTTCGGTACCAGCCAGGGTGT
AACGGTAGATGTTGTCCACGAAGAACAATACGTGCGGCCCTTTGCCGTTTTCTGCTTTTTT

CGTCACGGAAGTATTCCGCCATGGTCAAACCGGTCAATGCGACGCGCAAACGGTTGCCCCG
GAGGTTTCGTTTCATCTGACCGTAAACCATTTGCCACTTTATCCAATACGTTGGAATCTTTCA
TCTCGTGGTAGAAGTCGTTACCTTCGCGGGTACGCTCACCCACGCCTGCGAACACGGACA
AGCCGCTGTGCGCTTTGGCGATGTTGTTGATCAATTCATCATGTTACGGTTTTACCCA
5 CACCGGCACCGCCGAACAGACCTACTTTACCGCCTTTGGCAAACGGACACAGCAAGTCAA
TCACTTTAAATGCCCCGTTTCGAGCAATTCGGTTGTGGAAGACAGTTTCGTCAAACCTTAGGGG
CAGCTTGGTGGATGGCAGGGCTCTTGTCGGTATCGATCGGACCTGCTTCGTCAACAGGCG
TTCCCAATACATCGACAATGCGTCCCAACGTACCTTTACCTACCGGCACAGTAATGGGCG
CACCGGTATTGCTCACAGTCATGCCGCGTTTCAAACCGTCCGAGCTGCCCATCGCAATGG
10 ATTTCAAAGCGTCGTAAACGCGCGGAATCATGTGCGGTGGAATTCACGTCAACAACCG
CACCGATAATTTGTACGATTTTGCTTGGCTCATTATCGTATCCTAATTTCCGTACAGGA
TTCAGACGGCATCAGACAGCCGCCGACCTGCTACAATTTCTGACAATTCGTGGTAATC
GCAGCTTGACGCGATTTGTTATATACCAAACGCAACTCTTTGATGGCATTGCCTGCATTG
15 TCTGTTGACGCTTTTCATGGCAACCATGCGGGCTGCCTGTTCCGATGCCATATTGTCGCTC
AACGCCCTGATAAACCACAGACTCTAAATAGCGGCGAACCAGATATTCCAACACTGCAAGT
GCAGTCGGTTCGTAGCGGTATTCCCAGCTGAACGGTGATTTGGGAGCTGAATCGCCAATC
ACGTTCTCACCGATAGGCAGCAATACTTCCATTCTCGGTTCTTGACGCATGGTATTGACA
AAACCCGAATACACAGATGGATTCTGTCAATTTTCATGTTTCTCATACCGTTGGAAGAGT
20 TCTGTCAAAGGTCCGAGCAGCATTTCATTTTGGGGTATCGCCCAAATTTACGGCACTG
GCAACCACATTACAGACCAATGCTCTGACACGCCATCAGACCTTTACTGCCAAAGCATACG
ATTTCTCTTCAATACCTTGATTCCGATACTCTTGAACCTGTGCCAAAACCTTTTCAGC
ACGTTGGCGTTCAAACCGCCACACAAACCTTATCAGACGTAATCAAATAAAACCGACA
CGTCTGATTTCCCGATGAGATTCCAGTAACGGAATACCATGATCGGTATTGGTTTGGCGCA
25 AGATGGCTCATCACCATACGCACTTTTTCGGCATACGGACGCGCCAAACGCATCCGTTCC
TGAGTCTTCCGCATTTTAGAGGTTGACACCATCTGCATCGCTTTAGTGATCTTTTGGGTA
TTCTGAACACTGCGGATTTTGGTGAGAATCTCTTTTCTACTGCCATTTACAGACTCCTTT
CACTTCAAGCCTTATGCCTGATAGGCGTAAGAAGATTTGAAGGATTTTCATGGCTGCTTCA
AGCGTTTTCTCGCTCTCGTCGGACATTGCACCTGAAGCATTGACGGCTTCCAAAACCTTCC
30 GGATGTTGGGTACGGACAAAGCTCAAAAATTCAGATTCAAAGCCAGAGCTTTGGCAACC
GGAACATCAGAATACGAACCGTTGTTGATTGCCCAAAGGGTCAAAGCCATTTACGCCGTA
TTCAACGTACTGAACGTCTTCTGTTTCATCAGTTCCGTTACGACTTCGCCATGCTCCAAT
TGTTTGGCGTAGCTTCATCCAAATCGGATGCAAATTCGAGAACGCGCCCAATTCACGA
TATTGTGCCAACGCCAAACGGATACCGCCACCCAGCTTTTTAATCACTTTGGTTTGTGCA
35 GCACCGCTACGCGGGATACGGAAATACCGGCATTGATTGCAGGACGGATACCGCGCTTG
AAGAGGTCGGTTTTCCAAGAAAATCTGACCGTCGGTAATCGAAATGACGTTAGTCGGAACG
AAAGCAGATACGTCGCCCGCTTGGGTTTCGATAATCGGCAACGCGGTACAGAGAACCGGTT
TTGCCTTTTACTTCGCCGTGGTCAATTTCTCCACTTCGTGTTTATTGACACGTGCCGCA
CGTTCCAACAGACGGGAGTGCAGGTAGAACACATCGCCGGGATAGGCTTCGCGGCCGGGC
40 GGACGGCGCAAAGCAGGGAATTTGACGGTAAGCCACAGCCTGTTTGGACAAATCGTCA
TAAACAATCAAGGCATCTTCGCCACGATCGCGGAAGAATTCACCCATCGTACAACCGGAG
TAAGGTGCGATATATTGCAATGCCGCCGCTTCAGATGCAGTTGCAGCAACCACGATGGTA
TGCTCCATCGCGCCATGCTCTTCCAATTTGCGGACCACGTTGGCAATAGAAGATGCTTTT
TGACCGATACGACATAGATACAGATAACACCCGTACCTTTTTGGTTGACGATGGCATCC
45 AATGCTACGGCCGTTTTACCTGTCTGACGGTCGCCAATAATCAACTCACGCTGACCGCA
CCGACAGGAACCATAGAGTCAATCGCCTTCAGACCGGTTTGATCGGCTCGTCAACCGAT
TTGCGCGCAATCACGCCCGGTGCGATTTTTTCGATAGGGGCGGTCAAAGTTGTATTAATC
GGGCCTTTGCCGTCGATAGGCCGACCCAATGCATCAACGACGCGTCCGACCAGTTTCGCGT
CCGACCGGCACITCCAAGATACGACCGGTACAGGTAACCGTGTGCGCTTCTTTAATGTGT
50 TCGTACTCGCCCAACACTACGGCGCCGACGGAGTCGCGCTCCAGGTTTCATCGCCAAGCCG
AAAGTGTTACCCGGGAATTCGAGCATCTCACCTTGCAATTGCATCTGACAAACCATGGATG
CGAAGCATACCGTCAGTTACCGAAATTACCGTACCACAGGTACGCACTTCGGCATTTACA
GACAGATTTTCGATCTTGGCTTTAATCAAATCGCTAATTTACGACAGGATTAAGCTGCATG
AAAACCTCTCCTAATTCGTATAGTCGTGTACAAGGCACTCAATTTGCCTTGTACAGACAA
55 ATCCAAAACCTGATACCCACTTCACTTTTATGCCGCCAATCAGCTCCGGTTTCGATTTTC
GACAGAGATTTTCAGCTCGCTGTGAAACGCTTATTCAGCATTTGCACCAACTCGCCGAC
CTGTTTTGTCGGTCAACGGATAGGCAGTGAATGACGGCAGATTTGATATGGTTGAATGA

TAAGGTCAAGTCTTGATATTGAGCATATACTTCCGGCAATATCGACAAACGTTTCTGCCC
GGCCAAGACGATAACAAAGTTTTTCAACTCCTTGTCTTTCAAACCGACCAAATCGATGAG
GATATCTGCTTTTTTCTGAAGCATTGCTTTTCAAGACGGTCAATCAATGAAGCCACCTTCCC
TTCCTGAACAACCGCCGCAAGTTTTTCCAGTCCGCCCAACCAAGACTCAATTTGGTTTTT
5 TTCCTGAGCCAGACCGAACAATGCCTTTGCATAAGGTCTGGCAATCGTTGCGAACTCTGC
CATAAGATTACAGTCTCTGTTTTCAGGGTATCGAGCAGTTTTGCGTGTTTGGAAGCATCGA
CTTCGCTGCGCAAAATAGATTTCGGCACCTTTGACAGCCAACACGGCAACCTGCTCGCGCA
GGGATTTCGCGTGC CGCGGAACAATTCCTGCTCCACATCGGCCTTTGCCTGAGCTGCAATGC
10 GCGCCGCTCGGAAGAAGCCTGTTCTTTGGCTTCTTCGACAATTTTGGCGGCACGTTTTT
CGGCGTTTGGCAACCATTTTCGGAACCTGATTACGCCCTTCTGCCAAGAGTTCTGCAACCT
TTTTTTTCAGCCTGCTCAAAATCGCTTTTACCACGCTCGGCGGCAGCCAAGCCTTCGGCGA
CTTTTTCGCGCACGCTCATCCAAAGCTTTTGAATCGGCGGCCACAGAAATTCATGGTAA
ACCATAACCAACCGAAAAAGACGATGATTTGAGCGAATAATGTTGCATTGATATTACGT
15 TACTTAACCTTCGTACTGGGGTTAATCAAACAGGCTGCGCCTGTACGGAACGGACGAATC
CGTCTGTATTATGCACCTGCAAACGGGTTAACGAAGGCGAACAGCAGTGCAATGGCGACA
CCAATCAAGAATGCGGCATCAATCAAACCGGCAATCAGGAACAGTTTGGTTTGCAGCGGA
CCGATCAGTTTCGGGCTGACGGGCAGAACTCCAAATATTTAGAACCGACCATTCGCGATA
CCGATAGAGGCACCCAATGCACCAATGCAACGATCAAACCATGCGATAGCAATCAAA
20 CCCATTTTAACTCCTTAAAGAAACAAAGGTTAAACTACAAAAACAACTACTTAGGAAA
ATCAGTGCGCATCATGTGCCTGTCCGATATAGACGAACGCCAACGCCATGAAAATAAACG
CCTGCAGGGTAATCACCAAAATATGAAAAATCGCCCATGCCAAACCGGCAATAATGTGGA
ATACAAACAGAATCGGATCCATGACTTCGACGCTGCCGGAAGCCGCCAAGCACCGCCAA
GCAAGGCTATCAACAAGAATACCAATTCGCCCCGATACATATTGCCGAACAACCGCATA
CGTGGGATACGGTTTTTAGAAAGAACTCGACCAATTCACAGAAAGTTTCGAGGTGCGA
25 GTTTTGCACCGAACGGCGCGCTGAACAACTCGTGAAACCAAGCCACCCAATCCTTTGATTT
TGATGTTGTAATAGATACAAATCAGCAACACGCCGACAGCGAGTGCCAAAGTGGTGTTC
AATCGGCAGTCGGTACGACGCGCAGCAGGGCGTGATGGTTGCCGGTAATGCCCTGCCATA
CCATCGGCAGCAAAATCGACCGGCAGCATATCCATCGCGTTTCATCAGAAAAATCCAGACAA
ACAGCGTCAGACCCAACGGCGCGACGGCTTTTCTAGACTTTTCGTTGTGAATGATGCTCT
30 TACACATATCGTCCACAACTCAAACAAGATTTCCACTGCGGCCTGGAACGTCCGGGAA
CGCTGCCGTCGCTTTTTTTTGCACCGCGCCACAACAGAAAGCTGCCGATTACGCCCAACA
GGACGGCAAAAAAGACGGCATCAAGGTTAATAAACGAAAAATCAGCAATGTTTTTCAGTC
CCTGACCTGAGTAACATCCGACAACTGGTCAAGCTCTGCAAGTGGTGCTTGATGTAGT
CGGCAGCGGTAATGGTTTCACCTGCCATAATCTTTCACCTCTCAACAATACTAAAAAAACC
35 AAATGGCTGACACCGAGCAGCCCCATCAGAAACGGGGCGAACACCAGCGATTGATGCCAT
ATTGCAAAATACGGCAAGCATGGACAACAGCGACGACTACTTTTAAATCTCTCCGAAG
ACGAACATCCTGCTTTGAGGAAGGGGTTTCCCTGAAAAGTTTAAAGGTAAGAACTGCA
ACAAACGTGGGAAGCAGGTAGGACAAACCGCCACCGACCGCGAAAGGAATCCGGCAAAA
CCCCATACAGCAAAGGCAACTGCGGCGCATATGGACAATACGGCGGATTGTAGGATGATA
40 ATCTGCTTCATAAAGGGAATGTTCCGCTCGGATTGGGGCGCGGCTAATATAATTTAG
AAGCCTTATTACGTCAAGCGACAGTTAATCTTTGTGAAACAACGTATCCCAATCCGCGC
GCTCGCCGCTGAATAACGGCGACAGGTGTATTCTAACACACATTACATATAATTACAG
GATATTAAGGAGTTTGTCCGCAATTTCTTTACATTTTAAATGTTCTTACGTGATTTGTTT
GCTTTACGTGGAATAATAAAAAATCAACGCGAAATGTAGCAGTTTATCGGTCGGATTG
45 TCGGCAGTTTGGGGAATTTGCTCAATAAATAAAAGGTCGTCTGAAAATATTTTCAGACGA
CCTTTTCCGAATAAAGGATTAGCAACTGCCTGCCGCTTTAAGCAAAGCATTGCATTGACT
TTTGCTTTGTGCGTTCCGCCCTCCCAACAAATTCATCGGAAGTGGTAACGCCGATTGT
GCTGATTACACTGGTAACATAGCATTGGCTCACGCGCTTACCCACAGTTGCCGTAAAGTT
GATGCGTATGCCTTCATTGTTGCGGTTGCTGATTTTACGGCATTGTTGGGCTGACGCCAA
50 GGCAACCGCGGCACGTTCCGTAAGTTTCTAGTCGGAAACGGTTACATTATTGATTGAGCC
GCAACCTGCTAATGCCAACGCAACGACGCGGAAACGATGATGCGTGTGTTTACATAAT
TTCCTCGAAAATTAATAAAGGAAACAGGAAACGATTCCTACGTGAAGCAGAAAAATGT
CAATAGAATTATATTTCCCACTTAAATCTGGAAAGCTATTCTCTATATTTACAGACGGTA
TATCCCGCAAAATTAAGGCCGTAATCTATGCCCAACTGCTCCAGCAGGTGGCCGAACGT
55 TTCAGGCGTATCGAAATACAGGACAATCCTGCCTTTTTTGTGGTTGGCGGTTTTGACTTC
AGCGTTGACACCCAGTTTTTCAGTCAGCAATCATTACGGCGGCCGATGTCCGCGCGCGC
AGTCTTTTTTGGGCTCGGGACGTTTGTTTTGAAGGCGGCCCTGGCTGCGGCGTTCGACTTC

CGGCACCGACCAGCCGTTTTTACGGCCTTTTGCGCCAATTCGAGCTGTTTCGACGAGTTT
TCGGAGAGGACCATGCGCGGGCGTGCCCCATTTTC

- 5 The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 5>:

gnm_5

CAGACATTACCGTGTACAACGGCCAACACAAACGAAGCAGCACAAGCCGTTGCAGATGCC
TTTACCCGGGCTACCGGCATCAAAGTCACACTCAACAGCGCCACACGCGACCAGCTTGCC
GGTCAAATCAAAGAAGAAGGCAGCCGAAGCCCCGCCGACGTATTCTATTCCGAACAAATC
10 CCGGCACTCGCCACCCTTTCCGCCGCCAACCTCCTAGAGCCCCCTGCCCGCCTCCACCATC
AACGAAACACGCGGCAAGGGCGTGCCGGTTGCCGCCAAAAAAGACTGGGTGGCACTGAGC
GGACGTTTCGCGCGTCGTCGTTTACGACACCCGCAAACTGTCTGAAAAAGATTGGAAAAA
TCCGTCCTGAATTACGCCACGCCGAAATGGAAAAACCGCATCGGTTACGCCCCCACTTCC
GGCGCGTTCTTGGAACAGGTTGTCGCCATCGTCAAACCTGAAAGGCGAAGCGGCCGATTG
15 AAATGGCTCAAAGGTCTGAAAGAATACGGCAAGCCTTACGCTAAAAACTCCGTCGCCCTT
CAAGCGGTTGAAAACGGCGAAATCGATGCCGCCCTCATCAACAATACTACTGGCAGCGT
TTTGC GCGTGAAAAAGGCGTACAAAATGTCCACACCCGCTGAATTTCTGTCGCCACAGA
GATCCCGGCGCACTCGTTACCTATTCCGGCGCAGCCGTGTTAAATCCTCCCAAAACAAG
GATGAGGCGAAAAAATTCGTCGCCTTCTCGCCAGCAAGGAAGGACAGCGCGCCCTGACC
20 GCCGTCCGTGCCGAATATCCTTTGAATCCGCACGTGGTATCCACTTTCAATTTGGAACCC
ATCGCCAAGTTGGAAGCACCCCAAGTGTCCGCCACCACTGTTTCCGAAAAAACAACACGCC
ACCCGGCTGCTTGAGCAAGCCGGTATGAAATAAGCCGTTTTCGGATTGTCAAACGGGTGG
ACATTTATACTGTCCGCCCGTTTGGCGATAAAAAACACTATGTCTCCTAAAAAATACC
CATTTGGCTTACCGGCCTCATCTACTGATTGCCCTACCGCTTACCCTGCCTTTTTTATA
25 TGTCGCTATGCGTTCTGTCGAGGTGCGGCATCAACCGCGCGCTCGAAGTGTGTTCCGCCC
GCGTATGTGGGATTTGCTCTCCAACACCTTGACGATGATGGCGGGCGTTACCCTGATTTT
CATTTGTTTTGGGCATTGCCTGCGCCCTTTTGTTCACGTTACCGCTTCTTCGGCAAAAC
CTTTTTTTCAGACGGCAATCACCTGCCTTTGTGCATCCCCGCATTGTGTCAGCTGTTTAC
CTGGATCAGCCTGACCTTCGCTGTCGAAGGCTTTTGGGGGACAGTGATGATTATGAGCCT
30 GTCTCGTTCCCGCTCGCCTACCTGCCCGTCGAGCGCGCACTCAAACGCATCAGCCTGTC
TTACGAAGAAGTCAGCCTGTCCTTGGGCAAAAGCCGCTGCAAACCTTTTTTTCCGCCAT
CCTCCCCCAGCTCAAACCCGCCATCGGCAGCAGCGTGTTACTGATTGCCCTGCATATGCT
GGTCAATTTGGCGCGGTATCCATTTTGAATACCCCACTTTTACCACCGCCATTTTCCA
AGAATACGAAATGTCCTACAACAACAATACCGCGGCCCTGCTTTCCGCTGTTTAAATGGC
35 GGTGTGCGGCATCGTCGTTTGGAGAAAGCATATTTTCGCGGCAAAGCCAAGATTTACCA
CAGCGGCAAAGGCGTTGCCCGTCCTTATCCCGTCAAACCCCTCAAACCTGCCCGGTGAGT
TGGCGCGATTGTTTTTTAAGCAGCTTGTGACTTTGGGCATTATTATCCCTTTGGCGT
ATTGATACATTGGATGATGGTCGGCACTTCCGGCACATTGCGGCTCGTATCCGTATTTGA
TGCTTTTATCCGTTCTTAAGCGTATCGGCTTAGGTGCGATTTGACTATATTATGTGC
40 CTTGCCCCCTGTTTTGGGCATCGGTTGCTATCGCAATTTTTTAACCGTTTGGATAGACAG
GCTGCCGTTTTTACTGCACGCCGTCCCCGGTTTGGTTATCGCCCTATCCTTGGTTATTT
CAGCATCAACTACACCCCTGCCGTTTACCAAACCTTTATCGTCGTCATCCTTGCTATTT
CATGCTTTACCTGCCGATGGCGCAAACCACCTGAGGACTTCCTTGGAACAACCTCCCAA
AGGGATGGAACAGGTCGGCGCAACATTGGGGCGCGGACACTTCTTTATTTTCAGGACGTT
45 GGTACTGCCGTCCATCCTGCCCGGCATTACCGCCGCATTGCACTCGTCTTCTCAAAC
GATGAAAGAGCTGACCGCCACCTGCTGCTGACCAACGACGATGTCCACACACTCTCCAC
CGCGTTTTGGGAATACACATCGGACGCACAATACGCCCGCCGCAACCTTACGCGCTGAT
GCTGGTATTATTTTCCGGCATCCCCGTATTCCTGCTGAAGAAATACGCCTTCAAATAACA
GCTTGAGGAAGTACCGCCATGACCGCGGCCCTGCACATCGGACACCTGTCCAAAGTTTT
50 CAAAACACCCAGTTTTAAACGACATTTGCTCAGCCTCGACCCGGGCGAAATCCTCTTT
ATCGTCGGCGCGTCCGCTGCGGCAAACACCCCTTTTACGCTGCCTTGCCGGTTTTGAA
CAACCCGATTTTGGCGAAATTTGCTTTCCGGCAGAACCATCTTCTCGAAAAATACCAAC
CTCCCCGTCCGCGAACGCCGTTTGGGTTATGTCGTACAGGAAGGTGTGCTGTTCCCCAC

CTGACCGTTTACCGCAACACCGCCTACGGGCTGGGCAACGGCAAAGGCAAGACGGCGCAA
GAGCGGCAGCGCATCGAAGCTATGTTGGAATTGACCGGCATTTCCGAACCTGCCGGACGC
TATCCGCACGAACCTTTCCGGGCGACAGCAACAGCGCGTCGCCCTCGCCCGCGCCCTCGCA
CCCCGATCCCGAAGTATTTTGTGGACGAACCCCTTACGCGCGCTGGACGAACAGTTGCGC
5 CGCCAGATTTCGGAAGACATGATTGCCGCCCTGCGCGCCAACGGCAAATCTGCCGTTTTT
GTCAGCCACGACCGCGAAGAAGCCCTGCAATACGCCGACCGGATTGCCGTGATGAAACAG
GGGCGCATCCTCCAAACTGCAAGCCCTCACGAATTGTACCGACAACCTGCCGACCTTGAT
GCCGCCCTGTTTTATCGGCGAAGGCATCGTGTTCCCGCGCGCTCAACGCCGACGGCACC
GCCGATTGCGGATTGGGCCGCTGCCCGTTCAAAGCGGCGCACCCGACGGCACACGCGGC
10 AACTGCTCATCCGTCCGGAACAGTTTACGCCCTTACCCCCATTCCGCACCCACCGCCTCC
ATTCACGCGCTGTTCTCAAACACGCCCCAAAGCGCGGCATACCGAAATCAGCCTCCGG
GTCGGACAAACCGTCTCTACGCTCAACCTCCCTTCCGCCCCCACCCTGTACAGCGGCATT
TCCGCCGTCTCCATTGTTGGACGGTCCCGCCCTGTTCTTCCCGGAAATACCCCTCTGAAAG
GCGGCAGCATCCACAAGCCTGCGGATATTTATCTTGTGGAAACAGAATTTGTTTGCTAT
15 ATTCAACCTGCGCGCCTCAAGCCAAACACGGCACGCACGGCACGCAGGCAGCCGTTTCTG
CCTATATGCCGCCCTTCCAAACACATATGCCGCACACCGCAGCATACGAAAGGATATAT
CATGGCAAAAGTACTCATCGTACCCGTATCTGCCGGACTGGACGCCTCCGCCGCCGCACA
AGCCTTTGCAAAAGCACTGGACGCACAAATTTTCAAAGCCGTTGACGCAACCGCCGAAAC
CCTGCTCGCGCAAGGCAAAAGCGACGACTGGTTCGACGCACTGGTCGGCAAAGTTGCCGC
20 ACTCGATGCCGCCAACCTCGTCATCGAAGGCATCGCGCCCGATGCCGACAAAATCTACCT
CGCAGGCAAAACGTCGAAGTGGCATTGTCCCTTGACGCGGCAGCCGTCTTCGCCGTCCG
TTCCGACAACGCCGATGCCGACGAAGTGGCAAATCGGGTGAACCTTGCCAAACAGTTCTT
CGCCGCCGCGCCGGGCGTATTGGAAGGTTTTGTCGTGGACGGCGCGCAGCCTCCGTTGC
CGAAGCGGCAGCCGAAAAAACCAGCCTGACCTTCTTCGGTTTCGAGCGACGCGCTGAAAGA
25 CGTATCCGTATTGGCAGGCCGGAAGCAAAACGCCTGTGCGCGGCGCAATTCCGCTACAA
CCTGATCGACTTCGCCCGCAAGCCGACAAACGCATCGTCTGCTGAGGGCGCAGAACC
CCGACCCGTCCAAGCCGCGCCATCTGCCACGAAAAAGGCATTGCCCGCTGCGTCTGCT
TGCCAAACGCGAAGAAGTCGAAGCCGTTGCCAAAGAACGCGGCATCAGCCTGCCCGACTC
TTTGGAAATCATCGATCCCGCCTCATTTGGTCGAACAATACGTCGAGCCGATGTGCGAACT
30 GCGCAAATCCAAAGCCTGACACCCGAAGACGCGCGCAAGCAACTGCAAGACACCGTGGT
ACTCGGTACGATGATGATGGCGCAAAATGATGTGGACGGTTTGGTATCCGGTGCGGTTCA
CACCACCGCCAACACCATCCGCCCGCTTTGCAACTGATTAACCGCACCGGGCGCAAG
CCTCGTGTCCAGCGTATTCTTTATGCTGCTGCCCAACCAAGTCCTCGTCTTCGGCGACTG
CGCGGTTAATCCGAACCCGACCGCGCAACAGCTTGCCGACATCGCCATCCAGTCTGCCGA
35 TTCCGCAAAAGCCTTCGGCATCGACCCGAAAGTGGCGATGATTTCTACTCCACCGTCAA
CTCCGGCAGCGGCCCCGATGTGATACCGTCATCGAAGCAACCAACTTGCCCGGGAAAA
ACGCCCCGACCTCGCCATCGACGGCCCCGCTGCAATATGATGCGGCAACCGTGCCGGGTGT
GGGCAATCCAAAGCTCCGGGCAGCCCGGTGGCAGGACAGGCAACCGTTTTTGGTCTTCCC
CGACCTGAACACCGGCAACTGCACCTATAAAGCCGTCCAACGCAACGCCAACGTCTTAAG
40 CGTCCGCCCCGCTGCTGCAAGGCCTGCGTAAACCGGTCAACGACCTCTCCCGCGGCGCACT
GGTAGAAGATATCGTGTTTACCATCGCCCTGACTGCCGTTTCAGGCAAAACAAATGGAAGG
CTGACAAACGGCTTTCCGGGTTTTAAACCTATGCCGTCTGAAGACAGACTCCCGTTTTCA
GACGGCATTTTTATCAGCACGGCACATTTGTTTGTAAATCGCAGCCATATTGCAAAAA
AAGAGGAGGAAGCCATGCAAAACGCCATTATCGATTACGGTATGGGCAACCTGCATTCCG
45 TATTGAAATCCGTCCGGACGGCGGGGCGAGCTTGCCGGAAAAAATACCGAAATCTTTTAA
GCGGCGACCCGACCGCGTGTCCCGCGCCGACAAAGTCATTTTCCCGGTGAGGGCGCGA
TGCCCGACTGTATGGCGGCATTAAACGAGACGGTTTGGACGAGGCAGTCAAAGATGCCT
TAAAAAACAAACCGTTTTTCGGAATCTGCGTCGGCGCGCAACTTTTATTCGACCACAGTG
AAGAAGGAAACACCGACGGCTTGGGCTGGTTCGGCGGCAAGTCAGACGCTTTGAGCGCG
50 ACCTCCGCGACCCGACGGGATGCCGTCTGAAAGTCCCGCATATGGGCTGGAACACCGTGC
GCCAAACCCAAACACCCGCTGTTTAAAGATATTCCCAAGACACGCGTTTTTACTTCG
TCCACAGCTACTATTTGCCCCCGAAAAATCCCGAAACCATATTGGGCGAAAGCGACTACC
CGTCCCGTTTTGCTGTCATCGTCGGCAAGACAACGTATTTCGCCACGCAATTTACACCG
AAAAAAGCCACGATGCCGGGTGACGATGTTGAAAAACTTTTTAAACTGGTAAGCCGGAC
55 ACGGCCCCGCACAAGGAGAAAAATTATGCTGCTGATACCCGCCATCGATTTGAAAGAAGG
ACGCTGCGTCCGCTGAAACAAGGGCTGATGGAAGAGGCGACCGTCTTTCCGATTCCGC
CGCCGAAACCGCGCTGCACTGGTTCAAACAAGGCGCGCGCCGCTGCATCTGGTAGATTT

GAACGGCGCGTTTGGCCGGCGTTCCGCAAAACCTGCCCGCCATCAAAGACATCCTTGCCGC
TGTCGCCAAAGACATCCCCGTACAGCTCGGCGGCGGCATACGCGATTTGAAAACCATCGG
ACAATATTGGATTGGGCTTAAACGACGTGATTATCGGCACGGCGCGGTCAAAAACCC
CGACTTCGTGCGGAGGCGTGCAAAGCCTTCCCCGGCAGGATTATTGTGGGCTGGATGC
5 CAAAGACGGTATGGCCGCCATCGACGGCTGGGCAACCGTAACCGGGCATCATGTAATTGA
TTTGGCAAACGCTTTGAAGACGACGGCTCAACAGCATCATCTACACCGACATCGGGCG
CGACGGTATGATGAGCGGCGTGAACATCGACGCGACGGTCAAACCTGCCCCAAACCGTCCG
CATTCCCCTCATCTCCTCCGGCGGACTGACCGGCTTGGACGACATCCGCGCCCTGTGTGC
CGCCGAAAAACATGGCGTAGCAGGCGCGATTACCGGCCGCGCGATTACGAGGGTAGCAT
10 CGATTTTGGCCAAAGCGCAGCACTGGCAGATTCCCTCGACTAAAGGCATCCGATTATGGC
ACTGGCAAAACGCATCATCCCCTGTCTCGACGTAAAAGACGGGCGCGTCGTCAAAGGCGT
GAACTTCATCGGTTTGCGCGACGCGGGCGACCCCGTCAAGCCGCCAAACGCTACAACGG
CGAAGGCGCGGACGAATTGACCTTCCTCGACATCACCGCCTCATCCGACAACCGCGACAC
CATCCTGCACATCATCGAAGAGGTTGCCGGACAAGTCTTCATCCCCCTGACCGTCGGCGG
15 CGGCGTACGCACCGTTGCCGACATCCGCCGCTGCTCAATGCCGGCGCGGACAAAGTCAG
CATCAACACCGCCGCGGTTACCCGTCGCCGATTAAATTGACGAAGCCGCGGATTTTTCGG
TTCGCAAGCCATCGTCGCCGCGCTCGATGCCAAAGCCGCCAACCCCGAAAAACACACGCTG
GGAAATCTTTACCCACGGCGGGCGAAATCCGACCGTTTGGATGCGGTGGAATGGGCGGT
CGAATGCAAAAACGCGGCGCGGGCGAAATCCTGCTCACCGGTATGGACAGGGACGGTAC
20 GAAACAGGGTTTCAACCTGCCGCTGACCCGCGCGGTTGCCGAAGCCGTCGACATCCCCGT
CATCGCCTCCGGCGGGGTGCGCAATGTCCGGCACCTGATTGAAGGCATAACCGAAGGCAA
AGCCGATGCCGTACTTGCCGCGGCGATTTTCCATTTCCGGGAAATCGCCATCCGCGAAGC
CAAACGCGCTATGCGCGAAGCCGGCATCGAAGTGCGCCTCTGACCGCTCGACTATGCCG
TCTGAAAGGAAATATGGATAAAAACCTGCTTGAAGCCGTCAAATTTGACGAAAAAGGTTT
25 GGTTTGCGCCATCGCCCAAGATGCCGAAACCAAACGTATTTAATGGTGGCGTGGATGAA
CGCCGAAGCCCTGCAAAAACCGTCGAAACCGGCTTTGCCCACTATTACAGCCGTTCCGCG
CCAAAAACAATGGATGAAGGGCGAAGAGTCGGGACACACGCAAAAAGTCCGCGCACTGCG
CCTCGACTGCGACGGCGACGCCATTGTGATGCTCATCGCCCAAAACGGCGGCATCGCCTG
CCACACCGGGCGAGAAAGCTGCTTTTACAAAGTCTGGCGTGGCAGCGCGTGGGAAACCGC
30 CGATGCCGTCTGAAAGACGAAAAAGAGATTTACGGCAGCACGCACTGACCGCCTCCAAC
ATTGAATTATCAGGCATTTTTTTGTACAATTTCCGCGTCTCAAACACTGTCCGGGCCGTC
TGAAAAGCGGCCTGAACCTTTTTGCAAAGAAAACCATGTCCCAAGAAATCCTCGACCAAG
TGCGCCGCCGCGCACGTTTGCCATCATCTCCACCCCTGACGCAGGTAAAACCACGTTGA
CTGAAAACTCTTGCTGTTTTCGGGCGCGATTACAGCGCGGGTACGGTAAAAGGCAAGA
35 AAACCGGCAAAATTCGCCACTTCCGACTGGATGGAATCGAGAAGCAGCGCGGCATTTCCG
TGGCATCAAGGTGATGACGTTTCGATTACAAAGACCACCCGTCAACCTCTTGACACGC
CGGGACACCAAGACTTCTCCGAAGACACCTACCGCGTTTAAACCGCCGTGGACAGCGCAT
TAATGGTCATCGACGCGGCAAAAGGCGTGGAAGCGCAAACCATCAAGCTCTTAAACGTCT
GCCGCTGCGGATACACCGATTGTTACGTTTATGAACAAATACGACCGCGAAGTGC GCG
40 ATTCCCTGGAACTTTTGGACGAAGTGGAAAACATTTTAAAAATCCGCTGCGCGCCCGTTA
CCTGCGCGATCGGTATGGGCAAAAACCTTCAAGGGCGTGTACCACATCCTGAACGATGAAA
TTTATCTCTTTGAAGCTGGCGGCGAACGCCTGCCGACGAGTTCGACATCATCAAAGGCA
TCGATAATCCTGAATTGGAACAACGCTTTCCGTTGGAAATCCAGCAGTTGCGCGACGAAA
TCACGCCCGTATTCTTCGGCTCTGCGATTAAACAACCTTCGGTATTCAGGAAATCCTCAATT
45 CATTGATTGACTGGGCGCCCGCGCCGAAACCGCGCGACGCGACCGTACGTATGGTCGAGC
CGGACGAGCCGAAGTTTTCCGGATTTATCTTCAAAATCCAAGCCAATATGGACCCGAAAC
ACCGCGACCGTATTGCCCTTCTGCGCGTCTGCTCCGGCAAATTCGAGCGCGGCATGAAGA
TGAAACACCTGCGTATCAACGCGAAATCGCCGCTCCAGCGTGGTTACCTTCATGTGCG
50 ACGACCGCGAGCTGGTTGAAGAAGCCTACGCCGGCGACATTATCGGCATCCCGAACACG
GCAACATCCAAATCGGCGACAGCTTCTCCGAAGGCGAACAACCTGGCGTTACCCGGCATCC
CATCTCTCGCACCCGAACTGTTCCGCAGCGTACGCATCAAAAACCCGCTGAAAAACAAAC
AAGTCAAAAAGGCTTGCAACAGCTCGGCGAAGAAGGCGCGGTGCAGGTGTTCAAACCGA
TGAGCGGCGCGGATTTGATTTTGGGCGCGGTGCGCGTGTTCAGTTTGAAGTCGTTACCT
55 CGCGCTCGCCAACGAATACGGCGTAGAAGCCGTGTTTCGACAGCGCATCCATCTGGTCGG
CGCGCTGGGTATCGTGCAGCACAAGAAAAAAGTGGCTGAATTTGAAAAGCCAACGCGG
GCAACCTCGCCATCGACGAGGCGGCAACCTCGCTACCTCGCCCCAACCGCGTGAATT

TGGGACTCACGCAAGAACGTTGGCCGGACATCGTGTTCACGAAACACGCGAACATTCCGG
TCAAACGTGTA AAAAGCAATCGGCGATAAAATGCCGTCTGAACCCGAAAAAAGGCTTTCAG
ACGGCATTTTTGCTTGCAACTCAAATGCACCGATCAAATCAAGACGCATCGGATACCGT
TATCGGGCATCCCGTCTCATGAATTTAGGGCTGACGCAAGAACGCTGGCCGGACATCGT
5 GTTCCACGAAACGCGCGAACATTGGTCAAACTTAAAAACAATCGGCAATAAAATGCC
GTCTGAACCCGAAAAAAGGCTTTCAGACGGCATTTTTGCTTGCAATTCAAACGCAGACGG
TCAAATCAAGGCGCATCGGATACCGTTATCGGATGCGTCCCATCCGCATGAATTTGGGG
CTGACGCAAGAACGCCGATGTGATTTACATCCCGTACTGTTTCGACAGCTTCACATAAT
GCGCGGCGGAATATTTCAAAAAGGCTTTTCTCATCGGTGAGCAGCGCACCTGTCTGA
10 CCGCGAACACGACATAAAGATAGCCGCCGCCAAGCGTTTGCGCGGCGGAACGAGGCTGC
CCGCGCCGATCATCTCGTCTCAATCACGGCATCGTCCAGAACCGTCGTCCCATGTC
CGACCAGGACGCGGTTGCCGATACGGCAGCCGTGCAGCATCACTTTGTGCCCCACGGTAA
CGTCTTCGCCGATAACCGCGCGATCCTTCGGGTTTGCGCGCGGTTTTGTGGGAAACGT
GCAAGACGCTGCCGTCTGTATATTGCTGCGCGCGCGACGGTGATGCTGTTACATCGC
15 CGCGCAACACGGCGCACGGCCACACGGAACATCTTCGGCAAGCGACACTTCGCCAATGA
CGACGCAGGCTTCGTCTATCATACAGGTTTCGTGGATTTCCGGCGTGCGGTTTTGGAAAG
TTCGGATTGCGTTCATTTTCTCTCTTCGGTAAGGTATATATTGTTAAAGGATTTATTAA
ATATTCCCCCTGATTGCTTTTAAATCCTGCCGTAAATATCGACCCGAGTAATGTGATT
ATCGGGAATATCAGCTTATATATCAATTTATTGGACTTTAACAGCATAAACCTTAAATGA
20 TACGCCCTTCTTTTTATATCAGCATCACACTCTATATTTTTACTCGTCATTATAAAAAGC
AAAACGAGATATTCGTAGGAAAGAAAAGAATAAAGATAACTCGATATATCCCTATTAAAT
TCCATTTCCGCATTTTTCTCCAAATATATAATAATGACTTTTATACTTTTTCCGAAACA
GTTCCCGTAATAGAATCTTTCTTCCCTGCCGATAATAGTAATAACAACCGTCCAAATAA
GAAAAAGTTGTTGCCGATTAATAACCTCATTGACCATTCGATATCTTCAGAATAAATT
25 CCCCTTTCAAAAACAGTTTTCTCTAATAATCAATTCTCTTTTTATAATCTTATTCAC
GCCGAACCCGGAATTTCTAAATCGGCATAATCCTTTCAAACCTTCGACTTTGGATTGA
TTGAGTATTTTTCAGGCTGATAATCTTCGCCAAATATGAAACACTTCCCTTATCATAT
TTAACCGCATTTAAAAACACCACATCCGGCATATCAGTATCATCTTTACTAAGAAAATCC
AGCAAAATCTGACAGTTAATAAATCATCCGAATCAATAAAGACTATATATTTCCGTTT
30 GAATTTTTTATTCGGGTATTTCTCGCTCCGACAACCTTGTTATCCTGATATATATAT
TTGATATTTGGTGTCCGGTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT
TGTTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT
TGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT
35 GTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT
TTCACTTCCGTCTTTTGACCCGTCATTACAAAGGATAAGTTTCGACATTTTCATTACTTAA
TATAGATTCTATGGAACCTAAACACGCTTCCAAATAACTTTTCGACATTATAAATAGGAAC
TACGATACTTAAATCCATATCTTCTCATTTTACTAAATCATTTTAATCTTAACCCAATC
ATAACCGGCAGGAGGGGAAACGCCCCCTGTTTGATAACGGACGCGCGGTTTCTGCCGC
40 CCGAAAGGTTTCAGACGGCAGGGATTCCGGTTATTTGCCCGCTTGAGCCCTTGCCACAG
CTTCACGCCAGTTTGACGGATTCTGCGGATTTGGGCGATACGATGAAACTTTTTCCAT
CAGTTCTTTGTTCCGGGAAATCGATGCGTCGGAGGTGATTTTTTCATCCATCAGCTCGCG
CGCGGGACGGCTGGCGGGCGCGTAGGTAACGAAGCTGCCGTTTTTCGCCGCCACCTCGGG
45 CCGAGCGTGTAGTCGATATAGCGGTGGGCATTGGCAACGTTTTGCGCGTCGCGCGGAAT
CATAAAGGAATCCACCCACACGCCCACGCCGTTTTTCGGGGTCAATACTTTGATTTCCAC
GCCGTTTGCGGCTTCTTCGGCACGGGTTTTGGCAATGTTCAAATCGCCGCCGTAACCGAT
GGCGGCACACAGGTTGCCCGCCGCCATATCGTCGATATAGCCGGAAGAGCTGAAGCGTTT
CACGTCGCCCGGACGGCTTTTCATCATATCGACGGCGGCTTTGATGTCTTCGGGATTCTC
ACTGTTGGGGTCTTTGCCCAAATAGTGCAACGCCAAGGGAACTGTTCGATTGCGCTGTC
50 GAAATAGCTGATGCCGAGGATTTGAGTTTGGCGGTGATTCGGGTTTGAACACCAAATC
CCATTCGTTTTCGGGCAGCTTGTCGTACCCAATGCTTTTTTACCTGCTGGGTATTGAT
TGCCAAGGTATTGATGCCCCAGAAATAGGGGACGGCGTATTGTTGCCCGGATCGACGGC
TTCCATCATTTTCAGCAAAATCTTTATCGATGTTGCCGTAATGGGGGATTTGCGCCTTGTC
GATTTTCTGATACGCGCCGCTTTGATTTGCCGGCCGACGTTGGCGATGGACGGCGCGGT
55 CAGGTCGTAGCCGGATTGCGGGTCAGGACTTTTGCCCTCCAGTGTTTCGTTGCTGTCGTA
ATAATCGGAACGCGTCTTGATGCCGGTTTCTTTTTCAAAGGCGGCAACGGTTTCGGGATC
GACATAATCCGACCAGTTGTAGATGTTGAGTTTGCCCGATTGTTCCGGCTTCGGGCTTGGC

GGAGGGGGTTTGGGCGGCGGTATCGCTTCCGCCGCCGCACGCAGTCAAGGCGAGGCTCAG
GATTGCCGCCGCCACCAGTGTTTTTTCATGGTTTTTCGACCTTCGTTCAAAAATAAAAA
ACATTGCAGGGACGGACGGGCGCCTGCATCGGAAGCTGTGGGGCGGCGCGGTTCGGCTTT
CTTGGCCCTTGGTGACGAAGGTTTGCAATTAACGGCAAAAACAGCCGGGGCGCAACCGT
5 TAATTTTACCGGTTTGCCGTTCCGGTGCCCGATCGGGCGGTAATGCGGGACATTGTTCC
GCCTGCGTAAAAATGCCGTCTGAAGCCTCGGCGGCTTTCAGACGGCATCGGGGCGGACGG
CATCAGTTGCTCAACACGTCCACGCCCTTGGGCGGGGTAAACTTGAACGCGCCGCGCGAG
AGTTGGGGATTGGTATTCAAACGCCGAAACTGATGGAGGTTTGGTTGCCGAAGCTGTCT
TTAAGCTGCATGGCGGCGAGGTTGCCGCCCTTGAAGCCGATGCGGATGTATTGGTAGCCG
10 CGGTTGTTGCGTTTGGGCGTTGCCAGCACATAATCGATGCCGTTGGACGAACCGTCTCTC
TTCAGCGTGTAGCTGCTTTCGAGGGCGGTTTTGTTTCGACAGGATGGCGGCGGGGCTGCCG
CCTATGGCCTGGTCTTGGGACGACTTGGTCACTTGTGCCAGATCAACATCGTAGAGCCAA
ACGGTTTGACCGTCGCCGACGATGGTTGCCTGTAAGGTTTGGTGTATTCCCATTGAAA
AGGCCCCGTGCGAGGATTTTGAACGTGCCGTGCCGCGTTTGGGTTTTCTTTTGGCTTTGG
15 ACGGTTTGGGTGAAGCTGCCGTGATACCGTCGGCATCGTTGTTGAATTGCTTAAGCGCG
TCTACCGCGCCCGCCTGTGCGGAAGCGACGGCGACGGTCAGGGAGCAAACGGCGAGGAAT
TGGAACAGGTTGTGCGGTTTCATCATTATTTTCTTGTGCGGATGAGTGTGGCGTAAAG
TATCGGCGCAGCAAAACAATCATACGGGCGGCGTTACGGGCGGTTTGCATTTTGCAAACC
GCGTTTTCCGAGGGCTGATTTTTTGGCCACCGGAAAAGGCGGCGGCCACGCTGCCCTTT
20 AATGTGTGCCGCTTATAGTGGATTAAACAAAATCAGGACAAGGCGACGAAGCCGCGAGAC
AGTACAAATAGTACGGAGCCGATTCACTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCT
TTGAGCTAAGGCGAGGCAACACCGTACTGGTTTTTGTAACTACTATATTTGACGGTTT
GGGCGCGGAATGCCGAATCGCGGAGATTATATGCCTCATCTGTTTTTTTAAACGCTAT
AATATTTGTTTTCCGAACACGGCGGACTTGAGATGAAACCCGATATTTATGCTTTGCTGG
25 AACGCGCCCTGCTTTCGGGCGACCCAGATGAAAAGGACGGCTGACGGATGAGGCGTTTG
CCGCCGTTCAAAATGCGGACGGGCGGAAACAACGCACCGCCGCGGCGGACTTCCCCCGCG
CGGGACGACCGGACAAGCCTGTTTTGGTCGCGCCGTCGAGCTGACGCCACGCAAAATGA
ACACAACCGAAGGCTATGCGGCGATGCTGCACGCGATTGCGCATATCGAATTCACGCCA
TCAATCTGGCTTTGGACGCGGCATACCGTTTTCCGCACGCTGCCGTTTTAGTTTTGTCGCG
30 ACTGGGTGAAAGTGGCGAAGGAAGAGGTGTACCATTTCGCCCTGATGCGCGAAAGGCTGC
GCGCTTTCGGCTTCGATTACGGCGATTTTGAAGCACACAATCATTTATGGGATATGGCAT
ACAAAACCGCCTACGATCCTTTGTTGCGTATGGCTTAGTGCCGCGCGTTTTTGAAGCGC
GCGGGCTGGACGTTACGCCCGGCATACGCGCGAAGGTGGCGCAGCGCGGTGATTCGGAAA
CCTGCGGCGTGTGGACATCATTACCGCGACGAAGTGGGACACGTCGCCATCGGCAACC
35 GGTGGTATCAACACCTTTGCCGGAACGCGGTTTTGGAGCCTGTGCCCTGTTCCGCGAGCC
TGATTGCCCGTTACGATATGTTATCTCCGGGGCTATGTGAACATCGAAGCGCGCGAAA
AAGCAGGCTTCAGCCGCTTTGAATTGGATATGTTGGAAGATTTGAGCAGGGTTTGA AAC
AAAAATAACATGCCGTCTGAAACCTTCGTCCCGCACTTTATAAAAAAGGAACACACATG
ATACAAGCCGTATTGTTGACCTCGATGGCACGCTCGCCGACACCGCCCTAGACCTCGGC
40 GCGCACTCAACACCCTGCTCGCCCGCCACGGACTACCTGCAAAAAGCATGGACGAAATC
CGCACCCAAGCCAGCCACGGCGCGGCGAGGACTGATCAAGCTCGGCGCAGGCATCACCCCC
GACCATCCCGACTATGCCCAGTGGCGCACCGAATACCTTGACGAATACGACAGCCGCTAC
GCCAAGACACCACCTCTTCGACGGCGTAACGAACCTCATCGCCGAACTCGGAAAACGC
GGCATCAAATGGGGCATCATCAACAAACCCATGCGCTTCACCGACAAACTCGTCCCC
45 AAACCTCGGCTTCATCATCCACCCGCGCTGTCGTCAGCGGCGACACCTGCGGCGAGCCC
AAGCCCAGCGTCAAACCCATGCTGTATGCGTGCGGACAAATCCACGCCGACCCGCAACAC
ACACTCTACGTCGGCGACGCGGAACGCGATATACAGGCGGGGCGCAACGCCGCTATGACG
ACCGTCTTCGCCGAATGGGGCTACATCGCTCCCGAAGACGATACCGGCTCATGGCAGGCG
GATTTCCACATCCGCACGCCACTCGATCTGCTCGAATGTCTGGACAAAATACAGCCCTGA
50 AAAATATCCGCCCCACAAACATATAGTGGATTAAACAAAACAGTACGGCGTTGCCTCGC
CTTAGCTCAAAGAGAACGATTCTCTAAGGTGCTGAAGCACCAAGTGAATCGGCTCCGTAC
TATTTGTAAGTGTCTGCGGCTTCGTGCGCTTGCTCTGATTTTTGTTAATCCACTATAAAAC
TGCCGTCTGAAGCCTGATTTTCAGACGGCAGTTCGCCCTTCAAACCGAATCAAAGCCCGTC
AAAACCTGCGTTTTGAGCTTGACGCGCTGAAGGATGTGTACCGCAATTCTCAACCGACT
55 TATCCGTGCTATTTCGAAAACGGAATCCCATGCCGTCTGAACATACTCTGCGCGTCCGCCA
CCTCGCTGCGGCATGTATCGATTTTGGCATAAGTTGAATTCGGGCGGCGCTCTTGGCGGA
TGGCCTGCAAACGTTCCGGCTGGATGGTCAACCCGAACAGCTTATCCCTATAAGGCTTGA

CCATACGCGGCAGATCGGCCGATTCCAAATCGTCGGGAATCAGCGGATAGTTTGCCGCAC
GGATGCCGTATTGCAGGGCGAGGTAAAGGCAGGTTCGGCGTTTGGCCGAACGCGATACAC
CCATCAAGATTACATCCGCTTCTGAAGGTTCTTATCGCTGACCCCGTCGTCGTGGTTCA
AAGAAAAATTGACCGCTTCCATACGCGCATCATAACGCTTCGTATTACCGATACTGTGAT
5 GCCCCTGCCCGGATGCCGTGGCTTCGGTATTGAGTTCCTTCTCCAACAGTCCCAAAAAAG
TCTCAAAGAAATTAATCTGAAAAGCATCCGCCCTTTGATAATCCGACGGATTTTCGTCAT
CAACCACACTGACAAACGCAATCGGACGCTGACCGTTTTCCTGCCGGCTCCGATTGACCT
TCTCCACCACCGCGCGCGCCTTTTCCGGCGTATCGACAAACGGATGCGTATGGCGTTTGA
ACGACAGATTGCCAAACTGGTTCAGCAACGCCTCGCCGATATTCTCAGCAGTCAGACCGG
10 TACGGTCGGAAATGTAAACACATGGCGCGGACTGCTCATCTTCCATCCTTAAACACAG
GTTTAAAAATCCCATCATAACAGCAGCAGCAGACACAAGGAAAGCACCCGCGAGCACACCTA
CCTCGGATTACCCCAAACAGACACAATATAATTTTGAATAAAATTATTTATATAAAGT
ATTTTTTGGCAGAAAATTTTAAAAAATAAACAAAAAATCAAACAGAAAAACATTAACC
TATTCAAACCACCTGTTTTACAAAGAAAATACCCAAAAAAGAAGTATACCGGCTGTAAG
15 TTTCAAACCGCTACACACGCCGAAACCGCAATTTTTCAGACGGCATCATGATTTTAAAC
GGATAAAACACATGACAGCAGAGGAACGAATCGCTTAAATAAGCACGCGGATTTGTTTT
TTTTTTAACATATTTTGGATTGGACACACAAATGGCCGACAACCTACGTAATCTGGTTTGA
AAACCTGCGTATGACAGATGTTGAACGCGTGGGCGGTAAAAACGCCTCGCTGGGCGAAAT
GATCAGTCAGCTGACCGAAAAAGGCGTTTCGCGTCCCGGCGGCTTTGCCACCACGGCCGA
20 AGCCTACCGCGCATTCCTCGCACACAACGGTCTGAGCGAACGCATTTCGCGCGCACTGGC
AAAATTGGATGTGGAAGACGTTGCCGAACGGCACGCGTCGGCAAAGAAATCCGCCAATG
GATTTTGGATACGCCTTTCCCGAACAGCTCGATGCCGAAATCGAAGCGGCATGGAACAA
AATGGTTGCCGATGCCGGCGGTGCGGACATTTCCGTTGCCGTACGTTCTTCCGCAACTGC
CGAAGACCTGCCGGACGCATCATTGCTGGACAACAGGAAACCTTCTTGAACATCAACGG
25 CTTGGATAACGTTAAAGAAGCGATGCACCATGTATTGCTTCCCTGTATAACGACCGTGC
CATTTCTTACCGTGTCCACAAAGGCTTCGAACACGACATCGTCGCCCTTTCCGCCGGCGT
TCAACGCATGGTGCCTTCGACAGCGGCGCATCAGGTGTGATGTTACCCCTCGACACCGA
ATCCGGCTACGATCAAGTCGTCTTTGTTACCTCCTCTTACGGTCTGGGCGAAAACGTCGT
ACAAGGTGCGGTCAACCCGGACGAATTTTATGTGTTCAAACCCACGCTCAAAGCGGGCAA
30 GCCCGCCATCCTGCGTAAAACCATGGGTTCAAAACACATCAAATGATTTTACCGACAA
AGCAGAAGCCGGTAAATCCGTAACCAACGTCGATGTCCCGAGGAAGACCGCAACCGCTT
CTCCATTACCGACGAAGAAATTACTGAGTTGGCGCATTACGCACTGACCATCGAAAAACA
CTACGGCCGCCGATGGATATCGAATGGGGACGCGACGGCTTGGACGGCAAACCTCTACAT
CCTGCAAGCCCGTCCCGAAACCGTAAAATCCCAAGAAGAGGGCAACCGCAACCTGCGCCG
35 CTTCCGCCATCAACGGCGACAAAACCGTATTATGCGAAGGCCGCGCCATCGGTGAGAAAGT
CGGTCAAGGCAAGGTGCGCCTGATTAAAGATGCTTCCGAGATGGATTCCGTGCAAGCCGG
CGACGTACTCGTTACCGACATGACCGATCCGGATTGGGAACCCGTGATGAAACGTGCTTC
TGCCATCGTTACCAACCGCGGCGGCCGTACCTGCCACGCGCCCATCATCGCGCGTGAATT
GGGCATTCTCGCTTGTGCGGCTGCGGCAATGCAACCGAATTGCTGAAAAACGGTCAAGA
40 AGTTACCGTATCCTGTGCCGAAGGCGATACCGGCTTTATCTATGCCGGTCTGTTGGACGT
ACAGATTACCGATGTCGCCCTTAGACAATATGCCTAAAGCACCTGTAAAAGTCATGATGAA
CGTCGGCAATCCCGAACTCGCATTAGCTTCGCCAACCTGCCAGCGAAGGCATCGGCTT
GGCGCGTATGGAATTTATCATCAACCGCCAAATCGGTATCCACCCCAAAGCCTTGTTGGA
ATTTGACAAACAAGACGACGAATTAAGCGGAAATTACCCGCCGTATCGCCGGTTACGC
45 GTCCCTGTGCACTTCTACGTCGATAAAATCGCCGAAGGCGTGGCGACATTGGCCGCATC
GGTTTATCCGCGTAAAACCATCGTCCGTATGTCCGACTTCAAATCCAACGAATACGCCAA
CCTGGTCCGGCGCAACGTATACGAACCGCATGAAGAAAACCCGATGTTGGGCTTCCGTGG
TGCGGCGCGTTATGTGCGCGACAACCTCAAAGACTGTTTCGCCTTGGAATGCAAAGCCTT
GAAACGCGTCCGCGATGAAATGGGGTTGACCAACGTTGAAATCATGATTCCGTTCCGTCCG
50 CACTTTGGGCGAAGCCGAAGCCGTTGTCAAAGCCCTGAAAGAAAACGGCTTGGAACGCGG
CAAAAACGGCTGCGCCTGATTATGATGTGCGAGCTGCCGAGCAACGCGGTATTGGCGGA
ACAATTCTGCAATACTTCGACGGCTTCTCCATCGGCTCGAACGACATGACCCAACTGAC
CCTCGGTCTCGACCGGACAGCGGCTTGGTATCCGAATCGTTTGACGAACGCAACCCCTGC
CGTCAAAGTGATGCTGCACCTTGCCATCTCCGCCTGCCGCAAGCAGAACAAATATGTCGG
55 CATCTGCGGTCAAGGCCGTCCGACCATCCGGACTTCGCCAAATGGCTGGTTGAGGAAGG
CATTGAAAGCGTTTCCCTGAACCCGGATACCGTCATCGAACTTGGCTATATTTGGCGAA
TGAATTGAACAAATAATCAATGCCCATACCCCGAGCCTGAAAAGCGCGGGGTATTTTT

TTCCAAGCAGCTCCGCTCAGACGGCATTTCCTGCCGATGCCCCGTCGCGATAATATTTG
ACACCCACGCGCGGACTGCCTACAATTCCCCCTTCCCCGAGCAACGGGCAACGGTCAGCT
TCTTCTTTTTCAGACGGCATCTGCCTGTCTTTTCTCTTCAAAATACATCATTATTATGCA
CGTCTCCGAATTACAAACCTGCACATTTCCAAACTCTTAGAATTGGCGGAAGAACACGG
5 CATCGAAAACGCCAACCGATTCCGCAAAACAAGACCTCGTATTTGCCATCGTCCGCCAGAT
GATGAAAAAAGGCGAGGGTTTCACCTGCTCCGGCAGCGTTGAAATCCTGCCGACGGCTT
CGGCTTCTCTCCGACGCGGACACGTCTTATCTTGCCGGCCCCGACGACATCTATGTCTC
GCCCCACCAATCCGCCGCTTCAACCTGCATACGGGCGACACCATCGAAGGAAGCGTGCG
CGTCCCCAAAAGACAACGAACGCTATTTTGCCCTGGTCAGGCTTGATACCATCAACGGCGA
10 CCACCCGGAAGTATGCCGCCATAAAATCCTGTTTGAACCTGACCCGCTGTTTCCGAC
CGAACAGTTGAAGCTGGAACGCGACTTAAAGTCCGAAGAAAACCTGACCGGACGTGCCAT
CGACCTGATTTCCCTATCGGCAAGGTACGCGCGCCCTCTTGGTTGCCCGCCCCAAAAG
CGGTAAACCGTGATGCTGCAAAACATTGCCACGCGCTTACCGCAAATATCCCGAAGT
CGAACTCATCGTCTCTGATTGACGAACGTCCCGAAGAAGTAACCGAAATGAGCCGCTC
15 CGTCCGTGGCGAAGTAGTCTCCTCCACCTTTGACGAGCCGGCTCAACGCCACGTCCAAGT
TGCCGAAATGGTGCTTGAAAAAGCCAAGCGTATGGTGGAACACAAAAAGACGTGGTCAT
CCTGCTGGATTGATTACCCGCTTGCCCGCGCTACAATACCGTCGTGCTACCTCGGG
CAAAATCCTGACCGCGGTGTCGATGCCAACGCGCTGCATCGTCCCAAACGTTTCTTCGG
CGCGGCGCGCAAGTGAAGAAGCGGTTTCGCTGACCATCATGCCACCGCATTTGGTTGA
20 AACCGGACGCGTATGGACGATGTGATTTACGAAGAATTCAAAGGCACCGGCAATATGGA
ATTGCACCTTGACCGCGTATGGCGGAAAAACGCTCTTCCCCGCCATCAACATCAACAA
ATCCGGCACGCGCGCGAAGAGCTGCTTGTCCAAACGACAGTTACAACGTATGTGGCT
CTTACGCAAGTTCTGCACCCGATGGACGAAATCGAGGCAGCCGAATTTTAAATCGGGAA
AATCAAAGCCTCTAAAAACAACGACGATTCTTTGAACTGATGCGCGGCAATAAACGCG
25 CCGCCCCGATTAAATGCGAAATGCCGTCTGAAGCCTGAAATCGGGTTTCAGACGGCACTT
TCATTACACGGTCGGCGCAGCTCCTCCCTCCCCCGTTAACGGCGCAACCGTCGGCAGT
GTCCGTGTCCGCTTGCCGAAAGCGCGGCTTTGCAAAGCCGGCTTGAAACGCATCCGTACC
GGCAATGAAAACCGATGCGGGAACCTTGATTCAAGGTTGCGCCGAACCGCACTCAITTTTG
TATAAATTTGGGGTGTCTAGATAACTAGGGAAATTCAAATTAAGTTAGAGTTGCCCCCT
30 ATGAGAAAAATTCGTCTAAGCCGGTATAAACAAAATAAACTCATTGAACTGTTTGTGCA
GGTGTAACTGCAAGAACAGCAGCAGAGTTAGTAGGCGTTAATAAAAGTACCTCAGCCTAT
TATTTTCATCGTTTACGATTACTTATTTATCAAACAGTCCGCATTTGGAATGTTTGAC
GGCGAAGTAGAAGCAGATGAAAGTTATTTTGTGTAACGACAAAACCATATCAATGGAATT
GGGAACTTTGGAAACCGGGCAAAACGTCATTTACGCAAGTTTGACGGCATTTCCCAAAGCG
35 CATTTTGAGCTGTATTTAAAGGGGTACGAACGACGTTTAAACAACAGCGAGATAAAAGTT
CAAATTTCCATTTTAAACAATTAGTAAATCGAGTTTATCCTAGTTATCTAGGACAGCC
CCATAAATTTTTATAGTGGATTAAACAAAACAGTACGGCGTTGCTCGCCTTAGCTCAA
AGAGAACGATTCTCTAAGGTGCTGAAGCACCAAGTGAATCGGTTCCGTACTATTTGTACT
GTCTGCGGCTTCGTGCGCTTGCTGATTTTGTTAATCCACTATATTTCCAATTAATAA
40 TTTTTAATATATTAATCAATAAATTAATTTATAAAATAAAAAATTTGTCAACAATATTT
TGCCTTATCGCCCAAACCTCTGTATATTTTCTACAGTAAATTGTTGACAATCCATACGC
CCACATATGCGCCGCTAAGGATAAATCCTCCCGCCGGACAACGGGTGCAAGGGATCGGA
TGCGATATTTCCATATTCAAACAAGGGATTGGCGGCACATCGGCAAAATCCCCGCGCCGC
CCCCGTCCGGCAGGGCTTGCGTCCCTCCCGGACAAGCCCCGACCCGCGCTTTCCGAAAGA
45 CGGGCTCAACCATTAAGGAAAACCTTAGTCAAAATGAAAAACACATATGGGCGGCATCTT
TGCTGCCGGCATCCCTATCGGCAGAACCTTTAAACTGGTGGAAGCCTTATTCGCCGTCA
ATTCCGGCGATACCGCTGGGTGATGACTGCGGCTGCCTTGGTACTGTTGATGACGCTTC
CCGGGCTGGCTTTATTCTACGGCGGTATGGTGCGGAAAAAAACCTGCTCTCGACGATGA
TGCACAGCTTTTCCATCGCGACATTGGTGGGCATCCTTTGGGTGCGCGTCGGCTATTCTT
50 TAGCGTTACGCGCGGGAATGCCTTTATCGGCGGTTTGGGGCGCGTATTTTTAAGCGGGA
TGCAGATAGACGCTACCGCACAGATGCTGACCGTGTGCGCCATGCGCCGACTGTTCCCG
AACCGGTATTTATGTTTTTTCAGATGACGTTTGCCATTATTTTCGACCGCCATTATTACCG
GCGCGTTTCCGAACGGATGAAATATCGGCAATGATGCTGTTTTCGGGCATATGGTTTT
TATTGGTTTTATGTCGGGCGCGCATTTGGGTGTGGGGCGCGGCTTTATGAGCAAGGGCG
55 GCGTATTGGATTATGCCGGCGGTACGGTGGTGACATCAATGCCGGTATCGCGGGACTCG
TCGCGCGCTTGGTTTTGGGCGAGGCGCATAGGCTACGGGCGCGAGGCGATGCCTCCGCACA
ATATGGCGATGACACTGATCGGCGCGCAATGTTGTGGTTCCGCTGGTTCCGCTTTAACG

CCGGATCGGCGCTTGGCGGACACGCGGCGGGGTATGGCGATGGCGGTAACGCAGGTGT
CGGCGGTATTTCGGCGCGGAGGCTGGCTTGCCTGCCGAAAAATAGCGGGACACAAACCTT
CCGCTTTGGGGCTGGCTTCCGGCGCGGTTTCCGGTCTGGTCCGCATCACCCCTGCCGCCG
GCTTTACCGGCCCGTCGGGCGCGGCCCATCGGTATATTGACTGCCGCCGCGTGTCTTG
5 TGTCCGTACCCGTCTGTCAAACACAAATTGCGTTACGATGATTCTTTGGACGCTTTCGGCA
TACACGGATTTCGGCGGGCTGGTGGGCGGAATATTGACCGGCATCTTTTTCGACAACCGCA
TTTTTCGGCGGGGATGCGGCAGTTTGGCAGCAGTTGTGGATACAGGTAAAAGACGGGGTCTG
TTATGGCGGCATACAGCGGGCTAATGAGTTGGGCGATTTTGAAGGTCGTGGGGAAAAATCT
GCGGCGGCTTGGCGTTCGGCAAGGATGTCGAACGCGAAGGTTTGGATCTGAATATCCACG
10 GCGAACGCGTGGAAATAAGGGCGGCTATGCCGTCTGAAGCCTGAAAATCGGGTTTCAGACG
GCATTTTTTCACGTTTGGCGCCGATGGATAAACATATAGTGGATTAACAAAAATCAGGACA
AGGCGACGAAGCCGACAGCAGTACAGATAGTACGGAACCGATTCACTTGGTGCTTCAGCA
CCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCCGTACTGGTTTTTGTTAAT
CCACTATACTGCCTGCGACGCTTAACGGCTGTCTTCCACTGATAATATTTCGAGCCGAG
15 GAAAGAACCGAGTTTGGCGAAAAACGGTTGCAGGATAATATTCCGGCTGGCGCAACCGCTC
AAACGGCTTCAGACGGCATTCGTCCCTTAAATTTGCTTCGGCAACCGCCAGACCTGCAAT
GCCTGTTATCGCCATCCCGTGTCCGGAATAACCTTGGCGATAAAAAACATTTCGGGGCTAA
ACGTCCGGAATGCGGGACAAGGTTGGCGGTAATGTGCGACTCCCCGCCACGAATATTC
GATTTTGACATTGCGCAAGCTGCGGAAAACTTTAAGCATATCTTGGCGGACAAGCTCGGT
20 CATACGCTCAGGATTGTCGATAAACTCGTTATCCTTACCGCCGAAAAGCAGTCTGCCGTC
CGCGCTGAGGCGGTAATAATCCAATATGGCGGTTGTGCGATACTGCCATATTGTTACG
GATAAGCCCTTTTGGCGCGCCCCCAAGGGTTCGGTCGCAATAATAAAGGTGCTGACAGC
AATCGCCTTGGCTTCCAAGGCCGGAATATCGGGTTCAAACCTGCATAAGTATTGACAGC
ATAGACCACATTTTTGCACTCGACGCTGCCCTTCGGGCGTGTAAACCAGCCAACCGTTTTG
25 ATGCGGTTTCGATGACGTCATCGGGATTGCTCGAAAATCTGCGCACCGGCTTCGGCAGC
GGCAGCAGCGATGCCCAAAGTGTAAGTGAGCGGATGCAGGTGTCCGATAAGGGGTGCA
TTGTGCCCTTGGTACATATCGCTGTCAAGCTGCTGTTTCAACTCGGCTTTATCCCAAAG
TTGATAATGACTCGCACCGTAATGCCGTTGGGCGTGTTCATGCCACTGCTGCAACTCTTC
CCAATGCTGCGGACGGACGGCAACCGTGGCATAACCGCGCTGCCAATCACAATCGACGGC
30 ATGTTTGGCGACGCTTCGTCCACAGTTCGACCGCCTGCAAAGACTGTTGCCAAAACCA
TTGGCGCTGCTCCAAGCCGACCTGTTTTCAATTTCCCCCATACCGCAGGCGTAATCGCT
GATAACCTGCCCGCCACTCCGTCCCGACGCGCGAAACCGATACGCGCGGCTTCCAACAC
AACCGTTTTCATGTCCCTGCTCCGCCAAGGGCAATGCAGTGCACAAACCAACCAATCCGCC
GCCGATGATACAGGTATCGGTTTTTCAGACGGCATTGAAGTTTCGGATAAACAGTATGAGG
35 ATTAACCGAACTGAAATAATAAGAGGCGAGATATTCTTGAAAATCAGGCGGAATCATTTGT
GTTTGCTTTTATCAGGTGTATTTTTCGACGGAATGATACAGGCTGTGGGGCCATATCGTCC
AAACAGAAAATCGGTTGAAGAAAACAGGCTGACCCAGTCATGCGGTGAGCCTGCCTTATT
AATTAATTTGCTTTCTCGGCAGCCAATTTTCTCGCGGTAGGCTTCTGCCGCTTCTCGG
TCACGCTTGGTTGCCTGCCTCATCATCAATAATTGACGATGATACCAATGTTCCGATG
40 ATGCCGATTAGGATGGTCGCCAAGACATTCATCTGAGGATCGAGACCAACTTGATTTTG
GAGAAAATCACCTGCGGCAATGTGGATGAACCGGGGCCGGAGAGGAATGAGGTAATCACC
AAATCATCCAAAGACAGGGTAATGCCGAGCAGAAAGCCTGAAGCGATGGCAGGGGCAATC
AAAGGCAAAGTGATGACAAAAAGATTTTCAGCGGGCGCGGCCCAAATCCATTGCGGCT
TCTTCGAGCGACTGGTCAAGCTCAACCAGACGCGAACGGATAACAACGGTAATGTACGCC
45 ATACACAGCGTCGTATGTCCGAGGAAGATGGTGAAAAGCCACGATCGAAGTAGAGATGT
TGTAACCATTCGCTGCCCTGCAAAAATATCTGTACCTGAATAATCAGCAGCAGCATAGAC
AGACCGGTAATCACGTGCGGCATCACCATAGGTGCGGAAATCATGCCAGCGAACAAAGGTA
CTGCCGCGAAAACGTTTAAATCCGCGCCATCGCATAGCCTGCCAGCGTGCCCAAAACGACG
GCGGCAAGCGAAGACACAACGGCAATCCGACGCGACAGCCAAGCGGCTTCCAAGATGGTG
50 TCGTTTTCCAGCAATGCGCCGTACCACTTGGTCGAAAAGCCGCCCCAAACGGTTACCAGC
TTGGATTCTTTAAACGAATAGATGACCAAAACAACCAGCGGGATATACAGAAACGCCAGC
GACAGTGCCAACATCAGTTTCAAGAACCAAGATAATTTGGATTCTGCATTATTTGGCTC
CTTCTTCCAATTTCGCGGTTTTTCATAATGCTGAAACAGGGCAATCGGCACGACGACGCG
CGACCATCACGACGGCGACGGCGGAAGCCAGCGGCCAGTTGTTTTGATCGAAGAACGCCT
55 GCCACAAGACTTTACCAATCATCAGGTTTTCCGAACCGCCGACCGCTCGGGAATGACGA
ACTCGCCGACAGCAGGGACGAAAACAGCATGGAGCCTGCAATAATGCCGGTTTTTCGACA
AAGGCAGGGTAATCGTCAAGAACGATTTGACCGGCCCGCGCCCAAATCGGAAGCCGCTT

CAAGCAGGCGGTTGTCGAGTTTCACCAGTTGCGTGTATAGCGGCAGAATCATAAACGGCA
GATAGGCGTAAACCATCACCAAATTGAGCGAAAAGGCATTGTAGAACAAATCCAAAGGCT
CGCTGATAATACCCATTTTAAATCAACAGGTTGTTTACAATGCCGTTATGCCCGAGCAGAC
CCATCCACGCATAGACGCGCAACAGGAACGATGTCCAAAAGGGCAGCATAATGGCAAGCA
5 GCAAACCATTTGCGGACAGAAGGATTGGCACGAGAAATCGCATAGGCGGTCGGATAACCGA
CCAACAGACAAATTACCGTCGTAGTCAGCGCAGTCTTAATTGAAGACCAATAAGTCATCA
GATAGATATTGCTGTTTTTCACCGTCGCCGAACGGATTGAGCGTACTCCAAAAATTTTGGA
AGATGTCTGCATAATTTTGGTAGCTGACAGCAATATTCAGACGACCCAAATCCTCATCTA
10 TCGTCGTTAAAGGAGTAAACGGCGGGATGGCGATTCTTGTTCGGCAAAGCTGATTTTCA
GCACGATGGCGAACGGAATCAGAAACAGCACCAAAGCCAAATATACGGTACGGCAATCA
CCGCACGCTGCCCGGACGGCGGAACAGTTTGTTCAGTTTATTAAGGTTTCATTGCAT
TCCCCTTAAATCAACGGAACAACGGAGTCGGTTGGTTTTCCGGCCAGCTGATATAGACGG
TTTCGTCCCAAGTCGGCGGTGTAATGTTGCGCACATAACCAGTAAGGGGCGGGGACTTGGC
TTTTGACGACGCGCCCGTTGCCGAGCTTGATATGTTAAATGGCGAAGCTGCCCAAATAGG
15 CGATTTCTTTTACCGTGCCCTTTCGCCCAGTTGTAGTCGCCCAAATATTCGGGTTTTTCTT
TATATAAATCAATATCCTCTGGTCTGAATACTAACCCAAAGGTCCTGCTCGCTCGGACCAC
CCAAACCGTGATCGATGCGGACGTGGTTTTCCAAACCTTCGCATTCGATAACGGCATAGT
CGGCATGATCTTCAATCACACACCGTCAAAGATGTTGGTTTCGCCGATAAACTCGGCAG
TGAAGCGGCTGTTGGGATAGTCGTACACGTCGCTGGGTGTGCCGACTTGTGCAACTGAC
20 CGTCAGACATAATGGCGATGCGGGTCGCCATCGTCATCGCCTCTTCTTGGTCGTGCGTAA
CCATAATACAGGTTACGCCGACTTGTTCAGCGTATTGACCAACTCAAGCTGGGTTTGT
GGCGCAGTTTTTTGTCCAATGCACCGAGGGGCTCATCCAGCAGTAGAATTTTCGGACGTT
TTGCCAGACTGCGTGCCAAAGCAATGCGCTGTGCTGACCGCCGGACAATTGGTGCGGTT
TGCGTTTTAGCAAATTTGGTCATCTGAACCAGGCGGAGCATTCTTCGACGCGCGCGGCGA
25 TTTTCGCTTTAGGCATTTTGTCTGTTTCAGACCGAAGGCAATGTTTTGTTCTACGGTCA
TATGCCGAAAAAGCGCGTAACTTTGGAACATCATATTGATGGGGCGATCATAGGGTGCAA
GTTTGGTAATATCCTGACCATCAAGGATAATTTTCCCTGATTGGGACTTTCATACCCG
CCAGCATACGCAGCAGTGTAGATTTTCCGCTGCCGGAAGTCCCAAAGGGCGAAGATTT
CGTGTTGATAAATGTCCAAGTCGATGTTATCGACAGCGTAATTGTCACCAAACCTTTTTCA
30 CCAAACCTTGGATTTTGAGATAAGGTTTGGCTGAAGACGCAGTGGTTGCGGTCATAATGG
CAATACTCCAATAAAAAGACGAGTACCGGCAAAACGGATTTTCGAATGGGTGATAAAAAG
CTGTTTGATTGCTGGCGGGAGTTAAACGTTTGATGCCGTCTGAAACTCTTGTAAGCGCA
CGGGCAGCATGAAATGGAACAAGATTCCAAAGAACTTTATATTATATTAGTTTATGCGGT
TTTCGGGCAATATAGTGGATTAAATTTAAACAGTACAGCGTTGCGTTGCCTTGCCGTAC
35 TATTTGTACTGTCTGCGGCTTCGTGCGCTTGTCTGATTAAATTTAATCCACTATAAAT
ATGGATTTGAGCTTGTGCGAAAGCAACAGAAAAGAAAACACCGCCCATTTTTCTGGGCGG
TGTCGGAAGCGTAATTATTTACGCAGACCCAAGCGGGTAATCAACGCGCGATACGTATC
GGGCTGGGTACGGCGCAAGTAGGCCAGCAGGCGGCGGCTTGGCTGACCATTTTCAACAG
GCCGCGACGGCTGTGGTGGTCTTTGGGGTTGGCTTTGAAGTGGGGGTCAGGTCGTTGAT
40 GCGGAAAGTCAACAGAGCGACTTGTACTTCGGAAGAGCCGGTGTGCGCTTCTTTGCGTTG
GAAATCTTTAACGATTTGTGCTTTTTGTTCTACGGTCAGTGCCATAATGAAAACCTCCAAA
AATATAAGAATCCCATAGGGATTACAGACAAGTTTGCCAAGCCTGAAGACAACGGCAAAC
TCCCTATGCCCAAGATAGGACAACGTGGCATTATGACACAATTCCCGCATTTCTGCACAA
TATTTTAAAGACCGTGGAAGTAACCGTTAAAAATGCCGTCTGAAGCATTGTCTGCTTGAGA
45 CGGCAATGTTTCAGACGGCATATGCGCTTCAAACACGATTTCTTCTTTCTTCTTCGGTTC
TTTACCGATATTGTGCGGGCTCAAACCGAACATTAGCAGAAGCGGGCTGGCAACCAATAC
GGAAGAATAAATGCCGAACACGATGCCAATGGTCAACGCCATAGAAAAGCCGTGCAAGGC
CGCACCGCCGAACACCAGCATGGATACGACCATCGCCTCGGTGCAACCGTGGGTAAATGAT
GGTGCGGTCATCGTTGCGGTAATCGCGTTGTGATGACTTCGGGCACGGCATGTCCGCG
50 CATCGCCGGCTTGCGGAAGTTTTACGGATACGGTCAAGACGACGACGGATTTCGTTAC
AGAATAGCCCAATACGGCAAGGATACCCGCCAAGACGGTCAGCGAAAATTTCCATTGGAA
GAAGGCAAGCAGCCGAGAATAATCAGATGTGTCGATATTGGCGATAATGGCAGATAC
GGCAAAACGCCATTCAAACGCATCGACAGGTAAATAATGATGCCGATAACGACAAAAACC
TAAAGCCATCAATCCATTACTTACCAATTCCTCACCAGCTTGGGGCCGATAAATTCGAC
55 TTGGCGCAAGGTAACGTGCGGACTGTCTTTTTTTCAGCAAATCCATAACCTGATTGGACAA
CTGTGCGGAAGTAACACCTTCTTTGTTCGGCAGGCGGATCATGATGTGTTTGTTCGTACC
CAATGCCTGAACCTGTACATCACCTATTTTCAGCGTATCGAGGCGTTTCGCGCATCTTATT

GACATCCGCACCCTGCTGATATTGGACTTCCATTACCGTACCGCCGGTAAATTTCGACAGA
GAAATTTCAGACCTCTGGTAACCAAAAAGAACCGGCAGCGATAAACGTAACCAACGAAAT
GAAGGTCGTACGTTTGGCGTAGCTCATAAACGGAATATCGCGTTTGATTTTAAAGAGTTC
CATAGCTTACTCCTTGCCCTCTGCCATTTTCGGCTTTTCGGCTTCCACACCGAACCAATGGA
5 AATATTCTGCAATTTGCGTCTGCGTCCGTACCACAGATTGACCAACGCACGGAATACGAC
GACGGATGAATACATCGAAGTCAGAATACCCAAACAGTGTACGACCGCAAAACCGCGTAC
CGGGCCGGAACCGAATACCAAAAGCGCGATACCGGCAATCAGCGAAGTCAGGTTTGAATC
GACAATGGTCGCCCATGCGTGTGGAACCGAGATTGATTGCCTGCTGCGGCGGCACGCC
GGCAGCAATTCTTCGCGGATACGTTTCGTTAATCAAGACGTTGGAGTCGATTGCCATACC
10 CAAAGTCAACGCCAGCGCGGCCATACCCGGTAACGTCAACGTTGCCATGGCAGACAA
AATACCGATTAGGAACAGTATGTTGGCACTCAATGCAATGGTAGAAAAGAAACCCATCAG
ACGATAGTAAACCACCATGAATGCAGCAACGATGGCAAAACCCCATAAAGTCGAATGGAA
GCCTTTTTTCGATGTTCTCCTTACCCAAAGACGGACCGATGGTACGTTCTTCGACAATCTG
CATCGGTGCGGCAAGAGAACCAGGCACGCAACAGCAAGACGTATCATTTGGCTTCGGCTGT
15 CGTCATGCTTCCGGAAATTTCCACGCGTCCGCCGGTAATGGCAGTACGGATAACCGGCGC
GGTTACAACCTCGGATTTTCTTGGTCGATCAAAACCATCGCCATGCGTTTTCGGACATT
TGCGGCAGTCAGTTTCGCCGAAAATGCTGCCGCCGCGCTGTCCAAGCTCAGACTGACGGC
AGGTGCGCCCATTTGGTCGAAACTCGGTTGCGCATCGTTGATGTTGTCGCCCGTCAGCTC
GACCTGTTTGTGATCAGCAATTTTCGGGACGATCTCCGCCGCTTGAAAGCAGCTCATA
20 ACCGCTCGGCACGTTGCCTTCCAATGCCTCGCGCAACTGGCAGGATCGTCCTCCACCAT
ACGCAATTCCAAAGTCGCGGTACGGCCGATGATGTCTTTTGCCTTGGCAGTATCCTGAAC
GCCCCGAAGCTGCACGACGATACGGTCTGCACCGGACTGCTGGATGACGGGCTCGGCCAC
GCCCAACTCGTTCACACGGTTGTGCAGGTTAGTGATGTTCTGTTTGACCGCATCGGAACA
CACTTTATTGACCGCCTCTTCCGAAAGCGTCAAGACGATATTGCTGCCGTCTGAATTCAG
25 CGTTGCTTCAGAACAGCTTGCAGCAACTGCGGCAGAGCCTTTTGCACATCACCTGCATCC
TGCAAAGGGACGCTCAGGCTGTTTCCAGCCTGACGCACCGTGCCGCTGcGGATTTTTTCG
CGGCGCAGTTTCGCGGCGGATGTGCCCCGAATAACGTTCAAACGTTTTCGTCATCGTTGCT
TTCATATCGACCTGCATGGTGAAATGCACGCCGCCGCGCAGGTCCAAACCCAAAAACATC
GGATTGGCTTTGATTTTCGCCATCCATTGCGGGCTGTCCGCCAACAGGTTGAGCGCGGTA
30 ATATACCCTTCGCCCAAAGTGTTTTTCGATGACGTGCGCGCTTAAAGCTGCGTTTCTGTG
TCTTTGAAACGCACTTTTCAGTGAATTGTCCACAACAAACATCCCGTCGGTCTGAATACCT
GCGTTTTTCAGCGCGGCATCCACTTTGAATTGAGTCTGTTTCGTTGATGATGATGGCTTGT
CGGTTGGTCGATACCTGCACGGCGGGTGTTTCGCCGAATAGGTTGGGCAGCGAATACACT
CGGCAACCCGAATCGTGAACACAATCAGCAGATATTTCCATAAAGGATAACGGTTCATC
35 ATTTGCTCCTTAATGTTTGAACCCACCTTTTCGGTGGTGTGGAATCGGGCTATTTTCAG
AAGAGGCAAAAACCTTCCAGCCAGGCAAGACCGGAAAGCGGCATCCTGAATATGCCGC
CCTGCGTGTGGAACATGGTCAAGCCTTCGGTTGGAATTCAAAACAAAGTGCCGATTTCG
GGCTTTCCAGATGCGGCTTGTGCGCACAAATCAATCGACTTTTGGCGCAATCGCATTTGCG
TTCCACTTCGACCTCGATTTTTGTACCTGTCCGATATCCACGGTAAAAAACTGTTTCGCC
40 GACTCTGGTTACCTTACCTTTGAAACCTGCCGCCAAGACCACTTTGTGCGCGACTTTCAA
GGCGGCAAGCATTGCTGATGCGCTTTGAATTTCTTTTGCTGCGGACGCATGATCAGGAA
GTAGAACACCACCATAACTAAAGGAGCAAATTTGTCAACAGCTTGATTCTAAT
TTATCCGTTCTTTCTAATATGGTTGAAAATCGAGAGGGGTATATAATAACATAAGACCGT
AAACAATATATCGGGTTTGCCGTCCGTACCGACCGTATACCGCAGCCTGCCCGTCCACAA
45 ACCCATGTCTTTGACCCGCCTAATCTTGAAATTCTATGCACTGTTGCGCCTTTTTTTGGG
CAAAAACGCCCGCACCGCATGGATTTGCATCCCGCCTGTGCCGGGCACGAACCCGGCGC
AAACCATCCCGATTGCGCCGACCGCATCCTCTGCATCGAGCAGGCATTGCGCCGCGCCGG
TATTTGGCAGCACCTCCAAACCATAGAGGCGGAAGAAATCAGCGATACGCGCCTCGCACT
TGTCCTACTCGAGCAAATATCTGAACCGTTTGGAATCTTGCTGCCCCAAAAGGCAAGAT
50 TTCCCGCTGGATAACGACACTGCAATCAGCACAGGATCGCTGTCTGCCGCACGCTTTCG
CGCGGTTTCGGCAGTTTCAGGCAGTCGACATGGTCATGAACCGTAAAGCATGGCATGCCTT
TTGCGCCGCCCGCCCGGACACCATGCGGGCAGCGGCAAGCCGGCGATTCTGCCT
GCTGAACAACGTTGCCGCCGGCGTCATGCGCATGCCATTGCCGAATACCGCCTGAAACGCAT
TGCCGTCATCGATTTTCGATGTCCACTACGGCGACGGTACGGCAGAAATATTCAAAGACGA
55 TCCGCGCATCCTGTTTTTCAACCTGTTTGAAACCGACCTTTTCCCCTTCCCCGAAAACAA
CGATATGCCCCGACGGCGGCAATATGGTGCACCTGCCCTTGCCGCCAGGAACGGGCAGCCG
CACATTCCGCGAAGCCGTCCGACGGCAGTGGCTACCCCGACTTGCCGCATTCAAACCCGA

ACTGGTGTCTGTGTCGGCAGGATTCGACGCACACCGTCTAGACGAATCGGGCAGGCTCAA
CCTGCACGAGGCGGATTTTGCCTGGCTGACACACAAAAATCATTACAGACGGCATCGGGCTG
CCCCGGCAAAATCATATCCGTACTCGAAGGCGGCTACACCCTTGAACCTCTGGCACAATC
TGCTGCCGAGCATATCCGCGTGTGGCAGGGCTGGGCAAAATCCGATGCCGCAACCGCCTA
5 TCAGAAAAACTGGACCCAACAAAAAACGGTTTGCCAAACCGAAAACCGACAGGTGCG
CCAACCTACCCAATCCGACCGTTACGACATATAGTGGATTAACAAAAATCAGGACAAGGC
GACGAAGCCCGACAGACAGTACAGATAGTACGGAACCGATCACTTGGTGTCTGAGCACCTT
AGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACACCGTACTGGTTTTTGTTAATCCAC
TATAAATGCCGTCTGAAGCCGATTGGTTTTTAGACGACATCATTATTTGACCTGACGCA
10 AACAGAAAGCCTTCCGCGTGTAAACACATCTCTTGAGACCTTTGCAAAAATAGTCTGT
TAACGAAATTTGACGCATAAAAAATGCGCCAAAAAATTTCAATTGCCTAAAACCTTCCTA
ATATTGAGCAAAAAGTAGGAAAAATCAGAAAAGTTTTGCATTTTGAAAATGAGATTGAGC
ATAAAATTTTAGTAACCTATGTTATTGCAAAGGTCTCCTCTTGTAGTAAAATATCTAAAC
AGATTCAACTGGAACGGTCAAGCTTCTTCACGCCATTCCCATTTCAACCGCCGCTGCC
15 AGATTACAGACGGTATTCCTACTTGAAAACAAGGAGCGTTACAATGAAAGCAGCAGTTTT
TACGACAAAGGCGACATCCGCATCGAAGACATCCCCGAACCGACCGTCGCCCCGGCACT
GTCGGCATCAATGTGCGCTGGTGCGGCATCTGCGGTACTGACCTGCACGAATTCATGGAA
GGCCCGATTTTCATTCGCGCTTGGCGTCAATCCGCACCCGATTTCCGGCGAGTCCGCACCC
GTAACGATGGGACACAGTTCTCCGGCGTGGTCTATGCCGTGCGCGAAGGCGTGGACGAC
20 ATCAAAGTCGCGCACACGTCGTTGGTGAACCCCTACATCATCCGCGATGACGTACCGACC
GGAGAAGGCAGCAACTACCACCTCTCCAAAGATATGAACCTTATCGGCTTGGGCGGCTGC
GGCGGGGCTGTGTCGAAAAAATCGCCGTCAAACGCCGTTGGGTGCATCCGATTTCCGAC
AAAATCCCGTTGGATCAAGCCGCTTTGATCGAACCGCTGTCTGTGCGACACCACGCTAT
GTACGCAGCGGCGCGAAAGAGGCGACGTGCGATTGGTTCGGCGGTGCAGGTCCGATCGGT
25 TTGCTGTTGGCTGCCGTGTTGAAAGCCAAAGGCATCAAAGTCATCATCACCAGTTGAGT
AAAGCACGCAAAGACAAAGCGCGCAATCCGGCGTTGCCGACTACATCCTCGACCCGCTCC
GAAGTCGATGTTGTTGCAGAAGTGAAAAAACTGACCAACGGCGAAGGCGTGGACGTGGCA
TTTGAGTGCACCGCGTCAACAAAGTGTGGATACTTTGGTTCGAAGCCTGCAAACTGCC
GCCAATTTGGTTATCGTATCCATCTGGAGCCACCCCGCCACCATCAACGTCCACAGCGTC
30 GTGATGAAAGAGTTGGACGTGCGCGGCACGATTGCCTACTGCAACGACCACGCCGAAACC
ATCAAACCTGGTGAAGAGGCAAAATCAACCTTGAGCCTTTCATCACCAGCGCATCAAG
CTGGACGAGCTGGTTTTCCAAAGGCTTCGAGCGTCTGATTACACAACGAATCCGCCGTT
AAAATTATTGTGAGTCCAAACCTGTAAGCAAATTACATTTGCAACAGCACAAATGCCGTC
TGAAACGCTCAGACGGCATTTTCCAACGAAGCGCAACAGGCGTATTGCCCGAGAGCAGCC
35 GTTTAGCCTATCATTCGAACAAACAGAAACAAACAGAAAGGAAATCATGGGAGATTCCG
TACTATCCGCCATCCAAACCAACCATCACCCAGCGAAATCTGCCAATCCGTCGGAATCTT
ACGTGCGACAGCTCTTGATTAAGGGCGAAGACAAAATCCTAAAAAAAGTGATTGAAGAGG
CGGGCGAAGTGTGATGGCATCCAAAGACAAAACCCGTCCCACCTGGTTTACGAAGTTG
CCGACTTATGGTTTCACACCATGATTCTTCTGACACACCACGACCTGAAGGCGGAAGACG
40 TATTGGACGAACCTGCGCGCCGTCAGGGGCTGTGCGGGCTGGTCGAAAAAGCCGCTCGCA
CAGAATCTTGAATTTATATTAAATCCGCACTTTCCACATTCAATCCGTCTGACCGCTT
TTCAGACGGCATCGGAGCCGTTATGGACAACTGTATTTCTGCAAAATCGCCGCCAAAGA
CATTCCGGCGCAACCGTCTATGAAGACGGCGAAATGGTTTGTTCAAAGACATCAACCC
CGCTGCTCCGTTTCATCTGCTGCTGATTCCCAAAGTCCATTTGATTCTGTTGGCACACGC
45 CGCGCCGAACATCAGATGCTGCTGGGCAAAATGATGTTGAAAGTTCCCGAAATCGCCAA
AGCGGCAGGACTGGCAGACGGCTTCAAACCCGTGATCAATACCGGAAAAGGCGGCGACA
AGAGGTCTTCCACCTGCATATACATCATGGGTACACCGTATAAACCGTTATTTTACA
ATCAACCCCTAATACTTACTTAAGGATACATCATGGGCAGTTTTTCTCTGACGCACTGGA
TTATCGTACTGATTATCGTCTGTTTTGATATTCGGCACCAAAAAACTGCGCAACGTCCGCA
50 AAGACCTCGGCGGTGCGGTTTCATGACTTCAAAACAGGGGCTGAACGAAGGTACAGACGGCA
AAGAAGCCCAAAAGACGATGTAATCGAACACAAAAAGACGAAGACAAAGCGTAATTTA
TGTTTGATTTCGGTTTGGGCGAGCTGGTTTTTGTGCGCATTATCGCCCTGATTGTCTCTG
GCCCGCAACGCTTCCGAGGCGCCGACCGCGGACGGCTCATCGGCGAGGCTGCAAC
GCTTTGTGCGGCAGCGTCAAACAGGAATTTGACACTCAAATCGAACTGGAAGAACTGAGGA
55 AGGCAAAGCAGGAATTTGAAGCTGCCGCCGCTCAGGTTTCGAGACAGCCTCAAAGAAACCG
GTACGGATATGGAAGGCAATCTGCACGACATTTCCGACGGTCTGAAGCCTTGGGAAAAAC
TGCCCGAACAGCGGACACCTGCCGATTTCCGGTGTGATGAAAACGGCAATCCGCTTCCCG

ATGCGGCAAAACCCCTATCAGACGGCATTTCGACGTTATGCCGTCCGAACGTTCCCTACG
CTTCCGCGCAAAACCCTTGGGGACAGCGGGCAAACCGGCAGTACAGCCGAACCCGCGGAAA
CCGACCAAGACCGCGCATGGCGGAATACCTGACTGCTTCTGCCGCGCACCCGTCGTAC
AGACCGTCGAAGTCAGCTATATCGATACTGCTGTTGAAACGCCTGTTCCGCACACCACTT
5 CCCTGCGCAAACAGGCAATAAGCCGCAAACGCGATTTTCGTCCGAAACACCGCGCCAAAC
CTAAATTGCGCGTCCGTAAATCATAAAGAGAGCAATCCGGTGTCCGAAACACAAAACGAA
CAACCCGTCCAACCGCTTGTGAGCATCTCATGAGCTGCGCCGCCGCTGATGTGGACG
GTTGTGGCATCTTAGTCTGCTTTTTCGGCCTAATGCCGTTTGCCCAACAACTCTATACT
TTTATCGCCGACCCGCTGATGGCAAACCTGCCCAAAGACACCAGCATGATTGCCACCGAT
10 GTCATCGCACCATTTCCTGCGCGGTCAAAGTTACCCTGATGGCGGCATTTTAAATTCG
CTGCCGCATACGCTCTACCAAATCTGGGCATTGTGCGCGCCCGCACTCTACCAAACGAA
AAACGCCTGATTACGCCGCTCGTCTCTCCAGCGTCAGCCTGTTTTTCATCGGCATGGCA
TTTGCTACTTTTTGGTTTTCCCGTCATTTTCAAATTCCTTGCCAGCGTTACCCCTGTC
GGTGTCAATATGGCGACAGACATCGACAAATACCTCTCCTTCATCTTGGGGATGTTTGT
15 GCGTTCCGGCACAACGTTTGAAGTCCCCATTGTGCTTATCCTGTAAACCAAATTTGGTGTG
GTAACAACCGGACAGCTCAAACGCGCCCGCCCTATGTGATTGTGCGCGCGTTTGTCAAT
GCCGCCATCATCAGCCGCCGATGTGATTTCACAAACCCTGCTTGCCATTCCGCTGATT
CTCTTATACGAAGCAGGTATTTGGTTCGGACGCTTTTCACGCCACGTTTCAAGACAGGAT
GGCGACATACGGCCGCTGCAACAACCTGACACTATGCCGTCCGAACCTCCGCTCATAC
20 CGCAACAGATTAAGGAATACCTTTGAATACCCTCTATTTAGGTTCAAACAGCCCGCGCG
AATGGAAATCCTGACACAGTTGGGCTACCGCGTCATCCAACCTGCCTGCCGCGCATCGACGA
ATCCGTTAAAGCCGGCGAAACACCTTTCGCTTACGTTCAAAGGATGGCAGAAGAAAAAA
CCGAACCGCCCTGACCTCTTTTGCGAACCAACGGCACAATGCCCGATTTCCTCCCTGAT
TACCGCCGACACCTCGGTGCTTTTACAGCGGCATCATATTGGGCAAACCCCGCTCCCAAGC
25 CGAAGCAATCGAATTTTTAAACCGATTGTCCGGCAAACAACATACCGTCCTGACTGCTGT
CTGCATTCAATATCGCGGCAAAACGTCAAGCCGCGTCCAAACCAACCGCGTCGTTTTCAA
GCCCTGAGTTTCGGAAGAAATTTCCGCTATGTGCAAAGCGGCGAGCCGATGGACAAAGC
CGGTGCCCTACGCCGTACAAGGCATAGGCGGCATCTTTATCCAATCTATCGAAGGCAGCTT
CAGCGGCATTATGGGACTGCCCGTTTATGAAACCGTTTCGATGTTGCAGGATTTGGGATA
30 CCGCTCCCCCTTGTCCGCCCTTAAACCGTAAAGACCGCCGTGAACAGACAAACCGCTTAC
CTCCTTGCCCTCTTTACGCTGATCGCACTGATAATCCTGTCCCTTTCTGGGAAGTGTGG
ATTGCACCGTTTGGCCCCGGGCGGCTCGTGGCTCGCGCTCAAAGCCCTCCCCCTCTGTCTG
CCGCTTTCAGGCATCTTGAAAAAGAAAATCTATACTTACCAATACAGCTCCATGCTGGTT
CTGATTTACTTTGCCGAAGCCGTCATGCGCCTGTTTCGACGCCATCCCGCAGAACAGATT
35 TGCGCCGCGCTTCCGCAAGTATTACGATCATCTTCTCATATCCTGCCTGTGTTTCGTC
AAACAATACAAGGAAACAAACAATGCCGCTGAAACGACCGTATCCGGCGCGCACCCCGC
CGCCAAACTGCCGATTTACATCCTGCCCTGCTTCTTTGGATAGGCATCGTCCCCCTTAC
CTTCGCGCTCAAACCTGAAACCGTCGCCCCGACTTTTACCACGATGCCGCCGCCGAGCCGG
CCTGATTGTCTGTTGTTTCTCACGGCAGGAAAAAACTGTTTGATGTCAAATCCCCGC
40 CATCAGCTTCTTCTGTTTGCAATGGCGGCGTTTTGGTATCTTCAGGCACGCCTGATGAA
CCTGATTTACCCCGGTATGAACGACATCGTCTCTTGGATTTTCATCTTGCTCGCCGTCAG
CGCGTGGGCTGCCGGAGCTTGGTCGCACACTTCGGACAAGAACGCATCGTGACCCTGTT
TGCTTGGTCGCTGCTTATCGGCTCCCTGCTTCAATCCTGCATCGTCGTCATCCAGTTTGC
CGGCTGGGAAGACACCCCTCTGTTTCAAACATCATCGTTTACAGCGGGCAAGGCGTAAT
45 CGGACACATCGGGCAGCGCAACAACCTCGGACACTACCTCATGTGGGGCATACTCGCCGC
CGCCTACCTCAACGGACAACGAAAAATCCCCGCCGCCCTCGCGCTAATCTGCCTGATTAT
GCAGACCGCGTTTTAGGTTTGGTCAACTCGCGCACCATCTTGACCTACATAGCCGCCAT
CGCCCTCACTCTTCCCTTCTGGTATTTCCGTTTCGGACAAATCCAACAGGCGGACGATGCT
CGGCATAGCCGAGCCGATTCCTTACCGCGCTGTTCCAATTTCCATGAACACCATTCT
50 GGAAACCTTTACTGGCATCCGCTACGAAACTGCCGTGAAACGCGTCGCCAACGGCGGTTT
CACAGACTTGCCGCGCCAAATCGAATGGAATAAAGCCCTTGCCGCTTCCAGTCCGCCCC
GATATTCCGGCAGCGCTGGAACAGTTTGGCCAAACAACTTCCTCATCAATGCCGAACA
GCACAACATATACGACAACCTCCTCAGCAACTTGTTCACCAATTCCCACAACATCGTCCT
CCAACCTCCTTGAGAGATGGGAATCAGCGGCACGCTTCTGGTTGCCGCAACCCTGCTGAC
55 GGGCATTGCCGGGCTGCTTAAACGCCCCCTGACCCCGCATCGCTTTTCTAATCTGCAC
GCTTGCCGTCAGTATGTGCCACAGTATGCTCGAATATCCTTTGTGGTATGTCTATTTCTT
CATCCCTTTCGGACTGATGCTCTTCTGTCCCCCGCAGAGGCTTCAGACGGCATCGCCTT

CAAAAAAGCCGCCAATCTCGGCATACTGACCGCCTCCGCCGCCATATTGCGAGGATTGCT
GCACTTGGACTGGACATACACCCGGTGGTTAACGCCTTTTCCCCCGCCACTGACGACAG
TGCCAAAACCTCAACCGGAAAATCAACGAGTTGCGCTATATTTCCGCAAACAGTCCGAT
GCTGTCTTTTATGCCGACTTCTCCCTCGTAAACTTCGCCCTGCCGGAATACCCCGAAAC
5 CCAGACTTGGGCGGAAGAAGCAACCCTCAAATCACTAAAATACCGCCCCCACTCCGCCAC
CTACCGCATCGCCCTCTACCTGATGCGGCAAGGCAAAGTTGCAGAAGCAAAACAATGGAT
GCGGGCGACACAGTCTATTACCCGTACCTGATGCCCCGATACGCCGACGAAATCCGCAA
ACTGCCCGTATGGGCGCCGCTGCTACCCGAAGTCTCAAAGACTGCAAAGCCTTCGCCCG
10 CGCGCCCGGTATCCGGAAGCAAAACCTGCAAATGACCCGCGCCGGCGGATGCGGATAC
CGCCCGAAATGTAAAGCTCCATGCAAGACATTGCAAAAAACAGCAAAACCGGTAGGGAAT
ACCGTATCAAAAAACATTGCAGCCGTGTTAAGATAAACCGTCAAAACAATCTTTTCACaGC
CCCGCCCGAAACAGGGTCGGGGCATACCCCTTACGAAAAGGAAACACCATGAGCCGCTAT
TACTCGTAGATGACGATGCCCTGCTAACCGAAGTCTGACCGAATACCTGAGCGCCGAAG
15 GTCTGAACGTCCGCAGCGTTCGCCAGGGGAAGCAGGCGTACAGGAAATCCTGAGCGGGC
AGTACGATGTAGTCGTATTGGATTCCATGATGCCCAAATGAACGGCTTGGATGTCTTGA
AAAACGTACGCGCCCGAAGCACCGTCCCATCATCATGCTGACCGCCAAAGGCGACGACA
TCGACCGAATCATCGGCTTGAAATGGGCGCGGACGACTATGTCCCCAAACCTGCACAC
CACGCGAATCTTGGCACGCATCAATGCCATCCTGCGCCGCGCACAAACACAGCGCGGAAC
20 AGAACACGCAACCAACAGCATCTCCGTGAGCGATGTGCTCCTGTACCCCGCCAAACGCC
AGGCATCCGTCAAAGACATGCGCTCGAACTGACGACACCGAATTCAACCTGCTCGAAG
TCCTGATGCGCCATGCCGACAGGTAGTCAGCAAAGAAACCTGTCCGTGAAAGCACTCG
ACCGCAAGCTGGCAAATTCGACCGCAGTATCGACGTACACATCTCCAGCATCCGCCACA
AGTTGGGCGATGCCTCTCTGATTCAAACCGTACGCGCTTGGGCTACCTGTTTGTCAAAA
25 ACTGAAATAAACAGATAAATGAAACTGTTCCAACGCATTTTCGCCACATTTTGC GCGGTT
ATCGTCTGTGCAATCTTTGTGGCGAGTTTTTCTTCTGCGTGGTGCAGAACACCTTGCC
GAAAACAGTTCAACCAACGCCGACCATCGAAACCACTTTGATGGGCAGCATCATTTCC
GCATTCCGGGACGCGGGGACGCGGGTGC GCGGAAATCCTGACGGAATGGAAAGACAGC
30 CCGTCTCATCGGGCGTGTACGTTATACAGGGCGACGAGAAAAAGATATCCTGAACCGG
TATATCGACAGCTATACCATCGAACGCGCCCGCTTTTCGCCCGCGGACACCCGCATTCC
AACCTCGTCCATATCGAATACGACCGCTTCGGCGAAGAATACCTGTTCTTCAACAAAGAC
TGGGACAAACTCCAAGCCCGCCGCTGCCAGCCCCCTGTTGATCCCCGGCCTGCCGCTC
GCCCCGATTTGGCACGAACTCATCATATTGCTCTCATCATCATCGTCGGAATGCTGATG
GCATATATCCTCGCCGCAACATTGCCAAACCATCAGAATCTTAGGCAACGGCATGGAC
35 AGGGTGGCAAACGGAGAATTGAAACCCGTATCTCCCAACAGGTGACGACCGCGACGAC
GAATTGTCCCATCTTGCCATCCAATTGACAAAAATGGTGAAAAACTCGAAAAACTCGTT
GCCAAGAAGCCCACTGCTCCATCACGTCTCCATGAAATGCGTTCTCCCTTGCGCGC
ATGCAAGCAATTGTGCGACTGATTGAGGCGCAGCCCCAAAAACAGGAGCAATATCTCAA
CGGCTGGAAGGCGAACTGACCCGATGGATACGCTGGCCGGGGAAGTGTAAACCTGTCC
40 CGTCTCGAAACTTCCAATATGGCTTTGGAAAAAGAAAGCCTGAAACTCCTGCCCTTCTG
GGCAACCTGGTAGAAGACAATCAAAGCATTGCCAGAAAAACGGACAAACGGTTACCTG
TCTGCCGACGGAATAATCCCCGAAAACACAACCATCCTTGCCAACGAAAGCTACCTGTAC
CGCGCCTTCGACAACGTATCCGCAACGCCGTCAACTACAGTCCCGAAGGCAGCACCATC
CTGATCAACATCGGACAAGACCAAACTGGATAATCGACGTTACCGACAACGGCCCC
45 GCGGTGGACGAAATGCAGCTCCCGCACATCTTACCGCTTTCTACCGTGACACTCCAGT
GCCAACAACCCCGAACAGGACTGGGGCTTGCAATTGACCCAACATATTATTGAACAGCAC
TGCGGCAAAATCATCGCCGAAAACATCAAACCGAACGGTCTGCGGATGCGCTTTATCCTG
CCCAAGAAAAAACCGGTTCCAAAACAGAAAAAGTGCGAACTGACCATAATACCGTCTG
AACCGGCTTCAGACGGCATTGCACAAACAGTTACCCCAAAACAAACACACAGCGGGTGT
50 TCTCCAAAAATCACGCACATACCGTCCGCAAAGGAATATATCATGTGCGCACAAACCGAT
CCGGGCTACTTCTCATGCCCAACCATCATCCTGATAGGCGGAGCGAACAACCGTAC
AGCCTGGGCGAACGTGTACTCAGCAACCTGCTGAGTACGCCCTTTCAAGGAAAAATCACC
CCCCGTAACCCGCGCCACCACACCATAGCCGACTGCCCGCTACACCAGCCTCAACAAA
ATCCCCGGCAATGCAGACCTGATTATTGCCGTTACCTTACCGACAGTTACGACACCCCT
55 TTCAAAACCTGCCGCAAAAAGCAGCTCCGACACATCATCCTCATACAGGACTGGGACAAC
CTGTCTGCCGAGAACTGCACACCGCGGAAACTGCCATCCGCAAAACACACGGCAACGGA
CTCAACATCACCGCTGCACACCGCAGGCATCCAATGCCCTCACTCGGACTCAACATC
AGTACCAAGACGGATACGCCGACGGCCATACCGCCATACTGACCGGCAATGCCGCCGTC

AGCCGCCAAATCGACAACATCCTGAACAACTCCGTCAAGGCACATCCCGCCACATCAGC
CTGCATCCCGGCATCAGCCCCATCACATCCGCGATTGGCTCAACCGCTTCGGACACAGC
CTGCACACCAAAACCGCGCTCTACACCACAACCTGAAGAGGATCAGCGCAAACCTGTTT
AGCGCAATCCGCCAATTTACCGCCATACGCGCTGATTCTCCACATCACCTGCCGACG
5 ACAGAAACCGACCGTGCCTACTGCACTGCCTCGCCGACACTGCAACTTCCTCGTCAGT
TTCAACGCGGACGACCTCGAAGCCGCACTGCGCGCCCAACTGTCCGACCTTCCACCCCTG
TCCCGACTCGACATCCTGTCCGACACGCTGCCGAATGGCTGCACGCGACGCGCCAAAA
AACCTCACCTCCACTTTCCTCAACCTTCCCCACCACATCCGCAACGGACACCTGACCGGC
10 ACACCCACACCTCAATCTGCCACGACATCGCCTCACGTACGCTTGCCCAACCCGACACC
CAAGCCGTCTAACCATCCTCAGTCCCTCCGGACACGAGGATTACAAAAAACAGCACGC
GCCCTTATCCGCTGTCCGAACAGACCGCCAAACCCCTGCTCGTCAGCAGCCCCCTTTTCA
GACGGCATAACCCATTTTCGACACCCCCACTCAGGCAATCCGCACCCCTTCTTACCGCAAC
ACCGCGCGCGCTGAAACAGGCACAGCTCGACATTGCACCGCGCAGCCATGCCGTCTG
15 AAAACACCGCAACCCCAAAACATCAAAAAAGCCCTTGACGCGGCAACCCCTCCCTGCTC
GCCGAAGCCCTGCACCTCCCCCCTACCGGCACACCACCCATAACGCCGTACAATTCCAA
TTCGACAGCCACCCCTCTATGGCGACATCCTGACCGCACGCTGCAACGGACAAACCACT
GCCGTACTCCCGCGCTTTACACGCTCGACAGCGCCACCTTGCCCGCTTTGCCGAACCTC
GACGGCACACAAACCTCGACCACTTCTGACACACTGACCGTCATTCCCGAATACCGC
20 CAACACTTCTCGGCATCACCTCAACCTCAACGGCGGACAATACAGCAGCGATTTCCTC
TTAAAGACACCCGAAACACACAGACACGCCCCAAACGCAAGAACACAGGCAAGCCGCCAA
ACCCCTCGAATATGCCGCGCAAAATGCGAGTGGCGCGCATACCTGAAACACAAAAAC
CCGACAGCGCGCAATTTCTCGCCACACAAGCGAAGCCGCGCAGAACTGCTCGGCAGC
AAAACCGAAACCGGAGCAGCCGTACCCAACGTACTTGCCCCCTATCCCGCAGCATACCCC
25 AAAACACTGTCCCTAAGAAACAACACGACCGTTACCATTACCCCATTTTGCCCGAAGAC
GCAGAAGCCAAACAGCAGTTTCGTCCGACGCTCGGTCCCGAAGCACGGTACACACGCTTC
ATGACCCACACCAACGAACCTGCCGCGAGCCACGTTGGCAGCGCTGTGCAACCCGATTAC
CACTGTGAAGCCGATGGACGGCAAGGATGCCGACAGCAACATCGTCGCGCTCGTCCGC
CACAGCCGCTGAATCGCAACGAATGCGAATTCGGCATCACACTGGCGGAACATATGCGC
GGCAGCGGACTGGACAGAAAATGATGGAACCTCATCATCCAAACCGCGCACAGCAAGGC
30 TACCGGACTATGAGTGGCGACATTCTCAAAACCAATACCCCATGATCAAACCTTGCTGAA
AAATCAGGATTTACCTCAAGGAATCGGACACCGAAAAAACCTGTACCGCGCATATCTG
AACCTTGCGGCAGACAAAACAACAGAAAAACAAATAAAACTTGCGCACCGACCACAAA
ATAACCTAAATCGGCAGTTTCCATATATCCGATTTTCTCAAAGGACTCAAATGGTAG
TTATCCGTTTGGCACGCGCGGCTCGAAACACCGCCCTTCTACAACGTCATCGTTACTG
35 ACTCACGCAGCCGCGCGACGCGCGCTTCATCGAACGCGTAGGCTTCTACAACCCCGTAG
CCAACGAAAAACAAGAGCGCTCCGCTCAATGCAGACCGCTGAACCACTGGATTGCAC
AAGGCGCGCAAGTCAAGCACTCCGTTGCAAACTGATTAAAGAACAAAAAGCCGCTAAT
CCGCATTTGCCGCGATGACAGACACTCAAAACCGGGTAGCCATGGGCTACATCAAAGGCG
TATTCGGCATAAAAGGCTGGTTGAAAATGCGGCCAACACCGAATATTCCGACAGCCTTT
40 TGGACTACCCGAGTGGCATTGTTGTTCAAGGACGGCAAAACCATCAGCGTTACCCTTGAAG
CCGGAAGTTCGTCAACGGCGAATCCAAGTCAAATTCGAAGGCATAAACGACCGCGACT
TGGCATTTCTCATTGCGCGGTTACACCATCGAAATACCCCGTGAAGCATTGCCCCGACAG
AAGAAGCAATACTACTGGACAGACTTGGTGGCATGACCGTTGTCAACAAAGACCATA
CCGTTTTAGGCAAGGTAAGCAACCTGATGGAACCGCGCAACGACGTATTGATGATTG
45 ACGGAGAACACGGGAGATTCTGATTCCGTTTCGTTTCCCAATATATCGAAACCGTCGATA
CCGGCAGCAAGACATTACTGCCGACTGGGGTTTGGACTACTGATGCTTATCCAGGCAGT
TACCATTTTCCCCGAAATGTTTCGACAGCATTACCCGCTACGGCGTAACGGGACGCGCGAA
CAGACAGGGAATCTGGCAGTTTGAAGCAGTCAATCCCCGAAAGTTTGCCGACAACAGATT
GGGCTACATCGACGACCGCCGTTTCGGCGGCGGCGGGAATGATTATGATGGCTCCGCC
50 GCTTCATGCGGCAATAGAACACGCCAAAAACACAATCCTCCCAAGCTGCAAAAGTCATCTA
CCTCAGCCCCCAAGGGAACCGCTTGACACACCAAAAAGCGGTAGAACTGGCAGAACTTC
CGCATCTGATTCTGCTGTGCGGACGGTATGAGGGCATAGACGAAAGGCTTCTGCAAAGCA
CGCTCGATGAAGAAATCAGCATCGGAGACTTCGTTGTTTCCGGCGGAGAGCTTCCGCCA
TGATGCTGATGGATGCGGTATTGAGGCTCGTACCCGGCGTATTGGGCGATATGCACTCTG
55 CCGAACAGGATTGTTCTCAAGCGGCATTTTGGACTGCCCCACTACACCAACCCCTTAG
AATTTCAAGGTATGGCTGTTCCGGAAGTATTGCGTTCCGGCAATCATGGCTTGATAGCGG
AATGGCGGTTGGAACAATCGCTGCGCCGACCTTGAGCGCAGACCCGATCTTTTGAAA

-57-

AGCGCGTTTTTAATCCCAAAGGAATCCCGCCTCTTAGAAACCATCCGGCAAGAGCAACGGG
 AAATCCAATCATAATTTAGGAAAAAACAATGAACCTGATTCAACAGCTCGAGCAAGAAG
 AAATTGCCCGCTGAATAAAGAAATCCCGAATTGCGACCGGGCGACACCGTAGTCGTAT
 5 CCGTACGCGTCGTGGAAGGTACCCGCGAGCCGTCTGCAAGCCTACGAAGGCGTGGTTATTG
 CCCGTCGCAACCGTGGTCTGAACAGCAACTTCATCGTCCGCAAAATCTCCAGCGGCGAAG
 GTGTTGAACGTACTTTTCCAACGTACTCTCCGACCGTCGAAAAAATCGAAGTCAAACGCC
 GTGGCGACGTACGCCGTGCCAACTGTACTACCTGCGCGCGCTGACCGGTAAAGCTGCAC
 GCATCAAAGAAAACTGCCTGCACGCAAGGTTGATTCAAACCGTTTTTCCCCAATGCCG
 TCTGAACCTTCAGACGGCATTCTTATTGCTGCGATGCCGGCAAGTCAACGATATGCCTG
 10 CCCCTCATCCACCTTGATTAAACAATCACTCCCGCCTATTCAAGCATAATTTACAGACCAA
 ACGTTATACAGTATCATATCAGCCATATAACGATAAAACGCTTTACCGCCTTCCCTTTCAA
 AACCGCAAATCATCATGACACCTTCCCTTTTACTATCAGGATTGACCTTCCGCCTCATCC
 TTGCCCTGATTGCCGTATCCCTTTTATGGGGCGTTTACTTTTGGGCAGTATCCGCATGAG
 CATCATTTGTCGAAAACCTGACCGTCAGcTACCGCCGCCGACCTGCCGTGCACCATGTGGA
 15 CATTACTTTTGAAGAACATAGTATGTGGGCGGTTTTTCGGTCCCAACGGCGCAGGGAAATC
 CACCTTTCTCAAATCCTTGATGGGATTGCAGCCTATCGATACAGGCAGCATCCGGCTGGA
 CGGATTGACCCGTCAGAACATCGCCTACCTTCCCCAGCAGTCCGATATCGACCGCTCCCA
 GCCTATGACCGTTTTTCGACTTGGCGGCAATGGGGCTATGGTATGAAATCGGCTTTTTCAA
 AGGGATAAATACCGCTCAAAAACAACGCGTTTACGAAGCCTTGGAGCGCGTCGGAATGCA
 20 ACGGTTTGGCGACCGTCAGATTGCCTATCTCTCAAACGGACAATTTACGCGTGTCTTTT
 TGCCCGAATGCTGGTTCAAATGCCAAATTCCTGCTGCTCGACGAACCCTTCAATGCCGT
 TGATGCACGGACAACCTACGAGCTTCTCGACGTATTGCAGAAATGCCATTGCGGCGGACA
 CGCCATCATCGCCGTACTGCACGATTACGAACAAGTCCGTGCCTACTTTCCCAATACCCT
 GCTGCTCGCCCCGCGAAAAATTCGCGGCAGGCGCAACCGAGACCATTCTGACAGAACCTTA
 25 CCTCGCCCCAAGCCAACGCCAAAATGCAGCAACAGGAAAGCCCCGACTGGTGCCCTCATA
 AATGCCGTCTGAAACCGAAAAaCCATGAATCTCTACGACCTGCTCCTTGCCCCCTTTGCA
 GAATTGCACTTTATGCGCTACGCCCTCGCATCCGTCTTCTGCCTGTCCCTCAGTGCCGCA
 CCGCTCGGCGTATTCCCTCGTCATGCGCCGTATGAGCCTGATAGGCGACGCATTGAGCCAC
 GCCGTCTGCCCCGTGCCGCCGTGCGCTACATGTTTGCCGGCTTGAGCCTGCCCGCCATG
 30 GGTTTGGGCGGCGTAGCCGCGAGGCATGCTGATGGCACTGCTTGCCGGACTCGTCAGCCGC
 TTCACCACCCTGAAAGAAGATGCCAACTTTGCCGCCCTTTTATCTCAGCAGCCTCGCCATC
 GGCGTAGTCCTCGTCAGCAAAAACGGGAGCAGCGTCGATTTGCTCCACCTCCTTTTCGGC
 TCTGTACTTGCCGTGATATTCTGCCCCTGCAGCTCATCGCCGCCGTCTCCAGCCTCACG
 CTCATTACCCTTGCCGTCTATACCGCCCCGCTCGTACTCGAAAGCATCGACCCCCTGTTT
 35 CTCAAATCCGTGCGGCGCAAGGCGGGCTTTGGCAGCTCCTCTTTCTCGTCTGGTCTGTC
 ATGAACCTCGTATCCGGCTTTCAAGCCCTCGGCACACTCATGTCCGTGCGACTCATGATG
 CTGCCAGCCATTACCGCCCCGCTGTGGGCGAAGCATATGGGCGCACTCATCCTCCTATCC
 GTTCTGACAGCCCTGCTGTGCGGCTTGAGCGGACTGCTCATTTCTACCACATCGAAATT
 CCTTCCGGTCCCGCCATCATCCTCTGTTGCGAGCGTCTTTATCTCTTTTCCGTCATACTC
 40 GGCAAGAAGGCGGCATTCTGACCGG

The following partial DNA sequence was identified in *N. meningitidis* <SEQ ID 6>:

gnm_6

GTTATGATATGTTTCGATATGTAAACATTTATAGGTTTGGAGCGATAAACAATGAATGCA
 45 GTCGTAGTTGCCGTAATCGTTATGCTGGTGTGTGCGCTGTGCGCGGTGCACGTGGTATTG
 AGCCTGACGGTCGGCGCGTTTGTGCGGCGGCGGTTGGCGGGTATGCCGCTGCAAAACATT
 GCCGATGCGGCGGGACAGGTCAAGTCAGGCGGGGATTATCCCCGTGTTCAACAAAGGTTTG
 GAAGGCGGTGCGAAGATTGCGCTTTCTTATGCGATGCTCGGCGCGTTTGCAATGGCGATT
 ACCCATTCGGCCTGCCGAGCAGCTTGCCGGCGCGGTGCTCCGCAAGCTGAACCGGGGC
 50 GGTATGCCCCACAGCGTGCGTTTGGGCGAGGGCGCGGTCAAATGGCTGCTGCTTTCCATC
 ATCCTTGTGATGGGCATGATGAGTCAGAACATCATCCCCATCCACATTGCCTTTATCCCG
 ATGATTGTTCCGCCGTGCTTTTGGTGTTCACCGCCTGAAAAATCGACCGCGCGCTGATT
 GCGTGCGTCATCACTTCGGGCTGGTTACGACTTATATGTTCTGCTTACGGCTTCGGC

5 GCGATTTTTTTTGAACGAAATCCTGTTGGGCAACATCCATTCCGCCGCGCCGAGCTTGAT
GTGAAAAACATTAACTGATGGCGGCAATGGCGATTCCCGCGTTGGGAATGCTGGCCGGA
CTCCTGCTGCGCTTTGTCCATTACCGCAAACCGCGCTGTACCAAAGCAACAATGCCGAT
ACGGCGGGCAACGCCGATGCGGCAACCGTCCGCAGCCGTCCGCCTACCGCAGCCTGGCC
10 GCCGCCGTCGCCATTGCCGTATGCTTTGCCATCCAGTTGATGTATGAAGACTCGCTGGTG
TTGGGCGCGATGCTCGGTTTTCGCCGATTTTATGATGTTGGGGGTCAATTAACCGCGACAAG
GCAAACGACGTATTCCGGCAAGGTATCAAGATGATGGCGATGGTCCGCTTCATTATGATT
GCCGCGCAGGGTTTTGCCGCCGTGATGAATGCGACCGGGCATATTACGCCGCTGGTGGAA
AGCAGTATGGCGATATTCCGGCAACGCAAAGGTATGGCGGCATTGGCGATGCTGGTGGTG
15 GGGCTTTTGGTAACGATGGGCATCGGTTCTGCTCTTTTCCACTTTGCCGATTATTGCCGCG
ATTTATGTGCCTTTTGTGTGTCGGTTTGGGTTTTTCGCCGCTTGCCACCGTCGCCATTGTC
GGCACGGCGGGGGCGTTGGGCGATGCCGGTTCCGCTGCGTCCGATTCCACGCTGGGCGCG
ACGATGGGGCTGAACGCCGACGGGCAGCACGACCACATCCGCGATTCCGTTATCCCGACC
TTCATCCACTACAACATCCCGCTGCTGATTGCCGGCTGGATTGCCGCGATGGTGTGTAA
20 ATGGACGCGGTTCAAGAGTTGGAACGCCGTATTGTGCAACTGGAAATCCAATCCGCGCTT
CAGGAGGACGTAATCGCCGGCTGAACGCGATGGTGGCGGAATTGCGGCAGACGCTGGAT
TTGCAGCAGGCTCAGTTGAGGCTGCTGTATCAAAAAATGCAGGACAGGAATCCCGACGCG
CAAGAGCCGTATTCCCTGCGCGACGAGATTCCGCCGCATTATTGATGCGCCGCGGTATCC
GGATTTCTTAAAAAAGGCTGTGTTGAATATTCGCCGATGCAAACCTAAGATATATAG
25 TGATTAACAAAAATCAGGACAAGGCGACGAAGCCGACAGTACAATAGTACGGAAC
CGATTCACTTGGTGCTTACGACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGCCAA
CGCTGTACTGGTTTTTGTTAATCCACTATAACTTTAATCAGTCGGACAAAATGCCTTTTA
TCCGATGGAACCGTTTTCCGCCCGAACGGAAATAAGCGGCTTCCCCCGCTGCAAACAGAT
AAAACCAACCGGGTATTCAAACACAGCCAAAAAAGCCGTCCGAACCCAAAGGGGACAG
30 ACGGCCAAACACATTACGGGGAAAACGTTTTACTCAATGAGTCTGCGAAACAGACATTGC
TAAAACAATTGCAATTATAAGGTAAGTTTTATTTTTTTTTTTTTTTTTTGGCAAAGAAATG
TAAATTTTTAAATTTTTAAACCGTTCCGCCGCATCCGTTTGGATGCCGTCTGAAACGGC
GGCAGGGTTTTATCGCGCTGTGCCGCAAACCGGGCATTCAGGGTTGCGCGGCAGGTGGA
TATTGCCAGCCCCCTTCCAAGGCACGGTAAACCGCCAGCCTGCCGTGCGACGGTTCCGCC
35 GCATCCAGCAGGATTTTCCAGAGCTCCGCCGCTTGGGTACTGCCGATGATGCCGACCAGC
GGCGAGAACACGCCGAAGAGAGAACAGATGCCGTCTGAAGCCGATCCGCCGTCAAACAGG
CAGGCGTAACACGGCGAGTCGGCAAGTCGGGACGGTACACGGCAAGTTGCCCTTCAAAG
CGTACCGCCGCCCTTGAACACAGCGGTGTTTTCGTTTGACGCGAGGCACGGTTGACGGCT
TGCCGCGTGGCGTAGTTGTGCAACAGTCTAAACGATGTGCGCGGCTTGAAACAAACCG
40 GTCAGGCGGCAGCCGTCGAGTTTTTCGTTGACGGCGCGGACGTTGACGGTATGGTTGATG
CGTTTTCAGGCGGCCTGCCAAGGCTTCGGTTTTGAGTTTGCCGACATGCCCTCGTCAAAT
GCGACTTGCGCTTGAGGTTGTGCAAGTTCCAGCGTGTGGAATCGGCTATGGTCAGCGTG
CCGACACCCGAAGCGGCAAGGTAGGGCAGTGGCGCGCACCCAAACCGCCGACGGGACG
ACCAAATATGCGCGGCGGAAAGTTTCTGCTGCCCTTCGATGCCGATTTCGTCCAAGAGG
45 ATGTGGCGGCTGTACCGCAGCAGGAATGCATCGTCTGTGCTGTTCCGTCGTGGTCATG
ATGATGTTCCGAAAAAACAGTTGCGGGCGATTGTAACGCTGCCGTCCGGCGCGGTTCAA
CTTCAGACGGCATTTCGGGACACGGGCGGTTAAAGTGTGAACGGTTTGGCACGGATGCGG
CATTTGGGGTACATTACAATATTTACGGCAGACGAGAGAAAAATCATGCAACTGCAT
50 ATTCTGAACAATCAAAGGACGCGGCTTTGGCGGCGGACGCGGAATTTCTGAAACAATCC
CTGTTCAACCTCCTGCACGAAGAAGCCTCGCCGTTGGTTGTGCAACAGTCAAACCTCTTG
TCCACTTCCGACGACAGCGCGGCTTGAATGAAAAAGTATTGCCGCAATTGGACGAACAA
CAAACCCACGATTTAACCTTGGCCTGCGGCCGTTCGCCAGATTTTGAACATCGCCGAA
GACGTGCACCACGAACGCCGCCCAAATCCACGAAGAAGCCGGACGCGGCGGCGCGGAA
GGCAGCCTGACGGAAACCGTCCGCAGGCTCAAAGCGGGGAAAGCCGACGGCAAATCGGTG
55 CAGCGGCAGTTGGACAATACGTCCGTTACCGCCGTTTTGACCGCGCACCCGACCGAAGTG
CAACGCCAAACCGTCTTAAGCTTCAACCGCCGCATCCGCGCACTGTTGCCGCAACGCGAA
CGCTGCACCAATGCCGACGCGCTGGCACGGCTGCGCCGCGAAATCGACACTATCCTGCTG
GGCTTGTGGCAGAACGCAACCGCGCCCAAACTCAGCGTCAACGACGAAATCAAC
AACGGCGTGTCCATCTTCCCGATGAGCTTTTTCGAAGCCCTGCCCAAGCTCTACCGCAAG
ATGGAACACGACTTTTCAGACGGCCTATCCCGCGCTCCGCGTTCGGGACATCCTCAAAATC
60 GCGCGCTGGATCGGCGGCGACCGCGACGGCAATCCGTTTGTCTGCCGAAACCTGCGC
TTTGCTTCCGCCGCCACCGCGATGCCGTGTTCCGCTTCTATCGCGGCGAACTCGACAAA

CTCTACCGCGAACTGCCGCTCTCCATCCGCCGCGTCAAAGTCAACGGCGATGTAACGGCG
TTGTCCGACAAATCGCCCCGACGAAGAAATCGCCCCGCGCGAAGAACCTACCGCCGCGCC
ATCGCCTACATTATGGCGCGCTATGGGCAAAGCGCGCGCTCGGTTTGGGTATGGGC
TGCAAATTCGGCTTTCTCGAGCCTTATGCTTCGGCACAAGAGTTTCTGGATGATTTGAAA
5 AAATTGCAACGTTCCCTTATCGACAACGGCAGCCGTCTGCTTGCCGAAGGCCGTTTGCA
GACCTCATCCGTTCCGTATCCGTGTTCCGCTTTTACATGATGCCGCTCGACTTGCGCCAA
CACGCAGGCAAACACGCCGATGTGGTTGCCGAGCTTTTCCAACACGCAGGCTTGAAGAC
TACAACCGCCTGAACGAAGAGCAAAAACAAACCGCCCTGTTGCGCGAATTGAGCCATCAA
10 CGTCCTCTGTACAGCCCGTTTATCACATACAGCGACCATACCCGCCACGAACTGGCAATT
TTCAACGAAGCGCGCAAAATCAAAGACGAATTTGGCGAAGATGCCGTAACACAAAGCATT
ATTTCCAACATGCGAACAACCCAGCGACCTGCTCGCCTTGGCATTGCTGCTGAAAGAAACC
GGCCTGTTGGCGGTGGAAAACGGCAAACCGCACAGCCGCATCAATATCGTGCCGCTGTTT
GAAACCATTGAAGCGTTGGAAAACGCTGTCCGGTCATGGAACCATTGTTCCGCTCGAC
15 TGGTACGATGCACTGCTCGAAAGCCGTGGAAACATCCAAGAAATCATGCTCGGCTATTCC
GACTCCAACAAGGACGGCGGCTACGTTACCAGCTCATGGTGCCTCTATCAGGCGGAATTG
GGCTTGGTTCGAACCTTTCAAAAATACGATGTCCGTATGCGCCTGTTCCACGACGCGGC
GGCAGCGTAGGTGCGCGCGCGGCCCTTCTTACCAAGCCATTCTCGCCCAACCGGCGGGC
AGCGTGGCGGGACAAATCCGCATCACCGAACAAGGCGAAGTCATTACCGCCAAATACGCC
GACCCCGGCAATGCCAACGCAACTTGGAACCTTGGTTGCCGCGACTTTGGAAGCCAGC
20 ATCTTGCCGGATAAAAAAGACCCTGATGCCAACTGATGCAGGCATTGTGCGACGTATCG
TTCAAATACTACCGCGAAGCTGATTACCCATCCCGACTTCATCGACTACTTTCTGCAAAAC
AGCCCGATTACAGAAATCGCCACCCTCAACCTAGGCAGCCGTCCCGCCAGCCGCAAAACC
TTGGCGCGGATTACGAGCTTGCGCGCGATTCCGTGGGTATTTTCTGGATGCAGAACCGC
25 CTCATGCTGCCGCTTGGTACGGTTTCCGCGAGCGCGTGGAAACCTTGTGCGAAGACAAA
CCCGAAACGCTCGCCGCCCTGCGCGAACACGCCCAAAGCAACCCGTCTTCCAAGCCATG
CTCTCCAATATGGAACAAGTGATGGCGAAAACCGACATCACCTCGCGGAAAACCTATGCC
GGCTTGAGCGAATCGCCCGATAAGGCAAAAATCATCTTCGGGATGATTAAGGAAGAATAC
CGCCGCGAGCCGCAAGCACTGCTCGACCTACTGCAAACCGAAGAGCTTTTGGCGGACAAC
30 CGCAGCCTCGCCCGTTTCGCTCGCTTGGAGGATTCCTTACCTGAACGCGCTCAACGGTTTG
CAAGTCGCCATGCTCAAACGCTGCGTAAAGAACCCGACAATCCGCACGCCCTTCTGATG
GTGCACCTGACCATCAACGGCGTGGCGCAAGGTTTGGCAATACAGGCTGATAGTGCCGC
ATCGGGGCAAAATGCCGTCTGAACGCCCTTTCAGACGGCATTTCCTTGACCGCACTTGCGAG
AGAAACACCGATTGTTTTAAAGTGAACGGCAGTGATATGTTGAAAGACGACCAATGAAAA
TTACCGTTATCGGCGCAGGTTTCGTGGGGTACGGCGCTCGCCCTGCATTTTTTCCAACACG
35 GCAACCGCGTATCCCTGTGGACGCGCAACGCGAGCAAGTCCGTCAAATGCAGGAAGCGC
GTGAAAACAAACGCGGACTGCCCGGCTTTTCTTTCCCGAAACCTTGAAGTGTGTGCGG
ATTTGGCAGACGCGCTCAAAGACAGCGGACTTGTCTTATCGTAACCTCCGTTGCCGAT
TGAGAAGCAGCGCAGAGCTGCTCAAACAGTACGGCGCGGGACACCTCCCCGTCTCGCCG
40 CCTGCAAAGGATTCGAGCAGGATACCGGGCTGCTGACCTTTCAAGTCTTGAAAGAAGTAT
TGCCCGACAATAAGAAAATCGGCGTACTTTCCGGCCCGAGTTTTGCACAGGAACCTCGCCA
AACAACCTGCCCTGCGCCGTGCTCCTTGCTCCGAAAACCAAGAGTGGATTGAAGAACTCG
TACCGCAGCTCAACACGACCGTCATGAGGCTTTACGGCAGTACCGATGTTATCGGCGTGG
CGGTTGGCGGCGCGGTAAAAAATGTTATGGCGATTGCCACCGGATTGTCCGACGGCCTAG
45 AGTACGGGCTTAACGCCCCTGCCGCACTGGTTACGCGCGGATTAGCTGAAATCACCCGCC
TTGCCTCCGCAATGGGCGCACAGCCCAAAACCATGATGGGGCTGGCAGGCATCGGCGACC
TCATCCTCACCTGCACCGCGCACTTTTCGCGCAACCGCCGCTCGGCTTGGGTTTGGCAG
AAGGCAAGGAACTGCATCAGGTGCTGGTCAAAATCGGACACGTTTCCGAAGGGGTAGCA
CGATAGAAGAAGTCTTCAATACTGCCTGTAAGTACCAAATCGACATGCCGATTACCCAAA
50 CTCTGCTGCAACTCATCCGCAAAGAAATGACCCCGCAACAGGTTGTGAAAGACTGATGG
AACGCAGCGCGGTTTTGAATAAACAACAGACAGATGCCGTCTGAAGCCTTCAGACGGCA
TACGGACAGGTAAGGTTATGAAACAAAATATCGAAAACTCGAAAGCAGCGTTTATACGT
TGGTACAAAAATTCGAAACCTCTGTCAGCGAAAACCGCCGCTCAAAGAAACCGTTCGCCG
AATCAAACGGGCGCAGGAGCGGCAAAAACCTCGAACACGAAACCGCCGTCGACGAACTCA
55 CGGAAGCCTGCTCGTCCAAGTCGGCAAACTCAAAGAAGACCTGCAAAACAAAATTGACA
GCCTGACAGAGAAAATACAGATACCGCAGCCTGCTCGAACAGAGCAGGGAAAAAATCA
GCGCACTGGCAGCGCGCCTCCCCAATGGCAGGAAACGCGCAATAAGGATTAAAGGATG
AACATCGAACAAGTCCACATCGAAGTCATGCACGCCCGGCTGACCGTCAACACGCCCGCA

GAAGAAAAAGACACACTGTTGCAGGCAGTCGGAATGCTCAACGGCAAAGCCGAAGCCATC
CGCGAAGGCGGACGCGTCGCGGACAGCGAAAAAATCGTCATTATGGCCGCGCTCAACGTC
GTCCACGACCTGTTGAAAACCTCCCTGAACGGCGGCGATTGGCAATCGGCGATTTGCG
CGTAAATAGCCGATATGGACAACGCTGCCAAAAGCACTATCCCGCTTGGCGCAGGAA
5 TAACCCCTTTTCCCTGCGGTGTCCGCGAAGGCATATATTCCTTTGAACCAATAAGTTTCG
CTTAAGGTTGCCGGGAGCAGTAGTGGGCGCGAGCGTCCTTTTGGGACGCACCCGAAACT
ACCCGAGGCAGCCGCTTGTCTAGCAAGGTTCAAGCGGATTTCGGCCGAAACGGCTCTCGCG
GGGATTCCCATTCAAAACCGCATCGCAACGATGCGGTTTTTTCACATTGGCCGCCGCCCG
CCCGAAAAAGCAGTATGCAGTCTGCCGAAATCCGGAAAAATCCTTCGGTAACGCGGTAATG
10 CGATTGACAAAATCGAATCCTGTCTTTAAATTTACAACCTTTCTATATCTATCTGGATTT
CCACTATGAAAACCTTTTCAGCGAAACCCACGAGGTGAAGCGCGAATGGTTTCGTATCG
ATGCCCCAAGACAAAGTCTTGGGTGCGGTTGCGGCCGAAGTCGCCAGCCGTCTGCGTGGCA
AACACAAACCTGAATACACCCCCACGTCGATACCGGCGATTACATCATTGTTATCAATG
CGGACAAACTGCGTGTAACCGGTGCCAAATTCGAAGATAAAAAATACTTCCGCCATTCCG
15 GTTTCACGAGCGGTATCTACGAACGCACCTTCCGCGAAATGCAAGAGCAATTCCCGGGCC
GCGCTTTGGAACAAGCTGTAAAAGGTATGCTGCCCAAAGGTCCTCTGGGTACGCCATGA
TTAAAAAAGTGAAGTGTATGCGGGTGCGGAACACGCCCATGCTGCGCAACAAACCAAAG
TTTTGGAAGTGAATAGGACGCGACATGAACGGTAAATACTACTACGGCACAGGCCGCC
GCAAAAGTTCAGTGGCTCGTGATTCTGATTAAAGGTACAGGTCAAATCATCGTAAACG
20 GTCGTCCCGTTGACGAATTCCTTCGCACGGGAAACACGCGAATGGTTGTTGCGCAACCT
TGGTTCTGACTGAAAACGCCGAATCTTTCGACATCAAAGTCAATGTTGTTGGCGGCGGCG
AAACCGGCCAGTCCGGCGCAATCCGCCACGGCATTACCCGTGCCCTGATCGACTTCGATG
CCGCGTTGAAACCCGCCTTGTCTCAAGCTGGTTTTGTTACCCGCGATGCCCGCAAGTCG
AACGTAAAAAACC GGCTGTCGCGAAAGCACGCGGTGCAAAACAATTCTCAAACGTTAAT
25 GTTGGAAATTCAAAAAACCTGCTTATCGCAGGGTTTTTTATTTGTAGTAGACGGTTTTCC
CATTGGCAATCTAAAGATTACAGATTGGGCAAAAATCAAAAACAGTATAGTGGATTAACA
AAAATCAGGACAAGGCGACGAAGCCGCAGACAGTACAAATAGTATGGCAAGGCGAGGCAA
CGCGTACTGGTTTTTTGTTAATCCACTATACATGAAAAAATAGAAAACTGCCGGGTATG
GTTGAATAAGGGGTGAGACCGGTTCCAGTTCGCTCAGTCCGGGCAATCTGCAAAACCGC
30 GTTCGCGTATGATTTGGCAAAAATGTTTCAGATAGCTCTTGTCCGTATCTTCGGTACGGA
TGGCGGCATACAGTTTGCTTTGCAGTCCGTCCGCAGTAATTTGGCGGTGGACGACATAGC
CTTTTTCAAGGTAGGCGATGACTGTCCAATAGGGAAGGGCGGCAATGCCACGTCTGCTGG
CAACCAGTTGGATAATGGCGATGGTCAGCTCGCTGTGTGCGCGCGCGGGTTGATGTTTT
TCGGAATCAGGATTTTTTTGGGCAATCCAGCATCTCGTCGGGAACGGGATAAGTAATCA
35 GGGTTTCCCGGATAAAGTCTTCCGCCGTCCAAACGTTTTTTGGCGCAAGCGGATGGTCTG
GTGCGCAATGCCGACCATTTTCGTAGGCAACAGCGGTTGGAAAGAAATACCGTTTTGTT
TTTCCGCTTCGGAACAATGGCAAGGTCCGCACGGTGTTGCAAGCAGCAGTCCGACGGGAT
CCGCTTGGAAATCCCGATACGATATCCAATTGACTTGGGGCCACATCGGGCGGAATTCGC
CCATGGCGGGCATCAGCCAGTCGAACAGGTATGGCATTTCGACGGCAATCCGCAGCTCTC
40 CCGCCTCTCCTTCCGTGATTTCGCGCCAAATCCCATTTCTGCAACAGCAACTTGAGGTATAA
GTTTCGTGGGCGAGGCGCAGCAGCCTTTCGCCCCACGGGGTAAAGCGCAAGGGCGTGGATT
TGCGTTCGAACAGCGGCGTGCCGTAGTGGTTTTTCGAGCATACGGATCTGGTGGGAAAGGG
CGGATTGGGTAAAGGAAAACCCGTTTTGGCGGCAAGGGAGACGCTGCCGGTTTTCTTCAAGTG
CCAGCAGGTTTTTGAGGTGGCGCAATTCGATAATGGAATCCATGGGGCTTCAGACGGCAT
45 ATTTAACC GGCGCATATTAATAAATTCATATGCGGGTGCAATCGGAAAAATGTGAATT
CCGGACATTTTCCGATTAGAATGCCCGCTTGTTTTAAAGCGATTAGGAAAAAAGATGGTAT
TGTGCAGGGATTTCTGACTTGGTGAATGAAACATTGCAGACAGCGTTGTTTTAAAGATT
ACGCCCTTAACGGTTTGAGGTTGAAGGGAGGGAATATATCGGAAAAATCGTTACGTCCG
TAACGGCAAGCAGGGCAGCGATTGATTTGCTGTGGAGCAGAAGGCAGATTTGCTTTTGG
50 TACATCACGGTATGTTCTGAAAAACGAGTTGCCGACCGTTACTGGTTGAAAAAAGAAC
GGATTGCCGCACTGTTACGGCACGACATCAATATGGCAGGCTACCATCTGCCCTGGATG
CACATCCCACTGGGCAACAATGCCCACTCGCCGACAGATTGGGTTTTGCGACAGAAA
AACGGTTCCGGCAACAACCTGCTCAACTCGGGCAGCCTGAAACAAGCCAAGCACTCG
GCGCATTTGCGGCGCATATTGAAACAGTTTTTGAACGTAAGCCTGTCTGTTATCGGCAATC
55 CCGAACGCGAAATCCGACGGGTTGCATGGTGCAGCGCGGGGCGCAGGGTTTTTTTTCAGA
CGGCAATAGACGAAGGTGTCTGATCTGATTTGACGGGGGAAATCTCTGAAGCCCAATACC
ACCTTGCCAATGAAACGGGTACGGCTTTCATTTCCGCAGGGCATCACGCGACGGAACGTT

ACGGCGTACGCGCGCTGGCAGAATCGGCGGCAGAGGTTTTCGGGTTGGAAGTGTGCCATT
TTGACGAAAACAATCCGGCTTGAGTCTTGAGAAATATCATAAACTTTACCTTATTTTAA
ATAATGCTTTGAGTATCACTGCAAACTGGGTAAAATTGCAACGTTTAAATGGCTCGGTATT
5 CCCCCAATATAGGACGACTGAATAATGGATAATCAAGAAATCAACAACGGCCGCCGCCG
TTTCCTGACACTCGCGACCTGCGGCGGGCGGAGTGGCAGCATTGGGTGTGGCAACGCC
GTTTGTGGCCAGTTTTTCCCTTCGAAAAAGCCAAGGCCGCCGGTGCTGCCGTGAGGT
GGATGTCAGTAAAATCGAAGCGGGTCAGCTGCTGACCGCCGAGTGGCAAGGCAAACCGAT
TTGGGTGCTCAACCGTACAGATCAGCAGCTTAAAGACCTGAAAGGCCTGAACGGCGAACT
10 TACCGATCCCAATTCGGATGCGGAACAGCAGCCGGAGTATGCTAAAAACGAGACCCGTTT
GATTAAGCCGAACATCCTTGTGCGCATCGGTATCTGCACCCATTGCGGTGCTCGCCAC
CTTCCGTCCCGACATTGCCCGCCCGGATTTGGGTGCAGACTGGAAAGGCGGCTTCTCTG
CCCCTGCCACGGTTCGAAATTCGACTTGGCCGGCCGCGTATATAAAGGTGTTCTGCCCC
GACCAACCTGGTTGTCCCGCATATAAATACTTGAGCGACACAACCTATCTTGGTGGGCGA
AGACTAAGAATAAGGAACGATAATTATGGCAAACCAAACCAATAGCAAAGCAAAGCATT
15 GTTAGGCTGGGTAGATGCCCGTTTTCCATTAAAGTAAATGTGGAAAGAGCATCTGTCTGA
ATACTATGCGCCTAAAACTTCAACTTCTGGTATTTCTTCGGCTCATTTGTCTATGCTGGT
GCTGGTGATTCAAATCGTCAGCGGTATTTTCCCTGACCATGAACTACAAACCGGACGGCAA
CCTTAACGCCCTACCATCTGCCGTGCTGCCTTTACCGCAGTAGAGTACATCATGCGCGACGT
GTCCGGCGGGCTGGATTATCCGCTATATGCAGTCTACCGCGCGCATCTTTCTTCTCATCGT
20 CGTTTATCTGCACATGTTCCGTGGTCTGATTTACGGTTCGTACAAAAAACCGCGCGAATT
GGTGTGGATTTTCGGTTCCTGATTTTCTTGGCATTGATGGCAGAAGCCTTTATGGGCTA
CCTGCTGCCTTGGGGTCAAATGTCTTCTGGGGTGGCAGGTAATTATTAACCTGTTCTC
CGCCATCCCTGTTATCGGTCCGTGATTTGTCCACTTGGATCCGCGGTGACTTCAACGTTTC
CGATGTTACTTTGAACCGATTCTTCGCCCTGCAGGTATCGCTGTACCTTTGGTATTGCT
25 CGGCTTGGTGTGGGCTCATATCATTGCCTTGCGATGAAGTGGGTTCACAAACCCCTGACGG
TGTAAGAAATCAAAAAGCTGAAAGATGAAAACGGTGTCCCTCTAGATGGCATACCTTTTTT
TCCGTATTATGTTGTGCATGATATATTGGCAGTAACGATATTCTTGATTGTCTTCTGTGC
CGTGATGTTCTTTGCACCTGAAGGCGCGGCTACTTCTTGAAGCGCCAACTTCGATGC
AGCGAATGCGCTGAAAACACCTCCGCACATTGCGCCGGTATGGTACTTCACTCCGTTCTA
30 CGCAATTCTGCGTGCATTCCTTCCCTTGCCGGTACTCAGGTATGGGGTGTAAATCGGTAT
GGGTGCAGCAGTTGTACTGATCGCCTTGCTGCCTTGGTTGGATAAAGGCGAGGTAAATC
TGTCCGCTATCGCGGCCAATCTTCAAACCGCATTGGTTCTGTTTCATCATTCGCTTCAT
CGGTTTGGGTATTTTGGGTGCAATGGTAGCAACTGATACGCGTACTTTGGTTGCACGTAT
CCTGTCTTTCTGCTACTTTGCATTCTTCCCTGGGTATGCCGTTCTATACCAAACCTGGATAC
35 CAACAAACCGATTCTCGAACGCGTAACCATGAGCACTACTAAACAAAAAATTATGTTCTT
TGTTTACGTCCGTTATTACCGTTGTTGGTGCTTACTTGTTTGAACCAATATCTGATGAGG
GCAGCGAAAATGAAACAACTCTGAAAACCTGGTTTGTGCTTATTGCTGGCAGTGCCT
ATGAGTGCAGCCGTCGCCAGCGGCGGCGGACACTACGAAAAGTCGATATCGACCTGCGT
GACCAAGTCAGCCTGCAGCAGGTGCGCAAATCTTTACAACTACTGTTTGTCTTGCCAC
40 TCTGCAAGCGGTATGCGCTTCAACCGTCTGAAAGACATCGGTTTGACTGACGAAGAAATC
AAGAAAAACCTGATGTTTACCACCGATAATGTGCGCGATGTCATGCATTCGGCGATGAAC
CCGAAAGATGCGGCAAAATGGTTTGGTGCTGCTCCGCCCGATTGACGTTGATTGCGCGT
TCCAAAGGTGCAGACTACCTTTACGCCATATGCGCGGCTTCTATAAAGATCCGACCCGT
CCGAGCGGCTGGAACAATACTGTATTTCGATAAAGTCGGTATGCCCCACCCGTTGTGGGAG
45 CAACAAGGTGTTCAAGCCGTTGAGTTGGATGCCAAAGGTCAGCCGTTATGGTAAAAGAC
GAACACGGCGAGATGAAGCCTAAGCTGTATTGGGAATCTACCGGTTTGCACAGCCGCCGC
CTGCCTAACGGCAAAGTGATCCAAAAGAGTACGACGCATATGTACGCGATTGGTCAAT
TACCTTGTGTACATGGGCGAACCTGCACAACTGCAACGCAAACGTATAGGCTATGTCTGTG
ATGATTTTCCCTATTTGCGGTTATGCTGCCTTTGGCTTACTTCCTAAATAAAGAATATTGG
50 AAAGACGTACACTAAGCGTTTGAACAAAAGGGCAAATCCTTTAGGGTTTGCCCTTTTTT
CATTTTGCCCTGCCGTTTGAAGCCCTGAATCCGTATGCCGCTGAACATAGCTGCAACAT
TTCAGACGGCATCATTTCTAAAAATGTCAGACATCGGGAACCTTAATCAGGGTTTGTGGCAG
ATTGATATTGAATTAGGAAAAGGTCTGAAACCGCAAGCAGCATGGTAAGGCGATGTCGAA
CAGGTTTAAAGCCAATCCGCTATATTTTTTGGAGCTATGTGGAACAAACAGGTAGAATCG
55 GAATAAGCGGCGGTTTTGTCCGGTGTGAAAATGTTTGAATATTAGGATAATTGATGGAAC
TGATGACTGTTTTGCTGCCTTTGGCGGCGTTGGTGTGCGGCGTGTGTTTACATGGTTGC
TGATGAAGGCGCGTTTTAGGGCGAGTTTGCCGGTTTGAACGCGCACCTGGCGGAAAAGG

CGGCAAGATGTGATTTTGTGCGAACAGGCACACGGCAAAACCGTGTGCGAATTGGCGGTGT
TGGACGGGAAATACCGGCATTTGCAGGACGAAAATTATGCTTTGGGCAACCGTTTTTCCG
CAGCCGAAAAGCAGATTGCCCATTTGCAGGAAAAAGAGGCGGAGTCGGCGCGGCTGAAGC
AGTCGTATATCGAGTTGCAGGAAAAGGCACAGGGTTTGGCGGTTGAAAACGAACGTTTGG
5 CAACGCAGCTCGGACAGGAACGGAAGGCGTTTGGCGACCAATATGCCTTGAACGCCAAA
TCCGCCAAAGAATCGAAACCGATTGGAAGAAAGCCGCCAAACTGTCCGCGACGTGCAAA
ACGACCTTTCCGATGTGCGGCAACCGTTTTTGGCGCAGCCGAAAAACAGATTGCCCATTTGC
AGGAAAAAGAGGCGGAAGCGGAGCGGTTGAGGCAGTCGCATACCGAGTTGCAGGAAAAGG
CACAGGGTTTGGCGGTTGAAAACGAACGTTTGGCAACGCAATCGAACAGGAACGCCTTG
10 CTTCTGAAGAGAAGCTGTCTTGCTGGGCGAGGCGCGCAAAAGTTTGAGCGATCAGTTTC
AAAATCTTGCCAACACGATTTTGAAGAAAAAGCCGCCGTTTTACCGAGCAGAACC CGC
AGCAGCTCCATCAGGTTTGAACCCGCTAAACGAACGCATCCACGGTTTCGGCGAGTTGG
TCAAGCAAACCTATGATAAGAATCGCGCGAGCGGCTGACGTTGAAAACGAATTGAAAC
GGCTTCAGGGGTTGAACGCGCAGCTGCACAGCGAGGCAAAGGCCCTGACCAACGCGCTGA
15 CCGGTACGCAGAATAAGGTTTCAAGGCAATTGGGGCGAGATGATTCTGGAAACGGTTTTGG
AAAATTCGGCCTTCAGAAAGGGCGGGGAATATGTGGTTTCAAGCGGCATCCGTCCGAAAAG
AGGAAGACGGCGGCACGCGCCGCTCCAGCCCGACGTTTTGGTCAACCTGCCCGACAACA
AGCAGATTGTGATTGATTCCAAGGTCTCGCTGACAGCTTATGTGCGCTACACGCAGGCGG
CGGATGCGGATACGGCGGCACGCGAATGCGCGGCACACGTTGCCAGCATCCGTGCACACA
20 TGAAAGGCTTGTGCTGAAGGATTACACCGATTTGGAAGGTGTAACACATTGGATTTTCG
TCTTTATGTTTATCCCTGTGCAACCGGCTACCTGTTGGCGTTGCAGAATGACGCGGGCT
TGTTCCAAGAGTGTTTCGACAAACGGATTATGCTGGTTCGGCCCCAGTACGCTGCTGGCGA
CTTTGAGGACGGTGGCGAATATTTGGCGCAACGAACAGCAAAATCAGAACGCACTGGCGA
TTGCGGACGAAGGCGGCAAGCTGTACGACAAGTTTGTGCGCTTCGTACAGACGCTCGAAA
25 GCGTCGGCAAAGGCATCGATCAGGCGCAAAGCAGTTTTTCAGACGGCATTCAAGCAACTTG
CCGAAGGGCGCGCGGAATCTGGTCGGACGCGCCGAGAACTGCGTCTGTTGGGCGTGAA
GGCAGGCAAAACAACCTTCAACGGGATTGGTTCGAGCGTTCCAATGAAACAACGGCGTTGTC
GGAATCTTTGGAATACGCGGCAGGAAGATGAAGCAGTCTGACTTGTGCGGAAAAATATTGT
TTCAGCCGGGGCGGGAATGCCGAAAGCGCGGCGTAACGTACTGGTTCTGATTTTGGGTT
30 TTTTGTGTTGAAGTACTTACCAAGCCTTGTCCGGCGAGGTACACCGCAAGGCGGCGGTT
GTCTGAGCCTTTTGTGTTTTCAGACGGCATCAGTGCAGATGATGCCGTCTGAAGACCGTAG
GGAAGGCGGTTAGAAAAACGGATTGTGCGCGTTTTCTGTGTCGATGGAAGTCATACGCC
GTGTCCGGCGACAACCTTGACCGGTTTCGGGAAGGGTGAATAATTTGTTGCGGATATTATT
GATTAAGTCGGCGTGGTTGCCGCGCGGAAATCGGTTCTGCCTATGGTTTCGTAAACAG
35 CACGTGCGCCGCAATCAGCAATTCCGCTCGGCACAATAAAGACGATATGTCCCGCGT
ATGGCCCGGAATATGCAGCACTTGAAAGGCATAGCGTCCGACCGTGAGCGTTTCGCCTTC
TTCGAGCCAACGGTTTCGGCGCAAAGGCGGGCGAGACGGGAAATCCGTATTGCGCGGTGGT
TTGCGGCAGCGATTGGAGCAGGAATTCATCGTCCGGATGCGGCCCCGAGGACAGGGACTTT
ATGCGTTTTTCAACATTTTCGACCACGCGCGCGCGTGATCGAGATGGCCGTGCGTCAGCCA
40 GATTGCCGTGAGCGTAAGTTTGGGTTTGCCAACGCTTGACAGCAGGAACGGCACGTGCGC
GCCGACATCGGTACGACGGCTTCGCGCGTTTTCTGTCGTCCCAATCAGGGTGACGTTTTG
GCGGAAGGGGGTAACGGGGAGATTTCTGAACGTAGGGTCATCGGCGTGTTCCTAAACGG
TTTTTCAGACGGCATCGGGTTTGGCGTTTGTGTTTATGGCGGTTTGCCGCCCGTTTTGATA
TTGGGGGAATCAGATGATTAAGAAGACAATCGGCGGCATCATACCGATTTTACGGCGGT
45 TTTTCATCCCTGCATCAGCAGGCGCGGCGGATTGATGCTGGCGCAGGAATACAAAGGGCA
GGATATTGCCGGCTGGGCGATGAGCGAGAACTCGACGGCGTGCGCGCCTATTGGGACGG
AAAGCACCTGATGAGCCGTACGGGCTACGCGTTTGTCCGCCCAAAGGTTTTACCGCTCA
GTTTCCGCTTATCCTTTGGACGGCGAATTGTATAGCGGACGTGGTCAGTTTCGAGCAGAT
TTCCGCTACCGTGCGTTCTGTTTCTTCAGACTGGCGCGGCATCCGCCTGCACGTTTTCGA
50 TGTACCCAAGGCGCAGGGCAACCTCTACCAACGTTTGGCAGTCGCAACGCAGTGGCTGAA
AACGCATCCGAACGCGCGGATTACCATCATCCGCAAAATCAAAGTGCGCGACCGGCAGCA
CGCGATGAACCTTTTAAACAAATCGAAGCGCAGGGCGGCGAAGGCGTGATGCTGCGTCA
GCCCCGATCCCGTTACAGCGCGCGGAGGAGCAGCAATATTGAAGCTGAAAAGCCAATA
CGACGACGAATGCACGGTAACGCGGCACTATGAGGGCAAAGGGCGAAACGCGGACGGCT
55 GGGCGCGGTGCGCTGCAAAAACCGGCACGGCGAATTCGCGCATCGGCAGCGGTTTCAAAGA
TAAAGACCGCGACAACCCGCCCAAAATCGGCACACTGATTACCTACCGTTACCGTGGCTT
TACGCGGAAAGGCACGCCGAAATTTGCCACATTTGTGCGCGTGCGTACCGACCGCTGAGC

AGGACAGTTTCAGACGGCATCCGATACTTTGGTTTATAATTTTCCTTTTACCGACCGATTTC
CGACATATGACCGATTTAGAAACCAAACGCCCTTGAAACACAGGCGATGCTTGAAAACGCC
GATCTTTTGTTCGACCAAGGCCAATGCCGTGCCGCACTGCAAAAAGTGGCGGACGAGATT
ACGCGTGATTTGGGCGGCAAATATCCGCTGCTGCTGCCGTGATGGGCGGCGCGGTGGTG
5 TTTACGGGGCAGTTGCTGCCGTGTTGCGTTTTCCCTTAGATTTTGATTATGTTACAGTT
TCCCGTTACGGCGACAAGCTGGAGGGCGGCGGTTCAACTGGAAGCGTATGCCCGATGCG
GAACAAATCCGGGGCAGGCACGTCGTCGTGCTGGACGATATTTTGGACGAAGGGCATACG
ATGTCCGCCATTCAAGCCAACTTTTGGAAATGGGTGCGGCAAGCTGCCGTGCGGCGGTG
10 TTCGCCAACAAGCTGATTGACAAACCAAGCCTATCCGAGCCGATTATGTCGGACTGGAT
GTGCCGAACCGTTATGTTTTCGGTTACGGCATGGATGCGGCGGGCTGCTGGCGCAATCTG
GGCGAGATTTACGCATTGGGCGGAAAAATAAGGGCGCGATGCCGTCTGAAGGCTGTTTACA
CGGCATCGCGGCCATACGCCGCGCAGGATAATGAGGAACAGGACGCATAATATGATAGGGC
TTTTAATCATCACACACGAAACCATAGGCGAAGCCTACCGCAAGCTGGCGCATCATTTTT
15 TTCCGGGCGGACTGCCTGAAAACGTCCGCATACTCGGCGTGCAGCCGACGGAAGACCAAG
ACGACATCAACAACAACGCCATTGCCGCGCTTCAGGAATTTCCCGACAACGACGGCGTGC
TGATTATGACCGATATTTTCGGTGCGACCCCCCTGCAATGCCGCCCGCCGCTCGTGCGCG
AAAACAAATCGGCGATTTTGACCGGGCTGAACGCGCCGATGATGGTTAAGGCCGTCCAAT
ATTTCGCCGGCGGCGGAAGACCTTGCCGCCTTTACCGAATGCGTCAGGGAGGCGGCGGTAA
AAGGCATTTTTCGCCATCAGTCCGCGCCCGAAGATTGGTGTGCCGGCGCAGCGGCGATG
20 CCGTCTGAAGAAGCGGCAAGGCGAGGCAAAAACATTTTAAACGGCGTCTGCTGCCGATATACA
TAACACGGGAATCGAATGCTCAAAACATCCATCGAAATCATCAACAACTCGGACTCCA
CGCCCGCGCGTCCAACAAGTTCACCCAAACCGCGTCCAATTCAAAAGCGAAGTCTGGGT
TACGAAAAACGACAGCCGCGTCAACGGCAAAAGCATTATGGGGCTGATGATGCTCGCCGC
CGCCAAGGGTACGGTCATCGAACTGGAGACGGACGCGCGGACGAGGCGGAAGCGATGCG
25 CGCCCTGACCGACTTAATCAACGGCTACTTCGGCGAGGGCGAATAATGAGTATCGTGCTG
CACGGCGTGCGGCGGGGCAAGGCATTGCCGTGCGTTGCGCCACCTGATTGCGCGCGGT
ACGGAGGAAGTGCCGCAATGATGTTGCGGAGGCGGACACCGATGCCGAAGCCGAACGT
TTCGATGCCGCCGTCAAAGCCACGCGCAAGAGTTGGAACAGCTCCGCAGCGCGATTCCC
GAAAACGCCCCGACCGAGTTGGGCGCGTTTCATCTCGCTACACCTGATGCTCTTGACCGAT
30 GTTACCTTGTGCGCGCAACCCGTCGATATTTTAAAGGGAACAAAAATCAACGCCGAGTGG
GCATTGAAGCAGCAGAGCGACAACTCGCCGCCCAATTCGACAATATGGACGATGCCTAT
TTGCGCGAAGCGAAGCAGGATATGCTGCAAGTCGTCCGCCGCATCCACAACAACCTGATC
GGGCAAGGCAACGAGTTGGAAGTTGCCGACAACCTGTTTGACGAAACCGTTCTGATTGCA
AACGACCTTTCCGCCCGGACACGGTTTTGTTTAAAGAGCAGCGCATTGCCGCCTTCGTT
35 ACCGATGCCGGCGGCCCCACCGGGCATAACGGCGATTTTGGGCAAGGAGCTTGGACATCCCG
TCCGTGTCGGGCTGCACAACCTCGGCGCAGACGGCATCGGGCTGTTCCGCAGCGAGTTTCTT
GACGGTATCAACGGCGTGTGATTATCGCGCCGATGAGTCGGTGTGTAACGAATACCGC
CGCCGTGCCCGCAATACCGCAGCCACAAACGCGATTGTAACAAGCTCAAAAAAACGCC
GCCGCCACCGCGACGGGCTGTCATCGAGCTTGTGGGCAATATAGAATCCGCCGAAGAC
40 GTGAAACCGCTGCACAACCTCGGCGCAGACGGCATCGGGCTGTTCCGCAGCGAGTTTCTT
TACCTGAACCGCGATACGATGCCGTCTGAAGACGAGCAGTACGAAGTGTACAGCGCGATT
GTCAAAAAATGAAAGGCAAAAGCGTAACGATACGGACAGTCGATTTAGGTGTGGACAAA
AACCCGCGCTGGTTCCGGAAAAACAGCACGCCCAACGGCAGCCTCAACCCCGCGCTGGGC
ATGACCGGCATCCGCCTGTGCCTTGCCGAACCGGTGATGTTCCGCACCCAGATGCGCGCC
45 ATCCTCCGTGCGGCGGTACACGGCCCCGTGCGGATGATGTGGCCGATGATTACCTCCGTA
TCCGAAGTGCGCCAGTGCCTCATCCACCTCGACACCGCGCAACGCCAGCTTGCCGAACGC
GGCGATGCCTTCGGTAAAGTCGGCATCGGCTGTATGATTGAAATTCCGTCTGCCGCGCTG
ACCGTGGCGAGTATTTGAAACTGGTCGATTTTCATCTCCGTGCGTACCAACGACCTGATT
CAATACATCTTGTCCGTGATCGCGGCGACGACAGCGTCAGCCACCTCTACCAGCCCGGC
50 CATCCCGCCGTGCTGAAAATGCTGCAACACGTGATCCGTACCGCCAACCGCATGGACAAA
GACGTATCCGTATGCGGCGAGATGGCGGGCGATACCGCGTTTACCCGCGTTTTATTGGGT
ATGGGGCTGCGCGTTTTTCCATGAACCCCAACAACATCCTGCCCGTCAAAAACATCATT
CTGCACAGCAATGTCGGACAGCTCGAAAGTGATATTGTGAAAGTCATCCGCTGCGAAGAC
GAAGAGAAGTCGGAAGAGCTGATCAAAACAGATGAACAGCGTGTCTGTGAGGAAGAAGCC
55 GACTTCAAGGGGCGGAAATAAATACGGCAGGTAAAAATAGAAATACTTAACAATGCCCG
CAATCTGAAATTTTGCCATTCTTGCAAAATAGAAAACCGAAACAGAAACCCAAAATCGGC
CATTCCCTCAAAAACAGAAAACCAAAATCAGAAACCTAAATCCGTGATTCCCGCGCAGG

CGGGAATCTAGGTTTGTGCGGCACGGAACTTATCGGGAAAAACGGTTTCTTTAGATTTTA
CGTTCTAGATTCCCGCCTGCGCGGGAATGACGATGAAAAGATTGTTGTCGCTTCGGATAA
ATTTTTGCCGTGTTGGGTTCTAGATTCCCGCTTTCGCGGGAATGACGGCAGAGTGGTTTC
AGTTGCTCTCGATAAATGCCGCCATCTCAAGTCTCGTCATTCCCTTAAACAGAAAACCG
5 AAATCAGAAAACCTAAAATCCCGTCATTCCCGCGCAGGCGGGAATCTAGGTCTGTCGGCAC
AGAACTTGTGCGGAAAAACGGTTTCTTTAGATTTTACGTTCTAGATTCCCGCCTGCGCG
GGAATGACGATGAAAAGATTGTTGTCGCTTCGGATAAATTTTGTGCGGTTGGGTTCTAG
ATTCGCCGTTCGCGGGAATGACGGCAGAGTGGTTTCTGTTGCTCCCGATAAATGCCGCC
ATCTCAAGTCTCGTCATTCCCTTAAACAGAAAACCGAAATCAGAAACCTAAAATCCCGT
10 CATTCGCCGCGCAGGCGGGAATCTAGGTTTGTGCGGTGCGGAACTTGTGAAAACCTTGCA
AAATCCCCTAAATCCCACCAAGACATTTAGGAGATTTTCCATGAGCACCTTCTCCAGC
AAACCCGACAAAGCCATGATTGCCAAACACATCAACCGCTTCCCGCTATTGAAGTTGGATC
AAGTGATTGATTGGCAGCCGATCGAACAATACCTGAACCGTCAAAAAACCGTTACCTTC
GAGACCACCGCGGCCGTCCCGCTATCCGCTGCTGTCCATGTTCAAAGCCGTCTGTCTCG
15 GACAATGGCACAGCCTCTCCGATCCCGAACTCGAACACAGCCTCATTACCCGCATCGACT
TCAACCTGTTTTGCCGTTTCGACGAACTGAGCATCCCCGATTACAGCACCTTATGCCGT
ACCGCAACTGGCTGGCGCAAGACGACACCCTGTCCGAATTGCTCAAACCTGATCAACCGCC
AACTGACCGAAAAGGTTTAAAAGTAGAGAAAGCATCCGCCGCCGTTCATTGACGCCACCA
TTATTCAGACCCGCGACGCCAAACAGCGCTCAGGCCATAGAAGTCGATGAAGAAGGACAAG
20 TCAGCGGCCAAACACACGCGGATTAAGGACAGCGATGCGCGTTGGATCAAGAAAAACCGCC
TCTACAAACTCGGTTACAAACAACATACCCGCACCGATGCGGAAGGCTATATCGAGAAAC
TGCACATTATAGTAGATTAAATTTAAATCAGGACAAGGCGACGAAGCCGCAGACAGTACA
GATAGTACGGCAAGGCGAGGCAACGCCGTACTGGTTTAAATTTAATCCACTATATTATGC
GCAAAGCCTGCCGCAACCGTCCGCTGACGAGGCGCAAACCAAACGCAACCGATATTTGT
25 CGAAGACCCGTTATGTGGTCTGAACAGAGCTTCGGTACGCTGCACCGTAAATTCGCTACG
CCCGGGCAGCCTATTCGGACTGATTAAAGTGAGTGCGCAAAGCCATCTGAAGGCGATGT
GTTTGAACCTGTTGAAAGCCGCCAACAGGCTAAGTGCGCCCGCTGCCGCCTAAAAGGCGA
CCGGATGCCGTGATTATCGGGTATCCGGGGAGGATTAAAGGGGTATTTGGGTAGAATTAGG
AGGTATTTGGGGCGAAAATAGACGAAAACCTGTGTTGGGTTTCGGCTGTTGTGAGGGAA
30 AGGAATTTTGCAAAGGTCTCAGATTGTTGTGCTTCGGATAAATTTTGCCGCGTTGGGT
TCTAGATTCCCGCTTTTGGCGGAATGACGGCAGGTTGGTTTCAAGTTGCTCCCGATAAATG
CCGCCATCTCAAGTCTCGTCATTCCCTCAAAAACAGAAAACCAAATCAGAAAACCTAAAA
TCCCGTCATTCCCGCGCAGGCGGGAATCTAGGTCTGTGCGGCACAGAACTTGTGCGGAAA
AACGGTTTCTTTAGATTTTACGTTCTGGATTCCCGCCTGCGCGGGAATGACGATGAAAAG
35 ATTGTTGTGCTTCGGATAAATTTTGGCGTGTGGGTTCTAGATTCCCGCTTTTGGCGG
AATGACGGCAGGTTGGTTTCAAGTTGCTCCCGATAAATGCCGCCATCTCAAGTCTCGTCAT
TCCCTCAAAAACAGAAAACCAAATCAGAAAACCTAAAATCCGTCAATCCCGCGCAGGCGG
GAATCTAGGTCTGTGCGGCACGGAACTTATCGGGAAAAACGGTTTCTTTAGATTTTACGT
TCTAGATTCCCGCCTGCGCGGGAATGACGATGAAAAGATTGTTGTTGTTTTCGGATAAAT
40 TTTGCAGCCCTGATAAAAAATATGGCTGCTTTGGTAAAAAATGCCGTCTGAAAGGTTT
TCAGACGGCATTTTGTTTTAAAGAAGCATCAGCGGAAGCGGACGATTTCCCGTTCTTCGA
TATGGATGCGTACCGTATCCCTGCCCGATACCGCCCCGGCGTGCCGCATATCGAGGTTCA
GCCACAGGATGCCGTGTTCGGATGGAGGACGGACAGGCTGAACGATTCCGGGCAAACAGG
TACGGGATAATACGCGGCACTCCATGCCGTCTTGGTCGAAACGCACCGCATGTTGCGGAA
45 TATGGCGGTTATCGTTCGTTATTGGGCAAACCCATCAGTCGGGCGACCTGCACGCAGGATG
GTGTTTTGACCAAGTTTCGGGCGTACCGTATTGTAGAATCCTCCCTTTATGCATCACGG
CGATTTCTGCTGCGCTCGTACAGGCTTCTTCGGGCGAATGCGTTACCAAAAACGGCAGGGA
TGCCGCCGTTTTCGGATACGTTTCGGCAGTCATACGGCGCAGCGTGCCGCGCAATGCGTGT
CCAAACTGGAAAACGATTTCGTCCAACAGCAGCAGGGAAGGGCGGACAACCAAAGCGCGCG
50 CCAACGCCAGCCGTTGCTTCTCGCCTCCGGAAGTTTTTTCAGGCTTGCGGTGCGCCTCGT
TTTCCAGTCCGACTTCGGCAAGTGCCGCCATGGCGAGGCGTTCCGGCTTTCGGCA
TTTTTTGCATTTTCAAACCGAATGCCGCATTTTCCAGCGCACTCATATGGGGAAACAGCG
CGTAATCTTGAAACATCAGCGAGATACGGCGTTTTTTCGGGCGGCATACGGGTAATGTTTT
CTCCGTTACGCCATATTTCCCGCGCTCCGGCCGGAACAATCCCGCAATTATATTACGCA
55 GGGTGGATTTTCCGCAGCCCGACCGCCCCAAAACGGCGAGTATTTTGCCGCGCCCGACAG
TCAGGCAGATGTTGTGCGGACGCTTTTATTGCCGAAGCGTTTGCAGAGTCCGTTCAAGT
CAAGCATGGCGCATCCTATAAACGTATGCCGTCCAGCCACTCGGACAGCGGATGGGCGGC

ATCAATCAGACCGTAACGGCAAAACGCGTCCAGCGTAACCAGTTGCGCGTCGTGCATCAT
GTTTCCCCGACAACATGGCATCCAACAGACCGCCGATGTCCATTTTCTCAAAACCCGCCAC
TTCGCCATCCTGATTTTCAGGCAGGAAGGTTTCGGGCAGGACGGCATCGAATACATACAG
5 GATTTTCATTGTGTACACCCCGGCTGACGGAGCGCAGGCTGTGCAGCTGCGATACCGGGCG
GATGAGCGGAAGCAGCGTTTTATCCAAACCGGCTTCTTCGCTGCTTTCGCGACACACGGC
TTCAGACGGCATTTCCGCCGCCGAAACACCGCCGGCGGCAGTATTGTGAGTTTGTGGG
ATCGACTGCTTTGTGCGGACTGCGCCTGCCTATCCAGAAATGCCATCGGCCGTCCGATT
GGTCAGACCGTTGAGATGGACGGCGCGGCTGAGCAGTCCGAAAGGACGGAAAGCGGCGCG
10 TTCGAGCGTGAACAAGGGGTTGCCGCCCGCTCGGTGAGTTCGAAACACTCGTTGCGCCA
ATCAGGCCAGCGTCCGCATTTCAGAAAATGCCGTCTGAAGACTCCGAGCAGCCTGCCTC
CCAGTCTTTTTTGACGCGTTCCACCCATTCCGGCGACAGGTTGCCCAAAGGCAGACCGTT
CAGATACAGCGTTTCCAGCAACTTTCTGCACCGTAACCTGCTTTTGCCTACTCGAACAG
AGCATCAAGTCTTGTGTTGCTGACGGATTTCGGTAAAACGGACGGTCGGCATGTTTGGCTT
15 TCTTGAAGACAATGCGGAAGATTGTAGCCAAACTGCCTGAATTTGCAACCGCAAACAGAC
GGCGGTCTGCCGTTCCGATATTGCGGCCGGAAGGAAAATCCGGCAAAAAACGGAGGCGGC
AGGAAACAGGAAACAGGAAACAGGCAAAACAAAACCCCTCGGCATTGAACCGAGGGGTTT
GATATTTGGTTGCGGGAGCAGGATTGCAACCTACGACCTTCGGGTATGAGCCCGACGAG
CTACCATGCTGCTCCATCCCGCGTCAAGATGAACTATACGGCAGATTTTTTATGTTG
20 TCAAACATTACTTCCGCGAAAAATCATAAAATTTTGCCGTCCGGCGGTTTATGCCTGATT
TGAAATATATTTTCTTTACAAAAGTTCATGTTCTGTGATTTAATTTTGGTTAACATTGAA
ACAGGGGTGCTGCCTGATGTTTAGGCGGCTGAGAAATACCCTTTACACCCGATCGGGATA
ATACCTGCGTGCGGGAGTTTTACGGAATTCTGCTTTTCAGACGGCATTTGGTTTTCAAATGC
CGTCTGAAAAACGCAAAACGCTCCTGTTTCTTTAATTCTAAACGAGAAAAACAGGAGCATTT
25 TTTTATGACTACGCCAAAAAAACCGCCAAAACTTCCGGCAACGAAGCGCGCGAGCTTGC
CGACTTGAGCGAAGACATCGGCATCTGCTTTAAATATCCGAACCTCGGAACGCGTGTATCT
GCAAGGCAGCCGCGACGACATCCGCGTGCCTTTGCGCGAAATCCGTGAGGACGACACCTA
CACGGCGCAAGGTACGGAAGCCATCCGCCGATTCCCGTCTACGACACCGCGCGGTGTA
CGGGCAGCCCGGCGCGCATATCGACCTGAAACAAGGTCTGCCGCACATCCGCACCGCGTG
30 GCTGGACGAACGCGGCGATACCGAAATCCTGCCAAGCTCTCCAGCGAATACGGCATCGA
ACGCGCACACGATCCGAAACCGCCCATCTGCGTTTCAACCAATCACCCGCCCGCGCCG
CGCGAAAAAGCGGCAGCAACGTAACCCAGCTTCACTACGCGCGCAAGGCATTATCACGCC
CGAAATGGAGTTTGTGCCATACCGGAACGTTTAAATTAGACGAATTGTCCCAAAAACC
GGAATACGCCAAACTCTTGGAACAGCAGCGGGGCAAAGTTTCGGTGCGAACATCCCGAC
35 CCATCCCGACCAATCACGCCGAATTCTGTGCGCCAAGAAATCGCCGCCGACGCGCGAT
TATTTCCCGCCAACATCAACACCCCGAACTCGAACCAGATGATTATCGGCCGCAACTTTTCG
TGTCAAAATCAACGGCAACTTGGGCAACTCCGCCGTCACTCCAGCCTGACCGAAGAAGT
CGAAAAATGGTGTGGTTCGCTGCGTTGGGGCGCGGACACGATTATGGATTTGTCCACCGG
CGCGCACATCCATGAAACGCGCAATGGATTATCCGCAACGCGCCCGTCCCATCGGCAC
40 CGTGCCGATTTACCAAGCGTTGAAAAAACCGGCGGCATCGCCGAAGATTTGACTTGGGA
TTTGTTCGCGACACCTCATCGAACAGGCGGAGCAAGGCGTGGACTATTTACCATACA
CGCGGGCGTGTGCTGCGTTATGTGCCGATGACCGCAACCGCCTCACCGGCATCGTCTC
GCGCGGCGGTTTCGATTATGGCGAAATGGTGTGTTGGCACATCATCGGGAAAATTTCTCTA
CACGCATTTTCGACGAAATCTGCGAAATTATGAAAGCGTATGACGTATCGTTACGCTCGG
45 CGACGGCCTGCGCCCCGGCTGCATTGCCGATGCCAACGACGAATCCCAATTCGCCGAAC
GCACACCTTGGGCGAATTGACCGATAAAGCGTGGAAACATGACGTACAAGTCATGATCGA
AGGCCCCCGCCATGTGCCGCTGCAACGCGTCAAAGAAAACATGACCGAAGAGCTGCAACA
CTGCTTTGAAGCACCTTTTACACGCTCGGCCCGCTCGTTACCGACATCGCACCCGGCTA
CGACCACATCACCTCGGGCATAGGCGCGGCCAATATCGGCTGGTACGGCACGCGATGCT
50 TTGTTACGTTACCCCGAAAGAGCATTTCGGGGTGCCTGACAAAGAAGACGTGCGCACCGG
CATCATCACCTACAACTCGCCGCCACGCGCCGATCTCGCCAAAGGCTGGCCGGGCGC
ACAATTACGTGACAACGCCCTGAGCAAGCGGTTTCGAGTTCCGCTGGCGCGACCAATT
TCGCTTAAGCCTCGACCTGAACGTCGCGAGAGCTTCCACGACGAAACCTCGCTGCCGA
AGGCGCGAAAATCGCCCACTTCTGCTCGATGTGCGGCCCAATTTCTGCTCGATGAAAAAT
55 CACGCAGGAAGTGCAGGACTACGCCGACAAGCAAAAAGCCCAACGGCAGGGCATGGAGGA
AAAAGCGGTGAGTTCTGCAAAAAGGCGCGAAGATTTACAGTTAAACGTCAAGCAAAAA
ATGCCGTCTGAAAACCGGAAAAAAGGCTTCAGACGGCATTTCTTCGTTGTGAAAAATATA

GTGGATTAACAAAAATCAGGACAAGGCGACGAAGCCGCAGACAGTACAGATAGTACGGAA
CCGATTCACTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCA
ACGCCGTACTGGTTTTTGTAAATCCACTATAATTTTAAAAATTTTATATTACATAGAT
GGGATGATGGGATTTAGGATTCTGATTTTGTGTTTGGAGAGAATGAAGGAATTTGAGATT
5 GTGGGCGATTATCGGGAATAAGAAATCTTCCGCCGTCATTCCCGCGCAGGCGGGAATC
TAGACATTCAATGCTAAGGCAATTTATCGGGAATGACTGAAACTCAAAAACTAGATTCC
CACTTTCGTGGGAATGACGGGATTAAAGTTTCAAAATTTATTCTAAATAGCTGAACTCA
ACGCACTGGATTCCCGCCTGCGCGGGAATGACGAAGTGAAGTTACCCGAAACTTAAAC
AAGCGAAACCGAACGAAGTATGCTTCCACTTTTCGTGGGAATGACGGCAGAGCGGATTCTG
10 TTGCTCCCGATAAATGCCGCAACCTCAAATCCCGTCATTCCCGCGCAGGCGGGAATCTAG
GTCTGTGCGTGGGAACTTATCGGGTAAACGGTTTCTTGAGATTTTTCGTCTGCGATT
CCCACTTTTCGTGGGAATGACGGGATTAAAGTTTCAAAATTTATTCTAAATAGCTGAAACT
CAACGCACTAGATTCCCGCCTGCGCGGGAATGACGGCATATTTTGACATTGAATAAAAAA
GACTAAAAACAGGAAAAAGCCAAACAGAAAAAGCCAAACAGAAAAAGCCAAACAGAAA
15 ACAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGCGAAACAGAAA
ACAGCGAAACAGAAAAACAGCGAAACAGAAAAACAGGAAAAAGCCAAACAGAAACAGGAAA
AAGCCAAACAGAAAAAGCCTGTCTGGCGACAGGCTTTTGTGATACCAATCTTTGCGAG
ATTAGAATTTGTGGCGCAGACCGACACCGCCGGCAGTCGCTACGAATTTGTTTTGCGCTT
TGCCTTCTTGCAACCAACCGGCAGAAACCAAGGCAGAAGTGCCTTTGGAGAAGTCGTATT
20 CCGCACCGACAACCCTTGGTCGTATTTCGTTGCCATGTCTGCATCATCAACCAACCTT
TGAAGCCGTGGGCGTAAGAACTCGGGGCGTTACGTTGCCGAAGCGGTATGCCAAGGTAG
CGGCAACTTCGGTTTGAGAGTTGTGCGAATTGGAAGCATCAGTCAGTTTCGCGTCTGTT
GCTGTACGGCTACGGAAGCGTACAGGGCATCATGTGTAACCGCTGACCAACCGGTGAA
TCTGGTATTTCTCAATATTCAAGCCCTCTTGCACTTGATGATGTCTTTTATAGGCACCGC
25 CATATTGCACGAAGAAGCCACCGTTTTTGTAGTTGAAGCCGGCGTGGTAAGATTTCGCTGT
TATGTCTGCCTGCATTGTCGTTAAGCGCGTATTGTACGCTGCCGCTGAGGCCGGCAAATT
CGGGAGAATCGTAGCGTACGGAATGAGGCGTGCTCGGGTTCGGCAATTTTGTTTACAC
CCAAATAGTCGCTTTTGCTATCCCAAGGATTGATGTCGCCGGTGTCTTTCAGGACGCTGT
TCAAACGACCGACGCGCAATTTACCGAAGCCGCTTTCAAGCCGATGAAGGATTGGCGGT
30 TGCCCCAACCGGAGTCAGTACCGCGCATAGATGCTTTTTGCTCAACCTGCCAAATGGCTT
TCAGGCCGTTACCGAGGTCTTCTTGGCCTTTGAAGCCGATTTTCGAACCCAAATCAACGA
TGCCGGTAGCGGTTGTAACCTCAGTAACCTTGCCGTTCTGGTGAAATACAGAGCGGGAAG
TTTCTACGCCGGCTTTGATGGTGCCGTACAGGGTAACGTACGCCATTGCTGCAACAGGAA
GGGCTGCCAAAGTCAGGGCAATCAGGGATTTTTTCATTGCTGTATTCTTTTTTGGTTAA
35 GAAATTAAGCCGGCCGGGCTTTCCAAGCCGCTTAGCTTTGCATTTACCGCCGACGTTTT
CGGCGATTCCATGTCTGAACTATAGATGTTCTGTCTGAAAAACAACTTCTGCCTGT
TTTTGTGTGGAATTCGATGTGATTTTTGAAGGCGGATAGAGATATTATGGGTATTTTTT
GTTTTATAACATATGGTTATTTAAATTTTTTAAGATTGTCATTTTACAACACTTACTCG
GGAGGGTATTGGAGGGCATTGCAACCGGGGGTTATAAAGACGGCAAAAAACGCGCACGT
40 GGTTCCTTTTCGGAACGGGCGGATGCAAAACCCGCCCTGCGGCAGGAGATAGTGGATTAA
CAAAATCAGGACAAGGCGACGAAGCCGCAGACAGTACAAATAGTACGGAACCGATTAC
TTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCTAACC
GTCATTCCCGCCACTTTTCGTCATTCCCGCTCAGGCGGGAATCTAGAATCTCGGACTTTC
AGATAATCTTTGAATATTGCCGCTGCCTTAAGGTCTGGATTCCCGCTGCGCGGGAATGA
45 CGGCTGCAGATGCCCCACGGTCTTTAGAGTGGATTACAAAAATCAGGACAAGGCGACGA
AGCCGCAGACAGTACAAATAGTACGGAACCGATTCACTTGGTGCTTCAACACCTTAGAGA
ATCGTTCTCTTTGAGCTAAGGCGAGGCAACGCTAACCGTCATTCCCGCCACTTTTCGTCA
TTCCCGCTCAGGCGGGAATCTAGAATCTCGGACTTTCAGATAATCTTTGAATATTGCTGT
TGTTCTAAGGTCTAGATTCCCGCTGCGCGGGAATGACGAATCCATCCGCACGGAAACCT
50 ATATCCCGTCATTCTACGAACCTACATCCCGTCATTCCCTCAAAACAGAAAACCAAAA
TTAGAAACCTAAATCCCGTCATTCCCGCGCAGGCGGGAATCCAACTTGTCCGCACGGA
AACTTATCGGATAAAACGGTTTCTTAGATTCCACGTTCTAGATTCCCGCTGCGCGGGAA
TGACGAATCCATCCGCACGGAAACCTATATCCCGTCATTCTACGAACCTACATCCCGTC
ATTCCCTCAAAACAGAAAAACCAAAATTAGAAACCTAAATCCCGTCATTCCCGCGCAGG
55 CGGGAATCTAGGTCTGTGCGGTGCGGAACTTATCGGGTAAACGGTTTCTTTAGATTCCA
CGTTCTAGATTCCCGCTGCGCGGGAATGACGGCTGCAGATGCCCCACGGTCTTTATAGT
GGATTACAAAAATCAGGATAAGGCGACGAAGCCGCAGACAGTACAAATAGTACGGAACC

-67-

GATTCACTTGGTGCTTCAACACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCGAGGCAAC
 ACCGTACTGGTTTTAAAGTTAATCCACTATAATGAACACAATCCATTACAGACTATTCAATC
 AGGCAAAACATCTCCTGCAATACTGCAAACAGTTTTTCAGCCGTACTGTTGTCTAAATTGC
 CAAGATGTTTGACCAATCCGGCTTTATCCACAGCCCTAATCTGTTTCGGGCAAAAGCAAAC
 5 CGTCTTTATCCTGAAAGCGGACATTGACGCGGAACGGGGCAGGACGGCTTCCGCTCGTCA
 TGGGAACGATCAGCACAGTCTTGAGATAGTTGTGTATTTTCAGGAGGAGAGACTACGACAC
 AAGGACGTGTCTTTTTGATTTTCGCTTCTACGGTCGGGTCTAAGGAGACCAGATAGATTCT
 CGCCGCTACTACCATATCCATTCTTTATCCGCTTCGTTTTCAATTTTCGAAAAAAATG
 CTCCTGCTCGGTTTCGACAAGCATTCGCGCAGCTTCTGCCCATCCCCTGCGAACGGTAGG
 10 ACAGCTTAAAAATAATATTGCCCTTTTCAACTGTAACAGCCAAGCTGTCTACTGCCCTTAT
 TTGACCCAATAATGATTTGGGCAGAATCACGCCTTGCAGTTTTCCCATTTTGCGTATGTT
 GAGAATCATATACGTACCATATTACCTGTTTATGTAATAACAATGTTAGTACCTTGATG
 AGGTAGTGTCAACATGGAAAAAGATTGCCTGACAGTTTGTCCGATTTCAAAATCTCCGCG
 ACAAGCATGTTTTAAAGCCATTTCGGGGATTTCGGGGCGGATGATGCCGTATGCCCTCGGGA
 15 TAGTCGACGCCCGTTCAGGTAAGTCCGTTCGGGCATGAAGGTCGGCGGGGCTTTGAGGCGG
 CTGCGTCTTTGAATCAGTGCAGCGAAGCCTTCGACGCTGAGTCTGCCGCTGCCGACATAA
 ACGAGCGCGCCCATGATGTTGCGTACCATGTGGTGCAAAmAgGCGTTGCCGTGCAAATCG
 AGGCGGACGAGTCTGAGCTTTGGGTAAGGTTTCGGCGCGGTAGATGGTTTTGACGGGGGA
 TTTTGCTTGGCATTTCGGCGCGCGGAAGCTGGAGAAGTCTTGTTCCGCGACCAATAAGGC
 20 GGCAGCCTGCCGCATCTGCCGATGTGAGTTTGAGGTGTGTCCAGCCTGCCCTGTTTTT
 GAGCAGGGGGGAACGGACGGGGCGGATTTCGAGCAGGTAGCGGTAGTGCCGTCCGTATGC
 GTCAAATCGTGCATGAAATTTCGGGGCGGACCTGTTCGGGCGTGCAAAACGGCAATGCCCTTC
 GGGCAGGTGGGCATTTACGCCGCGCACCCATGCCTGTTGGGGACGGGCGGCAGTTGTGTC
 GAAGTGGACGACTTGGGCGGTGGCATGCACGCCGCTGTCCGTCCTGCCGGCAACGGTGGT
 25 GGAAACCGCTTCCCCTGCTATTTGGGCGAGCGCGTTTCCAATGCCGCTGAACGGTCCG
 TACGCCGTGAGCCTGTTTTCTGCCAGCCGTAAAAGCGGCTGCCGTATAGGATAGGGTTAT
 TGCCAGCGTGTGTTTTGTGCGGTATCCATCGGATTTGGGATTTCGGATAAATGTTTCAGAC
 TGCATTGTATCGCAGATTTTGCAGGGAAACGGCAAACGCCAGGGCGAGCGCGTGTGTTT
 GGGGAGTTGTTGGGGGGGGGGATGCAGTTGCTACGAATCGCTATCCTGTGAATTTACCC
 30 TGTCAAGAGTGCCCGAATCGTCATTCCCGCGCAGGCGGGAATCTAGGACGTAAATCTAA
 AGAAACCATTTTTATAGTGGATTAAACAAAACAGTACAGCGTTGCCTCGCTTTAGCTCAA
 AGAGAACGATTCTCTCAGGTGCTGAAGCACCAAGTGAATCGGTTCCGTACTATTTGTA
 GTCTGCGGCTTCGTGCGCTTGTCTGATTTTTGTTAATCCACTATATCCGATAAGTTTCC
 GCACCGACAAAACCTAGATTCCCCTTTTCGTGGGAATGACGGGATGCAGGTTCGTGGGAAT
 35 GACCGGAACAGAAACCTCAAATCCCCTCATTCGCCGCGAGGCGGGAATCTAGACCTTAGA
 ACAACAGCAATATTCAAAGATTATCTGAAAGTCTGGGATTCTGGATTCCCCTTTTCGTGG
 GAATGACGGAATGTAGGTTTCGTAGGAATGACGGGATGCAGGTTCCTGATGGATGGATTCT
 GTCAATCCCAGCGAGGCGGGAATCTAGGTTCTGTGAGTGGGAACTTATCGGATAAAACG
 40 GTTTCTGGAGATTTTTCTGCTGATTCCCCTTTTCGTGGGAATGACGCGGTGCAGGTTT
 CCGTATGGATGGATTTCGTCAATCCCAGCGAGTTCGGGAATCTAGACATTCAATGCTAAGGC
 AATTTATCGGAAATGACTGAAACTCAAAAAACTGGATTCCCCTTTTCGTGGGAATGACGG
 GATGCAGGTTTTCTTAACCCCGGCTTCTAGATTCCCCTTTTCGTAGGAATGACGGCGGTA
 GATTTGGCAGATGCGGCGGATTTCGGCAGGTCTCAACCCATCCTACAATCCACCCTGACCG
 CCTTTTACGAATCCGCCGCCATCCTGGGAAACGCAAAAAAATGCCGTCCGAAAACCTTT
 45 CAGACGGCATTTCGCGGGCAAATCAGTAAAAGACTTCGCGTCAGCTTAAGCGTTTCATA
 CCGCAGCTCGGACCGGGCGGGTTTCGGGTTTCGGAAGAGCGGTGTGAAATGAAACGCGGC
 AGACGCGGTGTGTGCCGCCATCCTGCCCGAACCAGCGGCAAGCGTCATCGCGGTTTGA
 ATCGGGCGGGCGCGTGCCTGTTCCGGCACGGATGCCGTCTGAAAGCGGCGGGTTCGGTCCG
 50 GTCCGCGTCAGCCTAAGGCGAAAAGTTCCCTGCCGTGGATTTCGAGCCACTGTTTCGCTT
 TGGGCGGTGTAGGGGCGAAGCGGCGGGTCAGTTCCCAAAGGCGGGGTGTGGTTCGGGAT
 GGGCGAGGTGGCAGATTTCGTGTATGCAGACATAGTCGGCAACGTATTCGGGTGCGCCGA
 CCAGCCGCCAGTTGAAAGCGTATGCCTGTGGTTTTGCGGCACACGCCCCAGAAGGTTTTGG
 CAGAGGTGAGCGAGGAGGAGGCGGGGAACAGTTGTGTGGTGCGGGCGTGGCGTTCGAGGC
 55 GGGGAATCAGGTAAGTGTGCGCCTGCCGTTCCAAAAAGTCCCGCAGCAGCGCAAGCTGTT
 TTTCCAGGTGCGCTTCGGGAACACGGATTTCAGACGGCATCAGCAGGATTTCGCTGTCTT
 GATGGGCGGTGAGGCGAAGCTGTCTGCCGTGGAAGAGGATGGATTTCGGGACGCGGTTTT
 CGGCAGTTTTCGGGCGCGGTTGTTTCGCCAGTGTTCGCCGAGGACGGCTTCGTTTTTCAT

ACAGCCAGCGCTTTAGAGCGGAGACGGAGAAGCAGGGTGGGACGCTGATGCGGACGGTAT
GTGTGCCGGCGGGGCGGATAATCAGGTTTTCTTGGCACGGCGCTTGATTTGACGGTCA
GTTCCATGCCGTCTGAAAGGGTGTGGACAAAGGCGGTCTGCGGTTTCAGACGGCATT
GGCGGCAAACGGGCCTGCGCCGAAATAAGCGGTTGTTGCGTTTCGATGAGATGTTTCGCA
5 TTTTCCATCAATTTCGGCTTCGCTGCCGCTTGCGTGCGGGATGGTCGGACAGATGACGAC
GGTGATTTCCCCCGGATATTTAGAAAGGAGTTTTTCGGCCAAAATTCGCCGCTGTTGAG
GGCGACGGGGACGATGTCCATCTCAAACATTTTCGCCATGCGCGCGCCGCGAGTTTGTA
TTTGCCGCTTTTCGGGGCGCAAGGCGCGTGCCTTCGGGGAAAATGGTAATCCAATAGCC
TTCGTTTTTGCGCACCAACCCCTGTTTTATGAGCTGCTCGTTGGCTTCGCGGCGGTTGTT
10 GCGGTCTATGCCTATGGTTTTGACCAGTTTCAAGCCCCAGCCGAAAAAGGGGATTTTGAA
CAACTCGCGTTTGGAACGTAAACCTGCGGCGGAAAAATGTCTGAAGGGCGAGCGTTTC
CCAGCGCTTTGGTGTGTTGGCGCAGATGACGGCGGGCGGTTCGGGATGTTTTCCGCGCC
GATGATGCGGTATTTGAGCCCGACGATGTGTTGAGCGACCAAGTTGAGAATGCCGACCCA
GACCCGCGCCATCTTGTGCGCCCCGTCCCGGAAAGGCGAGGCGAGCAGCATAAAGGGAAA
15 GAGGAAAATCAGGGTGGAAACAGAGTATCAGCCAGTAAATCAGGTTGCGGATGATGAGCAT
GGTTTTGCCTTGTCGGAATGCGGTATGTTCACTCGGCTTGCGGTGCGGTGTTTTCTGCA
TGATGTATTGTGAGAAATCGAGCAGGTATCGAAAACCTGTGTGTGTTTCGGGCAATTCGT
GTCCGTGTTGGGAGAGCGTTTTTTGCCTTTTCGGGTGAGAACAGCGCGGGTTTGCCGC
CGACGGCATCGATTGCCTGCAAATCGCGCAGGCTGTGCGCGACAGCCAGGTTTCGAGG
20 CTTGGGCGTTGAAGCGTCCGATGATGTCTTCAATCATACCCGTTTGGGCTTGCGGCAGT
TGCACTTGTGCGGCATCGGTGTGCGGGCAGAACAGATGCCGTGATTTTCGCCGCTGCCT
GACGGACGAGGCGGTGCATTTTGCGGTGCATTTTCGGTAAGGTTTTGAACGGTAAAAATATT
TGCGCCCGATGCCGATTGGTTGGTGGCAACGGCGACGGGTAGCCTGCCTGCGTCAGAA
ATGCCACCGCATCCATGCTGCCTTCGACAGGTATCCACTCGTCAACGGATTTGACGAAGT
25 CGTCGCGGTCTGATTGATGACGCGCTGCGGGTCGAGAAATGATGAGTTTCATCGCGTTTC
CTTTGGATTGGGGCAGGTTCGGGGTGCGCATTATACTGAAATATCGGTGGAAATGCGCCTG
TGCCGCGCGATAACGCGCCTGTTCCGGCAACCGCTTGCAATGCGCGGGTACGGCGTTTCG
GGGGCGGTGCGGATGTTTTCTGCTGCTCCTGCAACGGCGGATTTCTGCCGGACGTA
TTTTCCGCTGCAAAAGTCTCGGCGCGAAGTTGCGGGCAATGCCGTTTGGGGACGCGGT
30 CAGGCGGCAAGCATTTCAAGAAATCAGCCGATGTGTTTGTCTAAAGCCGGTTGTAGTTC
AGTGCCCGCATCGGTCGGACAGGCGGTGTCCGCCCTGTTTTTAAGGCTGACGGCTTGG
GCAACGGCTTGCGCCAGGGTTTCCGGGTTTTGGCGTGAGAAAAAGAAGCCGGCTTCTTCG
TTCATGACCTCTGTACATGCCATGTTTTCGGAGAGGACGACGCGTGTGCCGCATAGGACG
GATTTCGACGCGGACAGCCGAAAGGGTTCGTACAGGGAAGCCATAATGGTAAAGTCGGCG
35 GCGCGGTAGAGTTCGGGCATATCGGTGCAAGGCCAGTCCGACGACGTTTTTCATAGGG
CGGGGAAGCGGGGAGCCGACAACGGCGAGCTTGACGGGCAGGCTGGTATGTTGCAAAAAG
TCGGCAAGCAGTTCCAGACCTTTGCGCGTGTGGCCGTCGATGGGAACAGGAAAACGGTT
TCATGGTCGGCAAGCCGATTTTGGCGCGCAGGTGCGGAGTTTCTCCGGGTTGTGGAAG
AAGCGTTCCGTATCTGCGGGGGGGGGGGGCGACTTGGATTCTTTAGGGGGAACGCCGTA
40 CAGTCCGACCAGTTCGCGCCGATCATATGGGAATGCGCCATAATCAGTTTGGCGGTGGC
CTAGTTGCTGCGGTTCGCGCGTATGGCGAGGCGGTGAGCAGGTTTCGGTTTTTGCGCCAT
ATGGTGACGAGTAGCCCAAGTGTGTGCCGCCGAGATGAGGAGGTGCGCGTAATCGGCGTG
GTGGCAGGCAATCAGTTTTGCGGGCACTGTTTTTCTGGTTTGAGCGAGCCGGCTTGAAAA
GAGGAATGAGCGTAGTTTTTTCAGCGTCCGGTGTGATCGACAAGATGGGGTTTCGATTAG
45 GGCGTATTCAGGAATGCTGTGATCAAATTTCTGCGCATAAACGGCCGGTGTGATGTTTTG
TCTGTTGAGACCTTTACCAAATCCAATGTGTAGCGTTCCGTGCCGCCGCGGTGTTGAA
GTTGTTGGTTGCAATGTCTATTTTGAGCTTCATCATTGTTCTCTTTATGGTTGCGTCCCG
TTTGTGCGGGCGGGATTTGTGCGTGAGGGGCGAGGTAATGCGCTGTGTGCCGGAATACGG
50 TTGCCGTTTTGTTGCCGCAATGCCGTCTGAAGCCGCCGCGGGCTTCAGACGGCATTTTGC
CTTTATCCTTTAAATACGGGGACGAGTTCCATTTGCTCAATACCTGTGCGGCGATGTTG
ACGATGCCGAAAAGGAAGACCCAAACCATCAGCCACAAGCCGCGTAAACTTTATAGGTT
TTGCCTGCGCCGAATTTTTTGCGCGAACGGTAGAGCAGCATGGCGGGGATGATGCCTGTC
CAGACGGTTGCCGCCAGGCGGACGTAGCCGATGGCGGTAAACGAAGCCGGTGGGGAAGAGC
AGGCAGAAATCAGGGGCGGCGAGGAGTTCAGCGCGGCGGTTTTGGTGCGGCCGAGATG
55 CTGTCGTTCCATTTGAAGATGTGCGCGATGTAGTTCGAAGAGTCCGAGCGTTACGCCTAAA
AACGAGGTGGCGATCGCCATATAGGAAAACAGGGACAATTTTTGTCCATATTGCCGGTT
TGGGCGAATTTGGACAGGGTTTCGATGAGGACGGAGACTGCCCTTCGGCGGCGATGACG

GGGGCGAACTCGTTGCGCGGCAGGTTGCCTTGGATGGCGGTTTGCCAGAGGACGTAAATT
ACCAGCGCAATCAGTGTGCCCGTCCAGATGGATTTAGCCACTTTGGGCGCGTCGCCTTTA
AAGTATTTGAGCAGGCTGGAGACGTTGCCGTGGAAGCCGAAGGAAGCGAGGCAGACGGGC
AGGGCGGTGGCGGCGTAAATCCAGTAGTTTGTGCCGGCGGGGCTTGGGTATCGAAGAGG
5 ACGGACGGCTTGCGCATCGGCAATCAGCCCGCGCGCCCAAATAAAGGTCAATACCATG
CCGCCGATAAAGACGCCGGTGAAGCGGTGACCAAGCGTGC GGATGCCCATACGCAAAAG
GCGAGGATGCCGAAGAAGACGAGTTGTCCGACGGTGAGTGAAACGTGCGCGCCTGCCGCG
CTGCCTAAGCCTTTGGCGGTGAGTGC CGCGCGGACGAAGATATAAGCGTAAGTAAGCAGG
TATAAAACGAAGGCGACGGCGATGCCGTTGATGATGTTCCAGCCGCGTCCGAGCAGGTCT
10 TTGACCATCGTGTGCAAACTTGCGCCGTGCGGATAATGGGTGTTGACTTCCAAAATCATC
AGGCCGCTGGAAAGCATAGAAAACCAGGTGTACAGCAACACGGCCAGCGAGCCGGTAAAC
CATACGCCGATGTGGCGGTGCGGTTGGCGAGCATGCCTGCGCCGATGACCGTGCCGGCG
ATAATCATCGCGCCGCGCAACAGTGAAGGGGTTTTGTTGGGCATATTTTGTCTTTCTGCC
AGAAAAAGCGAGCCGCCATTATGCCGTAAAGTGTAAGGATTGTGAAGGTATTTGCGCCGC
15 GCCGCCGAAAAGGCTTTTCCAGACGGCATTGTGTTCCATAGTATAATCTTGGGTTTTGGAG
TGGGCGGTTTCGTGAGATGGGAGGAAAATGTCCGACAAAAAATATAATGTGATGAGGGG
GAAATCGCCAAATTCAGCCGGATTGCCGACAAATGGTGGGACAAGTCGGGCGAGTTCAAA
ACCTTGACACGACATCAATCCGCTGCGGCTGGATTATATCGACGGACACGCGGATTTGTGC
GGCAAACGGGTTTTGGACGTGGGCTGCGGCGGCGGCATCTTGGCGGAAAGTATGGCGCGG
20 CGCGGCGCGCGCTTTGTAAAGGCATCGACATGGCGGAGCAGTCGTTGGAACCGCCCGC
CTGCACGCGGCTTTGAACAATGTGCGCGATATCGAATACGAATGTATCCGCGTGAAGAC
CTTGCCGAGGCGGAACCGCACTCGTTGATGTGGTAACGTGCATGGAAATGATGGAACAC
GTCCCGGATCCCGCGCCATCGTGCGTGCTTGTGCCAATCTGGTCAAACCGGACGGCATG
GTGTTTTTTTCCACCATCAATAAAAACCCGAAATCGTACCTGCATCTGATTGTGGCGGCG
25 GAATATCTGTTGAAGTTTGTCCCAAAGGCACGCACGACTGGAAAAAATTCATCGCACCT
GCCGAGCTGGCGCGAATGTGCCGTGAGGCAGGCTTGATGTGGCGGATACGAAGGGTATG
ACTTACCATGTGTTGTGCGAACTTATGCCCTGTGCGATTCGACCGATGTGAATTATATG
TTTGCTGCGCTCCGCGCTTCTGACGGCGGGTTTGCCCGTTTTTGAGCAAGTGAGTTGAT
ATGTCTGTCTATACAGTGTTCGATGATGAAATGCGCGGCTTCTGAGCGGTTACGAT
30 TTGGGGGAATTTGTTTTCCCTGCAGGGCATCGCGCAGGGGATTACCAACAGCAATTATTTT
CTGACGACGACTTCGGGACGTTATGTGCTGACCGTGTGTTGAAGTGTGAAACAGGAAGAG
CTGCCGTTTTTTCTGGAGCTTAACCGGCATTTGAGTATGAAGGGCGTGGCGGTTGCCGCG
CCGTTTGCGCGCAAAGACGGCGGCTTGATTCCGTTTTGGCGGGTAAGCCTGCCTGCCTG
GTTGCCTGCCTGAAAGGTTCCGATACCGCGCTGCCGACGGCTGAGCAGTGTTCATACC
35 GGTGCGATGTTGGCGAAAATGCACCTTGCCGCCCGGATTTCCCTTTGGAATGGAAAAC
CCGCGTTACAATGCGTGGTGACGGAGGCGTGCGCCCGGCTGCTGCCCGTCTGTGCGAA
GACGATGCCGCACTGCTGTGTTCCGAAATCGATGCGTTGAAGGACAATCTCGGCAATCAT
CTGCCTTCGGGCATCTCCATGCCGATCTGTTTAAAGACAATGTGTTGCTTGACGGCGGT
CAGGTATCGGGCTTCATCGATTTCTATTACGCCTGCCGGGGCAATTTTATGTATGACTTG
40 GCGATTGCGGTCAACGATTGGGCAAGGACGGCGGACAATAAGTTGGATGAGGCGTTGAAA
AAGGCGTTTTATCGGCGGTTATGAGGGCGTGCGCCCTTGAGTGCCGAAGAAAAGGCGTAT
TTCCCGACCGCCCAACGTGCCGGCTGCATCCGTTTTTGGGTGTGCGCGCTGTGGATTTT
CATTTTCCGACGGCGGGCGAGATGACGTTTATCAAAGACCCGAACGCGTTCGCAACCTG
CTGTTGAGTTTGGGTTGAGTGCGTCCGGCGTTTGACAGAAATGCCGTCTGAAAGGGTTT
45 AGACGGCATTTTTATGGCTGATTAAAACGAAAATGAGACGATAGCCGGGTATTTCCATT
TTATAGTGGATTAACAAAAATCAGGACAAGGCGACGAAGCCGACAGACGTACAGATAGTA
CGGAACCGATTCACTTGGTGCTTCAGCACCTTAGAGAATCGTTCTCTTTGAGCTAAGGCG
AGGCAACGCTGTACTGGTTTTTGTAAATCCACTATAAATCAATGTAATCCATTCTGTTCC
CGATGTTTATGCCGTCTGAAACCCATCCTGTGTCGGGCTTCAGACGGCATATTGCTTCAA
50 AGCAGGTTTTCCGAGGCAACCCAGTTTCAAAATATCGGCTTCGACCGCTTCGGGCGTGCCG
GGGTTGGCGATTTTGACCCCGTATTCGCCTTCGCCCAGTTCTCGAGGATTTCCAGTTGC
GAATCGAGCATCCCTGCTTTTATGTAATGTCCTTTGCGCGACATCATGCGCTCGAGGTTG
ATGTCTTGCGGCGGACTGAGGTGGATGAAGGCGAGCTTTGCCTTCGGCTCCGCGCAGAATG
TCGCGGTGACCGCGTTTGAGGGCGGAACAGGTTACGATGGTGTGGTTGCGACCGTTTTGC
55 CCCTGTTGCGTCATCCAGTCGCGCAGATTGCCCAACCACGGATAGCGGTCTTCATCGGTC
AGCGGAATACCCGCGCCCATCTTGTGCGGGTTGGCTTGGGTGTGGAACCTGTCGCTTCG
GCATAGGGACATTGACCGAGGTGTTTCTGCAGGGACAGCGCGGCGGTGGTCTTGCCGCG